fluorouracil has been researched along with Cancer of Rectum in 2610 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 9.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer." | 9.69 | Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0." | 9.51 | First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022) |
| "This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 9.24 | Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017) |
| "Between October 2006 and December 2009, 36 patients with non-metastatic rectal adenocarcinoma were treated with chemoradiotherapy of irinotecan (50 mg/m(2) weekly), 5-fluorouracil (250 mg/m(2) for 5 days/week) and pelvic radiation (45 Gy/1." | 9.16 | Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2012) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 9.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 9.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| "Forty-two rectal carcinoma (T(3-4)N(0-2)M(0)) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide." | 9.12 | Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. ( Karaoglu, A; Topkan, E, 2006) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 9.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum." | 9.09 | Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 9.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 9.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i." | 9.06 | A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 9.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 9.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs." | 9.04 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975) |
| "Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have comorbidities." | 8.31 | Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? ( Aravantinos, G; Dessypris, N; Gkoura, S; Karampinos, K; Mauri, D; Miaris, N; Samantas, E; Sgouros, J; Spathas, N; Stamoulis, G; Theodoropoulos, I; Tzoudas, F; Visvikis, A, 2023) |
| "To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy." | 8.12 | Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 8.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 8.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "Ocular toxicity derived from the use of systemic fluorouracil has been widely described in the literature, as well as the relationship between the use of capecitabine and the appearance of conjunctivitis." | 8.12 | Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions. ( Bello Crespo, M; Gajete Pablos, MA; Gioseffi, HA; Roa García, DM; Trujillano Ruiz, A, 2022) |
| "Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)." | 8.12 | Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 8.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| "Female patients and patients aged sixty-five or older had an increased risk of developing severe diarrhea during preoperative chemoradiation therapy with capecitabine." | 8.02 | Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. ( Hartman, W; Nuyttens, JJME; Oomen-de Hoop, E; Rothbarth, J; van Meerten, E; van Rees, JM; van Vugt, JLA; Verhoef, C, 2021) |
| "5-fluorouracil chemotherapy in patients with dihydropyrimidine dehydrogenase deficiency, can give rise to ocular and cutaneous toxicity." | 7.77 | A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Kemp, E; McDonald, A; Obi, EE, 2011) |
| "Over a period of 1 year in our hospital, 3 patients were diagnosed with 'ileitis following capecitabine use'." | 7.77 | [Ileitis following capecitabine use]. ( Bouma, G; Imholz, AL, 2011) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | 7.77 | Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993) |
| "A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described." | 7.75 | A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009) |
| "We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy." | 7.74 | [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
| "Headaches have been reported as a potential side effect of capecitabine therapy." | 7.74 | Capecitabine-induced headache responding to diltiazem. ( Fakih, MG; Raman, AK, 2007) |
| "The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation." | 7.74 | Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. ( Be'ery, E; Fenig, E; Koren, C; Lavi, I; Loven, D; Shaked, Y; Sulkes, A; Yerushalmi, R, 2008) |
| "During a 4-year period we treated 20 patients with locally advanced adenocarcinoma of the rectum using a protocol of preoperative simultaneous pelvic irradiation (4,030-6,040 cGy) and infusion chemotherapy (5-fluorouracil 100 mg/m2 per day over 96 hours and mitomycin 10 mg/m2) followed by surgical resection." | 7.70 | Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. ( Burke, SJ; Knight, DC; Kwasnik, EM; Percarpio, BA, 1998) |
| "To report 5-fluorouracil in combination with folinic acid as a cause of severe nonischemic heart failure and to demonstrate the potential usefulness of an intra-aortic balloon pump." | 7.70 | Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 7.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 7.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 7.67 | Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. ( Jakubowski, AA; Kemeny, N, 1988) |
| "Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX." | 7.67 | Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 7.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted." | 7.67 | Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985) |
| "The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma." | 7.66 | Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981) |
| "DPD deficiency was suspected because he developed many severe adverse events of capecitabine early and was finally confirmed based on the finding of a low DPD activity level in peripheral blood mononuclear cells." | 6.82 | Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review. ( Akutsu, D; Fukuda, S; Hagiwara, Y; Ikeda, N; Inagaki, Y; Kobayashi, M; Moriwaki, T; Narasaka, T; Niisato, Y; Onoda, T; Suzuki, H; Tange, Y; Tomisaki, R; Tsuchiya, K; Tsuji, M; Yamada, K; Yamada, T; Yamamoto, Y, 2022) |
| "With the changed dosing schedule, this regimen was very well tolerated." | 6.82 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016) |
| "Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT." | 6.73 | Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. ( Andrews, C; Bullarddunn, K; Fakih, MG; Levea, C; Park, YM; Pendyala, L; Puthillath, A; Rajput, A; Ross, ME; Rustum, YM; Toth, K; Yang, GY, 2008) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 6.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 6.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 6.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "5-Fluorouracil (5-FU) is a commonly used anti-neoplastic agent." | 6.47 | Symptomatic 5-fluorouracil-induced sinus bradycardia. ( Lee, AD; McKay, MJ, 2011) |
| " The efficacy and adverse effects of maintenance treatment were compared between the two groups." | 5.72 | Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022) |
| "Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin." | 5.69 | Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. ( Ando, M; Bando, H; Honda, K; Kadowaki, S; Kato, K; Masuishi, T; Matsubara, Y; Muro, K; Nakazawa, T; Narita, Y; Nozawa, K; Ogata, T; Tajika, M; Taniguchi, H, 2023) |
| "AtezoTRIBE phase II randomized study demonstrated that adding atezolizumab to first-line FOLFOXIRI (5-fluorouracil, oxaliplatin, irinotecan) plus bevacizumab prolongs progression-free survival (PFS) of patients with metastatic colorectal cancer (mCRC), with a modest benefit among proficient mismatch repair (pMMR)." | 5.69 | An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. ( Antoniotti, C; Bensi, M; Bergamo, F; Boccaccino, A; Boquet, I; Catteau, A; Conca, V; Cremolini, C; Galon, J; Giordano, M; Leonetti, S; McGregor, K; Morano, F; Murgioni, S; Nielsen, TJ; Papiani, G; Passardi, A; Pietrantonio, F; Ross, DT; Rossini, D; Salvatore, L; Schweitzer, BL; Seitz, R; Tamburini, E; Varga, MG, 2023) |
| "The PanaMa trial demonstrated significant benefit in progression-free survival with the addition of panitumumab (Pmab) to fluorouracil and folinic acid (FU/FA) as maintenance therapy following first-line induction therapy with FOLFOX/Pmab in patients with RAS wild-type metastatic colorectal cancer." | 5.69 | Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial. ( Alig, AHS; Ballhausen, A; Fruehauf, S; Goekkurt, E; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Karthaus, M; Kasper, S; König, AO; Kurreck, A; Meyer-Knees, JW; Modest, DP; Müller, L; Sommerhäuser, G; Stahler, A; Stintzing, S; Trarbach, T; von Weikersthal, LF, 2023) |
| "Cetuximab in combination with chemotherapy is a standard first-line treatment regimen for patients with metastatic colorectal cancer (mCRC) RAS wild-type (wt); however, the efficacy of cetuximab plus leucovorin, fluorouracil and oxaliplatin (FOLFOX) had never been demonstrated in a prospective, randomized, controlled phase III study." | 5.51 | [The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab]. ( Colombo, A; Porretto, CM; Rosati, G, 2022) |
| "The randomised open-label phase III XELAVIRI trial failed to demonstrate non-inferiority of the sequential application of fluoropyrimidine plus bevacizumab followed by additional irinotecan at first progression (Arm A) versus initial combination of all agents (Arm B) for untreated metastatic colorectal cancer in the initial analysis of time-to-failure-of-strategy (TFS, 90% confidence boundary of 0." | 5.51 | First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI ( Decker, T; Denzlinger, C; Fischer von Weikersthal, L; Gießen-Jung, C; Graeven, U; Heinemann, V; Heinrich, K; Held, S; Jung, A; Kaiser, F; Kirchner, T; Kurreck, A; Modest, DP; Neumann, J; Schenk, M; Schwaner, I; Stahler, A; Stintzing, S, 2022) |
| "The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin." | 5.51 | Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group. ( Acar, R; Akbas, S; Akinci, MB; Araz, M; Arslan, C; Artac, M; Bahceci, A; Bilgetekin, I; Bilici, A; Cakir, E; Celik, E; Cilbir, E; Cincin, I; Dede, DS; Demirkiran, A; Deniz, GI; Dogan, I; Erdem, D; Erdogan, AP; Eren, OO; Erol, C; Garbioglu, DB; Gulmez, A; Hacibekiroglu, I; Hamdard, J; Hizal, M; Inal, A; Kahraman, S; Kaya, AO; Koca, S; Kubilay, P; Kucukarda, A; Kut, E; Mandel, NM; Menekse, S; Nayir, E; Oksuzoglu, B; On, S; Oyman, A; Ozyukseler, DT; Paydas, S; Sakin, A; Sen, E; Sendur Mehmet, AN; Sevinc, A; Taskaynatan, H; Tastekin, D; Turhal, S; Uncu, D; Yalcin, B; Yildirim, ME, 2022) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 5.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "Aflibercept; a decoy receptor for vascular endothelial growth factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin calcium, fluorouracil, irinotecan hydrochloride) chemotherapy regime, was FDA approved in 2012 as second-line salvage chemotherapy for metastatic colorectal cancer (mCRC)." | 5.41 | A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety. ( Chorawala, MR; Patel, RS; Thakur, A, 2023) |
| "We encountered a case of colorectal cancer with pelvic abscess treated with radical surgery following colostomy and chemotherapy." | 5.39 | [A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab]. ( Goseki, N; Kuwabara, H; Liu, B; Mitsuoka, A; Nakajima, K; Sanada, T; Watanabe, S, 2013) |
| "Radiation enteritis is the main acute side-effect during pelvic irradiation." | 5.34 | Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. ( Bendahl, PO; Gunnlaugsson, A; Johnsson, A; Kjellén, E; Nilsson, P; Willner, J, 2007) |
| "Capecitabine was not resumed, and the rash resolved in 3 weeks with the use of pyridoxine and Udderly Smooth balm." | 5.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 5.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 5.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 5.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "This study examined the association between methylenetetrahydrofolate reductase (MTHFR) polymorphisms and survival of patients with colorectal cancer (CRC) treated with 5-fluorouracil (5-FU)-based chemotherapy in Taiwan." | 5.24 | Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy. ( Chang, SN; Hsieh, LL; Lai, CY; Lin, YK; Sung, FC; Tang, R; Yeh, CC, 2017) |
| " This study was to compare the efficacy of TME with versus without preoperative concurrent chemoradiotherapy (CCRT) involving XELOX regimen (oxaliplatin plus capecitabine) in Chinese patients with stages II and III mid/low rectal adenocarcinoma." | 5.20 | Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial. ( Chen, G; Ding, PR; Fan, WH; Gao, YH; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zeng, ZF, 2015) |
| "In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3-4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m(2) on days 1-5 and 29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m(2) on days 1-5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m(2) on days 1-14 and 22-35) and oxaliplatin (50 mg/m(2) on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m(2) on days 1 and 15), leucovorin (400 mg/m(2) on days 1 and 15), and infusional fluorouracil (2400 mg/m(2) on days 1-2 and 15-16)." | 5.20 | Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. ( Arnold, D; Fietkau, R; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hoffmanns, H; Hofheinz, RD; Hohenberger, W; Hothorn, T; Lang-Welzenbach, M; Liersch, T; Lindemann, F; Raab, HR; Rödel, C; Sauer, R; Schlenska-Lange, A; Staib, L; Ströbel, P; Wilhelm, M; Wittekind, C; Wolff, HA, 2015) |
| "Ninety-nine consecutive patients with cT2-4N0-2M0 distal rectal adenocarcinoma were enrolled in a clinical trial (NCT00254683) and underwent baseline PET/CT followed by 54 Gy and 5-fluorouracil-based CRT." | 5.17 | Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation. ( Bailão Aguilar, P; Buchpiguel, CA; Gama-Rodrigues, J; Habr-Gama, A; Lynn, P; Nahas, SC; Ono, CR; Perez, RO; Proscurshim, I; São Julião, GP, 2013) |
| "Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions)." | 5.17 | Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. ( Anselmi, E; Ardizzoni, A; Bui, S; Camisa, R; Cascinu, S; Crafa, P; Dell'abate, P; Fontana, E; Galdy, S; Leonardi, F; Losardo, PL; Negri, FV; Pucci, F; Roncoroni, L, 2013) |
| "Patients with T2-T4/N+ rectal adenocarcinoma were randomly assigned to arm A-preoperative CRT with 5-fluorouracil (5-FU) continuous infusion followed by surgery-or arm B-induction oxaliplatin, folinic acid and 5-FU followed by CRT and surgery." | 5.16 | Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. ( Delaunoit, T; Demetter, P; Demols, A; Franchimont, D; Hendlisz, A; Maréchal, R; Peeters, M; Polus, M; Van de Stadt, J; Van Houtte, P; Van Laethem, JL; Verset, G; Vos, B, 2012) |
| "Between October 2006 and December 2009, 36 patients with non-metastatic rectal adenocarcinoma were treated with chemoradiotherapy of irinotecan (50 mg/m(2) weekly), 5-fluorouracil (250 mg/m(2) for 5 days/week) and pelvic radiation (45 Gy/1." | 5.16 | Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2012) |
| "A regimen consisting of 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) is widely used in France in the first-line treatment of metastatic colorectal cancer (MCRC)." | 5.15 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Bergougnoux, L; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Lledo, G; Rebischung, C; Ychou, M, 2011) |
| "Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients." | 5.14 | Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009) |
| " Capecitabine (CAP) and oxaliplatin (OX) are synergistic with radiotherapy (RT) and active in colorectal neoplasms." | 5.14 | Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. ( Bucci, L; Cannella, L; Carlomagno, C; D'Armiento, FP; D'Armiento, MR; De Placido, S; De Stefano, A; Farella, A; Pacelli, R; Pepe, S; Pesce, G; Solla, R, 2009) |
| "Consenting operable patients with stage II or III adenocarcinoma of the rectum received capecitabine (825 mg/m2 PO BID, 5 days/wk x 5 weeks) and SIB-IMRT delivering 55 Gy (2." | 5.13 | Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. ( Ballonoff, A; Kane, M; Kavanagh, B; McCarter, M; Nash, R; Pearlman, N; Raben, D; Schefter, TE; Shah, RJ, 2008) |
| "This multicentre phase II study evaluated the efficacy and safety of preoperative capecitabine plus oxaliplatin and radiotherapy (RT) in patients with locally advanced rectal cancer (T3/T4 rectal adenocarcinoma with or without nodal involvement)." | 5.13 | Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. ( Bieri, G; Burkhard, R; Heitzmann, F; Hess, V; Koeberle, D; Neuweiler, J; Ruhstaller, T; Rust, C; Terraciano, L; Toepfer, M; von Moos, R; Winterhalder, R, 2008) |
| "Blood samples from 125 patients with primary adenocarcinoma of the mid-low rectum who received 5-fluorouracil-based chemotherapy and external beam radiotherapy (median dose 48." | 5.12 | A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. ( Agostini, M; Ambrosi, A; Friso, ML; Leon, A; Lise, M; Lisi, V; Nitti, D; Pasetto, LM; Pucciarelli, S; Terrazzino, S, 2006) |
| "Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50." | 5.12 | A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. ( Ben-Josef, E; Desai, SP; El-Rayes, BF; Greenson, JK; Griffith, KA; Huang, EH; Knol, JA; McGinn, CJ; Philip, PA; Zalupski, MM, 2007) |
| "Forty-two rectal carcinoma (T(3-4)N(0-2)M(0)) patients with grade 2 or 3 diarrhea refractory to loperamide were enrolled to receive octreotide." | 5.12 | Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma. ( Karaoglu, A; Topkan, E, 2006) |
| "Seventy-two patients suffering from a metastatic colorectal cancer received, as first line treatment, a combination chronotherapy with 5-FU and folinic acid (infused from 10 pm to 10 am with a peak at 4 am, respectively at doses of 700 and 300 mg/m2 per day) and carboplatin (infused at the dose of 40 mg/m2 per day from 10 am to 10 pm with a peak at 4 pm)." | 5.11 | [Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study]. ( Biquet, JF; David, A; Delforge, M; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Materne, R; Moeneclaey, N; Weerts, J, 2005) |
| "During adjuvant radiotherapy (RT) for rectal cancer, patients receiving 5-fluorouracil (5-FU) by protracted venous infusion have a higher risk of diarrhea than have patients receiving bolus 5-FU." | 5.10 | Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial. ( Cha, SS; Gunderson, LL; Haller, D; Macdonald, JS; Martenson, JA; Mayer, RJ; Miller, RC; O'Connell, MJ; Rich, TA; Sargent, DJ, 2002) |
| "The aim of this study was to determine whether the efficacy of the combination of 5-fluorouracil (5-FU), leucovorin (LV) and radiation therapy (RT) could be improved by the addition of interferon-alpha2b (IFN-alpha) in patients who have had a 'curative' resection, for rectal adenocarcinoma (Dukes' B2/C; T3 N0, T4 N0, N1-3)." | 5.10 | Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b. ( Andreadis, H; Androulakis, G; Batalis, T; Besbeas, S; Dardoufas, C; Gennatas, C; Hatzistylianos, G; Katsos, J; Komporozos, V; Legakis, N; Mallas, H; Mouratidou, D; Papadimitriou, J; Peros, G; Philippakis, M; Photopoulos, A; Pisiotis, C; Polymeneas, G; Pouli, A; Retalis, G; Samanidis, L; Smyrniotis, V; Stamatiadis, A; Tsavaris, N; Vasiliou, J; Voros, D, 2003) |
| "To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy." | 5.10 | Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003) |
| "Thirty-two consecutive patients with a palpable adenocarcinoma of the rectum received preoperative RT (45 Gy in 25 fractions over 5 weeks) plus continuous chemotherapy with doxifluridine and leucovorin or 5-fluorouracil by continuous intravenous infusion during RT." | 5.10 | Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. ( Andreola, S; Baratti, D; Bozzetti, F; Mariani, L; Spinelli, P; Stani, SC; Valvo, F, 2002) |
| "To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum." | 5.09 | Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001) |
| "Between 1966 and 1983 we selected 209 patients with colorectal adenocarcinomas, stage B (14%) and C (86%) of Dukes, treated with convenient surgery in 100% of cases, 5-fluorouracil in 85% and postoperative radiotherapy with telecobalt in 46." | 5.08 | [Is radiotherapy necessary in the control of colorectal cancer?]. ( Molina Esquivel, J; Rodríguez del Rincón, E; Vargas Sandoval, G; Velázquez López, J, 1995) |
| "The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative therapy for patients with adenocarcinomas of the rectum that extend through the bowel wall or with lymph nodes positive for tumor." | 5.08 | Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. ( Benson, AB; Cooke, E; Cummings, B; Gunderson, LL; Hollis, D; Macdonald, JS; Martenson, JA; O'Connell, MJ; Petroni, GR; Tepper, JE, 1997) |
| "The combination of pelvic radiotherapy and 5-fluorouracil-based chemotherapy is associated with an increase in acute gastrointestinal toxicity during rectal adjuvant therapy, most notably an increased incidence of diarrhea." | 5.08 | Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma. ( Kahn, MJ; Krook, JE; Martenson, JA; Miller, RC; Sargent, DJ, 1998) |
| "We have used a relatively new trial methodology, the group sequential design, to prospectively evaluate two dose levels of bolus/infusional 5-fluorouracil (5-FU) and folinic acid in 192 consecutive-patients with advanced colorectal carcinoma." | 5.08 | Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation. ( Canney, PA; Cassidy, J; Habeshaw, T; Jodrell, DI; Mackean, MJ; McInnes, A; Paul, J; Reed, NS; Robertson, AG; Twelves, CJ; Yosef, H, 1998) |
| "Data from 12 metastatic colorectal cancer patients who were submitted to a pilot study with a multistep subcutaneous (sc) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) administration were compared with those from 13 historical controls who were comparable for the major prognostic indices." | 5.08 | A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study. ( Anselmi, L; Carpi, A; Ferrari, P; Nicolini, A; Sagripanti, A, 1998) |
| "To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU." | 5.07 | Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992) |
| "One hundred twenty-two chemotherapy-naive patients with histologically confirmed colorectal adenocarcinoma were entered into a randomized trial comparing infusional fluorouracil (FU) versus cisplatin (CDDP) and FU." | 5.06 | Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. ( Bosselli, B; Botet, J; Chapman, D; Cochran, C; Israel, K; Kemeny, N; Minsky, B; Niedzwiecki, D; Rosenbluth, R; Vinciguerra, V, 1990) |
| "Seventy-four previously untreated patients with metastatic colorectal adenocarcinoma were prospectively randomized into one of three treatment regimens: (1) 5-fluorouracil (5-FU) 450 mg/m2 as an intravenous (IV) bolus daily for five days or toxicity, then 200 mg/m2 IV bolus every other day for six doses; (2) methotrexate (MTX) 50 mg/m2 in normal saline by IV infusion over four hours followed by an IV bolus of 5-FU 600 mg/m2." | 5.06 | A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. ( Burke, P; Creaven, P; Emrich, LJ; Herrera, L; Mittelman, A; Petrelli, N; Rustum, Y; Stulc, J, 1987) |
| "Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i." | 5.06 | A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989) |
| "In this prospective randomized study the effect of oral Ftorafur was compared with that of intravenous 5-fluorouracil in patients with advanced adenocarcinoma of the stomach, colon or rectum." | 5.06 | Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. ( Bjerkeset, T; Fjøsne, HE, 1986) |
| " Patients were stratified by the presence or absence of hepatic metastases and by performance status, and were subsequently randomized to receive fluorouracil (5-FU) (15 mg/kg/wk) alone or the same dose of 5-FU plus cisplatin (60 mg/m2 every 3 weeks)." | 5.06 | A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial. ( Ansari, R; Correa, J; Hui, S; Kubilis, P; Loehrer, PJ; Meyer, S; Stephens, D; Turner, S; Woodburn, R, 1988) |
| "Studies were analyzed to show the correlation of response with dose intensity of single-agent 5-fluorouracil (5-FU) against colorectal cancer, multiagent CMF (cyclophosphamide, methotrexate, 5-FU) regimens against advanced breast cancer, and adjuvant therapy in stage II breast cancer." | 5.06 | Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. ( Figueredo, A; Goodyear, M; Hryniuk, WM, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma." | 5.06 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986) |
| "Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin." | 5.05 | A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983) |
| "Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas." | 5.05 | Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984) |
| "In a randomized, multicenter study, 168 evaluable patients with colorectal adenocarcinoma at B2, C1 or C2 stages of the Dukes, Astler and Coller classification, were treated after radical surgery with BCG and 5-fluorouracil alone (regimen A) or in combination with hydroxyurea, methyl-CCNU and mitomycin C (regimen B)." | 5.05 | Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma. ( De Vecchis, L; Lagomarsino Caprino, MC; Mazzei, T; Periti, P; Popoli, P, 1984) |
| "To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients)." | 5.05 | Prolongation of the disease-free interval in surgically treated rectal carcinoma. ( , 1985) |
| "An adjuvant program of fluorouracil for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968." | 5.04 | Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report. ( Brown, PW; Horsley, JS; Lawrence, W; Romero, C; Terz, JJ, 1978) |
| "In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks." | 5.04 | Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- ( Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978) |
| "A combined intraoperative and postoperative adjuvant program of 5 minus Fluorouracil (5 FU) for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968." | 5.04 | Chemotherapy as an adjuvant to surgery for colorectal cancer. ( Brown, PW; Donaldson, M; Horsley, S; Lawrence, W; Lovett, WL; Regelson, W; Ruffner, BW; Terz, JJ, 1975) |
| "In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs." | 5.04 | Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975) |
| " Here, we review the case of a 76-year-old male rectal cancer patient with liver metastasis who suffered extensive bowel necrosis after administration of 5-fluorouracil-based chemotherapy with bevacizumab, and required a subtotal colectomy and end-ileostomy." | 4.91 | Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature. ( Endo, K; Furukawa, J; Hoshino, Y; Ito, H; Kimata, M; Kobayashi, K; Masugi, Y; Ogata, Y; Shinozaki, H; Takada, S; Terauchi, T, 2015) |
| "5-Fluorouracil (5-FU) has been available for over 40 years and has been used in a wide variety of different regimens for the treatment of advanced colorectal cancer, a malignancy with a poor prognosis that is common in industrialized countries." | 4.80 | Which 5-fluorouracil regimen?--the great debate. ( Harper, P; Labianca, R; Vincent, M, 1999) |
| "To evaluate the safety and effectiveness of aflibercept in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) in Korean patients with metastatic colorectal cancer (mCRC) who progressed with oxaliplatin-containing regimen." | 4.31 | Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen. ( Ahn, MS; Bae, BN; Baik, SH; Beom, SH; Han, SW; Jeon, SY; Jo, HJ; Kang, MH; Kim, DH; Kim, HK; Kim, JG; Kim, JH; Kim, JS; Kim, JY; Lee, MA; Lee, S; Oh, J; Park, I; Park, YS; Shin, SH; Yoon, JA; Zang, DY, 2023) |
| "Safety and effectiveness of aflibercept with 5-fluorouracil/levofolinate/irinotecan have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a real-world clinical setting." | 4.31 | Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance. ( Kazama, H; Terazawa, T; Uetake, H; Watanabe, J; Yamane, S; Yoshino, T, 2023) |
| "Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia." | 4.31 | Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. ( Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S, 2023) |
| "Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have comorbidities." | 4.31 | Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? ( Aravantinos, G; Dessypris, N; Gkoura, S; Karampinos, K; Mauri, D; Miaris, N; Samantas, E; Sgouros, J; Spathas, N; Stamoulis, G; Theodoropoulos, I; Tzoudas, F; Visvikis, A, 2023) |
| " This case report discusses the clinical trial treatment of a patient with rectal adenocarcinoma by a new ropidoxuridine-capecitabine-radiotherapy combination." | 4.31 | A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer. ( Collins, JM; Kinsella, TJ; Kunos, CA; Piekarz, R, 2023) |
| "This retrospective study included 289 patients with metastatic colorectal cancer treated with second-line folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors." | 4.31 | Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors. ( Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K, 2023) |
| "To assess the cost-effectiveness of cetuximab in combination with chemotherapy fluorouracil, oxaliplatin, and leucovorin (FOLFOX) or fluorouracil, irinotecan and leucovorin (FOLFIRI) compared to standard chemotherapy alone as a first-line treatment for metastatic colorectal cancer (mCRC) with positive KRAS wild type patients in Indonesia." | 4.31 | Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting. ( Armansyah, A; Khoe, LC; Megraini, A; Nadjib, M; Nugraha, RR; Permanasari, VY; Putri, S; Saldi, SRF; Santatiwongchai, B; Sastroasmoro, S; Setiawan, E, 2023) |
| "To evaluate the efficacy and safety of apatinib combined with FOLFIRI in the first-line treatment of advanced metastatic colorectal cancer (mCRC) and explore potential factors of efficacy." | 4.12 | Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. ( Liu, H; Rong, X; Wang, J; Wang, Y; Yu, H; Zhao, J, 2022) |
| "To compare the efficacy and safety of folinic acid, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab or aflibercept in metastatic colorectal cancer (mCRC) patients pretreated with oxaliplatin-based chemotherapy." | 4.12 | A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer. ( Hong, JY; Jo, H; Kang, WK; Kim, H; Kim, ST; Lee, J; Lee, MS; Lee, YP; Lim, HY; Park, JO; Park, SH; Park, YS, 2022) |
| "The oral fluoropyrimidine S-1 has shown comparable efficacy to capecitabine in Asian and some Western studies on metastatic colorectal cancer." | 4.12 | Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer. ( Kwakman, JJM; Mol, L; Punt, CJA, 2022) |
| "Ocular toxicity derived from the use of systemic fluorouracil has been widely described in the literature, as well as the relationship between the use of capecitabine and the appearance of conjunctivitis." | 4.12 | Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions. ( Bello Crespo, M; Gajete Pablos, MA; Gioseffi, HA; Roa García, DM; Trujillano Ruiz, A, 2022) |
| "Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is used as the first-line treatment for metastatic colorectal cancer (mCRC)." | 4.12 | Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study. ( Gao, L; Liu, X; Ma, X; Ou, K; Wang, Q; Yang, L; Zhang, H, 2022) |
| "a capecitabine and oxaliplatin drug combination regimen has shown a survival benefit in patients with advanced colorectal cancer, yet its administration represents an attractive option for low resource settings." | 4.12 | Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study. ( Begg, W; Kibudde, S, 2022) |
| "Female patients and patients aged sixty-five or older had an increased risk of developing severe diarrhea during preoperative chemoradiation therapy with capecitabine." | 4.02 | Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study. ( Hartman, W; Nuyttens, JJME; Oomen-de Hoop, E; Rothbarth, J; van Meerten, E; van Rees, JM; van Vugt, JLA; Verhoef, C, 2021) |
| "The objective is to investigate whether thymidylate synthase gene TS 5'-UTR polymorphism of peripheral blood mononuclear cells are associated with clinical outcomes of patients with stage II-III rectal adenocarcinoma treated with adjuvant 5-fluorouracil (5-FU) chemotherapy in Chinese population." | 3.91 | Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy. ( Chen, C; Li, S; Su, X; Wang, G; Xiao, H; Zhang, H, 2019) |
| " Interestingly, the panel also revealed that he had mismatch-repair(MMR)deficiency with MSH2 mutation, which is reported as a possible cause of resistance to 5-fluorouracil in colorectal cancer." | 3.88 | [A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer]. ( Hotta, S; Ichikawa, H; Kameyama, H; Maruyama, S; Miura, K; Nagahashi, M; Nakano, M; Nogami, H; Shimada, Y; Tajima, Y; Takii, Y; Tanaka, K; Wakai, T; Yamada, S, 2018) |
| " Sixty-four patients (41%) treated with INCT-CRT and 57 CRT-CNCT patients (34%) experienced a grade 3+ adverse event (P = ." | 3.83 | Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial. ( Garcia-Aguilar, J; Kim, JK; Lin, ST; Omer, DM; Qin, LX; Saltz, LB; Thompson, HM; Valdivieso, SC; Verheij, FS; Wu, AJ; Yuval, JB, 2024) |
| "Patients with biopsy-proven adenocarcinoma of the rectum staged cT3-T4 by endoscopic ultrasound or magnetic resonance imaging received neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy." | 3.80 | Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. ( Ayuso-Colella, JR; Bombí, JA; Burkholder, I; Castells, A; Conill, C; Cuatrecasas, M; Delgado, S; Feliz, L; Fernández-Esparrach, G; Gallego, R; García-Albéniz, X; Ginés, A; Hochhaus, A; Hofheinz, RD; María de Lacy, A; Maurel, J; Miquel, R; Pagés, M; Pereira, V; Pineda, E; Reig, O; Sosa, A; Victoria, I, 2014) |
| "When disseminated colorectal cancer is diagnosed the possibility of palliative chemotherapy should be conferred with an oncologist." | 3.79 | [Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer]. ( Raskov, HH; Wiboltt, K, 1999) |
| "Microsatellite instability (MSI) is a distinct molecular phenotype of colorectal cancer related to prognosis and tumour response to 5-fluorouracil (5-FU)-based chemotherapy." | 3.78 | The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. ( Cheon, JH; Hong, SP; Kim, H; Kim, NK; Kim, TI; Kim, WH; Min, BS, 2012) |
| "The patients with local advanced and metastatic colorectal cancer, receiving fluorouracil-based chemotherapy, and with an average plasma concentration of fluorouracil between 25 - 35 mg/L have a better prognosis, and lower incidence of adverse reactions such as bone marrow suppression, mucositis and diarrhea." | 3.78 | [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ( Cai, X; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2012) |
| "We describe an 80-year-old woman who presented with rectal bleeding and an increased INR due to the concomitant use of acenocoumarol and capecitabine for atrial fibrillation and metastatic cecal cancer, respectively." | 3.78 | [Increased INR from concomitant use of acenocoumarol and capecitabine]. ( Smorenburg, CH; Tomlow, B; Voll, ML, 2012) |
| " Two of the patients could not be treated with 5-FU any more because they had developed a myocardial ischemia, which was most likely caused by fluorouracil." | 3.78 | 5-FU-induced cardiac toxicity--an underestimated problem in radiooncology? ( Hautmann, MG; Kölbl, O; Steger, F, 2012) |
| "5-fluorouracil chemotherapy in patients with dihydropyrimidine dehydrogenase deficiency, can give rise to ocular and cutaneous toxicity." | 3.77 | A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. ( Kemp, E; McDonald, A; Obi, EE, 2011) |
| "Over a period of 1 year in our hospital, 3 patients were diagnosed with 'ileitis following capecitabine use'." | 3.77 | [Ileitis following capecitabine use]. ( Bouma, G; Imholz, AL, 2011) |
| "The aim of this study was to investigate efficacy and toxicity of a modified 5-fluorouracil (5-FU), folinic acid, oxaliplatin (mFOLFOX-4) regimen followed by infusional 5-FU concomitant with radiotherapy for curatively resected stage III rectum adenocarcinoma patients." | 3.77 | Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma. ( Aksoy, S; Babacan, NA; Cihan, Ş; Odabaş, H; Öksüzoğlu, B; Özdemir, N; Uncu, D; Zengin, N, 2011) |
| "Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required." | 3.77 | Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993) |
| "We examined the pre-treatment tumour biopsies (n=40) obtained from patients with rectal adenocarcinoma (clinical International Union Against Cancer stage ll/III) who were scheduled to receive neoadjuvant 5-fluorouracil-based chemoradiotherapy for EGFR, VEGF and HIF-1 expression by quantitative real-time polymerase chain reaction." | 3.76 | Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg ( Inoue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2010) |
| "We investigated the efficacy and toxicity of metronomic capecitabine administered at a fixed dose of 1,000 mg daily in three elderly or poor performance status patients with advanced colorectal cancer (CRC) and gastric cancer." | 3.75 | To widen the setting of cancer patients who could benefit from metronomic capecitabine. ( Biasco, G; Brandi, G; Di Cicilia, R; Maleddu, A; Nannini, M; Nobili, E; Pantaleo, MA, 2009) |
| "A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described." | 3.75 | A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009) |
| "One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens." | 3.75 | [Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009) |
| "Five-fluorouracil (5-FU) has become the standard chemotherapeutic agent for the treatment of advanced colorectal carcinoma." | 3.75 | An analysis of chemotherapy for colorectal carcinoma. ( Mittelman, A; Petrelli, NJ, 1984) |
| "Preoperative chemoradiation with 5-fluorouracil (5-FU) has improved local control and resectability in patients with locally advanced rectal adenocarcinoma." | 3.74 | Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer. ( Kauh, J; Koshy, M; Landry, J; Lawson, JD; Staley, C, 2008) |
| " When the total dose of 5-fluorouracil reached 21,200 mg and the total dose of oxaliplatin reached 880 mg after about 100 days of treatment, epiphora developed." | 3.74 | [Epiphora in a patient receiving FOLFOX therapy]. ( Iwagami, E; Niimi, M; Ono, Y; Tanaka, E; Uto, N; Yamato, M; Yatsuda, C, 2008) |
| "We present a case of hand-foot syndrome (HFS) induced by bolus 5-fluorouracil (5-FU) therapy." | 3.74 | [A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy]. ( Aoyagi, H; Enomoto, M; Higuchi, T; Iida, S; Ishikawa, T; Kobayashi, H; Matsuyama, T; Sugihara, K; Uetake, H; Yasuno, M, 2008) |
| "The aim of this study is to evaluate the safety and efficacy of hepatic artery infusion (HAI) of 5-fluorouracil (5FU) for patients with liver metastases from colorectal carcinoma after radiological placement of infusion catheters." | 3.74 | Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters. ( Hirayama, I; Horikoshi, H; Motegi, K; Saito, T; Sameshima, S; Sawada, T; Tomozawa, S, 2007) |
| "Headaches have been reported as a potential side effect of capecitabine therapy." | 3.74 | Capecitabine-induced headache responding to diltiazem. ( Fakih, MG; Raman, AK, 2007) |
| "The levels of both VEGF and PDGF-BB were measured in three time points, in the serum of 32 rectal carcinoma patients receiving daily reduced-dose/continuous capecitabine in combination with preoperative pelvic irradiation." | 3.74 | Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients. ( Be'ery, E; Fenig, E; Koren, C; Lavi, I; Loven, D; Shaked, Y; Sulkes, A; Yerushalmi, R, 2008) |
| "Formalin fixed, paraffin embedded pre-therapeutical tumor biopsies (n = 22) and post-therapeutical resection specimens (n = 40) from patients with rectal adenocarcinoma (clinical UICC stage II/III) receiving standardized neoadjuvant 5-fluorouracil (5-FU) based chemoradiotherapy were studied for Ki67 and p53 expression by immunohistochemistry and correlated with TS mRNA expression by quantitative TaqMan real-time PCR after laser microdissection." | 3.74 | Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. ( Aust, DE; Baretton, GB; Becker, H; Jakob, C; Liersch, T; Meyer, W, 2008) |
| "The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery." | 3.73 | Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. ( Baik, SH; Cho, CW; Kim, NK; Lee, KY; Park, YA; Seong, J; Sohn, SK, 2006) |
| "Forty patients with advanced adenocarcinoma of the rectum underwent preoperative chemoradiation on a prospective trial with irinotecan (50 mg/m2), 5-fluorouracil (225 mg/m2), and concomitant external-beam radiation (45-54 Gy) followed by complete surgical resection of the tumor with total mesorectal excision." | 3.72 | Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. ( Anné, PR; Fry, RD; Goldstein, SD; Isenberg, GA; Mahmoud, NN; Mitchell, E; Rose, DG; Stein, DE, 2003) |
| "One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy." | 3.71 | Long-term results of reirradiation for patients with recurrent rectal carcinoma. ( Marks, G; Marks, J; Mohiuddin, M, 2002) |
| "A retrospective chart review was performed on 141 consecutive patients who received neoadjuvant chemoradiation (5-fluorouracil +/- cisplatin and 4,500-5,040 cGy) for biopsy-proven locally advanced adenocarcinoma of the rectum." | 3.71 | Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. ( Anscher, MS; Clary, B; Hartwig, M; Hurwitz, H; Jowell, P; Lee, C; Ludwig, K; Mantyh, C; McGrath, K; Morse, M; Noone, RB; Onaitis, MW; Pappas, TN; Seigler, HF; Tyler , DS, 2001) |
| "Sixteen patients with rectal adenocarcinoma up to 3 cm above the pectineal line with initial indications for abdominoperineal resection (APR) were submitted to a 5040-cGy (28 x 180 cGy) radiotherapy dose and chemotherapy during the first 3 and last 3 days of radiotherapy, using 425 mg/m2/day of 5-fluorouracil (5FU) and 20 mg/m2/day of folinic acid." | 3.70 | Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial. ( Filho, WD; Lopes, A; Nakagawa, WT; Novaes, PE; Rossi, BM, 1998) |
| "During a 4-year period we treated 20 patients with locally advanced adenocarcinoma of the rectum using a protocol of preoperative simultaneous pelvic irradiation (4,030-6,040 cGy) and infusion chemotherapy (5-fluorouracil 100 mg/m2 per day over 96 hours and mitomycin 10 mg/m2) followed by surgical resection." | 3.70 | Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. ( Burke, SJ; Knight, DC; Kwasnik, EM; Percarpio, BA, 1998) |
| "For almost 40 years, 5-fluorouracil (5-FU) has been the only useful drug with clinically meaningful activity in metastatic colorectal carcinoma." | 3.70 | Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer. ( Au, E; Khoo, KS; Koo, WH; Lim, WT, 1999) |
| "Fifteen patients with rectal adenocarcinoma were endoscopically biopsied and given short-term [5 fluorouracil (5FU) (600 mg/m2) and Ca-Folinate (60 mg/m2) for two days] cytostatic therapy." | 3.70 | Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors. ( Benyó, I; Bodnár, Z; Farczádi, E; Kaszás, I; Szántó, J; Szende, B; Szlobodnyik, J, 1999) |
| "Adjuvant 5-fluorouracil (5-FU)-based chemotherapy is standard treatment for stage C colorectal cancer (CRC)." | 3.70 | Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. ( Aaltonen, LA; Hemminki, A; Järvinen, H; Joensuu, H; Mecklin, JP, 2000) |
| "To report 5-fluorouracil in combination with folinic acid as a cause of severe nonischemic heart failure and to demonstrate the potential usefulness of an intra-aortic balloon pump." | 3.70 | Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000) |
| "Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil." | 3.70 | Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000) |
| "Radiological and clinical evidence of acute necrosis in a meningioma following one cycle of chemotherapy with 5-fluorouracil, folinic acid, and levamisole was observed in a patient being treated for invasive rectal carcinoma." | 3.69 | Necrosis in a meningioma following systemic chemotherapy. Case report. ( Bernstein, M; Davidson, G; Erlichman, C; Villamil, A, 1994) |
| " The aim of this study was to define the toxicity (animal lethality) and the activity (growth delay assay, excision assay) of a bioreductive drug, tirapazamine, alone and combined with chemotherapy agents (5-FU, VP16, bleo, DTIC and c-DDP) on nude mice bearing xenografted human tumours: a rectal carcinoma (HRT18) and a melanoma (Na11+)." | 3.69 | The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. ( Guichard, M; Lartigau, E, 1996) |
| " In order to evaluate the HDRA with the 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide end point for clinical use, chemosensitivity to mitomycin C, doxorubicin, 5-fluorouracil, and cisplatin of 107 advanced gastric and 109 advanced colorectal cancers was determined in vitro in a correlative clinical trial." | 3.69 | Clinical applications of the histoculture drug response assay. ( Furukawa, T; Hoffman, RM; Kubota, T, 1995) |
| "A prospective trial was conducted involving 16 patients with colorectal adenocarcinoma using a regimen of continuous-infusion octreotide acetate (Sandostatin [octreotide acetate], Sandoz, East Hanover, NJ for the treatment of severe diarrhea induced by the weekly schedule of 5-fluorouracil (5-FU) in combination with leucovorin who were refractory to opiate therapy." | 3.68 | Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. ( Creaven, P; Herrera, L; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, Y, 1993) |
| " During a 12-month period seven patients with locally advanced adenocarcinoma of the rectum were treated preoperatively with simultaneous pelvic irradiation (4500-5040 cGy) and infusion chemotherapy (5-fluorouracil 1000 mg per m2 per day over 96 hours and mitomycin 10 mg per m2." | 3.68 | Combined modality preoperative therapy for unresectable rectal cancer. ( Alfano, F; Bitterman, J; Bowen, J; Percarpio, B; Ruszkowski, R; Sabbath, K, 1992) |
| "To determine if fluorouracil (5-FU) plus high-dose leucovorin (LV) enhances local response in patients receiving preoperative radiation therapy (RT) for adenocarcinoma of the rectum, we compared the degree of downstaging in patients receiving preoperative RT with or without chemotherapy." | 3.68 | Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. ( Cohen, AM; Enker, WE; Frankel, J; Kelsen, DP; Kemeny, N; Minsky, BD; Reichman, B; Saltz, L; Sigurdson, ER, 1992) |
| "Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma." | 3.67 | Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989) |
| "Twenty-one consecutive patients with primarily non-resectable adenocarcinoma of the rectum were treated with preoperative split-course radiotherapy (40 Gy) and simultaneous sequential methotrexate + 5-fluorouracil + leucovorin (MFL)." | 3.67 | Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum. Results from two consecutive studies. ( Frykholm, G; Glimelius, B; Påhlman, L, 1989) |
| "Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus." | 3.67 | Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986) |
| "Twenty-two patients with disseminated adenocarcinoma of the large bowel received therapy with 5-fluorouracil 800-1000 mg/m2 as a 24 h infusion for 4 consecutive days with 60 mg/m2 intravenous folinic acid administered every 6 hours." | 3.67 | Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. ( Higano, C; Mortimer, JE, 1988) |
| "Cardiac symptoms, including hypotension, developed in three patients with advanced colorectal carcinoma while being treated with cisplatin (CDDP) and 5-fluorouracil (5-FU)." | 3.67 | Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. ( Jakubowski, AA; Kemeny, N, 1988) |
| "Forty-four patients with locally recurrent or metastatic colorectal adenocarcinoma were treated with methotrexate (MTX) 100 mg/m2 i." | 3.67 | Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma. ( Anderson, T; Hansen, RM; Ritch, PS, 1986) |
| "Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX." | 3.67 | Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987) |
| "We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma." | 3.67 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987) |
| "To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted." | 3.67 | Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985) |
| "Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA." | 3.67 | Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985) |
| "Thirty-eight patients with advanced colorectal adenocarcinoma were treated with the following regimen: N5-10-methyltetrahydrofolate (MTHF) (200 mg/m2/day) and 5-fluorouracil (5-FU) (375 mg/m2/day) given concomitantly, consecutively for 5 days, every 4 weeks, in order to evaluate the potential advantage derived from the biochemical enhancement of cytotoxic activity of 5-FU by high-dose reduced folates." | 3.67 | Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. ( Bruzzone, M; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Tagarelli, G, 1985) |
| "The action of floxuridine depends greatly on its concentration for treatment of liver metastases of colorectal carcinomas and other tumors." | 3.66 | [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. ( Balch, CM; Urist, MM, 1983) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "A 72 year old man with rectal adenocarcinoma developed chronic renal failure when treated by surgery and subsequent chemotherapy (5-fluorouracil, Mitomycin C and Cytosine arabinoside) and immunotherapy." | 3.66 | Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs. ( Fornari, G; Mazzucco, G; Monga, G, 1982) |
| "Consecutive studies were undertaken in advanced colorectal adenocarcinoma, comparing two different schedules of the combination methyl-CCNU, 6-thioguanine, and 5-fluorouracil in 89 patients." | 3.66 | Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer. ( Aroney, RS; Bell, DR; Chan, WK; Dalley, DN; Levi, JA, 1981) |
| "The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma." | 3.66 | Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981) |
| "Fifty-four patients with clinical evidence of residual colorectal adenocarcinoma following surgical removal of the primary tumor were treated with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside." | 3.66 | Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study. ( Davis, S; Park, YK, 1978) |
| " 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma." | 3.64 | PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER. ( HART, GD, 1964) |
| "In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for patient survival." | 3.30 | Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306. ( D'Anastasi, M; Decker, T; Gesenhues, AB; Heinemann, V; Heintges, T; Hesse, N; Hofmann, FO; Holch, JW; Kahl, C; Kaiser, F; Kiani, A; Kullmann, F; Link, H; Modest, DP; Moehler, M; Scheithauer, W; Stintzing, S; von Weikersthal, LF, 2023) |
| "In metastatic colorectal cancer (mCRC), the role of Trop-2 and Nectin-4 has been poorly investigated." | 3.30 | Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development. ( Bergamo, F; Conca, V; Cremolini, C; Di Donato, S; Fanotto, V; Fontanini, G; Germani, MM; Giordano, M; Latiano, TP; Lonardi, S; Masi, G; Moretto, R; Niccoli, C; Passardi, A; Pietrantonio, F; Prisciandaro, M; Proietti, A; Tamburini, E; Ugolini, C; Zaniboni, A, 2023) |
| "Standard treatment of locally advanced rectal cancer (LARC) was neoadjuvant chemoradiotherapy (CRT), followed by total mesorectal excision (TME)." | 3.30 | Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. ( Bai, S; Cai, P; Chang, H; Chen, G; Gao, Y; Liu, S; Luo, H; Pan, Z; Wang, Q; Wang, X; Wu, X; Xiao, W; Ye, Y; Yu, H; Zeng, Z; Zhuang, Y, 2023) |
| "For patients with locally advanced rectal cancer choosing between neoadjuvant FOLFOX and 5FUCRT, the distinctive PRO profiles inform treatment selection and shared decision making." | 3.30 | Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). ( Basch, E; Chang, G; Colgrove, B; Denicoff, A; Dueck, AC; Farma, J; George, T; Ginos, B; Gollub, M; Mamon, H; Mazza, GL; Meyerhardt, JA; Minasian, L; Mitchell, SA; Musher, B; O'Reilly, E; Rogak, L; Saltz, L; Schrag, D; Shi, Q; Thanarajasingam, G; Venook, A; Weiser, M, 2023) |
| "Adults with rectal cancer that had been clinically staged as T2 node-positive, T3 node-negative, or T3 node-positive who were candidates for sphincter-sparing surgery were eligible to participate." | 3.30 | Preoperative Treatment of Locally Advanced Rectal Cancer. ( Al Baghdadi, T; Basch, E; Chang, GJ; Colgrove, B; Dueck, AC; Farma, JM; George, TJ; Goldberg, J; Gollub, MJ; Goodman, KA; Gordon, V; Kennecke, HF; Mamon, HJ; McWilliams, RR; Meyerhardt, JA; Montemurro, M; Musher, BL; Nelson, GD; O'Reilly, EM; Saltz, LB; Schrag, D; Shergill, A; Shi, Q; Venook, AP; Weiser, MR, 2023) |
| "In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs)." | 3.30 | Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. ( Boccaccino, A; Bustreo, S; Carullo, M; Clavarezza, M; Cremolini, C; Cupini, S; Daniel, F; Libertini, M; Lonardi, S; Morano, F; Niger, M; Palermo, F; Pietrantonio, F; Procaccio, L; Raimondi, A; Rossini, D; Santini, D; Tomasello, G; Zaniboni, A, 2023) |
| "The prognosis of mCRC (metastatic colorectal cancer) patients with RAS mutation is poor and capecitabine and oxaliplatin (CapeOx) plus bevacizumab has shown to be one of the standard therapeutic regimens as first line for these patients with objective response rate (ORR) of ~ 50% and median progression-free survival (mPFS) of 8-9 months." | 3.30 | Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study. ( Ding, K; Dong, C; Fang, X; Hu, H; Li, J; Liao, X; Sun, L; Wang, J; Weng, S; Xiao, Q; Xu, D; Yuan, Y; Zhang, S; Zhong, C, 2023) |
| " Patient characteristics were evaluated with multiple regression analyses for survival outcomes, using the Cox proportional hazard model and linear regression analyses for the worst grade of adverse events." | 3.11 | Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years. ( Amagai, K; Bando, Y; Denda, T; Endo, S; Hatachi, Y; Hyodo, I; Ikezawa, K; Ishida, H; Kobayashi, K; Kuramochi, H; Morimoto, M; Moriwaki, T; Nakajima, G; Negoro, Y; Nishina, T; Sakai, Y; Sato, M; Shimada, M; Tsuji, A; Yamamoto, Y, 2022) |
| "Fecal incontinence was high after sphincter preservation." | 3.11 | Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer-INCAGI004. ( Araujo, RO; Ferreira, CG; Guaraldi, S; Linhares, E; Martins, I; Thuler, LC; Torres, C; Valadão, M; Victorino, AP; Vieira, FM, 2022) |
| "This multicenter single-arm, phase II study evaluated the efficacy and safety of uninterrupted panitumumab usage combined with cytotoxic doublets for unresectable/metastatic colorectal cancer (mCRC)." | 3.11 | Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA. ( Akazawa, N; Ando, T; Hirata, K; Kagawa, Y; Kato, T; Maeda, H; Mishima, H; Nagasaka, T; Nagata, N; Oba, K; Sakamoto, J; Shiozawa, M; Watanabe, J; Yamada, T; Yokota, M, 2022) |
| "Locally advanced rectal cancer (LARC) is an area of unmet medical need with one third of patients dying from their disease." | 3.11 | Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP). ( Bärtschi, D; Bastian, S; Bovet, C; Csajka, C; Decosterd, LA; Guckenberger, M; Jaehde, U; Joerger, M; Largiadèr, CR; Prost, JC; Schmulenson, E; Theurillat, R; von Moos, R, 2022) |
| "The treatment of colorectal cancer (CRC) has evolved and become more personalized during the past several years." | 3.01 | Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review. ( Damato, A; Dottorini, L; Ghidini, A; Ghidini, M; Iaculli, A; Luciani, A; Petrelli, F; Tomasello, G, 2023) |
| "The meta-analysis aimed to assess the clinical efficacy of chemotherapeutic triplet-drug regimen combined with anti-EGFR antibody in patients with initially unresectable metastatic colorectal cancer (mCRC)." | 3.01 | Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis. ( Dong, W; Jiang, T; Jiang, X; Li, H; Li, Y; Lv, Y; Tian, M; Xiao, J; Yin, Z; Zeng, J, 2023) |
| "Overall, our results showed that preCRT was feasible and safe in older patients with rectal cancer who were evaluated as fit based on CGA, supporting the use of CGA to tailor oncological treatment and predict the tolerance of a specific therapy." | 3.01 | Safety and efficacy of preoperative chemoradiotherapy in fit older patients with intermediate or locally advanced rectal cancer evaluated by comprehensive geriatric assessment: A planned interim analysis of a multicenter, phase II trial. ( Chen, B; Cheng, YJ; Fang, H; Jin, J; Li, N; Li, YX; Liang, JW; Liu, WY; Liu, YP; Liu, Z; Lu, NN; Pei, W; Qi, SN; Song, YW; Tang, Y; Wang, J; Wang, SL; Wang, XS; Yang, L; Zhang, HZ; Zhou, HT; Zhou, ZX, 2021) |
| "Both LRC and DFS of rectal cancer patients treated with HART vs." | 3.01 | Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: interim analysis of phase III clinical study. ( Dębosz-Suwińska, I; Galwas-Kliber, K; Idasiak, A; Mrochem-Kwarciak, J; Rajczykowski, M; Stobiecka, E; Suwiński, R; Zeman, M, 2021) |
| "Hyperthermia was defined as feasible if 70% of patients received at least eight treatments." | 3.01 | Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. ( Bitzer, M; Fend, F; Gani, C; Gellermann, J; Heinrich, V; Königsrainer, A; Lamprecht, U; Moll, M; Wenz, S; Ziegler, A; Zips, D, 2021) |
| "4 Gy) with or without intravenous pembrolizumab administered at a dosage of 200 mg every 3 weeks for up to 6 doses before surgery." | 3.01 | Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. ( Colangelo, LH; Faller, BA; George, S; George, TJ; Gollub, MJ; Hall, WA; Hong, TS; Jacobs, SA; Kachnic, LA; Kainthla, R; Lucas, PC; O'Rourke, MA; Parker, W; Rahma, OE; Russell, MM; Schefter, TE; Sigurdson, E; Stella, PJ; Valicenti, RK; Vijayvergia, N; Wolmark, N; Yothers, G; You, YN, 2021) |
| "Radiation proctitis was identified by imaging in 9 (15." | 2.94 | Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial. ( Cheng, YK; Gao, X; Huang, XY; Lan, P; Ma, TH; Qin, QY; Wang, L, 2020) |
| "Patients with stage II/III rectal cancer who had completed neoadjuvant 5-fluorouracil-based chemoradiation and had undergone complete resection were enrolled." | 2.94 | Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Tri ( Atkins, JN; Awan, RA; Benson, AB; Brierley, JD; Catalano, P; Catalano, RB; Cella, D; Chakravarthy, AB; Cripps, C; Diasio, RB; Flynn, PJ; Giantonio, BJ; Haller, DG; Hamilton, SR; Leichman, CG; Meropol, NJ; Mitchell, EP; Mulcahy, MF; O'Brien, TE; O'Dwyer, PJ; Petrelli, NJ; Santala, R; Sigurdson, ER; Sinicrope, FA; Sloan, J; Tepper, JE; Wagner, LI; Weis, JR; Zhao, F, 2020) |
| "High-risk rectal cancer patients were randomized to SCRT followed by chemotherapy (6 cycles CAPOX or alternatively 9 cycles FOLFOX4) and subsequent surgery, or long-course radiotherapy (25-28 × 2-1." | 2.94 | Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. ( Bahadoer, RR; Capdevila, J; Cervantes, AMR; de Groot, DJA; Dijkstra, EA; Edhemovic, I; Fokstuen, T; Glimelius, B; Hendriks, MP; Hilling, DE; Hospers, GAP; Kranenbarg, EM; Marijnen, CAM; Nilsson, PJ; Putter, H; Roodvoets, AGH; Ten Tije, AJ; van de Velde, CJH; van der Valk, MJM; van Etten, B, 2020) |
| "Patients with locally advanced rectal cancer will be randomized to receive PCRT followed by TME and adjuvant chemotherapy (arm A) or upfront radical surgery with TME followed by adjuvant FOLFOX chemotherapy (arm B)." | 2.94 | Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial. ( Ahn, JB; Baek, JH; Beom, SH; Chang, JS; Hur, H; Jeong, SY; Jung, I; Kim, HS; Kim, NK; Kim, SH; Kim, TI; Koom, WS; Lee, JB; Lee, KY; Lim, JS; Min, BS; Park, S; Shin, SJ, 2020) |
| "KRAS wild-type clinical stage III rectal cancer patients were enrolled." | 2.94 | A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer. ( Endo, I; Ishibe, A; Kunisaki, C; Nakagawa, K; Ota, M; Suwa, H; Suwa, Y; Toritani, K; Watanabe, J; Yamanaka, T, 2020) |
| "Patients with locally advanced rectal cancers might benefit from treatment in specialized high-volume hospitals." | 2.94 | The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94. ( Beißbarth, T; Fietkau, R; Ghadimi, M; Hohenberger, W; Raab, HR; Rödel, C; Sauer, R; Sprenger, T; Staib, L; Tschmelitsch, J, 2020) |
| " Adverse event data collection is recorded at every visit." | 2.94 | Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. ( Al Awabdeh, T; Al Darazi, M; Al Masri, M; Alqasem, K; Amarin, R; Charafeddine, M; Dabous, A; Daoud, F; Deeba, S; El Husseini, Z; Elkhaldi, M; Geara, F; Hushki, A; Jaber, O; Jamali, F; Kattan, J; Khalifeh, I; Kreidieh, M; Mohamad, I; Mukherji, D; Shamseddine, A; Temraz, S; Turfa, R; Zeidan, YH, 2020) |
| "Patients affected with Stage IV colorectal cancer and unresectable metastases represent a heterogeneous group." | 2.90 | Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma. ( Crocetti, D; DE Felice, F; DE Toma, G; Fiori, E; Lamazza, A; Mingoli, A; Sapienza, P; Sterpetti, AV; Tarallo, M, 2019) |
| "More than half of the 40,000 incident rectal cancer patients in the United States each year are diagnosed at clinical stage II and III (locally advanced stage)." | 2.90 | Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). ( Basch, E; Gollub, M; Mamon, H; Saltz, L; Schrag, D; Shi, Q; Venook, A; Weiser, M, 2019) |
| "A radical rectal cancer surgery was performed 6 to 8 weeks after the simultaneous chemoradiotherapy." | 2.90 | Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. ( Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y, 2019) |
| " We included patients with rectal cancer who received 4 courses of modified FOLFOX6 (mFOLFOX6) before rectal surgery and examined the postoperative complication rate, the clinicopathological response, and the rate of chemotherapy-related adverse events (UMIN 000012559)." | 2.90 | Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. ( Funakoshi, T; Hattori, M; Hirose, K; Homma, S; Ichikawa, N; Iijima, H; Ishikawa, T; Ishizu, H; Kamiizumi, Y; Kawamata, F; Koike, M; Kon, H; Kuraya, D; Minagawa, N; Murata, R; Nomura, M; Ohno, Y; Omori, K; Sato, M; Takahashi, N; Takeda, K; Taketomi, A; Yokota, R; Yoshida, T, 2019) |
| "Peripheral blood leukocytosis and neutrophilia reflect cancer inflammation and have been proposed as prognostic immunological biomarkers in various malignancies." | 2.90 | Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial. ( Arnold, D; Beißbarth, T; Diefenhardt, M; Fietkau, R; Fokas, E; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Grützmann, R; Hartmann, A; Hofheinz, RD; Liersch, T; Martin, D; Rieger, M; Rödel, C; Rödel, F; Ströbel, P; von der Grün, J; Weitz, J, 2019) |
| "Patients with cT4 or fixed cT3 rectal cancer were randomized either to preoperative 5 × 5 Gy and three cycles of FOLFOX4 or to chemoradiation (50." | 2.90 | Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. ( Bębenek, M; Bujko, K; Cencelewicz, A; Ciseł, B; Jankiewicz, M; Jankowski, M; Kapturkiewicz, B; Kapuściński, W; Kępka, L; Kosakowska, E; Kładny, J; Las-Jankowska, M; Maciejczyk, A; Majewski, A; Markiewicz, W; Michalski, W; Pietrzak, L; Polkowski, W; Rutkowski, A; Sadowski, J; Socha, J; Spałek, M; Styliński, R; Suwiński, R; Toczko, Z; Wasilewska-Tesluk, E; Wyrwicz, L; Zegarski, W; Żelazowska-Omiotek, U; Zygulska, J, 2019) |
| "9%) in arm B experienced grade 3/4 adverse events related to bevacizumab; the most frequent were 2 anastomotic fistulas (both in arm A) and abscesses (1 in arm A and 2 in arm B)." | 2.90 | Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. ( Adenis, A; André, T; Azria, D; Bachet, JB; Balosso, J; Ben Abdelghani, M; Borg, C; Boudghène, F; Conroy, T; Coudert, M; François, Y; Ghiringhelli, F; Ionescu-Goga, M; Lakkis, Z; Mantion, G; Mornex, F; Quero, L; Rio, E; Roullet, B; Spaëth, D; Tanang, A; Vendrely, V, 2019) |
| "This study investigated the role of hyperthermia combined with preoperative concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer (LARC) according to hypoxic marker expression." | 2.87 | Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer. ( Gu, MJ; Kang, MK; Kim, JH; Kim, SW; Yea, JW, 2018) |
| " The objective of this study was to compare outcome measures, adverse effects, and cost of FOLFOX4 and FOLFIRINOX treatments in rectal cancer patients." | 2.87 | Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study. ( Chen, Y; Liu, J; Qi, F; Yan, Q; Zhang, G; Zheng, Z, 2018) |
| "Surrogate end points in rectal cancer after preoperative chemoradiation are lacking as their statistical validation poses major challenges, including confirmation based on large phase III trials." | 2.87 | Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial. ( Fietkau, R; Fokas, E; Ghadimi, M; Grabenbauer, GG; Graeven, U; Grützmann, R; Hartmann, A; Hofheinz, RD; Hohenberger, W; Hothorn, T; Kaufmann, M; Köhne, CH; Liersch, T; Rödel, C; Sauer, R; Ströbel, P; Wittekind, C, 2018) |
| "The German rectal cancer trial CAO/ARO/AIO-04 has shown a significant benefit in 3-year disease-free survival (DFS) of adding oxaliplatin to a standard preoperative 5-fluorouracil (5-FU)-based chemoradiotherapy (CRT) and adjuvant chemotherapy in patients with locally advanced rectal cancer." | 2.87 | Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial. ( Arnold, D; Fietkau, R; Fokas, E; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hofheinz, RD; Hohenberger, W; Hothorn, T; Kaufmann, M; Liersch, T; Rödel, C; Sauer, R, 2018) |
| "To compare acute adverse events (AE) and postoperative complication rates in a randomized trial of short-course (SC) versus long-course (LC) preoperative radiotherapy." | 2.84 | Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). ( Ackland, S; Ansari, N; Burmeister, B; Fisher, RJ; Heriot, A; Joseph, D; Mackay, J; McClure, B; McLachlan, SA; Ngan, SY; Solomon, MJ, 2017) |
| "The standard treatment of stage II-III rectal cancer is preoperative chemoradiotherapy (CRT), followed by total mesorectal excision (TME)." | 2.82 | Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis. ( Kim, SH; Lee, JH; Song, JH; Um, JW, 2022) |
| "DPD deficiency was suspected because he developed many severe adverse events of capecitabine early and was finally confirmed based on the finding of a low DPD activity level in peripheral blood mononuclear cells." | 2.82 | Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review. ( Akutsu, D; Fukuda, S; Hagiwara, Y; Ikeda, N; Inagaki, Y; Kobayashi, M; Moriwaki, T; Narasaka, T; Niisato, Y; Onoda, T; Suzuki, H; Tange, Y; Tomisaki, R; Tsuchiya, K; Tsuji, M; Yamada, K; Yamada, T; Yamamoto, Y, 2022) |
| "Localized rectal cancer should be managed surgically." | 2.82 | Management of Rectal Cancer. ( Schlechter, BL, 2022) |
| "In the remaining seven (20%), the residual tumour clinically appeared benign." | 2.82 | Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign. ( Bujko, K; Malinowska, M; Mroz, A; Pietrzak, L; Rupinski, M; Rutkowski, A; Szczepkowski, M; Wyrwicz, L, 2016) |
| "With the changed dosing schedule, this regimen was very well tolerated." | 2.82 | Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016) |
| "In this cohort of rectal cancer patients dominated by T4 and advanced T3 cases given sequential oxaliplatin-containing preoperative therapy with acceptable toxicity, high tumour response rates and overall survival were obtained, consistent with both local and systemic effects." | 2.82 | Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome. ( Boye, K; Dueland, S; Flatmark, K; Folkvord, S; Giercksky, KE; Grøholt, KK; Hole, KH; Larsen, SG; Ree, AH; Saelen, MG; Seierstad, T; Wiig, JN, 2016) |
| "Patients with cT2-4 N0-2 M0 rectal cancer treated by standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy) or extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy) underwent sequential PET/CT imaging at baseline, 6 weeks and 12 weeks from radiation completion." | 2.82 | Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. ( Buchpiguel, CA; Fernandez, LM; Figueiredo, MN; Gama-Rodrigues, J; Habr-Gama, A; Perez, RO; Proscurshim, I; São Julião, GP, 2016) |
| "Consecutive patients with distal rectal cancer undergoing neoadjuvant chemoradiation (50." | 2.82 | Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation. ( Fernandez, LM; Gama-Rodrigues, J; Habr-Gama, A; Jorge, JM; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2016) |
| "The rates of anastomotic leakage and stenosis were calculated for each treatment arm." | 2.82 | Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial. ( Deng, Y; Ma, T; Qin, Q; Wang, H; Wang, J; Wang, L; Zheng, J; Zhou, Z, 2016) |
| "Kaplan-Meier plots from colon cancer patients showed a significant treatment benefit in patients with low maspin expression, but not for individuals with medium/high expression." | 2.80 | Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer. ( Brydøy, M; Dahl, O; Hestetun, KE; Myklebust, MP, 2015) |
| "Dutch Colorectal Cancer group, CKTO 2003-16, ISRCTN36266738." | 2.80 | Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. ( Berglund, Å; Breugom, AJ; Fokstuen, T; Gelderblom, H; Glimelius, B; Kapiteijn, E; Leer, JWH; Marijnen, CAM; Martijn, H; Meershoek-Klein Kranenbarg, E; Muller, EW; Nagtegaal, ID; Påhlman, L; Punt, CJA; Putter, H; Roodvoets, AGH; Rutten, HJT; Steup, WH; van de Velde, CJH; van den Broek, CBM; van Gijn, W, 2015) |
| " The target was to achieve pathological complete response (pCR; residual disease-free stage) and toxicities of grade ≤2, using individual dosing predicted according to the steady-state plasma concentration (C ss) and pharmacokinetic parameters of 5-FU: the area under the time-concentration curve at steady state (AUC) and clearance (CL)." | 2.80 | Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer. ( Chládek, J; Grim, J; Hroch, M; Jaroslav, C; Jiří, P; Jiřina, M; Martínková, J; Miloš, H; Petera, J, 2015) |
| "Capecitabine (825 mg/m(2)) was delivered orally twice daily for the duration of radiotherapy." | 2.80 | Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer. ( Fan, YT; Feng, HY; Jin, T; Ju, HX; Li, DC; Liu, LY; Liu, Y; Luo, JL; Zhou, N; Zhu, Y; Zhu, YP, 2015) |
| "All clinical stage II and III rectal cancer patients received 50." | 2.80 | GRP78 Protein Expression as Prognostic Values in Neoadjuvant Chemoradiotherapy and Laparoscopic Surgery for Locally Advanced Rectal Cancer. ( Cho, HM; Jung, JH; Kim, HJ; Kim, SH; Lee, HY; Lee, JH; Lee, KM; Shim, BY, 2015) |
| "5-fluorouracil (5-FU) bolus was administrated during first and last 3 days of radiotherapy." | 2.80 | Induction FOLFOX followed by preoperative hyperfractionated radiotherapy plus bolus 5-fluorouracil in locally advanced rectal carcinoma: single arm phase I-II study. ( Aboelnaga, EM; Daoud, MA; Eladl, EI; Zaid, AM, 2015) |
| "Patients with locally advanced rectal cancer received sandwich-like neoadjuvant therapy with bevacizumab (induction therapy with bevacizumab and FOLFOX, concurrent chemoradiotherapy with bevacizumab and consolidation chemotherapy with FOLFOX)." | 2.80 | Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial. ( Chen, Z; Deng, Y; Huang, Y; Lan, P; Li, W; Peng, J; Ren, D; Wang, J; Wang, L; Xiao, J; Yang, Z; Zheng, J, 2015) |
| "Neoadjuvant radiotherapy of rectal cancer represents the current standard of care." | 2.80 | Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery. ( Ahmed, BM; AlGizawy, SM; Essa, HH, 2015) |
| "Patients with locally advanced rectal cancer who achieve a pathological complete response to neoadjuvant chemoradiation have an improved prognosis." | 2.80 | Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. ( Avila, K; Cataldo, PA; Chow, OS; Coutsoftides, T; Dietz, DW; Fichera, A; Garcia-Aguilar, J; Herzig, DO; Hunt, SR; Kumar, AS; Marcet, JE; Oommen, S; Patil, S; Polite, BN; Smith, DD; Stamos, MJ; Ternent, CA; Varma, MG, 2015) |
| "1804 rectal cancer patients, staged cT3-4N0-2M0, participated in a multicenter study." | 2.80 | Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12. ( Baek, JY; Chie, EK; Cho, HM; Jang, HS; Jeong, BK; Jeong, JU; Kim, DY; Kim, JH; Kim, JS; Kim, K; Kim, SH; Kim, SY; Kim, TH; Lee, JH; Nam, TK; Oh, JH; Shim, BY; Yoon, MS, 2015) |
| " Preclinical evidence suggests that the scheduling of bevacizumab may be crucial to optimize its combination with chemo-radiotherapy." | 2.80 | Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial. ( Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Comella, P; Delrio, P; Granata, V; Iaffaioli, VR; Leone, A; Marone, P; Muto, P; Pecori, B; Petrillo, A; Romano, C; Romano, G; Tatangelo, F, 2015) |
| "Patients with clinical stage II or III rectal cancer undergoing preoperative radiation were randomly assigned to one of four chemotherapy regimens in a 2x2 design: CVI 5-FU or oral capecitabine with or without oxaliplatin." | 2.80 | Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. ( Allegra, CJ; Arora, A; Bahary, N; Beart, RW; Eakle, JF; Evans, LS; Landry, JC; Marchello, BT; Moore, DF; Mullane, MR; O'Connell, MJ; Pitot, HC; Robertson, JM; Roh, MS; Ryan, DP; Sharif, S; Shields, AF; Soori, G; Ward, PJ; Wolmark, N; Wozniak, TF; Yothers, G, 2015) |
| "However, relevant stoma morbidity after rectal cancer surgery exists and has a significant impact on quality of life." | 2.80 | CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer. ( Herrle, F; Hinke, A; Hofheinz, RD; Kienle, P; Post, S; Rossion, I; Sandra-Petrescu, F; Suelberg, H, 2015) |
| "Stage II and III rectal cancer patients received, after total mesorectal excision, 2 cycles of XELOX regimen (oxaliplatin 130 mg/m(2) on day 1; capecitabine 1000 mg/m(2) bid on day 1 to 14, q21), followed by capecitabine (800 mg/m(2) bid daily; 20% dose at 12:00 AM and 80% dose at 12:00 PM) administered continuously during pelvic radiation (total 50." | 2.79 | Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. ( Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F, 2014) |
| "To establish a safe regimen of high-dose regional chemotherapy with NIPP using cisplatin in patients with incurable rectal cancer." | 2.79 | Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events. ( Kim, C; Kimata, R; Kumita, S; Murata, S; Onozawa, S; Tajima, H; Uchida, E, 2014) |
| "Data from 62 patients with rectal cancer (uT3-4; N0/1, M0) of the phase II trial were analyzed." | 2.79 | Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications. ( Arnold, D; Buller, J; Dellas, K; Dunst, J; Görtz, GJ; Höhler, T; Keck, T; Richter, M; Zühlke, H, 2014) |
| "Capecitabine dose was increased from 650 mg/m(2) to 825 mg/m(2) orally twice daily on the days of radiation therapy; erlotinib dose was increased from 50 mg orally daily in weeks 1 to 3, to 50 mg daily in weeks 1 to 6, to 100 mg daily in weeks 1 to 6." | 2.79 | Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. ( Chang, GJ; Clemons, MV; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kopetz, SE; Krishnan, S; Maru, DM; Munsell, MF; Rodriguez-Bigas, MA; Shureiqi, I; Skibber, JM; You, YN, 2014) |
| "Eighty patients with rectal cancer located in the mid to low rectum, staged cT3-4N0-2M0, were prospectively enrolled." | 2.79 | Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02). ( Baek, JY; Chie, EK; Choi, DH; Chun, HG; Jang, HS; Kim, DY; Kim, HC; Kim, JG; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Oh, JH; Oh, ST; Park, HC; Park, JW; Park, YS, 2014) |
| "Patients with cT3-4, any N, any M rectal cancer were eligible." | 2.79 | Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. ( Birnbaum, E; Fleshman, J; Gao, F; Hall, L; Hunt, S; Kodner, I; Lockhart, AC; Mutch, M; Myerson, RJ; Naughton, M; Olsen, J; Parikh, P; Picus, J; Rigden, C; Safar, B; Sorscher, S; Suresh, R; Tan, B; Wang-Gillam, A, 2014) |
| "Patients with clinical stage II or III rectal cancer who were undergoing preoperative RT (45 Gy in 25 fractions over 5 weeks plus a boost of 5." | 2.79 | Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. ( Allegra, CJ; Arora, A; Bahary, N; Beart, RW; Colangelo, LH; Eakle, J; Evans, LS; Landry, JC; Marchello, BT; Mohiuddin, M; Moore, DF; Mullane, MR; O'Connell, MJ; Parda, DS; Petrelli, NJ; Pitot, HC; Robertson, JM; Roh, MS; Ryan, DP; Sharif, S; Shields, AF; Soori, GS; Ward, PJ; Wolmark, N; Wozniak, TF; Yothers, G, 2014) |
| "Brunch Regimen for locally advanced rectal cancer consisting of neoadjuvant chronomodulated capecitabine and concurrent radiation therapy is effective and well tolerated with good safety profile, particularly with regard to the occurrence of hand and foot syndrome, in patients with locally advanced rectal cancer." | 2.79 | Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. ( Akgun, Z; Balik, E; Cipe, G; Gural, Z; Kaytan-Saglam, E; Kilickap, S; Okyar, A; Saglam, S; Yildiz, S; Yucel, S, 2014) |
| "In T3 rectal cancer (RC), preoperative chemoradiotherapy [5-fluorouracil (5-FU-RT)] reduces local recurrences, but does not affect overall survival." | 2.79 | Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study. ( Adenis, A; André, T; Azria, D; Borg, C; Bosset, JF; Boudghène, F; Maingon, P; Mantion, G; Mornex, F; Morsli, O; Piutti, M, 2014) |
| "Capecitabine was administered on weekdays concurrently with pelvic radiotherapy at a daily dose of 1." | 2.79 | Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study. ( Hirakawa, K; Hosono, M; Maeda, K; Miki, Y; Nagahara, H; Shimatani, Y; Tsutsumi, S, 2014) |
| "Patients (pts) with metastatic rectal cancer and symptomatic primary, require local and systemic control." | 2.79 | Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer. ( Bressel, M; Chander, S; Cooray, P; Heriot, A; Hicks, R; Jefford, M; Leong, T; MacKay, JR; McClure, B; McKendrick, J; Michael, M; Ngan, SY; Steel, M; Zalcberg, J, 2014) |
| "However, the role of MRI in restaging rectal tumors after neoadjuvant CRT is contentious." | 2.79 | Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02. ( Baek, JY; Chie, EK; Jang, HS; Jung, JH; Kim, DY; Kim, HC; Kim, JG; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Nam, TK; Oh, JH; Oh, ST; Park, HC; Park, SC, 2014) |
| "Their role in chemoradiotherapy for rectal cancers is unclear." | 2.79 | Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers. ( Bokey, L; Cheng, C; Chua, W; de Souza, P; Descallar, J; Lee, CS; Lee, MT; Lim, SH; Ng, W; Shin, JS; Solomon, M; Wong, K, 2014) |
| "Valproic acid (VPA) is an anti-epileptic drug with HDACi and anticancer activity." | 2.79 | Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial). ( Aloj, L; Avallone, A; Bianco, F; Botti, G; Budillon, A; Caracò, C; Cavalcanti, E; D'Angelo, V; Daniele, G; Delrio, P; Di Gennaro, E; Di Maio, M; Gallo, C; Granata, C; Iaffaioli, VR; Lastoria, S; Maiolino, P; Marone, P; Maurea, N; Montano, M; Muto, P; Pecori, B; Perrone, F; Petrillo, A; Piccirillo, MC; Roca, MS; Romano, G; Silvestro, L; Tatangelo, F; Terranova Barberio, M, 2014) |
| "Patients with cT3 or cN1 and cM0 rectal cancer were eligible." | 2.79 | A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. ( Cubillo, A; De Vicente, E; García-García, E; Hernando-Requejo, O; Hidalgo, M; López, U; López-Ríos, F; Morelli, P; Muro, A; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Rubio, C, 2014) |
| "Adults with primary metastasized rectal cancer were enrolled." | 2.78 | Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. ( Beets, GL; Beukema, JC; de Jong, KP; Gelderblom, AJ; Havenga, K; Hospers, GA; Nagtegaal, ID; Rutten, HJ; Tamas, K; van de Velde, CJ; van Dijk, TH; Wiggers, T, 2013) |
| "A total of 32 patients had lower rectal cancer, with 24 candidate for abdominal-perineal resection." | 2.78 | Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). ( Aglietta, M; Bertetto, O; Cassoni, P; Ciuffreda, L; Dongiovanni, V; Fanchini, L; Filippi, AR; Franco, P; Gabriele, P; Morino, M; Munoz, F; Racca, P; Ricardi, U; Rondi, N, 2013) |
| "Metronidazole 10 g/m(2) was administered per rectum on days 8 and 15." | 2.78 | Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer. ( Barsukov, YA; Fedyanin, MY; Gordeyev, SS; Perevoshikov, AG; Tkachev, SI, 2013) |
| "The purpose of this study was to investigate the association between single nucleotide polymorphism (SNP) of CCND1 A870G and acute adverse events (AEs) in postoperative rectal cancer patients who received capecitabine-based postoperative chemoradiotherapy (CRT)." | 2.78 | [Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy]. ( DU, ZL; Huang, Y; Jin, J; Li, YX; Lin, DX; Qiao, Y; Ren, H; Tan, W; Yu, DK, 2013) |
| "In selected patients with rectal cancer, laparoscopic surgery is as safe as open surgery, with similar resection margins and completeness of resection." | 2.78 | Postchemoradiation laparoscopic resection and intraoperative electron-beam radiation boost in locally advanced rectal cancer: long-term outcomes. ( Calvo, FA; del Valle, E; Diaz-Zorita, B; García-Sabrido, JL; Lopez-Baena, JA; Marcos, F; Muñoz-Calero, A; Rodriguez, M; Serrano, J; Sole, CV; Zorrilla, J, 2013) |
| "In stage IV rectal cancer, palliative surgery is often carried out upfront." | 2.78 | Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study. ( Bujko, K; Kepka, L; Michalski, W; Olszyna-Serementa, M; Palucki, J; Pietrzak, L; Rutkowski, A; Tyc-Szczepaniak, D; Wyrwicz, L, 2013) |
| "The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported." | 2.78 | HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. ( Cervantes, A; Chau, I; Cunningham, D; Eltahir, Z; Glimelius, B; Gonzalez de Castro, D; Oates, J; Peckitt, C; Roy, A; Sclafani, F; Tabernero, J; Wotherspoon, A, 2013) |
| "The overall toxicity of oxaliplatin and continuous 5-FU/leucovorin infusion in combination with radiation was well tolerated." | 2.78 | Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study. ( Baek, JH; Jung, DH; Kwon, KA; Lee, KC; Lee, SH; Lee, WS; Shin, DB; Sym, SJ, 2013) |
| "Seventy-three patients with cT3-4 rectal cancer were enrolled." | 2.78 | Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). ( Baek, JY; Chang, HJ; Jang, HS; Kim, DY; Kim, JG; Kim, MJ; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Nam, TK; Oh, JH; Park, JW; Yeo, SG, 2013) |
| "T3-4 and/or N+ rectal cancer patients were treated prospectively with capecitabine-based chemoradiation and total mesorectal excision 7-8 weeks later." | 2.78 | Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation? ( Alessi, A; Avuzzi, B; Bampo, C; Bertarelli, G; Biondani, P; Bombardieri, E; Chiruzzi, C; Crippa, F; de Braud, F; Di Bartolomeo, M; Fantini, S; Mariani, L; Milione, M; Pietrantonio, F; Valvo, F, 2013) |
| "Patients with locally advanced or low rectal cancer were treated with capecitabine 825 mg/m(2) twice daily on days 1-14 and 22-35, oxaliplatin 50mg/m(2) on days 1, 8, 22 and 29, bevacizumab 5mg/kg on days 14, 1, 15 and 29, and radiation 50." | 2.77 | Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. ( Berry, S; Easaw, J; Hay, J; Kennecke, H; Post, J; Rao, S; Tankel, K; Wong, R; Zhou, C, 2012) |
| "Patients with cT3 rectal cancer were eligible." | 2.77 | Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial. ( De Vries, A; Eisterer, W; Gnant, M; Jagoditsch, M; Öfner, D; Rabl, H; Resch, G; Thaler, J, 2012) |
| "Clinically staged T2N0 rectal cancer patients were treated with capecitabine and oxaliplatin during radiation followed by LE." | 2.77 | A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. ( Cataldo, P; Chan, E; Garcia-Aguilar, J; Marcet, J; Medich, D; Oommen, S; Pigazzi, A; Posner, MC; Shi, Q; Thomas, CR, 2012) |
| "Patients with Stage T3 or T4 rectal cancer of <12 cm from the anal verge were randomized to preoperative RT (50." | 2.77 | Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. ( Anne, PR; Erickson, BA; Haddock, M; Kachnic, L; Lee, RJ; Meropol, NJ; Mitchell, E; Pollock, J; Rashid, A; Watson, JC; Willett, CG; Winter, K; Wong, SJ, 2012) |
| "Transforming growth factor-beta1 is related to adverse events in radiochemotherapy." | 2.77 | Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant. ( Becker, H; Beissbarth, T; Brockmöller, J; Christiansen, H; Conradi, LC; Gaedcke, J; Ghadimi, M; Hennies, S; Herrmann, MK; Hess, CF; Jo, P; Mergler, CP; Rave-Fränk, M; Schirmer, MA; Wolff, HA, 2012) |
| "Patients with T3 to T4 and/or N+ rectal cancer received preoperative IMRT (47." | 2.77 | Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. ( Arbea, L; Aristu, J; Cambeiro, M; Chopitea, A; Díaz-González, JA; García-Foncillas, J; Gaztañaga, M; Hernández, JL; Martínez-Monge, R; Moreno, M; Nuñez, J; Ramos, LI; Rodríguez, J; Sola, JJ; Subtil, JC, 2012) |
| "Capecitabine was administered at 825 t." | 2.77 | Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer. ( Alberola Candel, V; Alberola, A; Garde Noguera, J; Gasent Blesa, JM; Giner Bosch, V; Laforga Canales, JB; Peris Godoy, M; Provencio Pulla, M; Sanchez, JL; Soler Tortosa, M, 2012) |
| "Locally advanced rectal cancer represents a major therapeutic challenge." | 2.77 | Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses. ( Appelt, A; Jakobsen, A; Lindebjerg, J; Ploen, J; Rafaelsen, SR; Vuong, T, 2012) |
| "Patients with T3/T4 or node positive rectal cancer were treated with capecitabine 1,000 mg/m(2) twice daily (BID) days 1-14, and irinotecan 200 mg/m(2) on day 1 every 21 days for 2 cycles, followed by capecitabine 825 mg/m(2) BID days 1-5 per week with concurrent radiotherapy 50." | 2.77 | Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. ( Bufill, J; Burns, M; Cardenes, H; Chiorean, EG; Clark, R; Coleman, N; Curie, C; Hinkle, DT; LeBlanc, J; Loehrer, PJ; Robb, B; Sanghani, S; Schiel, MA; Tong, Y; Yu, M, 2012) |
| "Capecitabine was administered at 825 mg/m(2) twice daily for 5 days/week and oxaliplatin at 50 mg/m(2) on day 1 weekly for 5 weeks starting the first day of RT (before RT)." | 2.77 | Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer. ( Alonso, V; Aranda, E; Benavides, M; Escudero, P; Gallén, M; Gómez, A; González, E; Losa, F; Majem, M; Massutí, B; Navarro, M; Rivera, F; Salazar, R, 2012) |
| "Patients with clinical T3, T4, or N1-2 rectal cancer were subjected to a preoperative CCRT protocol with FOLFOX and bevacizumab (5 mg/kg) biweekly for 6 cycles followed by a standardized laparoscopic TME procedure, as detailed in the attached video." | 2.76 | Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. ( Cheng, KW; Lai, HS; Liang, JT, 2011) |
| "Patients (N = 207) with nonresectable rectal cancer were randomized to preoperative CRT or RT (2 Gy × 25 ± 5-fluorouracil/leucovorin)." | 2.76 | Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. ( Berglund, Å; Bruheim, K; Brændengen, M; Cvancarova, M; Glimelius, B; Tveit, KM, 2011) |
| "In patients with locally advanced rectal cancer (LARC), preoperative chemoradiation is known to improve local control, and down-staging of the tumor serves as a surrogate for survival." | 2.76 | Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study. ( Devries, AF; Eisterer, W; Fastner, G; Gnant, M; Greil, R; Jäger, R; Kapp, KS; Keil, F; Offner, F; Ofner, D; Rabl, H; Schaberl-Moser, R; Thaler, J; Tschmelitsch, J; Zitt, M, 2011) |
| "Patients with locally advanced rectal cancer (cT3, potentially resectable cT4 or N+) were randomly assigned to receive preoperative or postoperative CRT." | 2.76 | Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. ( Kim, JC; Kim, JH; Kim, TW; Park, JH; Yoon, SM; Yu, CS, 2011) |
| "Grade 3-4 toxicity during neoadjuvant treatment was diarrhea (38." | 2.76 | Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). ( Aprile, G; Aschele, C; Bardelli, A; Bochicchio, A; Di Fabio, F; Garufi, C; Giaquinta, S; Gion, M; Latiano, T; Maiello, E; Martoni, A; Pini, S; Pinto, C; Rosati, G; Torri, V, 2011) |
| "Results of this small pilot study in rectal cancer patients receiving preoperative radiochemotherapy, showed that ingestion of larger quantities of glutamine given more often as previously reported did not diminish the incidence and severity of diarrhoea and did not affect inflammatory and metabolic activity compared to the placebo treatment with maltodextrin." | 2.76 | Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. ( Anderluh, F; Kompan, L; Mlakar Mastnak, D; Možina, B; Oblak, I; Rotovnik Kozjek, N; Soeters, P; Velenik, V; Zadnik, V, 2011) |
| "Among the 17 patients with lower rectal cancer, thirteen (76%) were originally indicated for abdominal-perineal resection (APR)." | 2.76 | A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. ( Bai, C; Chen, S; Guan, M; Jia, N; Qiu, H; Shao, Y; Xiao, Y; Yang, T; Zhang, F; Zhao, L; Zhong, G, 2011) |
| "This phase II study is performed to evaluate the efficacy and safety of capecitabine combined with preoperative radiotherapy (RT) in Chinese patients with locally advanced rectal cancer (LARC)." | 2.76 | Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer. ( Deng, J; Jin, J; Li, X; Lu, W; Meng, H; Wang, F; Xu, X; Xue, Z; Zhang, H; Zhou, G, 2011) |
| " Relationships between genetic variants and adverse events, tumour response, overall and disease-free survivals were assessed." | 2.76 | Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer. ( Alyasiri, A; Dvorak, A; Fleshman, JW; Hoskins, JM; McLeod, HL; Motsinger-Reif, AA; Myerson, RJ; Roy, S; Tan, BR; Thomas, F, 2011) |
| "Neoadjuvant chemoradiotherapy for rectal cancer can result in complete disappearance of tumor and involved nodes." | 2.76 | Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. ( Beets, GL; Beets-Tan, RG; Buijsen, J; Engelen, SM; Hulsewé, KW; Jansen, RL; Lambregts, DM; Lammering, G; Leijtens, JW; Maas, M; Nelemans, PJ; Sosef, M; van Dam, RM, 2011) |
| "A total of 41 patients of low rectal cancer were treated with CPT-11, 5-FU therapy or CPT-11 plus 5-FU combined short-term radiotherapy from April 2002 to April 2009." | 2.76 | [Pathological changes of rectal cancer after irinotecan, 5-fluorouracil or combined short-term radiotherapy]. ( Chen, MX; Fan, L; Hu, XZ; Jiang, HY; Li, CY; Liang, XB; Ma, JJ; Yan, D, 2011) |
| "Celecoxib dosage was fixed." | 2.75 | A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010) |
| "Preoperative treatment of rectal cancer with combined chemotherapy and radiation therapy has become a widely accepted strategy." | 2.75 | A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. ( Chang, M; George, TJ; Grobmyer, S; Hochwald, S; King, J; Larson, B; Marsh, Rde W; Mendenhall, WM; Siddiqui, T; Zlotecki, RA, 2010) |
| "Patients with poor-risk rectal cancer defined by MRI can be at high risk of disease recurrence despite standard chemoradiotherapy and optimum surgery." | 2.75 | Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. ( Barbachano, Y; Brown, G; Chau, I; Chua, YJ; Cunningham, D; Massey, A; Oates, JR; Tait, D; Tebbutt, NC; Wotherspoon, A, 2010) |
| "Cap 50 merits investigation for T3-4 rectal cancers." | 2.75 | Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. ( Azria, D; Bécouarn, Y; Berdah, JF; Bouché, O; Conroy, T; de La Roche, G; Denis, B; Dupuis, O; Etienne, PL; François, E; Gérard, JP; Gourgou-Bourgade, S; Hennequin, C; Lledo, G; Mahé, MA; Martel-Laffay, I; Mineur, L; Mirabel, X; Montoto-Grillot, C; Vendrely, V, 2010) |
| "Radiation injuries were reported in 37." | 2.75 | [Extended preoperative course of radiotherapy as component of combined and complex treatment of locally-advanced ampular rectal cancer]. ( Lukina, EIu; Nadvikova, EA; Semikopov, KV; Vazhenin, AV, 2010) |
| "Bortezomib was administered on days 1, 4, 8, and 11 every 21 days for 2 cycles with 5-fluorouracil at 225 mg/m2/day continuously and 50." | 2.75 | A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. ( Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE, 2010) |
| " Of all biomarkers, pretreatment plasma sVEGFR-1-an endogenous blocker of VEGF and PlGF, and a factor linked with "vascular normalization"-was associated with both primary tumor regression and the development of adverse events after neoadjuvant bevacizumab and chemoradiation." | 2.75 | Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. ( Ancukiewicz, M; Bentley, R; Carroll, M; Clark, JW; Czito, BG; di Tomaso, E; Duda, DG; Jain, RK; Lauwers, GY; Mantyh, C; Poleski, M; Shah, M; Shellito, P; Tyler, D; Willett, CG, 2010) |
| "The detection of somatic mutations in rectal cancer tumors led us to re-evaluate the utility of the tests performed in blood samples for these polymorphisms in rectal cancer." | 2.75 | Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response. ( Balboa, E; Barros, F; Carracedo, A; Celeiro-Muñoz, C; Duran, G; Gomez-Caamaño, A; Lamas, MJ; Lopez, R, 2010) |
| "Standard adjuvant chemoradiotherapy of rectal cancer still consists of 5-fluorouracil (5-FU) only." | 2.75 | Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α. ( Baumann, W; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Staib, L; Wiegel, T, 2010) |
| "Patients with T3, T4, or N+ rectal cancer received radiotherapy to a total dose of 50." | 2.75 | A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer. ( Alexander, HR; Camphausen, K; Citrin, D; Denobile, J; Libutti, SK; Pingpank, JF; Quezado, M; Royal, RE; Seidel, G; Shuttack, Y; Steinberg, SM; Wood, BJ, 2010) |
| " The purpose of this study was to evaluate whether preoperative chemoradiation therapy exerted an adverse influence on laparoscopic TME for low rectal cancer." | 2.74 | Safety of laparoscopic total mesorectal excision for low rectal cancer with preoperative chemoradiation therapy. ( Akiyoshi, T; Fujimoto, Y; Fukuda, M; Konishi, T; Kuroyanagi, H; Muto, T; Oya, M; Ueno, M; Yamaguchi, T, 2009) |
| "Oral capecitabine was well tolerated in all patients; grade 3 toxicity was seen in only one patient (3." | 2.74 | Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge. ( Elshazly, WG; Farouk, M; Samy, M, 2009) |
| "To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer." | 2.74 | Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009) |
| "However, the German Rectal Cancer Study Group recently demonstrated that preoperative radiochemotherapy (RCT) was better than postoperative radiochemotherapy in terms of local control." | 2.74 | Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. ( Budach, V; Burock, S; Dietel, M; Koswig, S; Kretzschmar, A; Loy, V; Schlag, PM; Siegel, R; Wernecke, KD, 2009) |
| "Fifty-four patients with T3/T4/N+ rectal cancers were treated on a Phase II trial using preoperative capecitabine and concomitant boost radiotherapy." | 2.74 | Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer. ( Cleeland, CS; Crane, CH; Das, P; Delclos, ME; Hundal, M; Janjan, NA; Krishnan, S; Lin, EH; Mendoza, TR; Park, HC; Vadhan-Raj, S; Wang, XS; Zhang, Y, 2009) |
| "However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs." | 2.74 | Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. ( Bjerkeset, O; Carlsen, E; Dahl, O; Eide, TJ; Fluge, Ø; Halvorsen, TB; Myrvold, HE; Podhorny, N; Tveit, KM; Vonen, B; Wiig, JN, 2009) |
| "Forty-one patients with rectal cancer (T3-4 and/or N+) received preoperative radiotherapy (1." | 2.74 | Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. ( Aydin, S; Daemen, A; De Moor, B; Debucquoy, A; Gevaert, O; Haustermans, K; Libbrecht, L; Machiels, JP; McBride, WH; Penninckx, F; Scalliet, P; Sempoux, C; Stroh, C; Tejpar, S; Vlassak, S, 2009) |
| "Between 1993 and 2003, 186 rectal cancer patients were enrolled." | 2.74 | Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection. ( Barbachano, Y; Chau, I; Chong, G; Cunningham, D; Watkins, D; Yau, T, 2009) |
| "Bevacizumab with chemoradiotherapy appears safe and active and yields promising survival results in locally advanced rectal cancer." | 2.74 | Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. ( Ancukiewicz, M; Bentley, R; Boucher, Y; Chen, HX; Chung, DC; Clark, JW; Czito, BG; di Tomaso, E; Duda, DG; Fischman, AJ; Jain, RK; Lahdenranta, J; Lauwers, GY; Paulson, E; Poleski, M; Sahani, DV; Shellito, P; Vujaskovic, Z; Willett, CG; Wong, TZ, 2009) |
| "Treatment of rectal cancer requires a multidisciplinary approach with standardized surgical, pathological and radiotherapeutic procedures." | 2.74 | Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial. ( Elsayed, MI; Elwanis, MA; Maximous, DW; Mikhail, NN, 2009) |
| "Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT." | 2.73 | Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. ( Andrews, C; Bullarddunn, K; Fakih, MG; Levea, C; Park, YM; Pendyala, L; Puthillath, A; Rajput, A; Ross, ME; Rustum, YM; Toth, K; Yang, GY, 2008) |
| "2004, 256 cases with stage III colorectal cancer randomized received de Gramont, modified FOLFOX4 (mFOLFOX4) and XELOX regimens." | 2.73 | [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer]. ( Cheng, RC; Diao, C; Liu, QY; Su, YJ; Wei, XP; Xu, JB; Zhang, JM, 2008) |
| "40 patients with rectal cancer UICC stage II/III, receiving pre-operative 5-FU-based CT/RT followed by standardized surgery, including total mesorectal excision, were investigated." | 2.73 | Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation. ( Aust, DE; Baretton, GB; Ehninger, G; Goekkurt, E; Jakob, C; Kramer, M; Liersch, T; Mogck, U; Stoehlmacher, J, 2008) |
| "Irinotecan 180 mg/m2 was administered biweekly on D1, LV 200 mg/m2 by intravenous infusion in 2 hours before bolus intravenous injection of 5-Fu 400 mg/m2, then followed immediately by intravenous infusion of 5-Fu 2." | 2.73 | [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]. ( Bai, Y; Chu, YP; Jin, ML; Li, J; Liu, DQ; Shen, L; Wang, YH; Xu, JM; Zhang, XD, 2008) |
| " The secondary aim was to evaluate whether distal bowel clearance < or =1 cm is safe after radiation." | 2.73 | Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe? ( Bujko, K; Chmielik, E; Nasierowska-Guttmejer, A; Nowacki, MP; Rutkowski, A; Wojnar, A, 2008) |
| "Capecitabine was given at an oral dosage of 825 mg/m(2)bid on each day of the radiotherapy period with the first daily dose applied 2 h before irradiation, followed by surgery 6 weeks later." | 2.73 | Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. ( Budach, W; Debus, J; Dunst, J; Hinke, A; Hoelscher, T; Mose, S; Reese, T; Roedel, C; Rudat, V; Wulf, J; Zuehlke, H, 2008) |
| "Capecitabine was administered concurrently at 1,650 mg/m2 on days 1 to 14 and 22 to 35, and oxaliplatin was administered at 50 mg/m2 on days 1, 8, 22, and 29." | 2.73 | Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. ( Arnold, D; Bieker, M; Ewald, H; Flentje, M; Fürst, A; Haier, J; Hellmich, G; Hermann, RM; Hipp, M; Hohenberger, W; Liersch, T; Lordick, F; Reese, T; Rödel, C; Sauer, R; Schwella, N; Sülberg, H, 2007) |
| "Forty patients with rectal cancer (T3-T4, and/or N+, endorectal ultrasound) received preoperative radiotherapy (1." | 2.73 | Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. ( Aydin, S; Bonny, MA; Canon, JL; Coche, JC; Coster, B; Daisne, JF; Duck, L; Haustermans, K; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Peeters, M; Roels, S; Scalliet, P; Sempoux, C; Van Cutsem, E, 2007) |
| "We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with capecitabine and concurrent radiotherapy (CapIri-RT) as neoadjuvant treatment in rectal cancer in a phase-II trial." | 2.73 | A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. ( Grobholz, R; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Leitner, A; Post, S; Wenz, F; Willeke, F; Willer, A, 2007) |
| "Capecitabine was given orally 825 mg/m(2) twice daily for 7 days each week during RT." | 2.73 | Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. ( Callahan, E; Cheng, J; Cohen, S; Freedman, GM; Hoffman, J; Konski, A; Lewis, N; Meropol, NJ; Price, R; Rogatko, A; Sigurdson, ER; Watkins-Bruner, D, 2007) |
| " This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events." | 2.73 | [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis]. ( Chen, G; Ding, PR; Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, GQ; Wu, XJ; Zhou, ZW, 2007) |
| " In locally advanced rectal cancer, preoperative infusional chemotherapy combined with radiation was found to be less toxic than bolus chemotherapy and radiotherapy." | 2.73 | Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. ( Elsaleh, H; Joseph, D; Kaminski, A, 2007) |
| "Ninety patients with metastatic colorectal cancer were included in the study." | 2.73 | TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. ( Berglund, A; Brünner, N; Byström, P; Christensen, IJ; Glimelius, B; Nielsen, HJ; Sørensen, NM, 2007) |
| "T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m(2) twice daily (days 1-14, 25-38) added to RT with 50." | 2.73 | Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. ( Cats, A; Havenga, K; Hospers, GA; Jansen, EP; Leer, JW; Marijnen, CA; Mulder, NH; Punt, CJ; Tesselaar, ME; Van de Velde, CJ; Van Krieken, HH; Wiggers, T, 2007) |
| "A total of 60 patients with rectal cancer (T3-T4 or N+, M1 allowed) entered the trial at five investigator sites; the data from 58 patients were assessable." | 2.73 | Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. ( Arnold, D; Dellas, K; Hermann, RM; Hinke, A; Hipp, M; Hohenberger, W; Iesalnieks, I; Liersch, T; Lordick, F; Rödel, C; Sauer, R, 2008) |
| "Capecitabine was given at a dose of 900 mg m(-2) for 5 days per week combined with 45 Gy of radiotherapy in 25 doses." | 2.73 | Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer. ( Byrne, P; Cooper, R; Craven, I; Crellin, A; Melcher, A; Sebag-Montefiore, D, 2007) |
| "Chemoradiotherapy of the last phase II study with intermittent capecitabine (1500 mg/m(2)/day, delivered on days 1-14 and 22-35) and irinotecan (4 x 60 mg/m(2)) concurrently to radiotherapy is a safe treatment with low toxicity and high efficacy." | 2.73 | Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response. ( Fietkau, R; Foitzik, T; Klar, E; Klautke, G; Küchenmeister, U; Ludwig, K; Prall, F; Semrau, S, 2007) |
| "Patients with rectal T3-T4 and/or N0-N+ rectal cancer received capecitabine 825 mg/m(2) twice daily Monday through Friday and oxaliplatin 60 mg/m(2) intravenously on Days 1, 8, and 15, concurrently with intensity-modulated radiotherapy." | 2.73 | Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. ( Arbea, L; Aristu, JJ; Azcona, JD; Díaz-González, JA; García-Foncillas, JM; Hernández-Lizoain, JL; Martínez-Monge, R; Moreno, M; Rodriguez, J; Sola, JJ, 2008) |
| "At surgery, the Rectal Cancer Regression Grade (RCRG) was registered." | 2.73 | Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer. ( Daemen, A; De Bie, T; De Moor, B; Debucquoy, A; Gevaert, O; Haustermans, K; Machiels, JP, 2008) |
| "Irinotecan (60 mg m(-2)) was given on days 1, 8, 15 and 22." | 2.73 | Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study. ( Biswas, A; Gollins, S; Haylock, B; Iles, S; Levine, E; Myint, S; Susnerwala, S; Swindell, R, 2008) |
| "A Phase I study was conducted to determine the maximal tolerated dose and the dose-limiting toxicity (DLT) of oxaliplatin (OXA) combined with capecitabine and radiotherapy as adjuvant treatment in patients with operable rectal cancer." | 2.73 | Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer. ( Fang, H; Jin, J; Li, YX; Liu, YP; Wang, JW; Wang, K; Wang, WH; Yu, ZH; Zhou, AP; Zhou, ZX, 2008) |
| "These tumours are assessed as rectal cancer using immunohistochemical and radiological tests, and certain criteria (localisation, relationship with neighbouring structures) have to be fulfilled to make the diagnosis." | 2.72 | Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations. ( Astaras, C; Bornand, A; Koessler, T, 2021) |
| "Capecitabine was administered concurrently with RT in escalating doses, twice daily with a 12-h interval, for two cycles of 14 days separated by a 7-day rest." | 2.72 | A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer. ( Jin, J; Li, N; Li, T; Li, YX; Liu, XF; Liu, YP; Song, YW; Wang, WH; Yu, ZH, 2006) |
| "The aim of the study was to evaluate tolerance and efficacy of preoperative treatment with capecitabine in combination with radiation therapy (RT) in patients with locally advanced, resectable, rectal cancer." | 2.72 | Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study. ( Beretta, GD; Chiara, S; Corvò, R; De Paoli, A; Del Prete, S; Friso, ML; Frustaci, S; Innocente, R; Luppi, G; Mantello, G; Pasetto, L; Rosso, R; Santantonio, M; Sarti, E, 2006) |
| "Patients with clinically unresectable rectal cancer or for whom resection with histologically clear (R0) surgical margins was unlikely received continuous capecitabine (500-825 mg/m2 twice daily, 7 days/week), oxaliplatin 2-h intravenous infusion (130 mg/m2 days 1 and 29) and pelvic radiotherapy (Monday-Friday for 5 weeks, total dose 45 Gy in 25 daily 1." | 2.72 | A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. ( Falk, SJ; Glynne-Jones, R; Maughan, TS; McDonald, AC; Sebag-Montefiore, D, 2006) |
| "7%); previous radiotherapy dosage ranged between 30 and 55 Gy (median, 50." | 2.72 | Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study. ( Bolzicco, G; Coco, C; Dalla Palma, M; De Paoli, A; Di Russo, A; Doglietto, GB; Gambacorta, MA; Mohiuddin, M; Morganti, AG; Rossi, C; Valentini, V; Valvo, F, 2006) |
| "Patients with clinical T3/T4 distal rectal cancers were randomly assigned in a phase II study to receive combined neoadjuvant chemoradiotherapy followed by surgical resection." | 2.72 | Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. ( Hanna, N; Hayostek, C; Mitchell, E; Mohiuddin, M; Nichols, C; Shane, R; Willett, C; Winter, K; Yuen, A, 2006) |
| "Capecitabine and gefitinib were administered throughout the radiation course." | 2.72 | Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. ( Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D, 2006) |
| "MRI criteria for poor-risk rectal cancer were tumors within 1 mm of mesorectal fascia (ie, circumferential resection margin threatened), T3 tumors at or below levators, tumors extending > or = 5 mm into perirectal fat, T4 tumors, and T1-4N2 tumors." | 2.72 | Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. ( Brown, G; Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, AR; Oates, J; Ross, PJ; Tait, D; Tebbutt, N; Wotherspoon, A, 2006) |
| "Approximately 1 out of 10 advanced rectal cancers after preoperative radiotherapy or radiochemotherapy was characterized by DIS of over 5 mm." | 2.72 | Distal intramural spread of rectal cancer after preoperative radiotherapy: the results of a multicenter randomized clinical study. ( Bujko, K; Chmielik, E; Huzarski, T; Karmolinski, A; Kepka, L; Majewski, P; Nasierowska-Guttmejer, A; Nowacki, MP; Sopylo, R; Sygut, J; Wandzel, P; Wojnar, A, 2006) |
| "To investigate the effect of three-dimensional conformal radiotherapy (3-DCRT) in combination with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer." | 2.72 | Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer. ( He, C; Hu, JB; Sun, XN; Wang, Q; Xu, J; Yang, QC, 2006) |
| "Capecitabine was given orally twice daily Monday through Friday concurrently with RT." | 2.72 | A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. ( Fakih, MG; Lawrence, DD; Pendyala, L; Rajput, A; Rustum, YM; Smith, JL; Toth, K; Yang, GY, 2006) |
| " CPT-11 (50 mg/m(2) weekly) and 5-FU (225 mg/m(2)/day continuous infusion, 5 days/week) were concurrently administered with radiation therapy (RT) (45 Gy, 1." | 2.72 | A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer. ( Aranda, E; Cervantes, A; Dotor, E; Gallén, M; García, JL; Navarro, M; Rivera, F; Sánchez-Rovira, P; Vega-Villegas, ME, 2006) |
| "One hundred and thirteen patients with rectal cancer were randomly classified into 2 groups." | 2.72 | [Chemoembolization of bilateral internal iliac arteries in Miles operation]. ( Hao, SH; Liu, FL, 2006) |
| "Some rectal cancers respond well to preoperative neoadjuvant therapy while others are inherently resistant or develop resistance during the treatment." | 2.72 | Molecular responses of rectal cancer to preoperative chemoradiation. ( Debucquoy, A; Geboes, K; Goethals, L; Haustermans, K; Mc Bride, WH; Roels, S, 2006) |
| "4 Gy/28 fractions) combined with 5-FU (200-225 mg/m(2)/day by continuous venous infusion) and weekly OXA (25-60 mg/m(2))." | 2.72 | 5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results. ( Aschele, C; Bruttocao, A; DeSalvo, GL; Fabris, G; Ferraro, B; Finco, C; Frego, M; Friso, ML; Lise, M; Lonardi, S; Nitti, D; Pucciarelli, S; Rugge, M; Toppan, P; Urso, E, 2006) |
| "In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival." | 2.72 | Chemotherapy with preoperative radiotherapy in rectal cancer. ( Bardet, E; Beny, A; Bosset, JF; Calais, G; Collette, L; Daban, A; Maingon, P; Mineur, L; Ollier, JC; Radosevic-Jelic, L, 2006) |
| "Twenty patients with rectal cancer (clinical Stage uT3-T4 or N+) received a standard dosing regimen of cetuximab (400 mg/m(2) on Day 1 and 250 mg/m(2) on Days 8, 15, 22, and 29) and escalating doses of irinotecan and capecitabine according to phase I methods: dose level I, irinotecan 40 mg/m(2) on Days 1, 8, 15, 22, and 29 and capecitabine 800 mg/m(2) on Days 1-38; dose level II, irinotecan 40 mg/m(2) and capecitabine 1000 mg/m(2); and dose level III, irinotecan 50 mg/m(2) and capecitabine 1000 mg/m(2)." | 2.72 | Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. ( Dinter, D; Grobholz, R; Heeger, S; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Post, S; Wenz, F; Willeke, F; Woernle, C, 2006) |
| "The 5-year incidence of local recurrence was lower with chemoradiotherapy (8." | 2.72 | Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. ( Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Chapet, O; Closon-Dejardin, MT; Conroy, T; Ducreux, M; Francois, E; Gérard, JP; Leduc, B; Mackiewicz, R; Maurel, J; Seitz, JF; Untereiner, M, 2006) |
| "Capecitabine was orally administered concurrently with radiotherapy for a total of 2 cycles in escalating doses: twice daily at 12 hour interval for consecutive 14 days as one cycle, separated by a seven day rest, then followed by another cycle." | 2.72 | [Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer]. ( Jin, J; Li, N; Li, T; Li, YX; Liu, YP; Song, YW; Wang, WH, 2006) |
| ") bolus, days 1-5) plus LEV (150 mg/day orally, days 1-3); postoperative RT was delivered during week 2 at the same dosage and schedule as in arm I." | 2.71 | Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report. ( Cafiero, F; Gipponi, M; Lionetto, R, 2003) |
| "Peripheral lymphocytes of twelve rectal cancer patients who had undergone postoperative radiochemotherapy 2-3 years ago were investigated for residual chromosomal damage using 24-color fluorescence in situ hybridization (24-color FISH)." | 2.71 | Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH. ( Claussen, U; Dreidax, M; Dunst, J; Kuechler, A; Liehr, T; Pigorsch, SU; Wendt, TG, 2003) |
| "Capecitabine was administered twice daily in escalating doses during the entire period of RT." | 2.71 | Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer. ( Androulakis, N; Ardavanis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Pallis, A; Souglakos, J; Vardakis, N; Varveris, C, 2003) |
| "Capecitabine was administered concurrently at 825 mg/m2 bid on days 1 to 14 and 22 to 35, with oxaliplatin starting at 50 mg/m2 on days 1, 8, 22, and 29 with planned escalation steps of 10 mg/m2." | 2.71 | Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. ( Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Rödel, C; Sauer, R; Schmoll, HJ, 2003) |
| "Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre or postoperative RCT: A total dose of 50." | 2.71 | Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. ( Becker, H; Fietkau, R; Hess, C; Hohenberger, W; Karstens, JH; Martus, P; Raab, R; Rödel, C; Sabitzer, H; Sauer, R; Tschmelitsch, J; Wittekind, C, 2003) |
| "Attempted surgical salvage of rectal cancer recurrence is performed commonly in the United States." | 2.71 | Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. ( Cooke, E; Hollis, D; Mayer, RJ; Niedzwiecki, D; O'Connell, M; Tepper, JE, 2003) |
| "Consenting patients with presumed colorectal cancer were randomized to surgery with or without 7 days of PVI (1 g 5-FU plus 5000 units heparin in 1 litre 5 per cent dextrose infused over each 24-h period)." | 2.71 | Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS). ( Donaldson, D; Gray, R; James, RD; Northover, JM; Stenning, SP; Taylor, I, 2003) |
| "Sixty lower rectal cancer patients were divided randomly into two groups." | 2.71 | [Combined preoperative xeloda and radiotherapy for lower rectal cancer]. ( Cai, GY; Li, TH; Wu, JW; Zhuang, CP, 2003) |
| "Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost." | 2.71 | A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004) |
| "The purpose of our study was to determine the maximum-tolerated dose, dose-limiting toxicity, safety profile, and pharmacokinetics of the polyamine synthesis inhibitor SAM486A given in combination with 5-fluorouracil/leucovorin (5-FU/LV) in cancer patients." | 2.71 | Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer. ( Bootle, D; Bridgewater, J; Choi, L; de Bruijn, P; Eskens, FA; Ledermann, JA; Mueller, C; Planting, AS; Sklenar, I; Sparreboom, A; van Zuylen, L; Verweij, J, 2004) |
| "Preoperative chemoradiotherapy in rectal cancer using chronomodulated 5-FU and LV is feasible." | 2.71 | Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer. ( Berry, S; Bjarnason, GA; Davey, P; de Marsh, RW; Mendenhall, W; Parulekar, W; Rout, WR; Wong, R; Zlotecki, R, 2004) |
| "A total of 760 patients with colon cancer and 669 patients with rectal cancer were entered into this randomized clinical trial (RCT)." | 2.71 | Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-flu ( Hojyo, K; Isomoto, H; Kato, T; Kodaira, S; Kunii, Y; Kunitomo, K; Niimoto, M; Nishida, O; Ohashi, Y; Takahashi, T; Tominaga, T; Watanabe, M; Yasutomi, M, 2004) |
| "For patients with resectable rectal cancer receiving concurrent, full dose radiotherapy, the recommended dose of capecitabine for further study is 1800 mg m(-2) day(-1) when given in this schedule." | 2.71 | A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. ( Leong, T; Lim Joon, D; Mackay, J; McKendrick, J; Michael, M; Ngan, SY; Zalcberg, JR, 2004) |
| " We assessed the feasibility and pharmacokinetic interactions of combining MMI270 with 5-fluorouracil (5-FU) and folinic acid (FA)." | 2.71 | A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid. ( Blackey, R; Cassidy, J; Choi, L; Devlin, M; Eatock, M; Johnson, J; Morrison, R; Owen, S; Twelves, C, 2005) |
| "To establish the feasibility and efficacy of capecitabine in combination with weekly irinotecan (CAPIRI) with concurrent pelvic radiotherapy (RT) in patients with locally advanced rectal cancer." | 2.71 | Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. ( Gnad, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kraus-Tiefenbacher, U; Müldner, A; Post, S; von Gerstenberg-Helldorf, B; Wenz, F; Willeke, F, 2005) |
| "The aim of this study was to define the recommended dose of oxaliplatin when combined with infusional 5-fluorouracil (5-FU) and concurrent pelvic radiotherapy." | 2.71 | Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial. ( Hicks, RJ; Leong, T; Lim-Joon, D; Loi, S; Mackay, J; Michael, M; Mitchell, P; Mukesh, B; Ngan, SY; Rischin, D; Zalcberg, J, 2005) |
| "Capecitabine is an attractive radiosensitizer which can be tumor specific." | 2.71 | Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. ( Ahn, SD; Chang, HM; Choi, EK; Kim, HC; Kim, JC; Kim, JH; Kim, JS; Kim, TW; Lee, SW; Park, JH; Ryu, MH; Shin, SS; Yu, CS, 2005) |
| "In patients with rectal cancer, preliminary results of EORTC Trial 22921 indicate that the addition of CT to preop RT induces down-sizing, downstaging, and significant changes in histologic characteristics." | 2.71 | Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. ( Bardet, E; Beny, A; Bosset, JF; Briffaux, A; Calais, G; Collette, L; Daban, A; Maingon, P; Mineur, L; Radosevic-Jelic, L, 2005) |
| "Forty patients with rectal cancer (T3-T4 and/or N+) received radiotherapy (1." | 2.71 | Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. ( Aydin, S; Baurain, JF; Canon, JL; Coche, JC; Coster, B; Duck, L; Gilbeau, L; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Octave-Prignot, M; Remouchamps, V; Scalliet, P; Sempoux, C; Van Maele, P, 2005) |
| "For patients with rectal cancer treated with full thickness local excision the risk of mesorectal nodal metastases has to be very low." | 2.71 | Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial: implication for subsequent local excision. ( Bujko, K; Kepka, L; Nasierowska-Guttmejer, A; Nowacki, MP; Oledzki, J; Rogowska, D; Serkies, K; Stryczyńska, G; Suwiński, R; Tokar, P; Wieczorek, A; Winkler-Spytkowska, B, 2005) |
| " The initial weekly oxaliplatin dosage was 30 mg/m2 and the 5FU dosage 150 mg/m2/d." | 2.71 | Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study. ( Bertheault-Cvitkovic, F; Conroy, T; Ducreux, M; François, E; Giovannini, M; Lemanski, C; Magnin, V; Thomas, O; Ychou, M, 2005) |
| "Capecitabine was administered at escalating doses from 250 to 1,250 mg/m(2) bid (including weekends) for the duration of radiotherapy." | 2.70 | Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. ( Dunst, J; Frings, S; Hinke, A; Kölling-Schlebusch, K; Reese, T; Sutter, T; Zühlke, H, 2002) |
| "Twenty-eight patients with rectal cancer, staged as over T3N1 or T4 by transrectal ultrasonography between July 1997 and December 1998, were included in this study." | 2.70 | Intravenous 5-fluorouracil versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials. ( Jung, HC; Kim, NK; Min, JS; Park, JK; Roh, JK; Sung, JS; Yun, SH, 2001) |
| "The aim of this study was to examine the efficacy and safety of both oxaliplatin as a single agent and oxaliplatin in combination with dailyx5 bolus 5-fluorouracil and folinic acid (5-FU/FA, Mayo clinic regimen) in the first-line treatment of metastatic colorectal cancer (CRC) patients." | 2.70 | A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. ( Balbiani, L; Bella, S; Blajman, C; Cazap, E; Chacón, M; Cóppola, F; Giglio, R; Lastiri, F; Mickiewicz, E; Montiel, M; Perazzo, F; Pujol, F; Recondo, G; Richardet, E; Rodger, J; Schmilovich, A; Simon, J; Van Kooten, M; Vilanova, M; Wasserman, E; Zori Comba, A, 2001) |
| "Patients with locally advanced operable rectal cancer (uT3/4 or uN+, Mason CS III/IV) were randomly assigned to pre- or postoperative radiochemotherapy: A total dose of 50." | 2.70 | Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94). ( Becker, H; Fietkau, R; Hess, C; Hohenberger, W; Jatzko, G; Karstens, JH; Martus, P; Raab, R; Rödel, C; Sabitzer, H; Sauer, R; Wittekind, C, 2001) |
| "Patients with stage II and III rectal cancer received weekly 2-hour infusions of FA 500 mg/m2 followed by continuous 24-hour infusions of 5-FU 2,600 mg/m2 postoperatively via a Port-A-Cath system." | 2.70 | Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility. ( Bambach, M; Dencausse, Y; Dietzler, P; Edler, L; Hartung, G; Lindemann, H; Qeisser, W; Sturm, J; Wojatschek, C, 2001) |
| " Both before and after the addition of OXA, the 5-FU dose was individually adjusted according to the pharmacokinetic follow-up (target steady-state plasma concentrations 2." | 2.70 | Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ( Boisdron-Celle, M; Brienza, S; Craipeau, C; Cvitkovic, E; Delva, R; Gamelin, E; Guérin-Meyer, V, 2002) |
| "Exclusive CRT approach is not safe to treat patients with low infiltrative rectal carcinoma." | 2.70 | Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? ( David Filho, WJ; de O Ferreira, F; Ferrigno, R; Lopes, A; Nakagawa, WT; Nishimoto, IN; Rossi, BM; Vieira, RA, 2002) |
| " In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L)." | 2.69 | Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ( Alleaume, C; Boisdron-Celle, M; Burtin, P; Cailleux, PE; Danquechin-Dorval, E; Delva, R; Dumesnil, Y; Fety, R; Gamelin, E; Geslin, J; Gesta, P; Goudier, MJ; Larra, F; Lortholary, A; Maigre, M; Maillart, P; Maillet, ML; Person-Joly, MC; Picon, L; Regimbeau, C; Robert, J; Sire, M, 1998) |
| " However, these results cannot eliminate a small benefit when PVI is used at a higher dosage or in combination with mitomycin." | 2.69 | Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv ( Apolone, G; Couvreur, ML; Curran, D; De Waele, B; Doci, R; Labianca, R; Lasser, P; Marsoni, S; Nakajima, T; Nitti, D; Pector, JC; Rauschecker, H; Rougier, P; Sahmoud, T; Wils, J, 1998) |
| " We administered pharmacokinetic modulating chemotherapy, based on the concept that the benefit of a continuous venous 5-fluorouracil (5FU) infusion can be potentiated by low-dose oral UFT, a combination of 1-(2-tetrahydrofuryl)-5-fluorouracil (tegafur) and uracil at a molar ratio of 1:4." | 2.69 | Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. ( Kotera, H; Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H, 1998) |
| "A total of 48 patients suffering from rectum cancer were included in this randomized study conducted at the Proctology Department of the Donetsk Regional Anti-Cancer Center." | 2.69 | Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy). ( Bondar, GV; Borota, AV; Yakovets, YI; Zolotukhin, SE, 1998) |
| "All patients had metastatic colorectal cancer, with adjuvant or palliative chemotherapy given to six patients (22%) on schedule A and 12 patients on schedule B (41%)." | 2.69 | Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion. ( Adam, R; Bismuth, H; Dallemagne, B; Focan, C; Focan-Henrard, D; Jasmin, C; Jehaes, C; Kreutz, F; Levi, F; Lobelle, JP; Markiewicz, S; Misset, JL; Weerts, J, 1999) |
| "Median times to disease progression for the three treatment arms were as follows: 9." | 2.69 | Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000) |
| "Standard adjuvant chemotherapy for colorectal cancer consists of fluorouracil with folinic acid or levamisole." | 2.69 | Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. ( , 2000) |
| " A dose-response relationship was observed between the radiation dose and the tumor downstaging and local control." | 2.69 | Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study. ( Buie, D; Chan, AK; Heine, J; Jenken, D; Johnson, DR; Langevin, J; Wong, AO, 2000) |
| " 5-FU chemotherapy was administered as 120-hours continuous infusion in the first and fifth radiation week via a central venous catheter in a daily dosage of 1,000 mg/m2." | 2.69 | Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. ( Dunst, J; Müller, AC; Pigorsch, S; Reese, T; Semlin, S, 2000) |
| " Patients in arm II began with 5-FU (450 mg/m(2)/day intravenous bolus, days 1-5) plus levamisole (150 mg/day orally, days 1-3); postoperative RT was delivered during week 2 at the same dosage and schedule as in arm I." | 2.69 | Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer. ( Bertoglio, S; Cafiero, F; Gipponi, M; Lionetto, R; Peressini, A, 2000) |
| "In locally advanced rectal cancer tumor-negative margins often cannot be obtained by surgery alone." | 2.69 | [First results of neoadjuvant simultaneious radiochemotherapy in advanced rectal carcinoma]. ( Fietkau, R; Hopt, UT; Kirchner, R; Klautke, G; Küchenmeister, U; Mellert, J; Mücke, R, 2000) |
| "The regimens for colon cancer were, Arm I: mitomycin C [intraoperative portal vein bolus (12 mg/m2) + postoperative, twice weekly and then three times bimonthly for six months intermittent i." | 2.68 | Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan. ( , 1995) |
| "Twenty patients with non-resectable rectal cancer (Mason CS III-IV) have been irradiated from September 1989 through February 1994." | 2.68 | [Preoperative radiochemotherapy in primary non-resectable rectal cancer]. ( Dunst, J; Dworak, O; Keilholz, L; Köckerling, F; Sauer, R; Schwarz, B, 1995) |
| "Thirty-five patients with rectal cancer underwent surgery after this treatment, and 41 patients underwent surgery without pretreatment." | 2.68 | Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia, and 5-fluorouracil suppository. ( Ichikawa, D; Sawai, K; Takahashi, T; Yamaguchi, T; Yoshioka, Y, 1996) |
| "5-FU; and arm III was surgery only." | 2.68 | Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. ( Hamano, K; Kato, T; Kodaira, S; Koyama, Y; Ogawa, N; Sakabe, T; Takahashi, T; Tominaga, T; Yasutomi, M, 1996) |
| " However, the combined therapy is associated with more toxic effects, raising the question of whether the benefits of the treatment justify its quality-of-life costs for the individual patient." | 2.68 | A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. ( Cole, BF; Gelber, RD; Goldhirsch, A; Krook, JE; Schroeder, G; Wieand, HS, 1996) |
| "Distant metastases occurred in two high-risk patients and in eight patients with a locally advanced tumor." | 2.68 | Intraoperative radiation therapy in integrated treatment of rectal cancers. Results of phase II study. ( Bellantone, R; Bossola, M; Cellini, N; Crucitti, F; Doglietto, GB; Ippoliti, M; Merico, M; Nucera, P; Ratto, C; Sofo, L; Trodella, L; Valentini, V, 1996) |
| " Laboratory studies of IFN-beta suggest that this agent may offer theoretical advantages over IFN-alpha in combination with 5-FU." | 2.68 | A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma. ( Bradley, C; Hallam, S; Illingworth, JM; Joffe, JK; Perren, TJ; Primrose, J; Selby, PJ; Ward, U, 1997) |
| "Patients with rectal cancer of stage dukes B and C were randomized into two groups." | 2.68 | [Preoperative intraluminal 5-FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer]. ( Liu, L; Lu, J; Zhao, L, 1996) |
| "Resection of colorectal cancer and portal infusion of adjuvant chemotherapy." | 2.68 | Association between blood transfusion and survival in a randomised multicentre trial of perioperative adjuvant portal chemotherapy in patients with colorectal cancer. The Swiss Group for Clinical Cancer Research (SAKK). ( , 1997) |
| "Some 978 patients with colon cancer and 713 patients with rectal cancer were enrolled in the study, 85 (5." | 2.68 | [Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer]. ( Hojo, K; Ichihashi, H; Kato, T; Kikuchi, K; Kodaira, S; Kunii, Y; Ogawa, M; Takahashi, T; Tamada, R; Tominaga, T; Yasutomi, M, 1997) |
| "In advanced colorectal cancer the addition of folinic acid (FA) has been shown to lead to increased activity, at least in terms of response rate, in comparison with 5-fluorouracil (5FU) alone." | 2.67 | Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer. ( Ambrosini, G; Barni, S; Duro, M; Fiorentini, G; Giaccon, G; Iirillo, A; Labianca, R; Oliani, C; Pancera, G; Piazza, E, 1994) |
| " Treatment was well tolerated; 4/27 patients experienced > or = ECOG grade 3 toxicity at full 5-FU dosage (500 mg/m2 bolus/infusion)." | 2.67 | A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. ( Canney, PA; Cassidy, J; Jodrell, DI; Kaye, SB; Kerr, DJ; Oster, W; Steward, WP; Yosef, H, 1994) |
| "Fifty-seven Dukes C colorectal cancer patients were given 5-fluorouracil-interferon-alpha 2b adjuvant treatment from October 1986 to September 1990." | 2.67 | 5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer. ( Cremone, L; Espinosa, A; Faiella, F; Frasci, G; Leone, F; Monaco, M; Persico, G; Sapio, U, 1994) |
| "Thirty-one patients with fixed rectal cancers (stage > or = cT3) were treated with concomitant preoperative chemotherapy and high-dose radiation in an effort to improve resectability." | 2.67 | Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation. ( Brodovsky, H; Chen, ET; Fishbein, G; Marks, G; Mohiuddin, M, 1994) |
| "To create hyperthermia in rectal cancer, an intraluminal electrode connected to a radiofrequency system was devised." | 2.67 | Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer. ( Horie, H; Itoh, M; Kojima, O; Takahashi, T, 1993) |
| "Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival." | 2.67 | Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study. ( Ackland, SP; Bonaventura, A; Cooper, SG; Denham, JW; Hamilton, CS; Joseph, DJ; Stewart, JF, 1993) |
| "Eleven patients with rectum cancer and four patients with colon cancer were treated according to the following schedule: 9 million units IFN-alpha subcutaneous three times a week; 500 mg/m2 5-FU via an intravenous bolus 1 hour after the initiation of a 2-hour infusion of 500 mg/m2 of FA, once a week." | 2.67 | Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a. ( Bernhard, H; Klein, O; Knuth, A; Meyer zum Büschenfelde, KH, 1992) |
| "Three patients with isolated liver metastases and one patient with local recurrence of rectal carcinoma received regional therapy with higher 5-FU doses." | 2.67 | Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer. ( Preiss, J, 1992) |
| " The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional infusions of 5-FU." | 2.67 | A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ( Anderson, JH; Cooke, TG; Kerr, DJ; McArdle, CS; Setanoians, A, 1992) |
| "Hypotension was observed in three of five patients at the highest dose level (0." | 2.67 | A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer. ( Botet, J; Crown, J; Gasparetto, C; Gordon, M; Jakubowski, A; Kemeny, N; Meisenberg, B; Sheridan, C; Toner, G; Wong, G, 1991) |
| "The value of adjuvant chemotherapy in rectal cancer is controversial with opinions varying from 'not be used' since randomized trials have not shown significant gains to 'be used as in colon cancer' as the need is the same and colon and rectal cancers are quite similar." | 2.66 | Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives. ( Glimelius, B, 2020) |
| "Eighty-two patients with colo-rectal cancers (29 colon and 53 rectum) were admitted and underwent radical resection from January 1982 to June 1984." | 2.66 | [Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial]. ( Wan, DS, 1988) |
| "Doxifluridine is an active agent in colorectal cancer." | 2.66 | A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. ( Alberto, P; Cavalli, F; Germano, G; Joss, R; Kaplan, S; Martz, G; Mermillod, B; Spati, B; Weber, W, 1988) |
| " No serious adverse effects were observed in any of the groups." | 2.66 | [Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan]. ( Abe, O; Hattori, T; Inokuchi, K; Kasai, Y; Kikuchi, K; Komi, N; Kondo, T; Kunii, Y; Ogawa, N; Taguchi, T, 1987) |
| "Fifty-five patients with advanced colorectal cancer were entered into a randomized controlled clinical trial to evaluate order of administration and sequential methotrexate (MTX) and 5-fluorouracil (5-FU) therapy." | 2.66 | Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil. ( Coates, A; Mackintosh, J; Raghavan, D; Swanson, C; Tattersall, MH, 1987) |
| "Following curative surgery for colorectal cancer 141 patients were randomized to receive a 6 month course of 5-fluorouracil (5FU) with or without postoperative levamisole or supportive treatment only." | 2.66 | Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. ( Bell, PR; Shaw, D; Windle, R, 1987) |
| "In rectosigmoid cancer the group on 5-FU included 26 patients who showed a response rate of 19% (5/26)." | 2.66 | Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. ( Kolarić, K; Potrebica, V; Stanovnik, M, 1986) |
| " This prospective study was undertaken to record possible adverse effects of surgery, external beam radiation therapy, and 5-fluorouracil (5-FU) chemotherapy in the treatment of large bowel cancer." | 2.66 | 5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route. ( Barofsky, I; Gianola, FJ; Hancock, SL; Sugarbaker, PH; Wesley, R, 1986) |
| " Alpha-2 interferon, alone or in combination with 5-FU, is ineffective in advanced colorectal cancer." | 2.66 | Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. ( Blomgren, H; Cedermark, B; Clark, PI; Fallenius, A; Kurschel, E; Lundell, G; Niederle, N; Ohman, U; Reznek, RH; Slevin, ML, 1987) |
| " The mean 5-FU half-life following the high dose was nearly twice as long as that observed for the low dose (12." | 2.66 | Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients. ( Dobbs, BR; Edwards, IR; Perrier, DG; Schaaf, LJ, 1987) |
| "Clinical studies were prospectively conducted to quantitate the toxic side-effects of 5-FU administered by either the intravenous (i." | 2.66 | Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. ( Barofsky, I; Gianola, FJ; Meyers, CE; Sugarbaker, PH; White, DE, 1986) |
| "Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA." | 2.65 | Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984) |
| "Three hundred and eleven cases of rectal cancer received treatment according to the protocol of a cooperative randomized study." | 2.65 | [Effectiveness of combined and complex treatment of patients with operable cancer of the rectum]. ( Aliev, BM; Barsukov, IuA; Bondar', GV; Dvoĭrin, VV; Knysh, VI, 1984) |
| "Oral tegafur and I." | 2.65 | A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983) |
| "With rectal cancer, 5-year survival was 57." | 2.65 | [Evaluation of preoperative administration of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) suppository in surgical adjuvant chemotherapy for large bowel cancer]. ( Fujita, H; Kosaka, T; Miyazaki, I; Takashima, S; Ueno, K, 1984) |
| "The razoxane-treated patients experienced no significant toxicity apart from a readily reversible mild leukopenia in 52% while gastrointestinal symptoms necessitated stopping the drug in only four patients." | 2.65 | A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer. ( Cassell, PC; Ellis, H; Evans, MG; Gilbert, JM; Hellmann, K; Stoodley, BJ; Wastell, C, 1981) |
| "Every third patient with colon cancer Dukes' C and every fourth patient with rectal cancer Dukes' C survives 5 years." | 2.65 | [Background and experience of adjuvant cytostatic therapy in gastrointestinal cancer (author's transl)]. ( Bengmark, S; Eriksson, S; Hafström, L; Hugander, A, 1981) |
| "Fifty-three patients with colorectal cancer Dukes' B2 and C were randomized after surgery." | 2.65 | Adjuvant therapy in colorectal cancer. (A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with the methanol extraction residue of BCG, MER). ( Bartal, A; Cohen, Y; Mekori, T; Milstein, D; Robinson, E, 1979) |
| "A clinical trial involving 462 colon, rectum, and breast cancer patients randomized among four different dosage regimens of 5-FU (an intravenous loading course, a weekly intravenous schedule, a nontoxic schedule, and an oral schedule) has shown a significantly better response among colon-rectum cancer patients for the intravenous loading course." | 2.64 | A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report. ( Ansfield, F; Cornell, G; Davis, H; Hill, G; Klotz, J; Minton, J; Nealon, T; Ramirez, G; Wilson, W, 1977) |
| "Fifty consecutive patients with colorectal cancer but no evidence of secondary deposits in the liver were included in an ongoing controlled clinical trial of adjuvant liver perfusion aimed at reducing the incidence of hepatic metastases." | 2.64 | Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial. ( Brooman, P; Rowling, JT; Taylor, I, 1977) |
| "Twenty patients with advanced colon cancer were treated with a combination of low-dose weekly cyclophosphamide, vincristine, and methotrexate (COM) after demonstrated progression of disease with 5-fluorouracil (5-FU)." | 2.64 | Phase II trial of a combination of cyclosphamide, vincristine, and methotrexate in advanced colorectal carcinoma. ( Desai, SA; DeWys, WD; Taylor, SG, 1978) |
| "Forty-six adult patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds." | 2.64 | Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil. ( Bedikian, AY; Bodey, GP; Burgess, MA; Livingston, R; Staab, R; Valdivieso, M, 1978) |
| "Fifty-two untreated patients with colorectal cancer were randomized to receive 5-fluorouracil (5-FU) alternating either with methotrexate (MTX) or Baker's Antifol (BAF) with or without the immunostimulant, levamisole (Program I)." | 2.64 | Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole. ( Bedikian, AY; Bodey, GP; Burgess, MA; Mavligit, GM; Rodriguez, V; Valdivieso, M, 1978) |
| "route." | 2.64 | A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. ( Bruckner, HW; Hahn, RG; Moertel, CG; Schutt, AJ, 1975) |
| "Omission of radiotherapy in rectal cancer is analyzed in the context of historical findings, as well as more recent data describing risk stratification of stage II-III disease, surgical optimization, imaging limitations, improvement in systemic chemotherapeutic agents, and contemporary studies evaluating selective omission of radiotherapy." | 2.58 | The Selective Use of Radiation Therapy in Rectal Cancer Patients. ( Czito, B; Martella, A; Palta, M; Willett, C, 2018) |
| "Multimodality management of rectal cancer continues to evolve; total mesorectal excision is the cornerstone." | 2.55 | Randomized Clinical Trials in Colon and Rectal Cancer. ( George, TJ; Iqbal, A, 2017) |
| "Rectal squamous cell carcinoma is a rare tumour; it management should be based on anal curative and conservative intent chemoradiation." | 2.53 | [Rectal squamous cell carcinoma treatment: Retrospective experience in two French university hospitals, review and proposals]. ( Bosset, JF; Huguet, F; Loganadane, G; Schernberg, A; Servagi-Vernat, S; Touboul, E, 2016) |
| "Solitary adrenal metastasis of rectal cancer is comparatively rare condition and it is difficult to be diagnosed because it doesn't have any characteristic symptoms." | 2.52 | [A CASE OF SOLITARY ADRENAL TUMOR METASTASIZED FROM RECTAL CANCER]. ( Fukuda, H; Iida, S; Iizuka, J; Ikeda, T; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Toda, N, 2015) |
| "Capecitabine has been widely recognized in the nCRT for patients with LARC, and has the tendency to replace 5-FU." | 2.50 | [Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer]. ( Gao, Y; Liu, M; Xiao, L, 2014) |
| "A 48-year-old man with colorectal cancer and right inguinal lymph node metastasis had previously undergone radiotherapy and chemotherapy (uracil/tegafur/leucovorin) after a colostomy in another hospital before being referred to us." | 2.50 | [Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review]. ( Aihara, T; Fukuda, S; Iino, C; Mikami, T; Sakamoto, J; Sawaya, M; Tanaka, M; Tono, H; Yamagata, R; Yoshida, K, 2014) |
| "Primary squamous cell carcinoma of the rectum is a rare malignancy." | 2.49 | Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum. ( Jeong, BG; Kim, DY; Kim, SY, 2013) |
| " We started combination chemotherapy with 5-fluorouracil, Leucovorin and oxaliplatin(modified FOLFOX6)at a 20% lower than standard dosage for safety." | 2.49 | [A case of metastatic colorectal cancer with icterus due to multiple liver metastases treated effectively by FOLFOX plus bevacizumab]. ( Fukuda, K; Koja, S; Terasawa, T; Yasuda, K, 2013) |
| "The treatment of rectal cancer has evolved significantly in recent decades." | 2.49 | [Radiotherapy-associated morbidity and mortality in rectal surgery]. ( Büchler, MW; Kulu, Y; Ulrich, A, 2013) |
| "Oxaliplatin (OX), in combination with fluoropyrimidine (5-fluorouracil or Capecitabine, FU)-based regimens and radiation, has been expected to both enhance primary tumour shrinkage and reduce micrometastases at distant sites in the neoadjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC)." | 2.49 | Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. ( An, X; Cai, PQ; Ding, PR; Fang, YJ; Gao, YH; Goodman, K; Kong, LH; Lin, JZ; Lin, X; Pan, ZZ; Wan, DS; Wang, FH, 2013) |
| "Overall, 16,215 patients with colorectal cancer were enrolled, 9,785 being affected with rectal carcinoma." | 2.48 | Postoperative adjuvant chemotherapy in rectal cancer operated for cure. ( Harling, H; Kirkeby, LT; Mocellin, S; Petersen, SH; Wille-Jørgensen, P, 2012) |
| "Capecitabine is a rationally designed oral prodrug that is converted into 5-FU by intracellular thymidine phosphorylase." | 2.48 | The role of capecitabine in locally advanced rectal cancer treatment: an update. ( Cejas, P; Feliu, J; Fernández-Martos, C; Machancoses, AH; Moreno-García, V; Nogué, M, 2012) |
| "Here, we report a case with recurrence of rectal cancer who received FOLFIRI with bevacizumab chemotherapy under haemodialysis, and obtained good tumor control." | 2.48 | [FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure]. ( Endo, T; Hasegawa, H; Hoshino, G; Hoshino, H; Hoshino, Y; Ishii, Y; Kitagawa, Y; Matsunaga, A; Ochiai, H; Seo, Y; Shigeta, K, 2012) |
| " Given the oral bioavailability of capecitabine as well as in-vitro and in-vivo findings showing higher expression of thymidine phosphorylase in tumor cells and xenografts compared with normal tissue, capecitabine is an evolving candidate in the management of colorectal cancer with antimetabolite-based therapy." | 2.47 | Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer. ( Patel, PA, 2011) |
| "He was diagnosed with interstitial pneumonitis." | 2.47 | [A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)]. ( Fukushima, M; Hamada, A; Ishizaka, T; Mukai, J; Nakagawa, M; Sawada, R; Takahashi, N; Yoshihara, Y, 2011) |
| "The management of rectal cancer has undergone significant evolution with advances in surgery, radiation therapy, and chemotherapy." | 2.47 | Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. ( Czito, BG; Willett, CG, 2011) |
| "5-Fluorouracil (5-FU) is a commonly used anti-neoplastic agent." | 2.47 | Symptomatic 5-fluorouracil-induced sinus bradycardia. ( Lee, AD; McKay, MJ, 2011) |
| "Keywords for the search were: "rectal cancer", "preoperative radiotherapy", "phase II-III", "preoperative chemotherapy", "adjuvant chemotherapy" and "surgery"." | 2.47 | [Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies]. ( Bosset, JF; Créhange, G; Maingon, P, 2011) |
| " The question to be addressed is how and when to apply intensified systemic therapy with adequate dosage and intensity as well as acceptable treatment-associated toxicity." | 2.47 | [Rectal cancer: current status of multimodal therapy--when and how?]. ( Becker, H; Gaedcke, J; Ghadimi, BM; Hess, C; Liersch, T; Rödel, C, 2011) |
| "A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen." | 2.46 | Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010) |
| "In colorectal cancer, increased response rates are achieved by cetuximab and panitumumab within standard chemotherapy schedules, but not in chemoradiation regimens." | 2.46 | Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? ( Glynne-Jones, R; Harrison, M; Mawdsley, S, 2010) |
| "Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug." | 2.45 | The role of capecitabine in the management of tumors of the digestive system. ( Gennatas, C; Gennatas, S; Michalaki, V, 2009) |
| "The successful management of rectal cancer requires a multidisciplinary approach, with treatment decisions based on precise patient evaluations by a group of clinicians, including surgeons, gastroenterologists, medical and radiation oncologists, radiologists, and pathologists." | 2.45 | The multidisciplinary management of rectal cancer. ( Hoffe, SE; Meredith, KL; Shibata, D, 2009) |
| "The basic principle in the treatment of rectal cancer is the complete surgical removal of the tumor together with the lymphatic drainage region, i." | 2.45 | Limitation of surgical radicality in rectal cancer responding to neoadjuvant therapy. ( Hempen, HG; Raab, HR; Troja, A, 2009) |
| "Standard therapy for locally advanced rectal cancer (LARC) is concurrent neo-adjuvant chemo-radiation using infusional 5-fluorouracil (CIV-5-FU)." | 2.44 | Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. ( Almhanna, K; Hashmi, S; Kim, R; Saif, MW; Zelterman, D, 2008) |
| "Treatment of rectal cancer over the last two decades has evolved with changes in techniques of surgery and radiation based on national and international trials." | 2.44 | Total mesorectal excision and management of rectal cancer. ( Phang, PT; Pinsk, I, 2007) |
| "The management of rectal cancer has undergone significant evolution with advances in surgery, radiation therapy, and chemotherapy." | 2.44 | Combined-modality therapy for rectal cancer: future prospects. ( Bendell, JC; Czito, BG; Willett, CG, 2007) |
| "Capecitabine is an oral fluoropyrimidine that generates 5-FU preferentially within the tumor." | 2.44 | Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer. ( Ben-Josef, E, 2007) |
| "Patients diagnosed with rectal cancer should undergo locoregional staging with transrectal endoscopic ultrasound (EUS) or surface coil array MRI of the pelvis if that technique is available." | 2.44 | Current options for the management of rectal cancer. ( O'Neil, BH; Tepper, JE, 2007) |
| "Capecitabine is an oral prodrug of 5-FU that has potential advantages compared with intravenous 5-FU, including ease of administration and potentially increased therapeutic effect." | 2.44 | The use of capecitabine in the combined-modality therapy for rectal cancer. ( Liauw, SL; Minsky, BD, 2008) |
| "Adjuvant chemotherapy for colon cancer and combined chemotherapy and radiation therapy (RT) for rectal cancer increases the proportion of patients cured of their disease." | 2.43 | An overview of approaches to adjuvant therapy for colorectal cancer in the United States. ( Hobday, TJ, 2005) |
| "We relate 2 cases reports about rectal cancer and pregnancy." | 2.43 | [Management of rectal cancer in pregnant women]. ( Benouna, J; Classe, JM; Dravet, F; Dupré, PF; Mahé, MA; Pigeau, H; Pioud, R, 2005) |
| "Formerly the treatment of gastrointestinal cancers was exclusively surgical." | 2.43 | [Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept]. ( Cseke, L; Esik, O; Horváth Ors, P; Kalmár, K; Papp, A; Yousuf, AF, 2006) |
| "The rare finding of heterotopic ossification in a case of primary rectal adenocarcinoma is described along with a review of the literature." | 2.42 | Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism. ( Gottfried, MR; Jones, R; Kypson, AP; Morphew, E; Seigler, HF, 2003) |
| "The standard in rectal cancer has been to add adjuvant radiation therapy to surgery in patients with stage II and III disease." | 2.42 | Adjuvant radiation therapy of patients with rectal cancer. ( Bechtel, J; Tepper, J, 2003) |
| "Adjuvant therapy of rectal cancer follow the progress obtained in colon cancer using adjuvant fluorouracil based chemotherapy and is also based on radiotherapy." | 2.42 | [Adjuvant therapy of rectal cancer]. ( Bouaouina, N; Boussen, H, 2003) |
| "Adjuvant therapy of colorectal cancer with oral fluorinated pyrimidines is attractive because of its ease of administration and good tolerability." | 2.42 | Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. ( Burzykowski, T; Buyse, M; Hamada, C; Ohashi, Y; Piedbois, P; Sakamoto, J, 2004) |
| "Adjuvant therapy for colorectal cancer has been one of the most important contributions of medical oncology to the health of the population, saving more lives annually than more effective therapy for less common cancers, such as Hodgkin's disease." | 2.42 | Adjuvant therapy for rectal cancer in the elderly. ( Cohen, SM; Neugut, AI, 2004) |
| "Adjuvant radiation therapy for rectal cancer is not widely used in Japan, while chemotherapy is considered the adjuvant treatment of choice." | 2.41 | [Progress in adjuvant therapy for colorectal cancer]. ( Kakeji, Y; Kohnoe, S; Maehara, Y, 2002) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and rationally designed to undergo tumor-selective activation." | 2.41 | [Capecitabine--a review of its antitumor activity and toxicity in clinical studies]. ( Maeda, Y; Sasaki, T, 2000) |
| "Advanced colorectal cancer has traditionally been treated with 5-fluorouracil, alone or in combination with leucovorin." | 2.41 | [New drugs in the treatment of advanced colorectal cancer]. ( Harboe, K; Lind, A; Ogreid, D; Todnem, K; Zotova, L, 2000) |
| "Capecitabine has the potential to replace bolus or continuous infusion 5-FU as the standard treatment for rectal cancer and offers a potentially enhanced therapeutic ratio." | 2.41 | Improving chemoradiotherapy in rectal cancer. ( Debus, J; Glynne-Jones, R, 2001) |
| "In patients with Dukes' B or C rectal cancer, combined radiation and FU increase survival and decrease local and distal recurrence." | 2.40 | Adjuvant therapy of colorectal cancer. ( Cohen, A; Kemeny, N; Saltz, L, 1997) |
| "In patients with resectable rectal cancer, randomized trials reveal an improvement in local control and survival with postoperative combined modality therapy." | 2.40 | The role of radiation therapy in rectal cancer. ( Minsky, BD, 1997) |
| "The management of distal rectal cancer is in evolution." | 2.40 | Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy. ( Willett, CG, 1998) |
| " Raltitrexed, a thymidylate synthase inhibitor, offers similar antitumoral activity together with a tolerability in comparison to standard 5-fluorouracil based chemotherapy and its simple dosage schedule also contributes to better quality of life." | 2.40 | [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "The majority of these cases were anal cancers with proximal extension into the rectum and were excluded." | 2.40 | Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature. ( Francis, B; Juturi, JV; Koontz, PW; Wilkes, JD, 1999) |
| "Despite of improvement of results in rectum cancer treatment after systematical introduction of total mesorectal excision as a standard procedure to control the compartment disease, surgical radicality may be limited in cases with large tumours in ventral position because of eccentric location of the rectum in the perirectal fat." | 2.40 | [Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?]. ( Fasolini, F, 1999) |
| "Sixty-six patients with colorectal cancer were studied regarding effects of prevention of hepatic recurrence in completely performed portal infusion chemotherapy." | 2.40 | [Is portal infusion chemotherapy uneffective for hepatic recurrence after resection for colorectal cancer?]. ( Akaishi, O; Tsukikawa, S; Yabe, K; Yamaguchi, S; Yamamura, T, 1999) |
| "We report herein a case of rectal carcinoid with multiple liver metastasis successfully treated with hepatic arterial infusion of methotrexate (MTX) and 5-fluorouracil (5-FU)." | 2.40 | [A case of liver metastases of rectal carcinoid successfully treated with hepatic arterial infusion of methotrexate and 5-fluorouracil]. ( Idezuki, Y; Ishida, H; Nakada, H; Suzuki, T; Tada, M; Takeuchi, I, 1999) |
| "Despite simple screening procedures rectal cancer is often advanced when discovered." | 2.40 | Combined modality therapy of rectal cancers. ( Juretic, A; Samija, M; Sobat, H, 1999) |
| "In the treatment of stages 2 and 3 rectal cancer, significant reductions in local recurrence and death rates have been achieved with the combination of 5-fluorouracil and radiation therapy." | 2.39 | Role of adjuvant therapy in surgically resected colorectal carcinoma. ( Sinicrope, FA; Sugarman, SM, 1995) |
| "We present an additional case of rectal squamous cell carcinoma (SCC) complicating chronic ulcerative colitis in a 33-year-old woman who had the disease for 15 years." | 2.39 | Squamous cell carcinoma complicating idiopathic inflammatory bowel disease. ( Butler, B; Doerr, R; Kulaylat, MN; Satchidanand, SK; Singh, A, 1995) |
| " Preoperative radiotherapy with a dosage of 35-45 Gy can lead to downstaging of rectal cancer." | 2.39 | [Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma]. ( Eble, MJ; Kraus, TW; Raeth, U, 1994) |
| "For Dukes' C colon cancer, postoperative adjuvant chemotherapy with a combination of fluorouracil and levamisole is now recommended as standard therapy." | 2.39 | Adjuvant postoperative therapy of gastrointestinal malignancies. ( Ilson, DH; Kelsen, DP, 1994) |
| "Work has been done in gastric cancer, pancreatic cancer, and colon and rectal cancer, all of which demonstrate an advantage in certain clinical situations for combined-modality therapy." | 2.38 | Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies. ( Tepper, JE, 1992) |
| "Some aspects of colorectal cancer remain controversial, particularly screening recommendations and monitoring of carcinoembryonic antigen levels." | 2.38 | Colorectal cancer. Recent developments and continuing controversies. ( Lee, MW, 1992) |
| "Several trials in rectal cancer show an advantage for 5-FU combined with semustine and radiation therapy in terms of disease-free survival, overall survival, or both; the contribution of semustine has been questioned and is currently being investigated." | 2.38 | Current treatment approaches in colorectal cancer. ( Grem, JL, 1991) |
| "Conservative procedures to treat rectal cancer are also gaining support because of reduced morbidity and mortality, avoidance of colostomy, and excellent survival figures in selected patients." | 2.38 | Surgical therapy of early rectal carcinoma. ( Curley, SA; Rich, TA; Roh, MS, 1989) |
| " To date, a lot of phase II studies have been conducted, but there are many distance in each clinical data concerning response rate and side effect by the difference between their clinical methods with respect to the interval between methotrexate and 5-fluorouracil, or the dosage of each drugs." | 2.37 | [Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy]. ( Murakami, M; Ota, K, 1988) |
| "Fluorouracil has been the mainstay of chemotherapy in colorectal cancer for many years." | 2.37 | Biochemical modulation of fluorouracil therapy in advanced colorectal cancer. ( Mackintosh, J; Tattersall, MH, 1987) |
| "Certainly in treatment of the carcinoid tumor surgery has a well-established curative and palliative potential." | 2.36 | Treatment of the carcinoid tumor and the malignant carcinoid syndrome. ( Moertel, CG, 1983) |
| "The clinical diagnosis was squamous cell carcinoma of the lower rectum, cT4b(bladder and seminal vesicle)N0M0, cStage Ⅱc." | 1.91 | [A Case of Squamous Cell Carcinoma of the Lower Rectum]. ( Doki, Y; Eguchi, H; Hata, T; Miyoshi, N; Ogino, T; Osaki, M; Sakai, D; Satoh, T; Sekido, Y; Takahashi, H; Uemura, M, 2023) |
| "To evaluate the association of age with treatment-related adverse events and survival in patients with mCRC and explore the potential underlying factors." | 1.91 | Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer. ( Delgado, MG; Gomez, MF; Hubbard, JM; Ji, R; Kim, RD; Knepper, TC; Laber, DA; Meng, L; Permuth, JB; Thapa, R; Wang, X; Xie, H, 2023) |
| "BRAF V600E mutant-metastatic colorectal cancer (mCRC) is characterized by its short survival time." | 1.91 | Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China. ( Chang, W; Fu, J; Lin, Q; Lv, Y; Tang, W; Wang, G; Xu, J; Xu, Y; Zhang, T; Zheng, X; Zhu, Z, 2023) |
| " We investigated whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemotherapy in first-line (1L) treatment in patients with RAS wild-type mCRC and the dynamics of plasma angiogenesis factors at progression during 1L treatment." | 1.91 | Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study. ( Abe, Y; Asano, C; Bando, H; Denda, T; Esaki, T; Kagawa, Y; Kato, T; Kawakami, H; Matsuhashi, N; Nishina, T; Nomura, S; Satake, H; Shiozawa, M; Sunakawa, Y; Takahashi, N; Takashima, A; Taniguchi, H; Yamazaki, K; Yasui, H; Yoshino, T; Yuki, S, 2023) |
| " Number of cycles, dose delays for any cause, and dose reductions for adverse events (AEs) were comparable between age classes." | 1.91 | Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study. ( Anchisi, S; Bohanes, P; Derigs, HG; Geffriaud-Ricouard, C; Grünberger, B; Gueldner, M; Hofheinz, RD; Piringer, G; Scholten, F; Schwarz, L; Thaler, J; von Moos, R, 2023) |
| "To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC)." | 1.72 | Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study. ( Aprile, G; Avallone, A; Bilancia, D; Brugnatelli, S; Carlomagno, C; Cicero, G; Cinausero, M; Colombo, A; Corsi, D; Dell'Aquila, E; Pinto, C; Rapisardi, S; Reggiardo, G; Rosati, G, 2022) |
| "The time elapsed between rectal cancer diagnosis and NCRT initiation is significantly associated with pCR." | 1.72 | Rapid Initiation of Neoadjuvant Chemoradiotherapy After Diagnosis is Associated With Improved Pathologic Response in Locally Advanced Rectal Cancer. ( Bar-Sela, G; Lutsyk, M; Turgeman, I, 2022) |
| " The efficacy and adverse effects of maintenance treatment were compared between the two groups." | 1.72 | Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer. ( Cha, Y; Huang, W; Tian, Y; Xiong, H; Yuan, X; Zhang, H, 2022) |
| "We diagnosed as having rectal cancer with multiple lung metastases." | 1.72 | [A Case of Rectal Cancer and Multiple Lung Metastases That Had Complete Response Treated by XELOX plus Bevacizumab after Primary Lesion Resection]. ( Aomatsu, K; Hiramatsu, S; On, O; Sugimoto, A, 2022) |
| " The most frequent grade 3/4 adverse events were: asthenia (21." | 1.72 | Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen. ( Alonso de Castro, B; Cameselle García, S; Carmona Campos, M; Cousillas Castiñeiras, A; De la Cámara Gómez, JC; Fernández-Montes, A; Gómez-Randulfe Rodríguez, MI; González Villarroel, P; Martínez-Lago, N; Méndez Méndez, JC; Romero Reinoso, C; Salgado Fernández, M; Vidal Insua, Y, 2022) |
| "Colorectal cancer is one of the most commonly diagnosed malignancies globally and nearly half of these patients develop metastatic colorectal cancer (mCRC)." | 1.72 | Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy. ( Liu, JY; Liu, X; Long, YX; Qiu, M; Zhou, YW, 2022) |
| "Obstructive colorectal cancer is locally advanced colorectal cancer with a poor prognosis." | 1.72 | A Prospective, Single-arm, Multicenter Trial of Diverting Stoma Followed by Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE Study). ( Endo, I; Ishibe, A; Misumi, T; Nakagawa, K; Ota, M; Suwa, H; Suwa, Y; Watanabe, J, 2022) |
| "Following the diagnosis of RS rectal cancer with muc, pT4a, N3(14/15), M1c, P1, pStage Ⅳc, RAS/BRAF: wild type, treatment was initiated with mFOLFOX6 plus panitumumab(Pmab)." | 1.62 | [A Case of Hyperammonemic Encephalopathy following mFOLFOX6 plus Panitumumab Therapy for Rectal Cancer]. ( Eguchi, S; Fukuoka, T; Iseki, Y; Lee, S; Miki, Y; Muguruma, K; Nagahara, H; Ohira, M; Shibutani, M; Tamura, T; Tanaka, H; Toyokawa, T; Tsujio, G; Yashiro, M; Yoshii, M, 2021) |
| "More capecitabine-treated patients received post-operative oxaliplatin (44." | 1.62 | Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer. ( Christie, M; Croxford, M; Faragher, I; Gibbs, P; Guerrieri, M; Jones, IT; Kosmider, S; Lee, M; Loft, M; Steel, M; Tie, J; Wong, HL; Wong, R, 2021) |
| "We present a case of locally advanced rectal cancer(LARC)treated by robot assisted intersphincteric resection(ISR)and lateral lymph node dissection(LLND)after neoadjuvant chemotherapy(NAC)." | 1.62 | [A Case of Locally Advanced Rectal Cancer Treated by Robot Assisted Intersphincteric Resection after Neoadjuvant Chemotherapy]. ( Hata, T; Imada, A; Kagawa, Y; Katsura, Y; Kawai, K; Kusafuka, H; Masuzawa, T; Murakami, K; Murata, K; Omura, Y; Sakamoto, T; Takeda, Y; Takeno, A, 2021) |
| "The overall mEHT group had a comparable response and survival using less radiation dosing compared with standard care; the subgroup with large tumors showed improved efficacy for tumor regression after mEHT." | 1.62 | Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer. ( Cha, J; Kim, S; Lee, JH; You, SH, 2021) |
| " The incidences of chemotherapy-related adverse reactions, postoperative complications, and clinical pathological reactions were analyzed." | 1.62 | Safety and efficacy of preoperative mFOLFOX6 regimen chemotherapy for locally resectable advanced rectal cancer. ( Jiang, Z; Liu, L, 2021) |
| "Our study revealed that there was no adverse pathologic or oncological outcome with the concurrent use of PPIs along with Cape-NACRT in the treatment of LARC." | 1.62 | Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe? ( Abraham, AG; Ghosh, S; Joseph, K; Mahfouz, M; Menon, A; Mulder, K; Nijjar, T; Paulson, K; Roa, W; Severin, D; Tankel, K; Thachuthara, JJ; Usmani, N; Warkentin, H, 2021) |
| "Progress in rectal cancer therapy has been hindered by the lack of effective disease-specific preclinical models that account for the unique molecular profile and biology of rectal cancer." | 1.56 | Modeling rectal cancer to advance neoadjuvant precision therapy. ( Becker, SA; Camp, ER; Cross, A; Curl, E; Findlay, VJ; Hill, EG; Hoffman, BJ; Janakiraman, H; Lewin, D; Timmers, C; Wang, C; Warren, GW; Zhu, Y, 2020) |
| "Endpoints were pathologic response, resection margin and overall survival (OS), disease free survival (DFS), local recurrence free survival (LRFS), and metastasis free survival (MFS)." | 1.56 | Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer. ( Bloemen, JG; Burger, JWA; Creemers, GJM; Kusters, M; Nederend, J; Nieuwenhuijzen, GAP; Peulen, HMU; Roef, MJ; Rutten, HJT; van Lijnschoten, G; van Zoggel, DMGI; Voogt, ELK, 2020) |
| "Metformin is an attractive alternative radiosensitizing agent to be considered in future studies/trials." | 1.56 | Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer. ( Asprino, PF; Camargo, AA; Costa, ÉT; Fernandes, JM; Jandrey, EHF; Koyama, FC; Leite, KRM; Perez, RO, 2020) |
| "A 68-year-old female with rectal cancer underwent low anterior resection with regional lymph node dissection." | 1.56 | [Long-Term Survival of a Patient with Advanced Recurrent Rectal Cancer Treated with a Multidisciplinary Therapy including Five Operations-A Case Report]. ( Adikrisna, R; Gokita, K; Nara, A; Onishi, I; Sueyoshi, K; Udagawa, M; Watanabe, Y, 2020) |
| "A 65-year-old male was diagnosed with rectal cancer invading the urinary bladder, swollen para-aorticlymph nodes, and multiple liver metastases in abdominal CT." | 1.56 | [Bladder-Sparing Surgery with Preoperative Chemotherapy for Rectal Cancer with Urinary Bladder Involvement-A Case Report]. ( Ishida, T; Kajiwara, T; Kamei, T; Karasawa, H; Kohyama, A; Kokubo, S; Naitoh, T; Ohnuma, S; Suzuki, H; Unno, M; Watanabe, K, 2020) |
| "Pathological diagnosis was carcinoid, se, ly2, v0, n1." | 1.56 | [A Case of Malignant Lymphoma Undergoing HAI Treatment for Multiple Liver Metastases of Carcinoid That Appeared about Nine Years after Resection of Rectal Carcinoid with Liver Metastases]. ( Gofuku, J; Hasuike, Y; Higuchi, I; Ishikawa, A; Miyamoto, M; Mori, Y; Tokunaga, M; Tsuchida, Y; Urano, N, 2020) |
| "Treatment options for locally advanced rectal cancer have continued to consist largely of chemotherapy, chemoradiation, and/or surgical resection." | 1.56 | Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series. ( Cho, M; Damle, N; Dayyani, F; Demisse, R; Eng, C; Fakih, M; Gholami, S; Gong, J; Halabi, W; Ji, J; Kim, E; Liu, J; Louie, R; McKenny, M; Monjazeb, A; Oesterich, L; Tam, K, 2020) |
| "The patient had locally advanced rectal cancer with widespread contact with the sacrum, and preoperative radiochemotherapy (S-1 100 mg/day plus radiotherapy 50 Gy/25 Fr)was performed." | 1.56 | [A Case of Advanced Rectal Cancer Successfully Treated with Preoperative Radiochemotherapy]. ( Ichikawa, J; Koreeda, N; Nishiki, M; Noritomi, T; Okamoto, T; Ryu, S; Sannomiya, H; Sato, K; Shin, Y; Yamana, I; Yanagisawa, J; Yoshida, Y, 2020) |
| "Sixty-two patients with metastatic colorectal cancer received aflibercept (4 mg/kg) plus FOLFIRI every 2 weeks." | 1.51 | Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer. ( Chiron, M; Denda, T; Esaki, T; Fujii, H; Hamaguchi, T; Itabashi, M; Kajiwara, T; Komatsu, Y; Kudo, T; Moriwaki, T; Nagashima, F; Nakajima, TE; Oki, E; Otsu, S; Sasaki, T; Sato, T; Sugimoto, N; Takahashi, S; Ura, T; Yamazaki, K; Yoshino, T, 2019) |
| "In 31 cases of rectal cancer, H19 and UCA1 expression levels in biopsy and resected tissue were comparable." | 1.51 | In vitro and in vivo studies on the association of long non‑coding RNAs H19 and urothelial cancer associated 1 with the susceptibility to 5‑fluorouracil in rectal cancer. ( Ishino, K; Koizumi, M; Kudo, M; Naito, Z; Sakatani, T; Wada, R; Yamada, T; Yokoyama, Y; Yoshida, H, 2019) |
| "Vulvar metastasis of colorectal cancer (CRC) and acquired resistance to cetuximab is a very rare phenomenon." | 1.51 | Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report. ( Ni, X; Qiang, W; Wu, Q; Zhang, C; Zhao, J, 2019) |
| "We report 2 cases of advanced colorectal cancer achieving complete response by FOLFOXIRI plus bevacizumab." | 1.51 | [Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report]. ( Aizawa, M; Endo, S; Isohata, N; Nemoto, D; Nemoto, T; Oshibe, I; Saito, T; Soeta, N; Takayanagi, D; Togashi, K; Utano, K, 2019) |
| "We report a case oflocally advanced rectal cancer with maintained long-term cCR after chemotherapy alone." | 1.51 | [A Case of Long-Term Clinical Complete Response after Chemotherapy for Locally Advanced Rectal Cancer]. ( Abe, T; Hayashi, K; Itoh, S; Kikuchi, I; Kimura, T; Kurihara, Y; Ota, S; Sato, T; Shimbo, T; Wakabayashi, T, 2019) |
| "A total of 118 rectal cancer patients receiving preoperative CRT were enrolled." | 1.51 | Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy. ( Araki, T; Fujikawa, H; Hiro, J; Ide, S; Kusunoki, M; Ohi, M; Okugawa, Y; Saigusa, S; Toiyama, Y; Yamamoto, A; Yasuda, H; Yoshiyama, S, 2019) |
| "The rates of locoregional recurrence (2." | 1.51 | Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study. ( Chung, MJ; Jang, HS; Jeong, JU; Jeong, S; Kim, SH; Lee, JH; Nam, TK; Song, JH; Yu, M, 2019) |
| "Preoperative radio(chemo)therapy in rectal cancer may irreversibly damage pelvic bone marrow (PBM) and impair the tolerance of subsequent chemotherapy." | 1.51 | Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancer. ( Michalski, W; Spalek, M; Wyrwicz, L, 2019) |
| "A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver." | 1.51 | Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019) |
| "Pathologists assess rectal cancers that have responded significantly to neoadjuvant therapy more thoroughly." | 1.51 | Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. ( Avila, K; Chow, OS; Chu, P; Garcia-Aguilar, J; Keskin, M; Patil, S; Shia, J; Smith, DD; Smith, JJ; Widmar, M, 2019) |
| "Examinations revealed advanced rectal cancer involving the anal canal with invasion of the left-sided levator ani muscle." | 1.51 | [Curative Transanal Resection after Neoadjuvant Chemotherapy for Lower Rectal Cancer-A Case Report]. ( Aizawa, M; Endo, K; Endo, S; Isohata, N; Nemoto, D; Nemoto, T; Oshibe, I; Saito, T; Soeta, N; Takayanagi, D; Togashi, K; Utano, K, 2019) |
| "We reported 2 cases of colorectal cancer receiving neoadjuvant chemotherapy(NAC)with the aim of curative resection or anal preservation." | 1.51 | [Two Cases of Locally Advanced Rectal Cancer and Lower Rectal Cancer Resected Successfully That Enabled Anus Preservation after Preoperative Chemotherapy]. ( Chiku, T; Hashiba, T; Sano, W; Shinoda, K; Togawa, Y; Yamashita, K, 2019) |
| "Distant metastasis still remained a major concern in pCR patients following nCRT and TME." | 1.51 | Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019) |
| "We report a case of locally advanced rectal cancer presenting with perforation that was successfully resected after preoperative chemotherapy." | 1.51 | [Locally Advanced Rectal Cancer Presenting with Perforation That Was Successfully Resected after Preoperative Chemotherapy with mFOLFOX6 plus Panitumumab]. ( Hotei, H; Kuwada, A; Maeda, Y; Murao, N; Sakabe, R; Sakoda, T; Tahara, K; Yoshimura, K, 2019) |
| "Patients with rectal cancer who achieve complete clinical response after neoadjuvant chemoradiation have been managed by organ-preserving strategies and acceptable long-term outcomes." | 1.51 | Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think! ( Andrade, A; Araújo, SEA; Fernandez, LM; Gama-Rodrigues, J; Habr-Gama, A; Perez, RO; São Julião, GP; Vailati, BB, 2019) |
| "Recurrence and chemoresistance in colorectal cancer remain important issues for patients treated with conventional therapeutics." | 1.51 | Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer. ( Jang, H; Kim, A; Kim, H; Kim, MJ; Kim, YH; Lee, SB; Lee, SJ; Myung, JK; Park, EH; Park, JH; Park, S; Shim, S, 2019) |
| "Capecitabine (Xeloda) is an oral 5-FU prodrug of comparable pharmacodynamic activity, currently preferred in place of 5-FU infusion, its established counterpart in neoadjuvant CRT for rectal cancer." | 1.48 | Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment. ( Evans, T; Jootun, N; Mak, J; Makin, G; Platell, C, 2018) |
| "For advanced rectal cancer with involved or threatened mesorectal fascia (MRF), current standard is pre-operative long course chemoradiotherapy (PLCRT) with either capecitabine or 5-fluorouracil (5-FU)." | 1.48 | Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients. ( Chiang, CL; Lee, FAS; Lee, SF; Poon, CM; Tung, SY; Wong, FCS; Wong, YW, 2018) |
| " Dosing and completion of prescribed chemotherapy were assessed on the subset of patients who received all therapy at MSK." | 1.48 | Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. ( Cercek, A; Crane, CH; Garcia-Aguilar, J; Gollub, MJ; Gonen, M; Guillem, JG; Nash, GM; Paty, PB; Reidy, DL; Roxburgh, CSD; Saltz, LB; Segal, NH; Seier, K; Shia, J; Smith, JJ; Stadler, ZK; Strombom, P; Temple, LKF; Vakiani, E; Varghese, A; Weiser, MR; Wu, AJ; Yaeger, R, 2018) |
| "The NCCN Guidelines for Rectal Cancer are now more closely aligned with those for colon cancer." | 1.48 | Management of Locoregional Rectal Cancer. ( Willett, CG, 2018) |
| "Data on patients with cT3/4 and N+ rectal cancer who were treated in our institution from April 2010 to February 2016 were reviewed retrospectively." | 1.48 | Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study. ( Noie, T; Okuyama, T; Ono, Y; Oya, M; Sameshima, S; Tagaya, N; Takeshita, E; Yamagata, Y; Yoshioka, R, 2018) |
| "A diagnosis of local recurrence of rectal cancer, peritoneal metastasis and metastatic liver cancer was confirmed." | 1.48 | [A Case Describing Treatment with FOLFIRI plus Bevacizumab after a Self-Expandable Metallic Stent Placement for Local Recurrence]. ( Kodama, M; Kondo, S; Miyahara, Y; Yamazaki, K; Yokoyama, M; Yoshida, A, 2018) |
| "A 56-year-old woman was diagnosed with rectal cancer and liver metastases(Stage IV), and underwent low anterior resection and laparoscopic partial hepatectomy." | 1.48 | [Primary Small Bowel Tumor with Simultaneous Lung Metastases from Rectal Cancer - A Case Report]. ( Hayashi, H; Hyodo, M; Inoue, Y; Lefor, AK; Okada, M; Ota, G; Sato, H; Shinohara, S; Tsukahara, M; Yasuda, Y, 2018) |
| "In order to reduce the frequency and the severity of oxaliplatin-related sensory-neuropathy and preserve antitumor efficacy, we performed alternating 4 mFOLFOX6 and 4 FOLFIRI cycles, in combination with bevacizumab, in patients with metastatic colorectal cancer." | 1.48 | [A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab]. ( O'hara, H; Yamamoto, H, 2018) |
| "Patients with locally advanced rectal cancer (LARC) achieving a pathological complete response (pCR) to neoadjuvant treatment usually have a good prognosis, but only accounted for less than 20%." | 1.48 | Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report. ( Jin, M; Lin, Z; Liu, H; Liu, J; Peng, L; Wang, J; Xue, J; Zhang, D; Zhang, T, 2018) |
| "Primary cutaneous mucormycosis is an opportunistic fungal infection caused by the order Mucorales, most frequently by the Rhizopus species." | 1.48 | Rapidly progressing ulcer and a urine drainage bag. ( Fernandez-Guarino, M; Jimenez-Cauhe, J; Molins-Ruiz, M, 2018) |
| "Patients with rectal cancer treated with chemoradiotherapy and radical surgery from 2003 to 2015 (N = 222) were included." | 1.46 | Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Tanaka, T; Watanabe, T, 2017) |
| "We report a case of locally advanced rectal cancer, treated effectively with chemotherapy consisting of mFOLFOX6 combined with radiotherapy." | 1.46 | [A Case of Effective Chemoradiotherapy Using mFOLFOX6 for Locally Advanced Rectal Cancer]. ( Hashimoto, Y; Hirata, Y; Ishizaki, Y; Kitamura, S; Kuga, Y; Miwata, T; Mouri, T, 2017) |
| "Distal resection margin (≤5 vs >5 mm) did not show any significant difference in cumulative incidence of locoregional recurrence (P=." | 1.46 | Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis. ( Bae, JM; Jang, HS; Jeong, S; Kim, SH; Lee, JH; Lee, JW; Nam, TK; Song, JH; Sung, S, 2017) |
| "Locally advanced rectal cancer (LARC) is frequently treated with neoadjuvant chemoradiotherapy (NACRT) to reduce the risk of local recurrence and improve survival." | 1.46 | Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study. ( Cai, S; Chen, Y; Lin, G; Lu, J; Qiu, H; Sun, X; Wu, B; Xiao, T; Xiao, Y; Xu, L; Zhou, W, 2017) |
| "Patients with ypT0-3N0 rectal cancer after preoperative CRT and TME were included using prospectively collected tumor registry cohort between January 2001 and December 2013." | 1.46 | Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. ( Ahn, JB; Beom, SH; Choe, EA; Heo, SJ; Hur, H; Jung, I; Jung, M; Kim, C; Kim, CG; Kim, H; Kim, JH; Kim, NK; Koom, WS; Min, BS; Park, HS; Shin, SJ, 2017) |
| "To investigate the association between polymorphisms of DNA repair genes and xenobiotic with acute adverse effects in locally advanced rectal cancer patients treated with neoadjuvant radiochemotherapy." | 1.46 | Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. ( Agolli, L; Borro, M; Bracci, S; De Sanctis, V; Di Nardo, F; Enrici, RM; Falco, T; Gentile, G; Maglio, M; Minniti, G; Nicosia, L; Osti, MF; Simmaco, M; Valeriani, M, 2017) |
| "Rectal cancer is a malignant disease requiring multidisciplinary management." | 1.46 | Management of rectal cancer: the 2016 French guidelines. ( Bridoux, V; Brouquet, A; de Chaisemartin, C; Kirzin, S; Lakkis, Z; Lefevre, JH; Maggiori, L; Manceau, G; Panis, Y, 2017) |
| "Patients with locally advanced rectal cancer (LARC) receiving neoadjuvant chemoradiation (nCRT) can have a complete pathologic response (pCR), and are given postoperative adjuvant chemotherapy (ACT)." | 1.46 | Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified? ( Church, JM; Gamaleldin, M; Gorgun, E; Kalady, M; Liska, D; Stocchi, L, 2017) |
| "Patients with ypN0 rectal cancer who have received preoperative chemoradiotherapy can be divided into those who initially were node negative and those whose positive nodes have been sterilized by preoperative therapy." | 1.46 | Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer. ( Agostini, J; Benoist, S; Boige, V; Brouquet, A; Dartigues, P; Dumont, F; Goéré, D; Julié, C; Lazure, T; Penna, C; Peschaud, F; Vychnevskaia, K, 2017) |
| "A total of 198 patients with rectal cancer underwent preoperative endoscopic assessments after chemoradiotherapy." | 1.46 | Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer. ( Fukayama, M; Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Watanabe, T, 2017) |
| "In pathological stage N2 rectal cancer patients, administering adjuvant chemotherapy before chemoradiotherapy led to a lower rate of treatment failure, especially with respect to distant metastasis." | 1.46 | Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate. ( Fang, H; Feng, YR; Jin, J; Li, N; Li, YX; Liu, XF; Liu, YP; Ren, H; Song, YW; Tang, Y; Wang, SL; Wang, WH; Wang, X; Yu, ZH, 2017) |
| "The rate of ypCR in advanced rectal cancer was about 10%." | 1.43 | The outcome and the frequency of pathological complete response after neoadjuvant radiotherapy in curative resections for advanced rectal cancer: a population-based study. ( Rekstad, LC; Tranø, G; Wasmuth, HH, 2016) |
| "The patient was diagnosed with thrombotic thrombocytopenic purpura and treated with a plasma exchange." | 1.43 | [A Case of Thrombotic Thrombocytopenic Purpura in a Patient Undergoing FOLFOX6 plus Panitumumab Therapy for Unresectable Recurrent Rectal Cancer with a Rapidly Progressive Course]. ( Hatano, Y; Ishibashi, M; Kato, K; Konda, R; Michishita, Y; Nozawa, T; Oyama, K; Sasaki, A, 2016) |
| "In patients with rectal cancer who have already received neoadjuvant chemoradiotherapy and undergone curative resection, adding oxaliplatin to 5-FU could prolong OS in patients aged < 73 years and ypN+ category." | 1.43 | Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy. ( Chen, XW; Gao, P; Huang, XZ; Ma, B; Song, YX; Sun, JX; Wang, J; Wang, ZN; Zhao, JH, 2016) |
| "Fifty patients with rectal cancer undergoing neoadjuvant (chemo)radiotherapy and surgery were included in the study." | 1.43 | NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival. ( Dvorak, J; Fanta, J; Kubecova, M; Rychterova, V; Voboril, R; Voborilova, J, 2016) |
| "Neoadjuvant RT for rectal cancer has lasting effects on the pelvic BM, which are demonstrable during adjuvant OxF." | 1.43 | Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy. ( Baby, R; Chen, T; Jabbour, SK; Lu, SE; Moss, RA; Newman, NB; Nissenblatt, MJ; Sidhu, MK, 2016) |
| "The effect of individual dose adjustment of 5-fluorouracil (5-FU) based on pharmacokinetic monitoring on the outcome of FOLFOX for metastatic colorectal cancer was analyzed retrospectively." | 1.43 | [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer]. ( Kanda, J; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2016) |
| "The mean recurrence-free survival was 13." | 1.43 | [Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer]. ( Amada, E; Baba, S; Kameyama, N; Mitsuhashi, H; Miyata, R; Tomita, M, 2016) |
| "Here, we present a case of rectal cancer that became curatively resectable after preoperative chemotherapy with mFOLFOX6 plus c-mab." | 1.43 | [A Case of an Unresectable Locally Advanced Rectal Cancer with Surrounding Organ Invasion Successfully Resected after Chemotherapy with mFOLFOX6 plus Cetuximab]. ( Ariake, K; Doi, T; Takagi, H; Takemura, S, 2016) |
| "Distant metastasis occurred in 86." | 1.43 | [Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy]. ( Chi, P; Huang, S; Huang, Y; Lin, H; Lu, X; Sun, Y; Wang, X; Xu, Z; Ye, D, 2016) |
| "The histological diagnosis was tubular adenocarcinoma (tub2-1), int, INF a, pMP, ly0, v0, pDM0, pPM0, R0." | 1.43 | [A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab]. ( Aomatsu, N; Dozaiku, T; Hanno, H; Hirakawa, T; Hirooka, T; Iwauchi, T; Kawamura, M; Morimoto, J; Nakazawa, K; Nishii, T; Takayanagi, S; Takeda, O; Takeuchi, K; Uchima, Y; Yukawa, Y, 2016) |
| "Between 2006 and 2015, patients with rectal cancer, stages I-III, without metastasis, treated with neoadjuvant CRT/CT, who had clinical complete response were included." | 1.43 | Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina. ( Chacon, M; Coraglio, M; Dieguez, A; Huertas, E; Iseas, S; Mariani, J; Mendez, G; O'Connor, JM; Pairola, A; Roca, E; Sanchez Loria, F, 2016) |
| "Radical resected rectal cancer specimens and clinicopathological data of 105 patients, including 60 men and 45 women with median age of 59 years, diagnosed as locally advanced rectal cancer in Peking Union Medical College Hospital from January 2008 to December 2014 were collected retrospectively." | 1.43 | [Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy]. ( Feng, R; Li, D; Luo, Y; Wu, H; Xiao, Y; Zhong, D, 2016) |
| "Data were validated in the rectal cancer cohort treated in the neoadjuvant setting." | 1.43 | Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer. ( Bacon, O; Carberry, S; Concannon, CG; Fay, J; Hector, S; Kay, EW; Lindner, AU; McCawley, N; McNamara, DA; Murphy, ÁC; Prehn, JH; Ryan, D, 2016) |
| "Many patients with rectal cancer undergo preoperative neoadjuvant chemoradiation, with approximately 70% exhibiting pathologic downstaging in response to treatment." | 1.43 | Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer. ( Carter, JV; Eichenberger, MR; Galandiuk, S; Nelson, B; Netz, U, 2016) |
| "Abdominal CT revealed Fournier's gangrene caused by small intestinal perforation." | 1.43 | [A Case of Fournier's Gangrene Caused by Small Intestinal Perforation during Bevacizumab Combination Chemotherapy]. ( Furukawa, J; Ishida, T; Kato, S; Kimata, M; Kobayashi, K; Kobayashi, T; Matsumoto, K; Ogata, Y; Ozawa, H; Sasakura, Y; Shimizu, T; Shinozaki, H; Terauchi, T; Wakabayashi, T, 2016) |
| "Overall and rectal cancer-specific survival were calculated by the Kaplan-Meier method." | 1.43 | DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics. ( Bednarski, B; Borras, E; Chang, GJ; de Rosa, N; Feig, BW; Krishnan, S; Lynch, PM; Messick, CA; Rodriguez-Bigas, MA; Skibber, JM; Veerapong, J; Vilar, E; You, YN, 2016) |
| "To compare the short-term efficacy and treatment-related adverse reaction between preoperative three dimensional conformal radiotherapy (3D-CRT) and volumetric modulated arc therapy (VMAT) concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma (LARC)." | 1.43 | [Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma]. ( Gao, Y; Liu, M; Xiao, L; Xiao, W; Yu, X; Zeng, Z; Zhang, R; Zhu, Y, 2016) |
| "A 68-year-old man was diagnosed with rectal cancer on colonoscopy and liver metastasis of rectal cancer on abdominal computed tomography(CT)." | 1.43 | [A Case of Liver Metastasis from Colorectal Cancer That Showed a Pathological Complete Response to mFOLFOX6 plus Cetuximab]. ( Chihara, T; Endo, S; Ikenaga, M; Konishi, K; Nakagawa, T; Nakashima, S; Nishijima, J; Ohta, K; Yamada, T, 2016) |
| "After local excision of early rectal cancer, revision radical resection is recommended for patients with high-risk pathologic stage T1 (pT1) or pT2 cancer, but the revision procedure has high morbidity rates." | 1.43 | Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer. ( Ahn, SJ; Chung, WK; Jeong, JU; Kim, HR; Kim, YH; Nam, TK; Shim, HJ; Song, JY; Yoon, MS, 2016) |
| "Adjuvant chemotherapy for resected rectal cancer is widely used." | 1.43 | Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database. ( Benckert, C; Benedix, F; Bruns, C; Garlipp, B; Gastinger, I; Lippert, H; Otto, R; Popp, F; Ptok, H; Ridwelski, K, 2016) |
| "For patients with locally advanced rectal cancer (LARC) treated with preoperation chemoradiation (pCRT), identifying differentially expressed (DE) genes between non-responders and responders is a common approach for investigating mechanisms of chemoradiation resistance." | 1.43 | Discriminating cancer-related and cancer-unrelated chemoradiation-response genes for locally advanced rectal cancers. ( Ao, L; Cai, H; Cheng, J; Gao, Q; Guan, Q; Guo, Y; Guo, Z; Jiang, W; Li, X; Yan, H; Zhang, J, 2016) |
| "We report 2 cases of metastatic rectal cancer patients who received chemotherapy with FOLFOXIRI plus bevacizumab(Bev)." | 1.43 | [Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab]. ( Aomatsu, N; Hirakawa, T; Iwauchi, T; Morimoto, J; Nagashima, D; Nakazawa, K; Nishii, T; Takeuchi, K; Tei, S; Uchima, Y; Wang, E; Yamakoshi, Y, 2016) |
| "Local recurrence was diagnosed 5 years and 4 months after the operation." | 1.43 | [A Patient with Colon Cancer Local Site Recurrence Who Experienced Difficulty Tolerating Intensive Chemotherapy Was Treated Effectively with sLV5FU2 Therapy]. ( Fukunaga, M; Honda, S; Kobayashi, K; Konishi, K; Miki, H; Okada, K; Ota, H; Saito, A; Tokuyama, S; Yokoyama, S; Yoshioka, S; Yukimoto, R, 2016) |
| "Of the 19 patients with Stage IV rectal cancer, 15 (79%) had liver surgery with curative intent." | 1.42 | Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation. ( Benoist, S; Bensignor, T; Brouquet, A; Dariane, C; Julié, C; Lazure, T; Nordlinger, B; Penna, C; Thirot-Bidault, A, 2015) |
| "For patients with locally advanced rectal cancer, higher radiation dose may contribute to the improvement of both LC and disease-free survival, without significantly increasing the incidence of acute and long-term complications compared with adjuvant chemoradiotherapy alone." | 1.42 | Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer. ( Fu, S; Huang, G; Li, P; Lu, JJ; Peng, L; Tey, J; Xiong, F; Yang, Z; Zhang, Q, 2015) |
| " It was designed to answer five research questions relating to safety, dosage and administration, and discontinuation from capecitabine-based adjuvant therapy." | 1.42 | Observational study of adjuvant therapy with capecitabine in colon cancer. ( Guggenberger, D; Hansen, R; Jacobs, G; Kröning, H; Schardt, C; Schmidt, P; Steffens, CC; Tschechne, B; Valdix, AR; Wohlfarth, T, 2015) |
| "In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy." | 1.42 | [Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015) |
| "Thirteen patients with colon cancer and 7 patients with rectal cancer were enrolled after curative surgery." | 1.42 | [The present status of CapeOX as adjuvant chemotherapy for colorectal cancer]. ( Ishii, K; Kanamoto, A; Miyanaga, S; Noto, M; Takeda, T; Tani, T; Yagi, M, 2015) |
| "Locally advanced rectal cancer patients who received neoadjuvant chemoradiotherapy following radical resection were retrospectively assessed for tumor response during 2005 to 2014 from the database of colorectal cancer." | 1.42 | [Predictive value of preoperative imaging and postoperative pathology on clinical complete response after neoadjuvant chemoradiation for locally advanced rectal cancer]. ( Du, X; Lin, G; Qiu, H; Wu, B; Xiao, Y; Xu, L; Xue, H; Zhang, G; Zhong, G; Zhou, W, 2015) |
| "The mainstay of treatment in rectal cancer is neoadjuvant radio chemotherapy prior to surgery, in an attempt to downstage the tumour, allowing for more complete removal during surgery." | 1.42 | High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer. ( Bacon, O; Deasy, J; Fay, J; Flanagan, L; Kay, EW; Kehoe, J; Lindner, AU; McNamara, DA; Prehn, JH, 2015) |
| "Primary rectal cancer patients with synchronous distant metastases between September 2001 and August 2011 were enrolled." | 1.42 | Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2015) |
| "In most institutions, locally advanced rectal cancer is treated with neoadjuvant chemoradiotherapy followed by surgery 6-8 weeks later, allowing time for tumor response and recovery from chemoradiotherapy-related toxicities." | 1.42 | The outcome of 5-fluorouracil chemotherapy after the completion of neoadjuvant chemoradiotherapy, administered until 2 weeks before rectal cancer resection. ( Chang, PK; Chiang, MH; Hsiao, CW; Jao, SW; Lee, CC; Lee, TY; Wu, CC, 2015) |
| "Locally advanced rectum cancer patients experience good results with surgery and adjuvant concurrent chemoradiation." | 1.42 | Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand. ( Boonyawan, K; Chansriwong, P; Dangprasert, S; Darunikorn, P; Dhanachai, M; Jiarpinitnun, C; Pattaranutaporn, P; Puataweepong, P; Sitathanee, C; Swangsilpa, T, 2015) |
| "This was a rare case of rectal cancer with submucosal invasion that showed recurrence in the bone and lymph nodes 78 months after the additional resection." | 1.42 | [Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report]. ( Amikura, K; Asayama, M; Fukuda, T; Ishikawa, H; Kawashima, Y; Kazama, S; Kurozumi, M; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y, 2015) |
| "We describe a case of perforated rectal cancer that became curatively resectable after FOLFOX4 chemotherapy." | 1.42 | [Conversion Therapy of Initially Unresectable Rectal Cancer with Perforation via FOLFOX4 Chemotherapy]. ( Fujita, Y; Ishikawa, F; Ito, H; Kamata, S; Nitta, H; Omoto, H; Yamada, C, 2015) |
| "A patient in his 70s was diagnosed with rectal cancer (pT3, pN1, cM0, and pStage IIIa) for which he underwent low anterior resection of the rectum and received adjuvant therapy with UFT/LV." | 1.42 | [A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab]. ( Goya, T; Hanaka, J; Kanamura, S; Nakayama, H; Takahashi, M; Takahashi, S; Wakamatsu, T, 2015) |
| "Adverse events seen with chemotherapy consisted of grade 2 leukopenia in 1 patient, but there were no cases of delayed administration or dosage reduction due to grade 2 neurotoxicity." | 1.42 | Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery. ( Arimitsu, H; Hirano, A; Koda, K; Kosugi, C; Matsuo, K; Shiragami, R; Shuto, K; Suzuki, M; Tanaka, K; Yamazaki, M; Yasuda, H, 2015) |
| "Recurrent rectal cancer appears radioresistant compared with primary tumors for tumor size after CRT." | 1.40 | Chemoradiotherapy response in recurrent rectal cancer. ( Bhangu, A; Brown, G; Tait, DM; Tekkis, P; Wotherspoon, A; Yu, SK, 2014) |
| "The presented patient with stage IV rectal cancer and liver metastases was in a unique situation linked to its inclusion in a reversed treatment and the use of neoadjuvant chemotherapy alone." | 1.40 | Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer. ( Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C, 2014) |
| "Metastasized rectal cancer has long been considered incurable." | 1.40 | A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach. ( Albertsson, M; Holmqvist, A; Jung, M; Sun, XF, 2014) |
| "Patients with cT2-4N0-2M0 distal rectal cancer treated with CRT (50." | 1.40 | Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. ( Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; Sabbagh, C; São Julião, GP, 2014) |
| "Patients with T4 or lymph node-positive rectal cancer were treated with three cycles of XELOX plus bevacizumab and one additional cycle of XELOX." | 1.40 | Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer. ( Doki, Y; Fujie, Y; Fujii, M; Hasegawa, J; Ikeda, M; Kato, T; Kim, HM; Miwa, H; Miyake, Y; Mizushima, T; Mori, M; Nezu, R; Nishimura, J; Noura, S; Sekimoto, M; Takemasa, I; Takemoto, H; Tamagawa, H; Yamamoto, H, 2014) |
| "She had been diagnosed with idiopathic thrombocytopenic purpura (ITP) in her 20s, with a platelet count maintained at approximately 1." | 1.40 | [Concomitant use of romiplostim and chemotherapy for advanced rectal cancer associated with idiopathic thrombocytopenic purpura]. ( Fujinaga, T; Hiramatsu, N; Iijima, H; Nishida, T; Shinzaki, S; Takehara, T; Tatsumi, T; Tsujii, M; Yakushijin, T; Yamada, M; Yamada, T, 2014) |
| "NACRT before major rectal cancer surgery significantly decreased physical fitness as assessed by CPET." | 1.40 | The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients. ( Barben, CP; Grocott, MP; Jack, S; Kemp, GJ; Loughney, L; Sripadam, R; West, MA, 2014) |
| "Radiotherapy for advanced rectal cancer is an important treatment to reduce local recurrence." | 1.40 | Late complications after proctectomy in rectal cancer patients who underwent radiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2014) |
| "Patients with T3/T4 and or N+ rectal cancer (n = 65) were treated with preoperative concomitant boost radiotherapy (55 Gy/25 fractions) associated to concurrent chemotherapy with oral capecitabine." | 1.40 | Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. ( Agolli, L; Bracci, S; De Sanctis, V; Falco, T; Masoni, L; Maurizi Enrici, R; Osti, MF; Valeriani, M, 2014) |
| "Rectal cancer was detected up to 13 cm proximal to the anal verge." | 1.40 | [A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11]. ( Konno, F; Matsumoto, H; Mitsui, K; Namiki, K; Takahashi, T; Yoshida, R, 2014) |
| "Postoperative complications were graded according to the Clavien-Dindo classification." | 1.40 | Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer. ( Berkel, AE; Klaase, JM; van der Palen, J; Woutersen, DP, 2014) |
| "Patients with locally advanced rectal cancer (LARC) have a dismal prognosis." | 1.40 | Post-chemoradiation intraoperative electron-beam radiation therapy boost in resected locally advanced rectal cancer: long-term results focused on topographic pattern of locoregional relapse. ( Alvarez, E; Calvo, FA; Del Valle, E; Deutsch, E; Garcia-Alfonso, P; García-Sabrido, JL; Muñoz-Calero, A; Peligros, I; Rivera, S; Rodriguez, M; Serrano, J; Sole, CV; Turégano, F, 2014) |
| "Aberrant expression of MRP3 in rectal cancer confers chemo-radioresistance." | 1.40 | Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway. ( Cao, G; Fu, C; Gong, H; Wang, H; Xing, J; Yu, E; Yu, Z; Zhang, C; Zhang, W; Zhang, X, 2014) |
| "Locally advanced rectal cancers are currently treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery, but stratification of risk and final outcomes remain suboptimal." | 1.40 | Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. ( Chen, TJ; Hsing, CH; Lee, SW; Lee, YY; Li, CF; Lin, CY; Lin, LC; Sheu, MJ; Wu, TF, 2014) |
| "We examined the outcomes of transanal endoscopic microsurgery excisions with entry into the peritoneal cavity and compared them with those that did not to address our hypothesis that entry is safe with no ill infectious or oncological consequences." | 1.40 | Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe? ( D'Andrea, AP; Frenkel, JL; Greenleaf, CE; Marks, JH, 2014) |
| "Computed tomography showed intussusception caused by a large tumor in the pelvis and absence of distant metastases." | 1.40 | Intussusception due to rectal adenocarcinoma in a young adult: a case report. ( Fujiwara, T; Inada, R; Kishimoto, H; Kondo, Y; Mori, Y; Nagasaka, T; Toshima, T, 2014) |
| "We analyzed 120 rectal cancer patients treated with neoadjuvant pelvic radiotherapy (PRT) with concurrent 5-fluorouracil-based chemotherapy." | 1.40 | Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy. ( Apte, A; Deasy, JO; Goodman, KA; Oh, JH; Son, CH; Yang, TJ, 2014) |
| "We report a case of rectal cancer, which was successfully treated with radical resection and neoadjuvant chemoradiotherapy." | 1.40 | [Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer]. ( Ami, K; Ando, M; Arai, K; Gokita, K; Hayasaka, J; Imai, K; Kitazume, A; Kondou, M; Okamoto, E; Shibayama, T; Takagi, K; Tamura, A; Tei, S; Watanabe, A, 2014) |
| "Herein, we present a case of advanced rectal cancer surgically resected after chemotherapy." | 1.40 | [Surgical resection after chemotherapy for advanced rectal cancer - report of a case]. ( Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nogami, H; Sakata, J; Shimada, Y; Suda, K; Wakai, T, 2014) |
| "The patient declined surgery for recurrence so radiotherapy was planned." | 1.40 | [Irradiation with carbon ions for locally recurrent rectal cancer]. ( Akita, H; Fujino, S; Fujiwara, Y; Fukata, T; Gotoh, K; Kishi, K; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2014) |
| "A colonoscopy detected KRAS wild-type rectal cancer." | 1.40 | [A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)]. ( Aisu, Y; Ando, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T, 2014) |
| "A 69- year-old man with metastatic rectal cancer received 4 courses XELOX therapy." | 1.40 | [A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Makino, H; Nagashima, A; Ohkubo, Y; Shimokawa, R; Suzuki, Y; Yamamuro, W; Yoneda, M, 2014) |
| "Stage III rectal cancer was found in 64." | 1.39 | Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. ( Arbea, L; Arredondo, J; Baixauli, J; Beorlegui, C; Chopitea, A; Hernández-Lizoáin, JL; Rodríguez, J; Sola, JJ, 2013) |
| "Postoperative complications have had occurred in 12." | 1.39 | [Immediate results of complex treatment of resectable rectal neoplasms of distal localization]. ( Basheev, VKh; Bondar', GV; Sovpel', IV; Sovpel', OV; Zolotukhin, SÉ, 2013) |
| "Twenty-five patients with T3/T4N0 or N+ rectal cancer were enrolled." | 1.39 | Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor. ( Broggi, S; Calandrino, R; De Cobelli, F; De Nardi, P; Di Muzio, N; Di Palo, S; Fiorino, C; Iacovelli, NA; Losio, C; Orsenigo, E; Passoni, P; Ricci, V; Ronzoni, M; Slim, N; Staudacher, C; Tamburini, A, 2013) |
| "Management of locally advanced rectal cancer is complex because curative treatment routinely involves administration of surgery, chemotherapy, and radiation." | 1.39 | Evolving role of neoadjuvant therapy in rectal cancer. ( Schrag, D, 2013) |
| "After local pelvic recurrence, she underwent radiation therapy(50 Gy in total), and then chemotherapy(XELOX+bevacizumab)was started." | 1.39 | [A case of necrotizing fasciitis developed in a patient with recurrent rectal cancer treated with chemotherapy]. ( Arisawa, Y; Chiba, N; Hashimoto, M; Ishii, M; Ishikawa, S; Nakamura, T; Shimada, A, 2013) |
| "We report a case of advanced rectal cancer treated with chemotherapy, for which laparoscopic splenectomy had been effective for thrombocytopenia." | 1.39 | [Successful management using laparoscopic splenectomy for splenomegaly and thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced rectal cancer]. ( Arita, S; Koike, N; Ohshima, Y; Shinozaki, E; Takeuchi, T, 2013) |
| "A total of 507 patients with rectal cancer underwent RT at HKL." | 1.39 | Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience. ( Lau, FN; Lee, WC; Phua, VC; Yusof, MM, 2013) |
| "Eighteen patients with rectal cancer and synchronous liver metastases, who had undergone laparoscopic colorectal resection and simultaneous treatment for liver metastases, were retrospectively reviewed." | 1.39 | The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy. ( Chen, F; Chen, K; Ding, XM; Hu, BS; Leng, JJ; Tan, HM; Tan, JW; Zhu, Z, 2013) |
| "Fecal incontinence was assessed by patient self-reported data without the use of a validated score." | 1.39 | Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer. ( Buchner, S; Dinnewitzer, A; Jäger, T; Nawara, C; Öfner, D; Wolfgang, H, 2013) |
| "Of all patients operated for rectal cancer, 27." | 1.39 | Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications. ( Fietkau, R; Gock, M; Klar, E; Klautke, G; Prall, F; Rau, B; Schiffmann, L; Wedermann, N, 2013) |
| " The clinical efficacy and bevacizumab-related adverse reactions were observed." | 1.39 | [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC]. ( Chen, Y; Cui, YH; Guo, X; Liu, TS; Yu, YY; Zhou, YH; Zhuang, RY, 2013) |
| "The 3-year local recurrence and distant metastasis rates in the adjuvant chemotherapy group were 4." | 1.39 | [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy]. ( Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ, 2013) |
| "A 69-year-old man diagnosed with lower rectal cancer was referred to our hospital." | 1.39 | [A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer]. ( Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Marubashi, S; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Sueda, T; Takahashi, H; Tomita, Y; Yano, M, 2013) |
| "In cases of advanced rectal cancer, preoperative chemoradiotherapy( CRT) serves to improve the local control rate, survival rate, radical resection rate, and/or probability of sphincter muscle preservation." | 1.39 | [A case of successful radical resection of rectal cancer with neo-adjuvant chemoradiotherapy]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fujiya, K; Fukuda, A; Ganno, H; Gokita, K; Imai, K; Kamikozuru, H; Kawai, Y; Nagahama, T; Okada, Y; Seki, R; Takasaki, J; Takeuchi, S; Tei, S, 2013) |
| "Colonoscopy revealed a lower rectal cancer just above the dentate line, and its biopsy showed endocrine cell carcinoma." | 1.39 | [A case of rectal endocrine cell carcinoma treated by laparoscopic assisted intersphincteric resection after neoadjuvant chemotherapy]. ( Arai, S; Kataoka, M; Miyazawa, K; Oeda, Y; Shiobara, M; Tonooka, T; Wakatsuki, K; Yoshioka, S, 2013) |
| "We encountered a case of colorectal cancer with pelvic abscess treated with radical surgery following colostomy and chemotherapy." | 1.39 | [A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab]. ( Goseki, N; Kuwabara, H; Liu, B; Mitsuoka, A; Nakajima, K; Sanada, T; Watanabe, S, 2013) |
| " Grade ≥3 adverse events (AEs) that occurred during 5-FU/RT and during combined 5-FU/RT + mFOLFOX-6 were recorded." | 1.39 | Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer. ( Chen, Z; Duldulao, MP; Garcia-Aguilar, J; Ho, J; Kim, J; Le, M; Lee, W; Li, W; Nelson, RA, 2013) |
| "In locally advanced rectal cancer (LARC) patients, major response to neoadjuvant radiotherapy (NR) has been associated with favorable long-term outcomes." | 1.39 | What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer? ( Flejou, JF; Lefèvre, JH; Parc, Y; Svrcek, M; Tiret, E; Tranchart, H, 2013) |
| "Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery." | 1.39 | Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. ( Bianchi, R; Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2013) |
| "The ulcer was relieved by conservative medical treatment." | 1.39 | [A case of an ulcer of the sigmoid colon during chemotherapy with FOLFOX4 and bevacizumab for recurrence of rectal carcinoma]. ( Hirata, K; Mizushima, Y; Okuya, K, 2013) |
| "We report a case of advanced rectal cancer with bladder carcinoma." | 1.39 | [A case of advanced rectal cancer with bladder carcinoma salvaged from myocardial infarction during operation, showing tumor regression by XELOX treatment, good quality of life]. ( Kodama, M; Mekata, E; Okumura, K; Shiogai, Y; Tani, S; Tani, T, 2013) |
| "A 59-years-old woman with metastatic rectal cancer treated with bevacizumab, who developed low back pain after 11 cycles of chemotherapy." | 1.38 | Perirenal hematoma associated with bevacizumab treatment. ( Hayashi, H; Nakagawa, K; Okamoto, I, 2012) |
| "A total of 93 Stage II-III rectal cancer patients were genotyped using peripheral blood samples." | 1.38 | X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. ( Anido, U; Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gomez, A; Lamas, MJ; Lopez, R; Rana-Diez, P, 2012) |
| "Carcinomas were categorized by MRI as mucinous (mucin proportion >50% within the tumor volume), and as nonmucinous." | 1.38 | Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation. ( Düber, C; Hansen, T; Heintz, A; Hötker, AM; Junginger, T; Kreft, A; Kreitner, KF; Menig, M; Oberholzer, K; Schmidberger, H; Schneider, A, 2012) |
| "To evaluate the efficacy and treatment-related toxicity of accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer (LRIRC)." | 1.38 | Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer. ( Dai, Y; Li, L; Shao, ZY; Sun, DS; Yu, JM; Zhang, JD, 2012) |
| "Sixty-eight patients with metastatic rectal cancer were enrolled and analyzed." | 1.38 | The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer. ( Chang, CY; Cho, YB; Choi, DH; Chun, HK; Kim, HC; Lee, WY; Park, HC; Park, JO; Park, YS; Yun, SH, 2012) |
| "High TS, DPD, and positive lymph node metastasis (pN) were significantly poorer prognostic factors for DFS (TS: P < 0." | 1.38 | TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy. ( Inoue, Y; Kobayashi, M; Koike, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2012) |
| "We obtained total RNA from residual cancer cells using microdissection from a total of 52 rectal cancer specimens from patients who underwent preoperative CRT." | 1.38 | Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy. ( Fujikawa, H; Inoue, Y; Kusunoki, M; Matsushita, K; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Uchida, K, 2012) |
| " Adverse effects ≥ grade 2 were observed in 32% of the patients and adverse effects ≥ grade 3 in 15%." | 1.38 | Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres. ( Bensadoun, RJ; Hamidou, H; Michel, P; Paillot, B; Roullet, B; Silvain, C; Tougeron, D; Tourani, JM, 2012) |
| "A total of 38 T3-4/N+ rectal cancer patients received capecitabine-oxaliplatin and radiotherapy followed by surgery." | 1.38 | A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. ( Carlomagno, C; D'Incalci, M; De Placido, S; De Stefano, A; Della Vittoria Scarpati, G; Falcetta, F; Marchini, S; Pepe, S; Singh, VK; Ubezio, P, 2012) |
| "After nCRT for rectal cancer, postsurgery CEA level may have more prognostic value than pretreatment level." | 1.38 | Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence. ( Chang, DT; Hong, JC; Koong, AC; Liauw, SL; McDonnell, SE; Minsky, BD; Song, S, 2012) |
| "The patient was a 60-year-old man with cancer of the rectum, with huge multiple hepatic metastases." | 1.38 | [Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report]. ( Bando, Y; Katakawa, M; Ogata, S; Tagami, Y, 2012) |
| "In spite of advances in rectal cancer surgery and the use of preoperative 5-fluorouracil-(5-FU) based chemoradiotherapy (CRT) in stage II and III disease distant metastases still occur in about 35-40% of the patients." | 1.38 | Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life. ( Brade, J; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kienle, P; Kripp, M; Post, S; Welzel, G; Wenz, F; Wieneke, J, 2012) |
| "An analysis of 162 rectal cancer patients who underwent curative surgery between 2005 and 2010." | 1.38 | Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer. ( Contu, PC; Damin, DC; Ferreira, PR; Kliemann, LM; Rosito, MA; Schwartsmann, G; Tarta, C, 2012) |
| "Nine cases with highly advanced rectal cancer for which curative surgery was potentially difficult were enrolled(clinical T4 in 7 cases, lateral node metastasis in 3 cases, M1 in 2 cases)." | 1.38 | [Evaluation of modified OPTIMOX1 plus bevacizumab as the neoadjuvant therapy for highly advanced rectal cancers]. ( Adachi, K; Hirano, A; Imai, K; Koda, K; Kosugi, C; Nakagawa, R; Shiragami, R; Suzuki, M; Tezuka, T; Yamazaki, M; Yasuda, H, 2012) |
| "After matching, only CEA and metastasectomy, but not CCRT, were independent prognostic factors." | 1.38 | Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer. ( Chang, SC; Chen, WS; Jiang, JK; Lan, YT; Lee, LK; Lin, CC; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH; Wang, HS; Yang, SH; Yen, CC, 2012) |
| "Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection." | 1.38 | MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. ( Fabian, P; Gombosova, J; Kocakova, I; Nekvindova, J; Radova, L; Sana, J; Slaby, O; Svoboda, M; Vyzula, R, 2012) |
| "Following diagnosis of T4 rectal cancer, preoperative chemotherapy was initiated with the aim of downstaging the tumor and avoiding total pelvic exenteration." | 1.38 | [Complete response obtained by preoperative chemotherapy in a case of T4 rectal cancer]. ( Akasaka, H; Hakamada, K; Koyama, M; Morohashi, H; Murata, A; Sakamoto, Y; Yokoyama, H, 2012) |
| "An approximately 50-year-old man with rectal cancer(RbP)[ cT3(cA), cN3, cM0, and cStage IIIb] who desired anus preservation was administered mFOLFOX6 therapy." | 1.38 | [A case of advanced rectal cancer treated effectively with intersphincteric resection and preoperative chemotherapy]. ( Ito, Y; Kimura, A; Kubo, N; Kudo, Y; Kurushima, M; Morita, T; Nishikawa, S; Takahashi, K; Tokura, T; Umehara, Y; Yachi, T, 2012) |
| "Sixteen months after the diagnosis of rectal cancer, the patient died." | 1.38 | [A case of advanced rectal cancer with lung and bone metastasis that was successfully treated with mFOLFOX6+bevacizumab]. ( Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kobayashi, H; Masuda, T; Matsuyama, T; Okazaki, S; Sugihara, K; Uetake, H; Yamauchi, S, 2012) |
| " This case demonstrates the successful treatment and CR of recurrent lung metastasis after surgery for rectal cancer using lung RFA therapy and long-term administration of FOLFIRI." | 1.38 | [A case report of recurrent lung metastasis after surgery for rectal cancer for which lung radiofrequency ablation therapy and long-term administration of FOLFIRI were effective]. ( Fukushima, M; Hoshino, M; Murakami, M; Naruse, H; Suzuki, N; Suzuki, S; Tominaga, K, 2012) |
| "A total of 238 rectal cancer patients treated in a neo-adjuvant setting by a fluoropyrimidines-based chemo-radiotherapy (RT) were genotyped for 25 genetic polymorphisms in 16 genes relevant for treatment-associated pathways." | 1.37 | Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy. ( Agostini, M; Biason, P; Canzonieri, V; Cecchin, E; De Mattia, E; De Paoli, A; Friso, ML; Nitti, D; Pucciarelli, S; Sigon, R; Toffoli, G; Visentin, M, 2011) |
| "Forty-four patients with rectal cancer treated with 5-FU-based preoperative CRT were prospectively enrolled in this study." | 1.37 | Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. ( Choi, J; Choi, SH; Hur, H; Kang, J; Keum, KC; Kim, H; Kim, NK; Lee, KY; Lee, MY; Min, BS; Shin, SJ, 2011) |
| "Stage II or III rectal cancer patients were evaluated and treated with RT and 5-FU preoperatively (neoadjuvant treatment, NG) or after surgical resection of the cancer (adjuvant treatment, AG)." | 1.37 | Imunoexpression of Ki-67 and p53 in rectal cancer tissue after treatment with neoadjuvant chemoradiation. ( Andrade, NR; Forones, NM; Gomes, TS; Neto, RA; Oshima, CT, 2011) |
| "Patients with rectal cancer, candidates to receive pCRT, were enrolled in a multicenter prospective observational trial." | 1.37 | Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. ( Amato, A; Capirci, C; Cuicchi, D; De Paoli, A; Del Bianco, P; Efficace, F; Nitti, D; Pucciarelli, S; Serpentini, S, 2011) |
| "Patients with locally advanced rectal cancer treated with neoadjuvant therapy can safely undergo laparoscopic proctectomy with a low rate of complications." | 1.37 | Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up. ( Cone, MM; Diggs, BS; Herzig, DO; Lu, KC; Oommen, SC; Rea, JD, 2011) |
| "Adjuvant chemotherapy in rectal cancer is not well defined." | 1.37 | Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. ( Alfonso, R; Corona, J; Custodio, A; de las Heras, M; Dıaz-Rubio, E; Ortega, L; Puente, J; Rodriguez, L; Sanchez, JC; Sastre, J, 2011) |
| "Capecitabine is an attractive radiosensitizer." | 1.37 | Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer. ( Cats, A; Gerhards, MF; Heuff, G; Marijnen, CA; Swellengrebel, HA; van Geloven, AA; van Tets, WF; Verheij, M; Verwaal, VJ; Vincent, A, 2011) |
| "Patients with mucinous rectal cancer experienced a lower rate of T-downstaging after PCRT and had a poorer prognosis than did patients with nonmucinous cancer." | 1.37 | Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. ( Kim, CW; Kim, JC; Kim, JH; Kim, TW; Lim, SB; Shin, US; Yoon, SN; Yoon, YS; Yu, CS, 2011) |
| "In 10-24% of patients with rectal cancer who are treated with neoadjuvant chemoradiation, no residual tumor is found after surgery (ypT0)." | 1.37 | Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. ( Bakers, FC; Barbaro, B; Beets, GL; Beets-Tan, RG; Haustermans, K; Lambrecht, M; Lambregts, DM; Maas, M; Valentini, V; Vandecaveye, V, 2011) |
| "Seventeen patients with Stage II or III rectal cancer had a planning CT scan with rectal contrast before commencement of preoperative chemoradiation." | 1.37 | Rectal motion in patients receiving preoperative radiotherapy for carcinoma of the rectum. ( Bayley, A; Brierley, JD; Brock, KK; Craig, T; Cummings, B; Dawson, LA; Dinniwell, R; Kim, JJ; Moseley, JL; Ringash, J; Sampson, E; Scott, S; Wong, R, 2011) |
| "We retrospectively evaluated 333 rectal cancer patients who received preoperative CRT followed by surgery with curative intent between January 2000 and December 2006." | 1.37 | Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. ( Kim, CW; Kim, JC; Kim, KH; Lim, SB; Yang, SS; Yoon, SN; Yoon, YS; Yu, CS, 2011) |
| "Patients with locally advanced rectal cancer (cUICC stages II/III) are typically treated with preoperative 5-fluorouracil-based (5-FU-based) radiochemotherapy (RCT)." | 1.37 | Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. ( Becker, H; Beissbarth, T; Christiansen, H; Conradi, LC; Hennies, S; Hess, CF; Liersch, T; Rave-Fränk, M; Schirmer, M; Sprenger, T; Wolff, HA, 2011) |
| "A 50-year-old man with advanced rectal cancer and multiple liver metastases experienced DIC during third-line treatment with cetuximab plus irinotecan, following 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) plus bevacizumab and 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab." | 1.37 | A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab. ( Kondo, C; Mizota, A; Muro, K; Nomura, M; Shitara, K; Takahari, D; Ura, T; Yokota, T, 2011) |
| "Ninety-six patients with rectal cancer received neoadjuvant therapy (41 were treated with radiotherapy and 55 with chemoradiotherapy) before surgery." | 1.37 | Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer. ( Lin, GL; Qiu, HZ; Wu, B; Xiao, Y, 2011) |
| "It is said that disseminated carcinomatosis of the bone marrow has a poor prognosis, but we were able to obtain a good response in this case by chemotherapy." | 1.37 | [Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia]. ( Abiko, S; Gotoh, J; Higashiyama, A; Kawamura, A; Kawamura, N; Kudo, M; Meguro, J; Nagasako, T; Takano, M; Tamaki, T; Tanino, M; Yamamoto, Y; Yonekawa, M, 2011) |
| "A detailed examination revealed a rectal cancer with metastasis to the right ovary." | 1.37 | [A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy]. ( Hatakeyama, K; Iiai, T; Kameyama, H; Nogami, H; Saitou, K; Umezu, H; Yagi, Y, 2011) |
| "The finding that some rectal cancers respond to neoadjuvant chemoradiation is broadening new surgical options for the treatment of some of these tumors that, until now, required a total mesorectal excision." | 1.37 | Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? ( Arbea, L; Aristu, J; Baixauli, J; Beorlegui, C; Hernandez-Lizoain, JL; Pastor, C; Sola, J; Subtil, JC, 2011) |
| "Seven patients with rectal cancers which were difficult to ensure surgical margins for because of huge tumors(over 60mm in diameter), invasion to other organs, or severe nodal metastases, were treated with preoperative chemotherapy consisting of 2-10 courses of mFOLFOX6." | 1.37 | [Pilot study of preoperative mFOLFOX6 chemotherapy for advanced rectal cancers which were difficult to ensure surgical margins]. ( Fuyuhiro, Y; Hirakawa, K; Inoue, T; Kashiwagi, S; Maeda, K; Nagahara, H; Nakamoto, K; Noda, E, 2011) |
| "For patients with locally advanced rectal cancer (LARC) neoadjuvant chemoradiotherapy is recommended as standard therapy." | 1.37 | Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. ( Bohn, B; Erben, P; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kähler, G; Kienle, P; Post, S; Schwaab, J; Ströbel, P; Wenz, F, 2011) |
| "He was diagnosed as advanced rectal cancer with an invasion of prostate, and we conducted neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy." | 1.37 | [A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy]. ( Arima, N; Shigaki, N; Sugita, H; Suzuki, S; Yamashita, H; Yokoyama, S, 2011) |
| "BACKGROUND Survival in rectal cancer remains unchanged despite improved treatment modalities." | 1.37 | Molecular changes consistent with increased proliferation and invasion are common in rectal cancer. ( Beynon, J; Hughes, R; Jenkins, G; Parry, J, 2011) |
| "Its prognostic value in rectal cancer is somewhat unknown." | 1.37 | Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy. ( Avoranta, ST; Korkeila, EA; Minn, HR; Pyrhönen, SO; Sundström, JT; Syrjänen, KJ, 2011) |
| "FOLFIRI was effective for recurrent rectal cancer with paraaortic LN metastasis." | 1.37 | [A case of recurrent rectal cancer with paraaortic lymph node metastasis treated by FOLFIRI therapy leading to complete response]. ( Nishimura, Y; Sakamoto, H; Tanaka, Y; Yamaguchi, K; Yatsuoka, T, 2011) |
| "Two years later, he was diagnosed for rectal cancer and bilateral lung metastases by TBLB." | 1.37 | [A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Kurokawa, T; Nagahama, T; Nakamura, M; Okada, Y; Tei, S; Watayo, Y, 2011) |
| "Local postoperative complications affected 25 of 61 patients, who had lower perioperative neutrophil increases than their counterparts (P = 0." | 1.36 | Suppression of the postoperative neutrophil leucocytosis following neoadjuvant chemoradiotherapy for rectal cancer and implications for surgical morbidity. ( Glynne-Jones, R; Kerr, SF; Klonizakis, M, 2010) |
| "Pelvic recurrent rectal cancer is still a challenging clinical problem, and patients generally have a dismal prognosis and a poor quality of life." | 1.36 | Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy. ( Bossola, M; Doglietto, GB; Pacelli, F; Papa, V; Rosa, F; Sanchez, AM; Tortorelli, AP; Valentini, V, 2010) |
| "Capecitabine was administrated 1,650 mg/m(2)/day, 7 days/week." | 1.36 | Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. ( Aygerinos, K; Baltatzis, G; Bamias, A; Beroukas, K; Boskos, CS; Dimopoulos, MA; Korkolis, D; Lamproglou, I; Liacos, C; Papasavvas, P; Stoupa, E; Terpos, E, 2010) |
| "Rectal tumors were localized within 12 cm from the anocutaneous verge." | 1.36 | Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment. ( Bartos, J; Czudek, S; Gruna, J; Kycina, R; Parvez, J; Skrovina, M; Soumarova, R; Wendrinski, A, 2010) |
| "Of 100 patients with locally advanced rectal cancer, 32 were clinically staged as T3N0M0." | 1.36 | Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? ( Ceccarelli, C; Cola, B; Cuicchi, D; Di Fabio, F; Di Tullio, P; Iacopino, B; Lecce, F; Lombardi, R; Martoni, A; Minni, F; Neri, S; Pini, S; Pinto, C; Taffurelli, M; Tardio, ML; Ugolini, G, 2010) |
| "Colonoscopy detected rectal cancer and sigmoid al polyps." | 1.36 | [A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy]. ( Baba, K; Ishigami, S; Kitazono, M; Matsushita, D; Natsugoe, S; Ogawa, H; Shinchi, H; Ueno, S, 2010) |
| "Fourty-six rectal cancer patients, 25 RCT- and 21 RT-patients, were included in this study." | 1.36 | Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings. ( Buijsen, J; de Ruysscher, D; Janssen, MH; Lambin, P; Lammering, G; Ollers, MC; van den Bogaard, J; van Stiphout, RG, 2010) |
| "Pre-operative chemoradiation in low rectal cancer is not associated with a higher incidence of peri-operative complications and its benefits may include reduction local recurrence." | 1.36 | Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers. ( Fan, JF; Law, WL; Lim, YK; Liu, R; Lo, OS; Poon, JT, 2010) |
| "She was diagnosed to have rectal cancer." | 1.36 | [Elderly patient with recurrent rectal cancer successfully responded to modified FOLFOX6 chemotherapy with bevacizumab--a case report]. ( Adachi, E; Hattori, M; Kato, N; Kawase, Y; Kuroiwa, M; Matsushita, H; Mizuno, A; Okochi, O; Sato, Y; Takami, Y; Takeda, S; Tsuboi, K, 2010) |
| "2 Gy/f, 2 f/d plus concurrent capecitabine at an oral dosage of 825 mg/m2 bid on each day of radiotherapy period." | 1.36 | [Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer]. ( Dai, Y; Shao, ZY; Yu, JM; Zhang, JD, 2010) |
| "CASE 2: A 67-year-old male with colon cancer and liver and lung metastases was referred to our Dept." | 1.36 | [Two cases of unstable angina in patients treated with bevacizumab]. ( Okada, Y; Okura, Y; Takii, Y, 2010) |
| "Tumor response of rectal cancer to preoperative chemoradiotherapy (CRT) varies considerably." | 1.36 | Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling. ( Boender, PJ; de Wijn, R; Dueland, S; Flatmark, K; Folkvord, S; Giercksky, KE; Grøholt, KK; Hole, KH; Johansen, M; Nesland, JM; Ree, AH; Ruijtenbeek, R, 2010) |
| "Twenty men with primary rectal cancer clinically involving the lower urinary tract organs underwent extended colorectal resection combined with radical prostatectomy." | 1.36 | Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract. ( Ito, M; Kobayashi, A; Minagawa, N; Nishizawa, Y; Saito, N; Sugito, M; Suzuki, T; Tanaka, T; Watanabe, K, 2010) |
| "We report two cases of colorectal cancer whose serum iron level demonstrated recurrent elevation after chemotherapy." | 1.36 | [Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron due to hemolysis after chemotherapy including 5-FU]. ( Furuse, J; Hosokawa, Y; Itabashi, M; Iwamoto, N; Kase, Y; Kitagawa, N; Miyazawa, T; Motoori, S; Saisho, H, 2010) |
| "Most colorectal cancer patients with liver metastases are not resectable upon initial diagnosis." | 1.36 | [Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection]. ( Chin, K; Fujimoto, Y; Hatake, K; Ichimura, T; Matsusaka, S; Mitsuhashi, K; Mizunuma, N; Ogura, M; Ozaka, M; Saiura, A; Shinozaki, E; Suenaga, M; Yamamoto, N, 2010) |
| "Patients with nonmetastatic distal rectal cancer treated by neoadjuvant chemoradiation therapy, including 50." | 1.36 | Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. ( Gama-Rodrigues, J; Habr-Gama, A; Kessler, H; Marks, J; Perez, RO; Wynn, G, 2010) |
| "We report two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer." | 1.36 | [Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer]. ( Hosokawa, T; Iwao, Y; Koshiishi, H; Koshinaga, T; Matsuyama, T; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H, 2010) |
| "The patient was diagnosed as idiopathic thrombocytopenic purpura (ITP) by several examinations but medical control including steroids failed." | 1.36 | [Idiopathic thrombocytopenic purpura during chemotherapy for liver metastasis of rectal cancer]. ( Ebisui, C; Ide, Y; Kinuta, M; Mikami, K; Momozane, T; Mukai, R; Murakami, M; Murata, K; Nagase, H; Nishigaki, T; Okada, K; Owada, Y; Yamada, M; Yanagisawa, T; Yokouchi, H, 2010) |
| "A 42-year-old man with advanced rectal cancer underwent a low anterior resection with TME and pelvic lateral lymph-node and paraaortic lymph-node dissections." | 1.36 | [A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes]. ( Gotoh, K; Ishikawa, O; Kano, S; Kishi, K; Miyashiro, I; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Takahashi, H; Yamada, T; Yano, M, 2010) |
| "A colonoscopy revealed primary rectal cancer." | 1.36 | [A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy]. ( Danno, K; Imaoka, S; Inatome, J; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Tsukao, Y; Watanabe, A, 2010) |
| "Colonoscopy detected an advanced rectal cancer." | 1.36 | [A case report of advanced rectal cancer showing a pathological complete response by neo-adjuvant FOLFOX chemotherapy]. ( Hirakawa, K; Inoue, T; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Noda, E; Ohira, M; Tanaka, H; Yamada, N, 2010) |
| "We report here a case of rectal cancer with synchronous multiple liver metastases successfully treated with a combined chemotherapy of modified FOLFOX6 (mFOLFOX6) and bevacizumab." | 1.36 | [A case of rectal cancer with synchronous multiple liver metastases successfully treated with combined chemotherapy of modified FOLFOX6 and bevacizumab]. ( Andou, S; Kitamura, Y; Tokunou, K; Toshimitsu, H; Tsushimi, K; Yamamoto, T, 2010) |
| "Local therapy for early rectal cancer is a valid alternative to the classical radical operation, which has a higher morbidity and mortality rate." | 1.35 | Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience. ( Baldarelli, M; Bartolacci, S; Grillo Ruggeri, F; Guerrieri, M; Lezoche, E; Mantello, G; Organetti, L, 2008) |
| "However, G-CSF-producing colorectal cancer (CRC) has never been reported in the English literature." | 1.35 | Granulocyte-colony stimulating factor producing rectal cancer. ( Akamo, Y; Funahashi, H; Ochi, N; Sakamoto, M; Satoh, M; Sawai, H; Takahashi, H; Takayama, S; Takeyama, H; Wakasugi, T; Yasuda, A, 2008) |
| "Tumor biopsies from 35 patients with rectal cancer before therapy and parallel tumor biopsies from 31 patients two weeks after starting preoperative capecitabine chemoradiotherapy were taken." | 1.35 | Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. ( Dvorak, J; Izakovicova Holla, L; Kocakova, I; Sefr, R; Svoboda, M; Tichy, B; Vrtkova, I, 2008) |
| "Locally advanced rectal cancer is frequently treated with neoadjuvant chemoradiotherapy to reduce local recurrence and possibly improve survival." | 1.35 | A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. ( Armstrong, J; Beddy, D; Fennelly, D; Gibbons, D; Hyland, JM; Lim, C; Moriarty, M; Sheahan, K; White, A; Winter, DC, 2008) |
| "We report a 59-year-old woman with rectal cancer who underwent low anterior resection in March 2007." | 1.35 | [A case with liver resection of metastasis from rectal cancer after FOLFOX4+bevacizumab treatment]. ( Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Uemura, T, 2008) |
| "Interstitial pneumonia was suspected, and we started treatment with steroid medication, but this had no effect." | 1.35 | [A case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa successfully treated with mFOLFOX6 chemotherapy as salvage]. ( Fujita, M; Ishikawa, M; Katano, K; Mizuno, A; Okada, Y; Yamagishi, Y, 2008) |
| "In total, 106 patients with cT3,4 rectal cancer who received preoperative radiotherapy alone or concurrently with capecitabine chemotherapy at Nottingham City Hospital, UK were studied." | 1.35 | Regression of rectal cancer with radiotherapy with or without concurrent capecitabine--optimising the timing of surgical resection. ( Bessell, EM; Dhadda, AS; Zaitoun, AM, 2009) |
| "Forty-three men with rectal cancer had baseline and postchemoradiation FSH, LH, and testosterone measured." | 1.35 | Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients. ( Fisher, B; Perera, F; Stitt, L; Yoon, FH, 2009) |
| "A treatment of 5-fluorouracil, 500 mg/body per day intravenously, or oral UFT-E (300 mg/m2) with l-leucovorin (75 mg) per day, or oral S-1 (80 mg/m2) per day five days a week, was given during radiotherapy." | 1.35 | [Our experiences of preoperative chemo-radiotherapy for T4 primary rectal cancer]. ( Agata, T; Aoyama, H; Funahashi, M; Hanai, T; Honda, K; Katsuno, H; Koide, Y; Maeda, K; Matsuoka, H; Noro, T; Sato, H; Shiota, M, 2008) |
| "He was diagnosed with lower rectal cancer by colonoscopy and referred to our hospital for therapy." | 1.35 | [Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report]. ( Akagi, K; Fujita, J; Hata, T; Hayashi, S; Ikeda, K; Kagawa, Y; Kato, H; Kawanishi, K; Kitada, M; Maeda, S; Nomura, M; Oshima, N; Sasaki, T; Shimano, T; Shimizu, J; Takamoto, K; Tsukahara, Y, 2008) |
| "Recently, standard therapies for either gastric cancer or colorectal cancer have been established through the development of multidrug systemic chemotherapy and the appearance of molecular targeting drugs." | 1.35 | [Hepatic artery infusion chemotherapy to three liver metastasis cases in which systemic chemotherapy was impossible or ineffective]. ( Ando, K; Emi, Y; Endo, K; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Saeki, H; Sugiyama, M, 2008) |
| "Serum levels of 5-fluorouracil(5-FU)were measured in a patient receiving pharmacokinetic modulation chemotherapy( PMC), with 5-FU, as well as a combination of oxaliplatin and infusional 5-FU plus leucovorin(FOLFOX)." | 1.35 | [Pharmacokinetic monitoring of 5-fluorouracil may improve the clinical benefit with an individualized regimen-a case report]. ( Asakura, T; Hatakeyama, K; Kanda, J; Muneoka, K; Sasaki, M; Shirai, Y; Wakabayashi, H; Wakai, T, 2009) |
| "We report a CR case of advanced rectal cancer successfully treated with 39 courses of mFOLFOX6." | 1.35 | [A CR case of colorectal cancer given 39 courses of FOLFOX]. ( Fujiwara, M; Imai, N; Isaka, T; Kaneko, M; Kobayashi, K; Naota, H; Ogura, S; Otsubo, M; Taniguchi, K, 2009) |
| "We report here two cases of interstitial lung disease occurring in association with the use of this combination chemotherapy." | 1.35 | [Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX)]. ( Kato, S; Miyate, Y; Ogasawara, N; Ohori, H; Suzuki, M; Takahashi, M, 2009) |
| "Up to 6% of women with colorectal cancer are diagnosed in the reproductive age and are at risk for premature ovarian failure and infertility due to pelvic irradiation and chemotherapy." | 1.35 | Fertility preservation for young women with rectal cancer--a combined approach from one referral center. ( Elizur, SE; Huang, JY; Levin, D; Meterissian, S; Tan, SL; Tulandi, T, 2009) |
| "The patient was diagnosed stageIV rectal cancer and resected primary focus and lymph node metastasis." | 1.35 | [A successfully resected case of rectal cancer with liver metastases treated with mFOLFOX6 and bevacizumab]. ( Fujino, Y; Fujita, T; Kanaji, S; Kanbara, Y; Kawasaki, K; Kobayashi, I; Nakamura, T; Ohno, M; Osawa, M; Tsuchida, S; Ueno, K, 2009) |
| "In patients with locally advanced rectal cancer (LARC) staging and, after preoperative chemo-radiation therapy (CRT), restaging workup could be useful to tailor therapeutic approaches." | 1.35 | The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery. ( Banti, E; Bianchini, E; Capirci, C; Crepaldi, G; Del Favero, G; Facci, E; Galeotti, F; Gava, M; Marano, G; Panzavolta, R; Pasini, F; Rampin, L; Rubello, D, 2009) |
| "Following preoperative treatment of rectal cancer with chemoradiotherapy (CRT), a complete pathological response (CPR) can be seen in the surgical specimen." | 1.35 | Complete pathologic response after preoperative rectal cancer chemoradiotherapy. ( Ciccocioppo, A; Hewett, PJ; Rieger, NA; Stephens, JH, 2009) |
| "A 75-year-old man was diagnosed with gastric cancer (UL post c0- II c (c T1N0) and M-less ctype II (cT2N0)) and rectal cancer (Rb ctype II (cT2N1) with multiple lung metastases (M1)." | 1.35 | [A case of advanced gastric and rectal cancer (double cancer) successfully treated with mFOLFOX6 therapy]. ( Furuta, A; Hatsugai, K; Ishibashi, S; Ishii, T; Kaneda, I; Masuoka, H; Ohara, M; Sarashina, H; Sekine, Y; Shoji, M; Watanabe, G, 2009) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used in a number of solid malignancies, including colorectal cancer." | 1.35 | A case of 5-fluorouracil-induced acute psychosis. ( Alabsi, E; Fakih, M; Fora, A, 2009) |
| "Thirty-three patients with rectal cancer underwent preoperative CRT." | 1.35 | Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. ( Ioue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| " The primary dose of oxaliplatin (L-OHP) ranged from 60 mg/m(2) to 85 mg/m(2), and adverse reactions and serum platinum concentration were monitored." | 1.35 | [The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy]. ( Fujita, M; Kataoka, Y; Katayama, T; Koide, T; Matsuda, H; Okuda, M; Yamagishi, Y, 2009) |
| "Approximately 20% of rectal cancer patients undergoing neoadjuvant chemoradiation achieve pCR, which has been associated with decreased local recurrence and improved recurrence-free survival." | 1.35 | Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. ( de Campos-Lobato, LF; Dietz, D; Fazio, VW; Geisler, DP; Kalady, MF; Lavery, IC; Stocchi, L, 2009) |
| "Forty patients with rectal cancer underwent 5-fluorouracil based chemoradiotherapy followed by curative surgery." | 1.35 | Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues. ( Inoue, Y; Kusunoki, M; Miki, C; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009) |
| "Prognosis of stage II colorectal cancer varies." | 1.35 | [Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy]. ( Ding, PR; Li, LR; Lin, JZ; Pan, ZZ; Peng, ZH; Wan, DS; Wu, XJ; Zhou, ZG, 2009) |
| "Patients with locally advanced rectal cancer undergoing preoperative radiotherapy have disparity in pathological tumor regression." | 1.35 | [Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma]. ( Ding, PR; Lin, JZ; Pan, ZZ; Wan, DS; Zeng, ZF, 2009) |
| "Twenty-two specimens of colorectal cancer were collected." | 1.35 | [Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues]. ( Chen, G; Fu, LW; Liang, YJ; Qiu, HB; Yuan, SQ; Zhang, LY; Zhou, ZW, 2009) |
| "Data concerning the type and stage of rectal cancer, multimodal treatment (surgery with or without neoadjuvant therapy or adjuvant therapy) and treatment according to the level of medical care of hospitals were recorded from 2000 to 2008." | 1.35 | [Practical neoadjuvant and adjuvant therapies for rectal cancer. How many patients are actually recruited in multimodality therapy concepts? An analysis of the Tumour Centre Schwerin]. ( Dommisch, K; Sauer, J; Sobolewski, K, 2009) |
| "A detailed examination revealed a rectal cancer with direct invasion of the primary rectal carcinoma into the prostate." | 1.35 | [Two cases of advanced rectal cancer resected successfully after neoadjuvant chemotherapy with FOLFOX regimen]. ( Ikeda, J; Itokawa, Y; Koide, K; Lee, CJ; Shimizu, H; Shioaki, Y; Sonoda, H; Takashina, K; Taniguchi, F; Ueshima, Y; Yamashita, T, 2009) |
| "A treatment of 5-fluorouracil (500 mg/body) with l-leucovorin (100 mg/body) intravenously once a week, or oral S-1 (100 mg/day/body) for four weeks, was given during radiation therapy." | 1.35 | [Assessment of chemoradiation therapy for advanced rectal cancer invaded the pelvic organ]. ( Doi, K; Hirano, Y; Ishihara, A; Kojima, K; Kudo, K; Ochi, T; Ogata, K, 2009) |
| "A man in his fifties with rectal cancer underwent low anterior resection in another Hospital in January 2006." | 1.35 | [A case of liver metastasis of rectal cancer demonstrating complete response for more than two years to mFOLFOX6]. ( Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Oshima, S; Sakamoto, T, 2009) |
| "We report a case of rectal cancer with unresectable multiple liver metastases, which was worried about the transition from liver dysfunction to liver failure." | 1.35 | [A case of advanced rectal cancer with severe liver dysfunction due to multiple liver metastases]. ( Enomoto, M; Fujimori, Y; Higuchi, T; Iida, S; Ishiguro, M; Ishikawa, T; Kobayashi, H; Oda, G; Okazaki, S; Sugihara, K; Tsukamoto, S; Uetake, H; Yasuno, M, 2009) |
| "A 63-year-old female diagnosed as rectal cancer underwent low anterior resection and received adjuvant chemotherapy (folinate/tegafur/uracil therapy)." | 1.35 | [A case of surgical approach to the recurrence of the para-aortic lymph nodes after resection of rectal cancer]. ( Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Kakutani, A; Maeura, Y; Ogino, T; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S, 2009) |
| "Previously irradiated recurrent rectal cancer is a formidable patient threat with limited treatment options." | 1.35 | Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum. ( Begossi, G; Belliveau, J; DiSiena, M; Gustafson, E; Wanebo, HJ, 2008) |
| "Therefore, ERUS-/MRI-staged T3N0 rectal cancer patients should continue to receive preoperative CMT." | 1.35 | cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. ( Aristu, JJ; Coco, C; Díaz-González, JA; Guillem, JG; Hernandez-Lizoain, JL; Jeong, SY; Leon, R; Minsky, BD; Nitti, D; Pucciarelli, S; Riedel, ER; Rodriguez-Bigas, MA; Valentini, V; Wong, WD, 2008) |
| "Sixty patients with locally advanced rectal cancer were treated with preoperative chemoradiation." | 1.35 | Preoperative chemoradiation with capecitabine in locally advanced rectal cancer. ( de Bruin, AF; de Wilt, JH; Ferenschild, FT; Nuyttens, JJ; Planting, AS; Verhoef, C, 2008) |
| "5-fluorouracil was given as continuous infusion 350 mg/m(2)/day five times weekly, and RHT (BSD-2000 system) was applied twice a week within 1 h after radiotherapy." | 1.35 | Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. ( Buecklein, V; Duehmke, E; Issels, RD; Milani, V; Pazos, M; Rahman, S; Schaffer, M; Schaffer, P; Tschoep, K; Wilkowski, R, 2008) |
| "The standard adjuvant therapy for rectal cancer is 5-fluorouracil (5-FU) often combined with radiotherapy." | 1.35 | A case of 5-fluorouracil-induced peripheral neuropathy. ( De Bleecker, JL; Pauwels, WJ; Werbrouck, BF, 2008) |
| "The rate of distant metastases increased from 18." | 1.34 | Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy. ( Eriksen, MT; Haffner, J; Wibe, A; Wiig, JN, 2007) |
| "In preoperative chemoradiotherapy for rectal cancer, the pathologic response could be improved by administering capecitabine 1 hour before radiotherapy." | 1.34 | Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer. ( Ahn, SD; Chang, HM; Choi, EK; Choi, WS; Jang, SJ; Kim, HC; Kim, JC; Kim, JH; Kim, TW; Lee, SW; Ryu, MH; Shin, SS; Yu, CS, 2007) |
| "19 out of 29 patients were colon cancer, and the other 10 were rectal cancer." | 1.34 | [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. ( Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2007) |
| "Patients aged > or = 70 years with colon cancer benefit from chemotherapy, with no major added toxicities compared with a younger population." | 1.34 | Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy. ( Fakih, MG; Reddy, N; Yu, J, 2007) |
| "Resection of locally recurrent rectal cancer (LRRC) after curative resection represents a difficult problem and a surgical challenge." | 1.34 | Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience. ( Asoglu, O; Emek, E; Igci, A; Kapran, Y; Karanlik, H; Kecer, M; Muslumanoglu, M; Ozmen, V; Parlak, M, 2007) |
| "Capecitabine is an oral fluoropyrimidine that mimics the pharmaconkinetics of infusional 5-FU." | 1.34 | A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. ( Arbea, L; Coma-Canella, I; García-Foncillas, J; Martinez-Monge, R, 2007) |
| "5-fluorouracil (5FU) has traditionally been the drug of choice in combination with radiation therapy." | 1.34 | Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma. ( Amichetti, M; Caraul, B; Casula, G; Deidda, MA; Dessì, M; Farci, D; Farigu, R; Lay, GC; Maxia, L; Murtas, R; Orrù, S, 2007) |
| "He was diagnosed as advanced sigmoid colon cancer which invaded the rectal colon (Ra) and prostate (SI, N 0, P 0, H 0, M (-), cStage IIIa)." | 1.34 | [A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery]. ( Maezawa, K; Mizukami, H; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2007) |
| "Grade 3/4 neutropenia was seen in 12 patients (60%), and neuropathy was observed in 11 patients (55%)." | 1.34 | Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer. ( Kasai, M; Mitobe, S; Munakata, M; Muto, O; Okada, R; Sakata, Y; Shitara, K, 2007) |
| "121 locally advanced middle-low rectal cancer patients were treated with preoperative radiotherapy or chemoradiotherapy followed by surgery after rest of 4 to 6 weeks." | 1.34 | [Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer]. ( Cao, WG; Che, JF; Jin, YN; Li, H; Ma, T; Xi, WQ; Xu, HP; Zhao, R, 2007) |
| "Radiation enteritis is the main acute side-effect during pelvic irradiation." | 1.34 | Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. ( Bendahl, PO; Gunnlaugsson, A; Johnsson, A; Kjellén, E; Nilsson, P; Willner, J, 2007) |
| "The standard management of rectal cancer continues to be defined by the results of randomized, clinical trials exploring the optimal timing and use of adjuvant chemotherapy and radiation therapy in relation to surgery." | 1.34 | Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. ( Chao, M; Fong, A; Gibbs, P; Jones, IT; Kipp, D; Lim, L; McLaughlin, S; Millar, JL; Rezo, A; Shapiro, J, 2007) |
| "Here, we report a case of metastatic rectal cancer showing a complete response (CR) to cycle 4 in FOLFIRI regimen, while maintaining a CR status for over 11 months and good QOL, as a result of chemotherapy with 4 cycles of FOLFIRI followed by UFT." | 1.34 | [A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT]. ( Baba, K; Matsuda, M; Tashima, R; Yamashita, Y; Yokoyama, S, 2007) |
| "Thirty-nine patients with colorectal cancer, who received m-FOLFOX6 in our institution, were studied." | 1.34 | [Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients]. ( Fukunaga, S; Hirakawa, K; Inoue, T; Kaizaki, R; Maeda, K; Nakano, T; Noda, E; Shinto, O; Wada, K; Young Kim, W, 2007) |
| " The dosage of FOLFOX 4 was reduced after three courses due to neutropenia and diarrhea." | 1.34 | [A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy]. ( Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M, 2007) |
| "Twenty-six patients with non-metastatic rectal cancer >T1 on pathologic TNM staging who underwent primary laparoscopic surgery were considered for comparison." | 1.34 | Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy. ( Bona, S; Elmore, U; Furlan, N; Romario, UF; Rosati, R, 2007) |
| "We report two cases of advanced low rectal cancer, with preoperative chemo-radiation therapy leading to a complete histological response." | 1.34 | [Two cases of advanced low rectal cancer, preoperative chemo-radiation therapy leading to complete histological response]. ( Fujita, H; Jida, M; Kubo, M; Maeda, H; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Waki, N, 2007) |
| "A 59-year-old man who had rectal cancer, multiple liver metastases and para-aortic LN metastasis underwent a laparoscopic rectal anterior resection." | 1.34 | [A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11]. ( Ide, Y; Kinuta, M; Maruyama, K; Murata, K; Ohta, H; Okada, K; Yasumoto, T; Yokouchi, H, 2007) |
| "In contrast, locally advanced rectal cancers in cUICC-II/-III stages (T3/T4 or N(+)) should receive long-term, 5-FU-based, neoadjuvant chemoradiotherapy according to the excellent results of the CAO/AIO/ARO-94 trial of the German Rectal Cancer Study Group." | 1.33 | [Present treatment strategies for rectal carcinoma]. ( Becker, H; Ghadimi, BM; Langer, C; Liersch, T, 2005) |
| " 5-FU serum concentrations were higher at night time and the peak concentration of 5-FU was obtained at 3 a." | 1.33 | [Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005) |
| "Patients with rectal cancer treated by preoperative chemoradiation showed a surprisingly low rate of micrometastasis detection (7%), even in high-risk patients (T3 and T4 tumors)." | 1.33 | Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. ( Coelho Siqueira, SA; Gama-Rodrigues, JJ; Habr-Gama, A; Kiss, DR; Nishida Arazawa, ST; Perez, RO; Rawet, V, 2005) |
| " This study was to explore relationship of DPD to serum concentration of 5-FU in colorectal cancer patients treated with FOLFOX6 regimen, and their correlation to treatment response and adverse events." | 1.33 | [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. ( Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005) |
| "Complete response (no residual tumour, TRG 1) was seen in 7% of the patients (3/44) and total or major regression (TRG 1-3) in 73% of the patients (32/44) treated with 50-Gy chemoradiation." | 1.33 | Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. ( Jantunen, I; Juhola, M; Kairaluoma, M; Kellokumpu, I; Vironen, J, 2005) |
| "The adjuvant treatment of rectal cancer is a rapidly evolving field." | 1.33 | Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer. ( Chao, M; Cullinan, M; Faragher, I; Gibbs, P; Jones, I; McLaughlin, S; Skinner, I; Tjandra, J, 2005) |
| " These data suggest that 5-FU/l-LV can be given in the outpatient and yields improved prognosis and minimal adverse reactions even in patients in reduced dose or prolonged interval." | 1.33 | [Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer]. ( Chiba, N; Ishioka, C; Kakudo, Y; Kato, S; Ohori, H; Otsuka, K; Sakayori, M; Shibata, H; Takahashi, M; Takahashi, S; Yamaura, G; Yasuda, K; Yoshioka, T, 2005) |
| "Intersphincteric resection of low rectal tumors is a surgical technique extending rectal resection into the intersphincteric space." | 1.33 | Technique and long-term results of intersphincteric resection for low rectal cancer. ( Feil, W; Hölbling, N; Holzer, B; Novi, G; Renner, K; Rosen, HR; Schiessel, R; Urban, M, 2005) |
| "We tested the hypothesis that rectal tumors are most responsive to neoadjuvant therapy if they possess p53 and/or caspase 8 activity." | 1.33 | Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. ( Coppola, D; Kelley, ST; Marcet, J; Yeatman, T, 2005) |
| "Patients with a locally advanced rectal cancer, treated by pre-operative CRT were studied." | 1.33 | Response to neoadjuvant therapy for rectal cancer: influence on long-term results. ( Arriola, E; Biondo, S; Cambray, M; Del Rio, C; Marti-Rague, J; Navarro, M; Novell, V; Pares, D, 2005) |
| "In locally advanced rectal cancer, neoadjuvant 5-fluorouracil (5-FU)-based long-term chemoradiotherapy leads to marked tumor reduction and decrease of local recurrence rate." | 1.33 | Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemorad ( Aust, DE; Baretton, GB; Becker, H; Häusler, P; Jakob, C; Liersch, T; Meyer, W; Schwabe, W, 2005) |
| "To investigate the effect and feasibility of concurrent radiation and chemotherapy combined with endorectal brachytherapy in T3 rectal cancer with complete pathologic remission as end point." | 1.33 | Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. ( Bisgaard, C; Hansen, JW; Jakobsen, A; Lindebjerg, J; Mortensen, JP; Rafaelsen, SR, 2006) |
| "Patients who had rectal cancer with a distal margin within 6 cm of the anal verge had the anus included in the field of radiotherapy (Group A, n = 26)." | 1.33 | Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. ( Chao, MW; Gibbs, P; Hiscock, R; Lim, JF; Tjandra, JJ, 2006) |
| " A decrease of dosage or abundance of continuation was done during the course due to complications." | 1.33 | [Five cases of locally advanced rectal cancer or local recurrence performed intra-arterial infusion chemotherapy via the internal iliac artery]. ( Agata, T; Aoyama, H; Funabashi, M; Hanai, T; Kamano, T; Katsuno, H; Koide, Y; Maeda, K; Masumori, K; Noro, T; Sato, H, 2005) |
| "Twenty pretreatment biopsy samples from rectal cancer patients and their paired, post-CRT surgical specimens (n = 17) were analyzed." | 1.33 | Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. ( El-Hajjar, D; Geradts, J; Groth, J; Iyer, R; Javle, M; Lawrence, D; Watwe, V, 2005) |
| "In 31 patients with a rectal cancer, tumor biopsies were performed before and after pre-operative venous administration of 4 mg/m2, 6 mg/m2, or 10 mg/m2 of MMC." | 1.33 | Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C. ( Fukumitsu, T; Ishibashi, N; Matono, K; Mizobe, T; Ogata, Y; Sasatomi, T; Shirouzu, K; Torigoe, S; Yamashita, N; Yanagawa, T, 2006) |
| "Patients with bilobar colorectal cancer metastases to the liver present a unique problem in terms of resection." | 1.33 | Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved. ( Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL, 2006) |
| "One hundred fifteen patients with rectal cancer were treated with oral 5-fluorouracil or Tegafur with preoperative radiotherapy, surgery, and intraoperative electron beam radiation therapy to identify potential pre- and on-treatment characteristics that might be of prognostic value for disease outcome." | 1.33 | Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. ( Alvarez, E; Calvo, FA; Cortés, J; Del Valle, E; Díaz-González, JA; García-Sabrido, JL; Gómez-Espí, M; Muñoz-Jiménez, F, 2006) |
| "To describe oncocytic change in rectal cancers that have been treated with chemoradiation before surgery." | 1.33 | Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy. ( Chetty, R; Rouzbahman, M; Serra, S, 2006) |
| "Stage II-III rectal cancer patients received 2 cycles of bolus 5-FU (425 mg/m2) and leucovorin (LV) (20 mg/m2) on days 1-5 q3w followed by oral capecitabine (800 mg/m2 bid) continuously during pelvic radiotherapy (total 50." | 1.33 | Capecitabine chemoradiation for rectal cancer after curative surgery. ( Bajetta, E; Beretta, E; Buzzoni, R; Di Bartolomeo, M; Dognini, G; Ferrario, E; Mancin, M; Mariani, L; Valvo, F, 2006) |
| "The clinical diagnosis of multiple pyogenic granulomas was confirmed by histological examination." | 1.33 | Multiple periungual pyogenic granulomas following systemic 5-fluorouracil. ( Cooray, P; Curr, N; Gin, D; Murugasu, A; Saunders, H; Schwarz, M, 2006) |
| " Taken together, the results suggest that a poloxamer gel system with 5-FU/P188/PG is an effective rectal dosage form for the treatment of both rectal and non-rectal cancers." | 1.33 | Poloxamer 188 and propylene glycol-based rectal suppository enhances anticancer effect of 5-fluorouracil in mice. ( Choi, HG; Jeong, TC; Jin, CH; Kim, JA; Lee, YS; Oh, YK; Paek, SH; Park, BC; Xuan, JJ, 2006) |
| "The files of 89 patients with rectal cancer, 43 treated preoperatively with oral capecitabine and 46 with intravenous 5-FU, were reviewed, and the outcome of the groups was compared." | 1.33 | Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil. ( Brenner, B; Dreznik, Z; Dror, Y; Fenig, E; Figer, A; Idelevich, E; Loven, D; Nudelman, I; Shani, A; Stemmer, SM; Sulkes, A; Yerushalmi, R, 2006) |
| "A sample of 83 rectal cancer patients in Dukes' stages B2 or C who started a chemoradiotherapy treatment followed by surgery, have filled in the EORTC core questionnaire QLQC30 and the colorectal module QLQ-CR38, in three moments during the treatment and follow-up periods: at the beginning of the treatment, at the end of the chemoradiotherapy, and after surgery." | 1.33 | Quality of Life assessment through the EORTC questionnaires of locally advanced rectal cancer patients treated with preoperative chemo-radiotherapy. ( Arias de la Vega, F; Arraras Urdaniz, JI; Manterola Burgaleta, A; Martínez Aguillo, M; Salgado Pascual, E; Vera García, R; Villafranca Iturre, E, 2006) |
| "A total of 183 patients with rectal cancer (cT3-T4 or N+) were enrolled in this study." | 1.33 | Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. ( Cho, MJ; Kim, JM; Kim, JS; Kim, KH; Li, S; Nam, JS; Song, KS; Yeo, SG; Yoon, WH, 2006) |
| "Tegafur levels were also higher in tumor samples than other sites (mean 3446." | 1.33 | Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation. ( Aldaz, A; Alvarado, A; Arranz, JA; Calvo, FA; de la Mata, D; García, R; Giráldez, J; Serrano, J; Zufía, L, 2006) |
| "Histologic tumor regression (TR) in rectal cancer after preoperative chemoradiotherapy (CT/RT) may be useful as a surrogate end point for early treatment efficacy, but little is known about its prognostic value." | 1.33 | Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. ( Aust, DE; Baretton, GB; Becker, H; Häusler, P; Jakob, C; Kulle, B; Liersch, T; Meyer, W; Schwabe, W, 2006) |
| "Forty patients with rectal cancer pretherapeutic UICC stage II/III, receiving preoperative FU-based CT/RT (CAO/ARO/AIO-94 trial) followed by standardized surgery, including total mesorectal excision, were investigated." | 1.33 | Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy. ( Aust, DE; Baretton, GB; Becker, H; Ghadimi, BM; Häusler, P; Jakob, C; Kulle, B; Langer, C; Liersch, T; Schwabe, W, 2006) |
| " We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer." | 1.33 | [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. ( Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006) |
| "Perforative rectal cancer was diagnosed, and an emergency laparotomy was done." | 1.33 | [A case of advanced rectal carcinoma, preoperative chemo-radiation therapy leading to histological complete response]. ( Aikou, T; Aridome, K; Baba, K; Hatanaka, S; Ishigami, S; Kato, K; Matsumoto, M; Natsugoe, S; Okumura, H; Onohara, S, 2006) |
| "Capecitabine was not resumed, and the rash resolved in 3 weeks with the use of pyridoxine and Udderly Smooth balm." | 1.33 | Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. ( Diasio, R; Elfiky, A; Saif, MW, 2006) |
| " After that his general condition recovered, and two cycles of neoadjuvant chemotherapy (NAC) by irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) therapy were performed on an outpatient basis." | 1.33 | [A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)]. ( Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K, 2006) |
| "In patients with locally advanced rectal cancer located 3-6 cm from anal verge who are traditionally treated with abdominoperineal resection, preservation of anal sphincter after preoperative chemoradiation therapy plus complete rectal excision with coloanal anastomosis is feasible and is associated with acceptable morbidity and no mortality." | 1.32 | Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis. ( Fernández, R; Gutiérrez De La Barrera, M; Hernández-Pacheco, F; Labastida, S; Luna-Pérez, P; Rodríguez-Ramírez, S, 2003) |
| "Initial treatments of locally advanced rectal cancers focus on local control, as local relapse of a rectal cancer is correlated with a high morbidity and mortality." | 1.32 | A favourable pathological stage after neoadjuvant radiochemotherapy in patients with initially irresectable rectal cancer correlates with a favourable prognosis. ( Hospers, GA; Mulder, NH; Reerink, O; Szabo, BG; Verschueren, RC, 2003) |
| "A remission of lymph node metastasis was accurately shown by rES in 17/19 cases (90%) and by CT in 10/12 cases (83%)." | 1.32 | [Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?]. ( Becker, H; Füzesi, L; Ghadimi, BM; Jakob, C; Langer, C; Liersch, T; Markus, PM; Müller, D; Siemer, A, 2003) |
| "Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy." | 1.32 | Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. ( Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC, 2003) |
| "The local recurrence rate of colorectal cancer has been significantly reduced due to the use of combined radiochemotherapy." | 1.32 | Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer--preliminary results. ( Abdel-Rahman, S; D hmke, E; Ertl-Wagner, B; Issels, RD; Krych, M; Pachmann, S; Schaffer, M; Schaffer, PM, 2003) |
| " At both institutions, concurrent chemotherapy consisted of a continuous infusion of 5-fluorouracil (5-FU) at a dosage of 1500 mg/m(2)/week." | 1.32 | The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. ( Birnbaum, EH; Chandra, A; Crane, CH; Delclos, ME; Feig, BW; Fleshman, JW; Janjan, NA; Kodner, IJ; Lin, EH; Lockett, MA; Myerson, RJ; Phan, T; Picus, J; Read, TE; Singh, AK; Skibber, JM; Thames, HD, 2003) |
| "Pre-operative perfusion in 16 rectal cancer patients achieved a complete response (no tumour in pelvis) in 1 patient and significant tumour regression in 8 patients rendering them potentially resectable." | 1.32 | Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer. ( Begossi, G; Belliveau, J; Levy, A; Wanebo, HJ, 2003) |
| "Capecitabine is an oral fluoropyrimidine used for cancer treatment." | 1.32 | Capecitabine-related neurotoxicity presenting as trismus. ( Couch, LS; Groteluschen, DL; Mulkerin, DL; Stewart, JA, 2003) |
| "The study reviewed Stage II and III rectal cancer patients treated with preoperative chemoradiation and resected for cure." | 1.32 | Response to preoperative chemoradiation in stage II and III rectal cancer. ( Blatchford, GJ; Brown, CL; Christensen, MA; Haynatzki, GR; Shashidharan, M; Ternent, CA; Thorson, AG, 2003) |
| "Curative surgery for rectal cancer seldom requires urinary tract resections." | 1.32 | Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival. ( Chwaliński, M; Nowacki, MP; Oledzki, J; Rogowski, W; Sopyło, R, 2004) |
| "The treatment of colorectal cancer with administration of a 2-h infusion of calcium folinate followed by a 24-h infusion of 5-fluorouracil (5-FU) is a standard therapy." | 1.32 | Catheter occlusion by calcium carbonate during simultaneous infusion of 5-FU and calcium folinate. ( Bruch, HR; Esser, M, 2003) |
| "Rectal cancer is a common malignant disease and occurs not infrequently in younger men." | 1.32 | [Male gonadal dose in adjuvant 3-d-pelvic irradiation after anterior resection of rectal cancer. Influence to fertility]. ( Hensley, F; Piroth, MD; Wannenmacher, M; Zierhut, D, 2003) |
| "We report a rectal cancer case with liver and lung metastases treated successfully with this protocol." | 1.32 | [A case of liver and lung metastases of rectal cancer responding well to 5-FU hepato-arterial infusion (HAI) with combined use of oral UFT]. ( Ebuchi, M; Hasegawa, K; Kato, K; Maruyama, M; Nagahama, T; Shinoura, H; Takashima, I, 2003) |
| "The accuracy of EUS restaging of rectal cancer after chemoradiation has not been extensively studied and its usefulness is unclear." | 1.32 | Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy. ( Lin, DE; Stryker, SJ; Vanagunas, A, 2004) |
| "In stage II (T3-4N0) and III (TxN1-2) rectal cancer, adjuvant radiochemotherapy improves overall survival and decreases the rate of local failure compared to only surgical therapy and is regarded as standard for patients with carcinoma of the lower and intermediate rectum." | 1.32 | [Principles of postoperative therapy in rectal carcinoma]. ( Folprecht, G; Köhne, CH, 2004) |
| " After the operation, weekly bolus of 5-fluorouracil combined with levofolinate was carried out." | 1.32 | [A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil]. ( Inoue, M; Jingu, K; Nakajima, Y; Ochiai, T, 2004) |
| "Twenty-five consecutive patients with rectal cancer were included, with tumor stages (c)T(2-4)N(x)M(0), during the period 1997-1999." | 1.32 | 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. ( Alvarez, E; Arranz, JA; Calvo, FA; Carreras, JL; Desco, M; Domper, M; Martínez-Lázaro, R; Matute, R, 2004) |
| "In the majority of patients with rectal cancer invading perirectal tissues or lymph nodes, lesions downstages by preoperative chemo radiotherapy." | 1.32 | [Preoperative radiation with chemotherapy for rectal cancer: its impact on downstaging of disease and the role of endorectal ultrasound]. ( Juska, P; Pavalkis, D; Pranys, D, 2004) |
| " For both men and women, overweight and obese patients experience less toxicity associated with adjuvant chemoradiotherapy, suggesting that actual body weight dosing of fluorouracil for obese patients is justified." | 1.32 | Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114. ( Benson, AB; Brady, D; Cummings, B; Fuchs, CS; Hollis, DR; Macdonald, JS; Mayer, RJ; McCollum, AD; Meyerhardt, JA; Niedzwiecki, D; O'Connell, MJ; Tepper, JE; Willett, C, 2004) |
| "A total of 145 rectal cancer patients were treated with surgery and postoperative radiochemotherapy." | 1.32 | Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer. ( Berger, J; Heide, J; Krüll, A, 2004) |
| "One hundred and fifty-five rectal cancer patients undergoing preoperative pelvic external beam radiation therapy and 5-fluorouracil-based chemotherapy followed by rectal resection were identified." | 1.32 | Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. ( Gittleman, AE; Guillem, JG; Minsky, BD; Moore, HG; Paty, PB; Saltz, L; Shia, J; Temple, L; Weiser, M; Wong, D, 2004) |
| "Colon and rectal cancer are in France a challenging problem in public health, reaching the second place in cancer related deaths." | 1.32 | [Colorectal cancer: what should be the management of primary tumour?]. ( Delpero, JR; Lelong, B; Moutardier, V, 2004) |
| "We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin." | 1.32 | [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. ( Aoki, T; Ichimiya, H; Kato, K; Katsumata, K; Okada, K; Wakana, Y, 2004) |
| "We report a patient with metastatic colon cancer who developed a hypersensitivity reaction to oxaliplatin during the sixth cycle of combination chemotherapy with oxaliplatin, high-dose 5-fluorouracil and leucovorin." | 1.32 | Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule. ( Chang, MC; Chang, YF; Hsieh, RK; Huang, MJ; Lim, KH; Lin, HC; Lin, J; Su, YW, 2004) |
| "For synchronous liver metastases from rectal cancer, after extirpation of the primary lesion, a transcatheter arterial embolization was postoperatively performed 3 times at 6-month intervals." | 1.32 | [Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report]. ( Ishimaru, S; Kanayama, T, 2004) |
| "To evaluate the effects of 3-dimensional conformal radiation therapy combined with chemotherapy for rectal cancer of postoperative local recurrence." | 1.32 | [Effecting observation of 3-dimensional conformal radiotherapy combined with chemotherapy for rectal cancer of postoperative local recurrence]. ( Chen, LH; Wu, DH, 2004) |
| "Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy." | 1.32 | Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. ( Campos, FG; Gama-Rodrigues, J; Habr-Gama, A; Kiss, DR; Nadalin, W; Perez, RO; Ribeiro, U; Sabbaga, J; Silva e Sousa, AH, 2004) |
| "Expression of p27 in the residual rectal cancer may therefore identify patients with disease likely to be refractory to standard therapy and for whom investigational approaches should be strongly considered." | 1.32 | Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome. ( Guillem, JG; Klimstra, DS; Mazumdar, M; Minsky, BD; Moore, HG; Ruo, L; Saltz, L; Schwartz, GK; Shia, J, 2004) |
| "30 colorectal cancer patients were enrolled into the study to receive adjuvant chemotherapy 2 weeks after cured resection." | 1.32 | [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients]. ( Chen, G; Li, S; Liao, H; Pan, ZZ; Wan, DS; Wang, GQ; Zhou, ZW, 2004) |
| "Surgical specimens were assessed for rectal cancer regression grade." | 1.32 | Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. ( Cunningham, C; Dodds, E; George, BD; Jones, AC; Mortensen, NJ; Warren, BF; Wheeler, JM, 2004) |
| "The utility of the proposed Rectal Cancer Regression Grade must be tested against long-term outcomes before its value in predicting prognosis and survival can be determined." | 1.31 | Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. ( Ekanyaka, N; George, BD; Jones, AC; Kettlewell, MG; Kulacoglu, H; Mortensen, NJ; Warren, BF; Wheeler, JM, 2002) |
| "Capecitabine (Xeloda) is a new orally administered fluoropyrimidine carbamate that was rationally designed to exert its effect by tumor-selective activation." | 1.31 | Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. ( Cho, MJ; Kim, JS; Song, KS; Yoon, WH, 2002) |
| "We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)." | 1.31 | [A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
| "Diarrhea was the major adverse effect of UFT/LV that made patients reduce dosage." | 1.31 | Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer. ( Chen, JS; Hsu, KC; Tang, R; Wang, JY; Yang, TS, 2002) |
| "We report a case of unresectable rectal cancer in a 53-year-old male treated with chemoradiation." | 1.31 | [Long-term complete response in a case of unresectable rectal cancer following chemoradiation]. ( Musha, N; Oka, K; Saito, H; Sando, N; Sasaki, M; Setu, M; Setu, Y; Sunami, E, 2000) |
| " Shaping this infusional 5-FU chemotherapy within the day so that most of the daily dose is delivered around the time of the radiation therapy may further modify the toxic therapeutic ratio of combined modality therapy." | 1.31 | Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer. ( Hrushesky, W; King, V; Rivera, W; Thrall, MM; Wood, P, 2000) |
| "Diarrhea was the most frequent acute toxicity." | 1.31 | Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response. ( Hagihara, PF; John, WJ; Kenady, DE; Marks, G; McGrath, PC; Mohiuddin, M; Regine, WF, 2000) |
| "Eight patients had synchronous distant metastases." | 1.31 | Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer. ( Grabenbauer, GG; Hohenberger, W; Papadopoulos, T; Rödel, C; Sauer, R; Schick, C, 2000) |
| "Patients with primary rectal cancer deemed eligible for preoperative radiation and 5-fluorouracil-based chemotherapy because of a clinically bulky or tethered tumor or endorectal ultrasound evidence of T3 and/or N1 were prospectively enrolled." | 1.31 | Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. ( Akhurst, T; Cohen, AM; Erdi, Y; Finn, RD; Gollub, MJ; Guillem, JG; Humm, J; Klimstra, DS; Larson, S; Macapinlac, H; Mazumdar, M; Minsky, BD; Paty, PB; Puig-La Calle, J; Ruo, L; Saltz, L; Tickoo, S; Yeung, H, 2000) |
| "Treatment of a patient with carcinoid metastases in the liver is discussed." | 1.31 | Targeted chemoembolization of tumors with poly(2-hydroxyethyl methacrylate) particles. ( Adamyan, A; Gumargalieva, K; Guseinov, E; Horák, D; Kokov, L; Skuba, N; Tchjao, A; Titova, M; Trostenyuk, N; Tsvirkun, V; Vishnevskii, V, 2000) |
| "The regimen appears active against rectal cancer, and appears to warrant further consideration as a treatment option for this patient population." | 1.31 | A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer. ( Anscher, MS; Dewhirst, MW; Hurwitz, H; Jowell, P; Lee, C; Prosnitz, LR; Rosner, G; Samulski, T; Tyler, D, 2000) |
| "A continuous, 24-hour 5-fluorouracil administration was made through the bilateral internal iliac artery at a dosage of 250 mg/m2/day by the subcutaneous reservoir located at both upper legs using a Baxter infusor." | 1.31 | Continuous intra-arterial 5-FU chemotherapy in a patient with a repeated recurrence of rectal cancer: report of a case. ( Araki, Y; Inuzuka, K; Isomoto, H; Matsumoto, A; Ogoh, Y; Ozaki, K; Shirouzu, K; Toh, U; Yasunaga, M, 2000) |
| "We report a case of advanced rectal cancer accompanied by unresectable liver metastasis in which remission has been achieved for 7 years." | 1.31 | [A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective]. ( Baba, H; Kikunaga, H; Matsudo, A; Miura, H; Morisue, A; Nakai, H; Osakabe, Y; Sotome, K; Takao, M, 2000) |
| "We discovered metastases in 6 patients (6%) after preoperative therapy." | 1.31 | [The importance of delay in patients with tumors exemplified by pretreatment of locally advanced rectal carcinoma]. ( Gretschel, S; Rau, B; Riess, H; Schlag, PM; Wust, P, 2000) |
| "A 67-year-old female with rectal cancer and multiple liver metastases underwent low anterior resection by total mesorectal excision (TME), cholecystectomy and hepatic arterial cannulation in June 1995." | 1.31 | [Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)]. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2001) |
| "Sixty-five patients with rectal cancer underwent tumor resection after preoperative 5-FU-based chemoradiation." | 1.31 | Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. ( Angeletti, S; Arias, F; Azinovic, I; Brugarolas, A; Dominguez, MA; García-Foncillas, J; Illarramendi, JJ; Martínez Monge, R; Martínez, E; Okruzhnov, Y; Salgado, E; Villafranca, E, 2001) |
| "Two patients were diagnosed with large rectal tumors and localized prostate cancer." | 1.31 | External beam radiotherapy for synchronous rectal and prostatic tumors. ( Kapp, DS; King, C; Siu, W; Terris, MK; Wren, SM, 2001) |
| "Deficiency of dihydropyrimidine dehydrogenase (DPD), the rate-limiting enzyme in 5-fluorouracil (5-FU) catabolism, has been linked to toxic side effects of 5-FU." | 1.31 | Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. ( Behnke, D; Häusler, P; Höffken, K; Raida, M; Schwabe, W; Van Gennip, AH; Van Kuilenburg, AB, 2001) |
| "Severe fatigue was defined as 7-10 on the "worst level of fatigue" item." | 1.31 | Fatigue during preoperative chemoradiation for resectable rectal cancer. ( Cleeland, CS; Crane, CH; Engstrom, MC; Guo, H; Janjan, NA; Johnson, BA; Mendoza, TR; Wang, XS, 2001) |
| "114 patients with rectal cancer were treated by selective preoperative intra-arterial infusion chemotherapy." | 1.31 | [Effects of selective preoperative intra-arterial infusion chemotherapy on apoptosis and proliferation of rectal cancer cells]. ( Li, J; Liu, F; Qi, X, 2000) |
| "Spontaneous apoptosis in rectal cancer may serve as an important predictor of tumor regression from RCT in rectal cancer and as a significant prognosticator of relapse-free survival." | 1.31 | Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer. ( Bigalke, M; Grabenbauer, GG; Günther, K; Papadopoulos, T; Peters, A; Rödel, C; Rödel, F; Sauer, R; Schick, C, 2002) |
| "We performed PMC-CPT-11 therapy (modified pharmacokinetic modulating chemotherapy plus irinotecan, or modified PMC) in a case of sigmoid colon cancer with local invasion and multiple hepatic metastases." | 1.31 | [A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy]. ( Chang, W; Kondo, Y; Kosaka, H; Maeda, S; Matsusaka, S; Okada, T; Oriyama, T, 2002) |
| "Ten patients with invasive distal rectal cancer (six T2, four T3) were treated with preoperative radiotherapy (3600-5040 cGy) with or without 5-fluorouracil based chemotherapy." | 1.31 | Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers. ( Cohen, AM; Guillem, JG; Minsky, BD; Paty, PB; Quan, SH; Ruo, L, 2002) |
| "Capecitabine is a member of a new class of oral fluoropyrimidines." | 1.31 | Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. ( Andrasch, H; Beck, FJ; Frickhofen, N; Fuhr, HG; Jung, B; Sigmund, M, 2002) |
| "For locally advanced primary colorectal cancer, our institution has combined intraoperative electron irradiation (IOERT) with external beam irradiation (EBRT) +/- 5-fluorouracil (5-FU) and surgical resection." | 1.30 | Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1997) |
| "In patients with stage III colon cancer, adjuvant chemotherapy with fluorouracil and levamisole has been shown to produce a 40 percent reduction in the recurrence rate at a median follow-up of 6." | 1.30 | Adjuvant therapy for colon and rectal cancer. ( Ratkin, GA, 1997) |
| "We retrospectively examined the acute toxicity of (neo-)adjuvant combined treatment for rectal cancer in an attempt to evaluate potential factors that influence the severity of toxic side effects." | 1.30 | [The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma]. ( Fietkau, R; Grabenbauer, GG; Keilholz, L; Kessler, H; Martus, P; Rödel, C; Sauer, R, 1997) |
| "Three rectal cancer patients were treated with arterial infusion chemotherapy through the internal iliac artery." | 1.30 | [Arterial infusion chemotherapy in pelvic space for advanced rectal cancer]. ( Aoyama, H; Fukunaga, T; Imazeki, H; Isono, K; Iwasaki, K; Maeda, T; Matsuzaki, H; Miyazaki, S; Nakajima, K; Okazumi, S; Shinotou, K; Shutou, K; Takayama, W; Takeda, A, 1997) |
| "He was diagnosed as rectal cancer with multiple liver metastases." | 1.30 | [A case of multiple liver metastasis and local recurrence from rectal cancer effectively treated by arterial infusion chemotherapy using low-dose 5-fluorouracil, cisplatin and LV]. ( Endo, Y; Kodama, M; Naitoh, H; Okauchi, H; Tani, T; Yamasaki, M, 1997) |
| "Mitomycin C suppository was significantly less toxic compared with intravenous delivery, and higher rectal tissue concentrations were observed from 10 to 30 minutes (P < 0." | 1.30 | Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. ( Ackerman, D; Galandiuk, S; Hofmeister, A; LaRocca, R; Lewis, RK; Myers, SR; Paris, KJ; Pokorny, RM; Wrightson, WR, 1997) |
| "Fluorouracil-induced pneumonitis was subsequently diagnosed." | 1.30 | [A case of fluorouracil-induced pneumonitis]. ( Andou, H; Itoh, K; Tsuda, T, 1997) |
| "5-Fluorouracil, 2600 mg/m2, was administered concurrently with 100 mg/m2 leucovorin over 24 hours of continuous intravenous infusion." | 1.30 | Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience. ( Chen, PM; Chen, WS; Chiou, TJ; Fan, FS; Hsieh, RK; Jiang, JK; Lin, JK; Lin, TC; Liu, JH; Wang, WS; Yen, CC, 1998) |
| "Fifty-five colorectal cancer patients who had continuous intraportal chemotherapy between 1990 and 1993 (treated group) and 130 colorectal cancer patients who did not have portal chemotherapy between 1982 and 1993 (untreated group) were studied to clarify the effects of continuous intraportal chemotherapy on the prognosis." | 1.30 | [Continuous intraportal chemotherapy for prevention of metachronous hepatic metastasis in colorectal cancer]. ( Adachi, W; Amano, J; Kajikawa, S; Koide, N; Koike, S; Kuroda, T; Mihara, M; Nakata, S; Watanabe, H; Yazawa, K, 1998) |
| "Twenty-nine patients with advanced colorectal cancer were divided into four groups, 3 days, 5 days, 7 days, and 10 days." | 1.30 | [Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern]. ( Kaibara, N; Kurayoshi, K; Makino, M; Taniguchi, T; Yamane, N, 1998) |
| "Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread." | 1.30 | [How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998) |
| "5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens." | 1.30 | Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998) |
| "Patients with resectable rectal cancer who received 20 Gy/5 fractions preoperative radiotherapy to the pelvis had excellent local and distant control of disease." | 1.30 | Five fractions of preoperative radiotherapy for selected cases of rectal carcinoma: long-term tumor control and tolerance to treatment. ( Birnbaum, E; Fleshman, J; Fry, R; Genovesi, D; Kodner, I; Lockett, MA; Menteer, J; Myerson, RJ; Picus, J; Read, T; Walz, B, 1999) |
| "The role in colorectal cancer is less clear, although there are some reports that suggest a benefit." | 1.30 | Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999) |
| "To determine the maximum-tolerated dose (MTD) and recommended dose of irinotecan (CPT-11) in combination with fluorouracil (5-FU) and leucovorin (LV), using a biweekly LV5FU2 regimen and increasing doses of CPT-11, and to assess the efficacy of this combination in pretreated patients with colorectal cancer (CRC)." | 1.30 | Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. ( Armand, JP; Bexon, A; Bonnay, M; Ducreux, M; Mahjoubi, M; Méry-Mignard, D; Rougier, P; Seitz, JF; Ychou, M, 1999) |
| "In locally advanced rectal cancer, pre-operative chemo-radiotherapy had a low toxicity profile." | 1.30 | Pre-operative chemo-radiotherapy in locally advanced rectal cancer: is this the way of future management? ( Cameron, F; Dewar, J; Einhorn, S; Elsaleh, H; Joseph, D; Latham, M; Levitt, M; Osborne, M; Robbins, P; Van Hazel, G, 1999) |
| "There was a high expression of PCNA in rectal cancer." | 1.30 | [The proper opportunity of surgery for rectal cancer after preoperative adjuvant chemotherapy]. ( Chen, X; Li, G; Li, J; Liu, F; Qi, X; Xu, Z; Ye, X, 1999) |
| "Patients with hepatic metastases from rectal cancer treated with hepatic artery (HA) chemotherapy have a life expectancy great enough to be at risk for pelvic failure." | 1.29 | Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases. ( Andrews, JC; Cha, C; Ensminger, WD; Lawrence, TS; Robertson, JM, 1996) |
| "Twenty patients with rectal cancer were treated with combined chemoradiation prior to operation, after pretreatment staging of all lesions with transrectal ultrasound (TRUS)." | 1.29 | Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer. ( Blatchford, GJ; Christensen, MA; Meade, PG; Ternent, CA; Thorson, AG, 1995) |
| "All 1992 phase II colorectal cancer abstracts from the 1992 Proceedings of the American Society of Clinical Oncology were reviewed and analyzed for descriptive and quantitative data and conclusions." | 1.29 | The style of early clinical research reporting: what are we saying and how do we say it? ( Gedney, C; Weissman, DE, 1993) |
| "5-Fluorouracil (5-FU) is a chemotherapeutic agent which has been used to treat many solid tumors including cancers of the breast, ovary, cervix, bladder, prostate gland and gastrointestinal tract." | 1.29 | Cardiotoxicity related to 5-fluorouracil chemotherapy: a report of two cases. ( Chao, TY; Wang, WB; Weng, MC, 1995) |
| "The another patient was 61 years old rectum cancer patient with lung and hepatic metastasis (stage V)." | 1.29 | [Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home]. ( Hayashi, K, 1994) |
| "51 patients with metastatic colorectal cancer (stage Dukes D) were treated with intravenous (i." | 1.29 | Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum. ( Dünser, E; Essl, R; Fritz, E; Mascher, H; Micksche, M; Sagaster, P; Teich, G; Umek, H; Wasilewski, M, 1994) |
| " 5-Fluorouracil is given in a dosage of 1000 mg/m2/day as a continuous 24-hour infusion for 4 days." | 1.29 | Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer. ( Cellini, N; Coco, C; De Franco, A; Magistrelli, P; Mattana, C; Netri, G; Picciocchi, A; Roncolini, G; Valentini, V; Vecchio, FM, 1994) |
| "Pharmacokinetic study of anticancer drug is essential for clinical application of cancer chemotherapy." | 1.29 | [Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results]. ( Hagiwara, A; Takahashi, T; Taniguchi, H; Yamaguchi, T, 1993) |
| "In the majority of patients with rectal cancer invading perirectal tissues or lymph nodes, lesions may be downstaged by preoperative adjuvant therapy." | 1.29 | Preoperative adjuvant radiation with chemotherapy for rectal cancer: its impact on stage of disease and the role of endorectal ultrasound. ( Bernini, A; Deen, KI; Madoff, RD; Wong, WD, 1996) |
| " The aim of this study was to evaluate intraoperative radiation therapy (IORT) (flab technique) combined with preoperative or postoperative radiochemotherapy." | 1.29 | Locally advanced rectal cancer: resection and intraoperative radiotherapy using the flab method combined with preoperative or postoperative radiochemotherapy. ( Fink, U; Huber, FT; Molls, M; Siewert, JR; Stepan, R; Zimmermann, F, 1996) |
| "To identify appropriate candidates with rectal cancer for preoperative chemoradiation therapy, the local recurrence rate and clinicopathological characteristics of 232 patients with rectal cancer undergoing curative resection in our department were investigated." | 1.29 | [Preoperative chemoradiation therapy for lower rectal cancer]. ( Iihara, K; Kimura, M; Kitada, M; Murotani, M; Niinobu, T; Nose, T; Ogawa, M; Shibata, T; Takada, T; Takami, M; Tsujinaka, T; Tsukahara, Y; Tsukamoto, F, 1996) |
| "These two cases suggest that dehydration and electrolyte disturbance from high stomal output could be a serious problem following chemoradiation therapy in patients with an ileostomy." | 1.29 | Ileostomy dysfunction with adjuvant chemoradiation for rectal carcinoma requiring in-hospital management: a cause for concern. ( Chen, FC; Mackay, JR; Woods, RJ, 1996) |
| "Distant metastases occurred in 66 patients (54 percent); five-year rate was 72 percent." | 1.29 | Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer. ( Cha, S; Devine, R; Dozois, R; Fieck, JM; Gunderson, LL; Haddock, M; Martenson, JA; Nelson, H; O'Connell, MJ; Wolff, B, 1996) |
| "Palliative treatment of recurrent rectal cancer remains to be a challenge." | 1.28 | Intraarterial 5-FU-infusion and simultaneous radiotherapy as palliative treatment of recurrent rectal cancer. ( Kolotas, C; Kuhn, FP; Schmitt, G; Schnabel, T; Zamboglou, N, 1992) |
| "Twenty patients with rectal cancer underwent the preoperative regimen that consisted of 3,000 cGy delivered in 10 fractions over 12 days with concomitant 5-fluorouracil and mitomycin-C." | 1.28 | Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma. ( Broadwater, JR; Gocio, JC; Hutchins, LF; Klimberg, VS; Lang, NP; Langston, JD; Maners, A; Westbrook, KC, 1992) |
| "5-fluorouracil (5-FU) was infused continuously through an Infuse-A-Port; 360 mg/m2/day for one week after operation, and 180 mg/m2/day for the following three weeks." | 1.28 | [Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer]. ( Kubota, Y; Masaki, T; Ooya, M; Sakaguchi, M; Sameshima, S; Sawada, T; Shinozaki, M; Tsuno, N; Uchiyama, M; Watanabe, T, 1992) |
| "Mitomycin C was given on Day 1 (dose: 15 mg/m2 i." | 1.28 | Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. ( Dobrowsky, W, 1992) |
| "We reported a case of metastatic liver cancer from rectal carcinoma, which was successfully treated by systemic continuous 5-Fluorouracil and intermittent Mitomycin C chemotherapy." | 1.28 | [A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy]. ( Noguchi, S; Shibata, N, 1992) |
| " When 50 U/ml IFN-gamma were combined with 5-FU or FUdR, the antiproliferative effects were synergistic in those cell lines with sensitivity to IFN-gamma as a single agent, but not in the IFN-gamma-insensitive cell lines." | 1.28 | The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines. ( Boven, E; Haisma, HJ; Maas, IW; Pinedo, HM; Schlüper, HM, 1991) |
| "Presence of hepatomegaly emerged as the more significant (P = 0." | 1.28 | Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. ( Ducreux, M; Elias, D; Lasser, PH; Lumbroso, J; Pignon, JP; Rougier, P; Ruffie, P; Tigaud, JM, 1991) |
| " The case history reported here is discussed in relation to dose and scheduling of mitomycin C, and a safe maximum dosage is suggested." | 1.28 | Cancer-associated hemolytic-uremic syndrome with spontaneous resolution. A case report. ( Abdolrahimzadeh, S; Barone, C; Franchi, F; Gozzer, M; Seminara, P, 1991) |
| "Only two of them bore colonic cancer." | 1.28 | Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases. ( Fujita, S; Kusunoki, M; Sakanoue, Y; Shoji, Y; Utsunomiya, J; Yamamura, T; Yanagi, H, 1991) |
| " The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0." | 1.28 | Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. ( Albright, MJ; Atkinson, D; Barker, PB; el-Tahtawy, A; King, M; Ong, R; Presant, CA; Ring, R; Servis, KL; Wolf, W, 1990) |
| "Twelve patients with advanced colorectal cancer were subjected to alternating cycles of treatment with low immunomodulating doses of recombinant alpha-interferon (alpha IFN) + 5-fluorouracil (5FU) or with 5FU alone." | 1.28 | Immunochemotherapy of advanced colorectal cancer with alpha-interferon and 5-fluorouracil. 1. Toxicological studies. ( Bonmassar, E; Bonmassar, G; Cucchiara, G; De Vecchis, L; Lagomarsino Caprino, M; Nunziata, C; Picconi, A; Ricci, F, 1989) |
| "Patients with inoperable rectal cancer have a remote chance of 5-year survival." | 1.27 | Ten years' experience with a multimodality treatment of advanced stages of rectal cancer. ( Wassif, SB, 1983) |
| " In bioavailability studies of CF p." | 1.27 | Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Campbell, J; Creaven, PJ; Herrera, L; Madajewicz, S; Mittelman, A; Perry, A; Petrelli, N; Rustum, YM, 1984) |
| " Isolated hyperthermic liver perfusion at 40 degrees C with an average dosage of 1000 mg 5-FU was performed in 32 patients with liver metastases (29 colorectal carcinomas, 2 carcinoids, 1 primary hepatoma)." | 1.27 | [Isolated liver perfusion in advanced metastases of colorectal cancers]. ( Aigner, KR; Link, KH; Schoch, P; Schwemmle, K; Tonn, JC; Walther, H, 1984) |
| "CR was observed in one case of breast cancer, and PR in 29 cases." | 1.27 | [Cooperative phase II study of spansule tegafur (SF-SP)]. ( Taguchi, T, 1984) |
| "Three rectal cancer patients with partial response (PR) were obtained by oral administration of 800-1200 mg/day of SF-SP." | 1.27 | [The case studies on oral administration of tegafur encapsulated with slow releasing granule (SF-SP) for three rectal patients]. ( Endo, S; Furukawa, R; Katsumi, S; Mukae, S; Sato, T; Sekine, S; Watanabe, I; Watanabe, S, 1984) |
| "Two cohorts of rats, 240 with colon cancer and 150 controls, were assessed clinically and immunologically for their response to tumour and its management which was either by surgical excision alone or by surgical excision combined with either adjuvant chemotherapy or immunotherapy." | 1.27 | Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model. ( House, AK; Maley, MA, 1983) |
| "Of 29 evaluable patients with breast cancer (six of whom had received prior chemotherapy), one achieved a complete response and five achieved a partial response (total response rate, 21%)." | 1.27 | Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers: a phase II study. ( Calman, KC; Crossling, F; Ferguson, C; George, WD; Habeshaw, T; Hutcheon, A; Kaye, SB; McArdle, C; Sangster, G; Smith, D, 1984) |
| "5-Fluorouracil was administered intraperitoneally in maximally tolerated doses from week 26 onwards and failed to influence significantly the development of either benign or malignant tumours." | 1.27 | Chemotherapy of chemically-induced colorectal tumours. ( Gilbert, JM; Kark, AE; Slavin, G; Thompson, EM, 1983) |
| "However, against colo-rectal and stomach cancer, the response rate was only 25% (2/8) and 28." | 1.27 | [Chemotherapy and total body hyperthermia]. ( Kato, N; Yamanaka, N, 1985) |
| "The chemosensitivity of human colorectal cancer was studied in relation to the biological features of the tumor using a human tumor/nude mouse in-vivo system." | 1.27 | Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice. ( Yamada, K, 1987) |
| " In 10 of these tumors, comparative dose-response curves were obtained." | 1.27 | Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA). ( Flentje, D; Flentje, M; Schlag, P, 1986) |
| " Furthermore the differing levels of 5-FU metabolites in normal and malignant tissue could not be correlated with the pharmacokinetic parameters studied." | 1.27 | The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer. ( Chisholm, EM; Finan, PJ; Giles, GR; Woodhouse, L, 1987) |
| "Effect of this treatment on the pain could be evaluated in 16 patients." | 1.27 | Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin. ( Chuang, VP; Claghorn, L; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1985) |
| "The mitomycin C and BCNU were alternated monthly at the start of each FUDR cycle." | 1.27 | Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy. ( Cohen, AM; Higgins, J; Schaeffer, N, 1986) |
| "Sixty-six patients with advanced colorectal cancer were treated with 5-fluorouracil, Mitomycin C, and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea." | 1.27 | The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer. ( Chapman, J; Chinn, B; Demitrish, MM; Enochs, K; Garland, M; Groshko, G; Pederson, B; Rocchio, R; Vaughn, CB; Ward, D, 1986) |
| " However, increase in tegafur dosage volume did not correlate with 5-FU levels." | 1.27 | [5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur]. ( Arima, S; Futami, K; Kinashi, M; Shigeta, M; Shimura, H, 1986) |
| "The sensitivity of human colorectal cancer to 5-fluorouracil (5-FU) and its derivatives: 1-(tetrahydro-2-furyl)-5-FU (tegafur) and 1-hexylcarbamoyl-5-FU (HCFU) was determined by in vitro succinate dehydrogenase inhibition (SDI) test and in vivo subrenal capsule (SRC) assay." | 1.27 | [Human colorectal carcinoma is more sensitive to HCFU than 5-FU and tegafur in in vitro and in vivo drug sensitivity tests]. ( Anai, H; Fukuchi, K; Kusumoto, H; Kusumoto, T; Maehara, Y; Miyamoto, K; Sugimachi, K, 1988) |
| "Since colorectal cancer tissues are resistant to various antitumor drugs, the chemosensitivity test of HCFU should aid in determining the effects of a particular drug for an individual patient." | 1.27 | Colorectal carcinoma in vitro is more sensitive to 1-hexylcarbamoyl-5-fluorouracil compared with six other antitumor drugs: carboquone, Adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil. ( Anai, H; Kusumoto, H; Kusumoto, T; Maehara, Y; Sugimachi, K, 1988) |
| "Fifteen patients with stomach cancer and colorectal cancer were orally administered 600 mg of UFT before operation and the concentration of tegafur, 5-fluorouracil (5-FU) and uracil in the tissues and serum were measured by chemical assay." | 1.27 | [The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT]. ( Kikuchi, K; Kunii, Y; Mori, Y; Nitta, A; Saitou, T; Takahashi, N, 1988) |
| "Excisions of metastatic liver cancer were performed in 23 pts and 15 pts had nonresectable metastatic liver cancer." | 1.27 | [Results of intra-arterial infusion chemotherapy in colorectal cancer patients with metastatic liver cancer]. ( Hojo, K; Moriya, Y; Sawada, T, 1988) |
| "Twenty-three patients with advanced colorectal cancer were treated with folinic acid (200 mg/m2/day 1-5 IV bolus injection) and 5-fluorouracil (400 mg/m2/day 1-5 IV in 15 minutes) every 28 days." | 1.27 | High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer. ( Bartolucci, R; Brugia, M; Buzzi, F; Di Costanzo, F; Padalino, D, 1988) |
| "However, it is unfortunate that colorectal cancer screening in young patients is difficult because of the low rates of precancerous states (4%)." | 1.27 | Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. ( Astre, C; Domergue, J; Ismail, M; Joyeux, H; Pujol, H; Saint-Aubert, B; Solassol, C, 1988) |
| "The results of combined treatment for rectal cancer including preoperative intraarterial chemotherapy are discussed." | 1.27 | [Preliminary results of preoperative regional chemotherapy of cancer of the rectum]. ( Mel'nikov, RA; Mosidze, BA, 1988) |
| " There have been a number of reports relating the plasma levels of cytotoxic agents with pharmacodynamic parameters." | 1.27 | Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases. ( Goldberg, JA; Kerr, DJ; McArdle, CS; McKillop, JH; Willmott, N, 1988) |
| "In patients with colorectal cancer metastatic to the liver, partial response (PR) rates in Regimens I and II were 38% and 62%, respectively." | 1.27 | Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers. ( Hamazoe, R; Ishiguro, M; Koga, S; Maeta, M; Murakami, A; Sawada, T; Shimizu, N, 1988) |
| "32 cases of colon cancer were given I/V 5-fluorouracil for at least one year." | 1.27 | Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital. ( Chia, KB; Chua, EJ; Khor, TH; Sethi, VK; Tan, BC; Tan, TM, 1987) |
| "Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d." | 1.27 | High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986) |
| "Colorectal cancer is one of the most resistant tumors to chemotherapy." | 1.27 | [Chemotherapy of advanced and recurrent colorectal cancer]. ( Tominaga, T, 1986) |
| "We treated 45 patients with advanced colon cancer with HDFA and 5-FU for 5 consecutive days." | 1.27 | High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer. ( Astone, A; Barone, C; Cassano, A; Cavallaro, A; Garufi, C; Grieco, A; Netri, G; Noviello, MR; Ricevuto, E; Rossi, S, 1987) |
| "In the colorectal cancer group, the response rate for Regimen A was 28." | 1.27 | [Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group]. ( Akazawa, S; Futatsuki, K; Kanamaru, R; Miyazaki, T; Murakami, M; Niitsu, Y; Ota, K; Sakai, Y; Wakui, A; Yokoyama, M, 1987) |
| "Patients with metastatic colorectal cancer confined to the liver received fluorodeoxyuridine (FUdR) through the hepatic artery or through the portal vein." | 1.27 | Tumor and liver drug uptake following hepatic artery and portal vein infusion. ( Daly, JM; Kemeny, N; Ridge, JA; Sigurdson, ER, 1987) |
| "Eleven non-resectable cancer patients have been successfully treated by means of a one-shot and continuous intra-arterial infusion chemotherapy, utilizing an implantable vascular access device (Catheter Access) connected to a continuous infusion pump (Nipro portable syringe infusion pump) via a non-corning needle (Nipro coreless needle set)." | 1.27 | [Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump]. ( Agishi, T; Fuchinoue, S; Honda, H; Nakagawa, Y; Nakazawa, H; Ohta, K; Takahashi, K; Teraoka, S, 1987) |
| "Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion." | 1.27 | Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986) |
| " While the in vitro studies failed to reveal any synergism between 5-FU and MND, pharmacokinetic evaluation revealed that 5-FU clearance was significantly reduced (26." | 1.27 | 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies. ( Ayoub, J; Bardakji, Z; Besner, JG; Jolivet, J; Langelier, Y, 1986) |
| " Since toxicity is a prominent impediment, the possibility of therapeutic synergy may perhaps be explored at drastically reduced doses of PALA, combined with other modulating measures." | 1.27 | Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer. ( Camacho, FJ; Engstrom, PF; Green, MD; Greenwald, ES; Kaplan, BH; Muggia, FM; Wernz, JC, 1987) |
| " Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs." | 1.27 | Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985) |
| "Five patients with colorectal cancer and unresectable synchronous liver metastases have survived for over five years at this writing." | 1.27 | Long-term survivors of colorectal cancer with unresectable hepatic metastases. ( Fujimoto, S; Higuchi, M; Kitsukawa, Y; Miyazaki, M; Okui, K, 1985) |
| "For many years surgery has been the treatment of choice for squamous cell carcinoma of the anus, but it is now becoming apparent that well-planned definitive radiation therapy combined with chemotherapy may obviate the need for an abdomino-perineal resection." | 1.27 | The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum. ( Sischy, B, 1985) |
| "Multimodality therapy for colorectal cancer is composed of surgery, chemotherapy and irradiation; and hyperthermia joins them recently." | 1.27 | [Multimodality therapy of colorectal cancer]. ( Fujimoto, S; Miyazaki, M; Okui, K, 1985) |
| "Thirty-six patients with advanced colorectal cancer whose disease progressed during treatment with 5-fluorouracil (5-FU) chemotherapy were treated with methyl-CCNU and methotrexate." | 1.27 | Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy. ( Bazos, MJ; Evans, WK; Myers, R; Shepherd, FA; Zorzitto, ML, 1986) |
| "In group A for gastric cancer and in group C for colon cancer, the histological response was stronger at the edge of the cancer than at its surface." | 1.27 | [Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer]. ( Hashizume, Y; Hirano, M; Iwa, T; Kawaura, Y; Ohmura, K; Sakatoku, M; Takayama, K; Yamada, T, 1985) |
| " In pharmacokinetic studies in five patients, both schedules produced prolonged plasma beta-half-lives of 5-FU (96-189 minutes)." | 1.27 | Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma. ( Chun, H; Kemeny, N; Lynch, G; Martin, D; Young, C, 1985) |
| "Twenty-nine patients with advanced colorectal cancer were treated with methotrexate (MTX) 200 mg/m2 followed 1 h later by fluorouracil (FU) (1000 mg/m2) and 24 h later by oral leucovorin 20 mg every 6 h for six doses." | 1.27 | A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer. ( Ford, J; Margolese, R; Panasci, L, 1985) |
| "Allopurinol has been shown to decrease the gastro-intestinal and bone marrow toxicity of 5-fluorouracil." | 1.27 | Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity. ( Clark, PI; Slevin, ML, 1985) |
| "Treatment of colorectal cancer beyond surgical resection has had only minimal success in the past." | 1.27 | Colorectal cancer: speculations on the role of intraperitoneal therapy. ( Muggia, FM, 1985) |
| "Other nonneoplastic gastrointestinal disorders showed an 18% abnormal CSAp titer frequency, of which more than half bordered the upper limit of normalcy." | 1.26 | Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer. ( Goldenberg, DM; Nelson, MO; Pant, KD; Shochat, D, 1982) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 1.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "A retrospective study of 37 colorectal cancer patients with synchronous liver metastases was made." | 1.26 | Comparative efficacy of antitumor treatment for liver metastases from colorectal cancer. ( Fujimoto, S; Kitsukawa, Y; Miyazaki, M; Okui, K, 1981) |
| " Further evaluation of vindesine will require dosage modification." | 1.26 | Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea. ( Bedikian, AY; Bennetts, RW; Bodey, GP; Karlin, DA; Stroehlein, JR; Valdivieso, M, 1982) |
| "Twenty-seven patients with liver metastasis from colorectal cancer were treated with intrahepatic arterial chemotherapy and external radiotherapy consisting of 5-fluorouracil (5-FU) (10 mg/kg/day for 8 days), adriamycin (5 mg/m2/day for 7 days) and methotrexate (MTX) (240 mg/m2/X1), combined with 2,100 rads of whole liver irradiation." | 1.26 | Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate. ( Friedman, MA; Phillips, TL; Resser, KJ; Volberding, PA, 1982) |
| "Two patients with advanced rectal cancer, women aged 73 and 49 years, have survived more than nine years with chemotherapy only and no surgical removal of the disease foci." | 1.26 | Long-term survivors with nonresectable advanced carcinoma of the rectum. ( Fukuda, I; Iwanaga, T; Koyama, H; Otani, T; Taniguchi, H, 1981) |
| "Treatment with Semustine (Methyl-CCNU) resulted in a partial response lasting 15 months." | 1.26 | Response of metastatic cloacogenic carcinoma to treatment with semustine. ( Wampler, GL; Zimm, S, 1981) |
| "Less than 20% of advanced colorectal cancers respond to chemotherapy." | 1.26 | Chemotherapy for gastrointestinal malignancy. ( Balint, JA; Van der Veer, LD, 1980) |
| "46 patients with rectal cancer were treated preoperatively with intrarectal administration of 5-FU emulsion (25 cases) or 5-FU suppositories (21 cases) for a period of 10 days before surgery, and the histological effect of this regimen on the metastatic lesion in the lymph nodes, as well as in the primary tumor was examined." | 1.26 | Clinical studies of intrarectal administration of 5-FU emulsion as an adjunct to surgical treatment of rectal cancer. ( Fijita, Y; Kojima, O; Majima, S; Morisawa, K; Nishioka, B; Umehara, M; Watanabe, S; Yamane, E, 1980) |
| "The role of chemotherapy in colorectal cancer is still not precisely defined." | 1.26 | [Incurable colorectal cancer. Possibilities and limits of differentiated therapy (author's transl)]. ( Rauchenberger, B; Winkler, R, 1977) |
| "A group of 24 patients with colorectal cancer and another group of 28 patients with 13 different primaries were treated." | 1.26 | Treatment of hepatic metastases by percutaneous hepatic arterial infusion. ( Minton, JP; Petrek, JA, 1979) |
| "Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2." | 1.26 | Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study. ( Buroker, T; Groppe, C; Guy, G; Heilbrun, L; Hoogstraten, B; McCracken, J; Padilla, F; Quagliana, J; Vaitkevicius, VK, 1979) |
| "Relief of pain was noted in two-thirds of the patients." | 1.26 | Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer. ( Hafström, L; Jönsson, PE; Landberg, T; Owman, T; Sundkvist, K, 1979) |
| "Fifty-two patients with advanced colorectal cancer were treated with a combination of 5-Fluorouracil (FU) plus methyl-1,3-cis (2-chlorethyl)-1-nitrosourea (MeCCNU)." | 1.26 | Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer. ( Frei, E; Lokich, JJ; Mayer, RJ; Skarin, AT, 1977) |
| "Although advanced gastrointestinal cancer is the most commonplace problem encountered by the medical oncologist, this group of diseases has proved exceedingly resistant to past chemotherapy efforts." | 1.25 | Clinical management of advanced gastrointestinal cancer. ( Moertel, CG, 1975) |
| "The roles of lysosomal enzymes in colorectal cancer are discussed." | 1.25 | Arylsulfatse B in colorectal cancer. ( Krementz, ET; Meeker, W; Morgan, LR; Samuels, MS; Thomas, W, 1975) |
| "There was no clinical evidence of carcinoid syndrome." | 1.25 | 5-Hydroxyindole-secreting rectal carcinoid tumour. ( Cheetham, HD; Murray-Lyon, IM; Sandler, M; Watts, JA; Williams, R, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 621 (23.79) | 18.7374 |
| 1990's | 350 (13.41) | 18.2507 |
| 2000's | 684 (26.21) | 29.6817 |
| 2010's | 765 (29.31) | 24.3611 |
| 2020's | 190 (7.28) | 2.80 |
| Authors | Studies |
|---|---|
| Tataryn, B | 1 |
| Kryzhanivska, A | 1 |
| Holotiuk, V | 1 |
| Andriiv, A | 1 |
| Ivantsіv, O | 1 |
| Catenacci, DVT | 1 |
| Diefenhardt, M | 4 |
| Ludmir, EB | 3 |
| Hofheinz, RD | 20 |
| Ghadimi, M | 13 |
| Minsky, BD | 41 |
| Fleischmann, M | 1 |
| Fokas, E | 12 |
| Rödel, C | 37 |
| Rosati, G | 4 |
| Corsi, D | 1 |
| Avallone, A | 7 |
| Brugnatelli, S | 1 |
| Dell'Aquila, E | 1 |
| Cinausero, M | 1 |
| Aprile, G | 2 |
| Cicero, G | 1 |
| Carlomagno, C | 4 |
| Colombo, A | 2 |
| Rapisardi, S | 1 |
| Pinto, C | 5 |
| Reggiardo, G | 1 |
| Bilancia, D | 1 |
| Marin, S | 1 |
| Pérez-Cordón, L | 1 |
| Salvà, F | 1 |
| Camps, M | 1 |
| Campins, L | 1 |
| Lianes, P | 1 |
| Touati, R | 1 |
| Cohen, R | 1 |
| Li, N | 5 |
| Zhu, Y | 8 |
| Liu, LY | 2 |
| Feng, YR | 2 |
| Wang, WL | 1 |
| Wang, J | 14 |
| Wang, H | 7 |
| Li, GF | 1 |
| Tang, Y | 6 |
| Hu, C | 2 |
| Liu, WY | 2 |
| Ren, H | 3 |
| Wang, SL | 3 |
| Wang, WH | 5 |
| Song, YW | 5 |
| Liu, YP | 6 |
| Fang, H | 5 |
| Lu, NN | 2 |
| Chen, B | 2 |
| Qi, SN | 2 |
| Liu, XF | 3 |
| Li, YX | 7 |
| Jin, J | 8 |
| Lutsyk, M | 2 |
| Turgeman, I | 1 |
| Bar-Sela, G | 1 |
| Lee, J | 3 |
| Koom, WS | 8 |
| Byun, HK | 1 |
| Yang, G | 2 |
| Kim, MS | 2 |
| Park, EJ | 2 |
| Ahn, JB | 9 |
| Beom, SH | 4 |
| Kim, HS | 3 |
| Shin, SJ | 6 |
| Kim, K | 3 |
| Chang, JS | 3 |
| De Felice, F | 5 |
| Musio, D | 4 |
| Tombolini, V | 4 |
| Cortesi, E | 3 |
| Ichikawa, N | 2 |
| Homma, S | 2 |
| Funakoshi, T | 2 |
| Hattori, M | 3 |
| Sato, M | 3 |
| Kamiizumi, Y | 2 |
| Omori, K | 2 |
| Nomura, M | 4 |
| Yokota, R | 2 |
| Koike, M | 2 |
| Kon, H | 2 |
| Takeda, K | 3 |
| Ishizu, H | 2 |
| Matsuoka, S | 2 |
| Hirose, K | 2 |
| Ishikawa, T | 8 |
| Murata, R | 2 |
| Iijima, H | 3 |
| Yoshida, T | 5 |
| Minagawa, N | 3 |
| Takahashi, N | 5 |
| Taketomi, A | 2 |
| Rong, X | 1 |
| Liu, H | 5 |
| Yu, H | 2 |
| Zhao, J | 2 |
| Wang, Y | 5 |
| Chiloiro, G | 1 |
| Cusumano, D | 1 |
| Boldrini, L | 1 |
| Romano, A | 1 |
| Placidi, L | 1 |
| Nardini, M | 1 |
| Meldolesi, E | 1 |
| Barbaro, B | 9 |
| Coco, C | 14 |
| Crucitti, A | 1 |
| Persiani, R | 1 |
| Petruzziello, L | 1 |
| Ricci, R | 3 |
| Salvatore, L | 2 |
| Sofo, L | 4 |
| Alfieri, S | 2 |
| Manfredi, R | 1 |
| Valentini, V | 27 |
| Gambacorta, MA | 11 |
| Yamada, K | 5 |
| Ioka, T | 2 |
| Suzuki, N | 3 |
| Yoshida, S | 5 |
| Tomochika, S | 1 |
| Matsukuma, S | 1 |
| Matsui, H | 2 |
| Shindo, Y | 2 |
| Tokumitsu, Y | 2 |
| Watanabe, Y | 5 |
| Iida, M | 4 |
| Takeda, S | 3 |
| Hazama, S | 2 |
| Ueno, T | 2 |
| Nagano, H | 3 |
| Tsujio, G | 1 |
| Muguruma, K | 4 |
| Eguchi, S | 2 |
| Iseki, Y | 2 |
| Miki, Y | 3 |
| Yoshii, M | 1 |
| Fukuoka, T | 3 |
| Tamura, T | 4 |
| Shibutani, M | 3 |
| Nagahara, H | 6 |
| Toyokawa, T | 3 |
| Tanaka, H | 8 |
| Lee, S | 3 |
| Yashiro, M | 2 |
| Ohira, M | 3 |
| Taniguchi, A | 1 |
| Adachi, Y | 2 |
| Kimura, Y | 4 |
| Iitaka, D | 1 |
| Nagata, T | 1 |
| Iwata, G | 1 |
| Yamaoka, N | 1 |
| Kagawa, Y | 6 |
| Inoue, A | 2 |
| Nishizawa, Y | 4 |
| Kawai, K | 7 |
| Ohta, T | 3 |
| Hata, T | 10 |
| Naito, A | 2 |
| Komatsu, H | 1 |
| Miyazaki, Y | 1 |
| Tomokuni, A | 1 |
| Motoori, M | 4 |
| Fujitani, K | 1 |
| Kato, T | 14 |
| Takeda, Y | 4 |
| Murata, K | 7 |
| Song, JH | 3 |
| Lee, JH | 19 |
| Kim, SH | 13 |
| Um, JW | 1 |
| McCleary, NJ | 1 |
| Zhang, S | 2 |
| Ma, C | 1 |
| Ou, FS | 1 |
| Bainter, TM | 1 |
| Venook, AP | 3 |
| Niedzwiecki, D | 6 |
| Lenz, HJ | 8 |
| Innocenti, F | 1 |
| O'Neil, BH | 3 |
| Polite, BN | 4 |
| Hochster, HS | 1 |
| Atkins, JN | 3 |
| Goldberg, RM | 3 |
| Ng, K | 1 |
| Mayer, RJ | 14 |
| Blanke, CD | 4 |
| O'Reilly, EM | 2 |
| Fuchs, CS | 4 |
| Meyerhardt, JA | 4 |
| Hagiwara, Y | 1 |
| Yamamoto, Y | 10 |
| Inagaki, Y | 1 |
| Tomisaki, R | 1 |
| Tsuji, M | 1 |
| Fukuda, S | 3 |
| Onoda, T | 1 |
| Suzuki, H | 4 |
| Niisato, Y | 1 |
| Tange, Y | 1 |
| Ikeda, N | 2 |
| Kobayashi, M | 4 |
| Akutsu, D | 1 |
| Yamada, T | 10 |
| Moriwaki, T | 3 |
| Narasaka, T | 1 |
| Tsuchiya, K | 1 |
| Tamburini, E | 3 |
| Tassinari, D | 2 |
| Ramundo, M | 1 |
| De Stefano, A | 4 |
| Viola, MG | 1 |
| Romano, C | 2 |
| Elia, MT | 1 |
| Zanaletti, N | 1 |
| Rudnas, B | 1 |
| Casadei-Gardini, A | 1 |
| Delrio, P | 4 |
| Toma, I | 1 |
| Granata, V | 2 |
| Petrucelli, L | 1 |
| Huang, W | 2 |
| Zhang, H | 6 |
| Tian, Y | 1 |
| Cha, Y | 1 |
| Xiong, H | 1 |
| Yuan, X | 1 |
| Ge, P | 1 |
| Reyila, A | 1 |
| Li, XY | 1 |
| Liu, SY | 1 |
| Jiang, YX | 1 |
| Yang, YJ | 2 |
| Li, XL | 1 |
| Bian, Y | 1 |
| Jo, H | 1 |
| Lee, MS | 1 |
| Lee, YP | 1 |
| Kim, H | 10 |
| Hong, JY | 1 |
| Park, SH | 3 |
| Park, JO | 5 |
| Park, YS | 9 |
| Lim, HY | 1 |
| Kang, WK | 3 |
| Kim, ST | 1 |
| Hiramatsu, S | 1 |
| Sugimoto, A | 1 |
| On, O | 1 |
| Aomatsu, K | 1 |
| Liang, YH | 1 |
| Liang, JT | 4 |
| Lin, BR | 1 |
| Huang, J | 1 |
| Hung, JS | 1 |
| Lai, SL | 1 |
| Chen, TC | 1 |
| Tsai, JH | 1 |
| Cheng, YM | 1 |
| Tsao, TH | 1 |
| Hsu, WL | 1 |
| Chen, KH | 1 |
| Yeh, KH | 1 |
| Matsubara, Y | 1 |
| Masuishi, T | 1 |
| Ogata, T | 1 |
| Nakazawa, T | 1 |
| Kato, K | 10 |
| Nozawa, K | 2 |
| Narita, Y | 1 |
| Honda, K | 4 |
| Bando, H | 2 |
| Taniguchi, H | 11 |
| Kadowaki, S | 1 |
| Ando, M | 5 |
| Tajika, M | 1 |
| Muro, K | 4 |
| Mehta, R | 1 |
| Frakes, J | 2 |
| Kim, J | 4 |
| Nixon, A | 1 |
| Liu, Y | 4 |
| Howard, L | 1 |
| Martinez Jimenez, ME | 1 |
| Carballido, E | 1 |
| Imanirad, I | 3 |
| Sanchez, J | 1 |
| Dessureault, S | 1 |
| Xie, H | 4 |
| Felder, S | 2 |
| Sahin, I | 1 |
| Hoffe, S | 2 |
| Malafa, M | 1 |
| Kim, R | 3 |
| Punt, CJA | 3 |
| Kwakman, JJM | 1 |
| Mol, L | 1 |
| Kim, JG | 10 |
| Baik, SH | 6 |
| Shin, SH | 1 |
| Park, I | 1 |
| Lee, MA | 4 |
| Jeon, SY | 1 |
| Han, SW | 1 |
| Kang, MH | 2 |
| Oh, J | 1 |
| Kim, JS | 12 |
| Kim, JY | 3 |
| Ahn, MS | 1 |
| Zang, DY | 2 |
| Bae, BN | 1 |
| Jo, HJ | 1 |
| Kim, HK | 2 |
| Kim, JH | 27 |
| Yoon, JA | 1 |
| Kim, DH | 3 |
| Bello Crespo, M | 1 |
| Trujillano Ruiz, A | 1 |
| Gajete Pablos, MA | 1 |
| Roa García, DM | 1 |
| Gioseffi, HA | 1 |
| Jimenez-Fonseca, P | 1 |
| Salazar, R | 2 |
| Valenti, V | 2 |
| Msaouel, P | 1 |
| Carmona-Bayonas, A | 1 |
| Nishina, T | 2 |
| Sakai, Y | 5 |
| Shimada, M | 2 |
| Ishida, H | 6 |
| Amagai, K | 1 |
| Endo, S | 6 |
| Negoro, Y | 2 |
| Kuramochi, H | 2 |
| Denda, T | 3 |
| Hatachi, Y | 1 |
| Ikezawa, K | 1 |
| Nakajima, G | 2 |
| Bando, Y | 2 |
| Tsuji, A | 2 |
| Morimoto, M | 1 |
| Kobayashi, K | 7 |
| Hyodo, I | 3 |
| Garcia-Aguilar, J | 12 |
| Patil, S | 5 |
| Gollub, MJ | 7 |
| Kim, JK | 2 |
| Yuval, JB | 2 |
| Thompson, HM | 2 |
| Verheij, FS | 2 |
| Omer, DM | 2 |
| Lee, M | 4 |
| Dunne, RF | 1 |
| Marcet, J | 4 |
| Cataldo, P | 3 |
| Polite, B | 1 |
| Herzig, DO | 4 |
| Liska, D | 2 |
| Oommen, S | 4 |
| Friel, CM | 2 |
| Ternent, C | 1 |
| Coveler, AL | 1 |
| Hunt, S | 4 |
| Gregory, A | 1 |
| Varma, MG | 3 |
| Bello, BL | 1 |
| Carmichael, JC | 1 |
| Krauss, J | 1 |
| Gleisner, A | 1 |
| Paty, PB | 16 |
| Weiser, MR | 9 |
| Nash, GM | 4 |
| Pappou, E | 2 |
| Guillem, JG | 18 |
| Temple, L | 2 |
| Wei, IH | 2 |
| Widmar, M | 2 |
| Lin, S | 1 |
| Segal, NH | 2 |
| Cercek, A | 5 |
| Yaeger, R | 3 |
| Smith, JJ | 5 |
| Goodman, KA | 6 |
| Wu, AJ | 3 |
| Saltz, LB | 10 |
| Araujo, RO | 1 |
| Vieira, FM | 1 |
| Victorino, AP | 1 |
| Torres, C | 1 |
| Martins, I | 1 |
| Guaraldi, S | 1 |
| Valadão, M | 1 |
| Linhares, E | 1 |
| Ferreira, CG | 1 |
| Thuler, LC | 1 |
| Shimano, R | 1 |
| Kotake, M | 1 |
| Ida, A | 2 |
| Hashimoto, M | 3 |
| Saito, H | 2 |
| Sawada, K | 1 |
| Oshima, M | 1 |
| Hada, M | 1 |
| Kato, Y | 1 |
| Oyama, K | 4 |
| Hara, T | 2 |
| Inaki, N | 1 |
| van Dijk, E | 1 |
| van Werkhoven, E | 1 |
| Asher, R | 1 |
| Mooi, JK | 1 |
| Espinoza, D | 1 |
| van Essen, HF | 1 |
| van Tinteren, H | 2 |
| van Grieken, NCT | 1 |
| Tebbutt, NC | 4 |
| Ylstra, B | 1 |
| Schlechter, BL | 1 |
| Fischer, LE | 1 |
| Stintzing, S | 12 |
| von Weikersthal, LF | 4 |
| Modest, DP | 9 |
| Decker, T | 3 |
| Kiani, A | 2 |
| Kaiser, F | 4 |
| Al-Batran, SE | 1 |
| Heintges, T | 2 |
| Lerchenmüller, C | 1 |
| Kahl, C | 3 |
| Seipelt, G | 1 |
| Kullmann, F | 2 |
| Stauch, M | 3 |
| Scheithauer, W | 6 |
| Giessen-Jung, C | 1 |
| Uhlig, J | 1 |
| Peuser, B | 1 |
| Denzlinger, C | 2 |
| Stahler, A | 7 |
| Weiss, L | 1 |
| Heinrich, K | 4 |
| Held, S | 6 |
| Jung, A | 2 |
| Kirchner, T | 2 |
| Heinemann, V | 12 |
| Martínez-Lago, N | 1 |
| Cameselle García, S | 1 |
| Alonso de Castro, B | 1 |
| Gómez-Randulfe Rodríguez, MI | 1 |
| Carmona Campos, M | 1 |
| González Villarroel, P | 1 |
| Salgado Fernández, M | 1 |
| De la Cámara Gómez, JC | 1 |
| Romero Reinoso, C | 1 |
| Cousillas Castiñeiras, A | 1 |
| Méndez Méndez, JC | 1 |
| Vidal Insua, Y | 1 |
| Fernández-Montes, A | 1 |
| Moretto, R | 3 |
| Elliott, A | 1 |
| Rossini, D | 5 |
| Intini, R | 1 |
| Conca, V | 3 |
| Pietrantonio, F | 8 |
| Sartore-Bianchi, A | 1 |
| Antoniotti, C | 4 |
| Rasola, C | 1 |
| Scartozzi, M | 1 |
| Salati, M | 1 |
| Pella, N | 1 |
| Calegari, MA | 1 |
| Carullo, M | 2 |
| Corti, F | 1 |
| Mauri, G | 1 |
| Fassan, M | 3 |
| Masi, G | 3 |
| Brodskiy, P | 1 |
| Shields, A | 1 |
| Lonardi, S | 11 |
| Korn, M | 1 |
| Cremolini, C | 8 |
| Arai, H | 3 |
| Millstein, J | 2 |
| Yang, Y | 3 |
| Battaglin, F | 2 |
| Kawanishi, N | 2 |
| Jayachandran, P | 2 |
| Soni, S | 2 |
| Zhang, W | 7 |
| Zhou, YW | 1 |
| Long, YX | 1 |
| Liu, X | 2 |
| Liu, JY | 1 |
| Qiu, M | 1 |
| Watanabe, J | 4 |
| Maeda, H | 3 |
| Nagasaka, T | 2 |
| Yokota, M | 1 |
| Hirata, K | 6 |
| Akazawa, N | 1 |
| Shiozawa, M | 3 |
| Ando, T | 3 |
| Mishima, H | 3 |
| Sakamoto, J | 6 |
| Oba, K | 3 |
| Nagata, N | 1 |
| Xiao, Y | 7 |
| Loupakis, F | 1 |
| Mancao, C | 1 |
| Liu, T | 5 |
| Falcone, A | 5 |
| Shen, L | 3 |
| Porretto, CM | 1 |
| Aparicio, J | 3 |
| Virgili Manrique, AC | 1 |
| Capdevila, J | 4 |
| Muñoz Boza, F | 1 |
| Galván, P | 1 |
| Richart, P | 1 |
| Oliveres, H | 1 |
| Páez, D | 3 |
| Hernando, J | 1 |
| Serrano, S | 1 |
| Vera, R | 4 |
| Hernandez-Yagüe, X | 1 |
| Gallego, RÁ | 1 |
| Riesco-Martinez, MC | 1 |
| García de Albeniz, X | 1 |
| Maurel, J | 6 |
| Schmulenson, E | 1 |
| Bovet, C | 1 |
| Theurillat, R | 1 |
| Decosterd, LA | 1 |
| Largiadèr, CR | 1 |
| Prost, JC | 1 |
| Csajka, C | 1 |
| Bärtschi, D | 1 |
| Guckenberger, M | 2 |
| von Moos, R | 3 |
| Bastian, S | 1 |
| Joerger, M | 1 |
| Jaehde, U | 2 |
| Chrabaszcz, S | 1 |
| Rajeev, R | 1 |
| Witmer, HDD | 1 |
| Dhiman, A | 1 |
| Klooster, B | 1 |
| Gamblin, TC | 1 |
| Banerjee, A | 1 |
| Johnston, FM | 1 |
| Turaga, KK | 1 |
| Ou, K | 1 |
| Ma, X | 1 |
| Gao, L | 1 |
| Wang, Q | 4 |
| Yang, L | 3 |
| Strickler, JH | 1 |
| Cubillo, A | 2 |
| Matrana, M | 1 |
| Kozloff, M | 1 |
| Lowe, T | 1 |
| Blaney, M | 1 |
| Sahtout, M | 1 |
| Naumovski, L | 1 |
| Wainberg, ZA | 1 |
| Wang, F | 3 |
| He, MM | 1 |
| Xiao, J | 4 |
| Zhang, YQ | 1 |
| Yuan, XL | 1 |
| Fang, WJ | 1 |
| Zhang, Y | 4 |
| Wang, W | 1 |
| Hu, XH | 1 |
| Ma, ZG | 1 |
| Yao, YC | 1 |
| Zhuang, ZX | 1 |
| Zhou, FX | 1 |
| Ying, JE | 1 |
| Yuan, Y | 2 |
| Zou, QF | 1 |
| Guo, ZQ | 1 |
| Wu, XY | 1 |
| Jin, Y | 1 |
| Mai, ZJ | 1 |
| Wang, ZQ | 3 |
| Qiu, H | 4 |
| Guo, Y | 2 |
| Shi, SM | 1 |
| Chen, SZ | 1 |
| Luo, HY | 2 |
| Zhang, DS | 4 |
| Wang, FH | 4 |
| Li, YH | 6 |
| Xu, RH | 6 |
| Fischer von Weikersthal, L | 3 |
| Graeven, U | 13 |
| Schwaner, I | 2 |
| Schenk, M | 1 |
| Kurreck, A | 6 |
| Gießen-Jung, C | 1 |
| Neumann, J | 1 |
| Hofmann, FO | 1 |
| D'Anastasi, M | 1 |
| Gesenhues, AB | 1 |
| Hesse, N | 1 |
| Moehler, M | 2 |
| Link, H | 2 |
| Holch, JW | 1 |
| Pointreau, Y | 1 |
| Moreau, J | 1 |
| Vendrely, V | 8 |
| Schipman, B | 2 |
| Gathirua-Mwangi, W | 1 |
| Yang, T | 2 |
| Khan, T | 1 |
| Wu, Y | 2 |
| Afable, M | 1 |
| van den Berg, K | 2 |
| Schaap, DP | 2 |
| Voogt, ELK | 3 |
| Buffart, TE | 1 |
| Verheul, HMW | 1 |
| de Groot, JWB | 1 |
| Verhoef, C | 4 |
| Melenhorst, J | 1 |
| Roodhart, JML | 1 |
| de Wilt, JHW | 2 |
| van Westreenen, HL | 1 |
| Aalbers, AGJ | 1 |
| van 't Veer, M | 1 |
| Marijnen, CAM | 3 |
| Vincent, J | 1 |
| Simkens, LHJ | 1 |
| Peters, NAJB | 1 |
| Berbée, M | 1 |
| Werter, IM | 1 |
| Snaebjornsson, P | 1 |
| Peulen, HMU | 3 |
| van Lijnschoten, IG | 1 |
| Roef, MJ | 2 |
| Nieuwenhuijzen, GAP | 3 |
| Bloemen, JG | 3 |
| Willems, JMWE | 1 |
| Creemers, GJM | 2 |
| Nederend, J | 3 |
| Rutten, HJT | 4 |
| Burger, JWA | 3 |
| Kibudde, S | 1 |
| Begg, W | 1 |
| Lv, T | 1 |
| Xu, X | 3 |
| Yao, Y | 1 |
| Mu, P | 1 |
| Wan, J | 1 |
| Guan, R | 1 |
| Li, X | 4 |
| Fu, G | 1 |
| Zhang, L | 5 |
| Xia, F | 1 |
| Clevers, H | 2 |
| Zhang, Z | 5 |
| Hua, G | 1 |
| Santos, A | 1 |
| Cristóbal, I | 1 |
| Rubio, J | 1 |
| Caramés, C | 1 |
| Luque, M | 1 |
| Sanz-Álvarez, M | 1 |
| Zazo, S | 1 |
| Madoz-Gúrpide, J | 1 |
| Rojo, F | 1 |
| García-Foncillas, J | 4 |
| Terazawa, T | 1 |
| Yamane, S | 1 |
| Kazama, H | 1 |
| Uetake, H | 6 |
| Yoshino, T | 6 |
| Kanesada, K | 1 |
| Tsunedomi, R | 1 |
| Ogihara, H | 1 |
| Hamamoto, Y | 1 |
| Sommerhäuser, G | 5 |
| Beck, A | 3 |
| Fehrenbach, U | 3 |
| Karthaus, M | 5 |
| Fruehauf, S | 4 |
| Mueller, L | 3 |
| Koenig, AO | 3 |
| V Weikersthal, LF | 3 |
| Goekkurt, E | 5 |
| Haas, S | 3 |
| Alig, AHS | 4 |
| Kasper, S | 4 |
| Trarbach, T | 5 |
| Shah, MA | 2 |
| Grothey, A | 2 |
| Tabernero, J | 4 |
| Cervantes, A | 5 |
| Oh, SC | 2 |
| Yamaguchi, K | 9 |
| Fakih, M | 5 |
| Wu, C | 3 |
| Chiu, VK | 2 |
| Tomasek, J | 2 |
| Bendell, J | 3 |
| Fontaine, M | 2 |
| Hitron, M | 2 |
| Xu, B | 4 |
| Taieb, J | 5 |
| Van Cutsem, E | 8 |
| Erol, C | 2 |
| Sendur Mehmet, AN | 2 |
| Bilgetekin, I | 2 |
| Garbioglu, DB | 2 |
| Hamdard, J | 2 |
| Akbas, S | 2 |
| Hizal, M | 2 |
| Arslan, C | 2 |
| Sevinc, A | 2 |
| Kucukarda, A | 2 |
| Erdem, D | 2 |
| Kahraman, S | 2 |
| Cakir, E | 2 |
| Demirkiran, A | 2 |
| On, S | 2 |
| Dogan, I | 2 |
| Erdogan, AP | 2 |
| Koca, S | 2 |
| Kubilay, P | 2 |
| Eren, OO | 2 |
| Cilbir, E | 2 |
| Celik, E | 2 |
| Araz, M | 3 |
| Ozyukseler, DT | 2 |
| Yildirim, ME | 2 |
| Bahceci, A | 2 |
| Taskaynatan, H | 2 |
| Oyman, A | 2 |
| Deniz, GI | 2 |
| Menekse, S | 2 |
| Kut, E | 2 |
| Gulmez, A | 2 |
| Sakin, A | 2 |
| Nayir, E | 2 |
| Acar, R | 2 |
| Sen, E | 2 |
| Inal, A | 2 |
| Turhal, S | 2 |
| Kaya, AO | 2 |
| Paydas, S | 2 |
| Tastekin, D | 3 |
| Hacibekiroglu, I | 2 |
| Cincin, I | 2 |
| Bilici, A | 2 |
| Mandel, NM | 2 |
| Dede, DS | 2 |
| Akinci, MB | 2 |
| Oksuzoglu, B | 4 |
| Uncu, D | 3 |
| Yalcin, B | 2 |
| Artac, M | 3 |
| François, E | 6 |
| De Bari, B | 1 |
| Ronchin, P | 1 |
| Nouhaud, E | 1 |
| Martel-Lafay, I | 2 |
| Artru, P | 2 |
| Clavere, P | 2 |
| Boige, V | 3 |
| Gargot, D | 1 |
| Lemanski, C | 2 |
| De Sousa Carvalho, N | 1 |
| Gal, J | 1 |
| Pernot, M | 1 |
| Magné, N | 1 |
| Liu, J | 4 |
| Wang, X | 8 |
| Sahin, IH | 2 |
| Felder, SI | 1 |
| Kim, RD | 2 |
| Aoyama, R | 1 |
| Hida, K | 2 |
| Hasegawa, S | 3 |
| Yamaguchi, T | 15 |
| Manaka, D | 2 |
| Kato, S | 9 |
| Yamada, M | 3 |
| Yamanokuchi, S | 2 |
| Kyogoku, T | 2 |
| Kanazawa, A | 2 |
| Kawada, K | 2 |
| Sakamoto, T | 7 |
| Goto, S | 2 |
| Obama, K | 1 |
| Toledano-Fonseca, M | 1 |
| Gómez-España, MA | 1 |
| Élez, E | 1 |
| Grávalos, C | 1 |
| García-Alfonso, P | 4 |
| Rodríguez, R | 1 |
| Losa, F | 4 |
| Alés Díaz, I | 1 |
| Graña, B | 1 |
| Valladares-Ayerbes, M | 1 |
| García-Ortiz, MV | 1 |
| Polo, E | 1 |
| Salgado, M | 2 |
| Rivera, F | 3 |
| Safont, MJ | 2 |
| Salud, A | 4 |
| Ruiz-Casado, A | 1 |
| Tabernero, JM | 1 |
| Riesco, MC | 1 |
| Rodríguez-Ariza, A | 1 |
| Aranda, E | 4 |
| Janssens, K | 1 |
| Vanhoutte, G | 1 |
| Lybaert, W | 1 |
| Demey, W | 1 |
| Decaestecker, J | 1 |
| Hendrickx, K | 1 |
| Rezaei Kalantari, H | 1 |
| Zwaenepoel, K | 1 |
| Pauwels, P | 1 |
| Fransen, E | 1 |
| Op de Beeck, K | 1 |
| Van Camp, G | 1 |
| Rolfo, C | 1 |
| Peeters, M | 4 |
| Raga, MG | 1 |
| Pérez, IP | 1 |
| Veiga, RC | 1 |
| Sosa, MM | 1 |
| Aguilera, MJS | 1 |
| Rodríguez, PL | 1 |
| Bonastre, MTT | 1 |
| Urtasun, JA | 1 |
| Abad, LP | 1 |
| Hernández, IB | 1 |
| Kocak, MZ | 1 |
| Er, M | 1 |
| Ugrakli, M | 1 |
| Hendem, E | 1 |
| Eryilmaz, MK | 1 |
| Germani, MM | 2 |
| Giordano, M | 2 |
| Proietti, A | 1 |
| Niccoli, C | 1 |
| Zaniboni, A | 3 |
| Passardi, A | 3 |
| Latiano, TP | 1 |
| Fanotto, V | 1 |
| Di Donato, S | 2 |
| Prisciandaro, M | 2 |
| Bergamo, F | 4 |
| Fontanini, G | 2 |
| Ugolini, C | 1 |
| Damato, A | 1 |
| Ghidini, M | 1 |
| Dottorini, L | 1 |
| Tomasello, G | 2 |
| Iaculli, A | 1 |
| Ghidini, A | 1 |
| Luciani, A | 1 |
| Petrelli, F | 1 |
| D'Angelo, E | 1 |
| Pastrello, C | 1 |
| Biccari, A | 1 |
| Marangio, A | 1 |
| Sensi, F | 1 |
| Crotti, S | 1 |
| Jurisica, I | 1 |
| Pucciarelli, S | 15 |
| Agostini, M | 5 |
| Sung, SY | 1 |
| Kim, DY | 17 |
| Jang, HS | 8 |
| Kim, TH | 11 |
| Park, HC | 6 |
| Chie, EK | 4 |
| Nam, TK | 9 |
| Okano, M | 2 |
| Tanizaki, K | 1 |
| Takayama, O | 1 |
| Kim, Y | 1 |
| Imamoto, H | 1 |
| Hasegawa, J | 3 |
| Sgouros, J | 1 |
| Gkoura, S | 1 |
| Spathas, N | 1 |
| Tzoudas, F | 1 |
| Karampinos, K | 1 |
| Miaris, N | 1 |
| Visvikis, A | 1 |
| Dessypris, N | 1 |
| Mauri, D | 1 |
| Aravantinos, G | 1 |
| Theodoropoulos, I | 1 |
| Stamoulis, G | 1 |
| Samantas, E | 4 |
| Boccaccino, A | 2 |
| Seitz, R | 1 |
| Catteau, A | 1 |
| McGregor, K | 1 |
| Leonetti, S | 1 |
| Morano, F | 4 |
| Papiani, G | 1 |
| Bensi, M | 1 |
| Murgioni, S | 1 |
| Ross, DT | 1 |
| Boquet, I | 1 |
| Nielsen, TJ | 1 |
| Galon, J | 2 |
| Varga, MG | 1 |
| Schweitzer, BL | 1 |
| Liao, CK | 1 |
| Kuo, YT | 1 |
| Hsu, YJ | 1 |
| Chern, YJ | 1 |
| Yu, YL | 1 |
| Lin, YC | 2 |
| Hsieh, PS | 1 |
| Chiang, JM | 1 |
| Yeh, CY | 1 |
| You, JF | 1 |
| Kang, S | 1 |
| Lee, MW | 2 |
| Song, IC | 1 |
| Lee, HJ | 1 |
| Yun, HJ | 1 |
| Jo, DY | 1 |
| Kwon, JH | 1 |
| Lee, KH | 4 |
| Ryu, H | 1 |
| Osaki, M | 1 |
| Sekido, Y | 1 |
| Ogino, T | 3 |
| Miyoshi, N | 4 |
| Takahashi, H | 6 |
| Sakai, D | 1 |
| Uemura, M | 4 |
| Satoh, T | 2 |
| Doki, Y | 5 |
| Eguchi, H | 1 |
| Liu, S | 1 |
| Zhuang, Y | 1 |
| Bai, S | 1 |
| Wu, X | 4 |
| Ye, Y | 1 |
| Luo, H | 1 |
| Chang, H | 3 |
| Zeng, Z | 3 |
| Cai, P | 1 |
| Pan, Z | 3 |
| Gao, Y | 5 |
| Chen, G | 10 |
| Xiao, W | 4 |
| Huang, CW | 3 |
| Hu, HM | 1 |
| Hsu, WH | 1 |
| Chen, CY | 1 |
| Huang, MY | 5 |
| Chen, CP | 1 |
| Wei, PL | 1 |
| Shen, BN | 1 |
| Wang, JY | 7 |
| Abe, S | 1 |
| Nozawa, H | 4 |
| Sasaki, K | 3 |
| Murono, K | 1 |
| Emoto, S | 1 |
| Yokoyama, Y | 5 |
| Matsuzaki, H | 3 |
| Nagai, Y | 2 |
| Yoshioka, Y | 6 |
| Shinagawa, T | 1 |
| Sonoda, H | 3 |
| Ishihara, S | 4 |
| Huang, C | 1 |
| Chen, J | 2 |
| Situ, Y | 1 |
| Thakur, A | 1 |
| Chorawala, MR | 1 |
| Patel, RS | 1 |
| Dote, S | 1 |
| Shiwaku, E | 1 |
| Kohno, E | 1 |
| Fujii, R | 1 |
| Mashimo, K | 1 |
| Morimoto, N | 1 |
| Yoshino, M | 2 |
| Odaira, N | 1 |
| Ikesue, H | 1 |
| Hirabatake, M | 1 |
| Takahashi, K | 8 |
| Takahashi, M | 8 |
| Takagi, M | 1 |
| Nishiuma, S | 1 |
| Ito, K | 3 |
| Shimato, A | 1 |
| Itakura, S | 1 |
| Takahashi, Y | 2 |
| Shigemori, M | 1 |
| Watanabe, H | 3 |
| Hayasaka, D | 1 |
| Nakao, M | 1 |
| Tasaka, M | 1 |
| Goto, E | 1 |
| Kataoka, N | 1 |
| Yokomizo, A | 1 |
| Kobayashi, A | 2 |
| Nakata, Y | 1 |
| Miyake, M | 2 |
| Hayashi, Y | 2 |
| Hirata, T | 2 |
| Azuma, K | 1 |
| Makihara, K | 1 |
| Fukui, R | 1 |
| Tokutome, A | 1 |
| Yagisawa, K | 1 |
| Honda, S | 3 |
| Meguro, Y | 1 |
| Suzuki, S | 5 |
| Yamaguchi, D | 1 |
| Miyata, H | 1 |
| Kobayashi, Y | 1 |
| Basch, E | 3 |
| Dueck, AC | 2 |
| Mitchell, SA | 1 |
| Mamon, H | 3 |
| Weiser, M | 4 |
| Saltz, L | 18 |
| Gollub, M | 2 |
| Rogak, L | 1 |
| Ginos, B | 1 |
| Mazza, GL | 1 |
| Colgrove, B | 2 |
| Chang, G | 1 |
| Minasian, L | 1 |
| Denicoff, A | 1 |
| Thanarajasingam, G | 1 |
| Musher, B | 1 |
| George, T | 1 |
| Venook, A | 2 |
| Farma, J | 1 |
| O'Reilly, E | 1 |
| Shi, Q | 4 |
| Schrag, D | 6 |
| Musher, BL | 1 |
| Goldberg, J | 1 |
| Al Baghdadi, T | 1 |
| McWilliams, RR | 1 |
| Farma, JM | 2 |
| George, TJ | 4 |
| Kennecke, HF | 1 |
| Shergill, A | 1 |
| Montemurro, M | 1 |
| Nelson, GD | 1 |
| Gordon, V | 1 |
| Chang, GJ | 10 |
| Mamon, HJ | 5 |
| Raimondi, A | 2 |
| Santini, D | 2 |
| Niger, M | 2 |
| Daniel, F | 1 |
| Bustreo, S | 1 |
| Procaccio, L | 1 |
| Clavarezza, M | 1 |
| Cupini, S | 1 |
| Libertini, M | 1 |
| Palermo, F | 2 |
| Tougeron, D | 3 |
| Eucker, J | 1 |
| Pihusch, R | 1 |
| Müller, C | 3 |
| Burkart, C | 1 |
| Reinacher-Schick, A | 1 |
| Kasper-Virchow, S | 1 |
| Krammer-Steiner, B | 1 |
| Prager, GW | 1 |
| Meng, L | 1 |
| Thapa, R | 1 |
| Delgado, MG | 1 |
| Gomez, MF | 1 |
| Ji, R | 1 |
| Knepper, TC | 1 |
| Hubbard, JM | 1 |
| Permuth, JB | 1 |
| Laber, DA | 1 |
| Kunos, CA | 1 |
| Piekarz, R | 1 |
| Collins, JM | 1 |
| Kinsella, TJ | 1 |
| Zhou, H | 3 |
| Jiang, J | 1 |
| Zou, S | 1 |
| Jiang, L | 1 |
| Liang, J | 1 |
| Sun, Y | 5 |
| Jiang, Z | 2 |
| Qu, W | 1 |
| Li, Y | 4 |
| Zhou, A | 1 |
| Vailati, BB | 2 |
| Cerdán-Santacruz, C | 1 |
| São Julião, GP | 9 |
| Corbi, L | 1 |
| Perez, RO | 17 |
| Pesántez, D | 1 |
| Ten Hoorn, S | 1 |
| Machado, I | 1 |
| García-Albéniz, X | 2 |
| Rodríguez-Salas, N | 1 |
| Heredia-Soto, V | 1 |
| Viñal, D | 1 |
| Pericay, C | 5 |
| García-Carbonero, R | 1 |
| Alonso, V | 3 |
| Feliu Batlle, J | 1 |
| Gallego, J | 2 |
| Nogué, M | 3 |
| Layos, L | 1 |
| Montagut, C | 1 |
| Vermeulen, L | 1 |
| Fernandez-Martos, C | 3 |
| Fukuda, K | 3 |
| Osumi, H | 1 |
| Yoshino, K | 1 |
| Nakayama, I | 1 |
| Fukuoka, S | 1 |
| Ogura, M | 2 |
| Wakatsuki, T | 1 |
| Ooki, A | 1 |
| Takahari, D | 5 |
| Chin, K | 2 |
| Shinozaki, E | 5 |
| Nichetti, F | 2 |
| Wasan, HS | 1 |
| Randon, G | 1 |
| Meade, AM | 1 |
| Díaz-Rubio, E | 3 |
| Fisher, D | 1 |
| Ballhausen, A | 1 |
| Müller, L | 2 |
| König, AO | 1 |
| Meyer-Knees, JW | 1 |
| Xu, Y | 2 |
| Wang, G | 2 |
| Zheng, X | 1 |
| Chang, W | 2 |
| Fu, J | 1 |
| Zhang, T | 3 |
| Lin, Q | 2 |
| Lv, Y | 2 |
| Zhu, Z | 2 |
| Tang, W | 1 |
| Xu, J | 4 |
| Fang, X | 1 |
| Zhong, C | 1 |
| Weng, S | 1 |
| Hu, H | 2 |
| Xiao, Q | 1 |
| Sun, L | 1 |
| Xu, D | 1 |
| Liao, X | 1 |
| Dong, C | 1 |
| Li, J | 9 |
| Ding, K | 1 |
| Lin, ST | 1 |
| Valdivieso, SC | 1 |
| Qin, LX | 1 |
| Germer, CT | 4 |
| Reibetanz, J | 2 |
| Putri, S | 1 |
| Saldi, SRF | 1 |
| Khoe, LC | 1 |
| Setiawan, E | 1 |
| Megraini, A | 1 |
| Santatiwongchai, B | 1 |
| Nugraha, RR | 1 |
| Permanasari, VY | 1 |
| Nadjib, M | 1 |
| Sastroasmoro, S | 1 |
| Armansyah, A | 1 |
| Hashimoto, T | 3 |
| Otsu, S | 2 |
| Hironaka, S | 1 |
| Takashima, A | 3 |
| Mizusawa, J | 2 |
| Kataoka, T | 2 |
| Fukuda, H | 3 |
| Tsukamoto, S | 3 |
| Hamaguchi, T | 6 |
| Kanemitsu, Y | 5 |
| Yuki, S | 1 |
| Yamazaki, K | 6 |
| Sunakawa, Y | 1 |
| Yasui, H | 1 |
| Esaki, T | 2 |
| Kawakami, H | 1 |
| Satake, H | 1 |
| Matsuhashi, N | 1 |
| Asano, C | 1 |
| Abe, Y | 1 |
| Nomura, S | 2 |
| Raunkilde, L | 1 |
| Hansen, TF | 2 |
| Havelund, BM | 1 |
| Thomsen, CB | 1 |
| Rafaelsen, SR | 3 |
| Lindebjerg, J | 4 |
| Jensen, LH | 1 |
| Piringer, G | 1 |
| Thaler, J | 4 |
| Anchisi, S | 2 |
| Geffriaud-Ricouard, C | 1 |
| Gueldner, M | 1 |
| Scholten, F | 1 |
| Derigs, HG | 1 |
| Bohanes, P | 2 |
| Grünberger, B | 1 |
| Schwarz, L | 1 |
| Huang, P | 1 |
| Guo, H | 2 |
| Huang, Z | 3 |
| Wei, M | 1 |
| Guo, J | 1 |
| Lin, C | 1 |
| Luo, B | 1 |
| Lin, J | 2 |
| Wang, L | 8 |
| Kang, MK | 5 |
| Park, SY | 4 |
| Park, JS | 5 |
| Kim, HJ | 8 |
| Kang, BW | 7 |
| Baek, JH | 6 |
| Cho, SH | 3 |
| Seo, AN | 3 |
| Kim, DW | 6 |
| Baek, SJ | 1 |
| Ha, GW | 1 |
| Park, IJ | 5 |
| Kim, CH | 1 |
| Kang, H | 1 |
| Choi, GS | 8 |
| Ghelardi, F | 1 |
| De Grandis, MC | 1 |
| Barsotti, G | 1 |
| Formica, V | 2 |
| Frassineti, GL | 1 |
| Boscolo, G | 1 |
| Cinieri, S | 1 |
| Antonuzzo, L | 1 |
| Ambrosini, M | 1 |
| Piva, VM | 1 |
| Tian, M | 1 |
| Li, H | 2 |
| Dong, W | 1 |
| Jiang, T | 1 |
| Zeng, J | 1 |
| Jiang, X | 1 |
| Yin, Z | 1 |
| Jia, AY | 1 |
| Narang, A | 1 |
| Safar, B | 3 |
| Zaheer, A | 1 |
| Murphy, A | 1 |
| Azad, NS | 1 |
| Gearhart, S | 1 |
| Fang, S | 1 |
| Efron, J | 2 |
| Warczynski, T | 1 |
| Hacker-Prietz, A | 1 |
| Meyer, J | 2 |
| Manceau, G | 2 |
| Margot, N | 1 |
| Augustin, J | 1 |
| Bardier, A | 1 |
| Simon, JM | 2 |
| Bachet, JB | 5 |
| Spano, JP | 3 |
| Maingon, P | 11 |
| Vaillant, JC | 1 |
| Karoui, M | 3 |
| Nougaret, S | 1 |
| Castan, F | 1 |
| de Forges, H | 1 |
| Vargas, HA | 2 |
| Gallix, B | 1 |
| Gourgou, S | 1 |
| Rouanet, P | 2 |
| Jain, C | 1 |
| Syed, A | 1 |
| Gupta, N | 1 |
| Kambhoj, M | 1 |
| Rao, A | 2 |
| Singh, S | 1 |
| Kudo, T | 1 |
| Sugimoto, N | 2 |
| Ura, T | 2 |
| Fujii, H | 1 |
| Kajiwara, T | 2 |
| Nakajima, TE | 1 |
| Takahashi, S | 3 |
| Komatsu, Y | 4 |
| Nagashima, F | 1 |
| Sato, T | 6 |
| Itabashi, M | 2 |
| Oki, E | 3 |
| Sasaki, T | 6 |
| Chiron, M | 1 |
| Terzi, C | 3 |
| Bingul, M | 1 |
| Arslan, NC | 1 |
| Ozturk, E | 1 |
| Canda, AE | 3 |
| Isik, O | 1 |
| Yilmazlar, T | 1 |
| Obuz, F | 2 |
| Birkay Gorken, I | 1 |
| Kurt, M | 1 |
| Unlu, M | 1 |
| Ugras, N | 1 |
| Kanat, O | 1 |
| Oztop, I | 4 |
| Ganesh, K | 1 |
| O'Rourke, KP | 1 |
| Szeglin, BC | 1 |
| Zheng, Y | 2 |
| Sauvé, CG | 1 |
| Adileh, M | 1 |
| Wasserman, I | 1 |
| Marco, MR | 2 |
| Kim, AS | 1 |
| Shady, M | 1 |
| Sanchez-Vega, F | 1 |
| Karthaus, WR | 1 |
| Won, HH | 1 |
| Choi, SH | 2 |
| Pelossof, R | 2 |
| Barlas, A | 1 |
| Ntiamoah, P | 1 |
| Elghouayel, A | 1 |
| Strong, JS | 1 |
| Chen, CT | 1 |
| Harris, JW | 1 |
| Kolesnick, RN | 1 |
| Veeraraghavan, H | 1 |
| Ortiz, EJ | 1 |
| Petkovska, I | 1 |
| Manova-Todorova, KO | 1 |
| Lavery, JA | 1 |
| DeMatteo, RP | 1 |
| Massagué, J | 1 |
| Chen, X | 2 |
| Berger, MF | 1 |
| Lowe, SW | 1 |
| Shia, J | 9 |
| Romesser, PB | 1 |
| Dow, LE | 1 |
| Sawyers, CL | 1 |
| Bruera, G | 1 |
| Giuliani, A | 1 |
| Romano, L | 1 |
| Chiominto, A | 1 |
| Di Sibio, A | 1 |
| Mastropietro, S | 1 |
| Cosenza, P | 1 |
| Ricevuto, E | 2 |
| Schietroma, M | 1 |
| Carlei, F | 1 |
| Yoshimatsu, K | 2 |
| Sano, M | 2 |
| Satake, M | 1 |
| Imaizumi, R | 1 |
| Ito, Y | 6 |
| Koike, T | 2 |
| Yamada, Y | 7 |
| Okayama, S | 1 |
| Yokomizo, H | 2 |
| Usui, T | 1 |
| Shimakawa, T | 2 |
| Katsube, T | 2 |
| Shiozawa, S | 2 |
| Sakatani, T | 1 |
| Wada, R | 1 |
| Ishino, K | 1 |
| Kudo, M | 2 |
| Koizumi, M | 2 |
| Yoshida, H | 5 |
| Naito, Z | 1 |
| Treder, M | 1 |
| Janssen, S | 1 |
| Schild, SE | 1 |
| Rades, D | 1 |
| Cienfuegos, JA | 2 |
| Rodríguez, J | 4 |
| Baixauli, J | 5 |
| Chopitea Ortega, A | 1 |
| García-Consuegra, A | 1 |
| Abengózar, M | 1 |
| Sánchez Justicia, C | 1 |
| Hernández Lizoain, JL | 1 |
| Nakamura, M | 3 |
| Ishigure, K | 2 |
| Watanabe, T | 10 |
| Mashita, N | 1 |
| Tobinaga, J | 1 |
| Fukuyama, R | 1 |
| Fiori, E | 1 |
| Crocetti, D | 1 |
| Lamazza, A | 1 |
| Tarallo, M | 1 |
| Sterpetti, AV | 1 |
| Mingoli, A | 1 |
| Sapienza, P | 1 |
| DE Toma, G | 2 |
| Cheng, YK | 1 |
| Qin, QY | 1 |
| Huang, XY | 1 |
| Lan, P | 5 |
| Gao, X | 1 |
| Ma, TH | 1 |
| Akiyoshi, T | 7 |
| Toda, S | 2 |
| Tominaga, T | 5 |
| Tomizawa, K | 2 |
| Hanaoka, Y | 2 |
| Nagasaki, T | 3 |
| Konishi, T | 5 |
| Matoba, S | 2 |
| Fukunaga, Y | 3 |
| Ueno, M | 7 |
| Kuroyanagi, H | 4 |
| Qiang, W | 1 |
| Wu, Q | 2 |
| Ni, X | 1 |
| Zhang, C | 2 |
| Chakravarthy, AB | 2 |
| Zhao, F | 1 |
| Meropol, NJ | 7 |
| Flynn, PJ | 1 |
| Wagner, LI | 1 |
| Sloan, J | 1 |
| Diasio, RB | 3 |
| Mitchell, EP | 3 |
| Catalano, P | 1 |
| Giantonio, BJ | 2 |
| Catalano, RB | 1 |
| Haller, DG | 8 |
| Awan, RA | 1 |
| Mulcahy, MF | 1 |
| O'Brien, TE | 1 |
| Santala, R | 1 |
| Cripps, C | 3 |
| Weis, JR | 1 |
| Leichman, CG | 2 |
| Petrelli, NJ | 11 |
| Sinicrope, FA | 2 |
| Brierley, JD | 2 |
| Tepper, JE | 11 |
| O'Dwyer, PJ | 3 |
| Sigurdson, ER | 12 |
| Hamilton, SR | 2 |
| Cella, D | 1 |
| Benson, AB | 11 |
| Sun, Q | 1 |
| Liu, P | 2 |
| Lu, K | 2 |
| Zhang, N | 2 |
| Liu, L | 4 |
| Janakiraman, H | 1 |
| Becker, SA | 1 |
| Wang, C | 3 |
| Cross, A | 1 |
| Curl, E | 1 |
| Lewin, D | 1 |
| Hoffman, BJ | 1 |
| Warren, GW | 1 |
| Hill, EG | 1 |
| Timmers, C | 1 |
| Findlay, VJ | 1 |
| Camp, ER | 1 |
| You, SH | 2 |
| Kim, S | 2 |
| Sarathy, V | 1 |
| Kothandath Shankar, RK | 1 |
| Mufti, SS | 1 |
| Naik, R | 1 |
| Nemoto, T | 2 |
| Isohata, N | 2 |
| Takayanagi, D | 2 |
| Nemoto, D | 2 |
| Aizawa, M | 2 |
| Utano, K | 2 |
| Togashi, K | 2 |
| Oshibe, I | 2 |
| Soeta, N | 2 |
| Saito, T | 3 |
| Kikuchi, I | 1 |
| Abe, T | 5 |
| Kurihara, Y | 1 |
| Hayashi, K | 5 |
| Kimura, T | 2 |
| Shimbo, T | 2 |
| Wakabayashi, T | 2 |
| Ota, S | 1 |
| Itoh, S | 1 |
| van Zoggel, DMGI | 1 |
| Kusters, M | 2 |
| van Lijnschoten, G | 2 |
| Fernandes, JM | 1 |
| Jandrey, EHF | 1 |
| Koyama, FC | 2 |
| Leite, KRM | 1 |
| Camargo, AA | 2 |
| Costa, ÉT | 1 |
| Asprino, PF | 2 |
| van der Valk, MJM | 1 |
| van Etten, B | 1 |
| Dijkstra, EA | 1 |
| Hilling, DE | 1 |
| Kranenbarg, EM | 1 |
| Putter, H | 2 |
| Roodvoets, AGH | 2 |
| Bahadoer, RR | 1 |
| Fokstuen, T | 2 |
| Ten Tije, AJ | 1 |
| Hendriks, MP | 1 |
| Edhemovic, I | 2 |
| Cervantes, AMR | 1 |
| de Groot, DJA | 1 |
| Nilsson, PJ | 1 |
| Glimelius, B | 21 |
| van de Velde, CJH | 2 |
| Hospers, GAP | 1 |
| Lee, JB | 2 |
| Jung, I | 3 |
| Kim, TI | 4 |
| Hur, H | 5 |
| Min, BS | 7 |
| Kim, NK | 14 |
| Park, S | 2 |
| Jeong, SY | 7 |
| Lim, JS | 2 |
| Lee, KY | 9 |
| de Torres-Olombrada, MV | 1 |
| Juez-Martel, I | 1 |
| Rodríguez-Caravaca, G | 1 |
| Duran-Poveda, M | 1 |
| Palma, S | 1 |
| Raffa, CI | 1 |
| Garcia-Fabiani, MB | 1 |
| Ferretti, VA | 1 |
| Zwenger, A | 1 |
| Perez Verdera, PV | 1 |
| Llontop, A | 1 |
| Rojas Bilbao, E | 1 |
| Cuartero, V | 1 |
| Abba, MC | 1 |
| Lacunza, E | 1 |
| Nara, A | 1 |
| Udagawa, M | 1 |
| Onishi, I | 1 |
| Sueyoshi, K | 1 |
| Gokita, K | 3 |
| Adikrisna, R | 1 |
| Kokubo, S | 1 |
| Karasawa, H | 1 |
| Ohnuma, S | 1 |
| Kohyama, A | 1 |
| Watanabe, K | 3 |
| Ishida, T | 3 |
| Kamei, T | 1 |
| Naitoh, T | 1 |
| Unno, M | 3 |
| Yamaguchi, S | 6 |
| Inoue, Y | 10 |
| Torashima, Y | 1 |
| Ito, S | 1 |
| Kanetaka, K | 1 |
| Takatsuki, M | 1 |
| Hasuike, Y | 2 |
| Higuchi, I | 1 |
| Mori, Y | 7 |
| Ishikawa, A | 1 |
| Urano, N | 1 |
| Gofuku, J | 1 |
| Tsuchida, Y | 1 |
| Miyamoto, M | 1 |
| Tokunaga, M | 1 |
| Crimì, F | 1 |
| Capelli, G | 1 |
| Spolverato, G | 1 |
| Bao, QR | 1 |
| Florio, A | 1 |
| Milite Rossi, S | 1 |
| Cecchin, D | 1 |
| Albertoni, L | 1 |
| Campi, C | 1 |
| Stramare, R | 1 |
| Brouquet, A | 4 |
| Huguet, F | 3 |
| Sabbagh, C | 2 |
| Lefèvre, JH | 4 |
| Vernerey, D | 1 |
| Mariette, C | 1 |
| Vicaut, E | 1 |
| Benoist, S | 5 |
| Sakr, A | 1 |
| Elsherbiny, M | 1 |
| Abdel Moneim, R | 1 |
| Shaaban, S | 1 |
| Aldaly, M | 1 |
| Demisse, R | 1 |
| Damle, N | 1 |
| Kim, E | 1 |
| Gong, J | 1 |
| Eng, C | 8 |
| Oesterich, L | 1 |
| McKenny, M | 1 |
| Ji, J | 1 |
| Louie, R | 1 |
| Tam, K | 1 |
| Gholami, S | 1 |
| Halabi, W | 1 |
| Monjazeb, A | 1 |
| Dayyani, F | 1 |
| Cho, M | 1 |
| El Sissy, C | 1 |
| Kirilovsky, A | 1 |
| Van den Eynde, M | 1 |
| Muşină, AM | 1 |
| Anitei, MG | 1 |
| Romero, A | 3 |
| Marliot, F | 1 |
| Junca, A | 1 |
| Doyen, J | 1 |
| Mlecnik, B | 1 |
| Haicheur, N | 1 |
| Fredriksen, T | 1 |
| Lagorce, C | 1 |
| Jouret-Mourin, A | 1 |
| Leonard, D | 1 |
| Bibeau, F | 1 |
| Iseas, S | 2 |
| Roca, EL | 2 |
| Cabanne, AM | 1 |
| Vaccaro, CA | 1 |
| Santino, JP | 1 |
| Huertas, E | 3 |
| Carvalho, C | 1 |
| Figueiredo, N | 1 |
| Habr-Gama, A | 16 |
| Scripcariu, V | 1 |
| Gerard, JP | 11 |
| Zeitoun, G | 1 |
| Pagès, F | 1 |
| Ye, W | 1 |
| Shi, L | 1 |
| Qian, L | 1 |
| Sun, X | 2 |
| Toritani, K | 1 |
| Suwa, Y | 2 |
| Nakagawa, K | 5 |
| Suwa, H | 2 |
| Ishibe, A | 2 |
| Ota, M | 3 |
| Kunisaki, C | 1 |
| Yamanaka, T | 1 |
| Endo, I | 3 |
| Fujiwara, Y | 5 |
| Nakane, M | 1 |
| Yano, Y | 2 |
| Kuriyama, A | 1 |
| Fukuda, M | 2 |
| Nabeta, M | 1 |
| Muta, T | 1 |
| Cho, T | 1 |
| Shimamatsu, Y | 1 |
| Shimotsuura, Y | 1 |
| Fukami, K | 1 |
| Takasu, O | 1 |
| Shamseddine, A | 2 |
| Zeidan, YH | 2 |
| Kreidieh, M | 2 |
| Khalifeh, I | 2 |
| Turfa, R | 2 |
| Kattan, J | 2 |
| Mukherji, D | 2 |
| Temraz, S | 2 |
| Alqasem, K | 2 |
| Amarin, R | 2 |
| Al Awabdeh, T | 2 |
| Deeba, S | 2 |
| Jamali, F | 2 |
| Mohamad, I | 2 |
| Elkhaldi, M | 2 |
| Daoud, F | 2 |
| Al Masri, M | 2 |
| Dabous, A | 2 |
| Hushki, A | 2 |
| Jaber, O | 2 |
| Khoury, C | 1 |
| El Husseini, Z | 2 |
| Charafeddine, M | 2 |
| Al Darazi, M | 2 |
| Geara, F | 2 |
| Sprenger, T | 7 |
| Beißbarth, T | 2 |
| Sauer, R | 29 |
| Tschmelitsch, J | 5 |
| Fietkau, R | 30 |
| Hohenberger, W | 20 |
| Staib, L | 7 |
| Raab, HR | 6 |
| Loft, M | 1 |
| Wong, HL | 1 |
| Kosmider, S | 1 |
| Tie, J | 1 |
| Wong, R | 7 |
| Jones, IT | 2 |
| Croxford, M | 1 |
| Steel, M | 4 |
| Faragher, I | 3 |
| Guerrieri, M | 4 |
| Christie, M | 1 |
| Gibbs, P | 5 |
| Misumi, T | 1 |
| Shulman, K | 1 |
| Musallam, S | 1 |
| Epelbaum, R | 1 |
| Haim, N | 2 |
| Ben-Yosef, R | 1 |
| Kaidar-Person, O | 1 |
| Shinji, S | 1 |
| Matsuda, A | 1 |
| Takahashi, G | 2 |
| Iwai, T | 2 |
| Hara, K | 1 |
| Ng, SP | 1 |
| Chu, J | 2 |
| Chander, S | 3 |
| Bressel, M | 3 |
| McKendrick, J | 5 |
| Murray, WK | 1 |
| Leong, T | 8 |
| Heriot, A | 5 |
| Michael, M | 7 |
| Ngan, SY | 8 |
| Cheng, YJ | 1 |
| Liu, Z | 1 |
| Zhou, HT | 1 |
| Liang, JW | 1 |
| Pei, W | 1 |
| Wang, XS | 3 |
| Zhang, HZ | 1 |
| Zhou, ZX | 2 |
| Gilshtein, H | 1 |
| Ghuman, A | 1 |
| Dawoud, M | 1 |
| Yellinek, S | 1 |
| Kent, I | 1 |
| Sharp, SP | 1 |
| Nagarajan, A | 1 |
| Wexner, SD | 3 |
| Huang, D | 1 |
| Song, J | 2 |
| Hagen, ER | 1 |
| Cleary, RK | 1 |
| Garant, A | 2 |
| Kavan, P | 1 |
| Martin, AG | 1 |
| Azoulay, L | 1 |
| Lavoie, C | 1 |
| Vasilevsky, CA | 1 |
| Boutros, M | 1 |
| Faria, J | 1 |
| Nguyen, TN | 1 |
| Ferland, E | 1 |
| Des Groseilliers, S | 1 |
| Cloutier, AS | 1 |
| Diec, H | 1 |
| Drolet, S | 1 |
| Richard, C | 2 |
| Batist, G | 1 |
| Vuong, T | 3 |
| Kosmala, R | 1 |
| Flentje, M | 4 |
| Liersch, T | 32 |
| Arnold, D | 12 |
| Ströbel, P | 8 |
| Grabenbauer, GG | 11 |
| Folprecht, G | 6 |
| Kirste, S | 1 |
| Uter, W | 1 |
| Gall, C | 1 |
| Polat, B | 1 |
| Miwa, K | 2 |
| Enomoto, M | 5 |
| Ihara, K | 1 |
| Ando, K | 2 |
| Fujita, F | 2 |
| Tominaga, M | 1 |
| Mori, S | 1 |
| Nakayama, G | 4 |
| Shimokawa, M | 1 |
| Saeki, H | 2 |
| Baba, H | 4 |
| Mori, M | 8 |
| Akagi, Y | 1 |
| Kusafuka, H | 1 |
| Imada, A | 1 |
| Murakami, K | 1 |
| Katsura, Y | 1 |
| Omura, Y | 1 |
| Masuzawa, T | 1 |
| Takeno, A | 2 |
| Sato, H | 6 |
| Ii, T | 1 |
| Rikiyama, N | 1 |
| Noguchi, A | 2 |
| Aoki, Y | 1 |
| Sato, J | 1 |
| Kikuchi, D | 1 |
| Yamanami, H | 1 |
| Nakatsukasa, R | 1 |
| Hayashi, N | 3 |
| Urabe, S | 1 |
| Nakagawa, T | 3 |
| Michiura, T | 1 |
| Yamabe, K | 1 |
| Nishiki, M | 1 |
| Yoshida, Y | 3 |
| Ryu, S | 1 |
| Ichikawa, J | 1 |
| Shin, Y | 1 |
| Sannomiya, H | 1 |
| Koreeda, N | 1 |
| Yamana, I | 1 |
| Sato, K | 4 |
| Okamoto, T | 1 |
| Yanagisawa, J | 1 |
| Noritomi, T | 1 |
| Takei, S | 1 |
| Homma, Y | 1 |
| Matsuyama, R | 1 |
| Song, SH | 1 |
| Baek, DW | 1 |
| Kim, JC | 17 |
| Cha, J | 1 |
| Bigness, A | 1 |
| Laskowitz, D | 1 |
| Idasiak, A | 2 |
| Galwas-Kliber, K | 2 |
| Rajczykowski, M | 1 |
| Dębosz-Suwińska, I | 1 |
| Zeman, M | 1 |
| Stobiecka, E | 2 |
| Mrochem-Kwarciak, J | 1 |
| Suwiński, R | 4 |
| Bellyei, S | 1 |
| Boronkai, Á | 1 |
| Pozsgai, E | 1 |
| Fodor, D | 1 |
| Mangel, L | 1 |
| Gani, C | 3 |
| Lamprecht, U | 2 |
| Ziegler, A | 1 |
| Moll, M | 1 |
| Gellermann, J | 7 |
| Heinrich, V | 1 |
| Wenz, S | 1 |
| Fend, F | 1 |
| Königsrainer, A | 1 |
| Bitzer, M | 1 |
| Zips, D | 2 |
| Giunta, EF | 1 |
| Bregni, G | 1 |
| Pretta, A | 1 |
| Deleporte, A | 1 |
| Liberale, G | 1 |
| Bali, AM | 1 |
| Moretti, L | 1 |
| Troiani, T | 2 |
| Ciardiello, F | 2 |
| Hendlisz, A | 3 |
| Sclafani, F | 4 |
| Li, K | 1 |
| He, X | 1 |
| Tong, S | 1 |
| Kurokawa, T | 3 |
| Kanemoto, Y | 1 |
| Azuma, Y | 1 |
| Iimura, Y | 1 |
| Kuroda, S | 1 |
| Yazawa, K | 2 |
| Tsurita, G | 2 |
| Socha, J | 2 |
| Bujko, K | 17 |
| Kelm, M | 1 |
| Schollbach, J | 1 |
| Anger, F | 1 |
| Wiegering, A | 1 |
| Klein, I | 1 |
| Schlegel, N | 1 |
| Kunzmann, V | 1 |
| Löb, S | 1 |
| Creemers, GJ | 2 |
| Willems, J | 1 |
| Cnossen, JS | 1 |
| Abdel-Rahman, O | 1 |
| King, K | 1 |
| Scarfe, A | 1 |
| Astaras, C | 1 |
| Bornand, A | 1 |
| Koessler, T | 1 |
| Mas, L | 1 |
| D'Ambrosio, G | 1 |
| Iafrate, F | 1 |
| Gelibter, A | 1 |
| Magliocca, FM | 1 |
| Caponetto, S | 1 |
| Casella, G | 1 |
| Clementi, I | 1 |
| Picchetto, A | 1 |
| Sirgiovani, G | 1 |
| Parisi, M | 1 |
| Orciuoli, C | 1 |
| Torrese, G | 1 |
| Rahma, OE | 1 |
| Yothers, G | 4 |
| Hong, TS | 8 |
| Russell, MM | 1 |
| You, YN | 3 |
| Parker, W | 1 |
| Jacobs, SA | 1 |
| Colangelo, LH | 3 |
| Lucas, PC | 1 |
| Hall, WA | 1 |
| Kachnic, LA | 2 |
| Vijayvergia, N | 1 |
| O'Rourke, MA | 1 |
| Faller, BA | 1 |
| Valicenti, RK | 1 |
| Schefter, TE | 2 |
| George, S | 1 |
| Kainthla, R | 1 |
| Stella, PJ | 1 |
| Sigurdson, E | 4 |
| Wolmark, N | 10 |
| Menon, A | 1 |
| Abraham, AG | 1 |
| Mahfouz, M | 1 |
| Thachuthara, JJ | 1 |
| Usmani, N | 1 |
| Warkentin, H | 1 |
| Ghosh, S | 1 |
| Nijjar, T | 1 |
| Severin, D | 1 |
| Tankel, K | 2 |
| Paulson, K | 1 |
| Mulder, K | 1 |
| Roa, W | 1 |
| Joseph, K | 1 |
| Awawda, M | 1 |
| Gourevich, K | 1 |
| Ben Yosef, R | 1 |
| van Rees, JM | 1 |
| Hartman, W | 1 |
| Nuyttens, JJME | 1 |
| Oomen-de Hoop, E | 1 |
| van Vugt, JLA | 1 |
| Rothbarth, J | 1 |
| van Meerten, E | 1 |
| Squire, T | 1 |
| Buchanan, G | 1 |
| Rangiah, D | 1 |
| Davis, I | 1 |
| Yip, D | 1 |
| Chua, YJ | 3 |
| Rich, T | 1 |
| Elsaleh, H | 6 |
| Tanaka, T | 4 |
| Kiyomatsu, T | 3 |
| Hata, K | 3 |
| Morikawa, T | 3 |
| Guren, TK | 1 |
| Thomsen, M | 1 |
| Kure, EH | 1 |
| Sorbye, H | 2 |
| Pfeiffer, P | 5 |
| Österlund, P | 2 |
| Sigurdsson, F | 1 |
| Lothe, IMB | 1 |
| Dalsgaard, AM | 1 |
| Skovlund, E | 2 |
| Christoffersen, T | 1 |
| Tveit, KM | 8 |
| Gelsomino, F | 1 |
| Bertolini, F | 4 |
| Luppi, G | 6 |
| Spallanzani, A | 1 |
| Pettorelli, E | 1 |
| Reggiani Bonetti, L | 1 |
| Meduri, B | 1 |
| Manco, G | 1 |
| Conte, P | 1 |
| Cascinu, S | 6 |
| Sadahiro, S | 2 |
| Suzuki, T | 3 |
| Tanaka, A | 1 |
| Okada, K | 7 |
| Saito, G | 1 |
| Miyakita, H | 1 |
| Ogimi, T | 1 |
| Nagase, H | 2 |
| Fu, XL | 1 |
| Fang, Z | 1 |
| Shu, LH | 1 |
| Tao, GQ | 1 |
| Wang, JQ | 1 |
| Rui, ZL | 1 |
| Zhang, YJ | 1 |
| Tian, ZQ | 1 |
| Behrendt, K | 1 |
| Wziętek, I | 1 |
| Kryj, M | 4 |
| Chmielik, E | 4 |
| Brown, G | 9 |
| Cunningham, D | 11 |
| Rao, S | 3 |
| Tekkis, P | 2 |
| Tait, D | 7 |
| Baratelli, C | 1 |
| Kalaitzaki, E | 1 |
| Rasheed, S | 2 |
| Watkins, D | 2 |
| Starling, N | 1 |
| Wotherspoon, A | 9 |
| Chau, I | 8 |
| Moore, J | 1 |
| Price, T | 2 |
| Carruthers, S | 1 |
| Selva-Nayagam, S | 1 |
| Luck, A | 1 |
| Thomas, M | 1 |
| Hewett, P | 1 |
| Kanamori, M | 1 |
| Kurumiya, Y | 1 |
| Mizuno, K | 2 |
| Sekoguchi, E | 1 |
| Kobayashi, S | 5 |
| Fukami, Y | 1 |
| Kiriyama, M | 2 |
| Aoyama, H | 6 |
| Oiwa, T | 1 |
| Miyamura, K | 1 |
| Jinno, T | 1 |
| Nakashima, Y | 1 |
| Kuga, Y | 1 |
| Kitamura, S | 1 |
| Mouri, T | 2 |
| Miwata, T | 1 |
| Hirata, Y | 1 |
| Ishizaki, Y | 1 |
| Hashimoto, Y | 1 |
| Badakhshi, H | 1 |
| Ismail, M | 2 |
| Boskos, C | 1 |
| Zhao, K | 1 |
| Kaul, D | 1 |
| Sung, S | 1 |
| Jeong, S | 2 |
| Lee, JW | 1 |
| Bae, JM | 1 |
| Xu, L | 4 |
| Cai, S | 4 |
| Xiao, T | 1 |
| Chen, Y | 5 |
| Wu, B | 4 |
| Lin, G | 2 |
| Lu, J | 2 |
| Zhou, W | 2 |
| Huang, JJ | 1 |
| Huang, CM | 3 |
| Lin, CH | 3 |
| Tsai, HL | 4 |
| Chai, CY | 3 |
| Lin, CY | 3 |
| Hernandez-Aragues, I | 1 |
| Baniandrés-Rodríguez, O | 1 |
| Avilés-Izquierdo, JA | 1 |
| Vilas-Boas, PT | 1 |
| Matsumoto, T | 2 |
| Matsusue, R | 1 |
| Nishitai, R | 2 |
| Kadokawa, Y | 2 |
| Kawamura, J | 1 |
| Zaima, M | 1 |
| Kanai, M | 1 |
| Matsumoto, S | 2 |
| Kairevičė, L | 1 |
| Latkauskas, T | 2 |
| Tamelis, A | 2 |
| Petrauskas, A | 1 |
| Paužas, H | 2 |
| Žvirblis, T | 1 |
| Jaruševičius, L | 1 |
| Saladžinskas, Ž | 2 |
| Pavalkis, D | 3 |
| Jančiauskienė, R | 2 |
| Bendell, JC | 5 |
| Thompson, D | 1 |
| Hemphill, BM | 1 |
| Wenk, D | 1 |
| Earwood, C | 1 |
| Lane, CM | 1 |
| Kennedy, A | 1 |
| Ohue, M | 6 |
| Kobatake, T | 1 |
| Ito, M | 4 |
| Moriya, Y | 5 |
| Saito, N | 2 |
| Thavaneswaran, S | 1 |
| Kok, PS | 1 |
| Kim, CG | 1 |
| Heo, SJ | 1 |
| Park, HS | 2 |
| Choe, EA | 1 |
| Kim, C | 3 |
| Jung, M | 4 |
| Markovina, S | 2 |
| Youssef, F | 1 |
| Roy, A | 3 |
| Aggarwal, S | 1 |
| Khwaja, S | 1 |
| DeWees, T | 1 |
| Tan, B | 3 |
| Myerson, RJ | 9 |
| Chang, DT | 4 |
| Parikh, PJ | 2 |
| Olsen, JR | 2 |
| Iqbal, A | 1 |
| Jootun, N | 1 |
| Evans, T | 1 |
| Mak, J | 1 |
| Makin, G | 1 |
| Platell, C | 1 |
| Tate, T | 1 |
| Fukui, Y | 1 |
| Yeom, SS | 1 |
| Jung, SW | 1 |
| Oh, SH | 1 |
| Lee, JL | 2 |
| Yoon, YS | 4 |
| Kim, CW | 5 |
| Lim, SB | 13 |
| Kim, N | 1 |
| Yu, CS | 15 |
| Lee, SF | 1 |
| Chiang, CL | 1 |
| Lee, FAS | 1 |
| Wong, YW | 1 |
| Poon, CM | 1 |
| Wong, FCS | 1 |
| Tung, SY | 1 |
| Kim, SW | 1 |
| Yea, JW | 1 |
| Gu, MJ | 1 |
| Wewala, NT | 1 |
| Jameson, MB | 1 |
| Tseng, MSF | 1 |
| Zheng, H | 1 |
| Ng, IWS | 1 |
| Leong, YH | 1 |
| Leong, CN | 1 |
| Yong, WP | 1 |
| Cheong, WK | 1 |
| Tey, JCS | 1 |
| Hartmann, A | 5 |
| Kaufmann, M | 3 |
| Hoffmanns, H | 3 |
| Hothorn, T | 5 |
| Wittekind, C | 11 |
| Aschele, C | 10 |
| Barina, A | 1 |
| Nakao, S | 1 |
| Maeda, K | 13 |
| Matsutani, S | 1 |
| Doi, Y | 2 |
| Ohtani, H | 1 |
| Yamazaki, T | 1 |
| Amano, R | 1 |
| Hirakawa, K | 8 |
| Hagino, S | 1 |
| Miyata, T | 2 |
| Sakamoto, K | 2 |
| Palmisano, A | 1 |
| Esposito, A | 1 |
| Di Chiara, A | 1 |
| Ambrosi, A | 4 |
| Passoni, P | 3 |
| Slim, N | 3 |
| Fiorino, C | 3 |
| Albarello, L | 1 |
| Di Muzio, N | 2 |
| Calandrino, R | 3 |
| Rosati, R | 2 |
| Del Maschio, A | 1 |
| De Cobelli, F | 2 |
| Roxburgh, CSD | 1 |
| Strombom, P | 1 |
| Temple, LKF | 1 |
| Stadler, ZK | 1 |
| Seier, K | 1 |
| Gonen, M | 2 |
| Reidy, DL | 1 |
| Varghese, A | 1 |
| Vakiani, E | 1 |
| Crane, CH | 16 |
| Shida, D | 1 |
| Tanabe, T | 1 |
| Ochiai, H | 3 |
| Qi, F | 1 |
| Zheng, Z | 1 |
| Yan, Q | 1 |
| Zhang, G | 2 |
| Michalski, W | 9 |
| Martella, A | 1 |
| Willett, C | 4 |
| Palta, M | 1 |
| Czito, B | 1 |
| Baretti, M | 1 |
| Rimassa, L | 1 |
| Personeni, N | 1 |
| Giordano, L | 1 |
| Tronconi, MC | 2 |
| Pressiani, T | 1 |
| Bozzarelli, S | 1 |
| Santoro, A | 2 |
| Tokoro, T | 1 |
| Nakamura, K | 1 |
| Hirose, A | 1 |
| Nakanuma, S | 1 |
| Okamoto, K | 3 |
| Kinoshita, J | 1 |
| Makino, I | 1 |
| Hayashi, H | 4 |
| Miyashita, T | 1 |
| Tajima, H | 2 |
| Takamura, H | 1 |
| Ninomiya, I | 2 |
| Fushida, S | 2 |
| Rombouts, AJM | 1 |
| Hugen, N | 1 |
| Verhoeven, RHA | 1 |
| Elferink, MAG | 1 |
| Poortmans, PMP | 1 |
| Nagtegaal, ID | 4 |
| Wawok, P | 1 |
| Polkowski, W | 4 |
| Richter, P | 2 |
| Szczepkowski, M | 4 |
| Olędzki, J | 6 |
| Wierzbicki, R | 2 |
| Gach, T | 1 |
| Rutkowski, A | 7 |
| Dziki, A | 1 |
| Kołodziejski, L | 1 |
| Sopyło, R | 3 |
| Pietrzak, L | 6 |
| Kryński, J | 3 |
| Wiśniowska, K | 2 |
| Spałek, M | 2 |
| Pawlewicz, K | 1 |
| Polkowski, M | 1 |
| Kowalska, T | 1 |
| Paprota, K | 2 |
| Jankiewicz, M | 3 |
| Radkowski, A | 2 |
| Chalubińska-Fendler, J | 1 |
| Grützmann, R | 4 |
| Köhne, CH | 3 |
| Benassi, M | 1 |
| Del Vecchio Blanco, G | 1 |
| Doldo, E | 1 |
| Martano, L | 1 |
| Portarena, I | 1 |
| Nardecchia, A | 1 |
| Lucchetti, J | 1 |
| Morelli, C | 1 |
| Giudice, E | 1 |
| Rossi, P | 1 |
| Anselmo, A | 1 |
| Sileri, P | 1 |
| Sica, G | 1 |
| Orlandi, A | 1 |
| Santoni, R | 1 |
| Roselli, M | 1 |
| André, T | 7 |
| Brændengen, M | 2 |
| Willett, CG | 19 |
| Okuyama, T | 2 |
| Sameshima, S | 3 |
| Takeshita, E | 1 |
| Yoshioka, R | 1 |
| Yamagata, Y | 1 |
| Ono, Y | 2 |
| Tagaya, N | 1 |
| Noie, T | 1 |
| Oya, M | 3 |
| Haderlein, M | 2 |
| Lettmaier, S | 1 |
| Langheinrich, M | 1 |
| Schmid, A | 1 |
| Semrau, S | 2 |
| Hecht, M | 2 |
| Beck, M | 1 |
| Schmidt, D | 1 |
| Denz, A | 1 |
| Chen, S | 3 |
| Wang, P | 1 |
| Aimono, Y | 1 |
| Kamoshida, T | 1 |
| Okawara, A | 1 |
| Ogawa, T | 1 |
| Sakamoto, R | 1 |
| Saito, Y | 1 |
| Aoyama, Y | 1 |
| Yokoyama, M | 5 |
| Kodama, M | 3 |
| Kondo, S | 2 |
| Yoshida, A | 1 |
| Miyahara, Y | 1 |
| Gollins, S | 5 |
| West, N | 2 |
| Sebag-Montefiore, D | 11 |
| Susnerwala, S | 5 |
| Falk, S | 3 |
| Brown, N | 1 |
| Saunders, M | 2 |
| Quirke, P | 4 |
| Ray, R | 1 |
| Parsons, P | 1 |
| Griffiths, G | 1 |
| Maughan, T | 2 |
| Adams, R | 1 |
| Hurt, C | 1 |
| Zhou, L | 1 |
| Marcet, JE | 2 |
| Cataldo, PA | 2 |
| Hunt, SR | 2 |
| Kumar, A | 2 |
| Fichera, A | 2 |
| Hyman, NH | 1 |
| Ternent, CA | 4 |
| Stamos, MJ | 2 |
| Pigazzi, A | 2 |
| Dietz, D | 3 |
| Yakunina, Y | 1 |
| Domati, F | 1 |
| Bonetti, LR | 1 |
| Barresi, V | 1 |
| Zizzo, M | 1 |
| Manenti, A | 1 |
| Yamamoto, A | 1 |
| Toiyama, Y | 9 |
| Okugawa, Y | 7 |
| Saigusa, S | 8 |
| Ide, S | 1 |
| Fujikawa, H | 2 |
| Hiro, J | 4 |
| Yasuda, H | 3 |
| Yoshiyama, S | 1 |
| Ohi, M | 1 |
| Araki, T | 1 |
| Kusunoki, M | 14 |
| Shinohara, S | 1 |
| Hyodo, M | 1 |
| Ota, G | 1 |
| Tsukahara, M | 1 |
| Okada, M | 1 |
| Lefor, AK | 1 |
| Yasuda, Y | 2 |
| Chung, MJ | 1 |
| Yu, M | 2 |
| Jeong, JU | 4 |
| Kim, WR | 1 |
| Han, YD | 1 |
| Clifford, R | 1 |
| Govindarajah, N | 1 |
| Parsons, JL | 1 |
| West, NP | 2 |
| Vimalachandran, D | 1 |
| Lucidarme, O | 1 |
| Levache, CB | 1 |
| Barbier, E | 1 |
| Raoul, JL | 2 |
| Lecomte, T | 1 |
| Desauw, C | 1 |
| Brocard, F | 1 |
| Pernot, S | 1 |
| Breysacher, G | 1 |
| Lagasse, JP | 1 |
| Di Fiore, F | 3 |
| Etienne, PL | 4 |
| Dupuis, OJM | 1 |
| Aleba, A | 1 |
| Lepage, C | 1 |
| O'hara, H | 1 |
| Yamamoto, H | 8 |
| Lin, Z | 1 |
| Peng, L | 2 |
| Zhang, D | 1 |
| Jin, M | 1 |
| Xue, J | 1 |
| Bottarelli, L | 1 |
| De' Angelis, GL | 1 |
| Azzoni, C | 1 |
| Di Mario, F | 1 |
| De' Angelis, N | 1 |
| Leandro, G | 1 |
| Fornaroli, F | 1 |
| Gaiani, F | 1 |
| Negri, F | 1 |
| Spalek, M | 2 |
| Wyrwicz, L | 6 |
| Peng, T | 1 |
| Ouyang, Y | 1 |
| Tong, K | 1 |
| Tsujimura, N | 1 |
| Takemoto, H | 2 |
| Nakahara, Y | 1 |
| Wakasugi, M | 1 |
| Hirota, M | 2 |
| Takachi, K | 1 |
| Nishioka, K | 1 |
| Oshima, S | 3 |
| Tanaka, K | 11 |
| Shimada, Y | 10 |
| Tajima, Y | 1 |
| Yamada, S | 1 |
| Hotta, S | 1 |
| Nakano, M | 2 |
| Kameyama, H | 3 |
| Miura, K | 3 |
| Ichikawa, H | 1 |
| Nagahashi, M | 2 |
| Nogami, H | 3 |
| Maruyama, S | 4 |
| Takii, Y | 3 |
| Wakai, T | 6 |
| Iwazu, Y | 1 |
| Kotani, K | 1 |
| Jimenez-Cauhe, J | 1 |
| Molins-Ruiz, M | 1 |
| Fernandez-Guarino, M | 1 |
| Margalit, O | 1 |
| Mamtani, R | 1 |
| Kopetz, S | 1 |
| Yang, YX | 1 |
| Lawrence, YR | 1 |
| Abu-Gazala, S | 1 |
| Reiss, KA | 1 |
| Golan, T | 1 |
| Halpern, N | 1 |
| Aderka, D | 1 |
| Giantonio, B | 1 |
| Shacham-Shmueli, E | 1 |
| Boursi, B | 1 |
| Chow, OS | 3 |
| Keskin, M | 1 |
| Smith, DD | 3 |
| Avila, K | 3 |
| Chu, P | 1 |
| Vivaldi, C | 1 |
| Fornaro, L | 1 |
| Buccianti, P | 1 |
| Sainato, A | 2 |
| Marcucci, L | 1 |
| Martignetti, A | 1 |
| Luca Urso, ED | 1 |
| Castagna, M | 1 |
| Musettini, G | 1 |
| Urbani, L | 1 |
| Sensi, E | 1 |
| Balestri, R | 1 |
| Montrone, S | 1 |
| Pasqualetti, F | 1 |
| Di Paolo, A | 1 |
| Zagonel, V | 1 |
| Endo, K | 4 |
| Yamashita, K | 3 |
| Chiku, T | 1 |
| Sano, W | 1 |
| Hashiba, T | 1 |
| Shinoda, K | 1 |
| Togawa, Y | 1 |
| Liu, Q | 1 |
| Jia, B | 1 |
| Du, X | 2 |
| Dai, G | 1 |
| Zeng, M | 1 |
| Wen, K | 1 |
| Feng, L | 1 |
| Su, X | 1 |
| Li, S | 4 |
| Xiao, H | 1 |
| Chen, C | 1 |
| Kuraya, D | 1 |
| Kawamata, F | 1 |
| Ohno, Y | 1 |
| Martin, D | 2 |
| von der Grün, J | 1 |
| Rieger, M | 1 |
| Weitz, J | 1 |
| Rödel, F | 5 |
| Lin, H | 2 |
| Lu, X | 2 |
| Huang, Y | 6 |
| Chi, P | 4 |
| Zhang, MX | 1 |
| Li, XB | 1 |
| Guan, BJ | 1 |
| Guan, GX | 1 |
| Lin, XY | 1 |
| Wu, XD | 1 |
| Xu, BH | 1 |
| Renz, P | 1 |
| Wegner, RE | 1 |
| Hasan, S | 1 |
| Brookover, R | 1 |
| Finley, G | 1 |
| Monga, D | 1 |
| Raj, M | 1 |
| McCormick, J | 1 |
| Kirichenko, A | 1 |
| Sakabe, R | 1 |
| Sakoda, T | 1 |
| Yoshimura, K | 2 |
| Murao, N | 1 |
| Kuwada, A | 2 |
| Tahara, K | 1 |
| Hotei, H | 1 |
| Maeda, Y | 2 |
| Murofushi, K | 2 |
| Taguchi, S | 1 |
| Nagayama, S | 4 |
| Fujimoto, Y | 5 |
| Suenaga, M | 3 |
| Chino, A | 1 |
| Kawachi, H | 1 |
| Yamamoto, N | 3 |
| Ishikawa, Y | 2 |
| Oguchi, M | 2 |
| Ishizuka, N | 2 |
| Zhu, J | 4 |
| Zeng, W | 1 |
| Ge, L | 1 |
| Yang, X | 1 |
| Qin, S | 1 |
| Ng, SY | 1 |
| Colborn, KL | 1 |
| Cambridge, L | 1 |
| Reidy-Lagunes, DL | 2 |
| Segal, N | 1 |
| Stadler, Z | 1 |
| Guillem, J | 4 |
| Nash, G | 1 |
| Braun, LH | 1 |
| Baumann, D | 1 |
| Zwirner, K | 1 |
| Eipper, E | 1 |
| Hauth, F | 1 |
| Peter, A | 1 |
| Bedoui, S | 1 |
| Dallel, M | 1 |
| Barbirou, M | 1 |
| Stayoussef, M | 1 |
| Mokrani, A | 1 |
| Mezlini, A | 1 |
| Bouhaouala, B | 1 |
| Almawi, WY | 1 |
| Yacoubi-Loueslati, B | 1 |
| Shigoka, M | 1 |
| Wada, T | 2 |
| Mazaki, J | 1 |
| Kuwabara, H | 2 |
| Ishizaki, T | 2 |
| Ishibashi, Y | 1 |
| Nagakawa, Y | 1 |
| Katsumata, K | 3 |
| Tsuchida, A | 2 |
| Yoon, G | 1 |
| Park, JY | 2 |
| Fernandez, LM | 3 |
| Andrade, A | 1 |
| Araújo, SEA | 1 |
| Gama-Rodrigues, J | 14 |
| Suganuma, Y | 1 |
| Nishida, T | 2 |
| Ishimoto, T | 2 |
| Sai, S | 1 |
| Nomi, S | 1 |
| Ciseł, B | 2 |
| Kosakowska, E | 3 |
| Cencelewicz, A | 1 |
| Styliński, R | 2 |
| Bębenek, M | 4 |
| Kapturkiewicz, B | 1 |
| Maciejczyk, A | 2 |
| Sadowski, J | 1 |
| Zygulska, J | 1 |
| Zegarski, W | 2 |
| Jankowski, M | 2 |
| Las-Jankowska, M | 1 |
| Toczko, Z | 2 |
| Żelazowska-Omiotek, U | 1 |
| Kępka, L | 8 |
| Wasilewska-Tesluk, E | 1 |
| Markiewicz, W | 2 |
| Kładny, J | 2 |
| Majewski, A | 2 |
| Kapuściński, W | 1 |
| Wang, S | 1 |
| Wen, F | 1 |
| Zhang, P | 1 |
| Li, Q | 1 |
| Park, JH | 6 |
| Kim, YH | 3 |
| Park, EH | 1 |
| Lee, SJ | 4 |
| Kim, A | 1 |
| Lee, SB | 1 |
| Shim, S | 1 |
| Jang, H | 1 |
| Myung, JK | 1 |
| Kim, MJ | 4 |
| Borg, C | 2 |
| Mantion, G | 3 |
| Boudghène, F | 2 |
| Mornex, F | 4 |
| Ghiringhelli, F | 1 |
| Adenis, A | 4 |
| Azria, D | 7 |
| Balosso, J | 1 |
| Ben Abdelghani, M | 1 |
| François, Y | 1 |
| Conroy, T | 9 |
| Rio, E | 1 |
| Roullet, B | 2 |
| Spaëth, D | 1 |
| Quero, L | 1 |
| Lakkis, Z | 2 |
| Coudert, M | 1 |
| Ionescu-Goga, M | 1 |
| Tanang, A | 1 |
| Yasuda, T | 1 |
| Tanaka, O | 2 |
| Hayashi, S | 2 |
| Nakahata, Y | 1 |
| Omatsu, T | 1 |
| Obora, A | 1 |
| Kojima, T | 3 |
| Matsuo, M | 1 |
| Yagi, N | 1 |
| Li, A | 1 |
| He, K | 1 |
| Guo, D | 1 |
| Liu, C | 2 |
| Wang, D | 1 |
| Mu, X | 1 |
| Yu, J | 2 |
| Zhang, J | 3 |
| Huang, M | 2 |
| Cai, Y | 5 |
| Ling, J | 1 |
| Peng, J | 4 |
| Chen, D | 2 |
| Kang, L | 2 |
| Ren, D | 3 |
| Lin, F | 1 |
| Zheng, J | 5 |
| Zhou, Z | 3 |
| Deng, Y | 5 |
| Nakae, S | 1 |
| Mizojiri, G | 1 |
| Fujikawa, M | 1 |
| Ishida, J | 1 |
| Yamamoto, M | 2 |
| Harada, N | 2 |
| Haji, S | 1 |
| Toyoda, M | 2 |
| Senzaki, H | 1 |
| Bajetta, E | 3 |
| Buzzoni, R | 3 |
| Ferrario, E | 2 |
| Valvo, F | 6 |
| Mariani, L | 4 |
| Dotti, KF | 1 |
| Biondani, P | 2 |
| Formisano, B | 1 |
| Gevorgyan, A | 1 |
| Grassi, P | 1 |
| Di Bartolomeo, M | 3 |
| Arredondo, J | 2 |
| Beorlegui, C | 3 |
| Arbea, L | 7 |
| Sola, JJ | 4 |
| Chopitea, A | 2 |
| Hernández-Lizoáin, JL | 7 |
| Martin, LK | 1 |
| Bekaii-Saab, T | 1 |
| Ha, YJ | 1 |
| Roh, SA | 1 |
| Cho, DH | 1 |
| Choi, EY | 1 |
| Kim, TW | 17 |
| Kang, TW | 1 |
| Kim, SY | 13 |
| Kim, YS | 1 |
| van Dijk, TH | 1 |
| Tamas, K | 1 |
| Beukema, JC | 1 |
| Beets, GL | 7 |
| Gelderblom, AJ | 1 |
| de Jong, KP | 1 |
| Rutten, HJ | 2 |
| van de Velde, CJ | 5 |
| Wiggers, T | 2 |
| Hospers, GA | 3 |
| Havenga, K | 2 |
| Mohiuddin, M | 8 |
| Paulus, R | 1 |
| Mitchell, E | 4 |
| Hanna, N | 3 |
| Yuen, A | 2 |
| Nichols, R | 1 |
| Yalavarthi, S | 1 |
| Hayostek, C | 2 |
| Lin, SC | 1 |
| Chen, PC | 1 |
| Lee, CT | 1 |
| Tsai, HM | 1 |
| Lin, PC | 1 |
| Chen, HH | 2 |
| Wu, YH | 1 |
| Lin, BW | 1 |
| Su, WP | 1 |
| Lee, JC | 1 |
| Kiel, K | 2 |
| Engstrom, PF | 7 |
| Engelen, SM | 2 |
| Maas, M | 3 |
| Lahaye, MJ | 1 |
| Leijtens, JW | 2 |
| van Berlo, CL | 1 |
| Jansen, RL | 3 |
| Breukink, SO | 1 |
| Dejong, CH | 1 |
| Beets-Tan, RG | 5 |
| Glynne-Jones, R | 22 |
| Blackstock, W | 1 |
| van de Velde, C | 2 |
| Dellas, K | 5 |
| Höhler, T | 2 |
| Reese, T | 5 |
| Würschmidt, F | 1 |
| Engel, E | 1 |
| Wagner, W | 1 |
| Richter, M | 2 |
| Dunst, J | 10 |
| Nasierowska-Guttmejer, A | 7 |
| Malinowska, M | 3 |
| Radziszewski, J | 2 |
| Olszyna-Serementa, M | 2 |
| Bujko, M | 2 |
| Danek, A | 2 |
| Wydmanski, J | 1 |
| Lesniak, T | 2 |
| Zygulski, I | 1 |
| Porzuczek-Zuziak, D | 1 |
| Czeremszynska, B | 1 |
| Cieslak-Zeranska, E | 1 |
| Kolodziejski, L | 1 |
| Ricardi, U | 1 |
| Racca, P | 1 |
| Franco, P | 1 |
| Munoz, F | 1 |
| Fanchini, L | 1 |
| Rondi, N | 1 |
| Dongiovanni, V | 2 |
| Gabriele, P | 1 |
| Cassoni, P | 1 |
| Ciuffreda, L | 1 |
| Morino, M | 1 |
| Filippi, AR | 1 |
| Aglietta, M | 1 |
| Bertetto, O | 1 |
| Jeong, BG | 1 |
| Le Fur, E | 1 |
| Chatellier, G | 1 |
| Berger, A | 2 |
| Emile, JF | 1 |
| Dousset, B | 1 |
| Nordlinger, B | 3 |
| Berges, O | 1 |
| Deberne, M | 1 |
| Dessard-Diana, B | 1 |
| Henni, M | 1 |
| Giraud, P | 1 |
| Housset, M | 1 |
| Durdux, C | 1 |
| Barsukov, YA | 1 |
| Gordeyev, SS | 1 |
| Tkachev, SI | 2 |
| Fedyanin, MY | 1 |
| Perevoshikov, AG | 1 |
| Bondar', GV | 2 |
| Basheev, VKh | 1 |
| Zolotukhin, SÉ | 2 |
| Sovpel', IV | 1 |
| Sovpel', OV | 1 |
| Elezkurtaj, S | 1 |
| Moser, L | 1 |
| Budczies, J | 1 |
| Müller, AJ | 1 |
| Bläker, H | 1 |
| Buhr, HJ | 2 |
| Dietel, M | 2 |
| Kruschewski, M | 1 |
| Bulzonetti, N | 2 |
| Guarnaccia, R | 1 |
| Caiazzo, R | 2 |
| Bangrazi, C | 1 |
| Raffetto, N | 1 |
| Gu, W | 2 |
| Lian, P | 3 |
| Sheng, W | 2 |
| Cai, G | 3 |
| Shi, D | 2 |
| Chang, RY | 1 |
| Lee, MY | 2 |
| Kan, CB | 1 |
| Hsu, WP | 1 |
| Hsiao, PC | 1 |
| Ronzoni, M | 1 |
| Ricci, V | 1 |
| Di Palo, S | 1 |
| De Nardi, P | 1 |
| Orsenigo, E | 1 |
| Tamburini, A | 1 |
| Losio, C | 1 |
| Iacovelli, NA | 1 |
| Broggi, S | 2 |
| Staudacher, C | 1 |
| Rashidi, A | 1 |
| Man, L | 1 |
| Howard, JR | 1 |
| Atienza, D | 1 |
| Fisher, SI | 1 |
| Shimada, A | 1 |
| Nakamura, T | 5 |
| Ishii, M | 1 |
| Chiba, N | 2 |
| Ishikawa, S | 1 |
| Arisawa, Y | 2 |
| Koike, N | 2 |
| Ohshima, Y | 2 |
| Takeuchi, T | 2 |
| Arita, S | 2 |
| Hamano, G | 1 |
| Ikebe, T | 1 |
| Mayumi, K | 1 |
| Takemura, M | 2 |
| Hori, T | 1 |
| Nishioka, T | 1 |
| Boisen, MK | 1 |
| Johansen, JS | 1 |
| Dehlendorff, C | 1 |
| Larsen, JS | 1 |
| Østerlind, K | 1 |
| Hansen, J | 1 |
| Nielsen, SE | 1 |
| Tarpgaard, LS | 1 |
| Holländer, NH | 1 |
| Keldsen, N | 1 |
| Jensen, BB | 1 |
| Jensen, BV | 2 |
| Lee, WC | 1 |
| Yusof, MM | 1 |
| Lau, FN | 1 |
| Phua, VC | 1 |
| Lu, JY | 1 |
| Qiu, HZ | 2 |
| Lin, GL | 2 |
| Zhang, GN | 1 |
| Hu, K | 1 |
| Tan, JW | 1 |
| Tan, HM | 1 |
| Hu, BS | 1 |
| Chen, K | 1 |
| Ding, XM | 1 |
| Leng, JJ | 1 |
| Chen, F | 1 |
| Uehara, K | 6 |
| Hiramatsu, K | 2 |
| Maeda, A | 2 |
| Sakamoto, E | 3 |
| Inoue, M | 6 |
| Tojima, Y | 3 |
| Yatsuya, H | 2 |
| Ohmiya, N | 1 |
| Goto, H | 5 |
| Nagino, M | 5 |
| Lupinacci, RM | 1 |
| Menegaux, F | 1 |
| Qiao, Y | 1 |
| DU, ZL | 1 |
| Yu, DK | 1 |
| Lin, DX | 1 |
| Tan, W | 1 |
| Terasawa, T | 1 |
| Koja, S | 1 |
| Yasuda, K | 4 |
| Calvo, FA | 9 |
| Sole, CV | 3 |
| Serrano, J | 5 |
| Rodriguez, M | 4 |
| Marcos, F | 1 |
| Muñoz-Calero, A | 3 |
| Zorrilla, J | 1 |
| Lopez-Baena, JA | 1 |
| Diaz-Zorita, B | 1 |
| García-Sabrido, JL | 4 |
| del Valle, E | 4 |
| Russo, AL | 1 |
| Ryan, DP | 9 |
| Borger, DR | 2 |
| Wo, JY | 2 |
| Szymonifka, J | 2 |
| Liang, WY | 1 |
| Kwak, EL | 2 |
| Blaszkowsky, LS | 4 |
| Clark, JW | 7 |
| Allen, JN | 2 |
| Zhu, AX | 5 |
| Berger, DL | 2 |
| Cusack, JC | 2 |
| Haigis, KM | 1 |
| Qvortrup, C | 2 |
| Mortensen, JP | 2 |
| Tyc-Szczepaniak, D | 1 |
| Palucki, J | 1 |
| Saur, G | 1 |
| Wehner, D | 1 |
| Thalheimer, A | 1 |
| Kim, M | 1 |
| Sabbaga, J | 3 |
| Proscurshim, I | 7 |
| Bailão Aguilar, P | 2 |
| Nadalin, W | 6 |
| Dinnewitzer, A | 1 |
| Jäger, T | 1 |
| Nawara, C | 1 |
| Buchner, S | 1 |
| Wolfgang, H | 1 |
| Öfner, D | 5 |
| Korytova, LI | 2 |
| Masliukova, EA | 1 |
| Korytov, OV | 2 |
| Gopta, EV | 1 |
| Oltarzhevskaia, ND | 3 |
| Korotina, MA | 1 |
| Milgrom, SA | 1 |
| Sala, E | 1 |
| Kelvin, JF | 1 |
| Hricak, H | 1 |
| Schiffmann, L | 2 |
| Wedermann, N | 1 |
| Gock, M | 1 |
| Prall, F | 6 |
| Klautke, G | 8 |
| Rau, B | 10 |
| Klar, E | 4 |
| Fan, CW | 1 |
| Chen, T | 2 |
| Shang, YN | 1 |
| Gu, YZ | 1 |
| Zhang, SL | 1 |
| Lu, R | 1 |
| OuYang, SR | 1 |
| Zhou, X | 2 |
| Meng, WT | 1 |
| Hu, JK | 1 |
| Lu, Y | 1 |
| Sun, XF | 2 |
| Bu, H | 1 |
| Zhou, ZG | 3 |
| Mo, XM | 1 |
| Murata, S | 1 |
| Onozawa, S | 1 |
| Kimata, R | 1 |
| Uchida, E | 1 |
| Kumita, S | 1 |
| Madbouly, KM | 1 |
| Abbas, KS | 1 |
| Hussein, AM | 1 |
| Abdul-Jalil, KI | 1 |
| Sheehan, KM | 1 |
| Kehoe, J | 2 |
| Cummins, R | 1 |
| O'Grady, A | 1 |
| McNamara, DA | 3 |
| Deasy, J | 3 |
| Breathnach, O | 1 |
| Grogan, L | 1 |
| O'Neill, BD | 1 |
| Faul, C | 1 |
| Parker, I | 1 |
| Kay, EW | 3 |
| Hennessy, BT | 1 |
| Gillen, P | 1 |
| Genovesi, D | 5 |
| Cèfaro, GA | 1 |
| Vinciguerra, A | 1 |
| Augurio, A | 1 |
| Trignani, M | 1 |
| DI Tommaso, M | 1 |
| Nuzzo, M | 1 |
| Lupattelli, M | 4 |
| Aristei, C | 2 |
| Bellavita, R | 2 |
| Scandolaro, L | 1 |
| Cosentino, D | 1 |
| Pani, G | 1 |
| Ziccarelli, L | 2 |
| Barba, MC | 2 |
| Maranzano, E | 2 |
| Trippa, F | 1 |
| Sciacero, P | 1 |
| Niespolo, R | 1 |
| Leonardi, C | 1 |
| Iannone, T | 2 |
| Rosetto, ME | 3 |
| Fusco, V | 1 |
| Sanpaolo, P | 1 |
| Melano, A | 1 |
| Capirci, C | 3 |
| DE Paoli, A | 8 |
| DI Nicola, M | 1 |
| Mantello, G | 5 |
| Peckitt, C | 2 |
| Gonzalez de Castro, D | 2 |
| Eltahir, Z | 1 |
| Oates, J | 4 |
| Bazan, JG | 1 |
| Luxton, G | 1 |
| Kozak, MM | 1 |
| Anderson, EM | 1 |
| Hancock, SL | 2 |
| Kapp, DS | 2 |
| Kidd, EA | 1 |
| Koong, AC | 2 |
| Kulu, Y | 1 |
| Büchler, MW | 1 |
| Ulrich, A | 1 |
| Lee, SU | 1 |
| Baek, JY | 6 |
| Chang, HJ | 11 |
| Park, JW | 6 |
| Oh, JH | 11 |
| Conradi, L | 1 |
| Weiss, C | 3 |
| Middel, P | 2 |
| Rau, T | 1 |
| Kitz, J | 2 |
| Rüschoff, J | 2 |
| Beissbarth, T | 7 |
| Ghadimi, BM | 9 |
| Kawamura, M | 3 |
| Kawamoto, A | 2 |
| Mohri, Y | 2 |
| Noguchi, Y | 1 |
| Tsurushima, M | 1 |
| Tamura, Y | 1 |
| Aoyama, K | 1 |
| Tokuyama, Y | 1 |
| Uchiyama, K | 1 |
| Shimizu, Y | 3 |
| Gao, YH | 6 |
| An, X | 5 |
| Sun, WJ | 1 |
| Cai, J | 1 |
| Cai, MY | 3 |
| Kong, LH | 5 |
| Lin, JZ | 7 |
| Liu, GC | 2 |
| Tang, JH | 2 |
| Wu, XJ | 6 |
| Pan, ZZ | 10 |
| Ding, PR | 9 |
| Peligros, I | 2 |
| Alvarez, E | 6 |
| Buller, J | 1 |
| Görtz, GJ | 1 |
| Keck, T | 1 |
| Zühlke, H | 2 |
| Guo, X | 1 |
| Liu, TS | 2 |
| Yu, YY | 1 |
| Zhou, YH | 1 |
| Zhuang, RY | 1 |
| Cui, YH | 1 |
| Das, P | 9 |
| Rodriguez-Bigas, MA | 10 |
| Skibber, JM | 16 |
| Maru, DM | 2 |
| Munsell, MF | 1 |
| Clemons, MV | 1 |
| Kopetz, SE | 1 |
| Garrett, CR | 1 |
| Shureiqi, I | 1 |
| Delclos, ME | 9 |
| Krishnan, S | 9 |
| You, KY | 1 |
| Peng, HH | 1 |
| Chen, L | 2 |
| Zhou, GQ | 1 |
| Du, XJ | 1 |
| Xiao, L | 4 |
| Zeng, ZF | 5 |
| Wen, BX | 1 |
| Liu, MZ | 1 |
| Nakano, E | 1 |
| Kuroki, M | 1 |
| Kanno, N | 1 |
| Matsumura, Y | 2 |
| Miura, A | 1 |
| Kikuchi, Y | 1 |
| Hirakawa, H | 1 |
| Vasudev, E | 1 |
| Shellito, PC | 6 |
| Iwata, N | 1 |
| Masuda, T | 2 |
| Okazaki, S | 3 |
| Matsuyama, T | 6 |
| Ishiguro, M | 5 |
| Kobayashi, H | 6 |
| Iida, S | 6 |
| Sugihara, K | 7 |
| Sueda, T | 1 |
| Noura, S | 6 |
| Shingai, T | 4 |
| Gotoh, K | 3 |
| Kishi, K | 3 |
| Marubashi, S | 2 |
| Ohigashi, H | 2 |
| Yano, M | 4 |
| Tomita, Y | 1 |
| Ishikawa, O | 2 |
| Ami, K | 4 |
| Kawai, Y | 1 |
| Seki, R | 2 |
| Takeuchi, S | 1 |
| Fujiya, K | 1 |
| Takasaki, J | 1 |
| Amagasa, H | 2 |
| Kamikozuru, H | 2 |
| Ganno, H | 2 |
| Imai, K | 3 |
| Fukuda, A | 2 |
| Nagahama, T | 3 |
| Okada, Y | 4 |
| Tei, S | 4 |
| Arai, K | 3 |
| Okamura, S | 2 |
| Okubo, H | 1 |
| Owada, Y | 2 |
| Nishigaki, T | 2 |
| Wada, Y | 3 |
| Kato, R | 3 |
| Makino, S | 3 |
| Takeoka, T | 1 |
| Fukuchi, N | 2 |
| Ebisui, C | 3 |
| Kinuta, M | 5 |
| Tsukiyama, G | 1 |
| Hasegawa, M | 3 |
| Yabuki, S | 1 |
| Tanahashi, C | 1 |
| Wakatsuki, K | 1 |
| Yoshioka, S | 5 |
| Shiobara, M | 1 |
| Kataoka, M | 1 |
| Arai, S | 1 |
| Tonooka, T | 1 |
| Miyazawa, K | 1 |
| Oeda, Y | 1 |
| Nakayasu, Y | 1 |
| Osawa, G | 1 |
| Nakayama, M | 1 |
| Sakuma, A | 2 |
| Naritaka, Y | 1 |
| Watanabe, S | 4 |
| Liu, B | 1 |
| Mitsuoka, A | 1 |
| Sanada, T | 2 |
| Nakajima, K | 2 |
| Goseki, N | 1 |
| Yu, SK | 1 |
| Bhangu, A | 2 |
| Tait, DM | 2 |
| Zhang, X | 2 |
| Wan, DS | 10 |
| Oh, ST | 3 |
| Chun, HG | 1 |
| Choi, DH | 2 |
| Kim, HC | 7 |
| Gourgou-Bourgade, S | 4 |
| Jarlier, M | 1 |
| Martel-Laffay, I | 2 |
| Hennequin, C | 5 |
| Seitz, JF | 5 |
| Juzyna, B | 3 |
| Hollywood, E | 1 |
| Temple, LK | 4 |
| Naiken, SP | 1 |
| Toso, C | 1 |
| Rubbia-Brandt, L | 1 |
| Thomopoulos, T | 1 |
| Roth, A | 2 |
| Mentha, G | 1 |
| Morel, P | 1 |
| Gervaz, P | 2 |
| Maggiori, L | 2 |
| Bretagnol, F | 1 |
| Aslam, MI | 1 |
| Guedj, N | 1 |
| Zappa, M | 1 |
| Ferron, M | 1 |
| Panis, Y | 3 |
| Bosset, JF | 15 |
| Calais, G | 6 |
| Mineur, L | 8 |
| Stojanovic-Rundic, S | 1 |
| Bensadoun, RJ | 2 |
| Bardet, E | 4 |
| Beny, A | 3 |
| Ollier, JC | 2 |
| Bolla, M | 1 |
| Marchal, D | 1 |
| Van Laethem, JL | 2 |
| Klein, V | 1 |
| Giralt, J | 4 |
| Glanzmann, C | 1 |
| Cellier, P | 1 |
| Collette, L | 5 |
| Holmqvist, A | 1 |
| Albertsson, M | 1 |
| Lynn, PB | 3 |
| Liu, M | 4 |
| Aiba, T | 1 |
| Nihashi, T | 1 |
| Tsuzuki, T | 1 |
| Allen, J | 1 |
| Williamson, S | 1 |
| Babacan, T | 1 |
| Turkbeyler, IH | 1 |
| Dag, MS | 1 |
| Dilli, I | 1 |
| Balakan, O | 1 |
| Altundag, K | 2 |
| Gonzalez, D | 1 |
| Hulkki Wilson, S | 1 |
| Roselló Keränen, S | 1 |
| Nishimura, J | 4 |
| Mizushima, T | 4 |
| Miyake, Y | 2 |
| Kim, HM | 2 |
| Tamagawa, H | 1 |
| Fujii, M | 1 |
| Fujie, Y | 2 |
| Miwa, H | 2 |
| Takemasa, I | 4 |
| Ikeda, M | 3 |
| Sekimoto, M | 2 |
| Nezu, R | 1 |
| Shinzaki, S | 1 |
| Fujinaga, T | 1 |
| Yakushijin, T | 1 |
| Tatsumi, T | 1 |
| Hiramatsu, N | 1 |
| Tsujii, M | 1 |
| Takehara, T | 1 |
| Olsen, J | 2 |
| Birnbaum, E | 3 |
| Fleshman, J | 3 |
| Gao, F | 1 |
| Hall, L | 1 |
| Kodner, I | 3 |
| Lockhart, AC | 3 |
| Mutch, M | 1 |
| Naughton, M | 1 |
| Picus, J | 6 |
| Rigden, C | 1 |
| Sorscher, S | 1 |
| Suresh, R | 1 |
| Wang-Gillam, A | 1 |
| Parikh, P | 1 |
| Liu, F | 4 |
| Gomez-Millan, J | 2 |
| Perez, L | 1 |
| Aroca, I | 1 |
| Del Mar Delgado, M | 1 |
| De Luque, V | 1 |
| Román, A | 1 |
| Torres, E | 1 |
| Ramos, S | 1 |
| Perez, S | 1 |
| Bayo, E | 1 |
| Medina, JA | 1 |
| Shimizu, T | 5 |
| Mekata, E | 2 |
| Endo, Y | 2 |
| Ishida, M | 4 |
| Tani, T | 5 |
| Huang, R | 2 |
| You, K | 1 |
| Qiu, B | 1 |
| Ferreira, AO | 1 |
| Loureiro, AL | 1 |
| Marques, V | 1 |
| Sousa, HT | 1 |
| Sim, SH | 1 |
| Kim, YJ | 4 |
| Lee, KW | 3 |
| Kang, SB | 5 |
| Eom, KY | 1 |
| Lee, HS | 2 |
| Counsell, N | 1 |
| Mortensen, N | 1 |
| Maraveyas, A | 1 |
| Meadows, HM | 3 |
| Ledermann, J | 1 |
| Goto, N | 1 |
| Mimura, J | 1 |
| West, MA | 1 |
| Loughney, L | 1 |
| Barben, CP | 1 |
| Sripadam, R | 1 |
| Kemp, GJ | 1 |
| Grocott, MP | 1 |
| Jack, S | 1 |
| Daniel, ES | 1 |
| Jung, SH | 2 |
| O'Connell, MJ | 21 |
| Beart, RW | 3 |
| Allegra, CJ | 6 |
| Sharif, S | 2 |
| Pitot, HC | 2 |
| Shields, AF | 2 |
| Landry, JC | 6 |
| Parda, DS | 1 |
| Arora, A | 2 |
| Evans, LS | 2 |
| Bahary, N | 2 |
| Soori, GS | 1 |
| Eakle, J | 1 |
| Robertson, JM | 7 |
| Moore, DF | 2 |
| Mullane, MR | 2 |
| Marchello, BT | 2 |
| Ward, PJ | 2 |
| Wozniak, TF | 2 |
| Roh, MS | 4 |
| Osti, MF | 2 |
| Agolli, L | 2 |
| Bracci, S | 2 |
| Masoni, L | 1 |
| Valeriani, M | 2 |
| Falco, T | 2 |
| De Sanctis, V | 2 |
| Maurizi Enrici, R | 1 |
| Luo, NQ | 1 |
| Zhang, ZH | 1 |
| Ma, Y | 1 |
| Morillo, V | 1 |
| Santos, M | 1 |
| Gomez-Espí, M | 4 |
| Del Vale, E | 1 |
| Gracia-Sabrido, JL | 1 |
| Ferrer, C | 1 |
| Sole, C | 1 |
| Takahashi, T | 16 |
| Namiki, K | 1 |
| Matsumoto, H | 2 |
| Konno, F | 1 |
| Mitsui, K | 1 |
| Yoshida, R | 1 |
| Richter, I | 2 |
| Dvořák, J | 5 |
| Bartoš, J | 3 |
| Fujii, T | 3 |
| Ide, M | 1 |
| Takada, T | 3 |
| Sutoh, T | 1 |
| Morita, H | 2 |
| Yajima, R | 2 |
| Tsutsumi, S | 4 |
| Asao, T | 4 |
| Oyama, T | 1 |
| Kuwano, H | 4 |
| Ema, A | 1 |
| Naito, M | 1 |
| Watanabe, M | 4 |
| Berkel, AE | 1 |
| Woutersen, DP | 1 |
| van der Palen, J | 1 |
| Klaase, JM | 1 |
| Chen, CF | 2 |
| Yeh, YS | 3 |
| Ma, CJ | 2 |
| Wu, CH | 2 |
| Lu, CY | 2 |
| Huang, CJ | 2 |
| Turégano, F | 1 |
| Rivera, S | 1 |
| Deutsch, E | 2 |
| Ihn, MH | 1 |
| Oh, HK | 3 |
| Lee, SY | 1 |
| Hong, SM | 1 |
| Carmona, R | 1 |
| Pritz, J | 1 |
| Bydder, M | 1 |
| Gulaya, S | 1 |
| Zhu, H | 1 |
| Williamson, CW | 1 |
| Welch, CS | 1 |
| Vaida, F | 1 |
| Bydder, G | 1 |
| Mell, LK | 1 |
| Swellengrebel, HA | 2 |
| Bosch, SL | 1 |
| Cats, A | 4 |
| Vincent, AD | 1 |
| Dewit, LG | 1 |
| Verwaal, VJ | 2 |
| Marijnen, CA | 3 |
| Sebio, A | 1 |
| Salazar, J | 2 |
| Berenguer-Llergo, A | 1 |
| Del Río, E | 2 |
| Tobeña, M | 1 |
| Martín-Richard, M | 1 |
| Sullivan, I | 1 |
| Targarona, E | 1 |
| Balart, J | 1 |
| Baiget, M | 2 |
| Barnadas, A | 2 |
| Ulrich, CM | 2 |
| Rankin, C | 1 |
| Toriola, AT | 1 |
| Makar, KW | 2 |
| Altug-Teber, Ö | 1 |
| Benedetti, JK | 3 |
| Holmes, RS | 1 |
| Smalley, SR | 3 |
| Bucci, L | 2 |
| Pepe, S | 3 |
| Romano, FJ | 1 |
| Cella, AC | 1 |
| Attademo, L | 1 |
| Rosanova, M | 1 |
| De Falco, S | 1 |
| Fiore, G | 1 |
| Raimondo, L | 1 |
| De Placido, S | 3 |
| Yu, Z | 1 |
| Xing, J | 1 |
| Gong, H | 1 |
| Yu, E | 1 |
| Cao, G | 1 |
| Fu, C | 1 |
| Lee, YY | 1 |
| Li, CF | 2 |
| Lee, SW | 4 |
| Sheu, MJ | 2 |
| Lin, LC | 2 |
| Chen, TJ | 2 |
| Wu, TF | 1 |
| Hsing, CH | 2 |
| Akgun, Z | 1 |
| Saglam, S | 1 |
| Yucel, S | 1 |
| Gural, Z | 1 |
| Balik, E | 1 |
| Cipe, G | 1 |
| Yildiz, S | 1 |
| Kilickap, S | 1 |
| Okyar, A | 1 |
| Kaytan-Saglam, E | 1 |
| Piutti, M | 1 |
| Morsli, O | 1 |
| Hosono, M | 1 |
| Shimatani, Y | 1 |
| Su, M | 1 |
| Zhu, LC | 1 |
| Wei, HP | 1 |
| Luo, WH | 1 |
| Lin, RF | 1 |
| Zou, CL | 1 |
| Rotellar, F | 1 |
| Pastor, C | 4 |
| Breugom, AJ | 2 |
| Hong, YS | 5 |
| Nam, BH | 1 |
| Kim, KP | 1 |
| Kim, JE | 1 |
| Park, SJ | 2 |
| Kim, TY | 1 |
| Yun, SH | 4 |
| Jung, KH | 7 |
| Marks, JH | 1 |
| Frenkel, JL | 1 |
| Greenleaf, CE | 1 |
| D'Andrea, AP | 1 |
| Cheng, AL | 1 |
| Vaid, AK | 1 |
| Ma, BB | 1 |
| Teh, C | 1 |
| Bello, M | 1 |
| Charoentum, C | 1 |
| Chen, LT | 2 |
| de Lima Lopes, G | 1 |
| Ho, GF | 1 |
| Kong, HL | 1 |
| Lam, KO | 1 |
| Sriuranpong, V | 1 |
| Sudoyo, AW | 1 |
| Zhang, SZ | 1 |
| Shaw, M | 1 |
| MacKay, JR | 3 |
| Hicks, R | 1 |
| Cooray, P | 3 |
| Jefford, M | 2 |
| Zalcberg, J | 4 |
| McClure, B | 3 |
| Hestetun, KE | 1 |
| Brydøy, M | 1 |
| Myklebust, MP | 1 |
| Dahl, O | 4 |
| Park, SC | 1 |
| Jung, JH | 2 |
| Inada, R | 1 |
| Toshima, T | 2 |
| Kondo, Y | 3 |
| Kishimoto, H | 1 |
| Fujiwara, T | 1 |
| Iino, C | 1 |
| Mikami, T | 1 |
| Sawaya, M | 1 |
| Yoshida, K | 1 |
| Aihara, T | 1 |
| Yamagata, R | 1 |
| Tono, H | 1 |
| Tanaka, M | 3 |
| Yang, TJ | 1 |
| Apte, A | 1 |
| Son, CH | 1 |
| Deasy, JO | 1 |
| Dzhugashvili, M | 1 |
| Luengo-Gil, G | 1 |
| García, T | 1 |
| González-Conejero, R | 1 |
| Conesa-Zamora, P | 1 |
| Escolar, PP | 1 |
| Calvo, F | 2 |
| Vicente, V | 1 |
| Ayala de la Peña, F | 1 |
| Holck, S | 1 |
| Nielsen, HJ | 2 |
| Hammer, E | 1 |
| Christensen, IJ | 2 |
| Larsson, LI | 1 |
| Blüml, A | 1 |
| Cermáková, E | 1 |
| Urbanec, M | 1 |
| Sitorová, V | 1 |
| Ryška, A | 1 |
| Sirák, I | 1 |
| Buka, D | 1 |
| Ferko, A | 1 |
| Melichar, B | 2 |
| Petera, J | 2 |
| Lim, SH | 1 |
| Chua, W | 1 |
| Cheng, C | 1 |
| Descallar, J | 1 |
| Ng, W | 1 |
| Solomon, M | 1 |
| Bokey, L | 2 |
| Wong, K | 1 |
| Lee, MT | 1 |
| de Souza, P | 1 |
| Shin, JS | 1 |
| Lee, CS | 1 |
| Eisterer, W | 3 |
| De Vries, A | 3 |
| Rabl, H | 3 |
| Koplmüller, R | 1 |
| Greil, R | 2 |
| Schmid, R | 1 |
| Kapp, K | 1 |
| Lukas, P | 3 |
| Sedlmayer, F | 1 |
| Höfler, G | 1 |
| Gnant, M | 3 |
| Wang, CC | 1 |
| Tsai, CL | 1 |
| Chen, YH | 3 |
| Lin, YL | 1 |
| Shun, CT | 1 |
| Cheng, JC | 1 |
| Perez, K | 1 |
| Safran, H | 2 |
| Sikov, W | 2 |
| Vrees, M | 2 |
| Klipfel, A | 2 |
| Shah, N | 1 |
| Schechter, S | 1 |
| Oldenburg, N | 1 |
| Pricolo, V | 2 |
| Rosati, K | 1 |
| Dipetrillo, T | 2 |
| Gallego, R | 2 |
| Fernández-Esparrach, G | 1 |
| Ayuso-Colella, JR | 1 |
| Bombí, JA | 1 |
| Conill, C | 2 |
| Cuatrecasas, M | 1 |
| Delgado, S | 3 |
| Ginés, A | 2 |
| Miquel, R | 2 |
| Pagés, M | 1 |
| Pineda, E | 1 |
| Pereira, V | 1 |
| Sosa, A | 1 |
| Reig, O | 1 |
| Victoria, I | 1 |
| Feliz, L | 1 |
| María de Lacy, A | 1 |
| Castells, A | 2 |
| Burkholder, I | 3 |
| Hochhaus, A | 8 |
| Piccirillo, MC | 1 |
| Pecori, B | 3 |
| Di Gennaro, E | 1 |
| Aloj, L | 2 |
| Tatangelo, F | 3 |
| D'Angelo, V | 1 |
| Granata, C | 1 |
| Cavalcanti, E | 1 |
| Maurea, N | 1 |
| Maiolino, P | 1 |
| Bianco, F | 2 |
| Montano, M | 1 |
| Silvestro, L | 1 |
| Terranova Barberio, M | 1 |
| Roca, MS | 1 |
| Di Maio, M | 1 |
| Marone, P | 3 |
| Botti, G | 2 |
| Petrillo, A | 3 |
| Daniele, G | 1 |
| Lastoria, S | 2 |
| Iaffaioli, VR | 3 |
| Romano, G | 2 |
| Caracò, C | 2 |
| Muto, P | 2 |
| Gallo, C | 1 |
| Perrone, F | 1 |
| Budillon, A | 4 |
| Ito, A | 1 |
| Kawamoto, K | 1 |
| Park, T | 1 |
| Ito, T | 2 |
| Luo, JL | 2 |
| Cai, PQ | 2 |
| Wong, SJ | 2 |
| Moughan, J | 2 |
| Anne, PR | 4 |
| Rashid, A | 4 |
| Watson, JC | 3 |
| Pollock, J | 2 |
| Lee, RJ | 4 |
| Haddock, M | 4 |
| Erickson, BA | 2 |
| Cernusco Luna Nunzia, V | 1 |
| Maurizi, ER | 1 |
| Vidali, C | 1 |
| Conti, M | 1 |
| Galardi, A | 2 |
| Ponticelli, P | 1 |
| Friso, ML | 12 |
| Osti, FM | 1 |
| Manfredi, B | 1 |
| Coppola, M | 1 |
| Orlandini, C | 1 |
| Cionini, L | 2 |
| González-González, M | 1 |
| Garcia, J | 1 |
| Alcazar, JA | 1 |
| Gutiérrez, ML | 1 |
| Gónzalez, LM | 1 |
| Bengoechea, O | 1 |
| Abad, MM | 1 |
| Santos-Briz, A | 1 |
| Blanco, O | 1 |
| Martín, M | 2 |
| Rodríguez, A | 1 |
| Fuentes, M | 1 |
| Muñoz-Bellvis, L | 1 |
| Orfao, A | 1 |
| Sayagues, JM | 1 |
| van Gijn, W | 1 |
| Muller, EW | 1 |
| Berglund, Å | 4 |
| van den Broek, CBM | 1 |
| Gelderblom, H | 1 |
| Kapiteijn, E | 1 |
| Leer, JWH | 1 |
| Martijn, H | 2 |
| Meershoek-Klein Kranenbarg, E | 1 |
| Påhlman, L | 8 |
| Steup, WH | 1 |
| Takada, S | 1 |
| Hoshino, Y | 2 |
| Ito, H | 2 |
| Masugi, Y | 1 |
| Terauchi, T | 2 |
| Kimata, M | 2 |
| Furukawa, J | 5 |
| Shinozaki, H | 2 |
| Ogata, Y | 5 |
| Grim, J | 1 |
| Hroch, M | 1 |
| Miloš, H | 1 |
| Chládek, J | 1 |
| Jaroslav, C | 1 |
| Jiří, P | 1 |
| Martínková, J | 1 |
| Jiřina, M | 1 |
| Park, P | 1 |
| Bensignor, T | 1 |
| Dariane, C | 1 |
| Thirot-Bidault, A | 1 |
| Lazure, T | 2 |
| Julié, C | 2 |
| Penna, C | 2 |
| Berdov, BA | 4 |
| Erygin, DV | 2 |
| Nevol'skikh, AA | 2 |
| Titova, LN | 1 |
| Zamulaeva, IA | 1 |
| Kondrashova, LM | 1 |
| Jin, T | 1 |
| Zhou, N | 1 |
| Li, DC | 1 |
| Ju, HX | 1 |
| Fan, YT | 1 |
| Zhu, YP | 1 |
| Feng, HY | 1 |
| Li, ZY | 2 |
| Li, ZW | 2 |
| Sun, YS | 1 |
| Ji, JF | 2 |
| Gu, J | 1 |
| Rankin, CJ | 1 |
| Winder, T | 1 |
| Rich, TA | 14 |
| Martensen, JA | 1 |
| Cripps, CM | 1 |
| Danenberg, K | 1 |
| Poulsen, LØ | 1 |
| Yilmaz, M | 1 |
| Falkmer, U | 1 |
| Hess, C | 7 |
| Becker, H | 22 |
| Zhang, Q | 2 |
| Tey, J | 1 |
| Yang, Z | 2 |
| Li, P | 1 |
| Fu, S | 1 |
| Huang, G | 1 |
| Xiong, F | 1 |
| Lu, JJ | 1 |
| Steffens, CC | 1 |
| Tschechne, B | 1 |
| Schardt, C | 1 |
| Jacobs, G | 1 |
| Valdix, AR | 1 |
| Schmidt, P | 1 |
| Hansen, R | 2 |
| Kröning, H | 1 |
| Wohlfarth, T | 1 |
| Guggenberger, D | 1 |
| Lee, HY | 2 |
| Cho, HM | 2 |
| Lee, KM | 1 |
| Shim, BY | 2 |
| Cao, C | 1 |
| Li, D | 2 |
| Feng, H | 1 |
| Luo, J | 1 |
| Tang, Z | 1 |
| Ju, H | 1 |
| Tamura, A | 2 |
| Watanabe, A | 3 |
| Hayasaka, J | 1 |
| Takagi, K | 1 |
| Okamoto, E | 1 |
| Kitazume, A | 1 |
| Kondou, M | 1 |
| Shibayama, T | 1 |
| Suda, K | 1 |
| Sakata, J | 3 |
| Kobayashi, T | 4 |
| Minagawa, M | 1 |
| Kosugi, S | 1 |
| Koyama, Y | 4 |
| Kitahara, T | 3 |
| Osawa, H | 1 |
| Miyo, M | 2 |
| Mokutani, Y | 1 |
| Ogawa, H | 2 |
| Hamabe, A | 1 |
| Hiraki, M | 2 |
| Munakata, K | 2 |
| Fukata, T | 1 |
| Fujino, S | 2 |
| Sugimura, K | 1 |
| Akita, H | 1 |
| Sakon, M | 3 |
| Kimura, K | 4 |
| Morimoto, Y | 1 |
| Matusita, K | 1 |
| Kusama, H | 1 |
| Katura, Y | 1 |
| Nitta, K | 1 |
| Nakahira, S | 2 |
| Okishiro, M | 1 |
| Sakisaka, H | 1 |
| Egawa, C | 1 |
| Tamura, S | 2 |
| Ando, Y | 1 |
| Aisu, Y | 1 |
| Nishino, H | 2 |
| Nishiuchi, A | 1 |
| Machimoto, T | 1 |
| Asao, Y | 1 |
| Furuyama, H | 1 |
| Yoshimura, T | 2 |
| Noda, E | 4 |
| Kitayama, K | 1 |
| Teraoka, H | 1 |
| Kemmochi, T | 1 |
| Suzuki, Y | 3 |
| Yoneda, M | 1 |
| Ohkubo, Y | 1 |
| Egawa, T | 1 |
| Nagashima, A | 1 |
| Shimokawa, R | 1 |
| Makino, H | 1 |
| Yamamuro, W | 1 |
| Delbaldo, C | 1 |
| Ychou, M | 5 |
| Zawadi, A | 1 |
| Douillard, JY | 3 |
| Guerin-Meyer, V | 2 |
| Rougier, P | 11 |
| Dupuis, O | 4 |
| Faroux, R | 2 |
| Jouhaud, A | 1 |
| Quinaux, E | 1 |
| Buyse, M | 7 |
| Piedbois, P | 4 |
| Huang, XE | 1 |
| Yu, DS | 1 |
| Zhou, JN | 1 |
| Li, DZ | 1 |
| Guan, X | 1 |
| Aboelnaga, EM | 1 |
| Daoud, MA | 1 |
| Eladl, EI | 1 |
| Zaid, AM | 1 |
| Iwasa, S | 2 |
| Souda, H | 1 |
| Miyamoto, Y | 2 |
| Ikeda, S | 1 |
| Lescut, N | 1 |
| Lepinoy, A | 1 |
| Cerda, T | 1 |
| Guimas, V | 1 |
| Bednarek, C | 1 |
| Heo, J | 1 |
| Chun, M | 1 |
| Noh, OK | 1 |
| Oh, YT | 1 |
| Suh, KW | 1 |
| Park, JE | 1 |
| Cho, O | 1 |
| Nicosia, L | 1 |
| Gentile, G | 1 |
| Di Nardo, F | 1 |
| Minniti, G | 1 |
| Maglio, M | 1 |
| Borro, M | 1 |
| Simmaco, M | 1 |
| Enrici, RM | 1 |
| Ishii, K | 1 |
| Kanamoto, A | 1 |
| Miyanaga, S | 1 |
| Noto, M | 1 |
| Takeda, T | 1 |
| Yagi, M | 1 |
| Bini, R | 1 |
| Comelli, S | 1 |
| Addeo, A | 1 |
| Viora, T | 1 |
| Vana, F | 1 |
| Vaudano, GP | 1 |
| Savio, D | 1 |
| Leli, R | 1 |
| Chamorey, E | 1 |
| Benezery, K | 1 |
| de Laroche, G | 1 |
| Mahé, MA | 4 |
| Feng, Y | 2 |
| Prabhu, RS | 2 |
| Cohen, SJ | 4 |
| Staley, CA | 2 |
| Whittington, R | 2 |
| Nimeiri, H | 2 |
| Verma, U | 2 |
| Chen, Z | 3 |
| Li, W | 3 |
| Chae, YS | 3 |
| Lopes-Ramos, C | 1 |
| Salim, AC | 1 |
| Bettoni, F | 1 |
| França, GS | 1 |
| Parmigiani, RB | 1 |
| Galante, PA | 1 |
| Illum, H | 1 |
| Wang, DH | 1 |
| Dowell, JE | 1 |
| Hittson, WJ | 1 |
| Torrisi, JR | 1 |
| Huerta, S | 1 |
| Xue, H | 1 |
| Zhong, G | 2 |
| Sandalevskaya, AG | 1 |
| Krasnikoval, VG | 1 |
| Meshechkin, AV | 1 |
| Yoon, HI | 1 |
| Chung, Y | 1 |
| Lee, JY | 1 |
| Wen, B | 1 |
| Peng, H | 1 |
| Dong, J | 1 |
| AlGizawy, SM | 1 |
| Essa, HH | 1 |
| Ahmed, BM | 1 |
| Marks, EI | 1 |
| Brennan, M | 1 |
| El-Deiry, WS | 1 |
| Kim, HR | 6 |
| Lee, WY | 2 |
| Flanagan, L | 1 |
| Fay, J | 2 |
| Bacon, O | 2 |
| Lindner, AU | 2 |
| Prehn, JH | 2 |
| Fan, WH | 1 |
| Wang, FL | 1 |
| Lu, ZH | 3 |
| Li, LR | 4 |
| Chang, PK | 1 |
| Chiang, MH | 1 |
| Jao, SW | 1 |
| Wu, CC | 1 |
| Lee, CC | 1 |
| Lee, TY | 1 |
| Hsiao, CW | 1 |
| Chang, KH | 1 |
| Kelly, NP | 1 |
| Duff, GP | 1 |
| Condon, ET | 1 |
| Waldron, D | 1 |
| Coffey, JC | 1 |
| Garofalo, MC | 1 |
| Berger, AC | 1 |
| Oldenburg, NB | 2 |
| Perera, F | 2 |
| Jabbour, SK | 2 |
| Nowlan, A | 1 |
| DeNittis, A | 1 |
| Crane, C | 3 |
| Kumar, AS | 1 |
| Coutsoftides, T | 1 |
| Dietz, DW | 2 |
| Wolff, HA | 7 |
| Lang-Welzenbach, M | 2 |
| Wilhelm, M | 1 |
| Lindemann, F | 2 |
| Schlenska-Lange, A | 2 |
| Fleming, GF | 1 |
| Ohtsuka, M | 2 |
| Takeyama, H | 2 |
| Nonaka, R | 1 |
| Wasmuth, HH | 1 |
| Rekstad, LC | 1 |
| Tranø, G | 1 |
| Jiang, DM | 1 |
| Raissouni, S | 1 |
| Mercer, J | 1 |
| Goodwin, R | 1 |
| Heng, DY | 1 |
| Tang, PA | 1 |
| Doll, C | 1 |
| MacLean, A | 1 |
| Powell, E | 1 |
| Price-Hiller, J | 1 |
| Monzon, J | 1 |
| Cheung, WY | 1 |
| Vickers, MM | 1 |
| Voong, KR | 1 |
| Yao, JC | 1 |
| Wolff, RA | 8 |
| Feig, BW | 12 |
| Yoon, MS | 3 |
| Jeong, BK | 1 |
| Leone, A | 1 |
| Comella, P | 5 |
| Matsusaka, S | 3 |
| Kondo, K | 1 |
| Horie, H | 3 |
| Mizunuma, N | 2 |
| Kato, D | 1 |
| Okuda, J | 1 |
| Hashiguchi, Y | 1 |
| Nakazawa, M | 1 |
| Sunami, E | 3 |
| Yamashita, H | 3 |
| Okada, T | 2 |
| Nakajima, T | 2 |
| Bang, JI | 1 |
| Ha, S | 1 |
| Kim, SE | 1 |
| Soori, G | 1 |
| Eakle, JF | 1 |
| Sastre, J | 2 |
| Serrano, JJ | 1 |
| Fernández, C | 2 |
| Ramirez, C | 1 |
| Ortega, L | 2 |
| García-Paredes, B | 1 |
| Corona, J | 2 |
| Alfonso, R | 2 |
| Córdoba, S | 1 |
| Korovina, MA | 1 |
| Barsukov, IuA | 4 |
| Kuz'michev, DV | 2 |
| Malikhova, OA | 1 |
| Ikeda, T | 2 |
| Toda, N | 1 |
| Omae, K | 1 |
| Takagi, T | 1 |
| Iizuka, J | 1 |
| Kondo, T | 5 |
| Tanabe, K | 1 |
| Yamashita, S | 3 |
| Tominaga, H | 1 |
| Odagiri, K | 1 |
| Yamaguchi, M | 1 |
| Sawada, G | 1 |
| Moon, J | 1 |
| Irei, T | 1 |
| Hatanaka, N | 1 |
| Serra-Aracil, X | 1 |
| Ocaña-Rojas, J | 1 |
| Mora-López, L | 1 |
| Dotor, E | 3 |
| Casalots, A | 2 |
| Pisa, A | 1 |
| Saigí, E | 3 |
| Rupinski, M | 1 |
| Mroz, A | 1 |
| Darunikorn, P | 1 |
| Puataweepong, P | 1 |
| Dhanachai, M | 1 |
| Dangprasert, S | 1 |
| Swangsilpa, T | 1 |
| Sitathanee, C | 1 |
| Jiarpinitnun, C | 1 |
| Pattaranutaporn, P | 1 |
| Boonyawan, K | 1 |
| Chansriwong, P | 1 |
| Keum, KC | 3 |
| Hong, SP | 2 |
| Roh, JK | 2 |
| Sandra-Petrescu, F | 1 |
| Herrle, F | 1 |
| Hinke, A | 5 |
| Rossion, I | 1 |
| Suelberg, H | 1 |
| Post, S | 10 |
| Kienle, P | 6 |
| Yuan, H | 1 |
| Zheng, B | 1 |
| Tu, S | 1 |
| Isaka, N | 1 |
| Tato-Costa, J | 1 |
| Casimiro, S | 1 |
| Pacheco, T | 1 |
| Pires, R | 1 |
| Fernandes, A | 1 |
| Alho, I | 1 |
| Pereira, P | 1 |
| Costa, P | 1 |
| Castelo, HB | 1 |
| Ferreira, J | 1 |
| Costa, L | 1 |
| Boustani, J | 1 |
| Caubet, M | 1 |
| Kim, KH | 4 |
| Cho, MS | 1 |
| Renehan, AG | 1 |
| Malcomson, L | 1 |
| Emsley, R | 1 |
| Maw, A | 1 |
| Myint, AS | 1 |
| Rooney, PS | 1 |
| Blower, A | 1 |
| Saunders, MP | 1 |
| Wilson, MS | 1 |
| Scott, N | 2 |
| O'Dwyer, ST | 1 |
| Kodali, S | 1 |
| Bathini, V | 1 |
| Rava, P | 1 |
| Tipirneni, E | 1 |
| Note, H | 1 |
| Shimizu, S | 1 |
| Ariga, T | 1 |
| Suzuki, K | 3 |
| Sawada, N | 1 |
| Kanada, Y | 1 |
| Senba, Y | 1 |
| Yoshioka, T | 3 |
| Sato, Y | 3 |
| Miyazaki, A | 1 |
| Natsume, T | 1 |
| Maruyama, T | 1 |
| Yasui, M | 2 |
| Okami, J | 1 |
| Higashiyama, M | 1 |
| Mitsuhashi, N | 1 |
| Kuboki, S | 1 |
| Yoshitomi, H | 1 |
| Kato, A | 2 |
| Shimizu, H | 2 |
| Miyazaki, M | 5 |
| Ikeya, T | 1 |
| Ohira, G | 1 |
| Sakurai, K | 1 |
| Yamazoe, S | 2 |
| Kubo, N | 4 |
| Takenoya, T | 1 |
| Nishimura, Y | 3 |
| Asayama, M | 1 |
| Takano, M | 2 |
| Ishikawa, H | 2 |
| Fukuda, T | 1 |
| Kazama, S | 1 |
| Amikura, K | 1 |
| Kurozumi, M | 1 |
| Kawashima, Y | 1 |
| Tanaka, Y | 5 |
| Sakamoto, H | 2 |
| Yamada, C | 1 |
| Ishikawa, F | 1 |
| Nitta, H | 2 |
| Fujita, Y | 1 |
| Omoto, H | 1 |
| Kamata, S | 1 |
| Hanaka, J | 1 |
| Kanamura, S | 1 |
| Wakamatsu, T | 1 |
| Nakayama, H | 2 |
| Goya, T | 1 |
| Michishita, Y | 1 |
| Hatano, Y | 1 |
| Nozawa, T | 1 |
| Ishibashi, M | 1 |
| Konda, R | 1 |
| Sasaki, A | 1 |
| Ueki, T | 1 |
| Manabe, T | 1 |
| Inoue, S | 1 |
| Ienaga, J | 1 |
| Yamanaka, N | 3 |
| Egami, T | 1 |
| Ishikawa, M | 2 |
| Konomi, H | 1 |
| Ikubo, A | 1 |
| Nagayoshi, K | 1 |
| Prithviraj, GK | 1 |
| Shridhar, R | 1 |
| Hoffe, SE | 2 |
| Jiang, K | 1 |
| Zhao, X | 1 |
| Chen, DT | 1 |
| Almhanna, K | 2 |
| Strosberg, J | 1 |
| Campos, T | 1 |
| Shibata, D | 3 |
| Dueland, S | 3 |
| Ree, AH | 3 |
| Grøholt, KK | 2 |
| Saelen, MG | 1 |
| Folkvord, S | 2 |
| Hole, KH | 2 |
| Seierstad, T | 1 |
| Larsen, SG | 2 |
| Giercksky, KE | 3 |
| Wiig, JN | 5 |
| Boye, K | 1 |
| Flatmark, K | 4 |
| Kosugi, C | 2 |
| Koda, K | 2 |
| Suzuki, M | 5 |
| Yamazaki, M | 3 |
| Shuto, K | 1 |
| Matsuo, K | 1 |
| Hirano, A | 2 |
| Arimitsu, H | 1 |
| Shiragami, R | 2 |
| Huang, XZ | 1 |
| Gao, P | 1 |
| Song, YX | 1 |
| Sun, JX | 1 |
| Chen, XW | 1 |
| Zhao, JH | 1 |
| Ma, B | 1 |
| Wang, ZN | 1 |
| Figueiredo, MN | 1 |
| Buchpiguel, CA | 2 |
| Lund, JL | 1 |
| Sturmer, T | 1 |
| Sanoff, HK | 2 |
| Voboril, R | 1 |
| Rychterova, V | 1 |
| Voborilova, J | 1 |
| Kubecova, M | 1 |
| Fanta, J | 1 |
| Magnante, AL | 1 |
| Benevento, I | 1 |
| Nahas, SC | 3 |
| Rizkallah Nahas, CS | 1 |
| Sparapan Marques, CF | 1 |
| Ribeiro, U | 4 |
| Cotti, GC | 1 |
| Imperiale, AR | 1 |
| Capareli, FC | 1 |
| Chih Chen, AT | 1 |
| Hoff, PM | 7 |
| Cecconello, I | 1 |
| Jorge, JM | 1 |
| Kamiya, T | 1 |
| Kawai, S | 1 |
| Kodera, Y | 2 |
| Mazzola, R | 1 |
| Ferrera, G | 1 |
| Cucchiara, T | 1 |
| Figlia, V | 1 |
| Gueci, M | 1 |
| Sciumè, F | 1 |
| Di Paola, G | 1 |
| Scibetta, N | 1 |
| Lo Casto, A | 1 |
| Pappalardo, MP | 1 |
| Lagalla, R | 1 |
| Alongi, F | 1 |
| Newman, NB | 1 |
| Sidhu, MK | 1 |
| Baby, R | 1 |
| Moss, RA | 1 |
| Nissenblatt, MJ | 1 |
| Lu, SE | 1 |
| Muneoka, K | 4 |
| Shirai, Y | 4 |
| Sasaki, M | 3 |
| Kanda, J | 2 |
| Wakabayashi, H | 2 |
| Miyata, R | 1 |
| Kameyama, N | 2 |
| Tomita, M | 3 |
| Mitsuhashi, H | 2 |
| Baba, S | 1 |
| Amada, E | 1 |
| Takagi, H | 3 |
| Ariake, K | 1 |
| Takemura, S | 1 |
| Doi, T | 5 |
| Xu, Z | 2 |
| Huang, S | 1 |
| Ye, D | 1 |
| Yu, T | 1 |
| Cao, XL | 1 |
| Wu, GJ | 1 |
| Zhao, G | 1 |
| Jia, WW | 1 |
| Xiao, G | 1 |
| Chien, CR | 1 |
| Chen, WT | 1 |
| Wang, HM | 2 |
| Li, CC | 1 |
| Zhao, L | 4 |
| Liu, R | 2 |
| Li, T | 5 |
| Li, F | 1 |
| Li, G | 2 |
| Jung, SM | 1 |
| Khwaja, SS | 1 |
| Dewees, TA | 1 |
| Shibano, N | 1 |
| Yukawa, Y | 1 |
| Uchima, Y | 2 |
| Takeda, O | 1 |
| Hanno, H | 1 |
| Takayanagi, S | 1 |
| Hirooka, T | 2 |
| Dozaiku, T | 1 |
| Aomatsu, N | 2 |
| Hirakawa, T | 2 |
| Iwauchi, T | 2 |
| Nishii, T | 2 |
| Morimoto, J | 2 |
| Nakazawa, K | 2 |
| Takeuchi, K | 2 |
| Sanchez Loria, F | 1 |
| O'Connor, JM | 1 |
| Pairola, A | 1 |
| Chacon, M | 2 |
| Mendez, G | 1 |
| Coraglio, M | 1 |
| Mariani, J | 1 |
| Dieguez, A | 1 |
| Roca, E | 1 |
| Cao, L | 1 |
| Wu, HF | 1 |
| Yue, D | 1 |
| Yang, JL | 1 |
| Zhou, ZR | 1 |
| Liu, SX | 1 |
| Zhang, R | 3 |
| Lu, Z | 2 |
| Ding, P | 1 |
| Wan, D | 1 |
| Wu, H | 2 |
| Feng, R | 1 |
| Zhong, D | 1 |
| Luo, Y | 1 |
| Ryan, D | 2 |
| Carberry, S | 1 |
| Murphy, ÁC | 1 |
| Hector, S | 2 |
| McCawley, N | 1 |
| Concannon, CG | 1 |
| Nelson, B | 1 |
| Carter, JV | 1 |
| Eichenberger, MR | 1 |
| Netz, U | 1 |
| Galandiuk, S | 3 |
| Ozawa, H | 2 |
| Matsumoto, K | 2 |
| Sasakura, Y | 1 |
| de Rosa, N | 1 |
| Veerapong, J | 1 |
| Borras, E | 1 |
| Bednarski, B | 1 |
| Messick, CA | 1 |
| Lynch, PM | 4 |
| Vilar, E | 1 |
| Kotti, S | 1 |
| Rullier, E | 4 |
| de Chaisemartin, C | 3 |
| Meunier, B | 1 |
| Mehrdad, J | 1 |
| Cotte, E | 1 |
| Desrame, J | 1 |
| Kirzin, S | 2 |
| Piessen, G | 1 |
| Saudemont, A | 1 |
| Prudhomme, M | 1 |
| Peschaud, F | 2 |
| Dubois, A | 1 |
| Loriau, J | 1 |
| Tuech, JJ | 1 |
| Meurette, G | 1 |
| Lupinacci, R | 1 |
| Goasgen, N | 1 |
| Parc, Y | 2 |
| Simon, T | 1 |
| Tiret, E | 2 |
| Yu, X | 1 |
| Büttner-Herold, M | 1 |
| Erlenbach-Wünsch, K | 1 |
| Croner, R | 1 |
| Distel, LV | 1 |
| Chen, W | 1 |
| Cui, L | 1 |
| Cao, J | 1 |
| Wei, H | 1 |
| Peng, X | 1 |
| Zhao, R | 3 |
| Wei, Y | 1 |
| Supaadirek, C | 1 |
| Pesee, M | 1 |
| Thamronganantasakul, K | 1 |
| Thalangsri, P | 1 |
| Krusun, S | 1 |
| Supakalin, N | 1 |
| Konishi, K | 2 |
| Ikenaga, M | 1 |
| Ohta, K | 2 |
| Nakashima, S | 2 |
| Chihara, T | 1 |
| Nishijima, J | 1 |
| Zwoliński, J | 1 |
| Winiarek, M | 1 |
| Kuśnierz, J | 1 |
| Zając, L | 1 |
| Bednarczyk, M | 1 |
| Tarnowski, W | 1 |
| Paśnik, K | 1 |
| Partycki, M | 1 |
| Bęczkowska, K | 1 |
| Bury, P | 1 |
| Lewicka, M | 1 |
| Skórzewska, M | 1 |
| Mielko, J | 1 |
| Nawrocki, G | 1 |
| Shim, HJ | 1 |
| Song, JY | 1 |
| Ahn, SJ | 1 |
| Chung, WK | 1 |
| Qin, Q | 1 |
| Ma, T | 2 |
| Ansari, N | 1 |
| Solomon, MJ | 1 |
| Fisher, RJ | 1 |
| Mackay, J | 5 |
| Burmeister, B | 1 |
| Ackland, S | 1 |
| Joseph, D | 9 |
| McLachlan, SA | 2 |
| Choi, Y | 1 |
| Kim, JW | 3 |
| Song, C | 2 |
| Katayama, H | 1 |
| Krug, D | 1 |
| Häfner, MF | 1 |
| Schernberg, A | 1 |
| Servagi-Vernat, S | 2 |
| Loganadane, G | 1 |
| Touboul, E | 1 |
| Bridoux, V | 1 |
| Garlipp, B | 1 |
| Ptok, H | 2 |
| Benedix, F | 1 |
| Otto, R | 1 |
| Popp, F | 1 |
| Ridwelski, K | 2 |
| Gastinger, I | 1 |
| Benckert, C | 1 |
| Lippert, H | 1 |
| Bruns, C | 1 |
| Cheng, J | 3 |
| Ao, L | 1 |
| Guan, Q | 1 |
| Yan, H | 1 |
| Cai, H | 1 |
| Gao, Q | 1 |
| Jiang, W | 1 |
| Guo, Z | 1 |
| Shi, C | 1 |
| Gamaleldin, M | 1 |
| Church, JM | 1 |
| Stocchi, L | 3 |
| Kalady, M | 1 |
| Gorgun, E | 1 |
| Vychnevskaia, K | 1 |
| Dumont, F | 1 |
| Agostini, J | 1 |
| Dartigues, P | 1 |
| Goéré, D | 1 |
| Yeh, CC | 1 |
| Lai, CY | 1 |
| Chang, SN | 1 |
| Hsieh, LL | 1 |
| Tang, R | 2 |
| Sung, FC | 1 |
| Lin, YK | 1 |
| Park, BS | 1 |
| Hall, M | 1 |
| Gounaris, I | 1 |
| Yamakoshi, Y | 1 |
| Wang, E | 1 |
| Nagashima, D | 1 |
| Fukunaga, M | 1 |
| Tokuyama, S | 1 |
| Yukimoto, R | 1 |
| Saito, A | 1 |
| Ota, H | 3 |
| Yokoyama, S | 4 |
| Miki, H | 1 |
| Shuto, T | 1 |
| Muratsu, A | 1 |
| Yasuyama, A | 1 |
| Matsumura, T | 1 |
| Koga, C | 1 |
| Kameda, C | 1 |
| Murakami, M | 5 |
| Kawabata, R | 1 |
| Yoshikawa, M | 1 |
| Shimizu, J | 3 |
| Kamiya, M | 1 |
| Yoneyama, K | 2 |
| Shirai, J | 1 |
| Hatori, S | 1 |
| Oshima, T | 1 |
| Yukawa, N | 1 |
| Yoshikawa, T | 2 |
| Rino, Y | 3 |
| Masuda, M | 2 |
| Minoji, T | 1 |
| Nushijima, Y | 1 |
| Hamano, R | 1 |
| Yanagisawa, T | 2 |
| Yokouchi, H | 5 |
| Ohishi, K | 1 |
| Fukayama, M | 1 |
| Yu, ZH | 3 |
| Ben-Yakov, M | 1 |
| Mattu, A | 1 |
| Brady, WJ | 1 |
| Dubbs, SB | 1 |
| Zou, XC | 1 |
| Wang, QW | 1 |
| Zhang, JM | 2 |
| Bird, T | 1 |
| Ngan, S | 2 |
| Mimatsu, K | 1 |
| Oida, T | 1 |
| Kawasaki, A | 1 |
| Kano, H | 1 |
| Kuboi, Y | 1 |
| Aramaki, O | 1 |
| Amano, S | 1 |
| Ballonoff, A | 1 |
| Kavanagh, B | 1 |
| McCarter, M | 1 |
| Kane, M | 1 |
| Pearlman, N | 1 |
| Nash, R | 1 |
| Shah, RJ | 1 |
| Raben, D | 1 |
| Greenberg, JA | 1 |
| Herndon, JE | 1 |
| Steele, GD | 1 |
| Mayer, R | 1 |
| Bleday, R | 1 |
| Pasetto, LM | 2 |
| Terrazzino, S | 2 |
| Bedin, C | 2 |
| Galdi, F | 1 |
| Mescoli, C | 2 |
| Urso, E | 5 |
| Leon, A | 2 |
| Lise, M | 9 |
| Nitti, D | 11 |
| Baldarelli, M | 1 |
| Organetti, L | 1 |
| Grillo Ruggeri, F | 1 |
| Bartolacci, S | 1 |
| Lezoche, E | 1 |
| Fakih, MG | 8 |
| Bullarddunn, K | 1 |
| Yang, GY | 2 |
| Pendyala, L | 3 |
| Toth, K | 2 |
| Andrews, C | 1 |
| Rustum, YM | 8 |
| Ross, ME | 1 |
| Levea, C | 1 |
| Puthillath, A | 2 |
| Park, YM | 1 |
| Rajput, A | 2 |
| Spindler, KL | 1 |
| Ploen, J | 2 |
| Jakobsen, A | 3 |
| Yasuda, A | 1 |
| Ochi, N | 1 |
| Sakamoto, M | 2 |
| Takayama, S | 1 |
| Wakasugi, T | 1 |
| Funahashi, H | 1 |
| Sawai, H | 1 |
| Satoh, M | 1 |
| Akamo, Y | 1 |
| Ngeow, JY | 1 |
| Prakash, KM | 1 |
| Chowbay, B | 1 |
| Quek, ST | 1 |
| Choo, SP | 1 |
| Bondar, HV | 1 |
| Borota, OV | 1 |
| Kiiashko, OIu | 1 |
| Handera, VF | 1 |
| Bazarbashi, S | 1 |
| El-Bassiouni, M | 1 |
| Abdelsalam, M | 1 |
| Soudy, H | 1 |
| Sanea, NA | 1 |
| Jabbar, AA | 1 |
| Manji, M | 1 |
| Fagih, M | 1 |
| Ajarim, D | 1 |
| Patel, A | 1 |
| Radovanovic, Z | 1 |
| Breberina, M | 1 |
| Petrovic, T | 1 |
| Golubovic, A | 1 |
| Radovanovic, D | 1 |
| Kubo, H | 2 |
| Kitahara, M | 1 |
| Kanekiyo, S | 1 |
| Tada, K | 1 |
| Katayama, S | 1 |
| Katayama, K | 2 |
| Nagamine, Y | 1 |
| Kajiura, K | 1 |
| Kohagura, F | 1 |
| Shinzato, S | 1 |
| Warchoł, R | 1 |
| Szymański, L | 1 |
| Seichter, A | 1 |
| Kalofonos, HP | 1 |
| Bamias, A | 2 |
| Koutras, A | 1 |
| Papakostas, P | 1 |
| Basdanis, G | 2 |
| Karina, M | 1 |
| Misailidou, D | 1 |
| Pisanidis, N | 1 |
| Pentheroudakis, G | 1 |
| Economopoulos, T | 1 |
| Papadimitriou, C | 1 |
| Skarlos, DV | 1 |
| Pectasides, D | 1 |
| Stavropoulos, M | 1 |
| Bafaloukos, D | 1 |
| Kardamakis, D | 1 |
| Karanikiotis, C | 1 |
| Vourli, G | 1 |
| Fountzilas, G | 3 |
| Muto, Y | 1 |
| Diao, C | 1 |
| Cheng, RC | 1 |
| Wei, XP | 1 |
| Su, YJ | 1 |
| Liu, QY | 1 |
| Xu, JB | 1 |
| Roels, S | 6 |
| Slagmolen, P | 2 |
| Nuyts, J | 2 |
| Lee, JA | 2 |
| Loeckx, D | 2 |
| Maes, F | 2 |
| Stroobants, S | 2 |
| Penninckx, F | 7 |
| Haustermans, K | 11 |
| Braendengen, M | 1 |
| Birkemeyer, E | 1 |
| Frykholm, G | 3 |
| Byström, P | 2 |
| Svoboda, M | 4 |
| Izakovicova Holla, L | 1 |
| Sefr, R | 2 |
| Vrtkova, I | 1 |
| Kocakova, I | 4 |
| Tichy, B | 1 |
| Massidda, B | 2 |
| Filippelli, G | 2 |
| Farris, A | 2 |
| Natale, D | 1 |
| Barberis, G | 1 |
| Maiorino, L | 1 |
| Palmeri, S | 2 |
| Cannone, M | 1 |
| Condemi, G | 1 |
| Stoehlmacher, J | 1 |
| Mogck, U | 1 |
| Aust, DE | 6 |
| Kramer, M | 1 |
| Baretton, GB | 6 |
| Ehninger, G | 1 |
| Jakob, C | 7 |
| Rosenthal, DI | 1 |
| Catalano, PJ | 1 |
| Spitz, FR | 2 |
| Xu, JM | 3 |
| Zhang, XD | 1 |
| Bai, Y | 1 |
| Chu, YP | 1 |
| Wang, YH | 3 |
| Liu, DQ | 1 |
| Jin, ML | 1 |
| Nowacki, MP | 7 |
| Wojnar, A | 3 |
| Holm, T | 2 |
| Blomqvist, L | 2 |
| Lawson, JD | 1 |
| Kauh, J | 2 |
| Koshy, M | 1 |
| Staley, C | 1 |
| Landry, J | 1 |
| Beddy, D | 1 |
| Hyland, JM | 1 |
| Winter, DC | 2 |
| Lim, C | 1 |
| White, A | 1 |
| Moriarty, M | 1 |
| Armstrong, J | 1 |
| Fennelly, D | 1 |
| Gibbons, D | 1 |
| Sheahan, K | 1 |
| Ugidos, L | 1 |
| Ayuso, JR | 1 |
| Tosca, M | 1 |
| de Lacy, A | 1 |
| Matsui, T | 1 |
| Uemura, T | 1 |
| Fujimitsu, Y | 1 |
| Kure, N | 1 |
| Kojima, H | 1 |
| Hada, T | 1 |
| Hirabayashi, T | 1 |
| Masubuchi, M | 1 |
| Nishiofuku, H | 1 |
| Sakaguchi, H | 1 |
| Yamamoto, K | 3 |
| Sueyoshi, S | 1 |
| Shinnkai, T | 1 |
| Kichikawa, K | 1 |
| Chiara, S | 3 |
| Bengala, C | 3 |
| Antognoni, P | 1 |
| Dealis, C | 2 |
| Zironi, S | 2 |
| Malavasi, N | 3 |
| Scolaro, T | 1 |
| Depenni, R | 2 |
| Jovic, G | 1 |
| Sonaglio, C | 2 |
| Rossi, A | 1 |
| Conte, PF | 3 |
| Konski, A | 5 |
| Small, W | 1 |
| Spies, S | 1 |
| Yu, JQ | 2 |
| Wahl, A | 1 |
| Stryker, S | 1 |
| Yamagishi, Y | 2 |
| Mizuno, A | 2 |
| Katano, K | 1 |
| Fujita, M | 5 |
| Hoshikawa, K | 1 |
| Aoki, K | 1 |
| Noda, H | 1 |
| Wakabayashi, G | 1 |
| Yatsuda, C | 1 |
| Niimi, M | 1 |
| Uto, N | 1 |
| Iwagami, E | 1 |
| Tanaka, E | 1 |
| Yamato, M | 1 |
| Muto, T | 2 |
| Debus, J | 2 |
| Rudat, V | 1 |
| Wulf, J | 1 |
| Budach, W | 1 |
| Hoelscher, T | 1 |
| Mose, S | 1 |
| Roedel, C | 1 |
| Zuehlke, H | 1 |
| Vliegen, RF | 1 |
| Vanhauten, B | 1 |
| Driessen, A | 1 |
| Oellers, M | 1 |
| Kessels, AG | 1 |
| Arens, A | 1 |
| Buijsen, J | 3 |
| van Baardwijk, A | 1 |
| de Ruysscher, D | 2 |
| Lammering, G | 4 |
| Dhadda, AS | 1 |
| Zaitoun, AM | 1 |
| Bessell, EM | 1 |
| Okita, NT | 1 |
| Honda, T | 1 |
| Hirashima, Y | 1 |
| Matsubara, J | 1 |
| Shirao, K | 5 |
| Shimoda, T | 1 |
| Fanning, DM | 1 |
| Prichard, RS | 1 |
| Roche-Nagle, G | 1 |
| McNamara, D | 1 |
| Li, ZP | 1 |
| Elshazly, WG | 1 |
| Farouk, M | 1 |
| Samy, M | 1 |
| Yoon, FH | 1 |
| Fisher, B | 6 |
| Stitt, L | 1 |
| Bettelli, S | 2 |
| Salvi, S | 1 |
| Losi, L | 1 |
| Bigiani, N | 1 |
| Sartori, G | 2 |
| D'Amico, R | 1 |
| Gatteschi, B | 1 |
| Maiorana, A | 1 |
| Hanai, T | 2 |
| Koide, Y | 4 |
| Matsuoka, H | 5 |
| Katsuno, H | 3 |
| Funahashi, M | 1 |
| Agata, T | 2 |
| Noro, T | 2 |
| Shiota, M | 1 |
| Sakakura, C | 4 |
| Nishio, M | 1 |
| Miyashita, A | 1 |
| Nagata, H | 1 |
| Hamada, T | 1 |
| Nakanishi, M | 1 |
| Ikoma, H | 2 |
| Kubota, K | 1 |
| Ichikawa, D | 7 |
| Kikuchi, S | 2 |
| Fujiwara, H | 2 |
| Ochiai, T | 4 |
| Kokuba, Y | 1 |
| Sonoyama, T | 2 |
| Otsuji, E | 3 |
| Ishiguro, T | 1 |
| Kitaoka, T | 1 |
| Sakimoto, T | 1 |
| Miyazaki, T | 3 |
| Ishibashi, K | 2 |
| Matsuki, M | 1 |
| Inoue, N | 1 |
| Aoyagi, H | 1 |
| Higuchi, T | 4 |
| Yasuno, M | 3 |
| Ide, Y | 3 |
| Yasumoto, T | 2 |
| Maruyama, K | 3 |
| Mikami, K | 2 |
| Ikeda, K | 2 |
| Kato, H | 3 |
| Takamoto, K | 2 |
| Oshima, N | 1 |
| Maeda, S | 2 |
| Kawanishi, K | 2 |
| Fujita, J | 2 |
| Akagi, K | 2 |
| Tsukahara, Y | 3 |
| Kitada, M | 4 |
| Shimano, T | 2 |
| Kakeji, Y | 2 |
| Sugiyama, M | 1 |
| Morita, M | 1 |
| Emi, Y | 1 |
| Maehara, Y | 5 |
| Lim, KH | 2 |
| Kang, BM | 1 |
| Jun, SH | 2 |
| Capalbo, G | 1 |
| Horisberger, K | 6 |
| Treschl, A | 1 |
| Mai, S | 1 |
| Barreto-Miranda, M | 1 |
| Erben, P | 3 |
| Woernle, C | 2 |
| Dinter, D | 2 |
| Kähler, G | 5 |
| Willeke, F | 4 |
| Wenz, F | 9 |
| Yau, I | 1 |
| Ducruet, T | 1 |
| Doran, P | 1 |
| Faria, S | 1 |
| Liberman, S | 1 |
| Letellier, F | 1 |
| Charlebois, P | 1 |
| Loungnarath, R | 1 |
| Stein, B | 1 |
| Devic, S | 1 |
| Gennatas, C | 2 |
| Michalaki, V | 1 |
| Gennatas, S | 1 |
| Asakura, T | 1 |
| Hatakeyama, K | 4 |
| Kaneko, M | 3 |
| Fujiwara, M | 1 |
| Otsubo, M | 1 |
| Ogura, S | 1 |
| Isaka, T | 1 |
| Imai, N | 2 |
| Naota, H | 1 |
| Taniguchi, K | 1 |
| Nannini, M | 1 |
| Nobili, E | 1 |
| Di Cicilia, R | 1 |
| Brandi, G | 1 |
| Maleddu, A | 1 |
| Pantaleo, MA | 1 |
| Biasco, G | 1 |
| Farella, A | 1 |
| D'Armiento, FP | 1 |
| Pesce, G | 2 |
| Cannella, L | 1 |
| Pacelli, R | 1 |
| Solla, R | 1 |
| D'Armiento, MR | 1 |
| Meredith, KL | 1 |
| Siegel, R | 1 |
| Burock, S | 1 |
| Wernecke, KD | 2 |
| Kretzschmar, A | 1 |
| Loy, V | 1 |
| Koswig, S | 1 |
| Budach, V | 3 |
| Schlag, PM | 5 |
| Zampino, MG | 1 |
| Magni, E | 1 |
| Leonardi, MC | 1 |
| Petazzi, E | 1 |
| Santoro, L | 1 |
| Luca, F | 1 |
| Chiappa, A | 1 |
| Petralia, G | 1 |
| Trovato, C | 1 |
| Fazio, N | 1 |
| Orecchia, R | 1 |
| Nolè, F | 2 |
| de Braud, F | 2 |
| Huh, JW | 5 |
| Ohori, H | 2 |
| Ogasawara, N | 1 |
| Miyate, Y | 1 |
| Kiba, T | 1 |
| Oikawa, M | 1 |
| Hokkoku, K | 1 |
| Shintaku, K | 1 |
| Yoshimitsu, Y | 1 |
| Sakuma, H | 1 |
| Ueda, H | 1 |
| Nakai, M | 1 |
| Elizur, SE | 1 |
| Tulandi, T | 1 |
| Meterissian, S | 1 |
| Huang, JY | 1 |
| Levin, D | 1 |
| Tan, SL | 1 |
| Janjan, NA | 16 |
| Mendoza, TR | 2 |
| Lin, EH | 5 |
| Vadhan-Raj, S | 2 |
| Hundal, M | 1 |
| Cleeland, CS | 2 |
| Fluge, Ø | 1 |
| Carlsen, E | 2 |
| Myrvold, HE | 1 |
| Vonen, B | 1 |
| Podhorny, N | 1 |
| Bjerkeset, O | 1 |
| Eide, TJ | 1 |
| Halvorsen, TB | 1 |
| Vandecaveye, V | 3 |
| Ectors, N | 2 |
| Kobayashi, N | 1 |
| Hata, N | 1 |
| Shinada, T | 1 |
| Shirakabe, A | 1 |
| Debucquoy, A | 4 |
| Daemen, A | 2 |
| Aydin, S | 3 |
| Libbrecht, L | 2 |
| Gevaert, O | 2 |
| De Moor, B | 2 |
| Tejpar, S | 1 |
| McBride, WH | 2 |
| Scalliet, P | 3 |
| Stroh, C | 1 |
| Vlassak, S | 1 |
| Sempoux, C | 3 |
| Machiels, JP | 4 |
| Lahmer, G | 1 |
| Croner, RS | 1 |
| Merkel, S | 4 |
| Göhl, J | 1 |
| Bonfill, T | 1 |
| Darnell, A | 1 |
| Bombardó, J | 1 |
| Kume, S | 1 |
| Kubota, T | 2 |
| Hashimoto, D | 3 |
| Torigoe, Y | 1 |
| Ikeda, O | 1 |
| Fujita, T | 1 |
| Kawasaki, K | 1 |
| Ohno, M | 1 |
| Kanaji, S | 1 |
| Kobayashi, I | 1 |
| Ueno, K | 4 |
| Tsuchida, S | 1 |
| Osawa, M | 1 |
| Fujino, Y | 1 |
| Kanbara, Y | 1 |
| Segami, K | 1 |
| Sakurai, J | 1 |
| Noda, A | 1 |
| Suwa, T | 1 |
| Enomoto, T | 1 |
| Makizumi, R | 1 |
| Tsukikawa, S | 2 |
| Miyajima, N | 2 |
| Otsubo, T | 1 |
| Garajová, I | 1 |
| Slabý, O | 2 |
| Fabian, P | 2 |
| Kocák, I | 1 |
| Vyzula, R | 2 |
| Lee, JM | 1 |
| Eun, HW | 1 |
| Han, JK | 1 |
| Choi, BI | 1 |
| Wexner, S | 2 |
| Cruz-Correa, M | 1 |
| Berho, M | 3 |
| Yau, T | 1 |
| Barbachano, Y | 3 |
| Chong, G | 1 |
| Rubello, D | 1 |
| Pasini, F | 1 |
| Galeotti, F | 1 |
| Bianchini, E | 1 |
| Del Favero, G | 1 |
| Panzavolta, R | 1 |
| Crepaldi, G | 1 |
| Rampin, L | 1 |
| Facci, E | 1 |
| Gava, M | 1 |
| Banti, E | 1 |
| Marano, G | 1 |
| Troja, A | 1 |
| Hempen, HG | 1 |
| Hamilton, S | 1 |
| Ellis, LM | 7 |
| Duda, DG | 4 |
| di Tomaso, E | 3 |
| Boucher, Y | 2 |
| Ancukiewicz, M | 5 |
| Sahani, DV | 2 |
| Lahdenranta, J | 1 |
| Chung, DC | 4 |
| Fischman, AJ | 2 |
| Lauwers, GY | 6 |
| Shellito, P | 3 |
| Czito, BG | 8 |
| Wong, TZ | 1 |
| Paulson, E | 1 |
| Poleski, M | 3 |
| Vujaskovic, Z | 1 |
| Bentley, R | 3 |
| Chen, HX | 1 |
| Jain, RK | 4 |
| Kerr, SF | 1 |
| Klonizakis, M | 1 |
| Okoshi, K | 1 |
| Furu, M | 1 |
| Yoshizawa, A | 2 |
| Toguchida, J | 1 |
| Keilholz, L | 3 |
| Mese, M | 1 |
| Henneking, K | 1 |
| Willner, J | 2 |
| Elwanis, MA | 1 |
| Maximous, DW | 1 |
| Elsayed, MI | 1 |
| Mikhail, NN | 1 |
| Degirmenci, M | 1 |
| Karaca, B | 1 |
| Gorumlu, G | 1 |
| Durusoy, R | 1 |
| Demir Piskin, G | 1 |
| Bozkurt, MT | 1 |
| Cirak, Y | 1 |
| Tunali, D | 1 |
| Karabulut, B | 1 |
| Sanli, UA | 1 |
| Uslu, R | 1 |
| Ciccocioppo, A | 1 |
| Stephens, JH | 1 |
| Hewett, PJ | 1 |
| Rieger, NA | 1 |
| Ishii, T | 2 |
| Kaneda, I | 1 |
| Furuta, A | 1 |
| Shoji, M | 1 |
| Ishibashi, S | 1 |
| Hatsugai, K | 1 |
| Ohara, M | 1 |
| Sarashina, H | 1 |
| Masuoka, H | 1 |
| Sekine, Y | 1 |
| Watanabe, G | 1 |
| Hyspler, R | 1 |
| Krcmová, L | 1 |
| Urbánek, L | 1 |
| Kalábová, H | 1 |
| Kasparová, M | 1 |
| Solichová, D | 1 |
| Fora, A | 1 |
| Alabsi, E | 1 |
| Tsikitis, VL | 1 |
| Larson, DW | 1 |
| Poola, VP | 1 |
| Nelson, H | 5 |
| Wolff, BG | 2 |
| Pemberton, JH | 1 |
| Cima, RR | 1 |
| Yokoe, T | 4 |
| Ioue, Y | 1 |
| Miki, C | 7 |
| Söhn, M | 1 |
| Yan, D | 4 |
| Tardío, JC | 1 |
| Nájera, L | 1 |
| Alemany, I | 1 |
| Martín, T | 1 |
| Castaño, A | 1 |
| Pérez-Regadera, JF | 1 |
| Gollins, SW | 1 |
| Myint, S | 2 |
| Haylock, B | 3 |
| Wise, M | 2 |
| Topham, C | 2 |
| Samuel, L | 2 |
| Swindell, R | 2 |
| Morris, J | 3 |
| Mason, L | 1 |
| Levine, E | 2 |
| Koide, T | 1 |
| Katayama, T | 1 |
| Matsuda, H | 1 |
| Okuda, M | 2 |
| Kataoka, Y | 1 |
| Bedi, M | 1 |
| Kalady, MF | 2 |
| de Campos-Lobato, LF | 2 |
| Geisler, DP | 1 |
| Lavery, IC | 2 |
| Fazio, VW | 2 |
| Peng, ZH | 1 |
| Feng, F | 2 |
| Jiang, WQ | 3 |
| He, YJ | 4 |
| Yuan, SQ | 1 |
| Zhou, ZW | 4 |
| Liang, YJ | 1 |
| Fu, LW | 1 |
| Qiu, HB | 1 |
| Zhang, LY | 1 |
| Xiang, XJ | 1 |
| Goethals, L | 2 |
| Geboes, K | 2 |
| D'Hoore, A | 3 |
| Shoji, T | 1 |
| Matsuda, I | 1 |
| Misumi, K | 1 |
| Taniguchi, M | 1 |
| Yonekawa, H | 1 |
| Szynglarewicz, B | 1 |
| Matkowski, R | 1 |
| Halon, A | 1 |
| Lacko, A | 1 |
| Stepien, M | 1 |
| Forgacz, J | 1 |
| Pudelko, M | 1 |
| Kornafel, J | 1 |
| Sauer, J | 1 |
| Sobolewski, K | 1 |
| Dommisch, K | 1 |
| Vilella Martorell, A | 1 |
| Deutsch, M | 4 |
| Kahlenberg, MS | 1 |
| Baez-Diaz, L | 1 |
| Ursiny, CS | 1 |
| Gorken, IB | 2 |
| Sokmen, S | 1 |
| Fuzun, M | 2 |
| Küronya, Z | 1 |
| Bodrogi, I | 1 |
| Lövey, J | 1 |
| Plótár, V | 1 |
| Manninger, S | 1 |
| Pápai, Z | 1 |
| Malik, I | 1 |
| Hussein, F | 1 |
| Bush, D | 1 |
| Alqaisi, M | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Garberoglio, C | 1 |
| Marsh, Rde W | 1 |
| Siddiqui, T | 1 |
| Mendenhall, WM | 2 |
| Zlotecki, RA | 1 |
| Grobmyer, S | 1 |
| Hochwald, S | 1 |
| Chang, M | 1 |
| Larson, B | 1 |
| King, J | 1 |
| Rothe, H | 4 |
| Homayounfar, K | 2 |
| Pacelli, F | 3 |
| Tortorelli, AP | 2 |
| Rosa, F | 1 |
| Bossola, M | 3 |
| Sanchez, AM | 2 |
| Papa, V | 1 |
| Doglietto, GB | 11 |
| Nishigami, K | 1 |
| Kawami, H | 1 |
| Boskos, CS | 1 |
| Liacos, C | 1 |
| Korkolis, D | 1 |
| Aygerinos, K | 1 |
| Lamproglou, I | 1 |
| Terpos, E | 1 |
| Stoupa, E | 1 |
| Baltatzis, G | 1 |
| Beroukas, K | 1 |
| Papasavvas, P | 1 |
| Dimopoulos, MA | 1 |
| Soumarova, R | 1 |
| Skrovina, M | 1 |
| Gruna, J | 1 |
| Wendrinski, A | 1 |
| Czudek, S | 1 |
| Kycina, R | 1 |
| Parvez, J | 1 |
| Wang, ML | 1 |
| Lombardi, R | 2 |
| Cuicchi, D | 3 |
| Di Fabio, F | 3 |
| Iacopino, B | 2 |
| Neri, S | 1 |
| Tardio, ML | 1 |
| Ceccarelli, C | 2 |
| Lecce, F | 1 |
| Ugolini, G | 1 |
| Pini, S | 3 |
| Di Tullio, P | 2 |
| Taffurelli, M | 1 |
| Minni, F | 1 |
| Martoni, A | 2 |
| Cola, B | 2 |
| Taniguchi, F | 1 |
| Itokawa, Y | 1 |
| Ikeda, J | 1 |
| Yamashita, T | 1 |
| Koide, K | 3 |
| Ueshima, Y | 1 |
| Takashina, K | 1 |
| Lee, CJ | 1 |
| Shioaki, Y | 1 |
| Doi, K | 4 |
| Ogata, K | 3 |
| Hirano, Y | 1 |
| Kudo, K | 2 |
| Ochi, T | 1 |
| Ishihara, A | 1 |
| Kojima, K | 2 |
| Shomura, H | 1 |
| Nakano, S | 1 |
| Akabane, H | 1 |
| Yanagida, N | 1 |
| Takaoka, M | 1 |
| Hanamoto, T | 1 |
| Kuji, M | 1 |
| Kita, K | 1 |
| Oikawa, F | 2 |
| Miyagi, H | 1 |
| Yoneya, R | 1 |
| Hoshi, M | 1 |
| Makari, Y | 1 |
| Iijima, S | 2 |
| Kurokawa, E | 2 |
| Kikkawa, N | 3 |
| Fujimori, Y | 1 |
| Oda, G | 1 |
| Satoh, E | 1 |
| Maruyama, M | 3 |
| Uehira, D | 1 |
| Mitsuhashi, Y | 1 |
| Ebana, K | 1 |
| Ohinata, R | 1 |
| Koide, A | 1 |
| Sakoma, T | 1 |
| Fukunaga, H | 1 |
| Shimizu, K | 1 |
| Toyoda, Y | 1 |
| Yoshioka, A | 1 |
| Hojou, S | 1 |
| Endo, W | 1 |
| Kakutani, A | 1 |
| Maeura, Y | 1 |
| Velenik, V | 5 |
| Ocvirk, J | 2 |
| Oblak, I | 5 |
| Anderluh, F | 5 |
| Safont, M | 1 |
| Massuti, B | 2 |
| Escudero, P | 2 |
| Marcuello, E | 2 |
| Mengual, JL | 1 |
| Estevan, R | 2 |
| Mira, M | 1 |
| Polo, S | 1 |
| Hernandez, A | 1 |
| Gallen, M | 3 |
| Arias, F | 5 |
| Serra, J | 1 |
| Gaedcke, J | 4 |
| Jung, K | 3 |
| Hermann, RM | 4 |
| Schirmer, M | 4 |
| Herrmann, MKA | 1 |
| Hennies, S | 4 |
| Rave-Fränk, M | 5 |
| Hess, CF | 5 |
| Christiansen, H | 6 |
| Watayo, Y | 2 |
| Matsushita, D | 1 |
| Kitazono, M | 1 |
| Baba, K | 3 |
| Ishigami, S | 2 |
| Shinchi, H | 1 |
| Ueno, S | 2 |
| Natsugoe, S | 2 |
| Kim, NS | 1 |
| Sohn, SK | 6 |
| Moon, JH | 1 |
| Ryoo, HM | 1 |
| Bae, SH | 1 |
| Shin, US | 2 |
| Jung, KY | 1 |
| Yoon, SN | 3 |
| Oates, JR | 1 |
| Massey, A | 3 |
| Janssen, MH | 1 |
| Ollers, MC | 1 |
| van Stiphout, RG | 1 |
| van den Bogaard, J | 1 |
| Lambin, P | 1 |
| Hipp, M | 4 |
| García-Montesinos-De la Peña, M | 1 |
| Oteiza-López, L | 1 |
| Aldunate-Calvo, S | 1 |
| Gómez-Sánchez, MJ | 1 |
| Sáenz-Bañuelos, JJ | 1 |
| Tihista-Jiménez, JA | 1 |
| Paré, L | 1 |
| Altés, A | 1 |
| Sancho-Poch, FJ | 1 |
| Petriz, L | 1 |
| Garriga, J | 1 |
| Monill, JM | 1 |
| Chen, RC | 2 |
| Gelman, RS | 1 |
| Suh, WW | 1 |
| Talcott, JA | 1 |
| Richetti, A | 1 |
| Fogliata, A | 1 |
| Clivio, A | 1 |
| Nicolini, G | 1 |
| Salati, E | 1 |
| Vanetti, E | 1 |
| Cozzi, L | 1 |
| Mawdsley, S | 3 |
| Harrison, M | 3 |
| Vidaurreta, M | 1 |
| Sánchez-Muñoz, R | 1 |
| Veganzones, S | 1 |
| Rafael, S | 1 |
| Gutiérrez, M | 1 |
| de-la-Orden, V | 1 |
| Arroyo, M | 1 |
| Cerdán, FJ | 1 |
| Maestro de las Casas, ML | 1 |
| de La Roche, G | 2 |
| Bouché, O | 5 |
| Mirabel, X | 2 |
| Denis, B | 2 |
| Berdah, JF | 2 |
| Bécouarn, Y | 5 |
| Lledo, G | 4 |
| Montoto-Grillot, C | 1 |
| Tunio, MA | 2 |
| Hashmi, AH | 1 |
| Rullier, A | 1 |
| Laurent, C | 1 |
| Capdepont, M | 1 |
| Bioulac-Sage, P | 1 |
| Chan, AK | 4 |
| Wong, AO | 3 |
| Jenken, DA | 2 |
| Lim, YK | 1 |
| Law, WL | 1 |
| Poon, JT | 1 |
| Fan, JF | 1 |
| Lo, OS | 1 |
| Semikopov, KV | 1 |
| Vazhenin, AV | 1 |
| Nadvikova, EA | 1 |
| Lukina, EIu | 1 |
| Cecchin, E | 1 |
| Canzonieri, V | 1 |
| Sigon, R | 1 |
| De Mattia, E | 1 |
| Biason, P | 1 |
| Visentin, M | 1 |
| Toffoli, G | 1 |
| Raftery, L | 1 |
| Calvo, BF | 1 |
| Ivanova, A | 1 |
| Myers, MO | 1 |
| Chan, E | 2 |
| Wise, PE | 1 |
| Caskey, LS | 1 |
| Bernard, SA | 1 |
| Oukkal, M | 1 |
| Djilat, K | 1 |
| Hadjam, RM | 1 |
| Mahgoun, M | 1 |
| Bentabak, K | 1 |
| Graba, A | 1 |
| Smail, N | 1 |
| Kaci, NA | 1 |
| Ahmed, RB | 1 |
| Bouzid, K | 1 |
| Conradi, LC | 6 |
| Ahmed, S | 1 |
| Ali, M | 1 |
| Fareed, M | 1 |
| Bilal, M | 1 |
| Sumi, T | 1 |
| Shimazu, M | 1 |
| Aoki, T | 3 |
| Arikawa, S | 1 |
| Uchida, M | 1 |
| Ogoh, E | 1 |
| Uozumi, J | 1 |
| Kaida, H | 1 |
| Ishibashi, N | 3 |
| Shirouzu, K | 5 |
| Hayabuchi, N | 1 |
| Ishiguro, S | 2 |
| Nishio, H | 1 |
| Ebata, T | 1 |
| Kokuryo, T | 1 |
| Tsunoda, N | 1 |
| Igami, T | 1 |
| Sugawara, G | 1 |
| Fukaya, M | 1 |
| Aloi, L | 1 |
| Sandomenico, C | 1 |
| Scala, D | 1 |
| Iodice, G | 1 |
| Ducreux, M | 10 |
| Bennouna, J | 1 |
| Hebbar, M | 1 |
| Rebischung, C | 1 |
| Bergougnoux, L | 1 |
| Kockler, L | 1 |
| Shah, M | 2 |
| Carroll, M | 2 |
| Tyler, D | 3 |
| Mantyh, C | 5 |
| Spanos, CP | 1 |
| Syrakos, T | 1 |
| Balboa, E | 2 |
| Duran, G | 2 |
| Lamas, MJ | 2 |
| Gomez-Caamaño, A | 1 |
| Celeiro-Muñoz, C | 1 |
| Lopez, R | 3 |
| Carracedo, A | 2 |
| Barros, F | 2 |
| Kitayama, J | 1 |
| Nagawa, H | 6 |
| Lai, HS | 1 |
| Cheng, KW | 1 |
| Ishii, Y | 3 |
| Hasegawa, H | 2 |
| Endo, T | 3 |
| Okabayashi, K | 1 |
| Moritani, K | 1 |
| Kitagawa, Y | 2 |
| Deguchi, Y | 2 |
| Tanaka, J | 3 |
| Kasugai, H | 1 |
| Ikehara, K | 1 |
| Hidaka, E | 1 |
| Ishida, F | 1 |
| Kudo, SE | 1 |
| Tsuboi, K | 1 |
| Kawase, Y | 1 |
| Kato, N | 2 |
| Okochi, O | 1 |
| Matsushita, H | 1 |
| Takami, Y | 1 |
| Adachi, E | 1 |
| Kuroiwa, M | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Tsoutsou, P | 1 |
| Lyratzopoulos, N | 1 |
| Pitiakoudis, M | 1 |
| Kouklakis, G | 1 |
| Chloropoulou, PA | 1 |
| Manolas, K | 1 |
| Sivridis, E | 1 |
| Choi, HS | 6 |
| Jeong, JY | 2 |
| Sohn, DK | 5 |
| Park, JG | 3 |
| Bruheim, K | 2 |
| Balteskard, L | 1 |
| Fosså, SD | 4 |
| Guren, MG | 1 |
| Nonaka, K | 2 |
| Sha, S | 1 |
| Ramani, VS | 1 |
| Sun Myint, A | 2 |
| Montazeri, A | 1 |
| Wong, H | 1 |
| Fekrazad, MH | 1 |
| Eberhardt, S | 1 |
| Jones, DV | 1 |
| Lee, FC | 1 |
| Zhang, JD | 2 |
| Dai, Y | 2 |
| Yu, JM | 2 |
| Shao, ZY | 2 |
| Okura, Y | 1 |
| Unger, KR | 1 |
| Romney, DA | 1 |
| Koc, M | 1 |
| Moskaluk, CA | 1 |
| Foley, EF | 1 |
| Fujita, H | 4 |
| de Wijn, R | 1 |
| Nesland, JM | 1 |
| Ruijtenbeek, R | 1 |
| Boender, PJ | 1 |
| Johansen, M | 1 |
| Díaz-González, JA | 7 |
| Subtil, JC | 3 |
| Sola, J | 2 |
| Martínez-Monge, R | 4 |
| Moreno, M | 3 |
| Aristu, J | 4 |
| Sugito, M | 1 |
| Hosokawa, Y | 1 |
| Motoori, S | 1 |
| Miyazawa, T | 3 |
| Iwamoto, N | 1 |
| Kase, Y | 1 |
| Kitagawa, N | 1 |
| Saisho, H | 1 |
| Furuse, J | 1 |
| Fontana, A | 1 |
| Del Giovane, C | 1 |
| Wolthuis, AM | 2 |
| Rafi, M | 1 |
| Hashmi, A | 1 |
| Mohsin, R | 1 |
| Qayyum, A | 1 |
| Hasan, M | 1 |
| Sattar, A | 1 |
| Mubarak, M | 1 |
| Martoni, AA | 1 |
| Castellucci, P | 1 |
| Giaquinta, S | 2 |
| Tardio, L | 1 |
| Fanti, S | 1 |
| Okamoto, I | 1 |
| Kornmann, M | 3 |
| Wiegel, T | 2 |
| Kreuser, ED | 2 |
| Kron, M | 3 |
| Baumann, W | 2 |
| Henne-Bruns, D | 2 |
| Link, KH | 6 |
| Im, SA | 2 |
| Lee, KS | 2 |
| Yun, T | 2 |
| Ahn, JH | 2 |
| Kang, YK | 4 |
| Ahn, SD | 4 |
| Kim, WK | 2 |
| Lee, JS | 2 |
| Kang, J | 2 |
| Choi, J | 1 |
| Cvancarova, M | 1 |
| Reboredo, M | 1 |
| Grande, C | 1 |
| Méndez, JC | 1 |
| Jorge, M | 1 |
| Romero, C | 2 |
| Quintero, G | 1 |
| de la Cámara, J | 1 |
| Candamio, S | 1 |
| Lagares-Garcia, J | 1 |
| Cataldo, T | 1 |
| McNulty, B | 1 |
| Shipley, J | 1 |
| Anderson, E | 1 |
| Khurshid, H | 1 |
| Oconnor, B | 1 |
| Radie-Keane, K | 1 |
| Husain, S | 1 |
| Popa, J | 1 |
| Bohn, B | 2 |
| Hanfstein, B | 1 |
| Murad-Regadas, SM | 1 |
| Regadas, FS | 1 |
| Rodrigues, LV | 1 |
| Crispin, FJ | 1 |
| Kenmoti, VT | 1 |
| Fernandes, GO | 1 |
| Buchen, G | 1 |
| Monteiro, FC | 1 |
| Spitzner, M | 1 |
| Emons, G | 1 |
| Kramer, F | 1 |
| Scharf, JG | 1 |
| Burfeind, P | 1 |
| Ried, T | 1 |
| Grade, M | 1 |
| Schalhorn, A | 1 |
| Quietzsch, D | 1 |
| Maubach, PA | 1 |
| Lambertz, H | 1 |
| Oruzio, D | 1 |
| Schlag, R | 1 |
| Weigang-Köhler, K | 2 |
| Vehling-Kaiser, U | 1 |
| Schulze, M | 1 |
| Truckenbrodt, J | 1 |
| Goebeler, M | 1 |
| Mittermüller, J | 1 |
| Bosse, D | 1 |
| Szukics, B | 1 |
| Grundeis, M | 1 |
| Zwingers, T | 1 |
| Giessen, C | 1 |
| Ebara, T | 1 |
| Kaira, K | 1 |
| Saito, J | 2 |
| Shioya, M | 4 |
| Sakurai, H | 2 |
| Kanai, Y | 1 |
| Nakano, T | 4 |
| Andrade, NR | 1 |
| Oshima, CT | 1 |
| Gomes, TS | 1 |
| Neto, RA | 1 |
| Forones, NM | 1 |
| Obi, EE | 1 |
| McDonald, A | 1 |
| Kemp, E | 1 |
| Mitsuhashi, K | 1 |
| Ichimura, T | 1 |
| Ozaka, M | 1 |
| Saiura, A | 1 |
| Hatake, K | 2 |
| Moureau-Zabotto, L | 1 |
| Farnault, B | 1 |
| Esterni, B | 1 |
| Lelong, B | 2 |
| Viret, F | 1 |
| Giovannini, M | 2 |
| Monges, G | 1 |
| Delpero, JR | 2 |
| Bories, E | 1 |
| Turrini, O | 1 |
| Viens, P | 1 |
| Salem, N | 1 |
| Deenen, MJ | 1 |
| Terpstra, WE | 1 |
| Boot, H | 1 |
| Schellens, JH | 1 |
| Del Bianco, P | 3 |
| Efficace, F | 1 |
| Serpentini, S | 2 |
| Amato, A | 1 |
| Hofheinz, R | 2 |
| Raab, R | 5 |
| Teke, Z | 1 |
| Nessar, G | 1 |
| Kiremitci, S | 1 |
| Aksoy, E | 1 |
| Elbir, OH | 1 |
| Nakamitsu, A | 1 |
| Imamura, Y | 1 |
| Kouyama, M | 1 |
| Uekami, S | 1 |
| Touge, K | 1 |
| Taogoshi, H | 1 |
| Fukuda, Y | 3 |
| Daimaru, H | 1 |
| Lin, L | 1 |
| Ge, FJ | 1 |
| Liu, LJ | 1 |
| Zhao, CH | 1 |
| Li, SS | 1 |
| Liu, JZ | 1 |
| Li, ZQ | 1 |
| Gomez, A | 2 |
| Anido, U | 1 |
| Bernardez, B | 1 |
| Rana-Diez, P | 1 |
| Wynn, G | 1 |
| Marks, J | 2 |
| Kessler, H | 2 |
| Cone, MM | 1 |
| Lu, KC | 1 |
| Rea, JD | 1 |
| Diggs, BS | 1 |
| Oommen, SC | 1 |
| Stojanovic, S | 1 |
| Popov, I | 1 |
| Radosevic-Jelic, L | 6 |
| Micev, M | 1 |
| Borojevic, N | 1 |
| Nikolic, V | 1 |
| Krivokapic, Z | 1 |
| Kecmanovic, D | 1 |
| Gavrilovic, D | 1 |
| Kezic, I | 1 |
| da Luz Moreira, A | 1 |
| Geisler, D | 1 |
| Amonkar, SJ | 1 |
| Cain, HJ | 1 |
| Hughes, T | 1 |
| Hemming, JD | 1 |
| Browell, DA | 1 |
| Custodio, A | 1 |
| Sanchez, JC | 1 |
| Rodriguez, L | 1 |
| Puente, J | 1 |
| de las Heras, M | 2 |
| Yanagawa, T | 2 |
| Watanabe, N | 1 |
| Iwazawa, T | 1 |
| Douno, K | 1 |
| Nishida, K | 2 |
| Masuda, D | 2 |
| Hosokawa, T | 2 |
| Tokita, H | 2 |
| Kakimoto, M | 1 |
| Koshiishi, H | 2 |
| Okamura, T | 2 |
| Katsumoto, Y | 4 |
| Aritake, N | 1 |
| Endoh, A | 1 |
| Iwao, Y | 1 |
| Koshinaga, T | 1 |
| Hirose, H | 1 |
| Ishii, H | 1 |
| Mukai, R | 1 |
| Momozane, T | 1 |
| Kano, S | 1 |
| Miyashiro, I | 1 |
| Kanoh, T | 1 |
| Ohnishi, T | 1 |
| Danno, K | 1 |
| Nakamura, H | 1 |
| Tsukao, Y | 1 |
| Inatome, J | 1 |
| Kagara, N | 1 |
| Tono, T | 1 |
| Nakano, Y | 2 |
| Monden, T | 1 |
| Imaoka, S | 1 |
| Murata, A | 2 |
| Inoue, T | 6 |
| Yamada, N | 1 |
| Tokunou, K | 1 |
| Yamamoto, T | 1 |
| Toshimitsu, H | 1 |
| Kitamura, Y | 2 |
| Andou, S | 1 |
| Tsushimi, K | 1 |
| Katayose, Y | 1 |
| Ottomo, S | 1 |
| Motoi, F | 1 |
| Rikiyama, T | 1 |
| Egawa, S | 1 |
| Sasaki, I | 1 |
| Herrmann, MK | 2 |
| Eickelmann, D | 1 |
| Virsik, P | 1 |
| Oberholzer, K | 1 |
| Menig, M | 1 |
| Kreft, A | 1 |
| Schneider, A | 1 |
| Junginger, T | 2 |
| Heintz, A | 1 |
| Kreitner, KF | 1 |
| Hötker, AM | 1 |
| Hansen, T | 1 |
| Düber, C | 1 |
| Schmidberger, H | 2 |
| Vincent, A | 1 |
| Heuff, G | 1 |
| Gerhards, MF | 1 |
| van Geloven, AA | 1 |
| van Tets, WF | 1 |
| Verheij, M | 1 |
| Neupane, R | 1 |
| Essapen, S | 1 |
| Dougal, M | 1 |
| Lloyd, A | 1 |
| Devries, AF | 2 |
| Schaberl-Moser, R | 1 |
| Zitt, M | 1 |
| Kapp, KS | 1 |
| Fastner, G | 1 |
| Keil, F | 1 |
| Jäger, R | 1 |
| Offner, F | 1 |
| Advani, PP | 1 |
| Hsu, HC | 1 |
| Chang, CL | 1 |
| Fang, FM | 1 |
| Wang, CJ | 1 |
| Chen, HC | 1 |
| Huang, YJ | 1 |
| Wang, CY | 1 |
| Wang, YM | 1 |
| Huang, EY | 1 |
| Yeo, SG | 4 |
| Patel, PA | 1 |
| Yoon, SM | 1 |
| Bleckmann, A | 1 |
| Jo, P | 2 |
| Ghadimi, MB | 1 |
| Lambregts, DM | 2 |
| Bakers, FC | 1 |
| Lambrecht, M | 2 |
| Kuboi, K | 1 |
| Matsumoto, N | 1 |
| Hasegawa, Y | 1 |
| Sekimoto, Y | 1 |
| Terasawa, H | 1 |
| Ojima, T | 1 |
| Tsujimura, H | 1 |
| Shimomura, T | 1 |
| Nakagawa, M | 2 |
| Hamada, A | 1 |
| Yoshihara, Y | 1 |
| Ishizaka, T | 1 |
| Fukushima, M | 2 |
| Sawada, R | 1 |
| Mukai, J | 1 |
| Maiello, E | 2 |
| Latiano, T | 1 |
| Garufi, C | 2 |
| Bochicchio, A | 1 |
| Torri, V | 1 |
| Bardelli, A | 1 |
| Gion, M | 1 |
| Sun, DS | 1 |
| Li, L | 1 |
| Tiramula, R | 1 |
| De Keyzer, F | 1 |
| Filip, C | 1 |
| Fukuhara, K | 1 |
| Terakura, M | 1 |
| Katsuragi, K | 1 |
| Enzo, MV | 1 |
| Briarava, M | 1 |
| Maretto, I | 1 |
| Toppan, P | 5 |
| Min, JJ | 1 |
| Eich, HT | 1 |
| Stepien, A | 1 |
| Zimmermann, C | 1 |
| Hellmich, M | 1 |
| Metzger, R | 1 |
| Hölscher, A | 1 |
| Müller, RP | 1 |
| Citrin, D | 1 |
| Camphausen, K | 1 |
| Wood, BJ | 1 |
| Quezado, M | 1 |
| Denobile, J | 1 |
| Pingpank, JF | 1 |
| Royal, RE | 1 |
| Alexander, HR | 1 |
| Seidel, G | 1 |
| Steinberg, SM | 1 |
| Shuttack, Y | 1 |
| Libutti, SK | 1 |
| Vicente, P | 1 |
| Arriví, A | 1 |
| Roca, JM | 1 |
| Ponce, J | 1 |
| Guasch, I | 1 |
| Moreno, I | 1 |
| Ruiz, A | 1 |
| Leibold, T | 1 |
| Akhurst, TJ | 1 |
| Chessin, DB | 3 |
| Yeung, HW | 1 |
| Macapinlac, H | 2 |
| Riedel, E | 2 |
| Mazumdar, M | 4 |
| Wong, WD | 6 |
| Larson, SM | 1 |
| Dawson, LA | 1 |
| Sampson, E | 1 |
| Bayley, A | 1 |
| Scott, S | 1 |
| Moseley, JL | 1 |
| Craig, T | 1 |
| Cummings, B | 5 |
| Dinniwell, R | 1 |
| Kim, JJ | 1 |
| Ringash, J | 2 |
| Brock, KK | 1 |
| Bouma, G | 1 |
| Imholz, AL | 1 |
| Strassburg, J | 1 |
| Ruppert, R | 1 |
| Maurer, C | 1 |
| Hermanek, P | 1 |
| Yang, SS | 1 |
| Mizota, A | 1 |
| Shitara, K | 2 |
| Kondo, C | 1 |
| Yokota, T | 1 |
| Kim, BC | 1 |
| Cordio, S | 1 |
| Artale, S | 1 |
| Tagliagambe, A | 1 |
| Ambrosini, G | 2 |
| Rosetti, P | 2 |
| Bonetti, A | 1 |
| Negru, ME | 1 |
| Silvano, G | 1 |
| Corsi, DC | 1 |
| Bochicchio, AM | 1 |
| Chiaulon, G | 1 |
| Gallo, M | 1 |
| Boni, L | 1 |
| Kennecke, H | 1 |
| Berry, S | 2 |
| Zhou, C | 1 |
| Easaw, J | 1 |
| Post, J | 1 |
| Hay, J | 1 |
| Edden, Y | 1 |
| Rotovnik Kozjek, N | 1 |
| Kompan, L | 1 |
| Soeters, P | 1 |
| Mlakar Mastnak, D | 1 |
| Možina, B | 1 |
| Zadnik, V | 1 |
| Higashiyama, A | 1 |
| Nagasako, T | 1 |
| Kawamura, N | 2 |
| Abiko, S | 1 |
| Gotoh, J | 1 |
| Tamaki, T | 1 |
| Meguro, J | 1 |
| Yonekawa, M | 1 |
| Kawamura, A | 1 |
| Tanino, M | 1 |
| Resch, G | 1 |
| Jagoditsch, M | 1 |
| Thomas, CR | 1 |
| Medich, D | 2 |
| Posner, MC | 1 |
| Lee, AD | 1 |
| McKay, MJ | 1 |
| Oyamatsu, M | 1 |
| Yagi, Y | 1 |
| Iiai, T | 1 |
| Saitou, K | 1 |
| Umezu, H | 1 |
| Winter, K | 2 |
| Kachnic, L | 1 |
| Bai, C | 1 |
| Shao, Y | 1 |
| Guan, M | 1 |
| Jia, N | 1 |
| Zhang, F | 1 |
| Cihan, Ş | 1 |
| Babacan, NA | 1 |
| Özdemir, N | 1 |
| Odabaş, H | 1 |
| Aksoy, S | 1 |
| Zengin, N | 1 |
| Martijnse, IS | 1 |
| Dudink, RL | 1 |
| Vermeer, TA | 1 |
| Nieuwenhuijzen, GA | 1 |
| van Lijnschoten, I | 1 |
| Lemmens, VE | 1 |
| Meng, H | 1 |
| Zhou, G | 1 |
| Xue, Z | 1 |
| Lu, W | 1 |
| Deng, J | 1 |
| Créhange, G | 2 |
| Omiya, N | 1 |
| Nakao, A | 3 |
| Shelygin, IuA | 1 |
| Rasulov, AO | 1 |
| Boĭko, AV | 1 |
| Droshneva, IV | 1 |
| Kashiwagi, S | 1 |
| Fuyuhiro, Y | 1 |
| Nakamoto, K | 1 |
| Dalton, RS | 1 |
| Velineni, R | 1 |
| Osborne, ME | 1 |
| Thomas, R | 1 |
| Harries, S | 1 |
| Gee, AS | 1 |
| Daniels, IR | 1 |
| Spigel, DR | 1 |
| McCleod, M | 1 |
| Shipley, DL | 1 |
| Arrowsmith, E | 1 |
| Barnes, EK | 1 |
| Infante, JR | 1 |
| Burris, HA | 1 |
| Greco, FA | 2 |
| Hainsworth, JD | 1 |
| Roy, P | 2 |
| Serra, S | 2 |
| Kennedy, E | 1 |
| Chetty, R | 2 |
| Schwaab, J | 1 |
| Gencer, D | 4 |
| Hofmann, WK | 2 |
| Madoff, RD | 3 |
| Music, M | 1 |
| Bracko, M | 1 |
| Brecelj, E | 1 |
| Kropivnik, M | 1 |
| Omejc, M | 1 |
| Tsariuk, VF | 2 |
| Gordeev, SS | 1 |
| Perevoshchikov, AG | 1 |
| Malikhov, AG | 1 |
| Aliev, VA | 1 |
| Glebovskaia, VV | 1 |
| Osombaev, MSh | 1 |
| Michel, P | 2 |
| Gineikiene, I | 1 |
| Juozaityte, E | 1 |
| Li, JL | 1 |
| Li, XF | 1 |
| Dou, FY | 1 |
| Bu, ZD | 1 |
| Wu, AW | 1 |
| Tham, IW | 1 |
| Zehentmayr, F | 1 |
| Wolf, M | 1 |
| Weissenborn, Y | 1 |
| Feldmann, HJ | 1 |
| Belka, C | 1 |
| Shigaki, N | 1 |
| Sugita, H | 1 |
| Arima, N | 1 |
| Hughes, R | 1 |
| Parry, J | 1 |
| Beynon, J | 1 |
| Jenkins, G | 1 |
| Chang, CY | 1 |
| Cho, YB | 1 |
| Chun, HK | 1 |
| Schirmer, MA | 2 |
| Mergler, CP | 1 |
| Brockmöller, J | 1 |
| Koike, Y | 1 |
| Engels, B | 1 |
| Tournel, K | 1 |
| Everaert, H | 1 |
| Hoorens, A | 1 |
| Sermeus, A | 1 |
| Christian, N | 1 |
| Storme, G | 1 |
| Verellen, D | 1 |
| De Ridder, M | 1 |
| Avoranta, ST | 1 |
| Korkeila, EA | 1 |
| Minn, HR | 1 |
| Syrjänen, KJ | 1 |
| Pyrhönen, SO | 2 |
| Sundström, JT | 1 |
| Maréchal, R | 1 |
| Vos, B | 1 |
| Polus, M | 1 |
| Delaunoit, T | 1 |
| Demetter, P | 1 |
| Demols, A | 1 |
| Franchimont, D | 1 |
| Verset, G | 1 |
| Van Houtte, P | 1 |
| Van de Stadt, J | 1 |
| Thomas, F | 1 |
| Motsinger-Reif, AA | 1 |
| Hoskins, JM | 1 |
| Dvorak, A | 1 |
| Roy, S | 1 |
| Alyasiri, A | 1 |
| Fleshman, JW | 4 |
| Tan, BR | 1 |
| McLeod, HL | 1 |
| Nelemans, PJ | 1 |
| van Dam, RM | 1 |
| Sosef, M | 1 |
| Hulsewé, KW | 1 |
| Cheon, JH | 1 |
| Kim, WH | 1 |
| Matsushita, K | 1 |
| Uchida, K | 1 |
| Itatani, Y | 1 |
| Yamakawa, K | 1 |
| Noaki, R | 1 |
| Hernández, JL | 1 |
| Ramos, LI | 1 |
| Nuñez, J | 1 |
| Cambeiro, M | 1 |
| Gaztañaga, M | 1 |
| Ma, JJ | 1 |
| Liang, XB | 1 |
| Fan, L | 1 |
| Chen, MX | 1 |
| Li, CY | 1 |
| Jiang, HY | 1 |
| Hu, XZ | 1 |
| Molinari, C | 1 |
| Ballardini, M | 1 |
| Teodorani, N | 1 |
| Giannini, M | 1 |
| Zoli, W | 1 |
| Emiliani, E | 1 |
| Lucci, E | 1 |
| Saragoni, L | 1 |
| Guidoboni, M | 1 |
| Amadori, D | 1 |
| Calistri, D | 1 |
| Tabe, Y | 1 |
| Suto, T | 1 |
| Paillot, B | 1 |
| Hamidou, H | 1 |
| Tourani, JM | 3 |
| Silvain, C | 1 |
| Wahba, HA | 1 |
| El-Hadaad, HA | 1 |
| Roshdy, S | 1 |
| Rose, MG | 1 |
| Perkal, MF | 1 |
| Chao, HH | 1 |
| Della Vittoria Scarpati, G | 1 |
| Falcetta, F | 1 |
| Ubezio, P | 1 |
| Marchini, S | 1 |
| Singh, VK | 1 |
| D'Incalci, M | 1 |
| Yatsuoka, T | 1 |
| Urakawa, M | 1 |
| Murakami, T | 1 |
| Amano, K | 1 |
| Ohsawa, T | 3 |
| Okada, N | 1 |
| Kumamoto, K | 1 |
| Ono, H | 1 |
| Yamauchi, S | 2 |
| Umemoto, S | 2 |
| Kawamoto, S | 1 |
| Yoshida, N | 2 |
| Gasparini, G | 2 |
| Torino, F | 1 |
| Ballestrero, A | 1 |
| Berardi, R | 2 |
| Shishido, J | 1 |
| Morosini, P | 1 |
| Toi, M | 1 |
| Seehaus, A | 1 |
| Vacaro, C | 1 |
| Ocantos, J | 1 |
| Varela, A | 1 |
| Savluk, L | 1 |
| Ojea Quintana, G | 1 |
| Rossi, G | 1 |
| Weimbaur, V | 1 |
| Pablo Santino, J | 1 |
| García-Mónaco, R | 1 |
| Vestermark, LW | 1 |
| Jensen, HA | 1 |
| Gehoff, A | 1 |
| Basten, O | 1 |
| Bismarck, C | 1 |
| Bandorski, D | 1 |
| Merkelbach-Bruse, S | 1 |
| Schneider-Stock, R | 1 |
| Stoehr, R | 1 |
| Wirtz, RM | 1 |
| Müller, A | 1 |
| Chang, SJ | 1 |
| Chen, MJ | 1 |
| Peccatori, FA | 1 |
| Giovannetti, E | 1 |
| Pistilli, B | 1 |
| Bellettini, G | 1 |
| Codacci-Pisanelli, G | 1 |
| Losekoot, N | 1 |
| Curigliano, G | 2 |
| Azim, HA | 1 |
| Goldhirsch, A | 3 |
| Peters, GJ | 4 |
| An, HJ | 1 |
| Yun, SC | 1 |
| Ryu, MH | 4 |
| Chang, HM | 4 |
| Song, S | 2 |
| Hong, JC | 2 |
| McDonnell, SE | 1 |
| Liauw, SL | 3 |
| Tagami, Y | 1 |
| Ogata, S | 1 |
| Katakawa, M | 1 |
| Yi, SK | 1 |
| Mak, W | 1 |
| Yang, CC | 1 |
| Cui, J | 1 |
| Chen, AM | 1 |
| Purdy, JA | 1 |
| Monjazeb, AM | 1 |
| Do, L | 1 |
| Kripp, M | 1 |
| Wieneke, J | 1 |
| Welzel, G | 1 |
| Brade, J | 1 |
| Lee, WS | 2 |
| Shin, DB | 2 |
| Sym, SJ | 1 |
| Kwon, KA | 1 |
| Lee, KC | 2 |
| Lee, SH | 3 |
| Jung, DH | 1 |
| Martin, ST | 1 |
| Heneghan, HM | 1 |
| Gasent Blesa, JM | 1 |
| Garde Noguera, J | 1 |
| Laforga Canales, JB | 1 |
| Giner Bosch, V | 1 |
| Alberola, A | 1 |
| Soler Tortosa, M | 1 |
| Peris Godoy, M | 1 |
| Sanchez, JL | 1 |
| Provencio Pulla, M | 1 |
| Alberola Candel, V | 1 |
| Bedford, MR | 1 |
| Anathhanam, S | 1 |
| Saleh, D | 1 |
| Hickson, A | 1 |
| McGregor, AK | 1 |
| Boyle, K | 1 |
| Burke, D | 1 |
| Shanmugan, S | 1 |
| Arrangoiz, R | 1 |
| Nitzkorski, JR | 1 |
| Cooper, H | 2 |
| Winkler, J | 1 |
| Zipp, L | 1 |
| Knoblich, J | 1 |
| Zimmermann, F | 2 |
| Polinder-Bos, HA | 1 |
| Kok, EE | 1 |
| van de Wiel, A | 1 |
| Spiering, W | 1 |
| Wielders, JP | 1 |
| Bloemendal, HJ | 1 |
| Petersen, SH | 1 |
| Harling, H | 1 |
| Kirkeby, LT | 1 |
| Wille-Jørgensen, P | 1 |
| Mocellin, S | 1 |
| Seshimo, K | 1 |
| Oishi, M | 1 |
| Ikeda, H | 2 |
| Yamamura, M | 1 |
| Kodera, M | 1 |
| Yamashita, Y | 2 |
| Tanaka, N | 2 |
| Shibagaki, K | 1 |
| Matsuki, T | 1 |
| Takita, K | 1 |
| Sun, PL | 1 |
| Li, B | 1 |
| Ye, QF | 1 |
| Del Vescovo, R | 1 |
| Trodella, LE | 1 |
| Sansoni, I | 1 |
| Cazzato, RL | 1 |
| Battisti, S | 1 |
| Giurazza, F | 1 |
| Ramella, S | 1 |
| Cellini, F | 2 |
| Grasso, RF | 1 |
| Trodella, L | 5 |
| Beomonte Zobel, B | 1 |
| Killoran, JH | 1 |
| Crowley, EM | 1 |
| De Hertogh, G | 1 |
| Fieuws, S | 1 |
| Koca, D | 1 |
| Yavuzsen, T | 1 |
| Ellidokuz, H | 1 |
| Yilmaz, U | 1 |
| Dewdney, A | 1 |
| Schou, JV | 1 |
| Larsen, FO | 1 |
| Rasch, L | 1 |
| Linnemann, D | 1 |
| Langhoff, J | 1 |
| Høgdall, E | 1 |
| Nielsen, DL | 1 |
| Vistisen, K | 1 |
| Fromm, A | 1 |
| Jang, SM | 1 |
| Cho, TH | 1 |
| Cai, X | 1 |
| Xue, P | 1 |
| Song, WF | 1 |
| Hu, J | 1 |
| Gu, HL | 1 |
| Yang, HY | 1 |
| Wang, LW | 2 |
| Maggiulli, E | 1 |
| Gianolini, S | 1 |
| Salvetti, C | 1 |
| Di Muzio, NG | 1 |
| Matzdorff, A | 1 |
| Laechelt, S | 1 |
| Hartmann, JT | 2 |
| Kettner, E | 2 |
| Fritz, E | 2 |
| Hieber, U | 1 |
| Lindemann, HW | 1 |
| Grunewald, M | 1 |
| Kremers, S | 1 |
| Constantin, C | 1 |
| Hartung, G | 4 |
| Tsuchida, K | 1 |
| Honjoh, Y | 1 |
| Asari, M | 1 |
| Osawa, E | 1 |
| Numata, K | 1 |
| Osaragi, T | 1 |
| Kasahara, A | 2 |
| Shibuya, H | 1 |
| Takizawa, K | 3 |
| Miura, Y | 1 |
| Yoshie, K | 1 |
| Mori, K | 1 |
| Kikunaga, H | 2 |
| Morisue, A | 2 |
| Fujita, K | 1 |
| Ishikawa, K | 2 |
| Sakuragawa, T | 1 |
| Kumai, K | 1 |
| Miura, H | 2 |
| Mikami, S | 1 |
| Tonoike, Y | 1 |
| Kawahara, M | 1 |
| Nishimura, A | 2 |
| Kawachi, Y | 2 |
| Nikkuni, K | 2 |
| Sato, A | 3 |
| Fukuhara, Y | 1 |
| Tomidokoro, T | 1 |
| Ikarashi, T | 3 |
| Bonnetain, F | 2 |
| Chapet, O | 4 |
| Methy, N | 1 |
| Qiao, J | 1 |
| Patel, UB | 1 |
| Rutten, H | 1 |
| Ricci, S | 1 |
| Kjell, P | 1 |
| Villanueva, MT | 1 |
| Witzigmann, H | 2 |
| Yoon, SC | 2 |
| Lee, DS | 2 |
| Takeuchi, M | 1 |
| Uchida, S | 1 |
| Murakami, N | 1 |
| Kibe, S | 1 |
| Yahara, T | 1 |
| Appelt, A | 1 |
| Chiorean, EG | 1 |
| Sanghani, S | 1 |
| Schiel, MA | 1 |
| Burns, M | 1 |
| Tong, Y | 1 |
| Hinkle, DT | 1 |
| Coleman, N | 1 |
| Robb, B | 1 |
| LeBlanc, J | 1 |
| Clark, R | 1 |
| Bufill, J | 1 |
| Curie, C | 1 |
| Loehrer, PJ | 3 |
| Cardenes, H | 1 |
| Damin, DC | 1 |
| Rosito, MA | 1 |
| Contu, PC | 1 |
| Tarta, C | 1 |
| Ferreira, PR | 1 |
| Kliemann, LM | 1 |
| Schwartsmann, G | 1 |
| Cejas, P | 1 |
| Moreno-García, V | 1 |
| Machancoses, AH | 1 |
| Feliu, J | 2 |
| Sülberg, H | 2 |
| Potapov, S | 1 |
| Díaz Beveridge, R | 1 |
| Tormo, A | 1 |
| Artes, J | 1 |
| Giménez, A | 1 |
| Segura, Á | 1 |
| Roldán, S | 1 |
| Palasí, R | 1 |
| Ramos, D | 1 |
| Shim, EK | 1 |
| Yeo, HY | 1 |
| Goi, T | 1 |
| Sawai, K | 3 |
| Iida, A | 1 |
| Yamaguchi, A | 1 |
| Hoshino, H | 1 |
| Matsunaga, A | 1 |
| Shigeta, K | 1 |
| Seo, Y | 2 |
| Hoshino, G | 1 |
| Ebe, K | 2 |
| Fujita, N | 2 |
| Koide, N | 3 |
| Honma, K | 2 |
| Yeh, J | 1 |
| Hastings, J | 1 |
| Abbas, MA | 1 |
| Tomlow, B | 1 |
| Voll, ML | 1 |
| Smorenburg, CH | 1 |
| Tezuka, T | 1 |
| Nakagawa, R | 1 |
| Adachi, K | 1 |
| Lin, JK | 5 |
| Lee, LK | 1 |
| Chen, WS | 3 |
| Lin, TC | 3 |
| Jiang, JK | 3 |
| Yang, SH | 3 |
| Wang, HS | 2 |
| Chang, SC | 1 |
| Lan, YT | 1 |
| Lin, CC | 1 |
| Yen, CC | 4 |
| Liu, JH | 4 |
| Tzeng, CH | 1 |
| Teng, HW | 1 |
| Goldberg, N | 1 |
| Kundel, Y | 1 |
| Purim, O | 1 |
| Bernstine, H | 1 |
| Gordon, N | 1 |
| Morgenstern, S | 1 |
| Idelevich, E | 2 |
| Wasserberg, N | 1 |
| Sulkes, A | 3 |
| Groshar, D | 1 |
| Brenner, B | 2 |
| Navarro, M | 3 |
| Benavides, M | 2 |
| González, E | 1 |
| Majem, M | 1 |
| del Moral-Avila, R | 1 |
| Jiménez, E | 1 |
| Wals, A | 1 |
| Tisaire, JL | 1 |
| Alcantara, MP | 1 |
| Ayez, N | 1 |
| Alberda, WJ | 1 |
| Burger, JW | 1 |
| Eggermont, AM | 1 |
| Nuyttens, JJ | 2 |
| Dwarkasing, RS | 1 |
| Willemssen, FE | 1 |
| Kwak, JY | 1 |
| Jang, SJ | 2 |
| Iqbal, MS | 1 |
| Hardman, J | 1 |
| Kho, P | 1 |
| Chapuis, PH | 2 |
| Beale, P | 3 |
| Dent, OF | 1 |
| Clarke, S | 3 |
| Tsukidate, H | 1 |
| Fukamachi, S | 1 |
| Ikezawa, F | 1 |
| Tezuka, F | 1 |
| Arrazubi, V | 1 |
| Suárez, J | 1 |
| Guerrero, D | 1 |
| Gómez, M | 1 |
| Viúdez, A | 1 |
| Balén, E | 1 |
| Kim, YB | 1 |
| Choi, JJ | 1 |
| Lee, I | 1 |
| Cho, JH | 1 |
| Niu, J | 1 |
| Mims, MP | 1 |
| Tsuruta, Y | 1 |
| Takamori, S | 1 |
| Shishikura, Y | 1 |
| Vassiliou, V | 1 |
| Kountourakis, P | 1 |
| Schroeder, C | 1 |
| von Weyhern, CH | 1 |
| Weinmann, M | 1 |
| Bamberg, M | 2 |
| Berger, B | 1 |
| Laubender, RP | 1 |
| Lin, X | 1 |
| Goodman, K | 1 |
| Fang, YJ | 2 |
| Duldulao, MP | 1 |
| Lee, W | 1 |
| Nelson, RA | 1 |
| Ho, J | 1 |
| Le, M | 1 |
| Formentini, A | 1 |
| Cetin, B | 1 |
| Kaplan, MA | 1 |
| Berk, V | 1 |
| Tufan, G | 1 |
| Benekli, M | 1 |
| Isikdogan, A | 1 |
| Ozkan, M | 1 |
| Coskun, U | 1 |
| Buyukberber, S | 1 |
| Bedenne, L | 2 |
| Helbling, D | 1 |
| Bodoky, G | 1 |
| Gautschi, O | 1 |
| Sun, H | 1 |
| Bosman, F | 1 |
| Gloor, B | 1 |
| Burkhard, R | 2 |
| Winterhalder, R | 2 |
| Madlung, A | 1 |
| Rauch, D | 1 |
| Saletti, P | 1 |
| Widmer, L | 2 |
| Borner, M | 1 |
| Baertschi, D | 1 |
| Yan, P | 1 |
| Benhattar, J | 1 |
| Leibundgut, EO | 1 |
| Bougel, S | 1 |
| Koeberle, D | 2 |
| Ye, T | 1 |
| Xia, JL | 1 |
| Yang, BW | 1 |
| Ge, NL | 1 |
| Gan, YH | 1 |
| Ren, ZG | 1 |
| Sana, J | 1 |
| Gombosova, J | 1 |
| Nekvindova, J | 1 |
| Radova, L | 1 |
| Banerjee, R | 1 |
| Chakraborty, S | 1 |
| Nygren, I | 1 |
| Sinha, R | 1 |
| Tranchart, H | 1 |
| Svrcek, M | 1 |
| Flejou, JF | 1 |
| Dogan, NU | 1 |
| Kerimoglu, OS | 1 |
| Pekin, A | 1 |
| Celik, C | 1 |
| Trojan, J | 1 |
| Bechstein, WO | 1 |
| Woeste, G | 1 |
| Hernando-Requejo, O | 1 |
| García-García, E | 1 |
| Rodriguez-Pascual, J | 1 |
| De Vicente, E | 1 |
| Morelli, P | 1 |
| Rubio, C | 1 |
| López-Ríos, F | 1 |
| Muro, A | 1 |
| López, U | 1 |
| Prados, S | 1 |
| Quijano, Y | 1 |
| Hidalgo, M | 1 |
| Tonlaar, N | 1 |
| Bianchi, R | 1 |
| Salmenkylä, S | 1 |
| Kouri, M | 1 |
| Pukkala, E | 1 |
| Luukkonen, P | 1 |
| Hyöty, M | 1 |
| Pääkkönen, M | 1 |
| Mäkelä, J | 1 |
| Mustonen, H | 1 |
| Järvinen, HJ | 1 |
| Steger, F | 1 |
| Hautmann, MG | 1 |
| Kölbl, O | 1 |
| Yokoyama, H | 1 |
| Akasaka, H | 1 |
| Morohashi, H | 1 |
| Sakamoto, Y | 1 |
| Koyama, M | 2 |
| Hakamada, K | 1 |
| Shioiri, M | 1 |
| Toura, I | 1 |
| Kudo, S | 1 |
| Inoue, K | 2 |
| Nakanishi, T | 1 |
| Nishiyama, S | 1 |
| Takebe, S | 1 |
| Ogino, Y | 1 |
| Ohsaki, S | 1 |
| Nagashima, Y | 1 |
| Kimura, A | 2 |
| Nishikawa, S | 1 |
| Yachi, T | 1 |
| Kudo, Y | 1 |
| Tokura, T | 1 |
| Umehara, Y | 1 |
| Kurushima, M | 1 |
| Morita, T | 1 |
| Nakatake, R | 1 |
| Kaibori, M | 1 |
| Ishizaki, M | 1 |
| Iwamoto, S | 2 |
| Matsui, K | 1 |
| Iwai, A | 1 |
| Tsuda, T | 2 |
| Matsushima, H | 1 |
| Yoshioka, K | 1 |
| Kwon, AH | 1 |
| Tominaga, K | 1 |
| Hoshino, M | 1 |
| Naruse, H | 1 |
| Guan, Z | 1 |
| Liang, L | 1 |
| Wang, M | 1 |
| Okuya, K | 1 |
| Mizushima, Y | 1 |
| Okumura, K | 1 |
| Tani, S | 1 |
| Shiogai, Y | 1 |
| Kilic, D | 1 |
| Yalman, D | 1 |
| Aksu, G | 1 |
| Atasoy, BM | 1 |
| Igdem, S | 1 |
| Dincbas, FO | 1 |
| Yalcin, S | 2 |
| Bampo, C | 1 |
| Alessi, A | 1 |
| Fantini, S | 1 |
| Bertarelli, G | 1 |
| Bombardieri, E | 1 |
| Crippa, F | 1 |
| Milione, M | 1 |
| Avuzzi, B | 1 |
| Chiruzzi, C | 1 |
| Tian, YF | 1 |
| Lee, HH | 1 |
| Shiue, YL | 1 |
| Huang, HY | 1 |
| Pan, HY | 1 |
| Chen, SH | 1 |
| Covino, M | 2 |
| Amajoyi, R | 1 |
| Lee, Y | 1 |
| Recio, PJ | 1 |
| Kondylis, PD | 1 |
| Greto, D | 1 |
| Paiar, F | 1 |
| Saieva, C | 1 |
| Mangoni, M | 2 |
| Livi, L | 1 |
| Agresti, B | 1 |
| Franceschini, D | 1 |
| Bonomo, P | 1 |
| Scotti, V | 1 |
| Detti, B | 1 |
| Tonelli, F | 1 |
| Valeri, A | 1 |
| Messerini, L | 1 |
| Biti, G | 1 |
| Ono, CR | 1 |
| Lynn, P | 1 |
| Grosso, F | 1 |
| Mandalà, M | 1 |
| Maglione, V | 1 |
| Berretta, L | 1 |
| Mariani, N | 1 |
| Rossi, M | 1 |
| Piovano, PL | 1 |
| Drago, D | 1 |
| Summa, M | 1 |
| Franzone, P | 1 |
| Musante, F | 1 |
| Spinoglio, G | 1 |
| Fontana, E | 1 |
| Pucci, F | 2 |
| Camisa, R | 2 |
| Bui, S | 2 |
| Galdy, S | 1 |
| Leonardi, F | 1 |
| Negri, FV | 2 |
| Anselmi, E | 1 |
| Losardo, PL | 2 |
| Roncoroni, L | 1 |
| Dell'abate, P | 1 |
| Crafa, P | 2 |
| Ardizzoni, A | 3 |
| Cha, C | 1 |
| Andrews, JC | 1 |
| Ensminger, WD | 1 |
| Lawrence, TS | 1 |
| Wheeler, JM | 2 |
| Warren, BF | 2 |
| Mortensen, NJ | 2 |
| Ekanyaka, N | 1 |
| Kulacoglu, H | 1 |
| Jones, AC | 2 |
| George, BD | 2 |
| Kettlewell, MG | 1 |
| Marks, G | 3 |
| Schaffer, M | 3 |
| Thoma, M | 1 |
| Wilkowski, R | 2 |
| Schaffer, P | 2 |
| Dühmke, E | 1 |
| Carraro, S | 1 |
| Cartelli, C | 1 |
| Rafailovici, L | 1 |
| Castillo Odena, S | 1 |
| Wasserman, E | 2 |
| Gualdrini, U | 1 |
| Barugel, M | 1 |
| Ballarino, G | 1 |
| Rodriguez, MC | 1 |
| Masciangioli, G | 1 |
| Cho, MJ | 3 |
| Song, KS | 3 |
| Yoon, WH | 3 |
| Miller, RC | 2 |
| Sargent, DJ | 3 |
| Martenson, JA | 9 |
| Macdonald, JS | 13 |
| Haller, D | 1 |
| Gunderson, LL | 11 |
| Cha, SS | 2 |
| Sutter, T | 1 |
| Kölling-Schlebusch, K | 1 |
| Frings, S | 1 |
| Inaba, Y | 1 |
| Watabe, S | 1 |
| Ohe, S | 1 |
| Kamio, Y | 1 |
| Chiba, M | 1 |
| Rosemergy, I | 1 |
| Findlay, M | 2 |
| Ojima, E | 2 |
| Hatada, T | 1 |
| Mohri, T | 1 |
| Azuma, T | 1 |
| Cummings, BJ | 3 |
| Yang, TS | 2 |
| Hsu, KC | 2 |
| Chen, JS | 1 |
| Sun, W | 2 |
| McMullen, KP | 1 |
| Blackstock, AW | 1 |
| Eraso, A | 1 |
| Armengol, M | 2 |
| Rosselló, J | 1 |
| Majó, J | 1 |
| Ares, C | 1 |
| Espin, E | 1 |
| Benavente, S | 1 |
| de Torres, I | 1 |
| Masumori, K | 5 |
| Maruta, M | 4 |
| Utsumi, T | 2 |
| Ishihara, O | 2 |
| Okamoto, N | 4 |
| Nakamura, S | 1 |
| Koga, T | 1 |
| Hirano, K | 1 |
| Nagai, K | 1 |
| Maruyama, N | 1 |
| Nakaguchi, K | 3 |
| Sue, F | 3 |
| Luna-Pérez, P | 3 |
| Rodríguez-Ramírez, S | 1 |
| Hernández-Pacheco, F | 1 |
| Gutiérrez De La Barrera, M | 1 |
| Fernández, R | 1 |
| Labastida, S | 3 |
| Mehta, VK | 2 |
| Cho, C | 1 |
| Ford, JM | 1 |
| Jambalos, C | 1 |
| Poen, J | 2 |
| Koong, A | 1 |
| Lin, A | 1 |
| Bastidas, JA | 1 |
| Young, H | 2 |
| Dunphy, EP | 1 |
| Fisher, G | 2 |
| Kohnoe, S | 1 |
| Reerink, O | 1 |
| Verschueren, RC | 1 |
| Szabo, BG | 1 |
| Mulder, NH | 3 |
| Vauthey, JN | 6 |
| Thames, HD | 2 |
| Curley, SA | 3 |
| Akbulut, H | 1 |
| Altuntas, F | 1 |
| Akbulut, KG | 1 |
| Ozturk, G | 1 |
| Cindoruk, M | 1 |
| Unal, E | 1 |
| Icli, F | 1 |
| Ratto, C | 8 |
| Morganti, AG | 9 |
| Balducci, M | 1 |
| Gentile, PC | 1 |
| Picciocchi, A | 9 |
| Cellini, N | 14 |
| Kypson, AP | 1 |
| Morphew, E | 1 |
| Jones, R | 2 |
| Gottfried, MR | 1 |
| Seigler, HF | 5 |
| Myerson, R | 2 |
| Zobeiri, I | 1 |
| Ratkin, G | 3 |
| Dardoufas, C | 1 |
| Mouratidou, D | 1 |
| Tsavaris, N | 4 |
| Pouli, A | 1 |
| Androulakis, G | 1 |
| Philippakis, M | 1 |
| Voros, D | 2 |
| Batalis, T | 1 |
| Besbeas, S | 1 |
| Hatzistylianos, G | 1 |
| Katsos, J | 1 |
| Komporozos, V | 1 |
| Legakis, N | 1 |
| Mallas, H | 1 |
| Peros, G | 1 |
| Photopoulos, A | 1 |
| Pisiotis, C | 1 |
| Polymeneas, G | 1 |
| Retalis, G | 1 |
| Samanidis, L | 1 |
| Smyrniotis, V | 1 |
| Stamatiadis, A | 1 |
| Vasiliou, J | 2 |
| Andreadis, H | 1 |
| Papadimitriou, J | 1 |
| Ohtsu, A | 3 |
| Boku, N | 4 |
| Saitoh, S | 1 |
| Nakamura, A | 1 |
| Yamamichi, N | 1 |
| Yamamoto, S | 1 |
| Bouillet, T | 1 |
| Morere, JF | 1 |
| Breau, JL | 1 |
| Bechtel, J | 1 |
| Tepper, J | 1 |
| Nakagoe, T | 1 |
| Yamaguchi, E | 1 |
| Sawai, T | 1 |
| Tsuji, T | 1 |
| Shibasaki, S | 1 |
| Nanashima, A | 1 |
| Yamaguchi, H | 2 |
| Yasutake, T | 1 |
| Ayabe, H | 1 |
| Nemoz, C | 1 |
| Romestaing, P | 3 |
| Coquard, R | 1 |
| Barbet, N | 2 |
| Atlan, D | 1 |
| Adeleine, P | 1 |
| Freyer, G | 3 |
| Langer, C | 3 |
| Müller, D | 1 |
| Siemer, A | 1 |
| Markus, PM | 1 |
| Füzesi, L | 2 |
| Allen, M | 1 |
| Hill, M | 3 |
| Sumpter, K | 1 |
| Rhodes, A | 1 |
| Norman, AR | 2 |
| Hill, A | 2 |
| Prior, Y | 1 |
| Hosokawa, A | 1 |
| Fujita, S | 2 |
| Akasu, T | 1 |
| Tai, CJ | 1 |
| Wang, WS | 3 |
| Chiou, TJ | 3 |
| Chen, PM | 3 |
| Stein, DE | 1 |
| Mahmoud, NN | 2 |
| Rose, DG | 1 |
| Isenberg, GA | 1 |
| Goldstein, SD | 1 |
| Fry, RD | 2 |
| Bouaouina, N | 1 |
| Boussen, H | 1 |
| Kelm, J | 1 |
| Ahlhelm, F | 1 |
| Weissenbach, P | 1 |
| Schliesing, P | 1 |
| Regitz, T | 1 |
| Deubel, G | 1 |
| Engel, C | 1 |
| Burmeister, BH | 3 |
| Schache, D | 2 |
| Burmeister, EA | 1 |
| Bell, A | 2 |
| Poulsen, MG | 1 |
| Walpole, ET | 1 |
| Mackintosh, J | 3 |
| Krych, M | 1 |
| Pachmann, S | 1 |
| Abdel-Rahman, S | 1 |
| Schaffer, PM | 1 |
| Ertl-Wagner, B | 1 |
| D hmke, E | 1 |
| Issels, RD | 2 |
| Magagnoli, M | 1 |
| Masci, G | 1 |
| Carnaghi, C | 1 |
| Zucali, PA | 1 |
| Castagna, L | 1 |
| Morenghi, E | 1 |
| Ishikura, S | 1 |
| Nihei, K | 1 |
| Cafiero, F | 3 |
| Gipponi, M | 3 |
| Lionetto, R | 2 |
| Kuechler, A | 1 |
| Dreidax, M | 1 |
| Pigorsch, SU | 1 |
| Liehr, T | 1 |
| Claussen, U | 1 |
| Wendt, TG | 1 |
| Souglakos, J | 1 |
| Androulakis, N | 1 |
| Mavroudis, D | 1 |
| Kourousis, C | 1 |
| Kakolyris, S | 1 |
| Vardakis, N | 1 |
| Kalbakis, K | 1 |
| Pallis, A | 1 |
| Ardavanis, A | 1 |
| Varveris, C | 1 |
| Georgoulias, V | 1 |
| Saif, MW | 5 |
| Quinn, MG | 1 |
| Thomas, RR | 1 |
| Ernst, A | 2 |
| Grem, JL | 6 |
| Birnbaum, EH | 3 |
| Singh, AK | 1 |
| Kodner, IJ | 3 |
| Lockett, MA | 2 |
| Phan, T | 2 |
| Chandra, A | 1 |
| Read, TE | 3 |
| Papadopoulos, T | 4 |
| Schmoll, HJ | 3 |
| Martus, P | 5 |
| Sabitzer, H | 2 |
| Karstens, JH | 3 |
| Wanebo, HJ | 3 |
| Belliveau, J | 2 |
| Begossi, G | 2 |
| Levy, A | 1 |
| Couch, LS | 1 |
| Groteluschen, DL | 1 |
| Stewart, JA | 1 |
| Mulkerin, DL | 1 |
| Günther, K | 2 |
| Dimmler, A | 1 |
| Reulbach, U | 1 |
| Bittorf, BR | 1 |
| Matzel, KE | 1 |
| Brown, CL | 1 |
| Thorson, AG | 2 |
| Christensen, MA | 2 |
| Blatchford, GJ | 2 |
| Shashidharan, M | 1 |
| Haynatzki, GR | 1 |
| SHARP, GS | 1 |
| BENEFIEL, WW | 1 |
| SULLIVAN, RD | 2 |
| NORCROSS, JW | 1 |
| WATKINS, E | 1 |
| BRINDLEY, CO | 1 |
| GOLOMB, FM | 2 |
| SAMMONS, BP | 1 |
| WRIGHT, JC | 1 |
| REITEMEIER, RJ | 6 |
| MOERTEL, CG | 22 |
| BLACKBURN, CM | 1 |
| HAHN, RG | 9 |
| KABAKOW, B | 1 |
| ALBAUM, H | 1 |
| ANTOPOL, W | 1 |
| BLINICK, G | 1 |
| SUSSMAN, L | 1 |
| GINZBURG, L | 3 |
| CHAN, DP | 1 |
| HO, JH | 1 |
| WOO, AW | 1 |
| HART, GD | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| NADLER, SH | 2 |
| MOORE, GE | 1 |
| WATSON, EC | 1 |
| HELSPER, JT | 2 |
| DEMOSS, EV | 1 |
| ANSFIELD, FJ | 5 |
| MCCAFFERY, JF | 1 |
| HOLSTI, LR | 1 |
| PACE, WG | 1 |
| KNOERNSCHILD, H | 1 |
| CHILDS, DS | 1 |
| HOLBROOK, MA | 1 |
| COLBY, MY | 1 |
| Ziras, N | 1 |
| Kosmas, C | 2 |
| Giannakakis, T | 1 |
| Gouveris, P | 2 |
| Vadiaka, M | 1 |
| Dimitrakopoulos, A | 2 |
| Karadima, D | 1 |
| Rokana, S | 1 |
| Papalambros, E | 2 |
| Papastratis, G | 2 |
| Margaris, H | 1 |
| Tsipras, H | 1 |
| Polyzos, A | 1 |
| O'Connell, M | 2 |
| Hollis, D | 3 |
| Cooke, E | 2 |
| James, RD | 1 |
| Donaldson, D | 1 |
| Gray, R | 1 |
| Northover, JM | 2 |
| Stenning, SP | 1 |
| Taylor, I | 8 |
| Friedemann, A | 1 |
| Tilly, W | 4 |
| Wust, P | 10 |
| Riess, H | 7 |
| Schwabe, W | 6 |
| Sander, S | 1 |
| Sträter, J | 1 |
| Polat, S | 1 |
| Weiser, HF | 1 |
| Schramm, H | 1 |
| Häusler, P | 6 |
| Ott, K | 1 |
| Behnke, D | 2 |
| Beger, HG | 1 |
| Chwaliński, M | 1 |
| Rogowski, W | 1 |
| Kaji, M | 2 |
| Mizuta, M | 3 |
| Clarke, PA | 1 |
| George, ML | 1 |
| Easdale, S | 1 |
| Swift, RI | 1 |
| Hill, ME | 1 |
| Workman, P | 1 |
| Bruch, HR | 1 |
| Esser, M | 1 |
| Piroth, MD | 1 |
| Hensley, F | 1 |
| Wannenmacher, M | 2 |
| Zierhut, D | 1 |
| Hasegawa, K | 1 |
| Takashima, I | 1 |
| Shinoura, H | 1 |
| Ebuchi, M | 1 |
| Tsujie, M | 1 |
| Handa, R | 1 |
| Naoi, Y | 1 |
| Kashiwazaki, M | 1 |
| Nishisyo, I | 1 |
| Tsujinaka, T | 3 |
| Kremser, C | 2 |
| Judmaier, W | 2 |
| Hein, P | 1 |
| Griebel, J | 2 |
| Sørbye, H | 2 |
| Coleman, TA | 1 |
| Redger, CD | 1 |
| Hamill, RL | 1 |
| Dainer, P | 1 |
| Peoples, GE | 1 |
| Arciero, C | 1 |
| Shriver, CD | 1 |
| Vanagunas, A | 1 |
| Lin, DE | 1 |
| Stryker, SJ | 2 |
| Zhuang, CP | 1 |
| Li, TH | 1 |
| Wu, JW | 1 |
| Cai, GY | 1 |
| Tekuzman, G | 1 |
| Engin, H | 1 |
| Celik, I | 1 |
| Turker, A | 1 |
| Barista, I | 1 |
| Gullu, I | 1 |
| Guler, N | 1 |
| Ozisik, Y | 1 |
| Kars, A | 1 |
| Daban, A | 3 |
| Berger, C | 1 |
| Pierart, M | 2 |
| Briffaux, A | 2 |
| Okushiba, S | 1 |
| Katoh, H | 1 |
| Jingu, K | 1 |
| Nakajima, Y | 1 |
| Domper, M | 1 |
| Matute, R | 1 |
| Martínez-Lázaro, R | 1 |
| Arranz, JA | 3 |
| Desco, M | 1 |
| Carreras, JL | 1 |
| Ohashi, Y | 3 |
| Hamada, C | 2 |
| Burzykowski, T | 1 |
| Juska, P | 1 |
| Pranys, D | 1 |
| Hollis, DR | 2 |
| McCollum, AD | 1 |
| Brady, D | 1 |
| Heide, J | 1 |
| Krüll, A | 1 |
| Berger, J | 1 |
| Hong, TJ | 1 |
| Cohen, DP | 1 |
| Tyler, DS | 5 |
| Lee, CG | 1 |
| Anscher, MS | 5 |
| Ludwig, KA | 4 |
| Morse, MA | 3 |
| Petros, WP | 1 |
| Honeycutt, W | 2 |
| Spector, NL | 1 |
| Ertel, PJ | 1 |
| Mangum, SG | 1 |
| Hurwitz, HI | 3 |
| Moore, HG | 3 |
| Gittleman, AE | 1 |
| Wong, D | 2 |
| Yumuk, PF | 1 |
| Abacioglu, U | 1 |
| Caglar, H | 1 |
| Gumus, M | 1 |
| Sengoz, M | 1 |
| Turhal, NS | 1 |
| Farczádi, E | 2 |
| Kaszás, I | 2 |
| Baki, M | 1 |
| Szende, B | 2 |
| van Zuylen, L | 1 |
| Bridgewater, J | 1 |
| Sparreboom, A | 1 |
| Eskens, FA | 1 |
| de Bruijn, P | 1 |
| Sklenar, I | 1 |
| Planting, AS | 2 |
| Choi, L | 2 |
| Bootle, D | 1 |
| Mueller, C | 1 |
| Ledermann, JA | 1 |
| Verweij, J | 1 |
| Tomita, N | 1 |
| Monden, M | 1 |
| Imamura, M | 1 |
| Ohtoshi, M | 1 |
| Ohhashi, S | 1 |
| Tanigawa, N | 2 |
| Nakano, H | 1 |
| Hioki, K | 1 |
| Yasutomi, M | 6 |
| Yamamura, T | 6 |
| Kameyama, M | 1 |
| Iwanaga, T | 2 |
| Parulekar, W | 1 |
| de Marsh, RW | 1 |
| Mendenhall, W | 1 |
| Davey, P | 1 |
| Zlotecki, R | 1 |
| Rout, WR | 1 |
| Bjarnason, GA | 1 |
| Moutardier, V | 1 |
| Dzik-Jurasz, A | 1 |
| Nishida, O | 1 |
| Kunii, Y | 4 |
| Kodaira, S | 6 |
| Hojyo, K | 1 |
| Niimoto, M | 2 |
| Kunitomo, K | 2 |
| Isomoto, H | 2 |
| Ichimiya, H | 1 |
| Wakana, Y | 1 |
| Terashima, M | 2 |
| Taguchi, T | 6 |
| Fritzmann, J | 1 |
| Hünerbein, M | 2 |
| Slisow, W | 1 |
| Cohen, SM | 2 |
| Neugut, AI | 2 |
| Akaike, M | 1 |
| Shiraishi, R | 1 |
| Ozawa, Y | 1 |
| Makino, T | 1 |
| Tamura, I | 1 |
| Tanabe, H | 1 |
| Hildebrandt, B | 4 |
| Dräger, J | 1 |
| Lüdemann, L | 1 |
| Sreenivasa, G | 1 |
| Tullius, SG | 1 |
| Amthauer, H | 1 |
| Neuhaus, P | 2 |
| Felix, R | 6 |
| Huang, MJ | 1 |
| Lin, HC | 1 |
| Su, YW | 1 |
| Chang, YF | 1 |
| Chang, MC | 1 |
| Hsieh, RK | 2 |
| Akhurst, T | 2 |
| Klimstra, DS | 4 |
| Ruo, L | 4 |
| Larson, S | 2 |
| Pudełko, M | 1 |
| Szmeja, J | 1 |
| Słuszniak, J | 1 |
| Serkies, K | 2 |
| Pamucka, M | 1 |
| Kukołowicz, P | 1 |
| Osugi, H | 1 |
| Nishizawa, S | 1 |
| Iwasaki, H | 1 |
| Lim Joon, D | 1 |
| Zalcberg, JR | 1 |
| Terada, I | 1 |
| Yoshizumi, T | 1 |
| Takino, T | 1 |
| Nagai, N | 1 |
| Morita, A | 1 |
| Nishimura, G | 1 |
| Fujimura, T | 1 |
| Kanayama, T | 2 |
| Ishimaru, S | 1 |
| Mantini, G | 8 |
| Miccichè, F | 3 |
| Di Miceli, D | 1 |
| Rotondi, F | 1 |
| Vargas, JG | 1 |
| Rossi, C | 4 |
| Smaniotto, D | 1 |
| Garcia-Vargas, JE | 1 |
| Magistrelli, P | 2 |
| Wu, DH | 1 |
| Chen, LH | 1 |
| Eatock, M | 1 |
| Cassidy, J | 3 |
| Johnson, J | 1 |
| Morrison, R | 1 |
| Devlin, M | 1 |
| Blackey, R | 1 |
| Owen, S | 1 |
| Twelves, C | 1 |
| Gennatas, K | 1 |
| Skopelitis, HM | 1 |
| Zacharakis, M | 1 |
| Kouraklis, G | 1 |
| Felekouras, E | 1 |
| Zografos, G | 1 |
| Balafouta, M | 1 |
| Paraskevaidis, M | 1 |
| Safioleas, M | 1 |
| Fotiadis, K | 1 |
| Karatzas, G | 1 |
| Silva e Sousa, AH | 2 |
| Campos, FG | 4 |
| Kiss, DR | 3 |
| Hager, E | 1 |
| Yu, ZG | 1 |
| Sun, JZ | 1 |
| Jia, HY | 1 |
| Wang, JX | 1 |
| Bonnen, M | 1 |
| Skibber, J | 6 |
| Rodriguez-Bigas, M | 2 |
| Lin, E | 1 |
| Wong, A | 5 |
| Schwartz, GK | 1 |
| Meyer, W | 4 |
| Ohchi, T | 2 |
| Kikuchi, N | 1 |
| Muranaka, T | 2 |
| Ogawa, M | 6 |
| Araki, Y | 3 |
| Ueda, Y | 1 |
| Hagiwara, A | 5 |
| Yamagishi, H | 1 |
| Inaba, S | 1 |
| Yoshitani, S | 1 |
| Imaizumi, H | 1 |
| Kuroda, M | 1 |
| Yokoi, M | 1 |
| Harada, H | 1 |
| Kosaka, T | 2 |
| Takashima, S | 3 |
| Kiyonaga, H | 1 |
| Miyashita, K | 1 |
| Okumura, N | 1 |
| Morioka, N | 1 |
| Aizawa, K | 1 |
| Tsuchida, M | 1 |
| Wang, GQ | 2 |
| Liao, H | 1 |
| Kamoshida, S | 1 |
| Shimomura, R | 1 |
| Inada, K | 1 |
| Tsutsumi, Y | 1 |
| Lukaschek, J | 1 |
| Nufer, M | 1 |
| Maurer, D | 1 |
| Asanger, M | 1 |
| Honegger, H | 1 |
| Malet-Martino, M | 1 |
| Legay, R | 1 |
| Martino, R | 1 |
| Russo, V | 1 |
| Pasetto, L | 2 |
| Marino, F | 1 |
| Dodds, E | 1 |
| Cunningham, C | 1 |
| Ikemoto, T | 1 |
| Nishioka, M | 1 |
| Yawata, Y | 1 |
| Terashima, Y | 1 |
| Ikushima, H | 1 |
| Beart, R | 1 |
| Petrelli, N | 4 |
| von Gerstenberg-Helldorf, B | 1 |
| Gnad, U | 1 |
| Kraus-Tiefenbacher, U | 3 |
| Müldner, A | 1 |
| Hehlmann, R | 1 |
| Loi, S | 1 |
| Hicks, RJ | 1 |
| Mukesh, B | 1 |
| Mitchell, P | 3 |
| Lim-Joon, D | 1 |
| Rischin, D | 3 |
| Park, DJ | 2 |
| Lu, B | 1 |
| Yang, DY | 1 |
| Gordon, M | 2 |
| Groshen, S | 2 |
| Yun, J | 1 |
| Press, OA | 1 |
| Vallböhmer, D | 1 |
| Rhodes, K | 1 |
| Jenken, D | 2 |
| Heine, J | 2 |
| Buie, D | 2 |
| Johnson, D | 1 |
| Chen, CC | 1 |
| Lee, RC | 1 |
| Yokoyama, N | 3 |
| Goldstein, D | 4 |
| Friedlander, M | 2 |
| White, S | 2 |
| Nishida Arazawa, ST | 1 |
| Rawet, V | 1 |
| Coelho Siqueira, SA | 1 |
| Gama-Rodrigues, JJ | 1 |
| Hibi, K | 1 |
| Akiyama, S | 2 |
| Feyerherd, P | 1 |
| Ludwig, K | 6 |
| Foitzik, T | 3 |
| Coward, J | 1 |
| Maisey, N | 1 |
| Beppu, T | 1 |
| Ishiko, T | 1 |
| Sumitsuzi, A | 1 |
| Kamohara, H | 1 |
| Kuwahara, N | 1 |
| Morinaga, H | 1 |
| Egami, H | 1 |
| Yamagami, T | 1 |
| Hirota, T | 1 |
| Nishimura, T | 1 |
| Dong, QM | 1 |
| Zhou, ZM | 1 |
| Xia, ZJ | 1 |
| Li, YY | 1 |
| Mazeron, JJ | 1 |
| Johnstone, P | 1 |
| Ji, SH | 1 |
| Lim, DH | 1 |
| Park, BB | 1 |
| Park, KW | 1 |
| Kang, JH | 2 |
| Kim, WS | 1 |
| Jung, CW | 1 |
| Im, YH | 1 |
| Park, K | 1 |
| Vironen, J | 1 |
| Juhola, M | 1 |
| Kairaluoma, M | 1 |
| Jantunen, I | 1 |
| Kellokumpu, I | 1 |
| Mermershtain, W | 1 |
| Gluzman, A | 1 |
| Gusakova, I | 1 |
| Walfish, S | 1 |
| Cohen, Y | 3 |
| Ariad, S | 1 |
| Hobday, TJ | 1 |
| Sartor, L | 1 |
| Fabris, G | 3 |
| Urso, ED | 1 |
| Sotti, G | 1 |
| Monfardini, S | 1 |
| Fisher, R | 2 |
| Kneebone, A | 2 |
| Shin, SS | 2 |
| Choi, EK | 2 |
| Aguiar, S | 1 |
| Lopes, A | 4 |
| Soares, FA | 1 |
| Rossi, BM | 4 |
| Ferreira, FO | 1 |
| Nakagawa, WT | 4 |
| Carvalho, AL | 1 |
| Filho, WJ | 1 |
| Chao, M | 2 |
| Tjandra, J | 2 |
| Cullinan, M | 1 |
| McLaughlin, S | 2 |
| Skinner, I | 1 |
| Jones, I | 1 |
| Henri, M | 1 |
| Latulippe, JF | 1 |
| Heyen, F | 1 |
| Dubé, S | 1 |
| Focan, C | 2 |
| Kreutz, F | 2 |
| Longrée, L | 1 |
| Graas, MP | 1 |
| Focan-Henrard, D | 2 |
| Moeneclaey, N | 1 |
| David, A | 1 |
| Biquet, JF | 1 |
| Materne, R | 1 |
| Weerts, J | 2 |
| Delforge, M | 1 |
| Palmer, G | 1 |
| Martling, A | 1 |
| Cedermark, B | 2 |
| Nudelman, IL | 1 |
| Fuko, V | 1 |
| Geller, A | 1 |
| Fenig, E | 3 |
| Lelchuk, S | 1 |
| Wlodarczyk, W | 1 |
| Ganter, H | 1 |
| Nicolau, A | 1 |
| Fähling, H | 1 |
| Nadobny, J | 1 |
| Kopp, HG | 1 |
| Moerike, K | 1 |
| Kanz, L | 1 |
| Kitano, S | 2 |
| Inomata, M | 1 |
| Katz, MS | 1 |
| Chen, YJ | 1 |
| Choti, MA | 2 |
| Dilawari, RA | 1 |
| Enke, CA | 1 |
| Fuchs, C | 1 |
| Knol, JA | 2 |
| Leong, LA | 1 |
| Martin, EW | 1 |
| Yeatman, TJ | 1 |
| Shibata, H | 1 |
| Sakayori, M | 1 |
| Otsuka, K | 1 |
| Kakudo, Y | 1 |
| Yamaura, G | 1 |
| Ishioka, C | 1 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 2 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takemiya, S | 2 |
| Nishiyama, K | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 5 |
| Takeo, Y | 1 |
| Tanaka, S | 2 |
| Hayashi, T | 2 |
| Hanyu, F | 1 |
| Ryoo, BY | 1 |
| Ahn, JS | 1 |
| Kim, SR | 1 |
| Gubanski, M | 1 |
| Naucler, G | 1 |
| Almerud, A | 1 |
| Lideståhl, A | 1 |
| Lind, PA | 1 |
| Schiessel, R | 1 |
| Novi, G | 1 |
| Holzer, B | 1 |
| Rosen, HR | 1 |
| Renner, K | 1 |
| Hölbling, N | 1 |
| Feil, W | 1 |
| Urban, M | 1 |
| Kelley, ST | 1 |
| Coppola, D | 1 |
| Yeatman, T | 1 |
| Biondo, S | 1 |
| Marti-Rague, J | 1 |
| Arriola, E | 1 |
| Pares, D | 1 |
| Del Rio, C | 1 |
| Cambray, M | 1 |
| Novell, V | 1 |
| Jain, V | 1 |
| Bhandary, S | 1 |
| Prasad, GN | 1 |
| Shenoi, SD | 1 |
| Beresford, M | 1 |
| Richman, P | 2 |
| Makris, A | 2 |
| Stott, D | 1 |
| Osborne, M | 3 |
| Ashford, R | 2 |
| Grainger, J | 2 |
| Al-Jabbour, J | 1 |
| Talbot, I | 1 |
| Mitchell, IC | 2 |
| Meyrick Thomas, J | 1 |
| Livingstone, JI | 2 |
| McCue, J | 1 |
| MacDonald, P | 2 |
| Northover, JA | 1 |
| Windsor, A | 2 |
| Novell, R | 2 |
| Wallace, M | 3 |
| Harrison, RA | 2 |
| Hartley, A | 3 |
| Ho, KF | 1 |
| McConkey, C | 1 |
| Geh, JI | 2 |
| Hata, Y | 1 |
| Nakajima, N | 1 |
| Yokoyama, R | 1 |
| Sano, F | 1 |
| Akasaka, Y | 1 |
| Ohmori, K | 1 |
| Meyrick-Thomas, J | 1 |
| Duck, L | 2 |
| Honhon, B | 2 |
| Coster, B | 2 |
| Coche, JC | 2 |
| Humblet, Y | 2 |
| Kerger, J | 2 |
| Remouchamps, V | 1 |
| Canon, JL | 2 |
| Van Maele, P | 1 |
| Gilbeau, L | 1 |
| Laurent, S | 2 |
| Kirkove, C | 2 |
| Octave-Prignot, M | 1 |
| Baurain, JF | 1 |
| Kartheuser, A | 2 |
| Bisgaard, C | 1 |
| Hansen, JW | 1 |
| Wiltshire, KL | 1 |
| Ward, IG | 1 |
| Swallow, C | 1 |
| Oza, AM | 1 |
| Pond, GR | 1 |
| Catton, P | 1 |
| Wong, CS | 2 |
| Siu, LL | 1 |
| Moore, M | 1 |
| Brierley, J | 1 |
| Papadoupolos, T | 1 |
| Klimpfinger, M | 1 |
| Munn, LL | 1 |
| Tong, RT | 1 |
| Kozin, SV | 1 |
| Petit, L | 1 |
| Kalva, SP | 1 |
| Cohen, KS | 1 |
| Scadden, DT | 1 |
| Mino-Kenudson, M | 1 |
| Winkler-Spytkowska, B | 1 |
| Stryczyńska, G | 1 |
| Wieczorek, A | 1 |
| Rogowska, D | 1 |
| Tokar, P | 2 |
| Beretta, GD | 1 |
| Del Prete, S | 1 |
| Santantonio, M | 1 |
| Sarti, E | 1 |
| Innocente, R | 2 |
| Frustaci, S | 2 |
| Corvò, R | 1 |
| Rosso, R | 5 |
| Shirakawa, K | 3 |
| Sobajima, J | 1 |
| Nakada, H | 3 |
| Maughan, TS | 2 |
| Falk, SJ | 1 |
| McDonald, AC | 2 |
| Hong, CW | 2 |
| Lim, JF | 1 |
| Tjandra, JJ | 2 |
| Hiscock, R | 1 |
| Chao, MW | 2 |
| Bertheault-Cvitkovic, F | 1 |
| Thomas, O | 1 |
| Magnin, V | 2 |
| Cheon, SH | 1 |
| Schulthess, G | 1 |
| Kolyvanos Naumann, U | 1 |
| Käser, L | 1 |
| Vetter, W | 1 |
| Funabashi, M | 1 |
| Kamano, T | 1 |
| Pigeau, H | 1 |
| Dupré, PF | 1 |
| Benouna, J | 1 |
| Classe, JM | 1 |
| Pioud, R | 1 |
| Dravet, F | 1 |
| Watwe, V | 1 |
| Javle, M | 1 |
| Lawrence, D | 1 |
| Groth, J | 1 |
| Iyer, R | 1 |
| El-Hajjar, D | 1 |
| Geradts, J | 1 |
| Widder, J | 1 |
| Herbst, F | 1 |
| Matono, K | 2 |
| Sasatomi, T | 2 |
| Torigoe, S | 1 |
| Fukumitsu, T | 1 |
| Mizobe, T | 1 |
| Yamashita, N | 1 |
| Malani, AK | 1 |
| Gupta, C | 1 |
| Rangineni, S | 1 |
| Gupta, V | 1 |
| Ambrosini-Spaltro, A | 1 |
| Salvi, F | 1 |
| Betts, CM | 1 |
| Frezza, GP | 1 |
| Piemontese, A | 1 |
| Del Prete, P | 1 |
| Baldoni, C | 1 |
| Foschini, MP | 1 |
| Viale, G | 1 |
| Horton, PJ | 1 |
| Chaudhury, PK | 1 |
| Znajda, TL | 1 |
| Martinie, JB | 1 |
| Rochon, C | 1 |
| Tzimas, GN | 1 |
| Metrakos, P | 1 |
| Hoffman, J | 3 |
| Haluszka, O | 1 |
| Engstrom, P | 1 |
| Cheng, JD | 1 |
| Eisenberg, D | 1 |
| McGarrity, E | 1 |
| Freedman, G | 2 |
| Kanazawa, T | 1 |
| Kazama, Y | 1 |
| Cortés, J | 1 |
| Muñoz-Jiménez, F | 1 |
| Fujio, N | 1 |
| Ihara, T | 1 |
| Tsukazaki, T | 1 |
| Takatori, H | 1 |
| Koyama, I | 1 |
| Tsukazaki, Y | 1 |
| Ohsugi, H | 1 |
| Di Russo, A | 1 |
| Bolzicco, G | 1 |
| Dalla Palma, M | 1 |
| Löffel, J | 2 |
| Nicolaou, A | 1 |
| Le Coutre, P | 1 |
| Dörken, B | 1 |
| Park, YA | 3 |
| Seong, J | 1 |
| Cho, CW | 1 |
| Nichols, C | 1 |
| Shane, R | 1 |
| Fernando, NH | 1 |
| Mantyh, CR | 2 |
| Blobe, GC | 2 |
| Yu, D | 2 |
| Clary, BM | 2 |
| Pappas, TN | 3 |
| Tebbutt, N | 1 |
| Ross, PJ | 1 |
| Theisen, J | 1 |
| Kauer, WK | 1 |
| Nekarda, H | 1 |
| Schmid, L | 1 |
| Stein, HJ | 1 |
| Siewert, JR | 2 |
| Manno, A | 1 |
| Mattana, C | 3 |
| Verbo, A | 1 |
| Pedretti, G | 1 |
| Petito, L | 1 |
| Rizzo, G | 1 |
| Cosimelli, M | 6 |
| Impiombato, FA | 1 |
| Rouzbahman, M | 1 |
| Tsoussis, S | 1 |
| Vourliotaki, I | 1 |
| Ekonomidou, F | 1 |
| Apostolakis, S | 1 |
| Roncalli, J | 1 |
| Delord, JP | 1 |
| Galinier, M | 1 |
| Massabuau, P | 1 |
| Lescure, M | 1 |
| Fauvel, JM | 1 |
| Sopylo, R | 1 |
| Majewski, P | 1 |
| Sygut, J | 1 |
| Karmolinski, A | 1 |
| Huzarski, T | 1 |
| Wandzel, P | 1 |
| Spinnler, MT | 1 |
| Ardine, M | 1 |
| Küchenmeister, U | 4 |
| Beretta, E | 1 |
| Mancin, M | 1 |
| Dognini, G | 1 |
| Weissenberger, C | 1 |
| Geissler, M | 1 |
| Otto, F | 1 |
| Barke, A | 1 |
| Henne, K | 1 |
| von Plehn, G | 1 |
| Rein, A | 1 |
| Bartelt, S | 1 |
| Henke, M | 1 |
| Sengul, N | 1 |
| Woodhouse, S | 1 |
| Arrigain, S | 1 |
| Xu, M | 1 |
| Larach, JA | 1 |
| Ahn, BK | 1 |
| Weiss, EG | 1 |
| Nogueras, JJ | 1 |
| Mediema, BE | 1 |
| Wadler, S | 2 |
| Curr, N | 1 |
| Saunders, H | 1 |
| Murugasu, A | 1 |
| Schwarz, M | 1 |
| Gin, D | 1 |
| Wöhlke, M | 1 |
| Barten, M | 2 |
| Moreno-Vega, AL | 1 |
| Fuentes-Pradera, J | 1 |
| Gordón-Santiago, Mdel M | 1 |
| Vargas-Machuca, JC | 1 |
| Paek, SH | 1 |
| Xuan, JJ | 1 |
| Choi, HG | 1 |
| Park, BC | 1 |
| Lee, YS | 1 |
| Jeong, TC | 1 |
| Jin, CH | 1 |
| Oh, YK | 1 |
| Kim, JA | 1 |
| Serrano, FJ | 1 |
| Lozano, E | 1 |
| Garcia, R | 2 |
| de la Mata, D | 2 |
| Pérez-Manga, G | 1 |
| Miyata, Y | 1 |
| Muto, M | 1 |
| Mera, K | 1 |
| Yano, T | 1 |
| Tanigawara, Y | 1 |
| Zhang, ZG | 1 |
| Hu, JB | 1 |
| Sun, XN | 1 |
| Yang, QC | 1 |
| He, C | 1 |
| Burton, S | 1 |
| Daniels, I | 1 |
| Norman, A | 2 |
| Swift, I | 1 |
| Abulafi, M | 1 |
| Morton, DG | 1 |
| Yerushalmi, R | 2 |
| Dror, Y | 1 |
| Stemmer, SM | 1 |
| Figer, A | 1 |
| Loven, D | 2 |
| Dreznik, Z | 1 |
| Nudelman, I | 1 |
| Shani, A | 1 |
| Ferrigno, R | 2 |
| Novaes, PE | 2 |
| Silva, ML | 1 |
| Nishimoto, IN | 2 |
| Ferreira, Fde O | 1 |
| Smith, JL | 1 |
| Lawrence, DD | 1 |
| Schulze, T | 1 |
| Levy, LB | 1 |
| Thomas, H | 2 |
| Brinckmann, W | 1 |
| Friedrich, A | 1 |
| Kundt, G | 1 |
| Yoon, S | 1 |
| Schmassmann-Suhijar, D | 1 |
| Zuber, M | 1 |
| Konietzny, P | 1 |
| Schmassmann, A | 1 |
| Arraras Urdaniz, JI | 1 |
| Arias de la Vega, F | 1 |
| Vera García, R | 1 |
| Manterola Burgaleta, A | 1 |
| Martínez Aguillo, M | 1 |
| Villafranca Iturre, E | 1 |
| Salgado Pascual, E | 1 |
| Sánchez-Rovira, P | 1 |
| Vega-Villegas, ME | 1 |
| García, JL | 1 |
| Arai, Y | 2 |
| Takiuchi, H | 1 |
| Uemura, N | 1 |
| Li, SY | 1 |
| Yu, B | 1 |
| An, P | 1 |
| Cai, HY | 1 |
| Kim, JM | 1 |
| Nam, JS | 1 |
| Schneider, S | 1 |
| Yang, D | 1 |
| El-Khoueiry, A | 1 |
| Sherrod, A | 1 |
| Streeter, O | 1 |
| Iqbal, S | 1 |
| Danenberg, KD | 1 |
| Hao, SH | 1 |
| Liu, FL | 2 |
| Stipa, F | 1 |
| Aldaz, A | 1 |
| Zufía, L | 1 |
| Alvarado, A | 2 |
| Giráldez, J | 1 |
| De Salvo, GL | 1 |
| Ferraro, B | 2 |
| Bruttocao, A | 2 |
| Williamson, SK | 1 |
| Estes, NC | 3 |
| Maher, T | 1 |
| Kugler, JW | 1 |
| Pedersen, J | 1 |
| Periman, PO | 1 |
| Tanaka, MS | 1 |
| Tho, LM | 1 |
| Glegg, M | 1 |
| Paterson, J | 1 |
| Yap, C | 1 |
| MacLeod, A | 1 |
| McCabe, M | 1 |
| Benzoni, E | 1 |
| Terrosu, G | 1 |
| Bresadola, V | 1 |
| Cerato, F | 1 |
| Cojutti, A | 1 |
| Milan, E | 1 |
| Dado, G | 1 |
| Bresadola, F | 2 |
| Harashima, K | 1 |
| Nonaka, T | 1 |
| Mc Bride, WH | 1 |
| Kulle, B | 2 |
| Johnston, PG | 2 |
| Peng, YL | 1 |
| Gong, QF | 1 |
| Wand, ZQ | 1 |
| Anyamene, N | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Sonoda, K | 1 |
| Onohara, S | 1 |
| Hatanaka, S | 1 |
| Aridome, K | 1 |
| Okumura, H | 1 |
| Matsumoto, M | 2 |
| Aikou, T | 2 |
| DeSalvo, GL | 1 |
| Rugge, M | 1 |
| Frego, M | 1 |
| Finco, C | 1 |
| Grobholz, R | 2 |
| Heeger, S | 1 |
| Ryu, SY | 1 |
| Choi, SI | 1 |
| Closon-Dejardin, MT | 1 |
| Untereiner, M | 2 |
| Leduc, B | 1 |
| Buecher, B | 1 |
| Mackiewicz, R | 1 |
| Brown, TD | 3 |
| Castri, F | 1 |
| Parello, A | 1 |
| Vecchio, FM | 4 |
| Movsas, B | 2 |
| Diratzouian, H | 1 |
| Hanlon, A | 1 |
| Weiner, LM | 3 |
| Coia, L | 1 |
| Lanciano, R | 2 |
| Stein, J | 1 |
| Kister, D | 1 |
| Eisenberg, B | 1 |
| Kendal, WS | 1 |
| Jonker, D | 1 |
| Stern, H | 1 |
| Moyana, T | 1 |
| Elfiky, A | 1 |
| Diasio, R | 1 |
| Yamane, M | 1 |
| Miyatani, K | 1 |
| Udaka, T | 2 |
| Kubo, M | 2 |
| Hosokawa, N | 1 |
| Suwaki, K | 1 |
| Haraguchi, Y | 1 |
| Sakamoto, F | 1 |
| Toyoyama, H | 1 |
| Kamikado, C | 1 |
| Tsuchiya, M | 1 |
| Takita, W | 1 |
| Otsuka, Y | 1 |
| Koshino, H | 1 |
| Kurihara, A | 1 |
| Kaneko, H | 1 |
| Teramoto, T | 3 |
| Strojan, P | 1 |
| Zakotnik, B | 1 |
| Lisi, V | 1 |
| Bhatia, S | 1 |
| Unsal Kilic, D | 1 |
| Uner, A | 1 |
| Akyurek, N | 1 |
| Erpolat, P | 1 |
| Dursun, A | 1 |
| Pak, Y | 1 |
| Lee, YC | 1 |
| Cho, CH | 2 |
| Son, SH | 1 |
| Fukada, T | 1 |
| Yasuno, K | 1 |
| Koyama, T | 1 |
| Seike, K | 1 |
| Kametaka, H | 1 |
| Hashimoto, R | 1 |
| Kawano, H | 1 |
| Hasegawa, A | 1 |
| Dymecki, D | 1 |
| Pawlak, M | 1 |
| Tytherleigh, MG | 1 |
| Birtle, AJ | 1 |
| Cohen, CE | 1 |
| Livingstone, J | 1 |
| Gilbert, J | 1 |
| Spitaleri, G | 1 |
| Zampino, G | 1 |
| Hoecht, S | 1 |
| Hinkelbein, W | 1 |
| Kiss, D | 1 |
| Eriksen, MT | 1 |
| Wibe, A | 1 |
| Haffner, J | 1 |
| Fürst, A | 1 |
| Schwella, N | 1 |
| Bieker, M | 1 |
| Hellmich, G | 1 |
| Ewald, H | 1 |
| Haier, J | 1 |
| Lordick, F | 2 |
| Choi, WS | 1 |
| Horváth Ors, P | 1 |
| Papp, A | 1 |
| Kalmár, K | 1 |
| Cseke, L | 1 |
| Yousuf, AF | 1 |
| Esik, O | 1 |
| Veerasarn, V | 1 |
| Phromratanapongse, P | 1 |
| Lorvidhaya, V | 2 |
| Lertsanguansinchai, P | 1 |
| Lertbutsayanukul, C | 1 |
| Panichevaluk, A | 1 |
| Boonnuch, W | 1 |
| Chinswangwatanakul, V | 1 |
| Lohsiriwat, D | 1 |
| Rojanasakul, A | 1 |
| Thavichaigarn, P | 1 |
| Jivapaisarnpong, P | 1 |
| Daisne, JF | 1 |
| Bonny, MA | 1 |
| Matsuo, A | 1 |
| Otao, R | 1 |
| Amano, M | 1 |
| Niinobu, T | 3 |
| Nishikawa, Y | 1 |
| Nakagawa, S | 1 |
| Higaki, N | 1 |
| Hayashida, H | 1 |
| Cicin, I | 1 |
| Karagol, H | 1 |
| Uzunoglu, S | 1 |
| Uygun, K | 1 |
| Tsuji, Y | 1 |
| Tsushima, T | 1 |
| Ohura, K | 1 |
| Sumiyoshi, T | 1 |
| Yoshizaki, N | 1 |
| Kondo, H | 1 |
| Reddy, N | 1 |
| Leitner, A | 1 |
| Willer, A | 1 |
| Diaz-Gonzalez, J | 1 |
| Beunza, JJ | 1 |
| Alvarez-Cienfuegos, JA | 1 |
| Kamoshita, N | 1 |
| Makita, F | 1 |
| Matsuzaki, Y | 1 |
| Kabeya, K | 1 |
| Zhao, ZY | 1 |
| Xu, N | 1 |
| Wu, CP | 1 |
| Xu, LG | 1 |
| Freedman, GM | 1 |
| Callahan, E | 1 |
| Price, R | 1 |
| Cohen, S | 1 |
| Lewis, N | 1 |
| Watkins-Bruner, D | 1 |
| Rogatko, A | 1 |
| Horikoshi, H | 1 |
| Motegi, K | 1 |
| Tomozawa, S | 1 |
| Hirayama, I | 1 |
| Sawada, T | 5 |
| Asoglu, O | 1 |
| Karanlik, H | 1 |
| Muslumanoglu, M | 1 |
| Igci, A | 1 |
| Emek, E | 1 |
| Ozmen, V | 1 |
| Kecer, M | 1 |
| Parlak, M | 1 |
| Kapran, Y | 1 |
| Cambray i Amenós, M | 1 |
| Navarro García, M | 1 |
| Martí Ragué, J | 1 |
| Pareja Fernández, L | 1 |
| Pera Fábregas, J | 1 |
| Meadows, H | 1 |
| Wood, W | 1 |
| Dolinsky, CM | 1 |
| Mick, R | 1 |
| Whittington, RW | 1 |
| Solin, LJ | 1 |
| Rosato, EF | 2 |
| Metz, JM | 1 |
| de Gramont, A | 3 |
| Tournigand, C | 2 |
| Larsen, AK | 1 |
| Louvet, C | 4 |
| Coma-Canella, I | 1 |
| Iwata, S | 1 |
| Imai, S | 1 |
| Mochiduki, H | 1 |
| Imazeki, M | 1 |
| Kaneko, J | 1 |
| Taguchi, Y | 1 |
| Suzuki, C | 1 |
| Lorchel, F | 1 |
| Peignaux, K | 1 |
| Bosset, M | 2 |
| Puyraveau, M | 1 |
| Mercier, M | 2 |
| Thomas, J | 1 |
| Ashton, J | 1 |
| Kaminski, A | 1 |
| Nabhan, C | 1 |
| Ragam, A | 1 |
| Samuels, B | 1 |
| Milton, DT | 1 |
| Prasad, L | 1 |
| Hooberman, A | 1 |
| Hartsell, W | 1 |
| Anthony, A | 1 |
| Weisman, R | 1 |
| Bitran, JD | 2 |
| Raman, AK | 1 |
| Lay, GC | 1 |
| Caraul, B | 1 |
| Dessì, M | 1 |
| Orrù, S | 1 |
| Murtas, R | 1 |
| Deidda, MA | 1 |
| Farigu, R | 1 |
| Farci, D | 1 |
| Maxia, L | 1 |
| Casula, G | 2 |
| Amichetti, M | 1 |
| Tampellini, M | 1 |
| Brizzi, MP | 1 |
| Bitossi, R | 1 |
| Alabiso, I | 1 |
| Sculli, CM | 1 |
| Chiusa, L | 1 |
| Papotti, M | 1 |
| Dogliotti, L | 1 |
| Kuo, LJ | 1 |
| Liu, MC | 1 |
| Jian, JJ | 1 |
| Horng, CF | 1 |
| Cheng, TI | 1 |
| Chen, CM | 1 |
| Fang, WT | 1 |
| Chung, YL | 1 |
| Mizukami, H | 1 |
| Yoshizawa, Y | 1 |
| Sasaya, S | 1 |
| Nemoto, H | 1 |
| Maezawa, K | 1 |
| Sanada, Y | 1 |
| Lin, HY | 1 |
| Jen, YM | 1 |
| Ezra, P | 1 |
| Sørensen, NM | 1 |
| Brünner, N | 1 |
| Munakata, M | 1 |
| Muto, O | 1 |
| Kasai, M | 2 |
| Okada, R | 1 |
| Mitobe, S | 1 |
| Sakata, Y | 1 |
| Paran, H | 1 |
| Edelstein, E | 1 |
| Klein, B | 1 |
| Gutman, M | 1 |
| Cao, WG | 1 |
| Xi, WQ | 1 |
| Xu, HP | 1 |
| Che, JF | 1 |
| Jin, YN | 1 |
| Punt, CJ | 1 |
| Tesselaar, ME | 1 |
| Leer, JW | 1 |
| Jansen, EP | 1 |
| Van Krieken, HH | 1 |
| Nahas, CS | 1 |
| Joseph, R | 1 |
| Tang, LH | 1 |
| Choi, MY | 1 |
| Hur, C | 1 |
| Kubosova, K | 1 |
| Chrenko, V | 1 |
| Roubalova, E | 1 |
| Krejci, E | 1 |
| Slampa, P | 1 |
| Frgala, T | 1 |
| Zaloudik, J | 1 |
| Baron, M | 1 |
| Resch, B | 1 |
| Tenière, P | 1 |
| Rives, N | 1 |
| Shi, YX | 1 |
| Sanghera, P | 2 |
| Ho, K | 1 |
| Muscroft, T | 1 |
| Desai, SP | 1 |
| El-Rayes, BF | 1 |
| Ben-Josef, E | 2 |
| Greenson, JK | 1 |
| Huang, EH | 1 |
| Griffith, KA | 1 |
| Philip, PA | 1 |
| McGinn, CJ | 1 |
| Zalupski, MM | 1 |
| Sagol, O | 1 |
| Atila, K | 1 |
| Sonmez, D | 1 |
| Iqbal, K | 2 |
| Chu, Q | 1 |
| Mei, Q | 1 |
| Grillo-Ruggieri, F | 1 |
| Cardinali, M | 1 |
| Fenu, F | 1 |
| Iovini, G | 1 |
| Montisci, M | 1 |
| Fabbietti, L | 1 |
| Marmorale, C | 1 |
| Saba, V | 2 |
| Bearzi, I | 1 |
| Mattioli, R | 1 |
| Bonsignori, M | 1 |
| Gunnlaugsson, A | 1 |
| Kjellén, E | 1 |
| Nilsson, P | 1 |
| Bendahl, PO | 1 |
| Johnsson, A | 1 |
| Be'ery, E | 1 |
| Koren, C | 1 |
| Lavi, I | 1 |
| Shaked, Y | 1 |
| de la Torre, A | 1 |
| García-Berrocal, MI | 1 |
| Mariño, A | 1 |
| Valcárcel, F | 1 |
| Magallón, R | 1 |
| Regueiro, CA | 1 |
| Romero, J | 1 |
| Zapata, I | 1 |
| de la Fuente, C | 1 |
| Fernández-Lizarbe, E | 1 |
| Vergara, G | 1 |
| Belinchón, B | 1 |
| Veiras, M | 1 |
| Molerón, R | 1 |
| Millán, I | 1 |
| Topkan, E | 1 |
| Karaoglu, A | 1 |
| Czaykowski, PM | 1 |
| Iesalnieks, I | 1 |
| Siperstein, AE | 1 |
| Berber, E | 1 |
| Ballem, N | 1 |
| Parikh, RT | 1 |
| Lim, L | 1 |
| Shapiro, J | 1 |
| Millar, JL | 2 |
| Kipp, D | 1 |
| Rezo, A | 1 |
| Fong, A | 1 |
| Nguyen, F | 2 |
| Sedrati, A | 1 |
| Lorgis, V | 1 |
| Lockman, D | 1 |
| den Dulk, M | 1 |
| Hashmi, S | 1 |
| Zelterman, D | 1 |
| La Torre, G | 1 |
| Portaluri, M | 1 |
| Maurizi-Enrici, R | 1 |
| Barbera, F | 1 |
| Jung, EJ | 2 |
| Tashima, R | 1 |
| Matsuda, M | 1 |
| Pinsk, I | 1 |
| Phang, PT | 1 |
| Mori, T | 3 |
| Craven, I | 1 |
| Crellin, A | 1 |
| Cooper, R | 1 |
| Melcher, A | 1 |
| Byrne, P | 1 |
| Tummala, R | 1 |
| Kisiel, ND | 1 |
| Diegelman, P | 1 |
| Vujcic, S | 1 |
| Clark, K | 1 |
| Kramer, DL | 1 |
| Porter, CW | 1 |
| Young Kim, W | 1 |
| Fukunaga, S | 1 |
| Kaizaki, R | 1 |
| Shinto, O | 1 |
| Wada, K | 1 |
| Fujisawa, M | 1 |
| Ono, S | 1 |
| Nakayama, Y | 1 |
| Nitta, S | 1 |
| Ishiyama, S | 1 |
| Shinjou, K | 1 |
| Machida, M | 1 |
| Kitabatake, T | 1 |
| Ishibiki, Y | 1 |
| Urao, M | 1 |
| Bona, S | 1 |
| Romario, UF | 1 |
| Elmore, U | 1 |
| Furlan, N | 1 |
| Hirayama, Y | 1 |
| Konuma, Y | 1 |
| Kohda, K | 1 |
| Yoshida, M | 1 |
| Nakamura, Y | 2 |
| Obata, M | 1 |
| Gong, ZJ | 1 |
| Ren, JQ | 1 |
| Kong, G | 1 |
| Qing, DJ | 1 |
| Liang, YQ | 1 |
| Garrido, M | 1 |
| O'Brien, A | 1 |
| González, S | 1 |
| Clavero, JM | 1 |
| Orellana, E | 1 |
| Jida, M | 1 |
| Waki, N | 1 |
| Sogabe, O | 1 |
| Campanini, N | 1 |
| Ceccon, G | 1 |
| Martinelli, R | 1 |
| Fumagalli, M | 1 |
| Bordi, C | 1 |
| Timova, LN | 1 |
| DiSiena, M | 1 |
| Gustafson, E | 1 |
| Aristu, JJ | 2 |
| Azcona, JD | 1 |
| García-Foncillas, JM | 1 |
| Chitapanarux, I | 1 |
| Kamnerdsupaphon, P | 1 |
| Siriwittayakorn, P | 1 |
| Tharavichitkul, E | 1 |
| Somwangprasert, A | 1 |
| Sukthomya, V | 1 |
| Leon, R | 1 |
| Riedel, ER | 1 |
| Beg, MS | 1 |
| Komrokji, RS | 1 |
| Ahmed, K | 1 |
| Safa, MM | 1 |
| Ohta, H | 1 |
| De Bie, T | 1 |
| Wong, DW | 1 |
| McConkey, CC | 1 |
| Ledbetter, L | 1 |
| Gallego-Plazas, J | 1 |
| Menarguez-Pina, F | 1 |
| Pons-Sanz, V | 1 |
| Ballester-Navarro, I | 1 |
| Choi, JH | 1 |
| Charúa-Guindic, L | 1 |
| de Bruin, AF | 1 |
| Ferenschild, FT | 1 |
| de Wilt, JH | 1 |
| Milani, V | 1 |
| Pazos, M | 1 |
| Buecklein, V | 1 |
| Rahman, S | 1 |
| Tschoep, K | 1 |
| Duehmke, E | 1 |
| Wang, JP | 1 |
| Ding, WX | 1 |
| Deng, YH | 1 |
| Pan, K | 1 |
| Dong, GH | 1 |
| Deng, JZ | 1 |
| Guo, XF | 1 |
| Werbrouck, BF | 1 |
| Pauwels, WJ | 1 |
| De Bleecker, JL | 1 |
| Hess, V | 1 |
| Heitzmann, F | 1 |
| Ruhstaller, T | 1 |
| Terraciano, L | 1 |
| Neuweiler, J | 1 |
| Bieri, G | 1 |
| Rust, C | 1 |
| Toepfer, M | 1 |
| Iles, S | 1 |
| Biswas, A | 1 |
| Gensheimer, M | 1 |
| Jones, CA | 1 |
| Graves, CR | 1 |
| Merchant, NB | 1 |
| Kadikoylu, G | 1 |
| Yavasoglu, I | 1 |
| Barutca, S | 1 |
| Meydan, N | 1 |
| Bolaman, Z | 1 |
| Boz, G | 1 |
| Frattegiani, A | 1 |
| Heudel, P | 1 |
| Falandry, C | 1 |
| You, B | 1 |
| Glehen, O | 1 |
| Nobuhara, Y | 1 |
| Sunami, T | 1 |
| Kanemura, M | 1 |
| Yo, T | 1 |
| Vie, B | 1 |
| Noirclerc, M | 1 |
| Bennamoun, M | 2 |
| Jacob, JH | 1 |
| Mundt, P | 1 |
| Mochmann, HC | 1 |
| Ebhardt, H | 1 |
| Zeitz, M | 1 |
| Duchmann, R | 1 |
| Pauschinger, M | 1 |
| Wang, JW | 1 |
| Wang, K | 1 |
| Zhou, AP | 1 |
| Yap, T | 1 |
| Zia, A | 1 |
| McDonald, PJ | 1 |
| Furuta, R | 1 |
| Ina, K | 1 |
| Nagao, S | 1 |
| Kayukawa, S | 1 |
| Mori, F | 1 |
| Masaki, A | 1 |
| Yamafuji, K | 1 |
| Asami, A | 1 |
| Takeshima, K | 1 |
| Ichisaka, S | 1 |
| Matsui, J | 1 |
| Gorgun, B | 2 |
| Goplerud, DR | 1 |
| Watne, AL | 2 |
| Balch, CM | 3 |
| Urist, MM | 2 |
| Hartenstein, R | 1 |
| Ehrhart, H | 1 |
| Possinger, K | 1 |
| Grage, TB | 5 |
| Moss, SE | 5 |
| Gustavsson, B | 5 |
| Hafström, L | 9 |
| Pant, KD | 1 |
| Shochat, D | 1 |
| Nelson, MO | 1 |
| Goldenberg, DM | 1 |
| Arnott, SJ | 3 |
| Theodors, A | 1 |
| Bukowski, RM | 3 |
| Lavery, I | 1 |
| Hewlett, JS | 1 |
| Livingston, RB | 1 |
| Buonocore, E | 1 |
| Gilbert, JM | 3 |
| Houghton, JA | 3 |
| Houghton, PJ | 3 |
| Wassif, SB | 3 |
| Heim, ME | 3 |
| Eberwein, S | 1 |
| Georgi, M | 1 |
| Kemeny, NE | 1 |
| Ahmed, T | 1 |
| Michaelson, RA | 1 |
| Harper, HD | 1 |
| Yip, LC | 1 |
| Higgins, GA | 5 |
| Donaldson, RC | 1 |
| Rogers, LS | 1 |
| Juler, GL | 1 |
| Keehn, RJ | 2 |
| Au, JL | 1 |
| Ledesma, EJ | 1 |
| Mittelman, A | 14 |
| Creaven, PJ | 3 |
| Queisser, W | 3 |
| Togni, P | 1 |
| Sessa, C | 1 |
| Varini, M | 1 |
| Cavalli, F | 2 |
| Kemeny, N | 21 |
| Yagoda, A | 3 |
| Braun, D | 3 |
| Presant, CA | 5 |
| Ardalan, B | 2 |
| Multhauf, P | 4 |
| Chan, C | 1 |
| Staples, R | 1 |
| Green, L | 1 |
| Browning, S | 2 |
| Carr, BI | 2 |
| Chang, FF | 1 |
| Thayer, W | 1 |
| Oberfield, RA | 4 |
| Huberman, MS | 3 |
| Weltz, MD | 1 |
| Perry, DJ | 1 |
| Blom, J | 1 |
| Butler, WM | 1 |
| Brückner, R | 2 |
| Rothmund, M | 1 |
| Hinterberger, R | 1 |
| Stagg, RJ | 1 |
| Lewis, BJ | 1 |
| Friedman, MA | 2 |
| Ignoffo, RJ | 1 |
| Hohn, DC | 1 |
| Benedetti, A | 1 |
| Carassai, A | 1 |
| Catalini, VL | 1 |
| Nosdeo, A | 1 |
| Potestà, P | 1 |
| Manguso, L | 1 |
| Coraggio, F | 1 |
| Grimaldi, G | 1 |
| Zito, GA | 1 |
| Grimaldi, F | 1 |
| Vespoli, F | 1 |
| Gentile, B | 1 |
| Grieco, A | 2 |
| Lasorella, A | 1 |
| Astone, A | 2 |
| Vagliviello, L | 1 |
| Bartoloni, C | 1 |
| Barone, C | 3 |
| Trotter, GA | 1 |
| Morgan, GR | 1 |
| Goeting, N | 1 |
| Cooper, AJ | 1 |
| Machover, D | 5 |
| Schwarzenberg, L | 5 |
| Goldschmidt, E | 5 |
| Michalski, B | 2 |
| Hayat, M | 2 |
| Dorval, T | 2 |
| Misset, JL | 6 |
| Delouche, C | 1 |
| Brochon, D | 1 |
| Fraioli, JP | 1 |
| Jasmin, C | 3 |
| Maral, R | 2 |
| Mathe, G | 4 |
| von der Maase, H | 2 |
| Magnusson, K | 1 |
| Sveinsson, T | 1 |
| Steele, G | 4 |
| Osteen, RT | 1 |
| Wilson, RE | 2 |
| Brooks, DC | 1 |
| Zamcheck, N | 1 |
| Ravikumar, TS | 2 |
| Herrmann, R | 4 |
| Spehn, J | 1 |
| Beyer, JH | 2 |
| von Franqué, U | 1 |
| Schmieder, A | 1 |
| Holzmann, K | 2 |
| Abel, U | 1 |
| Kopper, L | 1 |
| Magyarosy, E | 1 |
| Jeney, A | 1 |
| Lapis, K | 1 |
| Szabolcs, A | 1 |
| Otvös, L | 1 |
| Madajewicz, S | 2 |
| Campbell, J | 1 |
| Herrera, L | 6 |
| Perry, A | 1 |
| House, AK | 2 |
| Maley, MA | 2 |
| Gough, IR | 2 |
| Furnival, CM | 1 |
| Smith, BJ | 1 |
| Ashford, RF | 1 |
| Bakowski, M | 1 |
| Hellman, K | 1 |
| Newton, K | 1 |
| Phillips, R | 1 |
| Lambert, J | 1 |
| Peters, N | 1 |
| Evans, M | 1 |
| Amadeo, JH | 1 |
| McElhinney, J | 1 |
| McCaughan, JJ | 1 |
| Aigner, KR | 2 |
| Walther, H | 3 |
| Tonn, JC | 2 |
| Schoch, P | 1 |
| Schwemmle, K | 5 |
| Denes, AE | 1 |
| Bartolucci, AA | 1 |
| Hine, KR | 1 |
| Dykes, PW | 1 |
| Coates, AS | 1 |
| Tattersall, MH | 3 |
| Swanson, C | 2 |
| Hedley, D | 1 |
| Fox, RM | 1 |
| Raghavan, D | 2 |
| Komov, DV | 1 |
| Roshchin, EM | 1 |
| Chernova, MV | 1 |
| Dolgushin, BI | 1 |
| MacIntyre, JM | 4 |
| Klaassen, DJ | 5 |
| Knysh, VI | 5 |
| Aliev, BM | 1 |
| Dvoĭrin, VV | 1 |
| Sparsø, BH | 1 |
| Kristensen, D | 1 |
| Christiansen, J | 1 |
| Damgaard Nielsen, SA | 1 |
| Hebjørn, M | 1 |
| Andersen, B | 1 |
| Xavier, AM | 1 |
| Kasimis, BS | 1 |
| Wu, SY | 1 |
| Kaneshiro, CA | 1 |
| Bedikian, AY | 6 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Bodey, GP | 8 |
| Hojo, K | 3 |
| Tsunematsu, R | 1 |
| Schutt, AJ | 8 |
| Rubin, J | 5 |
| Creagan, ET | 1 |
| Saji, S | 2 |
| Kajima, T | 1 |
| Takao, H | 2 |
| Ban, K | 1 |
| Ohashi, H | 1 |
| Kunieda, T | 1 |
| Sakata, K | 1 |
| Kimoto, Y | 1 |
| Oota, J | 1 |
| Falkson, G | 2 |
| Pretorius, HL | 1 |
| Falkson, HC | 2 |
| Schoeman, HS | 1 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Boulis-Wassif, S | 1 |
| Gerard, A | 5 |
| Loygue, J | 1 |
| Camelot, D | 1 |
| Duez, N | 4 |
| Beck, TM | 2 |
| Curtis, PW | 1 |
| Woodard, DA | 2 |
| Hart, NE | 2 |
| Smith, CE | 2 |
| Sekine, S | 1 |
| Katsumi, S | 1 |
| Mukae, S | 1 |
| Furukawa, R | 1 |
| Watanabe, I | 1 |
| Duprat, G | 1 |
| Chalaoui, J | 1 |
| Sylvestre, J | 1 |
| Simard, P | 1 |
| Potvin, C | 1 |
| Cantin, J | 1 |
| Robidoux, A | 1 |
| Kumazawa, H | 1 |
| Fukaya, Y | 1 |
| Miyazaki, I | 2 |
| Zhou, XG | 3 |
| Lagomarsino Caprino, MC | 1 |
| Mazzei, T | 1 |
| De Vecchis, L | 4 |
| Popoli, P | 1 |
| Periti, P | 1 |
| Iliiazov, AI | 1 |
| Akao, S | 1 |
| Sternberg, A | 1 |
| Au, J | 1 |
| Rustum, Y | 3 |
| Creaven, P | 4 |
| Kvols, LK | 2 |
| Finan, PJ | 3 |
| Koklitis, PA | 1 |
| Chisholm, EM | 3 |
| Giles, GR | 5 |
| Martin, F | 1 |
| Kao, AK | 1 |
| Muggia, FM | 4 |
| Dubin, N | 1 |
| Lerner, WA | 1 |
| Stark, R | 1 |
| Wernz, JC | 2 |
| Speyer, JL | 2 |
| Blum, RH | 2 |
| Rabinovich, MG | 2 |
| Perez, JE | 2 |
| Macchiavelli, M | 2 |
| Kremer, A | 1 |
| Leone, BA | 2 |
| Strauss, E | 2 |
| Wils, J | 4 |
| Schlangen, J | 2 |
| Naus, A | 2 |
| Droz, JP | 2 |
| Kac, J | 1 |
| Spielmann, M | 1 |
| Crespon, B | 1 |
| Ley, G | 1 |
| Zimmermann, P | 1 |
| Theodore, C | 2 |
| Chavy, A | 1 |
| Kolarić, K | 2 |
| Windschitl, H | 1 |
| Scott, M | 3 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 2 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Schulz, A | 1 |
| Kracht, J | 1 |
| von Heyden, HW | 1 |
| Bartsch, HH | 1 |
| Klee, M | 1 |
| Nagel, GA | 2 |
| Schuster, R | 1 |
| von Romatowski, HJ | 1 |
| Bengmark, S | 5 |
| Nobin, A | 1 |
| Jeppsson, B | 3 |
| Tranberg, KG | 3 |
| Aigner, K | 2 |
| Tonn, J | 1 |
| Wenzl, A | 2 |
| Hechtel, R | 1 |
| Merker, G | 2 |
| Liberati, AM | 2 |
| Di Costanzo, F | 2 |
| Buzzi, F | 2 |
| Fatati, G | 2 |
| Biscottini, B | 2 |
| Ballatori, E | 1 |
| Falchi, R | 1 |
| Grignani, F | 2 |
| Fleischer, I | 2 |
| Wainstein, R | 2 |
| de Gibson, AS | 1 |
| Kaye, SB | 2 |
| Sangster, G | 1 |
| Hutcheon, A | 1 |
| Habeshaw, T | 2 |
| Crossling, F | 1 |
| Ferguson, C | 1 |
| McArdle, C | 1 |
| Smith, D | 1 |
| George, WD | 1 |
| Calman, KC | 2 |
| Niederle, N | 2 |
| Kurschel, E | 2 |
| Schmidt, CG | 1 |
| Bertoldi, I | 1 |
| Barzi, A | 1 |
| Cavaleri, V | 1 |
| D'Avena, C | 1 |
| Mangialardi, N | 1 |
| Chirletti, P | 1 |
| Kikuchi, K | 4 |
| Anderson, JM | 1 |
| Fujimoto, S | 3 |
| Kitsukawa, Y | 2 |
| Okui, K | 3 |
| Mechl, Z | 1 |
| Gisselbrecht, C | 1 |
| Belpomme, D | 1 |
| Mignot, L | 1 |
| Marty, M | 2 |
| Boiron, M | 1 |
| Cowan, JD | 1 |
| Easterbrock, J | 1 |
| Mills, GM | 1 |
| McCracken, JD | 3 |
| Ahmann, FR | 2 |
| de Gibson, AM | 1 |
| Mazzucco, G | 1 |
| Fornari, G | 1 |
| Monga, G | 1 |
| Kuwashima, T | 1 |
| Korematsu, H | 1 |
| Yoshikawa, H | 1 |
| Toyosaki, M | 1 |
| Komi, N | 2 |
| Ushijima, Y | 1 |
| Uematsu, Y | 1 |
| Douglass, HO | 8 |
| Muggia, F | 2 |
| Bleiberg, H | 6 |
| Thompson, EM | 1 |
| Slavin, G | 1 |
| Kark, AE | 1 |
| Moayeri, H | 2 |
| DiBenedetto, J | 2 |
| Choy, DS | 1 |
| Newman, H | 1 |
| Vieta, J | 1 |
| Weinerman, B | 1 |
| Schacter, B | 1 |
| Schipper, H | 1 |
| Bowman, D | 1 |
| Levitt, M | 3 |
| Mavligit, GM | 8 |
| White, DR | 2 |
| Richards, F | 3 |
| Muss, HB | 2 |
| Cooper, MR | 3 |
| Spurr, CL | 3 |
| Valdivieso, M | 6 |
| Vogl, SE | 2 |
| Lanham, R | 2 |
| Kaplan, BH | 3 |
| Bonomi, PD | 1 |
| Chandra, G | 1 |
| Rossof, AH | 1 |
| Klaassen, D | 1 |
| Vaughn, CB | 2 |
| Chapman, JL | 1 |
| Garland, M | 2 |
| Pederson, B | 2 |
| Demitrish, MM | 2 |
| Chinn, B | 2 |
| Ward, D | 2 |
| Brady, PR | 1 |
| Payne, JE | 2 |
| Pheils, MT | 2 |
| MacPherson, JG | 2 |
| Bancewicz, J | 1 |
| Macpherson, SG | 1 |
| McArdle, CS | 3 |
| McVie, JG | 1 |
| Soukop, M | 1 |
| Cassell, PC | 1 |
| Ellis, H | 1 |
| Wastell, C | 1 |
| Hellmann, K | 1 |
| Evans, MG | 1 |
| Stoodley, BJ | 1 |
| Eriksson, S | 1 |
| Hugander, A | 1 |
| Solan, A | 1 |
| Berenzweig, M | 1 |
| Richard, J | 1 |
| Trux, F | 1 |
| Kohno, K | 1 |
| Narisawa, T | 1 |
| Manegold, C | 2 |
| Fritze, D | 1 |
| Kies, MS | 1 |
| Navarra, S | 1 |
| Melita, P | 1 |
| Di Mauro, S | 1 |
| Cantrell, JE | 2 |
| Brunet, R | 2 |
| Lagarde, C | 1 |
| Schein, PS | 7 |
| Smith, FP | 1 |
| Robinson, E | 2 |
| Bartal, A | 2 |
| Mohilever, J | 1 |
| Mekori, T | 2 |
| Sokolova, VD | 2 |
| Platinskiĭ, LV | 2 |
| Ozhiganov, EL | 2 |
| Chebotareva, LI | 1 |
| Stroehlein, JR | 1 |
| Karlin, DA | 2 |
| Bennetts, RW | 1 |
| Whitehouse, JM | 1 |
| Duncan, W | 1 |
| Windschitl, HE | 1 |
| Krook, JE | 6 |
| Everson, LK | 3 |
| Cullinan, SA | 2 |
| Volberding, PA | 1 |
| Resser, KJ | 1 |
| Phillips, TL | 1 |
| Brahams, D | 1 |
| Seifart, W | 2 |
| Marx, G | 2 |
| Krahl, M | 1 |
| Hayakawa, M | 1 |
| Oouchi, A | 1 |
| Ariel, IM | 4 |
| Padula, G | 3 |
| Aroney, RS | 1 |
| Dalley, DN | 1 |
| Chan, WK | 1 |
| Bell, DR | 1 |
| Levi, JA | 1 |
| Giuliani, FC | 1 |
| Zirvi, KA | 1 |
| Kaplan, NO | 1 |
| Goldin, A | 1 |
| Goldobenko, GV | 3 |
| Lycev, VA | 1 |
| Sidorcenkov, VO | 1 |
| Gapanjuk, ON | 1 |
| Aleksanjan, AZ | 2 |
| Baranec, GV | 1 |
| Golbey, R | 2 |
| Wopfner, F | 1 |
| Schmitz, R | 3 |
| Hüper, J | 2 |
| Pichlmayr, R | 2 |
| Williams, GO | 1 |
| Brown, K | 1 |
| Miller, P | 1 |
| Miura, T | 3 |
| Haida, K | 1 |
| Haida, S | 1 |
| Fukuda, I | 1 |
| Koyama, H | 1 |
| Otani, T | 1 |
| Lance, JS | 1 |
| Hall, TC | 2 |
| Lokich, J | 1 |
| Bothe, A | 2 |
| Fine, N | 1 |
| Perri, J | 1 |
| Zimm, S | 1 |
| Wampler, GL | 1 |
| Joss, R | 2 |
| Tschopp, L | 1 |
| Brunner, K | 1 |
| Tarquini, A | 1 |
| Mascia, V | 1 |
| Chessa, PP | 1 |
| Pellegrini, A | 1 |
| Meyer, JH | 1 |
| Nelson, DS | 1 |
| Walls, RS | 1 |
| Schmitz, CA | 2 |
| Richlmayr, R | 1 |
| Sischy, B | 4 |
| Remington, JH | 1 |
| Sobel, SH | 1 |
| Savlov, ED | 1 |
| Van der Veer, LD | 1 |
| Balint, JA | 1 |
| Epenetos, AA | 1 |
| Amos, C | 1 |
| Collis, C | 1 |
| Slevin, M | 1 |
| Rohatiner, A | 1 |
| Baille-Johnson, H | 1 |
| Pitts, J | 1 |
| Wrigley, PF | 1 |
| Echtermeyer, V | 1 |
| Nishioka, B | 2 |
| Fijita, Y | 1 |
| Kojima, O | 2 |
| Morisawa, K | 1 |
| Yamane, E | 2 |
| Umehara, M | 1 |
| Majima, S | 1 |
| Maroda, SJ | 1 |
| Phillips, JO | 1 |
| Zagrebin, VM | 1 |
| Sacharova, OV | 1 |
| Benz, C | 1 |
| Cadman, E | 1 |
| Jäger, E | 1 |
| Klein, O | 2 |
| Wchter, B | 1 |
| Müller, B | 1 |
| Braun, U | 1 |
| Knuth, A | 2 |
| Meade, PG | 1 |
| Norum, J | 1 |
| Weissman, DE | 1 |
| Gedney, C | 1 |
| Arcangeli, G | 2 |
| Angelini, F | 1 |
| Tersigni, R | 1 |
| D'Aprile, M | 1 |
| Micheli, A | 1 |
| Veltri, E | 1 |
| Ambrogi, C | 1 |
| Alessandroni, L | 1 |
| Giovinazzo, G | 1 |
| Iizuka, R | 1 |
| Ajani, JA | 5 |
| Buchholz, DJ | 1 |
| Cleary, KR | 3 |
| Dubrow, RA | 1 |
| Levin, B | 7 |
| Meterissian, SH | 1 |
| Roubein, LD | 1 |
| Molina Esquivel, J | 1 |
| Vargas Sandoval, G | 1 |
| Rodríguez del Rincón, E | 1 |
| Velázquez López, J | 1 |
| Sugarman, SM | 1 |
| Di Somma, C | 1 |
| Scarpati, D | 1 |
| Sertoli, MR | 3 |
| Peressini, A | 2 |
| Percivale, P | 1 |
| Badellino, F | 1 |
| Turk, PS | 1 |
| Belliveau, JF | 2 |
| Darnowski, JW | 1 |
| Weinberg, MC | 1 |
| Leenen, L | 1 |
| Rosen, H | 2 |
| Kornek, GV | 2 |
| Sebesta, C | 2 |
| Depisch, D | 3 |
| Lévy, E | 1 |
| Le Bourgeois, JP | 1 |
| Martin, WR | 1 |
| Riemann, JF | 1 |
| Kallinowski, F | 1 |
| Eble, MJ | 2 |
| Herfarth, C | 2 |
| Kim, FP | 1 |
| Sørensen, P | 2 |
| Edal, AL | 2 |
| Madsen, EL | 2 |
| Fenger, C | 2 |
| Poulsen, MR | 2 |
| Petersen, OF | 2 |
| Kulaylat, MN | 1 |
| Doerr, R | 1 |
| Butler, B | 1 |
| Satchidanand, SK | 1 |
| Singh, A | 1 |
| Nicolson, V | 1 |
| Iveson, A | 1 |
| Evans, C | 1 |
| Joffe, J | 1 |
| Nicolson, M | 1 |
| Conti, JA | 1 |
| Knopf, K | 1 |
| Weng, MC | 1 |
| Wang, WB | 1 |
| Chao, TY | 1 |
| Mainwaring, P | 1 |
| Grygiel, JJ | 1 |
| Ragnhammar, P | 1 |
| Blomgren, H | 2 |
| Edler, D | 1 |
| Lundell, G | 2 |
| Magnusson, I | 1 |
| Sonnenfeld, T | 1 |
| Chari, RS | 1 |
| Russell, L | 1 |
| Hathorn, J | 1 |
| Braun, EM | 1 |
| Kikot', VA | 1 |
| Iugrinov, OG | 1 |
| Sorokin, BV | 1 |
| Ajao, OG | 2 |
| Grillo, IA | 1 |
| Malatani, T | 1 |
| al Shehri, MY | 1 |
| Labianca, R | 4 |
| Giaccon, G | 1 |
| Barni, S | 1 |
| Iirillo, A | 1 |
| Fiorentini, G | 1 |
| Duro, M | 1 |
| Piazza, E | 1 |
| Oliani, C | 1 |
| Pancera, G | 1 |
| Cohen, AM | 19 |
| Enker, WE | 11 |
| Kelsen, DP | 10 |
| Frankel, J | 8 |
| Veraldi, A | 1 |
| Foglietti, GP | 1 |
| Ghiselli, R | 1 |
| Lungarotti, F | 1 |
| Babini, L | 1 |
| Catalano, G | 2 |
| Kraus, TW | 1 |
| Raeth, U | 1 |
| Dworak, O | 1 |
| Köckerling, F | 2 |
| Schwarz, B | 1 |
| Weh, HJ | 2 |
| Dierlamm, J | 1 |
| Hossfeld, DK | 2 |
| Ilson, DH | 1 |
| Molls, M | 2 |
| Kolesnik, EA | 1 |
| Cherny?, VA | 1 |
| Kikot, VA | 1 |
| Jodrell, DI | 2 |
| Oster, W | 1 |
| Kerr, DJ | 3 |
| Canney, PA | 2 |
| Yosef, H | 2 |
| Steward, WP | 1 |
| Civalleri, D | 1 |
| Pector, JC | 5 |
| Håkansson, L | 1 |
| Arnaud, JP | 1 |
| Takamuro, T | 1 |
| Konishi, Y | 1 |
| Takada, Y | 1 |
| Mezger, J | 1 |
| Fisher, ER | 3 |
| Rockette, HE | 1 |
| Drake, JC | 1 |
| Chabner, BA | 1 |
| Sagaster, P | 1 |
| Essl, R | 1 |
| Teich, G | 1 |
| Wasilewski, M | 1 |
| Umek, H | 1 |
| Dünser, E | 1 |
| Mascher, H | 1 |
| Micksche, M | 1 |
| Sagasser, J | 1 |
| Meyer, FM | 1 |
| Witte, J | 1 |
| Frasci, G | 1 |
| Leone, F | 1 |
| Monaco, M | 1 |
| Cremone, L | 1 |
| Sapio, U | 1 |
| Faiella, F | 1 |
| Espinosa, A | 1 |
| Persico, G | 1 |
| Graf, W | 2 |
| Westlin, JE | 1 |
| Bernstein, M | 1 |
| Villamil, A | 1 |
| Davidson, G | 1 |
| Erlichman, C | 2 |
| Wieand, HS | 6 |
| Chen, ET | 1 |
| Brodovsky, H | 1 |
| Fishbein, G | 1 |
| Forman, WB | 1 |
| Lauwers, G | 1 |
| Itoh, M | 1 |
| Kornek, G | 1 |
| Pidlich, J | 1 |
| Karall, M | 1 |
| Prochaska, M | 1 |
| Eckhardt, S | 2 |
| Graham, RA | 2 |
| Atkins, MB | 1 |
| Karp, DD | 1 |
| Wazer, DE | 2 |
| Hackford, AW | 2 |
| Fuhrman, GM | 1 |
| Ota, DM | 3 |
| Hojyo, M | 1 |
| Maruo, H | 1 |
| Kosaka, A | 1 |
| John, WJ | 2 |
| Neefe, JR | 1 |
| Cantrell, J | 1 |
| Smith, M | 1 |
| Minsky, B | 2 |
| Cohen, A | 2 |
| Enker, W | 1 |
| Kelsen, D | 1 |
| Ilson, D | 3 |
| Conti, J | 2 |
| Papillon, J | 1 |
| Roncolini, G | 1 |
| Netri, G | 2 |
| De Franco, A | 2 |
| Koretz, MJ | 1 |
| Wood, WC | 3 |
| Bahri, S | 1 |
| Smith, RG | 1 |
| Costa, M | 1 |
| Daneker, GW | 1 |
| York, MR | 1 |
| Sarma, PR | 1 |
| Lynn, M | 1 |
| McAtee, N | 1 |
| Balis, F | 1 |
| Murphy, R | 1 |
| Venzon, D | 1 |
| Kramer, B | 1 |
| Goldspiel, B | 1 |
| Begley, M | 1 |
| Biganzoli, L | 1 |
| Cooper, SG | 1 |
| Bonaventura, A | 1 |
| Ackland, SP | 1 |
| Joseph, DJ | 1 |
| Stewart, JF | 1 |
| Hamilton, CS | 1 |
| Denham, JW | 1 |
| Su, JQ | 1 |
| Wei, LJ | 1 |
| Pavy, JJ | 1 |
| Hamers, HP | 1 |
| Horiot, JC | 2 |
| Fabri, MC | 1 |
| Eschwege, F | 1 |
| Schraub, S | 1 |
| Pazdur, R | 6 |
| Patt, YZ | 2 |
| Gomez, J | 1 |
| Bready, B | 1 |
| Ota, K | 3 |
| Wakui, A | 3 |
| Akazawa, S | 3 |
| Ariyoshi, Y | 1 |
| Yura, J | 1 |
| Inagaki, J | 1 |
| Hoshino, A | 1 |
| Carstensen, JM | 1 |
| Burcharth, F | 1 |
| Fujiki, T | 1 |
| Futatsuki, K | 2 |
| Kanda, Y | 1 |
| Amemiya, K | 1 |
| Uchida, N | 1 |
| Oishi, T | 1 |
| Chan, A | 1 |
| Langevin, J | 2 |
| Khoo, R | 2 |
| Schwartz, G | 1 |
| Dougherty, J | 1 |
| Wiseberg, J | 1 |
| Shumate, CR | 1 |
| Pouillart, P | 1 |
| Larsson, PA | 3 |
| Carlsson, G | 4 |
| Williamson, PR | 1 |
| Hellinger, MD | 1 |
| Larach, SW | 1 |
| Ferrara, A | 1 |
| Kiel, KD | 1 |
| Rademaker, A | 1 |
| Shaw, JM | 1 |
| Ujiki, GT | 1 |
| Poticha, SM | 1 |
| Bernini, A | 1 |
| Deen, KI | 1 |
| Lartigau, E | 1 |
| Guichard, M | 1 |
| Marsh, RD | 1 |
| Chu, NM | 1 |
| Bewsher, C | 1 |
| Copeland, EM | 3 |
| Dozois, RR | 2 |
| Devine, RM | 2 |
| Weaver, AL | 1 |
| Ilstrup, DM | 2 |
| Huber, FT | 1 |
| Stepan, R | 1 |
| Fink, U | 1 |
| Sakabe, T | 1 |
| Hamano, K | 1 |
| Gelber, RD | 3 |
| Cole, BF | 1 |
| Schroeder, G | 2 |
| Spears, CP | 2 |
| Wrightson, W | 1 |
| Marr, L | 1 |
| Myers, S | 1 |
| LaRocca, RV | 1 |
| Haas, NB | 1 |
| Schilder, RJ | 1 |
| Nash, S | 1 |
| Catalano, RC | 1 |
| Ozols, RF | 1 |
| Yie, QF | 1 |
| Yang, CY | 1 |
| Zhao, CL | 1 |
| Dai, ZB | 1 |
| Shibusawa, M | 1 |
| Takata, M | 1 |
| Kamiyama, G | 1 |
| Nakao, K | 1 |
| Yoshizawa, H | 1 |
| Choh, H | 1 |
| Yasuda, N | 1 |
| Tsunoda, Y | 1 |
| Tsunoda, A | 1 |
| Kusano, M | 1 |
| Petrov, VP | 1 |
| Perekhodov, SN | 1 |
| Lazarev, GV | 1 |
| Ichikawa, W | 1 |
| Nihei, Z | 1 |
| Sawai, S | 1 |
| Miyanaga, T | 1 |
| Hirayama, R | 1 |
| Mishima, Y | 1 |
| Murotani, M | 2 |
| Takami, M | 2 |
| Shibata, T | 2 |
| Iihara, K | 2 |
| Tsukamoto, F | 1 |
| Kimura, M | 2 |
| Nose, T | 2 |
| Kaneyasu, Y | 1 |
| Okawa, MK | 1 |
| Kokubo, N | 1 |
| Takemoto, M | 1 |
| Karasawa, K | 1 |
| Fukuhara, N | 1 |
| Toda, J | 1 |
| Okawa, T | 1 |
| Chen, FC | 1 |
| Woods, RJ | 1 |
| Sanchez, W | 1 |
| Alvarado, I | 1 |
| Kosmidis, PA | 1 |
| Skarlos, D | 2 |
| Theocharis, D | 1 |
| Pavlidis, N | 2 |
| Briassoulis, E | 1 |
| Shirasu, M | 3 |
| Kitamura, K | 2 |
| Inazawa, J | 3 |
| Murayama, H | 1 |
| Cha, S | 2 |
| Devine, R | 2 |
| Fieck, JM | 2 |
| Wolff, B | 2 |
| Dozois, R | 2 |
| Ippoliti, M | 1 |
| Nucera, P | 1 |
| Merico, M | 1 |
| Bellantone, R | 2 |
| Crucitti, F | 2 |
| Bugat, R | 1 |
| Culine, S | 1 |
| Suc, E | 1 |
| Brunet, P | 1 |
| Extra, JM | 1 |
| Bonneterre, J | 1 |
| Ganem, G | 1 |
| Namer, M | 2 |
| Negrier, S | 2 |
| Merrouche, Y | 1 |
| Burki, F | 1 |
| Mousseau, M | 2 |
| Herait, P | 1 |
| Mahjoubi, M | 2 |
| Joffe, JK | 1 |
| Perren, TJ | 1 |
| Bradley, C | 1 |
| Primrose, J | 1 |
| Hallam, S | 1 |
| Ward, U | 1 |
| Illingworth, JM | 1 |
| Selby, PJ | 1 |
| Asano, M | 1 |
| Kasimis, B | 1 |
| Schein, P | 1 |
| Capizzi, R | 1 |
| Kurman, M | 1 |
| Bass, J | 1 |
| Hyams, DM | 2 |
| Mamounas, EP | 1 |
| Rockette, H | 3 |
| Jones, J | 2 |
| Wickerham, L | 1 |
| Rubio, D | 1 |
| Maldonado, X | 1 |
| Naval, J | 1 |
| Casado, S | 1 |
| Lara, F | 1 |
| Roselló, JM | 1 |
| Ohno, S | 1 |
| Tomoda, M | 1 |
| Tomisaki, S | 1 |
| Sugimachi, K | 6 |
| Langevin, JM | 1 |
| Heine, JA | 1 |
| Buie, WD | 1 |
| Johnson, DR | 2 |
| Vignoud, J | 1 |
| Varette, C | 2 |
| Raymond, E | 1 |
| Moreau, S | 1 |
| Le Bail, N | 1 |
| Krulik, M | 1 |
| Grann, A | 2 |
| Bass-Loeb, J | 1 |
| Petroni, GR | 1 |
| Ratkin, GA | 3 |
| Okabo, S | 1 |
| Arai, T | 2 |
| Murase, N | 2 |
| Tsubaki, M | 2 |
| Endo, M | 1 |
| Shimoju, K | 1 |
| Sakurazawa, K | 1 |
| Yabata, E | 1 |
| Kawasaki, T | 1 |
| Fischbach, W | 1 |
| Iannace, C | 1 |
| De Cristofano, L | 1 |
| Caracciolo, F | 1 |
| Sanz-Altamira, PM | 1 |
| Spence, LD | 1 |
| Posner, MR | 2 |
| Perry, LJ | 2 |
| Stuart, KE | 2 |
| Maroun, JA | 1 |
| Goel, R | 1 |
| Dahrouge, S | 1 |
| Boisvert, D | 1 |
| Vaughn, DJ | 1 |
| De Santis, M | 1 |
| Turriziani, A | 1 |
| Guldvog, I | 1 |
| Hagen, S | 1 |
| Trondsen, E | 1 |
| Harbitz, T | 1 |
| Nygaard, K | 1 |
| Nilsen, JB | 1 |
| Wist, E | 1 |
| Hannisdal, E | 1 |
| Tokunaga, Y | 1 |
| Kaganoi, J | 1 |
| Nanbu, H | 1 |
| Ohsumi, K | 1 |
| Wakasa, M | 1 |
| Ogaki, M | 1 |
| Yamazaki, J | 1 |
| Guiney, M | 1 |
| Luzi, S | 1 |
| Salvi, G | 1 |
| Diaz-Canton, E | 1 |
| Ichihashi, H | 4 |
| Tamada, R | 2 |
| Furuta, K | 2 |
| Konishi, F | 3 |
| Kanazawa, K | 3 |
| Saito, K | 1 |
| Sugawara, T | 1 |
| Takayama, W | 1 |
| Imazeki, H | 1 |
| Okazumi, S | 1 |
| Takeda, A | 1 |
| Miyazaki, S | 1 |
| Fukunaga, T | 1 |
| Iwasaki, K | 2 |
| Shutou, K | 1 |
| Shinotou, K | 1 |
| Maeda, T | 2 |
| Isono, K | 1 |
| Naitoh, H | 1 |
| Okauchi, H | 1 |
| Yamasaki, M | 1 |
| Hino, K | 1 |
| Tazawa, K | 2 |
| Masuyama, K | 1 |
| Saitoh, T | 1 |
| Okamoto, M | 2 |
| Fujimaki, M | 2 |
| Koyanagi, Y | 1 |
| Katoh, K | 1 |
| Satoh, S | 1 |
| Hanada, M | 1 |
| Kakihara, N | 1 |
| Sato, S | 2 |
| Adachi, A | 1 |
| Tazaki, N | 1 |
| Kida, T | 1 |
| Igarashi, S | 1 |
| Yasuda, M | 1 |
| Pokorny, RM | 1 |
| Wrightson, WR | 1 |
| Lewis, RK | 1 |
| Paris, KJ | 1 |
| Hofmeister, A | 1 |
| LaRocca, R | 1 |
| Myers, SR | 1 |
| Ackerman, D | 1 |
| Hehr, T | 1 |
| Hoffmann, W | 1 |
| Khoo, VS | 3 |
| Evetts, PA | 2 |
| Goswitz, MS | 2 |
| Allen, PK | 3 |
| Streit, M | 1 |
| Stremetzne, S | 1 |
| Kerz, H | 1 |
| Strohbach, F | 1 |
| Hohenberger, P | 2 |
| Zwiebel, FM | 1 |
| Hebart, H | 1 |
| Böthig, R | 1 |
| Kairies, M | 1 |
| Zillig, D | 1 |
| Schuchmann, S | 1 |
| Warnecke, S | 1 |
| Thiel, E | 1 |
| Kulachek, FK | 1 |
| Ivashchuk, OI | 1 |
| Slonets'kyĭ, BI | 1 |
| Volianiuk, PM | 1 |
| Skylstad, D | 1 |
| Småland, R | 1 |
| Wakasa, T | 1 |
| Andou, H | 1 |
| Itoh, K | 1 |
| Kato, J | 1 |
| Yasue, M | 1 |
| Fan, FS | 2 |
| Wakayama, H | 1 |
| Nakayama, K | 1 |
| Hotta, M | 1 |
| Oota, K | 1 |
| Yamazaki, S | 1 |
| Byram, D | 1 |
| Bell, R | 1 |
| Bond, R | 1 |
| Vaughan, S | 1 |
| McLennan, R | 1 |
| Lim-Joon, M | 1 |
| Wada, M | 1 |
| Hagan, M | 1 |
| Daley, W | 1 |
| Warland, G | 1 |
| Compton, CC | 1 |
| Filho, WD | 1 |
| Cogliandolo, S | 4 |
| Ambesi-Impiombato, F | 4 |
| Tedesco, M | 3 |
| Gamelin, E | 4 |
| Boisdron-Celle, M | 2 |
| Delva, R | 2 |
| Regimbeau, C | 1 |
| Cailleux, PE | 1 |
| Alleaume, C | 1 |
| Maillet, ML | 1 |
| Goudier, MJ | 1 |
| Sire, M | 1 |
| Person-Joly, MC | 1 |
| Maigre, M | 1 |
| Maillart, P | 1 |
| Fety, R | 1 |
| Burtin, P | 1 |
| Lortholary, A | 1 |
| Dumesnil, Y | 1 |
| Picon, L | 1 |
| Geslin, J | 1 |
| Gesta, P | 1 |
| Danquechin-Dorval, E | 1 |
| Larra, F | 1 |
| Robert, J | 1 |
| Adachi, W | 2 |
| Koike, S | 1 |
| Mihara, M | 1 |
| Nakata, S | 1 |
| Kajikawa, S | 1 |
| Kuroda, T | 1 |
| Amano, J | 1 |
| Yamane, N | 1 |
| Makino, M | 1 |
| Taniguchi, T | 1 |
| Kurayoshi, K | 1 |
| Kaibara, N | 1 |
| Stein, ME | 1 |
| Drumea, K | 1 |
| Yarnitsky, D | 1 |
| Benny, A | 1 |
| Tzuk-Shina, T | 1 |
| Kahn, MJ | 1 |
| Gerard, B | 1 |
| Van Daele, D | 1 |
| Gil, T | 1 |
| Di Leo, A | 1 |
| Fernez, B | 1 |
| Brienza, S | 2 |
| Bours, V | 2 |
| Jerusalem, G | 2 |
| Fillet, G | 2 |
| Tannapfel, A | 1 |
| Nüsslein, S | 1 |
| Katalinic, A | 1 |
| Mackean, MJ | 1 |
| Paul, J | 1 |
| Reed, NS | 1 |
| Robertson, AG | 1 |
| McInnes, A | 1 |
| Twelves, CJ | 1 |
| Nøstdahl, T | 1 |
| Waagsbø, NA | 1 |
| Okabe, S | 1 |
| Burke, SJ | 1 |
| Percarpio, BA | 1 |
| Knight, DC | 1 |
| Kwasnik, EM | 1 |
| Nakfoor, BM | 1 |
| Kaufman, DS | 2 |
| Daly, WJ | 1 |
| Seymour, MT | 1 |
| Shimoda, K | 1 |
| Shiraishi, N | 1 |
| Busse, PM | 1 |
| Ng, A | 1 |
| Recht, A | 1 |
| Sahmoud, T | 1 |
| Curran, D | 1 |
| Doci, R | 1 |
| De Waele, B | 1 |
| Rauschecker, H | 1 |
| Marsoni, S | 1 |
| Apolone, G | 1 |
| Lasser, P | 6 |
| Couvreur, ML | 1 |
| Yanagi, H | 3 |
| Kotera, H | 1 |
| Noda, M | 2 |
| Hejna, M | 1 |
| Raderer, M | 1 |
| Brodowicz, T | 1 |
| Fiebiger, WC | 1 |
| Hanlon, AL | 1 |
| Scher, RM | 1 |
| Hoffman, JP | 1 |
| Eisenberg, BL | 1 |
| Cooper, HS | 1 |
| Provins, S | 1 |
| Coia, LR | 1 |
| de Souza, PM | 1 |
| Gansl, R | 1 |
| Sousa, AH | 1 |
| Oguro, A | 1 |
| Nanri, M | 1 |
| Chimori, Y | 1 |
| Dubé, P | 1 |
| Elias, D | 6 |
| Maeda, M | 1 |
| Koike, H | 1 |
| Kasai, H | 1 |
| Harrison, LB | 1 |
| Mychalczak, B | 1 |
| Anderson, L | 1 |
| White, C | 1 |
| Videtic, GM | 1 |
| Fisher, BJ | 1 |
| Perera, FE | 1 |
| Bauman, GS | 1 |
| Kocha, WI | 1 |
| Taylor, M | 1 |
| Vincent, MD | 1 |
| Plewes, EA | 1 |
| Engel, CJ | 1 |
| Stitt, LW | 1 |
| Nicolini, A | 1 |
| Carpi, A | 1 |
| Ferrari, P | 1 |
| Sagripanti, A | 1 |
| Anselmi, L | 1 |
| Giacco, GG | 1 |
| Hess, K | 1 |
| Larry, L | 1 |
| Janjan, N | 1 |
| Furukawa, T | 1 |
| Hoffman, RM | 1 |
| Sobrero, AF | 1 |
| Guglielmi, AP | 1 |
| Mori, AM | 1 |
| Tixi, LM | 1 |
| Bolli, EA | 1 |
| Mammoliti, S | 1 |
| Rollandi, GA | 1 |
| Bertoglio, S | 2 |
| Stahl, H | 1 |
| Schlag, P | 3 |
| Bulkley, GB | 1 |
| Aziz, SA | 1 |
| Tramboo, NA | 1 |
| Mohi-ud-Din, K | 1 |
| Jalal, S | 1 |
| Ahmad, M | 1 |
| Hagmüller, E | 1 |
| Sturm, J | 2 |
| Diezler, P | 1 |
| Schneider, I | 1 |
| Grabenbauer, G | 1 |
| Matzel, K | 1 |
| Stein, U | 1 |
| Walther, W | 1 |
| Korenaga, D | 1 |
| Yao, T | 1 |
| Maekawa, S | 1 |
| Fry, R | 1 |
| Menteer, J | 1 |
| Read, T | 1 |
| Walz, B | 1 |
| Nakazato, H | 1 |
| Colucci, G | 1 |
| Gebbia, V | 1 |
| Giuliani, F | 1 |
| Serravezza, G | 1 |
| Lelli, G | 1 |
| Leo, S | 1 |
| Nicolella, G | 1 |
| Brandi, M | 1 |
| Corral, P | 1 |
| Rodríguez-Coria, D | 1 |
| Bondar, GV | 1 |
| Borota, AV | 1 |
| Yakovets, YI | 1 |
| Juturi, JV | 1 |
| Francis, B | 1 |
| Koontz, PW | 1 |
| Wilkes, JD | 1 |
| Maylin, C | 1 |
| Vincent, M | 1 |
| Harper, P | 1 |
| Levi, F | 1 |
| Lobelle, JP | 1 |
| Adam, R | 1 |
| Dallemagne, B | 1 |
| Jehaes, C | 1 |
| Markiewicz, S | 1 |
| Bismuth, H | 1 |
| Takimoto, CH | 1 |
| Yee, LK | 1 |
| Venzon, DJ | 1 |
| Schuler, B | 1 |
| Grollman, F | 1 |
| Chabuk, C | 1 |
| Hamilton, JM | 2 |
| Chen, AP | 1 |
| Kronborg, O | 1 |
| Wiboltt, K | 1 |
| Raskov, HH | 1 |
| Fasolini, F | 1 |
| Abbruzzese, J | 4 |
| Dubrow, R | 5 |
| Glober, G | 1 |
| Wolff, R | 3 |
| Doidy, L | 1 |
| Lusinchi, A | 1 |
| Sabourin, JC | 1 |
| Bonvalot, S | 1 |
| Cleary, K | 5 |
| Ajani, J | 1 |
| Shanahan, TG | 1 |
| Cobau, CD | 1 |
| Burch, PA | 1 |
| Levitt, R | 1 |
| Rowland, KM | 1 |
| Zisiadis, A | 1 |
| Dafni, U | 1 |
| Konstantaras, C | 1 |
| Hatzitheoharis, G | 1 |
| Liaros, A | 1 |
| Athanassiou, E | 1 |
| Dombros, N | 1 |
| Dervenis, C | 1 |
| Gamvros, O | 1 |
| Souparis, A | 1 |
| Briasoulis, E | 1 |
| Kappas, A | 1 |
| Kosmidis, P | 1 |
| Soyannwo, OA | 1 |
| Ladipo, JK | 1 |
| Okeke, LI | 1 |
| Adebamowo, CA | 1 |
| Kono, T | 1 |
| Kakisaka, A | 1 |
| Tokusasi, Y | 1 |
| Miyokawa, N | 1 |
| Kasai, S | 1 |
| Maghfoor, I | 1 |
| Partridge, S | 1 |
| Leslie, M | 1 |
| Irvine, A | 1 |
| Otani, S | 1 |
| Iwagaki, H | 1 |
| Jikuhara, A | 1 |
| Tagashira, H | 1 |
| Nagao, A | 1 |
| Isozaki, H | 1 |
| Hizuta, A | 1 |
| Takakura, N | 1 |
| Allen, DC | 1 |
| Fon, LJ | 1 |
| McAleer, JJ | 1 |
| Irwin, ST | 1 |
| Lim, WT | 1 |
| Koo, WH | 2 |
| Au, E | 2 |
| Khoo, KS | 1 |
| Horsell, KW | 1 |
| Merten, S | 1 |
| Clingan, P | 1 |
| King, DW | 1 |
| Morris, DL | 1 |
| House, A | 1 |
| Robbins, P | 3 |
| Fornasiero, A | 1 |
| Vieceli, G | 1 |
| Marchiori, E | 2 |
| Furuhata, T | 1 |
| Yamamitsu, S | 2 |
| Kimura, H | 1 |
| Hata, F | 1 |
| Shirasaka, T | 2 |
| Kashiwagi, H | 1 |
| Ozawa, A | 1 |
| Masui, H | 1 |
| Ichikawa, Y | 1 |
| Togo, S | 1 |
| Ike, H | 1 |
| Shimada, H | 1 |
| Miya, K | 1 |
| Fukada, D | 1 |
| Umemoto, T | 1 |
| Kunieda, K | 1 |
| Sugiyama, Y | 1 |
| Kato, M | 1 |
| Kawaguchi, Y | 1 |
| Senda, K | 1 |
| Morimoto, T | 1 |
| Azama, T | 1 |
| Okajima, S | 2 |
| Akaishi, O | 1 |
| Yabe, K | 1 |
| Takeuchi, I | 2 |
| Tada, M | 1 |
| Idezuki, Y | 1 |
| Bonnay, M | 1 |
| Bexon, A | 1 |
| Armand, JP | 1 |
| Méry-Mignard, D | 1 |
| Tocchi, A | 1 |
| Lepre, L | 1 |
| Costa, G | 1 |
| Liotta, G | 1 |
| Mazzoni, G | 1 |
| Agostini, N | 1 |
| Miccini, M | 1 |
| Soontrapornchai, P | 1 |
| Grieu, F | 2 |
| Iacopetta, B | 2 |
| Battista Doglietto, G | 1 |
| Danikas, D | 1 |
| Theodorou, SJ | 1 |
| Arvanitis, ML | 1 |
| Zinterhofer, LM | 1 |
| Rienzo, AA | 1 |
| Marmiroli, L | 1 |
| Nuzzo, G | 3 |
| Rotman, M | 3 |
| Szántó, J | 1 |
| Benyó, I | 1 |
| Bodnár, Z | 1 |
| Szlobodnyik, J | 1 |
| Lorenz, M | 1 |
| Müller, HH | 1 |
| Musha, N | 1 |
| Sando, N | 1 |
| Setu, Y | 1 |
| Setu, M | 1 |
| Oka, K | 1 |
| Pelissier, EP | 1 |
| Chaillard, G | 1 |
| Sobat, H | 1 |
| Juretic, A | 1 |
| Samija, M | 1 |
| Takenoue, T | 1 |
| Miyagawa, S | 1 |
| Akiyama, Y | 1 |
| Koyama, K | 1 |
| Colangelo, L | 1 |
| Dimitrov, NV | 1 |
| Romond, EH | 1 |
| Wexler, M | 1 |
| Prager, D | 1 |
| Cruz, AB | 3 |
| Gordon, PH | 1 |
| Mamounas, E | 1 |
| Wickerham, DL | 2 |
| Thrall, MM | 1 |
| Wood, P | 1 |
| King, V | 1 |
| Rivera, W | 1 |
| Hrushesky, W | 1 |
| Regine, WF | 2 |
| Hagihara, PF | 2 |
| McGrath, PC | 1 |
| Kenady, DE | 1 |
| Allal, AS | 1 |
| Bieri, S | 1 |
| Pelloni, A | 1 |
| Spataro, V | 1 |
| Ambrosetti, P | 1 |
| Sprangers, MA | 1 |
| Kurtz, JM | 1 |
| Gertsch, P | 1 |
| Hay, JM | 1 |
| Msika, S | 1 |
| Kim, SK | 1 |
| Schick, C | 2 |
| Puig-La Calle, J | 1 |
| Tickoo, S | 1 |
| Yeung, H | 1 |
| Finn, RD | 1 |
| Erdi, Y | 1 |
| Humm, J | 1 |
| Horák, D | 1 |
| Guseinov, E | 1 |
| Vishnevskii, V | 1 |
| Adamyan, A | 1 |
| Kokov, L | 1 |
| Tsvirkun, V | 1 |
| Tchjao, A | 1 |
| Titova, M | 1 |
| Skuba, N | 1 |
| Trostenyuk, N | 1 |
| Gumargalieva, K | 1 |
| Crane, CN | 1 |
| Vauthey, J | 2 |
| Lenzi, R | 3 |
| Lynch, P | 3 |
| Brown, T | 2 |
| Allen, P | 3 |
| Brown, B | 1 |
| Lee, C | 3 |
| Hurwitz, H | 3 |
| Prosnitz, LR | 1 |
| Jowell, P | 3 |
| Rosner, G | 1 |
| Samulski, T | 1 |
| Dewhirst, MW | 1 |
| Manivit, P | 1 |
| Polo, R | 1 |
| Tabary, D | 1 |
| Nabet, M | 1 |
| Polo, M | 1 |
| Adamy, M | 1 |
| Rubini, B | 1 |
| Fromaget, JM | 1 |
| Chipponi, PN | 1 |
| De Vita, F | 1 |
| De Lucia, L | 1 |
| Casaretti, R | 1 |
| Orditura, M | 1 |
| Rivellini, F | 1 |
| Comella, G | 2 |
| Toh, U | 1 |
| Matsumoto, A | 1 |
| Yasunaga, M | 1 |
| Ogoh, Y | 1 |
| Inuzuka, K | 1 |
| Ozaki, K | 1 |
| Dewar, J | 1 |
| Van Hazel, G | 1 |
| Einhorn, S | 1 |
| Cameron, F | 1 |
| Latham, M | 1 |
| Abramson, RG | 1 |
| Rosen, MP | 1 |
| Brophy, DP | 1 |
| Raeburn, SL | 1 |
| Alektiar, KM | 1 |
| Zelefsky, MJ | 1 |
| Powell, B | 1 |
| Menso, L | 1 |
| Harder, C | 1 |
| Sotome, K | 1 |
| Matsudo, A | 1 |
| Nakai, H | 1 |
| Takao, M | 1 |
| Osakabe, Y | 1 |
| Waddell, BE | 1 |
| Weber, TK | 1 |
| Min, JS | 2 |
| Park, JK | 2 |
| Noh, JK | 1 |
| Nguyen, NP | 1 |
| Sallah, S | 1 |
| Karlsson, U | 1 |
| Ludin, A | 1 |
| Vos, P | 1 |
| Lepera, P | 1 |
| Jendrasiak, G | 1 |
| Chapman, W | 1 |
| Robiou, C | 1 |
| Salehpour, M | 1 |
| Hemminki, A | 1 |
| Mecklin, JP | 1 |
| Järvinen, H | 1 |
| Aaltonen, LA | 1 |
| Joensuu, H | 1 |
| Semlin, S | 1 |
| Pigorsch, S | 1 |
| Müller, AC | 1 |
| David, JS | 1 |
| Gueugniaud, PY | 1 |
| Hepp, A | 1 |
| Gaussorgues, P | 1 |
| Petit, P | 1 |
| Gretschel, S | 1 |
| Hayne, M | 1 |
| McGrath, P | 1 |
| Marks, GM | 1 |
| Matsuno, S | 1 |
| Ogasawara, T | 1 |
| Yamazaki, H | 2 |
| Ukei, T | 1 |
| Touno, T | 1 |
| Masutani, S | 1 |
| Oozato, H | 1 |
| Imamoto, E | 1 |
| Naito, Y | 1 |
| Kuchide, M | 1 |
| Tomatsuri, N | 1 |
| Kondo, M | 1 |
| Kou, T | 1 |
| Kunishima, S | 1 |
| Takekuni, K | 1 |
| Yukawa, M | 1 |
| Teshima, S | 1 |
| Harboe, K | 1 |
| Todnem, K | 1 |
| Zotova, L | 1 |
| Lind, A | 1 |
| Ogreid, D | 1 |
| Hartmann, KA | 1 |
| Frenken, M | 1 |
| Aryus, B | 1 |
| Döker, R | 1 |
| Ulrich, B | 1 |
| Kirchner, R | 1 |
| Mellert, J | 1 |
| Mücke, R | 1 |
| Hopt, UT | 1 |
| van Kuilenburg, AB | 2 |
| Haasjes, J | 1 |
| Richel, DJ | 1 |
| Zoetekouw, L | 1 |
| Van Lenthe, H | 1 |
| De Abreu, RA | 1 |
| Maring, JG | 1 |
| Vreken, P | 1 |
| van Gennip, AH | 2 |
| Debernardis, D | 1 |
| Tunesi, G | 1 |
| Maley, F | 1 |
| Sobrero, A | 1 |
| Abbruzzese, JL | 3 |
| Curley, S | 3 |
| Sawaf, HB | 1 |
| Hoff, P | 2 |
| Lindel, K | 1 |
| Ott, MJ | 1 |
| Clark, J | 1 |
| Grossbard, M | 1 |
| Rotholtz, N | 1 |
| Pisano, M | 1 |
| Kaplan, E | 1 |
| Secic, M | 1 |
| Coucke, P | 1 |
| Pikarsky, A | 1 |
| Weiss, E | 1 |
| Yoshikawa, R | 1 |
| Feng, C | 1 |
| Paty, PP | 1 |
| Tonini, G | 1 |
| Salerno, A | 1 |
| Vincenzi, B | 1 |
| Patti, G | 1 |
| Battistoni, F | 1 |
| Dicuonzo, G | 1 |
| Villafranca, E | 1 |
| Okruzhnov, Y | 1 |
| Dominguez, MA | 1 |
| Azinovic, I | 1 |
| Martínez, E | 1 |
| Illarramendi, JJ | 1 |
| Martínez Monge, R | 1 |
| Salgado, E | 1 |
| Angeletti, S | 1 |
| Brugarolas, A | 1 |
| Sung, JS | 1 |
| Jung, HC | 1 |
| Colin, P | 1 |
| Achille, E | 1 |
| Colbert, N | 1 |
| Boaziz, C | 1 |
| Tubiana-Mathieu, N | 1 |
| Boutan-Laroze, A | 1 |
| Flesch, M | 1 |
| Billiau, V | 1 |
| Gramont, A | 1 |
| Cappelletti, D | 1 |
| Cardillo, A | 1 |
| Bonanno, E | 1 |
| Prete, SP | 1 |
| Cucchiara, G | 2 |
| Turriziani, M | 1 |
| Greiner, JW | 1 |
| Cottarelli, A | 1 |
| Breda, E | 1 |
| Aquino, A | 1 |
| Bonmassar, E | 2 |
| Haddock, MG | 1 |
| Gneiting, T | 1 |
| Kreczy, A | 1 |
| Pfeiffer, KP | 1 |
| Brix, G | 1 |
| Siu, W | 1 |
| Wren, SM | 1 |
| King, C | 1 |
| Terris, MK | 1 |
| McNevin, MS | 1 |
| Gross, EK | 1 |
| Whiteford, HM | 1 |
| Lewis, JL | 1 |
| Bossard, N | 1 |
| Trillet-Lenoir, V | 1 |
| Zori Comba, A | 1 |
| Blajman, C | 1 |
| Richardet, E | 1 |
| Bella, S | 1 |
| Vilanova, M | 1 |
| Cóppola, F | 1 |
| Van Kooten, M | 1 |
| Rodger, J | 1 |
| Giglio, R | 1 |
| Balbiani, L | 1 |
| Perazzo, F | 1 |
| Montiel, M | 1 |
| Pujol, F | 1 |
| Mickiewicz, E | 1 |
| Cazap, E | 1 |
| Recondo, G | 1 |
| Lastiri, F | 1 |
| Simon, J | 1 |
| Schmilovich, A | 1 |
| Huguier, M | 1 |
| Schultze, J | 1 |
| Kimmig, B | 1 |
| Esposito, G | 1 |
| Alaggio, R | 1 |
| Giacomelli, L | 1 |
| Iaderosa, GA | 1 |
| Chieco-Bianchi, L | 1 |
| Jatzko, G | 1 |
| Onaitis, MW | 2 |
| Noone, RB | 2 |
| Hartwig, M | 1 |
| Morse, M | 2 |
| McGrath, K | 2 |
| Clary, B | 2 |
| Tyler , DS | 1 |
| Frykholm, GJ | 1 |
| Ono, T | 1 |
| Tarao, H | 1 |
| Tonouchi, H | 1 |
| Homma, H | 1 |
| Mezawa, S | 1 |
| Kukitsu, T | 1 |
| Miyanishi, K | 1 |
| Takada, K | 1 |
| Niitsu, Y | 2 |
| Chua, EJ | 2 |
| Soo, KC | 1 |
| Seow-Choen, F | 1 |
| Low, CH | 1 |
| Ng, BK | 1 |
| Hoe, M | 1 |
| Schache, DJ | 1 |
| Caponigro, F | 1 |
| Trisolini, R | 1 |
| Lazzari Agli, L | 1 |
| Rondelli, D | 1 |
| Cancellieri, A | 1 |
| Patelli, M | 1 |
| Falcone, F | 1 |
| Poletti, V | 1 |
| Sanfilippo, NJ | 1 |
| Feig, B | 1 |
| Böhm, B | 1 |
| Helfritzsch, H | 1 |
| Thiele, M | 1 |
| Altendorf-Hofmann, A | 1 |
| Scheele, J | 1 |
| Sterk, P | 1 |
| Schubert, F | 1 |
| Günter, S | 1 |
| Klein, P | 1 |
| Reading, DM | 1 |
| Gunn, IF | 1 |
| Green, MD | 2 |
| McLaughlin, SJ | 1 |
| Pedersen, JS | 1 |
| McGinty, J | 1 |
| Parda, D | 1 |
| Karlovits, S | 1 |
| Davis, C | 1 |
| Caushaj, P | 1 |
| Lembersky, B | 1 |
| Raida, M | 1 |
| Höffken, K | 1 |
| Fares, MC | 1 |
| Sunouchi, K | 1 |
| Higuchi, Y | 1 |
| Johnson, BA | 1 |
| Engstrom, MC | 1 |
| Goffre, B | 1 |
| Bonnel, C | 1 |
| Zerbib, F | 1 |
| Caudry, M | 1 |
| Saric, J | 1 |
| Dencausse, Y | 1 |
| Dietzler, P | 1 |
| Edler, L | 1 |
| Bambach, M | 1 |
| Wojatschek, C | 1 |
| Lindemann, H | 1 |
| Qeisser, W | 1 |
| Coudert, B | 1 |
| Pierga, JY | 1 |
| Provençal, J | 1 |
| Rixe, O | 1 |
| Krisch, C | 1 |
| Germa, C | 1 |
| Bekradda, M | 1 |
| Mignard, D | 1 |
| Taal, BG | 1 |
| Zoetmulder, FA | 1 |
| Cantalapiedra, R | 1 |
| Marcos, P | 1 |
| García Alfonso, P | 1 |
| Herranz, R | 1 |
| Spencer, MP | 1 |
| Fields, R | 1 |
| Baglan, KL | 1 |
| Frazier, RC | 1 |
| Huang, RR | 1 |
| Martinez, AA | 1 |
| Deng, Z | 1 |
| Lou, X | 1 |
| Kaya, A | 1 |
| Hazar, H | 1 |
| Ford, J | 2 |
| Edelstein, PS | 1 |
| Vierra, M | 1 |
| Bastidas, AJ | 1 |
| Nozoe, Y | 1 |
| Miyagi, Y | 1 |
| Wichmann, MW | 1 |
| Meyer, G | 1 |
| Strauss, T | 1 |
| Hornung, HM | 1 |
| Lau-Werner, U | 1 |
| Angele, MK | 1 |
| Schildberg, FW | 1 |
| Qi, X | 2 |
| Ye, X | 1 |
| Bigalke, M | 1 |
| Peters, A | 1 |
| Oriyama, T | 1 |
| Kosaka, H | 1 |
| Bahng, H | 1 |
| Craipeau, C | 1 |
| Cvitkovic, E | 1 |
| Inokuma, S | 1 |
| Hoshino, T | 1 |
| Daijo, H | 1 |
| Shinohara, H | 1 |
| Hara, H | 1 |
| Hiramatsu, M | 1 |
| Sako, S | 1 |
| Sikma, MA | 1 |
| Coenen, JL | 1 |
| Kloosterziel, C | 1 |
| Hasselt, BA | 1 |
| Ruers, TJ | 1 |
| Quan, SH | 2 |
| Fleischauer, AT | 1 |
| Sundararajan, V | 1 |
| Mitra, N | 1 |
| Heitjan, DF | 1 |
| Jacobson, JS | 1 |
| Grann, VR | 1 |
| Bozzetti, F | 1 |
| Andreola, S | 1 |
| Baratti, D | 1 |
| Stani, SC | 1 |
| Spinelli, P | 1 |
| Ciabattoni, A | 1 |
| Morelli, U | 1 |
| Calvilio, J | 1 |
| Escribano, A | 1 |
| de Castro, J | 1 |
| Sánchez, ME | 1 |
| Mata, A | 1 |
| Espinosa, E | 1 |
| García Grande, A | 1 |
| Mateo, A | 1 |
| González Barón, M | 1 |
| Frickhofen, N | 1 |
| Beck, FJ | 1 |
| Jung, B | 1 |
| Fuhr, HG | 1 |
| Andrasch, H | 1 |
| Sigmund, M | 1 |
| de O Ferreira, F | 1 |
| David Filho, WJ | 1 |
| Vieira, RA | 1 |
| Dent, RG | 1 |
| McColl, I | 1 |
| Wallack, MK | 1 |
| Rosato, FE | 1 |
| Brown, AS | 1 |
| Gutterman, JU | 5 |
| Burgess, MA | 7 |
| Khankhanian, N | 2 |
| Seibert, GB | 2 |
| Speer, JF | 2 |
| Jubert, AV | 4 |
| Martin, RC | 2 |
| McBride, CM | 4 |
| Gehan, EA | 2 |
| Hersh, EM | 5 |
| Hsu, LY | 1 |
| David, K | 1 |
| Serotkin, AV | 1 |
| Godmilov, L | 1 |
| Hirschhorn, K | 1 |
| Horton, J | 2 |
| Brickner, TJ | 1 |
| Illig, WP | 1 |
| Self, J | 1 |
| Thompson, CT | 1 |
| Winkler, R | 1 |
| Rauchenberger, B | 1 |
| Barrett, A | 1 |
| Gazet, JC | 1 |
| Bradbeer, JW | 1 |
| Peckham, MJ | 2 |
| Hartwich, G | 1 |
| Neidhardt, B | 1 |
| Hill, GJ | 4 |
| Cornell, GN | 2 |
| Frelick, RW | 2 |
| Huck, P | 1 |
| Cagetti, M | 1 |
| Uccheddu, A | 1 |
| Woolley, PV | 4 |
| Bland, KI | 1 |
| Garrison, RN | 1 |
| Knutson, CO | 1 |
| McCaffrey, JA | 1 |
| Polio, J | 1 |
| Clouse, ME | 1 |
| Hamilton, T | 1 |
| Golden, GT | 1 |
| Rosenthal, JD | 1 |
| Shaw, A | 1 |
| Pratt, CB | 1 |
| Rivera, G | 1 |
| Shanks, E | 1 |
| Johnson, WW | 1 |
| Howarth, C | 1 |
| Terrell, W | 1 |
| Kumar, AP | 1 |
| Bolton, PM | 2 |
| Clunie, GJ | 1 |
| Burnett, W | 1 |
| Rozencweig, M | 1 |
| von Hoff, DD | 1 |
| Louie, AC | 1 |
| Karrer, K | 1 |
| Denck, H | 1 |
| Pridun, N | 1 |
| Lehnert, M | 1 |
| Petrek, JA | 1 |
| Minton, JP | 1 |
| Ansfield, F | 1 |
| Klotz, J | 1 |
| Nealon, T | 1 |
| Ramirez, G | 3 |
| Minton, J | 1 |
| Hill, G | 1 |
| Wilson, W | 1 |
| Davis, H | 1 |
| Cornell, G | 1 |
| Golubeva, VA | 1 |
| Osipov, NE | 1 |
| Bukharova, IK | 1 |
| Johnson, RJ | 1 |
| Heal, JM | 1 |
| Grossi, CE | 6 |
| Wolff, WI | 2 |
| Nealon, TF | 3 |
| Pasternack, B | 2 |
| Rousselot, LM | 6 |
| Bedikian, A | 2 |
| Rodriguez, V | 2 |
| Buroker, T | 3 |
| Miller, A | 1 |
| Baker, L | 2 |
| McKenzie, M | 1 |
| Samson, M | 1 |
| Vaitkevicius, VK | 5 |
| Brooman, P | 1 |
| Rowling, JT | 1 |
| Lawrence, W | 2 |
| Terz, JJ | 3 |
| Horsley, JS | 2 |
| Brown, PW | 2 |
| Berman, R | 1 |
| Malhotra, A | 2 |
| Bird, GG | 2 |
| Gajjar, PD | 1 |
| Bunch, GA | 2 |
| Hall, R | 2 |
| Klahr, C | 2 |
| Smith, LF | 1 |
| Wojtaszak, B | 1 |
| Dindogru, A | 1 |
| DeMattia, M | 1 |
| Groth, C | 1 |
| Shioda, R | 1 |
| Taylor, SG | 1 |
| Desai, SA | 1 |
| DeWys, WD | 1 |
| Staab, R | 1 |
| Livingston, R | 1 |
| Lavin, PT | 2 |
| Woll, J | 1 |
| Conroy, JF | 2 |
| Carbone, P | 1 |
| Vogel, SJ | 1 |
| Padilla, F | 1 |
| Groppe, C | 1 |
| Guy, G | 1 |
| Quagliana, J | 1 |
| McCracken, J | 1 |
| Hoogstraten, B | 1 |
| Heilbrun, L | 1 |
| Milstein, D | 1 |
| Belt, RJ | 1 |
| Stephens, R | 1 |
| Vassilopoulos, PP | 1 |
| Shingleton, WW | 3 |
| Elias, EG | 4 |
| Aust, JB | 2 |
| Aleksanian, AZ | 1 |
| Gapaniuk, ON | 1 |
| Sidorchenkov, VO | 1 |
| Kessinger, MA | 1 |
| Foley, JF | 2 |
| Lemon, HM | 2 |
| Dionne, LJ | 1 |
| Kibrite, A | 1 |
| Krauss, S | 1 |
| Sonoda, T | 1 |
| Solomon, A | 1 |
| White, LA | 1 |
| Perry, MC | 1 |
| Kardinal, CG | 1 |
| Kennedy, BJ | 1 |
| Weiss, RB | 1 |
| Carey, RW | 2 |
| Jönsson, PE | 2 |
| Landberg, T | 1 |
| Owman, T | 1 |
| Sundkvist, K | 1 |
| Danjoux, CE | 2 |
| Catton, GE | 2 |
| Hartman, HA | 1 |
| Kessinger, A | 1 |
| Brutti, A | 1 |
| Sini, S | 1 |
| Barzi, AM | 1 |
| Marcuello Gaspar, E | 1 |
| Germa Lluch, JR | 1 |
| Abad Esteve, A | 1 |
| Badia Canto, A | 1 |
| Rowling, J | 1 |
| West, C | 2 |
| Windle, R | 3 |
| Macpherson, S | 1 |
| Bell, PR | 2 |
| Joss, RA | 1 |
| Goldberg, RS | 1 |
| Yates, JW | 1 |
| Kutzner, J | 1 |
| Kempf, P | 1 |
| Li, MC | 3 |
| Ecnow, B | 1 |
| Gold, BH | 1 |
| Sadove, M | 1 |
| Lokich, JJ | 5 |
| Skarin, AT | 2 |
| Frei, E | 1 |
| Kolleg, MK | 1 |
| Magill, GB | 1 |
| Leaming, RH | 1 |
| Hajdu, SI | 1 |
| Krein, BM | 1 |
| Brodsky, I | 1 |
| Fischetti, MR | 1 |
| Weitzman, SA | 1 |
| Kaufman, S | 1 |
| Kelley, RM | 1 |
| Sohier, WD | 1 |
| Evans, JT | 1 |
| Richardson, RL | 1 |
| Shulman, SF | 1 |
| Oldham, RK | 1 |
| Kane, RC | 1 |
| Cashdollar, MR | 1 |
| Bernath, AM | 1 |
| Davis, S | 2 |
| Park, YK | 1 |
| Baughman, BB | 1 |
| Kisner, D | 1 |
| Cedermark, BJ | 2 |
| Didolkar, MS | 2 |
| Carter, SK | 2 |
| Bullen, BR | 1 |
| Brown, GJ | 1 |
| Johnson, RO | 1 |
| Metter, G | 2 |
| Wilson, WL | 1 |
| Davis, HL | 3 |
| Grage, T | 1 |
| Fletcher, WS | 1 |
| Grage, TD | 1 |
| Metter, GE | 2 |
| Strawitz, JG | 1 |
| Nystrom, JS | 2 |
| Bateman, JR | 1 |
| Weiner, J | 1 |
| Kaufman, JH | 1 |
| Viola, MV | 1 |
| Malahy, MA | 1 |
| Jubert, A | 1 |
| Posey, LE | 1 |
| Morgan, LR | 2 |
| Ross, ST | 1 |
| Freireich, EJ | 2 |
| von Eyben, FE | 1 |
| Larsen, V | 1 |
| Pedersen, H | 2 |
| Blokhina, NG | 2 |
| Kisner, DF | 1 |
| Smythe, T | 1 |
| Smith, L | 1 |
| Almersjö, O | 2 |
| Hansen, RM | 5 |
| Stein, RS | 1 |
| Fischerman, K | 2 |
| Petersen, CF | 1 |
| Jensen, SL | 1 |
| Christensen, KC | 1 |
| Efsen, F | 1 |
| Blumenshein, G | 1 |
| Bruckner, HW | 2 |
| Welch, CE | 1 |
| Horsley, S | 1 |
| Donaldson, M | 1 |
| Lovett, WL | 1 |
| Ruffner, BW | 1 |
| Regelson, W | 1 |
| Pajak, TL | 1 |
| Seifert, P | 1 |
| Baker, LH | 1 |
| Reed, ML | 1 |
| Vongtama, V | 1 |
| Moore, RH | 1 |
| Holyoke, ED | 1 |
| Webster, JH | 1 |
| Pitman, SW | 1 |
| Samuels, MS | 1 |
| Thomas, W | 1 |
| Krementz, ET | 1 |
| Meeker, W | 1 |
| Reed, RC | 1 |
| Schulman, S | 1 |
| Thorp, GW | 1 |
| Kirsner, JB | 1 |
| Rosenberg, IH | 1 |
| Falk, RE | 1 |
| MacGregor, AB | 1 |
| Landi, S | 1 |
| Ambus, U | 1 |
| Langer, B | 1 |
| Nitter, L | 1 |
| Golematis, BC | 1 |
| Delikaris, PG | 1 |
| Haritopoulos, NK | 1 |
| Setakis, NG | 1 |
| Schnabel, T | 1 |
| Zamboglou, N | 1 |
| Kuhn, FP | 1 |
| Kolotas, C | 1 |
| Schmitt, G | 1 |
| Smith, FW | 1 |
| Heys, SD | 1 |
| Evans, NT | 1 |
| Roeda, D | 1 |
| Gvozdanovic, D | 1 |
| Eremin, O | 1 |
| Mallard, JR | 1 |
| Rivoire, M | 1 |
| Kouri, MO | 1 |
| Hemmingsson, A | 1 |
| Nyman, R | 1 |
| Sugenoya, A | 1 |
| Horigome, N | 1 |
| Takahashi, C | 1 |
| Iida, F | 1 |
| Nakayama, J | 1 |
| Kuroda, Y | 1 |
| Arima, S | 2 |
| Ohsato, K | 2 |
| Ohkuma, R | 1 |
| Fukuyama, N | 1 |
| Yamanouchi, A | 1 |
| Hisatsugu, T | 1 |
| Abe, R | 2 |
| Klimberg, VS | 1 |
| Langston, JD | 1 |
| Maners, A | 1 |
| Gocio, JC | 1 |
| Hutchins, LF | 1 |
| Lang, NP | 1 |
| Westbrook, KC | 1 |
| Broadwater, JR | 1 |
| Torisu, M | 2 |
| Lim Kok Hooi, A | 1 |
| Kotake, K | 1 |
| Namba, M | 1 |
| Shida, S | 1 |
| Nara, K | 1 |
| Kon, T | 1 |
| Eliseo, R | 1 |
| Convery, K | 1 |
| Kubota, Y | 1 |
| Ooya, M | 1 |
| Masaki, T | 1 |
| Shinozaki, M | 1 |
| Tsuno, N | 1 |
| Uchiyama, M | 1 |
| Sakaguchi, M | 1 |
| Dobrowsky, W | 2 |
| Percarpio, B | 1 |
| Bitterman, J | 1 |
| Sabbath, K | 2 |
| Alfano, F | 1 |
| Ruszkowski, R | 1 |
| Bowen, J | 1 |
| Platz, D | 1 |
| Braumann, D | 1 |
| Buggisch, P | 1 |
| Schmiegel, WH | 1 |
| Drescher, S | 1 |
| Kleeberg, UR | 1 |
| Müllerleile, U | 1 |
| Crone-Münzebrock, W | 1 |
| Hoffman, R | 1 |
| Köhne-Wömpner, CH | 1 |
| Hiddemann, W | 1 |
| Knipp, H | 1 |
| Wilke, H | 1 |
| Bodenstein, H | 1 |
| Schöffski, P | 1 |
| Bokemeyer, C | 1 |
| Lohrmann, HP | 1 |
| Preiss, J | 2 |
| Bernhard, H | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Richter, EI | 1 |
| Schultheis, KH | 1 |
| Gebhardt, C | 1 |
| Wurzer, W | 1 |
| Shibata, N | 1 |
| Noguchi, S | 1 |
| Wagener, DJ | 1 |
| Demuynck, B | 1 |
| Cady, J | 1 |
| Delfau, S | 1 |
| Grangé, JD | 1 |
| Chazouillères, O | 1 |
| Zylberait, D | 1 |
| Van Ginckel, R | 1 |
| Distelmans, W | 1 |
| De Brabander, M | 1 |
| Callens, M | 1 |
| Janssens, B | 1 |
| Jagers, E | 1 |
| Wouters, L | 1 |
| De Coster, R | 1 |
| Janssen, PA | 1 |
| Ueo, H | 1 |
| Reichman, B | 3 |
| van Groeningen, CJ | 3 |
| Laurensse, EJ | 1 |
| Pinedo, HM | 3 |
| Riechman, B | 1 |
| Anderson, JH | 1 |
| Setanoians, A | 1 |
| Cooke, TG | 1 |
| Schaldenbrand, JD | 1 |
| Siders, DB | 1 |
| Zainea, GG | 1 |
| Thieme, ET | 1 |
| Kanda, T | 1 |
| Kubo, T | 1 |
| Maruyama, Y | 1 |
| van der Wilt, CL | 1 |
| Smid, K | 1 |
| Meijer, S | 1 |
| Andrieu, J | 1 |
| Crenn, P | 1 |
| Schwob, J | 1 |
| Roussin-Bretagne, S | 1 |
| Jean, F | 1 |
| Maas, IW | 1 |
| Boven, E | 1 |
| Schlüper, HM | 1 |
| Haisma, HJ | 1 |
| Cheson, BD | 1 |
| Pignon, JP | 1 |
| Tigaud, JM | 1 |
| Lumbroso, J | 3 |
| Ruffie, P | 1 |
| Lasser, PH | 1 |
| Vukelja, SJ | 1 |
| Bonner, MW | 1 |
| McCollough, M | 1 |
| Cobb, PW | 1 |
| Gaule, DA | 1 |
| Fanucchi, PJ | 1 |
| Keeling, JH | 1 |
| Takemori, S | 1 |
| Crown, J | 1 |
| Jakubowski, A | 1 |
| Gasparetto, C | 1 |
| Wong, G | 1 |
| Sheridan, C | 1 |
| Toner, G | 1 |
| Meisenberg, B | 1 |
| Botet, J | 2 |
| Port, RE | 1 |
| Daniel, B | 1 |
| Ding, RW | 1 |
| Seminara, P | 1 |
| Franchi, F | 1 |
| Abdolrahimzadeh, S | 1 |
| Gozzer, M | 1 |
| Sakanoue, Y | 1 |
| Shoji, Y | 1 |
| Utsunomiya, J | 2 |
| Motwani, BT | 1 |
| Keane, TJ | 1 |
| O'Sullivan, B | 1 |
| Catton, CN | 1 |
| Mies, C | 1 |
| Collins, RT | 1 |
| Kubista, TP | 1 |
| Poon, MA | 1 |
| Meyers, WC | 1 |
| Mailliard, JA | 2 |
| Busse, P | 1 |
| LeClair, JM | 1 |
| Falchuk, ZM | 1 |
| Stone, M | 1 |
| Jessup, JM | 1 |
| Andrysek, O | 1 |
| Horák, J | 1 |
| Vítek, P | 1 |
| Gröhn, P | 1 |
| Heinonen, E | 1 |
| Kumpulainen, E | 1 |
| Länsimies, H | 1 |
| Lantto, A | 1 |
| Salmi, R | 1 |
| Pyrhönen, S | 1 |
| Numminen, S | 1 |
| Cleton, FJ | 1 |
| Welvaart, K | 1 |
| Zwaveling, A | 1 |
| Wolf, W | 1 |
| Servis, KL | 1 |
| el-Tahtawy, A | 1 |
| Albright, MJ | 1 |
| Barker, PB | 1 |
| Ring, R | 1 |
| Atkinson, D | 1 |
| Ong, R | 1 |
| King, M | 1 |
| Nakatsu, T | 1 |
| Yokoyama, I | 1 |
| Tsuyuki, K | 1 |
| Soh, Y | 1 |
| Hanai, G | 1 |
| Nohga, K | 1 |
| Koyanagi, H | 1 |
| Ashley, S | 1 |
| Sutton, G | 1 |
| Royle, G | 1 |
| Israel, K | 1 |
| Chapman, D | 1 |
| Vinciguerra, V | 1 |
| Rosenbluth, R | 1 |
| Bosselli, B | 1 |
| Cochran, C | 1 |
| Doroshow, JH | 3 |
| Leong, L | 3 |
| Margolin, K | 3 |
| Litchfield, T | 1 |
| Akman, S | 2 |
| Carr, B | 2 |
| Bertrand, M | 3 |
| Goldberg, D | 3 |
| Blayney, D | 2 |
| Ask, A | 1 |
| Kallum, B | 1 |
| Lunderquist, A | 1 |
| Taylor, RE | 1 |
| Kerr, GR | 1 |
| Burke, P | 1 |
| Stulc, J | 1 |
| Emrich, LJ | 1 |
| Molzahn, E | 1 |
| Gruenagel, HH | 1 |
| Freund, U | 1 |
| Gross, D | 1 |
| Colozza, M | 1 |
| Tonato, M | 1 |
| Belsanti, V | 1 |
| Mosconi, AM | 1 |
| Fiorucci, S | 1 |
| Gernini, I | 1 |
| Rambotti, P | 1 |
| Smith, DE | 2 |
| Muff, NS | 2 |
| Shetabi, H | 2 |
| Stutz, FH | 1 |
| Eiesland, H | 1 |
| Rios, AA | 1 |
| Ende, K | 1 |
| Edwards, C | 1 |
| Faintuch, JS | 1 |
| Saks, S | 1 |
| Itoh, H | 1 |
| Mibu, R | 1 |
| Terasaka, R | 1 |
| Willen, M | 1 |
| Molinaro, P | 1 |
| Lafleur, F | 1 |
| Tuchiya, S | 1 |
| Ohkawa, T | 1 |
| Hirose, T | 1 |
| Tani, C | 1 |
| Ohuchi, T | 1 |
| Nakajima, A | 1 |
| Sinha, PP | 2 |
| Nunziata, C | 1 |
| Ricci, F | 1 |
| Picconi, A | 1 |
| Bonmassar, G | 1 |
| Lagomarsino Caprino, M | 1 |
| Spain, M | 1 |
| McPherson, D | 1 |
| Sillman, FH | 1 |
| Sedlis, A | 1 |
| Ahlgren, JD | 1 |
| Gullo, JJ | 1 |
| Philips, JA | 1 |
| Fryer, JG | 1 |
| Buroker, TR | 1 |
| Fleming, TR | 3 |
| Marschke, RF | 1 |
| Laurie, JA | 1 |
| Ridge, JA | 2 |
| Daly, JM | 2 |
| Donegan, WL | 3 |
| Woodhouse, L | 2 |
| Clark, CG | 1 |
| Flentje, D | 1 |
| Mouroux, J | 1 |
| Deixonne, B | 1 |
| Eledjam, JJ | 1 |
| Baumel, H | 1 |
| Ghosn, M | 1 |
| Sidibe, S | 1 |
| Valone, FH | 1 |
| Kohler, M | 1 |
| Fisher, K | 1 |
| Hannigan, J | 1 |
| Flam, M | 2 |
| Gandara, D | 1 |
| Hendrickson, C | 1 |
| Richman, E | 1 |
| Yu, KP | 1 |
| Alberto, P | 2 |
| Mermillod, B | 2 |
| Germano, G | 1 |
| Kaplan, S | 1 |
| Weber, W | 1 |
| Spati, B | 1 |
| Martz, G | 1 |
| Koks, CH | 1 |
| Brouwers, JR | 1 |
| Sleijfer, DT | 1 |
| Peschau, K | 1 |
| Warthona, M | 1 |
| Danenberg, PV | 1 |
| Hoel, R | 1 |
| Heier, M | 1 |
| Loeb, M | 1 |
| Peters, RE | 1 |
| Chuang, VP | 1 |
| Wallace, S | 1 |
| Claghorn, L | 1 |
| Mavligit, G | 1 |
| Order, SE | 1 |
| Klein, JL | 1 |
| Leichner, PK | 1 |
| Ettinger, DS | 1 |
| Kopher, K | 1 |
| Finney, K | 1 |
| Surdyke, M | 1 |
| Leibel, SA | 1 |
| Horikoshi, N | 1 |
| Imajo, K | 1 |
| Mukaiyama, T | 1 |
| Miyaoka, K | 1 |
| Friedrich, M | 1 |
| Berger, T | 1 |
| Böse-Landgraf, J | 1 |
| La Ciura, P | 1 |
| La Grotta, G | 1 |
| Nigra, E | 1 |
| Comandone, A | 1 |
| Grecchi, G | 1 |
| Leria, G | 1 |
| Calciati, A | 1 |
| Bolton, JS | 1 |
| Sauter, ER | 1 |
| Schaeffer, N | 1 |
| Higgins, J | 1 |
| Pandya, KJ | 1 |
| Chang, AY | 1 |
| Qazi, R | 2 |
| Rubins, J | 1 |
| Asbury, R | 1 |
| Konno, K | 1 |
| Kanamaru, R | 2 |
| Nakai, Y | 1 |
| Koie, H | 1 |
| Masuda, H | 2 |
| Terabe, K | 1 |
| Yamauchi, M | 2 |
| Imaizumi, M | 1 |
| Lafreniere, R | 1 |
| Ketcham, AS | 1 |
| Bjerkeset, T | 1 |
| Fjøsne, HE | 1 |
| John, M | 1 |
| Wittlinger, P | 1 |
| Podolsky, W | 1 |
| Padmanabhan, A | 1 |
| Mowry, PA | 1 |
| Chapman, J | 1 |
| Enochs, K | 1 |
| Groshko, G | 1 |
| Rocchio, R | 1 |
| Futami, K | 1 |
| Shigeta, M | 1 |
| Kinashi, M | 1 |
| Shimura, H | 1 |
| Morphis, JG | 1 |
| Hornback, NB | 1 |
| Jewell, WR | 1 |
| Kasai, Y | 1 |
| Abe, O | 2 |
| Hattori, T | 3 |
| Inokuchi, K | 2 |
| Metzger, U | 2 |
| Aeberhard, P | 1 |
| Gloor, F | 1 |
| Bissat, A | 1 |
| Egeli, R | 1 |
| Laffer, U | 1 |
| Martinoli, S | 1 |
| Mueller, W | 1 |
| Schroeder, R | 1 |
| Rieck, B | 1 |
| Kimoto, M | 1 |
| Gunge, N | 1 |
| Murei, T | 1 |
| Sano, K | 1 |
| Kusumoto, T | 2 |
| Anai, H | 2 |
| Kusumoto, H | 2 |
| Miyamoto, K | 1 |
| Fukuchi, K | 1 |
| Takao, S | 1 |
| Ishizawa, T | 1 |
| Shimazu, H | 1 |
| Calabet, J | 1 |
| Andersen, E | 1 |
| Weder, W | 1 |
| Roethlin, M | 1 |
| Largiadèr, F | 1 |
| Nitta, A | 1 |
| Saitou, T | 1 |
| Haghbin, M | 1 |
| Hinson, J | 1 |
| Kaufman, SD | 1 |
| Cantwell, BM | 1 |
| Harris, AL | 1 |
| Yoshimori, M | 1 |
| Ookura, H | 1 |
| Okazaki, N | 1 |
| Tajiri, H | 1 |
| Saito, D | 1 |
| Frich, JC | 1 |
| Wang, YC | 2 |
| Yu, BM | 2 |
| Shen, YX | 2 |
| Jiang, JT | 1 |
| Ding, QG | 2 |
| Xia, ZQ | 1 |
| Xie, GP | 1 |
| Chen, ZR | 1 |
| Lin, LH | 1 |
| Yang, JS | 1 |
| Ma, L | 1 |
| Schwarz, V | 1 |
| Hines, JD | 1 |
| Zakem, MH | 1 |
| Adelstein, DJ | 1 |
| Mortimer, JE | 1 |
| Higano, C | 1 |
| Bartolucci, R | 1 |
| Padalino, D | 1 |
| Brugia, M | 1 |
| Trave, F | 2 |
| Frank, C | 1 |
| Gustavsson, BG | 1 |
| Frösing, R | 1 |
| Redmond, C | 1 |
| Caplan, R | 1 |
| Lerner, H | 1 |
| Stevens, L | 1 |
| Datena, S | 1 |
| Graffis, R | 1 |
| Fine, S | 1 |
| Elhakim, T | 1 |
| Turner, S | 1 |
| Kubilis, P | 1 |
| Hui, S | 1 |
| Correa, J | 1 |
| Ansari, R | 1 |
| Stephens, D | 1 |
| Woodburn, R | 1 |
| Meyer, S | 1 |
| Panettiere, FJ | 1 |
| Goodman, PJ | 1 |
| Costanzi, JJ | 1 |
| Brownlee, RW | 1 |
| Laufman, L | 1 |
| Stephens, RL | 1 |
| Bonnet, J | 1 |
| Zeleniuch-Jacquotte, A | 1 |
| Chalmers, TC | 1 |
| Banerjee, TK | 1 |
| Zaentz, SD | 1 |
| Schiferl, EA | 1 |
| Ousley, JL | 1 |
| Pogodzinski, AE | 1 |
| Trump, DL | 1 |
| Coates, A | 1 |
| Shaw, D | 1 |
| Weitberg, AB | 1 |
| Wiemann, MC | 1 |
| Cummings, FJ | 1 |
| Calabresi, P | 1 |
| Hryniuk, WM | 1 |
| Figueredo, A | 1 |
| Goodyear, M | 1 |
| Hoth, DF | 1 |
| King, SA | 1 |
| Leyland-Jones, B | 1 |
| Miller, RL | 1 |
| Andresen, S | 1 |
| Gahbauer, R | 1 |
| Domergue, J | 1 |
| Astre, C | 1 |
| Saint-Aubert, B | 1 |
| Joyeux, H | 1 |
| Solassol, C | 1 |
| Pujol, H | 1 |
| Saeki, K | 1 |
| Shimoyama, T | 1 |
| Makiyama, T | 1 |
| Kusano, H | 1 |
| Kawaguchi, A | 1 |
| Kajiwara, K | 1 |
| Mine, Y | 1 |
| Tagawa, Y | 1 |
| Ekberg, H | 2 |
| Persson, B | 1 |
| Nilsson, LG | 1 |
| Gustafson, T | 1 |
| Andersson, KE | 1 |
| Mel'nikov, RA | 1 |
| Mosidze, BA | 1 |
| Goldberg, JA | 1 |
| Willmott, N | 1 |
| McKillop, JH | 1 |
| Singh, G | 1 |
| Silberman, H | 1 |
| Jakubowski, AA | 1 |
| Mizusawa, H | 1 |
| Dalesio, O | 2 |
| Delvaux, G | 2 |
| Willems, G | 2 |
| Depadt, G | 1 |
| Sakurai, Y | 1 |
| Kuzuoka, M | 1 |
| Takabayashi, T | 1 |
| Maeta, M | 1 |
| Koga, S | 1 |
| Shimizu, N | 1 |
| Hamazoe, R | 1 |
| Murakami, A | 1 |
| Sethi, VK | 1 |
| Chia, KB | 1 |
| Khor, TH | 1 |
| Tan, BC | 1 |
| Tan, TM | 1 |
| Durrant, LG | 1 |
| Garnett, MC | 1 |
| Armitage, NC | 1 |
| Ballantyne, KC | 1 |
| Marksman, RA | 1 |
| Hardcastle, JD | 1 |
| Baldwin, RW | 1 |
| Pagana, TJ | 1 |
| Mishina, H | 1 |
| Okuyama, S | 1 |
| Virdis, A | 1 |
| Spissu, M | 1 |
| Soro, P | 1 |
| Masia, S | 1 |
| Trignano, M | 1 |
| Ginman, C | 1 |
| Graffman, S | 1 |
| Ståhle, E | 1 |
| Blayney, DW | 1 |
| Cecchi, G | 1 |
| Ritch, PS | 2 |
| Anderson, T | 2 |
| Quebbeman, EJ | 1 |
| Frick, J | 1 |
| Shoemaker, DD | 1 |
| Cavallaro, A | 1 |
| Rossi, S | 1 |
| Cassano, A | 1 |
| Noviello, MR | 1 |
| Wanderås, EH | 1 |
| Flokkmann, A | 1 |
| Newman, E | 1 |
| Chollet, P | 3 |
| Metzger, G | 2 |
| Zittoun, J | 2 |
| Marquet, J | 2 |
| Vandenbulcke, JM | 2 |
| Potrebica, V | 1 |
| Stanovnik, M | 1 |
| Case, LD | 1 |
| Jackson, DV | 1 |
| Zekan, P | 1 |
| Cruz, J | 1 |
| Stuart, JJ | 1 |
| Fourtillan, JB | 1 |
| Sugarbaker, PH | 5 |
| Gianola, FJ | 5 |
| Barofsky, I | 4 |
| Wesley, R | 3 |
| Irvin, T | 1 |
| Vowles, KD | 1 |
| Golby, MG | 1 |
| Budd, GT | 1 |
| Rivkin, SE | 1 |
| O'Bryan, RM | 1 |
| Balcerzak, SP | 1 |
| Kulemin, VV | 1 |
| Al'bitskiĭ, VB | 1 |
| Kotomin, SV | 1 |
| Varigin, IuA | 1 |
| Guarneri, D | 1 |
| Rubagotti, A | 2 |
| Porcile, G | 1 |
| Nobile, MT | 3 |
| Hart, RD | 1 |
| Taylor, RF | 1 |
| Harvey, JH | 1 |
| Gayral, F | 1 |
| Edouard, D | 1 |
| Bedossa, P | 1 |
| Dinh, A | 1 |
| Paoli, D | 1 |
| Larrieu, H | 1 |
| Hunt, TM | 1 |
| Nitenberg, G | 1 |
| Clark, PI | 2 |
| Slevin, ML | 2 |
| Reznek, RH | 1 |
| Fallenius, A | 1 |
| Ohman, U | 1 |
| Schaaf, LJ | 1 |
| Dobbs, BR | 1 |
| Edwards, IR | 1 |
| Perrier, DG | 1 |
| Kido, C | 1 |
| Wicks, LJ | 1 |
| Galligioni, E | 1 |
| Canobbio, L | 2 |
| Figoli, F | 1 |
| Fassio, T | 1 |
| Crivellari, D | 1 |
| Vaccher, E | 1 |
| Lo Re, G | 1 |
| Veronesi, A | 1 |
| Wile, A | 1 |
| Smolin, M | 1 |
| Honda, H | 1 |
| Agishi, T | 1 |
| Nakazawa, H | 1 |
| Teraoka, S | 1 |
| Fuchinoue, S | 1 |
| Nakagawa, Y | 1 |
| Richter, C | 1 |
| Rettenmaier, G | 1 |
| Dy, C | 1 |
| Gil, A | 1 |
| Algarra, SM | 1 |
| Aparicio, LA | 1 |
| Herranz, P | 1 |
| Thirlwell, MP | 1 |
| Hollingsworth, LM | 1 |
| Herba, MJ | 1 |
| Boileau, G | 2 |
| Boos, G | 1 |
| MacFarlane, JK | 1 |
| Lundstedt, C | 1 |
| Hanff, G | 1 |
| Ranstam, J | 1 |
| Garewal, H | 1 |
| Planting, A | 1 |
| Hillen, H | 1 |
| de Jong, M | 1 |
| Papaioannou, AN | 1 |
| Polychronis, AP | 1 |
| Kozonis, JA | 1 |
| Nomicos, J | 1 |
| Tsamouri, M | 1 |
| Plataniotis, GA | 1 |
| Papageorgiou, JK | 1 |
| White, DE | 1 |
| Meyers, CE | 2 |
| Büyükünal, E | 1 |
| Berkarda, N | 1 |
| Serdengeçti, S | 1 |
| Derman, U | 1 |
| Berkarda, B | 1 |
| Zambruni, A | 1 |
| Marpicati, P | 1 |
| Gorni, F | 1 |
| Simoncini, E | 1 |
| Ragni, F | 1 |
| Marini, G | 1 |
| Bardakji, Z | 1 |
| Jolivet, J | 1 |
| Langelier, Y | 1 |
| Besner, JG | 1 |
| Ayoub, J | 1 |
| Kuruvilla, AM | 1 |
| Choi, K | 1 |
| Bhutiani, I | 1 |
| Aziz, H | 1 |
| Rosenthal, J | 1 |
| Braverman, A | 1 |
| Marti, J | 1 |
| Brandys, M | 1 |
| Bilynskiĭ, BT | 1 |
| Ogorchak, MA | 1 |
| Camacho, FJ | 1 |
| Greenwald, ES | 1 |
| Clark, JL | 1 |
| Berger, SH | 1 |
| Berger, FG | 1 |
| Caruso, U | 1 |
| Elli, M | 1 |
| Cravotto, E | 1 |
| Tisone, G | 1 |
| Lombardo, PA | 1 |
| Silvaroli, M | 1 |
| Ficorella, C | 1 |
| Casciani, CU | 1 |
| Vanden-Bulcke, JM | 1 |
| Rudenstam, CM | 1 |
| Domellöf, L | 1 |
| Machin, D | 1 |
| Mullee, M | 1 |
| Trotter, G | 1 |
| Cooke, T | 1 |
| Adson, MA | 1 |
| Speyer, JC | 1 |
| Myers, CE | 1 |
| Rominger, CJ | 1 |
| Conner, N | 1 |
| Furue, H | 2 |
| Itoh, I | 1 |
| Graney, MJ | 1 |
| Hinson, EJ | 1 |
| Higuchi, M | 1 |
| Sako, T | 1 |
| Weber-Stadelmann, W | 1 |
| Smith, RA | 1 |
| Stubblefield, GC | 1 |
| Brock, DT | 1 |
| Reagan, MT | 1 |
| Quebbeman, E | 1 |
| Ausman, R | 1 |
| Becker, T | 1 |
| Caballero, G | 1 |
| Ritch, P | 1 |
| Jenkins, D | 1 |
| Blake, D | 1 |
| Tangen, L | 1 |
| Schulte, W | 1 |
| Zorzitto, ML | 1 |
| Myers, R | 1 |
| Bazos, MJ | 1 |
| Shepherd, FA | 1 |
| Evans, WK | 1 |
| Kinami, Y | 1 |
| Tomita, F | 1 |
| Tatarek, R | 1 |
| Pelikán, A | 1 |
| Kawaura, Y | 1 |
| Ohmura, K | 1 |
| Hashizume, Y | 1 |
| Takayama, K | 1 |
| Sakatoku, M | 1 |
| Hirano, M | 1 |
| Iwa, T | 1 |
| August, DA | 1 |
| Ottow, RT | 1 |
| Schneider, PD | 1 |
| Kemeny, MM | 1 |
| Goldberg, DA | 1 |
| Miner, PJ | 1 |
| Lynch, G | 1 |
| Chun, H | 1 |
| Young, C | 1 |
| Dias Wickramanayake, P | 1 |
| Klein, HO | 1 |
| Pape, S | 1 |
| Meyer-Hofmann, H | 1 |
| Fischer, HP | 1 |
| Kaalhus, O | 1 |
| Whitley, NO | 1 |
| Keramati, B | 1 |
| Jackson, AJ | 1 |
| Hebel, RJ | 1 |
| Jordan, TE | 1 |
| Kanojia, MD | 1 |
| Korinek, JK | 1 |
| Stein, SH | 1 |
| Espinoza, EG | 1 |
| Boublil, JL | 1 |
| Milano, G | 1 |
| Khater, R | 1 |
| Bourry, J | 1 |
| Thyss, A | 1 |
| Bruneton, JN | 1 |
| Renée, N | 1 |
| Philip, C | 1 |
| Chiuten, DF | 1 |
| Panasci, L | 1 |
| Margolese, R | 1 |
| Shepard, KV | 1 |
| Faintuch, J | 1 |
| Sweet, DL | 1 |
| Robin, E | 1 |
| Kok, RM | 1 |
| de Jong, AP | 1 |
| Lankelma, J | 1 |
| Einhorn, LH | 1 |
| Williams, SD | 1 |
| Hui, SL | 1 |
| Pennington, K | 1 |
| Drewinko, B | 1 |
| Yang, LY | 1 |
| Bruzzone, M | 1 |
| Tagarelli, G | 1 |
| Leone, LA | 1 |
| Leissner, KH | 1 |
| Rosengren, K | 1 |
| Wedel, N | 1 |
| Yoshikawa, K | 1 |
| Kitaoka, H | 1 |
| Pettavel, J | 1 |
| Morgenthaler, F | 1 |
| Navashin, SM | 1 |
| Fomina, IP | 1 |
| Osokina, LI | 1 |
| Zharikov, AA | 1 |
| Kissel, P | 1 |
| Bessot, M | 2 |
| Duprez, A | 2 |
| Griffen, WO | 1 |
| Humphrey, L | 1 |
| Sosin, H | 1 |
| Harris, HS | 2 |
| Takatani, O | 1 |
| Hattori, N | 1 |
| Gear, EV | 1 |
| Meyza, J | 2 |
| Lipton, A | 1 |
| Ratner, LH | 1 |
| Weiner, MJ | 1 |
| Greenspan, EM | 1 |
| Krakoff, IH | 1 |
| Briand, P | 1 |
| Nielsen, OV | 1 |
| Morrow, LB | 1 |
| Burrow, GN | 1 |
| Kaplan, SR | 1 |
| Mulrow, PJ | 1 |
| Rottenberg, VI | 1 |
| Kenis, Y | 1 |
| Ferguson, E | 1 |
| Obi, LJ | 1 |
| Stehlin, JS | 1 |
| Greeff, PJ | 1 |
| Hacker, CB | 1 |
| Cunningham, TJ | 1 |
| Sponzo, RW | 1 |
| Raventos, A | 1 |
| Gottlieb, JA | 1 |
| Mackman, S | 1 |
| McElwain, TJ | 1 |
| Larsen, RR | 1 |
| Priestman, TJ | 1 |
| Hanham, IW | 1 |
| Van Eden, EB | 1 |
| Van der Merwe, AM | 1 |
| Van Dyk, JJ | 1 |
| Mayr, AC | 1 |
| Vitvitskiĭ, KF | 1 |
| Glumenson, LE | 1 |
| Witek, JT | 1 |
| Spencer, RP | 1 |
| Astrakhan, VI | 1 |
| Tsuya, A | 1 |
| Kaneda, K | 1 |
| Okano, S | 1 |
| Ermolenko, AS | 1 |
| Tarasova, GV | 1 |
| Murray-Lyon, IM | 1 |
| Sandler, M | 1 |
| Cheetham, HD | 1 |
| Watts, JA | 1 |
| Williams, R | 1 |
| Vozny, EK | 1 |
| Garin, AM | 1 |
| Nakao, I | 1 |
| Furukawa, K | 1 |
| Kanko, T | 1 |
| Harashima, S | 1 |
| From, P | 1 |
| Morrissey, WJ | 1 |
| Sams, J | 1 |
| Lahiri, SR | 1 |
| Freckman, HA | 1 |
| Naess, A | 1 |
| Hatano, S | 1 |
| Cole, DR | 3 |
| Conte, AJ | 2 |
| Gonzalez, EM | 3 |
| Rowe-Jones, DC | 1 |
| McKinna, JA | 1 |
| Korbitz, BC | 1 |
| Rapoport, AH | 1 |
| Burleson, RL | 1 |
| Brix, M | 1 |
| Börjesson, B | 1 |
| Olsson, A | 1 |
| Szatkowska, R | 1 |
| Yamada, E | 1 |
| Miyaishi, S | 1 |
| Kuroyanagi, Y | 1 |
| Smolianskaia, AZ | 1 |
| Gofman, AM | 1 |
| Faĭn, SN | 1 |
| Neubauer, HW | 1 |
| Pasternack, BS | 1 |
| Henderson, IW | 1 |
| Lipowska, B | 1 |
| Lougheed, MN | 1 |
| Rowe, DS | 1 |
| Donaldson, MH | 1 |
| Benabderrahmane, M | 1 |
| Hamaguchi, E | 1 |
| Hishigi, S | 1 |
| Spratt, JS | 1 |
| Lee, TC | 1 |
| Lowenfels, AN | 1 |
| Rohmans, M | 1 |
| Slattery, J | 1 |
| Zurek, WZ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rect[NCT00349076] | Phase 3 | 1,256 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077] | 570 participants (Anticipated) | Observational | 2008-04-30 | Recruiting | |||
| Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours[NCT03256981] | Phase 2/Phase 3 | 113 participants (Actual) | Interventional | 2017-11-27 | Active, not recruiting | ||
| Precision Radiation for OligoMetastatIc and MetaStatic DiseasE (PROMISE)-004: Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression[NCT03808662] | Phase 2 | 107 participants (Actual) | Interventional | 2019-01-16 | Active, not recruiting | ||
| Stereotactic Radiotherapy for Oligo-Progressive Metastatic Cancer (The STOP Trial): A Randomized Phase II Trial[NCT02756793] | 90 participants (Actual) | Interventional | 2016-10-31 | Active, not recruiting | |||
| TRAP - Targeted Radiotherapy in Androgen-suppressed Prostate Cancer Patients.[NCT03644303] | 84 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | |||
| THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy[NCT04815694] | 63 participants (Anticipated) | Interventional | 2021-03-17 | Recruiting | |||
| Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT02935309] | Phase 1 | 20 participants (Actual) | Interventional | 2016-10-14 | Completed | ||
| Randomized Multicentre Phase III Study of Short Course Radiation Therapy Followed by Prolonged Pre-operative Chemotherapy and Surgery in Primary High Risk Rectal Cancer Compared to Standard Chemoradiotherapy and Surgery and Optional Adjuvant Chemotherapy.[NCT01558921] | Phase 3 | 920 participants (Actual) | Interventional | 2011-06-21 | Active, not recruiting | ||
| A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Managem[NCT02008656] | Phase 2 | 358 participants (Actual) | Interventional | 2013-11-30 | Active, not recruiting | ||
| Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529] | Phase 2/Phase 3 | 63 participants (Actual) | Interventional | 2011-01-12 | Completed | ||
| Multicenter Randomized Trial Evaluating FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab in First Line Treatment of Metastatic Colorectal Cancer.[NCT00433927] | Phase 3 | 568 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab[NCT03368859] | Phase 2 | 70 participants (Actual) | Interventional | 2018-03-20 | Terminated (stopped due to Study may continue) | ||
| Randomized, Open, Multicenter Phase III Study With Capecitabine Plus Bevacizumab Versus Capecitabine Plus Irinotecan Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer[NCT01249638] | Phase 3 | 516 participants (Anticipated) | Interventional | 2010-12-31 | Recruiting | ||
| "Neo-adjuvant FOLFOXIRI and Chemoradiotherapy for High Risk (Ugly) Locally Advanced Rectal Cancer"[NCT04838496] | Phase 2 | 128 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | ||
| Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case[NCT01991873] | Phase 2 | 387 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy[NCT04749108] | Phase 2/Phase 3 | 1,075 participants (Anticipated) | Interventional | 2021-11-26 | Recruiting | ||
| A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen[NCT01882868] | Phase 2 | 62 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| Drug Response in Patient-derived Organoids Models of Advanced or Recurrent Ovarian Cancer, an Exploratory Research[NCT05290961] | 30 participants (Anticipated) | Observational [Patient Registry] | 2022-03-09 | Recruiting | |||
| PATHOS Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.[NCT04925154] | 192 participants (Anticipated) | Observational [Patient Registry] | 2021-12-13 | Recruiting | |||
| Adjuvant Chemotherapy With FOLFOX After Total Mesorectal Excision for Locally Advanced Rectal Cancer; an Open-label, Multicenter, Prospective, Randomized Phase 3 Trial[NCT02167321] | Phase 2 | 90 participants (Actual) | Interventional | 2014-12-31 | Active, not recruiting | ||
| Non Inferiority Multicenter Phase III Randomized Trial Comparing Preoperative Chemotherapy Only to Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer (Intergroup FRENCH-GRECCAR- PRODIGE)[NCT03875781] | Phase 3 | 540 participants (Anticipated) | Interventional | 2019-06-05 | Recruiting | ||
| Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma[NCT03503630] | Phase 2 | 44 participants (Actual) | Interventional | 2018-07-20 | Active, not recruiting | ||
| A Prospective, Open-Label, Single-Arm and Multicentre Phase II Study to Explore the Efficacy and Safety of Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Middle and Lower Locally Advanced Rectal Cancer[NCT05792735] | Phase 2 | 27 participants (Anticipated) | Interventional | 2023-04-11 | Recruiting | ||
| Rationale and Design of a Prospective, Multicenter Phase Ⅱ Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.[NCT04911517] | Phase 2 | 50 participants (Anticipated) | Interventional | 2021-06-01 | Recruiting | ||
| Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial.[NCT01814969] | Phase 3 | 260 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| Preoperative Radiochemotherapy With Concurrent Deep Regional Hyperthermia for Locally Advanced Rectal Cancer. A Prospective Phase II Trial[NCT02353858] | Phase 2 | 78 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Neoadjuvant Chemoradiotherapy and Consolidation Chemotherapy for Rectal Cancer: A Randomized Controlled Trial[NCT05496491] | 84 participants (Anticipated) | Interventional | 2022-08-30 | Recruiting | |||
| Patient Reported Outcomes Following Cancer of the Rectum[NCT04936581] | 200 participants (Anticipated) | Observational | 2021-09-01 | Recruiting | |||
| A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer[NCT02921256] | Phase 2 | 363 participants (Actual) | Interventional | 2017-01-11 | Completed | ||
| MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)[NCT04850027] | 268 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| Evaluation of the Efficacy and Toxicity of Neo-adjuvant Short Course Radiation Therapy Concurrently With Continuous Infusion 5-fluorouracil in the Management of Locally Advanced Rectal Cancer Patients[NCT04370418] | Phase 2/Phase 3 | 8 participants (Anticipated) | Interventional | 2020-05-01 | Recruiting | ||
| An In Depth Study Evaluating Patterns in the Colon Cancer Patients Clinical Trials[NCT05715905] | 500 participants (Anticipated) | Observational | 2024-02-29 | Not yet recruiting | |||
| Incidence of The Bowel, Bladder, and Sexual Dysfunction Following Surgery for Colorectal Malignancy[NCT04134104] | 38 participants (Actual) | Observational [Patient Registry] | 2014-12-31 | Completed | |||
| Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309] | Phase 2 | 65 participants (Actual) | Interventional | 2012-04-30 | Completed | ||
| A Phase II/III Trial of Neoadjuvant FOLFOX With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Exci[NCT01515787] | Phase 2/Phase 3 | 1,194 participants (Anticipated) | Interventional | 2012-06-12 | Active, not recruiting | ||
| Phase I Trial of Dose-escalation Preoperative Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy in Locally Advanced Rectal Cancer : the FJUHR-01 Trial[NCT03466424] | 9 participants (Anticipated) | Observational | 2022-08-01 | Recruiting | |||
| Study Protocol - The Development of a Novel Patient Reported Outcomes Measure Committed to the Watch-and-wait Program for Rectal Cancer: An International Delphi Study Protocol[NCT05040646] | 80 participants (Actual) | Observational | 2021-11-01 | Completed | |||
| Short-course Preoperative Radiotherapy With Consolidating Chemotherapy vs. Preoperative Chemoradiation in Patients With Unresectable Rectal Cancer: Phase III Study[NCT00833131] | Phase 3 | 540 participants (Anticipated) | Interventional | 2008-11-30 | Recruiting | ||
| Preoperative Short Course Radiotherapy With Consolidation Chemotherapies and Camrelizumab Followed by Delayed Surgery in Locally Advanced Rectal Cancer[NCT04231552] | Phase 1/Phase 2 | 30 participants (Actual) | Interventional | 2019-11-10 | Active, not recruiting | ||
| Randomized Phase II Trial of Preoperative Combined Modality Chemoradiation for Distal Rectal Cancer[NCT00006366] | Phase 2 | 0 participants | Interventional | 2001-02-28 | Completed | ||
| XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615] | Phase 2/Phase 3 | 116 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Palliative Radiotherapy Followed by Chemotherapy Against Palliative Surgery in Patients With Rectal Cancer With Unresectable Synchronous Distant Metastases[NCT01157806] | Phase 2 | 20 participants (Anticipated) | Interventional | 2010-01-31 | Recruiting | ||
| Preoperative Short-course Radiotherapy With Local Boost Versus Conventional Preoperative Short-course Radiotherapy for Rectal Cancer[NCT02498353] | 100 participants (Anticipated) | Interventional | 2015-07-31 | Not yet recruiting | |||
| Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473] | 200 participants (Actual) | Interventional | 2011-08-31 | Active, not recruiting | |||
| A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer[NCT00307736] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Two-Week COurse Versus Conventionally Fractionated Preoperative Chemoradiotherapy In Locally Advanced Rectal Cancer (TwoArc Trial): A Phase III Randomized Clinical Trial[NCT02484040] | Phase 3 | 370 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| Two Week-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Rectal Cancer: Phase II Multicenter Clinical Trial (KROG 11-02)[NCT01431599] | Phase 2 | 80 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly[NCT02992886] | Phase 2 | 68 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Early Evaluation of Chemosensitivity for Low-risk Stage II/III Rectal Cancer[NCT03666442] | Phase 2 | 61 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.[NCT03042000] | 1,200 participants (Anticipated) | Interventional | 2017-02-28 | Not yet recruiting | |||
| FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY[NCT00002523] | Phase 3 | 1,011 participants (Actual) | Interventional | 1993-04-30 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Complete Pathologic Response Rectal Cancers EYSAC.1 Study[NCT03351959] | 1,000 participants (Anticipated) | Observational | 2018-01-01 | Recruiting | |||
| "Radical External Beam Chemoradiation in Patients With Rectal Cancer: a Wait-and-see Approach"[NCT03001362] | 48 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | |||
| Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator：A Prospective Phase 2 Trial[NCT05338866] | 58 participants (Anticipated) | Observational | 2022-01-01 | Enrolling by invitation | |||
| Multicenter Randomized Controlled Phase III Trial Comparing Ileostomy Closure Before or After Adjuvant Therapy in Patients Operated for Rectal Cancer[NCT04372992] | 14 participants (Actual) | Interventional | 2020-09-01 | Terminated (stopped due to Low accrual - no restart after pandemic suspension) | |||
| Chemotherapy or No Chemotherapy in Clear Margins After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. A Randomised Phase III Trial of Control Vs Capecitabine Plus Oxaliplatin [CHRONICLE][NCT00427713] | Phase 3 | 800 participants (Anticipated) | Interventional | 2004-11-30 | Completed | ||
| The Effect of Neoadjuvant Chemoradiotherapy on Exercise Capacity in Colrectal Cancer Patients[NCT01334593] | 25 participants (Actual) | Observational | 2011-08-31 | Completed | |||
| A Clinical Trial Comparing Preoperative Radiation Therapy And Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy And Continuous Intravenous Infusion Of 5-Fluorouracil With or Without Oxaliplatin In The Treatment Of Patients With [NCT00058474] | Phase 3 | 1,608 participants (Actual) | Interventional | 2004-07-31 | Active, not recruiting | ||
| Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in Locally Advanced Resectable Rectal Cancer: A Randomized, Non-Comparative Phase II Study[NCT00865189] | Phase 2 | 91 participants (Actual) | Interventional | 2007-10-23 | Completed | ||
| Randomized Phase II Study of Adjuvant Chemotherapy With 5-FU/Leucovorin vs. Oxaliplatin/5-FU/Leucovorin After Preoperative Chemoradiotherapy With Fluoropyrimidines Followed by Surgery in Patients With Locally Advanced Rectal Cancer[NCT00807911] | Phase 2 | 320 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191] | Phase 3 | 358 participants (Anticipated) | Interventional | 2016-12-31 | Recruiting | ||
| Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142] | Phase 2 | 21 participants (Actual) | Interventional | 2020-07-15 | Active, not recruiting | ||
| 5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial[NCT01500993] | Phase 3 | 401 participants (Actual) | Interventional | 2002-03-31 | Completed | ||
| Phase 1/2 Study of Valproic Acid and Short-course Radiotherapy Plus Capecitabine as preoperatIve Treatment in Low-moderate Risk Rectal Cancer[NCT01898104] | Phase 1/Phase 2 | 152 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer[NCT05673343] | 100 participants (Anticipated) | Observational | 2023-01-04 | Not yet recruiting | |||
| Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer[NCT00321685] | Phase 2 | 57 participants (Actual) | Interventional | 2006-07-25 | Completed | ||
| Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma[NCT01554059] | Phase 2 | 25 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Rectal Microbiome Variability Among Rectal Cancer Cohorts Including Complete Clinical Responders, Pathologic Responders, and Early Recurrence[NCT04223102] | 40 participants (Anticipated) | Interventional | 2020-02-18 | Active, not recruiting | |||
| A Prospective Multicenter Randomized Controlled Trial of the Clinical Efficacy of Neoadjuvant Therapy Based on Organoids Drug Sensitivity Versus Empirical Neoadjuvant Therapy in the Treatment of Advanced Rectal Cancer[NCT05352165] | 192 participants (Anticipated) | Interventional | 2023-01-01 | Not yet recruiting | |||
| Timing of Rectal Cancer Response to Chemoradiation[NCT00335816] | Phase 2 | 248 participants (Anticipated) | Interventional | 2008-08-31 | Active, not recruiting | ||
| Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial[NCT03038256] | Phase 2 | 244 participants (Anticipated) | Interventional | 2018-01-31 | Recruiting | ||
| Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group[NCT03561142] | Phase 2 | 94 participants (Anticipated) | Interventional | 2018-06-15 | Recruiting | ||
| An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262] | Phase 2 | 30 participants (Actual) | Interventional | 2019-07-19 | Completed | ||
| The New Challenge of Decoding Rectal Cancer Signatures By Non-Invasive Imaging: A Retrospective Radiomics Study[NCT05331040] | 350 participants (Anticipated) | Observational | 2020-05-01 | Active, not recruiting | |||
| Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal Cancer[NCT04304209] | Phase 2 | 195 participants (Anticipated) | Interventional | 2019-10-28 | Active, not recruiting | ||
| Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Therapy in Rectal Cancers: Focus on Cyclomodulin-producing Escherichia Coli[NCT04103567] | 220 participants (Anticipated) | Interventional | 2020-01-14 | Recruiting | |||
| Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT01376453] | Phase 1 | 18 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin[NCT03388190] | Phase 2 | 80 participants (Actual) | Interventional | 2018-05-29 | Active, not recruiting | ||
| Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy[NCT00254683] | Phase 2 | 100 participants (Anticipated) | Interventional | 2005-09-30 | Recruiting | ||
| Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Multicenter Randomised Controlled Trial[NCT03465982] | 340 participants (Anticipated) | Interventional | 2018-06-05 | Recruiting | |||
| Randomized Control Trial Comparing the Impact of a Lengthening of the Interval Between the Radiochemotherapy and Surgery (7 Weeks vs. 11 Weeks) on Complete Pathological Response in Rectal Cancer[NCT01648894] | Phase 3 | 265 participants (Actual) | Interventional | 2012-10-25 | Completed | ||
| A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer[NCT01211210] | Phase 2/Phase 3 | 495 participants (Actual) | Interventional | 2010-06-30 | Active, not recruiting | ||
| Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy of Lower Rectal Cancer With Suspected Local Lymph Node Metastasis[NCT03587480] | 250 participants (Anticipated) | Interventional | 2018-12-17 | Recruiting | |||
| A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum[NCT00145769] | Phase 3 | 326 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction After Sphincter-preserving Surgery Among Rectal Cancer Patients[NCT03569488] | 1,100 participants (Anticipated) | Observational | 2020-01-24 | Recruiting | |||
| A Phase I/II Study of Weekly Intravenous Oxaliplatin in Combination With Oral Daily Capecitabine and Radiation Therapy in the Neoadjuvant Treatment of Rectal Cancer[NCT00086931] | Phase 1/Phase 2 | 37 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal Cancer[NCT03714490] | Phase 2 | 200 participants (Anticipated) | Interventional | 2018-10-23 | Recruiting | ||
| Resource-Sparing Curative Treatment for Rectal Cancer[NCT01459328] | Phase 3 | 350 participants (Anticipated) | Interventional | 2009-09-30 | Recruiting | ||
| The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer[NCT02077296] | 34 participants (Actual) | Observational | 2014-03-31 | Completed | |||
| Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy[NCT01308034] | Phase 1 | 25 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694] | Phase 3 | 49 participants (Actual) | Interventional | 2019-05-11 | Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.) | ||
| Induction Chemotherapy, Preoperative Radiochemotherapy, Consolidation Chemotherapy, Operation and Adjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer- OIGIT 5-01 Phase II Trial[NCT01489332] | Phase 2 | 60 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer[NCT01613469] | Phase 2 | 5 participants (Actual) | Interventional | 2011-08-31 | Terminated (stopped due to Re-eval of patient population) | ||
| Induction Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan) Followed by Short Course Radiotherapy in Locally Advanced Rectal Cancer[NCT05868317] | Phase 2 | 70 participants (Anticipated) | Interventional | 2020-11-01 | Active, not recruiting | ||
| Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147] | Phase 2 | 25 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| A Phase II Study of Oxaliplatin (Eloxatin) Capecitabine (Xeloda) and Pre-operative Radiotherapy for Patients With Locally Advanced and Inoperable Rectal Cancer.[NCT00220051] | Phase 2 | 109 participants (Actual) | Interventional | 2001-11-30 | Completed | ||
| Randomized Phase III Trial Comparing in a Preoperative Schedule the Result of Two Concurrent Chemoradiation Schemes (45 Gy + Capecitabine vs 50 Gy + Capecitabine - Oxaliplatin) on the Rate of Sterilization of the Operative Specimen in Resectable Rectal Ca[NCT00227747] | Phase 3 | 598 participants (Anticipated) | Interventional | 2005-11-08 | Completed | ||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER[NCT02268006] | Phase 2 | 50 participants (Anticipated) | Interventional | 2014-01-31 | Recruiting | ||
| Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer[NCT02278653] | 100 participants (Anticipated) | Observational [Patient Registry] | 2014-03-31 | Active, not recruiting | |||
| Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer[NCT01721785] | 307 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum[NCT00297141] | Phase 2 | 60 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Usefulness of Cell-free DNA Quantification With Fluorescent Assay in Response Evaluation of Palliative Chemotherapy[NCT05227950] | 100 participants (Anticipated) | Observational [Patient Registry] | 2022-01-01 | Recruiting | |||
| Frequency and Classification of Radiation-induced Diarrhoea in Patients With Prostate and Rectal Cancer During Curative External Radiotherapy[NCT05684432] | 100 participants (Anticipated) | Observational | 2022-06-01 | Recruiting | |||
| A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer[NCT00114231] | Phase 2 | 90 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Randomized Phase II Trial Of Neoadjuvant Combined Modality Therapy For Locally Advanced Rectal Cancer[NCT00081289] | Phase 2 | 146 participants (Actual) | Interventional | 2004-03-31 | Completed | ||
| A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer[NCT00308516] | Phase 2 | 66 participants (Actual) | Interventional | 2006-03-31 | Completed | ||
| Minimal Invasive Treatment for Patients With Good Response to Chemoradiation With Selection and Follow-up by MRI: a Single Arm Phase-II Feasibility Study in Rectal Cancer[NCT00939666] | 28 participants (Actual) | Interventional | 2009-07-01 | Completed | |||
| DETECT: Defining the Target Volume for Endoluminal Radiation Boosting in Patients With Rectal Cancer[NCT04927897] | 50 participants (Anticipated) | Observational | 2022-08-16 | Recruiting | |||
| Timing To Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy For Rectal Cancer: A Multicenter Randomized Controlled Trial - Biomarkers SubStudy[NCT03962088] | 200 participants (Anticipated) | Observational | 2019-04-01 | Recruiting | |||
| Total Neoadjuvant Therapy in Rectal Cancer Treatment[NCT04747951] | Phase 4 | 280 participants (Anticipated) | Interventional | 2020-10-30 | Recruiting | ||
| Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535] | Phase 3 | 710 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Preoperative Radiotherapy With or Without Concurrent Chemotherapy (5-Fluorouracil and Leucovorin) in T3-4 Rectal Cancers - Randomized Trial[NCT00296608] | Phase 3 | 762 participants (Actual) | Interventional | 1993-04-30 | Completed | ||
| Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicentre Study[NCT05671809] | 402 participants (Anticipated) | Observational [Patient Registry] | 2023-01-01 | Not yet recruiting | |||
| Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group[NCT02363374] | Phase 2 | 311 participants (Actual) | Interventional | 2015-03-25 | Completed | ||
| A Phase II Trial of Preoperative Capecitabine Plus Irinotecan Followed by Combined Modality Capecitabine and Radiation for Locally Advanced Rectal Cancer: Hoosier Oncology Group GI03-53[NCT00216086] | Phase 2 | 22 participants (Actual) | Interventional | 2005-05-31 | Terminated (stopped due to Funding withdrawn) | ||
| Retrospective Study Comparing Neoadjuvent Short Course of Radiotherapy to Conventional Chemoradiation in Cancer Rectum[NCT04814784] | 48 participants (Anticipated) | Observational | 2021-03-31 | Not yet recruiting | |||
| Evaluation of Computed Tomography and Magnetic Diffusion Resonance Imaging in the Preoperative Staging of Colon Cancer[NCT05727007] | 120 participants (Actual) | Interventional | 2019-01-23 | Completed | |||
| Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial[NCT00814619] | Phase 2 | 68 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer[NCT01152710] | Phase 2 | 57 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686] | Phase 2 | 60 participants (Anticipated) | Interventional | 2009-01-31 | Active, not recruiting | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| Phase I Study of Erlotinib and Temsirolimus in Resistant Solid Malignancies[NCT00770263] | Phase 1 | 46 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy[NCT00855946] | 46 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone[NCT01072513] | 31 participants (Actual) | Interventional | 2010-03-31 | Completed | |||
| MRI for Response Evaluation After Chemoradiation for Locally Advanced Rectal Cancer[NCT04790227] | 50 participants (Anticipated) | Observational | 2022-01-31 | Not yet recruiting | |||
| Prediction of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.[NCT02439086] | 20 participants (Anticipated) | Interventional | 2015-09-30 | Not yet recruiting | |||
| A Phase III, Multi-institutional Randomised Trial Comparing Neoadjuvant Chemoradiotherapy (NARCT) and Total Neoadjuvant Therapy (TNT) in Patients With T3 (a/b/c) Rectal Cancer[NCT06097416] | Phase 3 | 100 participants (Anticipated) | Interventional | 2024-10-31 | Not yet recruiting | ||
| A Randomized, Phase II Study of Concurrent Radiotherapy and Oxaliplatin, Capecitabine With or Without Cetuximab in Rectal Cancer Tumor Stratified by KRAS Mutation Status.[NCT00795301] | Phase 2 | 74 participants | Interventional | 2008-07-31 | Active, not recruiting | ||
| Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405] | 97 participants (Actual) | Interventional | 2016-10-31 | Terminated (stopped due to Withdrawal of analysis study Partner.) | |||
| Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer[NCT06114420] | 500 participants (Anticipated) | Observational | 2023-01-30 | Recruiting | |||
| Pre-operative Radiation Therapy (RT) and Temozolomide (TMZ) in Patients With Newly Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)[NCT03480867] | Phase 1 | 0 participants (Actual) | Interventional | 2017-03-31 | Withdrawn (stopped due to competing study was opened by the surgeon after this trial was opened) | ||
| Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study[NCT00689702] | Phase 2 | 43 participants (Actual) | Interventional | 2007-02-28 | Active, not recruiting | ||
| Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)[NCT02942238] | 582 participants (Anticipated) | Interventional | 2017-01-31 | Not yet recruiting | |||
| Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649] | Phase 2 | 60 participants (Actual) | Interventional | 2013-05-31 | Completed | ||
| Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662] | Phase 2 | 4 participants (Actual) | Interventional | 2014-01-31 | Terminated (stopped due to due to poor recrutment) | ||
| AVF3963s Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer[NCT00600210] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn (stopped due to low patient accrual) | ||
| Postoperative Evaluation of 5-FU by Bolus Injection vs. 5-FU by Prolonged Venous Infusion Prior to and Following Combined Prolonged Venous Infusion Plus Pelvic XRT vs. Bolus 5-FU Plus Leucovorin Plus Levamisole Prior to and Following Combined Pelvic XRT P[NCT00002551] | Phase 3 | 1,917 participants (Actual) | Interventional | 1994-03-31 | Completed | ||
| PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer[NCT04301557] | Phase 2 | 25 participants (Anticipated) | Interventional | 2020-07-31 | Recruiting | ||
| Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemo-radiation for Preoperative Enlarged Lateral Nodes in Advanced Low Rectal Cancer: a Phase III Randomized Controlled Trial[NCT02614157] | 51 participants (Actual) | Interventional | 2016-05-31 | Terminated (stopped due to The enrollment was too low) | |||
| A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma[NCT00901836] | 2 participants (Actual) | Interventional | 2009-05-31 | Terminated (stopped due to Study closed due to feasability) | |||
| Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer[NCT00075556] | Phase 2 | 0 participants | Interventional | 2002-01-31 | Active, not recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Prospective, Randomized, Active-Control, Multi-Center Study Assessing Overall Survival Using Chemotherapy With or Without Impedance-Based Radiofrequency Ablation for Subjects With Colorectal Cancer and Incurable Metastatic Liver Disease, Failing at Leas[NCT00510627] | Phase 4 | 0 participants (Actual) | Interventional | 2007-08-31 | Withdrawn (stopped due to Boston Scientific has decided to close the Study.) | ||
| A Phase I Trial of Isolated Hepatic Perfusion With Oxaliplatin Followed by Hepatic Arterial Infusion of FUDR and Leucovorin for Patients With Unresectable Colorectal Liver Metastases[NCT01042691] | Phase 1 | 10 participants (Actual) | Interventional | 2003-05-31 | Completed | ||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| Prospective Evaluation of 18F-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in the Multimodality Management of Locally Advanced Primary Rectal Cancer[NCT00004891] | 149 participants (Actual) | Interventional | 1999-09-30 | Completed | |||
| Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients[NCT02579980] | 32 participants (Actual) | Interventional | 2015-10-31 | Completed | |||
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis[NCT00001569] | Phase 1 | 74 participants | Interventional | 1997-01-31 | Completed | ||
| MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171] | 180 participants (Anticipated) | Observational | 2022-10-25 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ORR is defined as the proportion of participants with a complete response (CR) or partial response (PR) as determined by a investigator assessment based on Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1. (NCT03368859)
Timeframe: From randomization up to 30 days after last dose of study drug; median time on follow-up was 25.6 (0.3 - 64.4) and 37.6 (0.3 - 66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab plus FOLFIRI, respectively
| Intervention | percentage of participants (Number) |
|---|---|
| ABT-165 Plus FOLFIRI | 5.6 |
| Bevacizumab Plus FOLFIRI | 14.7 |
OS is defined as the time from randomization until death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively
| Intervention | Months (Median) |
|---|---|
| ABT-165 Plus FOLFIRI | 7.95 |
| Bevacizumab Plus FOLFIRI | NA |
PFS is defined as the time from randomization until the first occurrence of radiographic progression determined by investigator assessment or death from any cause. (NCT03368859)
Timeframe: Follow up continued until the first occurrence of radiographic progression, death from any cause or termination of the study; median follow-up time was 25.6(0.3-64.4) and 37.6(0.3-66.3) weeks in ABT-165 plus FOLFIRI and Bevacizumab + FOLFIRI, respectively
| Intervention | Months (Median) |
|---|---|
| ABT-165 Plus FOLFIRI | 3.78 |
| Bevacizumab Plus FOLFIRI | 7.36 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non - compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ratio (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 0.0313 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | mcg*day/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 304.6 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg*day/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 355 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | mcg*day/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 246.9 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of 5-FU in combination with aflibercept and irinotecan in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 2.5, 21 and 45 hours post 5-FU infusion on Day 1 of Cycle 1
| Intervention | liter/hour (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 122 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed pharmacokinetic (PK) analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | mcg/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 73.19 |
Adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. TEAEs were defined as AEs that developed or worsened during the on--treatment period which was defined as the period from the time of first dose of study treatment until 30 days after the last dose of study treatment. (NCT01882868)
Timeframe: First dose (Day 1 of Cycle 1) of study treatment up to end of treatment visit (30 days after last dose of study treatment) (maximum duration: 77 weeks)
| Intervention | participants (Number) |
|---|---|
| Aflibercept + FOLFIRI | 62 |
OS was defined as the time interval from the date of first study drug administration to the date of death due to any cause. If death was not observed, the participant was censored at the last date the participant was known to be alive or the study cut-off date, whichever was first. OS was estimated by Kaplan-Meier estimates. (NCT01882868)
Timeframe: Baseline up to death or study cut--off (maximum duration: 24.7 months)
| Intervention | months (Median) |
|---|---|
| Aflibercept + FOLFIRI | 15.59 |
Overall response in participants was defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) assessed by an independent radiological review committee (IRRC) according to response evaluation criteria in solid tumors (RECIST) version 1.1. CR was defined as disappearance of all target lesions; any lymph node (target or non-target) must have reduction in the short axis to <10 mm; PR was defined as at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters. Percentage of participants with overall response and the 95% confidence interval (CI) were provided. The 95% CI was calculated using normal approximation. (NCT01882868)
Timeframe: Baseline and every 6 weeks until DP (maximum duration: 16.4 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Aflibercept + FOLFIRI | 8.3 |
PFS was defined as the time interval from the date of first study drug administration to the date of first observation of DP or death due to any cause, whichever came first. If death or progression was not observed, the participant was censored at the date of participant's last valid progression-free tumor assessment prior to the study cut-off date. DP for PFS was assessed by the IRRC based on tumor imaging according to RECIST 1.1. Progression in disease was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study with absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions. PFS was estimated by Kaplan-Meier estimates. (NCT01882868)
Timeframe: Baseline and every 6 weeks until DP or death, due to any cause (maximum duration: 16.4 months)
| Intervention | months (Median) |
|---|---|
| Aflibercept + FOLFIRI | 5.42 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of 5-FU in combination with aflibercept and irinotecan in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 2.5, 21 and 45 hours post 5-FU infusion on Day 1 of Cycle 1
| Intervention | ng/mL (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 930 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | days (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 4.47 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | liter/day (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 0.8053 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | liter/day (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 0.716 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | liter/hour (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 18.3 |
Sparse blood sampling was performed on 52 participants and additional blood sampling for detailed PK analysis was performed on 10 participants as per protocol. A population PK analysis was performed and an overall data is reported for all the participants. (NCT01882868)
Timeframe: Pre-dose, 1, 4, 24, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with sparse sampling & pre-dose, 1, 2, 4, 8, 24, 48, 168, 336 hours post aflibercept infusion on Day 1 of Cycle 1 for participants with additional sampling
| Intervention | liters (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 6.197 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | liters (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 3.53 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | liter (Mean) |
|---|---|
| Aflibercept + FOLFIRI | 92.5 |
Blood samples of participants were analyzed by using a titer-based, bridging immunoassay developed and validated to detect aflibercept ADA in human serum. Samples with positive antibody levels were further analyzed using a validated, non-quantitative, competitive ligand binding assay to detect NAb. (NCT01882868)
Timeframe: Baseline, at any time post baseline and 90 days after the last dose of aflibercept
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At baseline in the ADA assay (n=62) | At any time post-baseline in the ADA assay (n=62) | At any time post-baseline in the NAb assay (n=62) | At 90 days after last dose in the ADA assay (n=50) | At 90 days after last dose in NAb assay (n=50) | |
| Aflibercept + FOLFIRI | 1 | 0 | 0 | 0 | 0 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ng*h/mL (Mean) | |
|---|---|---|
| Plasma Irinotecan (n=10) | Plasma SN-38 (n=4) | |
| Aflibercept + FOLFIRI | 17700 | 341 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg*day/mL (Mean) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=5) | |
| Aflibercept + FOLFIRI | 312 | 23.3 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg*day/mL (Mean) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=8) | |
| Aflibercept + FOLFIRI | 321 | 24.4 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ng*h/mL (Mean) | |
|---|---|---|
| Plasma Irinotecan | Plasma SN-38 | |
| Aflibercept + FOLFIRI | 16900 | 344 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | mcg/mL (Mean) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=8) | |
| Aflibercept + FOLFIRI | 90.8 | 2.83 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Plasma Irinotecan | Plasma SN-38 | |
| Aflibercept + FOLFIRI | 2220 | 32.2 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of irinotecan and SN-38 in combination with aflibercept and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Pre-dose (prior to aflibercept infusion), 1.5, 2, 4.5 and 23 hours post irinotecan infusion on Day 1 of Cycle 1
| Intervention | hours (Mean) | |
|---|---|---|
| Plasma Irinotecan (n=10) | Plasma SN-38 (n=5) | |
| Aflibercept + FOLFIRI | 5.19 | 10.3 |
In 10 participants of ITT population, additional blood samples were obtained for detailed non-compartmental PK analysis of free and VEGF-bound aflibercept in combination with irinotecan and 5-FU in Cycle 1. (NCT01882868)
Timeframe: Predose (prior to aflibercept infusion), 1, 2, 4, 8, 24, 48, 168 and 336 hours post aflibercept infusion on Day 1 of Cycle 1
| Intervention | days (Median) | |
|---|---|---|
| Plasma Free-Aflibercept (n=10) | Plasma VEGF-Bound Aflibercept (n=8) | |
| Aflibercept + FOLFIRI | 0.07 | 13.97 |
A linear regression model that controls for the stratification factors (cT-stage and cN-stage) will be used. Mean NAR scores along with standard errors and confidence intervals will be reported by treatment. The NAR score ranges from zero to 100 with lower values corresponding to better prognosis. (NCT02921256)
Timeframe: Baseline to up to 3 years
| Intervention | score on a scale (Mean) |
|---|---|
| Arm Ia (mFOLFOX6, RT, Capecitabine) | 12.6 |
| Arm II (mFOLFOX6, RT, Capecitabine, Veliparib) | 13.7 |
| Arm Ib (mFOLFOX6, RT, Capecitabine) | 14.1 |
| Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 11.5 |
Pathologic Complete Response means no remaining cancer detectable in the pathology sample. Analyzed by a logistic regression model that controls for the stratification factors (cT-stage and cN-stage). Observed proportions along with confidence intervals will be presented by treatment. (NCT02921256)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Mean) |
|---|---|
| Arm Ia (mFOLFOX6, RT, Capecitabine) | 21.6 |
| Arm II (mFOLFOX6, RT, Capecitabine, Veliparib) | 33.8 |
| Arm Ib (mFOLFOX6, RT, Capecitabine) | 29.4 |
| Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 31.9 |
Sphincter preservation means that the surgical procedure used to remove the tumor did not disturb the sphincter muscle. Analyzed by a logistic regression model that controls for the stratification factors (cT-stage and cN-stage). Observed proportions along with confidence intervals will be presented by treatment. (NCT02921256)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Mean) |
|---|---|
| Arm Ia (mFOLFOX6, RT, Capecitabine) | 52.5 |
| Arm II (mFOLFOX6, RT, Capecitabine, Veliparib) | 59.3 |
| Arm Ib (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 71.0 |
| Arm III (mFOLFOX6, RT, Capecitabine, Pembrolizumab) | 59.4 |
MTD of Erlotinib was determined using a traditional 3 + 3 dose escalation scheme of three dose levels (50,100,150mg). Successive cohorts of 3-6 patients were enrolled into dose escalation cohorts for 14 day cycles. MTD reflects the highest dose of Erlotinib that had ≤1 out of 6 patients with Dose-Limiting Toxicity (DLT) at the highest dose level below the maximally administered dose. The maximally administered dose is the first dose that causes DLT in >33% of patients. DLT was defined as: Any grade 4 neutropenia, Any grade 3 thrombocytopenia, or Any ≥ grade 3 non-hematologic toxicity that results in greater than 7 days interruption in therapy. (NCT00307736)
Timeframe: 3 years
| Intervention | mg (Number) |
|---|---|
| 5-FU, Bevacizumab, Erlotinib and Radiation | 100 |
The number of subjects who achieved a pathologic complete response as determine by pathologist, following completion of the study therapy. Pathologic complete response represents the absence of residual invasive disease in the rectum and in the regional lymph nodes. (NCT00307736)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Completed Study Therapy | 9 |
| Underwent Resection | 10 |
| Treated at MTD | 7 |
Summary of disease free survival at 1, 2, and 3 years. Disease free survival is the length of time after primary treatment for cancer ends that the participant survives without any clinical signs or symptoms of that cancer. The data is shown of the percentage of participants still in disease free survival at one, two, and three years. (NCT00307736)
Timeframe: 1, 2, 3 years
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 Year | 2 Years | 3 Years | |
| 5-fluorocuracil, Bevacizumab, Erlotinib and Radiation | 93.4 | 83.4 | 75.5 |
Surgical morbidity following R0 resection with one of the following procedures: abdominal perineal resection, low anterior resection, and low anterior resection with coloanal anastomosis. (NCT00307736)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| anastomotic leaks | intra-abdominal infection | wound infections | pulmonary embolus | small bowel obstruction | urinary obstruction/retention | fever | |
| Surgery, 5-fluorocuracil, Bevacizumab, Erlotinib and Radiation | 4 | 2 | 2 | 1 | 1 | 5 | 1 |
"Summary of grade 3 or greater toxicity by grade and type. All adverse events were evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.~Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.~Grade 4 Life-threatening consequences; urgent intervention indicated." (NCT00307736)
Timeframe: 3 years
| Intervention | participants (Number) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lymphopenia | Diarrhea w/o prior colostomy | Hypophosphatemia | Rash: acne/acneiform | ALT-SGPT | AST-SGOT | Cardiac-ischemia | Colitis | Dehydration | Fatigue | Febrile neutropenia | Hypertension | Hyperuricemia | Hypokalemia | Hyponatremia | Muco/stomatitis (symptom) oral cavity | Muco/stomatitis by exam-oral cavity | Proteinuria | Radiation dermatitis | Rash/desquamation | Rectum-pain | |
| Grade 3 | 16 | 6 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Grade 4 | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
The DFS was defined as the time from the first treatment intake to disease recurrence assessed (second primary cancer, local or distant recurrence, distant metastases) or death from any cause. The DFS was analyzed using Kaplan-Meier method. (NCT00865189)
Timeframe: From first time of the treatment administration to the date of second cancer, local or regional recurrence, distant metastasis or death from any cause (up to approximately 6 years)
| Intervention | months (Median) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 68.3 |
| Arm B (Bevacizumab, Chemoradiotherapy) | NA |
(NCT00865189)
Timeframe: Arm A: Week 16 to Week 23; Arm B: Week 1 to Week 7
| Intervention | cycles (Mean) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 4.4 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 4.8 |
(NCT00865189)
Timeframe: 6 cycles (12 weeks; cycle length = 14 days)
| Intervention | cycles (Mean) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 5.8 |
(NCT00865189)
Timeframe: Arm A: Week 16 to Week 23; Arm B: Week 1 to Week 7
| Intervention | cycles (Mean) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 4.5 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 5.0 |
The overall survival was defined as the time from the first treatment intake to death from any cause. (NCT00865189)
Timeframe: From the first treatment administration to the date of death (up to approximately 6 years)
| Intervention | months (Median) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | NA |
| Arm B (Bevacizumab, Chemoradiotherapy) | NA |
(NCT00865189)
Timeframe: Baseline up to approximately 6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 8.7 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 24.4 |
(NCT00865189)
Timeframe: Baseline up to approximately 6 years
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 30.4 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 33.3 |
The surgery involving a radical rectal excision using the TME technique. (NCT00865189)
Timeframe: Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 91.3 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 97.8 |
Tumor sterilization was defined as the absence of residual tumor cells in the resected specimen including lymph nodes (ypT0-N0). The rate of sterilization of the tumoral specimen was assessed after surgery on the surgical specimen by local review. Analyses were performed for participants who have been operated as defined by the protocol (within the study and TME technique) and for all participants who have been operated. Reported is the percentage of participants with tumor sterilization. (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 23.8 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 11.4 |
The percentage of participants with a recurrence was described by type of recurrence (local and distant recurrence). (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Local recurrence | Distant recurrence | |
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 2.2 | 17.4 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 6.7 | 13.3 |
A participant with a downstaging was defined as a participant with T3 (T describes the size of the original [primary] tumor) at inclusion and T2 or T1 or T0 after surgery, or with N+ (N describes lymph nodes involvement) at inclusion and N- after surgery and if T is equal at inclusion and after surgery. The clinical tumor-node-metastasis (cTNM) classification was used at inclusion and the pathological staging tumor and nodes (ypTN) classification after surgery. Reported is the percentage of participants with tumor downstaging of the surgical specimen according to the local review and centralized review. (NCT00865189)
Timeframe: After surgery (Arm A: approximately 28-31 weeks after initiation of treatment; Arm B: approximately 13-15 weeks after initiation of treatment)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Downstaging, local review (n=41, 44) | Downstaging, centralized review (n=39, 43) | |
| Arm A (Bevacizumab, Induction Chemotherapy, Chemoradiotherapy) | 65.9 | 64.1 |
| Arm B (Bevacizumab, Chemoradiotherapy) | 54.5 | 55.8 |
Overall survival is defined as time from registration to death from any cause. 5-year overall survival rate is estimated using Kaplan-Meier method. (NCT00321685)
Timeframe: survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 80 |
Recurrence free survival is defined as time from surgery to disease recurrence or death without recurrence (whichever occurred first) among resected patients. 5-year recurrence-free survival rate is estimated using Kaplan-Meier method, with 90% confidence interval calculated using Greenwood's formula. (NCT00321685)
Timeframe: recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 81 |
Pathologic complete response to preoperative therapy was determined at the time of surgical resection. Pathologic complete response (pCR) is defined as no evidence of invasive cells on pathologic examination of the primary rectal cancer (or tissue from the area where the tumor had been if there is a complete clinical response). Pathologic complete response rate is calculated as number of patients achieving pathologic complete response divided by all eligible and treated patients (NCT00321685)
Timeframe: Assessed at surgery time
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 17 |
Resection rate is defined as number of patients with T3 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T3 rectal cancers (NCT00321685)
Timeframe: Assessed at surgery time
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 92 |
Resection rate is defined as number of patients with T4 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T4 rectal cancers (NCT00321685)
Timeframe: Assessed at surgery time
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 75 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
The primary endpoint was 3-year disease-free survival (DFS). Evidence of local recurrence, distant metastasis, or death from any cause within 3 years counted as events in the time-to-event Kaplan-Meier analysis of disease-free survival. (NCT00114231)
Timeframe: Up to 3 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 88.2 |
The local recurrence rate (percentage) is defined as the percentage of patients who had local recurrence as initial sites of failure at the end of follow-up. (NCT00114231)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 4 |
The rate (percentage) of patients with negative resection margins after undergoing local excision is reported below. (NCT00114231)
Timeframe: At time of surgery
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 98.7 |
The rate (percentage) of patients with pathologic complete response (pCR) is reported below. Pathologic response will be determined by comparing tumor width and stage in the surgical specimen with the same parameters as determined by pre-CRT ERUS: PATHOLOGIC COMPLETE RESPONSE (pCR): no residual tumor. (NCT00114231)
Timeframe: Up to 5 years
| Intervention | percentage of patients (Number) |
|---|---|
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 44 |
Morbidity and mortality after neoadjuvant cheoradiotherapy and local excision. (NCT00114231)
Timeframe: Up to 30 days
| Intervention | percentage of patients (Number) | |
|---|---|---|
| Mortality | Morbidity | |
| Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery) | 6 | 10 |
"The defecation symptom score is calculated from seven symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 not at all to 4 very much such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and completion of chemoradiation, approximately 6-8 weeks from randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 4.8 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 8.8 |
"The defecation symptom score is calculated from seven symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 not at all to 4 very much such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and completion of post-operative chemotherapy, approximately 32 to 40 weeks from randomization based on 18 weeks of post-operative chemotherapy
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | -1.6 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 14.6 |
"The defecation symptom score is calculated from seven symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 not at all to 4 very much such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and two years
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 0.4 |
| Neoadjuvant Chemoradiation With Oxaliplatin | -1.6 |
The gastro-intestinal (GI) symptom score is calculated from five symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 (not at all) to 4 (very much) such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms. (NCT00081289)
Timeframe: Baseline and completion of chemoradiation approximately 6-8 weeks from randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 5.9 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 20.3 |
The gastro-intestinal (GI) symptom score is calculated from five symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 (not at all) to 4 (very much) such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms. (NCT00081289)
Timeframe: Baseline and completion of post-operative chemotherapy approximately 32 to 40 weeks from randomization based on 18 weeks of post-operative chemotherapy
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | -1.5 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 3.9 |
The gastro-intestinal (GI) symptom score is calculated from five symptom questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-CR38. The question responses range from 1 (not at all) to 4 (very much) such that a higher response indicates worse symptoms. The mean of these responses is linearly transformed to a range of 0 (best) to 100 (worst). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates improvement in symptoms. A negative number indicates improvement in symptoms. (NCT00081289)
Timeframe: Baseline and two years
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 0.4 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 6.7 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates decline in quality of life. A positive number indicates improvement in QOL." (NCT00081289)
Timeframe: Baseline and completion of chemoradiation, approximately 6-8 weeks from randomization
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | -10.3 |
| Neoadjuvant Chemoradiation With Oxaliplatin | -12.2 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates decline in quality of life. A positive number indicates improvement in QOL." (NCT00081289)
Timeframe: Baseline and completion of post-operative chemotherapy approximately 32 to 40 weeks from randomization based on 18 weeks of post-operative chemotherapy
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | -12.5 |
| Neoadjuvant Chemoradiation With Oxaliplatin | -7.1 |
"Global Health Status is calculated from two questions on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire [EORTC QLQ]-C30. The question responses range from 1 very poor to 7 excellent such that a higher response indicates better quality of life (QOL). The mean of these responses is linearly transformed to a range of 0 (worst) to 100 (best). Change from baseline is calculated as the time point value - baseline value and a decrease from baseline indicates decline in quality of life. A negative number indicates improvement in symptoms." (NCT00081289)
Timeframe: Baseline and two years
| Intervention | score on a scale (Mean) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | -6.8 |
| Neoadjuvant Chemoradiation With Oxaliplatin | -1.3 |
Disease-free survival time is defined as time from randomization to date of local-regional failure, the appearance of distant metastases, the appearance of a second primary failure, or date of death from any cause/ Disease-free survival rates are estimated by the Kaplan-Meier method. Patients last known to be alive without failure are censored at the date of last contact. (NCT00081289)
Timeframe: From randomization to four years
| Intervention | percentage of participants (Number) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 68 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 62 |
Time to distant failure is defined as time from randomization to date of the appearance of distant metastases, last known follow-up (censored), or death without distant failure (competing risk). Distant failure rates are estimated by the cumulative incidence method. (NCT00081289)
Timeframe: From randomization to four years
| Intervention | percentage of participants (Number) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 24 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 30 |
Local-regional failure is defined as any of the following: no clinical complete response (cCR) in the primary site and/or nodes at any time after treatment completion (persistence), recurrence and/or progression in the primary site and/or nodes after cCR, and nonprotocol surgery to the primary site after cCR. Time to local-regional failure is defined as time from randomization to date of failure, last known follow-up (censored), or death without local-regional failure (competing risk). Local-regional failure rates are estimated by the cumulative incidence method. (NCT00081289)
Timeframe: From randomization to four years
| Intervention | percentage of participants (Number) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 16 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 18 |
"A pathologic complete response (pCR) was defined as no evidence of residual cancer histologically; disease progression or death before surgery was considered less than pCR (even without surgical specimen). All cases were reviewed by the study's surgical oncology co-chair for the determination of pCR.~Each arm was first analyzed alone. If the arm had 9 or more pCRs in 48 evaluable pts, then the null hypothesis (H0) of 10% pCR rate would be rejected in favor of the alternative hypothesis of 25%, providing 90% power with a two-sided 10% type I error rate. If both arms reject H0, then statistical selection theory would be used to choose the arm for further study in a phase III trial. If only one arm has acceptable pCR rate, then that arm would be pursued in a phase III trial." (NCT00081289)
Timeframe: After protocol surgery, approximately 10-16 weeks from randomization based on surgery occurring 4-8 weeks after chemoradiation
| Intervention | percentage of participants (Number) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 10.4 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 20.8 |
Time to second primary is defined as time from randomization to date of the appearance of a second primary cancer, last known follow-up (censored), or death without second primary (competing risk). Second primary rates are estimated by the cumulative incidence method. (NCT00081289)
Timeframe: From randomization to four years
| Intervention | percentage of participants (Number) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 2 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 6 |
Survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Survival rates are estimated by the Kaplan-Meier method. (NCT00081289)
Timeframe: From randomization to four years
| Intervention | percentage of participants (Number) |
|---|---|
| Neoadjuvant Chemoradiation With Irinotecan | 85 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 75 |
Highest grade adverse event per subject were counted. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. (NCT00081289)
Timeframe: From start of treatment to end of follow-up. Maximum follow-up is 5.2 years.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Hematologic | Non-Hematologic | Overall | |
| Neoadjuvant Chemoradiation With Irinotecan | 20 | 32 | 38 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 19 | 29 | 36 |
Highest grade adverse event per subject were counted. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. (NCT00081289)
Timeframe: From post-surgery to before chemotherapy (CT), or within 60 days of surgery if no postoperative CT. Approximately 10-16 weeks to 14-22 weeks from randomization based on CT starting 4-6 weeks after surgery.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Hematologic | Non-Hematologic | Overall | |
| Neoadjuvant Chemoradiation With Irinotecan | 1 | 9 | 9 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 3 | 9 | 10 |
Highest grade adverse event per subject were counted. Adverse events were graded using the Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. (NCT00081289)
Timeframe: From start of treatment to surgery, approximately 10-16 weeks from randomization based on surgery occurring 4-8 weeks after chemoradiation. If no surgery, then <= 90 days from start of treatment.
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Hematologic | Non-Hematologic | Overall | |
| Neoadjuvant Chemoradiation With Irinotecan | 5 | 11 | 14 |
| Neoadjuvant Chemoradiation With Oxaliplatin | 2 | 14 | 14 |
The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment (NCT00308516)
Timeframe: 24 months
| Intervention | percentage of participants (Number) |
|---|---|
| Preoperative 5FU/Radiation/Bevacizumab | 85 |
| Postoperative 5FU/Radiation/Bevacizumab | 97 |
Overall Survival (OS) is defined ad the Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00308516)
Timeframe: 24 months
| Intervention | months (Median) |
|---|---|
| Preoperative 5FU/Radiation/Bevacizumab | NA |
| Postoperative 5FU/Radiation/Bevacizumab | NA |
The three year rate of Disease-Free Survival (NCT00216086)
Timeframe: 36 months
| Intervention | percentage (Number) |
|---|---|
| Single Group Assignment | 75.5 |
To determine the rates of local and distant disease recurrence after treatment. (NCT00216086)
Timeframe: 36 months
| Intervention | percentage of particpants (Number) | |
|---|---|---|
| metastatic disease recurrence | locally recurrence | |
| Single Group Assignment | 22 | 0 |
"· To determine the pathological response rate of preoperative chemotherapy with capecitabine and irinotecan followed by combined modality chemoradiation with capecitabine in patients with locally advanced rectal cancer.~Pathological response was defined in the protocol as the proportion of complete (pCR) and non-complete pathological response (pNCR) among all evaluable patients." (NCT00216086)
Timeframe: 36 months
| Intervention | percentage of patients (Number) | |
|---|---|---|
| pCR | pNCR | |
| Single Group Assignment | 33 | 56 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
228 reviews available for fluorouracil and Cancer of Rectum
| Article | Year |
|---|---|
Oxaliplatin-based adjuvant chemotherapy rather than fluorouracil-based chemotherapy in rectal cancer is more efficient to decrease distant metastasis and increase survival after preoperative chemoradiotherapy and surgery: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-F | 2022 |
Severe Gastrointestinal Disorder Due to Capecitabine Associated with Dihydropyrimidine Dehydrogenase Deficiency: A Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Fluoroura | 2022 |
Adjuvant chemotherapy after neoadjuvant chemo-radiotherapy and surgery in locally advanced rectal cancer. A systematic review of literature with a meta-analysis of randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Fluoroura | 2022 |
Efficacy and safety of aflibercept plus chemotherapy in metastatic colorectal cancer: A systematic review and PRISMA-Compliant single-arm Meta-Analysis of noncomparative clinical studies and randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2022 |
Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemoradiotherapy; Chemotherapy, Adju | 2022 |
Management of Rectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Fluoroura | 2022 |
A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
[Impact of IMRT for neoadjuvant rectal cancer?]
Topics: Fluorouracil; Humans; Neoadjuvant Therapy; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulate | 2022 |
Chemotherapy Duration for Various Indications in Colorectal Cancer: a Review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Fluorou | 2023 |
A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2023 |
A systemic review and meta-analysis of Aflibercept plus FOLFIRI regimen as a second-line treatment for metastatic colorectal cancer: A PRISMA compliant pooled analysis of randomized controlled trials and single arm studies to assess efficacy and safety.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
Phase II biomarker identification study of anti-VEGF agents with FOLFIRI for pretreated metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Camptothecin; Clinical Tria | 2023 |
Triplet-drug chemotherapy combined with anti-EGFR antibody as an effective therapy for patients with initially unresectable metastatic colorectal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Colon | 2023 |
Oxaliplatin-Induced Multiple Focal Nodular Hyperplasia Masquerading as Colorectal Liver Metastasis-Case Report and Review of Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Digestive System S | 2020 |
Adjuvant chemotherapy in rectal cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as | 2020 |
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Clinical Trials, Ph | 2021 |
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Clinical Trials, Ph | 2021 |
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Clinical Trials, Ph | 2021 |
Total neoadjuvant therapy for rectal cancer: Making sense of the results from the RAPIDO and PRODIGE 23 trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Clinical Trials, Ph | 2021 |
Squamous rectal carcinoma: a rare malignancy, literature review and management recommendations.
Topics: Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Fluorouracil; Humans; Rectal Neoplasms | 2021 |
[Neoadjuvant treatment for rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical | 2021 |
Meta-analysis of oxaliplatin-based versus fluorouracil-based neoadjuvant chemoradiotherapy and adjuvant chemotherapy for locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans | 2017 |
Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Fl | 2017 |
Randomized Clinical Trials in Colon and Rectal Cancer.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Neoadjuvant Therapy; Randomized Con | 2017 |
The Selective Use of Radiation Therapy in Rectal Cancer Patients.
Topics: Chemoradiotherapy; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Neop | 2018 |
Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2018 |
Potential predictive biomarkers in locally advanced rectal cancer treated with preoperative chemo-radiotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Biomarkers, Tumor; Chemoradiotherapy; Fluorouracil; Gen | 2018 |
[Acute Kidney Injury in a Patient with Diarrhea and Vomiting Undergoing Chemotherapy for Colorectal Cancer].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Diarrhea; Fluoroura | 2016 |
Capecitabine versus 5-fluorouracil in neoadjuvant chemoradiotherapy of locally advanced rectal cancer: A meta-analysis.
Topics: Anal Canal; Capecitabine; Chemoradiotherapy, Adjuvant; Clinical Studies as Topic; Fluorouracil; Huma | 2019 |
Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials as Topic | 2013 |
Radiochemotherapy in rectal cancer: the role of oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dige | 2003 |
Concurrent chemoradiotherapy for squamous cell carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2013 |
[A case of metastatic colorectal cancer with icterus due to multiple liver metastases treated effectively by FOLFOX plus bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fata | 2013 |
Postoperative 5-FU based radiochemotherapy in rectal cancer: retrospective long term results and prognostic factors of a pooled analysis on 1,338 patients.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Fluorouracil; Humans; Kap | 2013 |
[Radiotherapy-associated morbidity and mortality in rectal surgery].
Topics: Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Guideline Adherence; Humans; Infusio | 2013 |
[Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorourac | 2014 |
[Penile metastasis from rectal carcinoma: a case report and literature review].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2014 |
[Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Ma | 2014 |
Extensive bowel necrosis related to bevacizumab in metastatic rectal cancer patient: a case report and review of literature.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2015 |
Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease- | 2015 |
Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: A meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery + a fluoropyrimidine ± oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality T | 2015 |
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials | 2015 |
[A CASE OF SOLITARY ADRENAL TUMOR METASTASIZED FROM RECTAL CANCER].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy P | 2015 |
Adjuvant Chemotherapy in Rectal Cancer after Chemoradiotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Survival; | 2016 |
[A Case of Pathologically Complete Response of a Rectal Cancer after Preoperative Treatment with mFOLFOX6 and Radiation Therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 2015 |
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; D | 2016 |
Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Fluorouracil; Humans; N | 2016 |
[Rectal squamous cell carcinoma treatment: Retrospective experience in two French university hospitals, review and proposals].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2016 |
Synchronous quintuple primary gastrointestinal tract malignancies: Case report.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer | 2017 |
Comparison of 5-FU-based and Capecitabine-based Neoadjuvant Chemoradiotherapy in Patients With Rectal Cancer: A Meta-analysis.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2017 |
Capecitabine-induced oromandibular dystonia: a case report and literature review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Asian People; Brain Stem; Capecitabine; Deoxycytidi | 2008 |
Neoadjuvant chemoradiation for rectal cancer: is more better?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
Chemotherapy in addition to preoperative radiotherapy in locally advanced rectal cancer - a systematic overview.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Evidence-Based Medicine; Fluorouracil; H | 2008 |
[Advance in preoperative radiochemotherapy for resectable rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptotic Protease-Activating Factor 1; Carcinoembry | 2008 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms | 2009 |
The multidisciplinary management of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diagnostic Imaging; Digestive System Surgic | 2009 |
[Neoadjuvant radiochemotherapy for rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose Fractionation, Radia | 2009 |
[Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adju | 2008 |
Limitation of surgical radicality in rectal cancer responding to neoadjuvant therapy.
Topics: Antineoplastic Agents; Fluorouracil; Germany; Neoadjuvant Therapy; Practice Patterns, Physicians'; R | 2009 |
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant | 2010 |
Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials.
Topics: Age Factors; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine | 2010 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 2010 |
[A case of poorly differentiated adenocarcinoma of the rectum with disseminated carcinomatosis of the bone marrow successfully treated with mFOLFOX-6/bevacizumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2010 |
[Difference of colon cancer and rectal cancer-from the view of an oncological physician].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Chromosomal In | 2010 |
Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer : is it time for a randomized phase III trial?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as | 2010 |
Evolution of 5-fluorouracil-based chemoradiation in the management of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoadjuvant Ther | 2011 |
[A case of interstitial lung diseases in patient treated with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Lung Disease | 2011 |
[Severe gastric and duodenal ulcer after chemotherapy of mFOLFOX6 and bevacizumab].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2011 |
Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2011 |
Symptomatic 5-fluorouracil-induced sinus bradycardia.
Topics: Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Bradycardia; Fluorouracil; Humans; Infusions, In | 2011 |
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2011 |
[Rectal cancer: current status of multimodal therapy--when and how?].
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy, Adjuvant; Combine | 2011 |
[Chemotherapy and rectal cancer].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop | 2011 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F | 2012 |
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.
Topics: Antineoplastic Agents; Biological Products; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Huma | 2012 |
Rectal cancer: state of the art in 2012.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Fluoro | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Pha | 2012 |
The role of capecitabine in locally advanced rectal cancer treatment: an update.
Topics: Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; | 2012 |
[FOLFIRI with bevacizumab chemotherapy for a patient with recurrence of rectal cancer under haemodialysis for chronic renal failure].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2012 |
Addisonian crisis secondary to bilateral adrenal metastases in rectal carcinoma: report of a rare case and literature review.
Topics: Addison Disease; Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Capecitab | 2013 |
Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2012 |
Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluo | 2013 |
Neoadjuvant short- or long-term radio(chemo)therapy for rectal cancer: how and who should be treated?
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Fluorou | 2012 |
Combined-modality therapy for rectal cancer using irinotecan.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Top | 2002 |
Future directions in adjuvant therapy for rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Co | 2002 |
[Adjuvant and neoadjuvant radiochemotherapy of rectal carcinoma].
Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Humans; N | 2002 |
Chemotherapy for colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 2002 |
Chemoradiation with novel agents for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Chemotherapy, Ad | 2002 |
[Progress in adjuvant therapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug A | 2002 |
Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bone Morphogenetic Protein 2; Bone Morphogen | 2003 |
Adjuvant radiation therapy of patients with rectal cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Colectomy; Combined Modality Therapy; Dos | 2003 |
[Adjuvant therapy of rectal cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorour | 2003 |
[Radiotherapy for locally relapsed rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Camptothecin; Combined Modality Thera | 2003 |
Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2003 |
Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research: 2002 Sir Godfrey Hounsfield lecture delivered at the President's Day, Manchester.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract; Biomarkers; Fluorouracil; Forecastin | 2004 |
Adjuvant therapy for rectal cancer in the elderly.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cli | 2004 |
Combined-modality therapy of rectal cancer with irinotecan-based regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
Combined modality treatment for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
Commentary on Wang et al., "Pre-operative chemotherapy with oral tegafur-uracil and leucovorin for rectal cancer" (J Surg Oncol 89: 256-263).
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Combined Modalit | 2005 |
An overview of approaches to adjuvant therapy for colorectal cancer in the United States.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2005 |
Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2005 |
[Management of rectal cancer in pregnant women].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Case Management; Cesarean Section; Chemotherapy, Adjuv | 2005 |
The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
Preoperative and adjuvant treatment of localized rectal cancer.
Topics: Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Huma | 2006 |
[FOLFIRI regimen for metastatic or recurrent colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; C | 2006 |
Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
[Progress in the treatment of gastrointestinal cancers due to introduction of neoadjuvant concept].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Ci | 2006 |
[Adjuvant chemotherapy for colorectal cancer in Japan-current state and problem areas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colonic Neopla | 2007 |
Integration of novel agents into combined-modality treatment for rectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; | 2007 |
Radiotherapy for localized rectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2007 |
[Bevacizumab (Avastin)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
[Preoperative treatments of rectal cancers].
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as T | 2007 |
Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2008 |
Total mesorectal excision and management of rectal cancer.
Topics: Adenocarcinoma; Anastomosis, Surgical; Antineoplastic Agents; Combined Modality Therapy; Disease Man | 2007 |
Combined-modality therapy for rectal cancer: future prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Capecitabine and radiotherapy as neoadjuvant treatment for rectal cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant | 2007 |
Current options for the management of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; | 2007 |
Chemo-radiotherapy: an alternative to surgery for squamous cell carcinoma of the rectum--report of six patients and literature review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2009 |
The use of capecitabine in the combined-modality therapy for rectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemo | 2008 |
Treatment of the carcinoid tumor and the malignant carcinoid syndrome.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Appendectomy; Ap | 1983 |
Chemotherapy in alimentary tract malignomas.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Cytarabine; Doxor | 1981 |
Intraarterial hepatic infusion chemotherapy in metastatic liver cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio | 1983 |
Comparison of systemic chemotherapy with hepatic arterial infusion in metastatic colorectal carcinoma.
Topics: Antineoplastic Agents; Catheterization; Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; F | 1983 |
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridin | 1984 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
An analysis of chemotherapy for colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1984 |
[Treatment of metastatic liver tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Emboli | 1984 |
Systemic adjuvant therapy with BCG versus BCG + 5FU in colorectal cancer Dukes' Class C: updated critical analysis.
Topics: Aged; BCG Vaccine; Carcinoembryonic Antigen; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl | 1980 |
Systemic chemotherapy for advanced gastrointestinal cancer.
Topics: Antineoplastic Agents; Apudoma; Biliary Tract Neoplasms; Colonic Neoplasms; Drug Therapy, Combinatio | 1980 |
Studies on the treatment and prevention of colorectal liver metastases.
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Hemodynamics; Humans; Liv | 1981 |
Large bowel cancer: an overview.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Femal | 1982 |
Possibilities and limitations of the cytostatic treatment of gastrointestinal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Es | 1982 |
[Choice of treatment in rectal cancer. Consensus Conference, Chamber of Commerce and Industry, Paris, December 1-2, 1994].
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 1995 |
Adjuvant chemotherapy for colon and rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1995 |
Adjuvant radiation for rectal cancer: when and with what?
Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Fluorouracil; Humans; R | 1994 |
Role of adjuvant therapy in surgically resected colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1995 |
[Chemotherapy of metastasizing cancers of the colon and rectum].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neopla | 1993 |
Squamous cell carcinoma complicating idiopathic inflammatory bowel disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transiti | 1995 |
[Developments up to now and current status of adjuvant chemo- and radiotherapy in colonic and rectal carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 1994 |
[Adjuvant chemotherapy in cancers of the colon and rectum].
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Levamisole; Rectal Neoplasms | 1994 |
Adjuvant postoperative therapy of gastrointestinal malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1994 |
[Pre- and postoperative radiotherapy with and without chemotherapy in rectal cancer].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Staging; Radiother | 1994 |
[Adjuvant chemotherapy in rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans | 1994 |
[Adjuvant therapy in colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1994 |
Preoperative combined modality treatment for rectal cancer.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Randomized Controlled Trials as Topic; | 1994 |
The role of chemotherapy and adjuvant therapy in the management of colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Colonic Neo | 1994 |
Surgical adjuvant therapy for rectal cancer: present options.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 1994 |
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
Primary linitis plastica of the rectum: report of four cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease- | 1996 |
The role of adjuvant radiation therapy in the treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Colonic Neoplasms | 1997 |
The role of adjuvant chemotherapy in the treatment of colorectal cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1997 |
[The current status of postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colect | 1997 |
Adjuvant therapy of colorectal cancer.
Topics: Adjuvants, Immunologic; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemother | 1997 |
Current and future directions in adjuvant combined-modality therapy of rectal cancer.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations | 1997 |
Results of local excision followed by postoperative radiation therapy for rectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Recurrence, | 1997 |
[Chemoradiation for rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autonomic Pathways; Drug Administration Schedule; Fl | 1997 |
The role of radiation therapy in rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1997 |
[Surgery and multidisciplinary treatment for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1998 |
Sphincter preservation in rectal cancer. Local excision followed by postoperative radiation therapy.
Topics: Abdomen; Anal Canal; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Colostomy; | 1998 |
[Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic | 1998 |
Colorectal cancer: treatment of advanced disease.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 1998 |
Induction therapy for rectal carcinoma.
Topics: Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; Fluorouracil; Huma | 1998 |
[Treatment of peritoneal carcinosis of colorectal origin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemothe | 1997 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
Management of hepatic metastases.
Topics: Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; | 1999 |
[Chemoradiotherapy in treatment of cancer of the anal canal].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, | 1998 |
Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 1999 |
Squamous-cell carcinoma of the colon responsive to combination chemotherapy: report of two cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squamous Cell; Cisp | 1999 |
[Continuous radiosensitizing chemotherapy].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Combined Modalit | 1999 |
[Treatment with cytostatic agents should be considered in colorectal cancer. It improves prognosis and quality of life].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1999 |
Which 5-fluorouracil regimen?--the great debate.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1999 |
[Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
[Rectal carcinoma. Optimizing treatment by neoadjuvant and adjuvant therapy?].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Hu | 1999 |
Adenosquamous carcinoma of the rectum showing endocrine-cell differentiation: report of a case.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Fluorouraci | 1999 |
Infusional chemoradiation for rectal and anal cancers.
Topics: Anal Gland Neoplasms; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluoroura | 1999 |
[Is portal infusion chemotherapy uneffective for hepatic recurrence after resection for colorectal cancer?].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1999 |
[A case of liver metastases of rectal carcinoid successfully treated with hepatic arterial infusion of methotrexate and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Combined Modality Therapy; Dr | 1999 |
Combined modality therapy of rectal cancers.
Topics: Antineoplastic Agents; Fluorouracil; Humans; Hyperthermia, Induced; Neoadjuvant Therapy; Neoplasm St | 1999 |
[Radiotherapy and chemotherapy in the treatment of cancer of the rectum].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Contro | 2000 |
[Conceptual changes in cancer chemotherapy--biochemical modulation of 5-FU].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; | 2000 |
[Capecitabine--a review of its antitumor activity and toxicity in clinical studies].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabin | 2000 |
Treatment of colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasms; Colorectal Ne | 2000 |
[New drugs in the treatment of advanced colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2000 |
Irinotecan in preoperative combined-modality therapy for locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Radi | 2000 |
Rectal cancer: integrating oxaliplatin into chemoradiation studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, | 2000 |
Raltitrexed/5-fluorouracil-based combination chemotherapy regimens in anticancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Fluo | 2001 |
Chemoradiotherapy for rectal cancer--is there an optimal combination?
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials, Phas | 2001 |
Improving chemoradiotherapy in rectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Clinica | 2001 |
Progress in treatment of cancer of the large bowel.
Topics: Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Humans; Intestinal Obstru | 1976 |
[Current trends of complementary therapy in radical surgery of colo-rectal cancer].
Topics: Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Postoperative Care; P | 1979 |
Chemotherapy of colorectal carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Drug Administration Sche | 1976 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
Chemotherapy of gastrointestinal cancer.
Topics: Apudoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms; Hum | 1978 |
[Basic trends in the combined treatment of locally spread rectal cancer].
Topics: Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperati | 1979 |
[Symposium on carcinoma of colon and rectum: 4. The role of adjuvant therapy with surgery in cancers of the colon and rectum].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunosuppressive Agents; Neoplasm Metastasis; Nitrosourea | 1978 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Abdominal surgery (second of three parts).
Topics: Abdomen; Acute Disease; Anus Diseases; Appendectomy; Appendicitis; Appendix; Carcinoembryonic Antige | 1975 |
Combined radiotherapy and chemotherapy in the treatment of gastrointestinal malignancies.
Topics: Combined Modality Therapy; Fluorouracil; Humans; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neo | 1992 |
Accomplishments in surgical adjuvant therapy for large bowel cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Drug T | 1992 |
Chemotherapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined | 1992 |
Colorectal cancer. Recent developments and continuing controversies.
Topics: Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Levamisol | 1992 |
Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Drug Eruptions; Fluorouracil; Humans; Infusions, Intravenous; Male; Photosensi | 1991 |
Role of radiation therapy in the treatment of carcinoma of the rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Fluorourac | 1991 |
Chemotherapy of advanced cancer of the colon and rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Fluorouracil; Huma | 1991 |
Current treatment approaches in colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neop | 1991 |
The role of immunotherapy in colorectal cancer.
Topics: Antibodies, Monoclonal; Colonic Neoplasms; Fluorouracil; Humans; Immunologic Factors; Immunotherapy; | 1991 |
Management of colorectal cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hu | 1990 |
Surgical therapy of early rectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Fluorourac | 1989 |
Anogenital papillomavirus infection and neoplasia in immunodeficient women.
Topics: Acquired Immunodeficiency Syndrome; Combined Modality Therapy; Female; Fluorouracil; Genital Neoplas | 1987 |
Treatment of colorectal hepatic metastases.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; F | 1985 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
Colorectal cancer: surgical management of recurrent and metastatic disease.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Rectal Neoplas | 1988 |
Hepatic artery ligation or embolization and locoregional chemotherapy of liver metastases from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Emboli | 1988 |
[Current studies of sequential methotrexate and 5-fluorouracil treatment in cancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedule; Dru | 1988 |
Evaluation and treatment of hepatic metastasis from colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1988 |
Surgical adjuvant therapy of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modali | 1988 |
Adjuvant therapy of colorectal cancer. Why we still don't know.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neopla | 1988 |
Role of chemotherapy in the treatment of colorectal carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined M | 1987 |
Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Fluorou | 1987 |
Biochemical modulation of fluorouracil therapy in advanced colorectal cancer.
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Interactions; F | 1987 |
[Chemotherapy of cancer of the large intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms | 1985 |
Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continuous infusion?
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusi | 1985 |
Potentiation of antimetabolite action by alkylating agents.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brea | 1985 |
The prognosis and management of recurrent abdominal malignancies.
Topics: Abdominal Neoplasms; Adolescent; Adult; Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Ca | 1969 |
Dobbins WO 3d,+DOBBINS WO III: Rectal biopsy. A review of its diagnostic usefulness.
Topics: Amyloidosis; Biopsy; Colitis, Ulcerative; Crohn Disease; Cystic Fibrosis; Cysts; Deficiency Diseases | 1968 |
[Chemotherapy of cancer of the rectum and the colon].
Topics: Antimetabolites; Colonic Neoplasms; Drug Synergism; Floxuridine; Fluorouracil; Humans; Injections, I | 1970 |
Chemotherapy of residual disease in solid tumours.
Topics: Colonic Neoplasms; Cyclophosphamide; Floxuridine; Fluorouracil; Head and Neck Neoplasms; Humans; Lun | 1971 |
Newer concepts in chemotherapy of cancer.
Topics: Breast Neoplasms; Colonic Neoplasms; Dysgerminoma; Female; Fluorouracil; Humans; Injections, Intra-A | 1972 |
Obstacles to the improvement of radiotherapy of rectal cancer.
Topics: Adenocarcinoma; Animals; Cyclophosphamide; Fluorouracil; Humans; Laparotomy; Lymphography; Methods; | 1973 |
Chemotherapy in colorectal cancer.
Topics: Carmustine; Chlorambucil; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorourac | 1973 |
773 trials available for fluorouracil and Cancer of Rectum
| Article | Year |
|---|---|
Impact of body-mass index on treatment and outcome in locally advanced rectal cancer: A secondary, post-hoc analysis of the CAO/ARO/AIO-04 randomized phase III trial.
Topics: Body Mass Index; Fluorouracil; Humans; Male; Neoadjuvant Therapy; Rectal Neoplasms; Treatment Outcom | 2021 |
Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; China; Fema | 2021 |
THUNDER 2: THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI guided radiotherapy.
Topics: Adult; Antineoplastic Agents; Capecitabine; Feasibility Studies; Female; Fluorouracil; Humans; Magne | 2022 |
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
Topics: Adenocarcinoma; Capecitabine; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm | 2022 |
Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neopla | 2022 |
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dis | 2022 |
Quality of life in a randomized trial comparing two neoadjuvant regimens for locally advanced rectal cancer-INCAGI004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fecal Incontinence; | 2022 |
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chromosome Deletion; Chromosomes; Colon | 2022 |
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic | 2022 |
Germline Polymorphisms in Genes Involved in the Antioxidant System Predict the Efficacy of Cetuximab in Metastatic Colorectal Cancer Patients Enrolled in FIRE-3 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Bevacizumab; Camptothecin; Cetuximab; | 2022 |
Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer: Exploratory sequential examination of acquired mutations in circulating cell-free DNA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell-Free Nucleic Acids; Colonic Neopl | 2022 |
[The TAILOR study establishes, in patients mCRC wt, the first line use of FOLFOX in combination with cetuximab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating Tu | 2022 |
Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Phenylurea Compo | 2022 |
Efficacy and safety of dilpacimab (ABT-165) versus bevacizumab plus FOLFIRI in metastatic colorectal cancer: a phase II study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2022 |
A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ± Bevacizumab versus FOLFOX ± Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Bevacizumab; C | 2022 |
First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI
Topics: Aged; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2022 |
Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2023 |
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Ph | 2022 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Comparison of short course radiotherapy with chemoradiotherapy for locally advanced rectal cancers in the elderly: A multicentre, randomised, non-blinded, phase 3 trial.
Topics: Activities of Daily Living; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chem | 2023 |
Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Long-term results of a phase 2 study of neoadjuvant chemotherapy with molecularly targeted agents for locally advanced rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Follow-Up Studi | 2023 |
NPY Methylated ctDNA is a Promising Biomarker for Treatment Response Monitoring in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Colonic Neoplasms; Colorect | 2023 |
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
One-Week versus Two-Week Chemoradiotherapy Followed by Curative Surgery in Rectal Cancer: Long-Term Comparative Pooled Analysis of Two Prospective Multicenter Phase II Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fluorouracil; Human | 2023 |
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Clinical Trials, Ph | 2023 |
A phase Ib/II trial of PEP503 (NBTXR3, radioenhancer) with radiotherapy and chemotherapy in patients with rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials | 2023 |
Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Phase II as Topi | 2023 |
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048).
Topics: Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; | 2023 |
Preoperative Treatment of Locally Advanced Rectal Cancer.
Topics: Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, | 2023 |
Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; C | 2023 |
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant | 2023 |
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fluorouracil; Human | 2023 |
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; | 2023 |
Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Fluorouraci | 2023 |
Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; C | 2023 |
Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fluorouracil; Human | 2024 |
Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; | 2023 |
Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Clinical Trials, Phase II as Topi | 2023 |
Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant | 2023 |
Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2019 |
Early MRI predictors of disease-free survival in locally advanced rectal cancer from the GRECCAR 4 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant | 2019 |
Randomized controlled trial of 8 weeks' vs 12 weeks' interval between neoadjuvant chemoradiotherapy and surgery for locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fluorouracil; Human | 2020 |
Association of Sex With Toxic Effects, Treatment Adherence, and Oncologic Outcomes in the CAO/ARO/AIO-94 and CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trials of Rectal Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Ma | 2020 |
Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2019 |
Effect of interval between preoperative radiotherapy and surgery on clinical outcome and radiation proctitis in rectal cancer from FOWARC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cohort Stu | 2020 |
Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Tri
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Disease-Free Su | 2020 |
Feasibility of modulated electro-hyperthermia in preoperative treatment for locally advanced rectal cancer: Early phase 2 clinical results.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Feasibility Studies | 2020 |
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Fluoroura | 2020 |
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Fluoroura | 2020 |
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Fluoroura | 2020 |
Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Fluoroura | 2020 |
Upfront radical surgery with total mesorectal excision followed by adjuvant FOLFOX chemotherapy for locally advanced rectal cancer (TME-FOLFOX): an open-label, multicenter, phase II randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical | 2020 |
NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Ad | 2020 |
Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Flu | 2020 |
Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi | 2020 |
A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therap | 2020 |
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antin | 2020 |
The long-term influence of hospital and surgeon volume on local control and survival in the randomized German Rectal Cancer Trial CAO/ARO/AIO-94.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Germany; Hos | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological | 2020 |
Results of phase II trial of intensified neoadjuvant treatment with interdigitating radiotherapy and chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with locally advanced rectal cancer (PROARCT trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoad | 2021 |
Safety and efficacy of preoperative chemoradiotherapy in fit older patients with intermediate or locally advanced rectal cancer evaluated by comprehensive geriatric assessment: A planned interim analysis of a multicenter, phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Neoad | 2021 |
Optimizing treatment sequencing of chemotherapy for patients with rectal cancer: The KIR randomized phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Fluor | 2021 |
Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial.
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ri | 2021 |
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2021 |
Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: interim analysis of phase III clinical study.
Topics: Chemoradiotherapy; Dose Fractionation, Radiation; Fluorouracil; Humans; Neoplasm Recurrence, Local; | 2021 |
Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial.
Topics: Adenocarcinoma; Chemoradiotherapy; Fluorouracil; Humans; Hyperthermia; Neoadjuvant Therapy; Neoplasm | 2021 |
Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: A Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Neoadjuvant | 2021 |
Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Topics: Anal Canal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2021 |
Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease-F | 2017 |
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Combined Mo | 2017 |
Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dose Fr | 2017 |
Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free | 2017 |
Prospective randomized trial of neoadjuvant chemotherapy during the 'wait period' following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; Fluorourac | 2017 |
Treatment of Locally Advanced Rectal Cancer: Turning Good Rationale Into Good Evidence?
Topics: Antineoplastic Agents; Camptothecin; Chemoradiotherapy; Colectomy; Dose-Response Relationship, Drug; | 2017 |
A Multicenter Phase 2 Study on the Feasibility and Efficacy of Neoadjuvant Chemotherapy Without Radiotherapy for Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Feasibili | 2017 |
Preoperative long-course chemoradiotherapy plus adjuvant chemotherapy versus short-course radiotherapy without adjuvant chemotherapy both with delayed surgery for stage II-III resectable rectal cancer: 5-Year survival data of a randomized controlled trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2017 |
A Phase 2 Study of 5-Fluorouracil (5-FU), Ziv-Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2017 |
Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colectomy | 2017 |
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2017 |
Selecting patients for hyperthermia combined with preoperative chemoradiotherapy for locally advanced rectal cancer.
Topics: Aged; Antigens, Neoplasm; Carbonic Anhydrase IX; Chemoradiotherapy; Combined Modality Therapy; Femal | 2018 |
Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Disease-Free | 2017 |
Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Sur | 2018 |
Preoperative radiotherapy and local excision of rectal cancer: Long-term results of a randomised study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Mo | 2018 |
Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemoradiotherapy, Adjuvant; Femal | 2018 |
Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2018 |
Preoperative radiotherapy or chemoradiotherapy in rectal cancer - Is survival improved? An update of the "Nordic" LARC study in non-resectable cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Human | 2018 |
Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, | 2018 |
Repeating of local therapy of distant metastases increases overall survival in patients with synchronous metastasized rectal cancer-a monocentric analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Fol | 2018 |
A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Feasib | 2018 |
Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Dis | 2018 |
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2018 |
Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2019 |
Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemoradioth | 2019 |
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2019 |
Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2019 |
Leukocytosis and neutrophilia as independent prognostic immunological biomarkers for clinical outcome in the CAO/ARO/AIO-04 randomized phase 3 rectal cancer trial.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2019 |
Dose escalation of preoperative short-course radiotherapy followed by neoadjuvant chemotherapy in locally advanced rectal cancer: protocol for an open-label, single-centre, phase I clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Fluorouracil; Hum | 2019 |
Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemoradioth | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolid | 2019 |
Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiotherapy vs. 5x5Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Decision Support Techniques; Fluo | 2019 |
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2019 |
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2019 |
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2014 |
Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Camptothecin; Chemoradiotherapy; | 2013 |
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Neoadjuvant treatment for unresectable rectal cancer: an interim analysis of a multicentre randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil | 2013 |
Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2013 |
Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2013 |
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com | 2013 |
Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimeta | 2013 |
Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2013 |
[Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2013 |
Postchemoradiation laparoscopic resection and intraoperative electron-beam radiation boost in locally advanced rectal cancer: long-term outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2013 |
Palliative radiotherapy and chemotherapy instead of surgery in symptomatic rectal cancer with synchronous unresectable metastases: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Disease-Free Survival; Female; Fluorourac | 2013 |
Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2013 |
Negative-balance isolated pelvic perfusion in patients with incurable symptomatic rectal cancer: results and drug dose correlation to adverse events.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ca | 2014 |
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B | 2014 |
Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2014 |
Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2014 |
Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2014 |
Two-week course of preoperative chemoradiotherapy followed by delayed surgery for rectal cancer: a phase II multi-institutional clinical trial (KROG 11-02).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2014 |
Results in the elderly with locally advanced rectal cancer from the ACCOR12/PRODIGE 2 phase III trial: tolerance and efficacy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2014 |
RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cape | 2014 |
Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Radiation; Drug Admi | 2014 |
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi | 2014 |
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined | 2014 |
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined | 2014 |
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined | 2014 |
Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined | 2014 |
Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2014 |
Neoadjuvant chemoradiation therapy using concurrent S-1 and irinotecan in rectal cancer: impact on long-term clinical outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Analysis of Variance; Antineoplastic Combined Chemo | 2014 |
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Fluorouracil; Folic Acid; Genetic Ass | 2014 |
Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycyt | 2014 |
Pathological response and safety of two neoadjuvant strategies with bevacizumab in MRI-defined locally advanced T3 resectable rectal cancer: a randomized, noncomparative phase II study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2014 |
Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Deoxycytidine; F | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2014 |
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Nuclear maspin expression as a predictive marker for fluorouracil treatment response in colon cancer.
Topics: Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Nucleus; Chem | 2015 |
Prediction of pathologic staging with magnetic resonance imaging after preoperative chemoradiotherapy in rectal cancer: pooled analysis of KROG 10-01 and 11-02.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2014 |
Effect of neoadjuvant chemoradiation on tumor-infiltrating/associated lymphocytes in locally advanced rectal cancers.
Topics: Antimetabolites, Antineoplastic; Case-Control Studies; Chemoradiotherapy; Female; Fluorouracil; Foll | 2014 |
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short Radiotherapy--rectum 3rd trial).
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Moda | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2014 |
Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2015 |
No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Female; F | 2014 |
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2015 |
Kinetically guided neoadjuvant chemoradiotherapy based on 5-Fluorouracil in patients with locally advanced rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiothe | 2015 |
Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Pharmacogenetic Analysis of INT 0144 Trial: Association of Polymorphisms with Survival and Toxicity in Rectal Cancer Patients Treated with 5-FU and Radiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Disease-Free Survival; Fem | 2015 |
GRP78 Protein Expression as Prognostic Values in Neoadjuvant Chemoradiotherapy and Laparoscopic Surgery for Locally Advanced Rectal Cancer.
Topics: Aged; Biomarkers, Tumor; Chemoradiotherapy, Adjuvant; Endoplasmic Reticulum Chaperone BiP; Female; F | 2015 |
Preoperative chemoradiotherapy with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer: long-term results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Surviva | 2015 |
Postoperative irinotecan in resected stage II-III rectal cancer: final analysis of the French R98 Intergroup trial†.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2015 |
Carcinoma microsatellite instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for stage II rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Female; Fluorourac | 2015 |
Induction FOLFOX followed by preoperative hyperfractionated radiotherapy plus bolus 5-fluorouracil in locally advanced rectal carcinoma: single arm phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose Fractionation, | 2015 |
Clinical complete response (cCR) after neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Dise | 2015 |
Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecit | 2015 |
Sandwich-like neoadjuvant therapy with bevacizumab for locally advanced rectal cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Beva | 2015 |
Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuva | 2015 |
Phase I dose escalation trial of nitroglycerin in addition to 5-fluorouracil and radiation therapy for neoadjuvant treatment of operable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
[Immediate results of combined therapy for local recurrences of rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2015 |
Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2015 |
Chemotherapy Alone for Patients With Stage II/III Rectal Cancer Undergoing Radical Surgery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Fluorour | 2015 |
Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com | 2015 |
NRG Oncology Radiation Therapy Oncology Group 0822: A Phase 2 Study of Preoperative Chemoradiation Therapy Using Intensity Modulated Radiation Therapy in Combination With Capecitabine and Oxaliplatin for Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2015 |
Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoem | 2015 |
Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: Results of the BRANCH trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2015 |
A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2015 |
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2015 |
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2015 |
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2015 |
Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2015 |
Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera | 2015 |
Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2016 |
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2015 |
CoCStom trial: study protocol for a randomised trial comparing completeness of adjuvant chemotherapy after early versus late diverting stoma closure in low anterior resection for rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Digestive Syst | 2015 |
Clinical research of intraperitoneal implantation of sustained-release 5-fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Agents; Colectomy; Colonic Neoplasms; Delayed-Action Preparations; Disease-Free Survi | 2015 |
A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2016 |
A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcin | 2016 |
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose | 2016 |
Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease Progression | 2016 |
Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Consolidation Chemotherapy; Double-B | 2016 |
Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2016 |
Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorouraci | 2016 |
Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
Topics: Adenocarcinoma; Aged; Anal Canal; Antimetabolites, Antineoplastic; Chemoradiotherapy; Fecal Incontin | 2016 |
Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2016 |
Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2016 |
Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free | 2016 |
Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free | 2016 |
Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free | 2016 |
Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2016 |
Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Digestive S | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora | 2016 |
Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04).
Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Chemoradiotherapy; Colectomy; Disease-Free Survival; Do | 2017 |
A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administrat | 2017 |
[Neoadjuvant short-term radiotherapy followed by FOLFOX chemotherapy : No standard treatment for rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Guide | 2016 |
[Inclusion of oxaliplatin in the multimodal treatment of locally advanced rectal cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherap | 2017 |
Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Haplotypes; Humans; Male; Methy | 2017 |
Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy | 2008 |
Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2008 |
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Ch | 2008 |
A modern regimen of pre-operative concurrent chemo-radiation therapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modalit | 2008 |
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2008 |
[Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2009 |
Thymidylate synthase genotypes and tumour regression in stage II/III rectal cancer patients after neoadjuvant fluorouracil-based chemoradiation.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Genotype; Humans; Male; Mid | 2008 |
Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2008 |
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Diseas | 2008 |
Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe?
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Human | 2008 |
Phase I trial of neoadjuvant chemoradiotherapy (CRT) with capecitabine and weekly irinotecan followed by laparoscopic total mesorectal excision (LTME) in rectal cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camp | 2009 |
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2009 |
Safety of laparoscopic total mesorectal excision for low rectal cancer with preoperative chemoradiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Dose Fractionation, | 2009 |
Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2008 |
Preoperative concomitant radiotherapy with oral capecitabine in advanced rectal cancer within 6 cm from anal verge.
Topics: Administration, Oral; Adult; Anal Canal; Antimetabolites, Antineoplastic; Capecitabine; Combined Mod | 2009 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2009 |
Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society.
Topics: Adult; Female; Fluorouracil; Follow-Up Studies; Germany; Humans; Male; Middle Aged; Neoadjuvant Ther | 2009 |
Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality The | 2009 |
Temporal patterns of fatigue predict pathologic response in patients treated with preoperative chemoradiation therapy for rectal cancer.
Topics: Activities of Daily Living; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidin | 2009 |
Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Antirheumatic Agents; Chemotherapy, | 2009 |
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2009 |
Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant | 2009 |
Effect of total mesorectal excision on the outcome of rectal cancer after standardized postoperative radiochemotherapy: do randomized studies translate into clinical routine?
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Incidence; | 2009 |
Surgical treatment for locally advanced lower third rectal cancer after neoadjuvent chemoradiation with capecitabine: prospective phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2009 |
Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Mo | 2009 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Combined Modality Therapy; D | 2009 |
Association between histological type of tumour growth and patient survival in t2-t3 lymph node-negative rectal cancer treated with sphincter-preserving total mesorectal excision.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2009 |
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2010 |
A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2010 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov | 2009 |
A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capec | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, l
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administrati | 2010 |
Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Deoxycytidine; Femal | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2010 |
Preoperative capecitabine and pelvic radiation in locally advanced rectal cancer--is it equivalent to 5-FU infusion plus leucovorin and radiotherapy?
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adju | 2010 |
[Extended preoperative course of radiotherapy as component of combined and complex treatment of locally-advanced ampular rectal cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluoro | 2010 |
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids; | 2010 |
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Coloni | 2011 |
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2010 |
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: high incidence of somatic mutations and their relation with response.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Ch | 2010 |
Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Medium-term results of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Adm | 2010 |
Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibod | 2011 |
Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Mo | 2011 |
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
High-dose-rate intraluminal brachytherapy during preoperative chemoradiation for locally advanced rectal cancers.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Brachytherapy; Capecitabine; Combined Modality T | 2010 |
Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Pro | 2010 |
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2011 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; | 2010 |
Randomized trial of postoperative adjuvant therapy in Stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: 10-year follow-up.
Topics: Antineoplastic Agents; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Dose Fracti | 2011 |
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Diagnostic | 2011 |
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas | 2012 |
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2011 |
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2011 |
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclon | 2010 |
Preoperative radiotherapy with capecitabine and mitomycin C in locally advanced rectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2011 |
Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin | 2011 |
Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Combined Modality Ther | 2011 |
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2011 |
Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2011 |
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; | 2011 |
A pilot feasibility study of TNFerade™ biologic with capecitabine and radiation therapy followed by surgical resection for the treatment of rectal cancer.
Topics: Adult; Capecitabine; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorour | 2010 |
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad | 2011 |
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemical Phenomena; Chemoradiotherapy, Adjuvant | 2011 |
Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer--a two stage phase II clinical trial.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; B | 2012 |
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2012 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2012 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2012 |
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; | 2012 |
A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2011 |
T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv | 2011 |
Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C | 2011 |
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2012 |
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2011 |
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2011 |
[Effectiveness of neoadjuvant chemoradiotherapy of locally advanced rectal cancer in conjunction with local hyperthermia and metronidazole].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; D | 2011 |
Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Drug Administrat | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Preoperative concomitant boost intensity-modulated radiotherapy with oral capecitabine in locally advanced mid-low rectal cancer: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2012 |
Acute toxicity of radiochemotherapy in rectal cancer patients: a risk particularly for carriers of the TGFB1 Pro25 variant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2012 |
Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Disease-Free Survival; Dose Fract | 2012 |
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2012 |
Methylenetetrahydrofolate reductase genetic polymorphisms and toxicity to 5-FU-based chemoradiation in rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studie | 2011 |
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2012 |
[Pathological changes of rectal cancer after irinotecan, 5-fluorouracil or combined short-term radiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hum | 2011 |
Genomic alterations in rectal tumors and response to neoadjuvant chemoradiotherapy: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy, Adjuvan | 2011 |
Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi | 2012 |
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo | 2012 |
High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Feas | 2012 |
Neoadjuvant treatment of mid-to-lower rectal cancer with oxaliplatin plus 5-fluorouracil and leucovorin in combination with radiotherapy: a Korean single center phase II study.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meie | 2013 |
Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape | 2012 |
Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2012 |
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, H | 2012 |
Characterisation of rectal motion during neo-adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy: implications for adaptive dose escalation strategies.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Cross-Over S | 2012 |
Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Confidence In | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Mo | 2012 |
Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Sur | 2012 |
Dose-effect relationship in chemoradiotherapy for locally advanced rectal cancer: a randomized trial comparing two radiation doses.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Denmark; Dose-Response Relationship, Ra | 2012 |
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiot | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2012 |
KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antin | 2013 |
Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.
Topics: Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabi | 2012 |
Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxy | 2013 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2012 |
Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Surv | 2012 |
[Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin in rectal cancer: initial results of the CAO/ARO/AIO-04 study].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined | 2012 |
Long-term results of 2 adjuvant trials reveal differences in chemosensitivity and the pattern of metastases between colon cancer and rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2013 |
Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deo | 2012 |
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem | 2013 |
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Combined-modality therapy for rectal cancer: analysis of potential differences in disease presentation, treatment adherence, and treatment outcome according to race.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Chemoradiotherapy, | 2014 |
Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Co | 2012 |
Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dose Fractionation, | 2013 |
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECO
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2013 |
Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidi | 2013 |
Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; De | 2013 |
Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-F | 2013 |
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dise | 2013 |
Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Acute diarrhea during adjuvant therapy for rectal cancer: a detailed analysis from a randomized intergroup trial.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fluorouracil; Humans; Infus | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2002 |
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2003 |
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti | 2002 |
Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2003 |
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
Synchronous postoperative adjuvant chemoradiation therapy for locally advanced carcinoma of the rectum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; | 2004 |
Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2003 |
Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Su | 2003 |
Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH.
Topics: Aged; Amifostine; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Aberrations; C | 2003 |
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2003 |
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2003 |
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2003 |
Multicenter dose-finding study of concurrent capecitabine and radiotherapy as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2003 |
Results of a randomized trial with or without 5-FU-based preoperative chemotherapy followed by postoperative chemotherapy in resected colon and rectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 2003 |
Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy | 2003 |
Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Germany; | 2003 |
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2003 |
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2003 |
Randomized clinical trial of adjuvant radiotherapy and 5-fluorouracil infusion in colorectal cancer (AXIS).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Colonic Neoplasms; | 2003 |
[Preoperative chemoradiotherapy for locally advanced rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; | 2003 |
[Combined preoperative xeloda and radiotherapy for lower rectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2003 |
Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2004 |
[Appropriate duration of postoperative oral adjuvant chemotherapy with HCFU for colorectal cancer].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Diseas | 2004 |
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2004 |
Phase I and pharmacokinetic study of the polyamine synthesis inhibitor SAM486A in combination with 5-fluorouracil/leucovorin in metastatic colorectal cancer.
Topics: Adult; Aged; Amidines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Coloni | 2004 |
Phase I study of 5-fluorouracil and leucovorin by continuous infusion chronotherapy and pelvic radiotherapy in patients with locally advanced or recurrent rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Combined Modality Therapy; Diarrhea; Di | 2004 |
Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl-5-flu
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2004 |
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplas | 2004 |
[Influence of preoperative (hyperthermic) radiochemotherapy on manometric anal sphincter function in locally advanced rectal cancer].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluor | 2004 |
[An institution-randomized trial of 5-fluorouracil and l-leucovorin therapy given monthly versus every two months to patients with advanced colorectal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Case-Control Studies; Colo | 2004 |
Regional pelvic hyperthermia as an adjunct to chemotherapy (oxaliplatin, folinic acid, 5-fluorouracil) in pre-irradiated patients with locally recurrent rectal cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combine | 2004 |
Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2004 |
Chemoradiation with raltitrexed (Tomudex) in preoperative treatment of stage II-III resectable rectal cancer: a phase II study.
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Folic Acid; Follow-Up Studies; Hematini | 2004 |
Chemoradiation with raltitrexed and oxaliplatin in preoperative treatment of stage II-III resectable rectal cancer: Phase I and II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorouraci | 2004 |
A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2005 |
Leucovorin and fluorouracil vs levamisole and fluorouracil as adjuvant chemotherapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorou | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Preoperative versus postoperative chemoradiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studi | 2004 |
Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capec | 2005 |
Oxaliplatin combined with infusional 5-fluorouracil and concomitant radiotherapy in inoperable and metastatic rectal cancer: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2005 |
Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovo | 2005 |
How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined | 2005 |
Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptoth | 2005 |
A phase I-II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Drug Administration Sch | 2005 |
Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dose Fractionation, Radia | 2005 |
Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Human | 2005 |
Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Human | 2005 |
Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Human | 2005 |
Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Human | 2005 |
Postoperative complications in patients irradiated pre-operatively for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs chemoradiation.
Topics: Antineoplastic Agents; Colectomy; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Postoperati | 2005 |
[Chronotherapy combining 5-fluorouracil, folinic acid and carboplatin as first line treatment in metastatic colorectal cancer. A phase 2 study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chronob | 2005 |
Treatment of rectal cancer by chemoradiation followed by surgery: analysis and early clinical outcome in 66 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Endosonography; Fem | 2005 |
Noninvasive magnetic resonance thermography of recurrent rectal carcinoma in a 1.5 Tesla hybrid system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidi | 2005 |
Randomized controlled trial to evaluate laparoscopic surgery for colorectal cancer: Japan Clinical Oncology Group Study JCOG 0404.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2005 |
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot | 2005 |
Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
A phase I study of concurrent radiotherapy and capecitabine as adjuvant treatment for operable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorou | 2006 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom | 2005 |
A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2005 |
Prediction of mesorectal nodal metastases after chemoradiation for rectal cancer: results of a randomised trial: implication for subsequent local excision.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modality Therapy; Fluorouracil; | 2005 |
Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2006 |
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2006 |
Combined radiotherapy, 5-fluorouracil continuous infusion and weekly oxaliplatin in advanced rectal cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Fluor | 2005 |
Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Combined Modality Therapy; Dose Fractionat | 2006 |
Adjuvant chemotherapy with folinic acid and 5-fluorouracil in patients with locally advanced rectal cancer previously treated by preoperative radiochemotherapy and curative tumor resection.
Topics: Adolescent; Adult; Aged; Chemotherapy, Adjuvant; Colectomy; Drug Therapy, Combination; Female; Fluor | 2006 |
Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemot | 2006 |
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2006 |
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
Comparison of the efficacy of oral capecitabine versus bolus 5-FU in preoperative radiotherapy of locally advanced rectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2006 |
Distal intramural spread of rectal cancer after preoperative radiotherapy: the results of a multicenter randomized clinical study.
Topics: Adult; Aged; Anal Canal; Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality | 2006 |
Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Combined Modality | 2006 |
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2006 |
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2006 |
Three-dimensional conformal radiotherapy combined with FOLFOX4 chemotherapy for unresectable recurrent rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2006 |
A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine | 2006 |
Influence of neoadjuvant radiochemotherapy combined with hyperthermia on the quality of life in rectum cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2006 |
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy | 2006 |
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; | 2006 |
[Chemoembolization of bilateral internal iliac arteries in Miles operation].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Female; Fluor | 2006 |
Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2006 |
The synchronization of chemotherapy to circadian rhythms and irradiation in pre-operative chemoradiation therapy with hyperthermia for local advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Combined Modality Therapy; Fem | 2006 |
Molecular responses of rectal cancer to preoperative chemoradiation.
Topics: Adult; Aged; Biomarkers, Tumor; Celecoxib; Cyclooxygenase 2; Female; Fluorouracil; Humans; Immunohis | 2006 |
[The prospective study on application of parenteral nutrition with alanyl-glutamine dipeptide in chemotherapy of gastrointestinal neoplasms patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Complement C3; Compl | 2006 |
5-fluorouracil and weekly oxaliplatin combined with radiotherapy for locally advanced rectal cancer: surgical complications and long-term results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Chemotherapy with preoperative radiotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2006 |
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2006 |
Preoperative chemoradiotherapy with concomitant small field boost irradiation for locally advanced rectal cancer: a multi-institutional phase II study (KROG 04-01).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; Female; Fluorouracil; H | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; | 2006 |
Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2006 |
[Phase I study of postoperative concurrent chemoradiation with capecitabine as adjuvant treatment for stage II/III operable rectal cancer].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deox | 2006 |
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2006 |
Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: An analysis of outcomes in a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Confidence Intervals; Disea | 2007 |
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2007 |
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2007 |
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2007 |
Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2007 |
Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; F | 2006 |
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Combined | 2007 |
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2007 |
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2006 |
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Dose | 2007 |
Preoperative radio-chemotherapy (RT-CT) in rectal cancer. Prospective study with postoperative RT-CT control group.
Topics: Adenocarcinoma; Amputation, Surgical; Antimetabolites, Antineoplastic; Colostomy; Combined Modality | 2007 |
[Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2007 |
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2007 |
Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2007 |
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise | 2007 |
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic An | 2007 |
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti | 2007 |
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi | 2007 |
Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2008 |
Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Diarrhea; Dose-Response Re | 2006 |
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Rad
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Fluorourac | 2007 |
Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Rad
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Fluorourac | 2007 |
Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Rad
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Fluorourac | 2007 |
Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Rad
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Fluorourac | 2007 |
Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2008 |
Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Digestive System Surgical Procedures; Disease | 2007 |
Preoperative radiotherapy combined with 5 days per week capecitabine chemotherapy in locally advanced rectal cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease Pro | 2007 |
Intensified irinotecan-based neoadjuvant chemoradiotherapy in rectal cancer: four consecutive designed studies to minimize acute toxicity and to optimize efficacy measured by pathologic complete response.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capec | 2007 |
[Impact of perioperative chemotherapy on prognosis of colorectal cancer: a report of 82 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2007 |
Phase I-II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; | 2008 |
Integrating microarray and proteomics data to predict the response on cetuximab in patients with rectal cancer.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Artifi | 2008 |
[Preoperative chemoradiotherapy with FOLFOX in low rectal cancer: a multicenter study].
Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Fluorouracil; Formyltetrahydrofolates; Humans; Male; Mi | 2008 |
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother | 2008 |
Irinotecan+5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy | 2008 |
Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Dru | 2008 |
Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2008 |
Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap | 2007 |
Phase I study of oxaliplatin in combination with capecitabine and radiotherapy as postoperative treatment for stage II and III rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2008 |
Adjuvant chemotherapy in cancer of the colon and rectum: demonstration of effectiveness of prolonged 5-FU chemotherapy in a prospectively controlled, randomized trial.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Neo | 1981 |
Adjuvant chemotherapy of large bowel cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Floxu | 1982 |
Chemotherapy after palliative resection of colorectal cancer. Yorkshire Gastrointestinal Tumour Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Th | 1984 |
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
Efficacy of MER immunotherapy when added to a regimen of 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical Trials as Topic; | 1984 |
Metastatic colorectal carcinoma. A prospective randomized trial of Methyl-CCNU, 5-Fluorouracil (5-FU) and vincristine (MOF) versus MOF plus streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials | 1983 |
Methyl-CCNU, 5-fluorouracil, vincristine, and streptozocin (MOF-STREP) in metastatic colo-rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topi | 1983 |
Combined irradiation and three-drug chemotherapy in inoperable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug | 1982 |
High-dose intermittent iv 5-FU and melphalan in advanced colorectal carcinoma.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug The | 1983 |
The systemic chemotherapy of hepatic metastases.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; D | 1983 |
A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedu | 1983 |
Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1984 |
Adjuvant therapy for colo-rectal cancer.
Topics: Adjuvants, Immunologic; BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality | 1983 |
An analysis of chemotherapy for colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1984 |
Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine.
Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Female; Fluorour | 1984 |
Prospective randomised trial of early cytotoxic therapy for recurrent colorectal carcinoma detected by serum CEA.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Clinical Trials as Topic; | 1984 |
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T | 1984 |
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1984 |
[Effectiveness of combined and complex treatment of patients with operable cancer of the rectum].
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cobalt Radioisotopes; Combined Modality Thera | 1984 |
Complications following postoperative combined radiation and chemotherapy in adenocarcinoma of the rectum and rectosigmoid. A randomized trial that failed.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M | 1984 |
Combination chemotherapy with 5-fluorouracil, CCNU, and vincristine in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections, | 1983 |
Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastroint
Topics: Adenocarcinoma; Clinical Trials as Topic; Colectomy; Combined Modality Therapy; Fluorouracil; Follow | 1984 |
[Evaluation of preoperative administration of N1-(2-tetrahydrofuryl)-5-fluorouracil (FT-207) suppository in surgical adjuvant chemotherapy for large bowel cancer].
Topics: Adult; Colonic Neoplasms; Colostomy; Female; Fluorouracil; Humans; Male; Middle Aged; Preoperative C | 1984 |
Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Ne | 1984 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
[Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].
Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Herpes Labialis; Humans; Hypotension | 1984 |
[Antiblastic therapy of nonadvanced colorectal cancer: preliminary results of a randomized therapeutic trial].
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1982 |
[Clinical evaluation of combination chemotherapy of aclacinomycin A (ACM) and 5-fluorouracil (5-FU) for advanced carcinoma of gastrointestinal tract].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Bile Duct Neoplasms; Clinical Trials as Topic; Colonic Neo | 1982 |
Methyl-CCNU and ftorafur in treatment of rectosigmoidal tumors and ftorafur capsules in treatment of colorectal tumors.
Topics: Capsules; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Huma | 1981 |
Adjuvant chemotherapy of colorectal carcinoma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neo | 1982 |
Combination chemotherapy containing semustine (MeCCNU) in patients with advanced colorectal cancer previously treated with 5-fluorouracil (5-Fu).
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; | 1983 |
Systemic adjuvant therapy with BCG versus BCG + 5FU in colorectal cancer Dukes' Class C: updated critical analysis.
Topics: Aged; BCG Vaccine; Carcinoembryonic Antigen; Clinical Trials as Topic; Colonic Neoplasms; Female; Fl | 1980 |
Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide | 1980 |
Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Drug Therapy, C | 1980 |
MItomycin C, methyl-CCNU and 5-fluorouracil in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; F | 1980 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dru | 1981 |
The effect of fluorouracil on survival in metastatic colorectal cancer fluorouracil response improves survival.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Prognosis; R | 1981 |
Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Immuno | 1980 |
A controlled prospective trial of adjuvant razoxane in resectable colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Piperazines; Razoxane; Rectal Neo | 1981 |
[Background and experience of adjuvant cytostatic therapy in gastrointestinal cancer (author's transl)].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1981 |
Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275).
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration | 1982 |
Sequential chemotherapy of advanced colorectal cancer with standard or high-dose methotrexate followed by 5-fluorouracil.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; Drug Therapy, Combination; Fluo | 1982 |
Large bowel cancer: an overview.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Femal | 1982 |
The role of pre-operative adjuvant therapy in the management of borderline operability rectal cancer.
Topics: Clinical Trials as Topic; Fluorouracil; Humans; Preoperative Care; Prognosis; Rectal Neoplasms; Rect | 1982 |
Combined adjuvant therapy of radically operated colorectal cancer patients. (chemotherapy, radiotherapy, and MER-BCG).
Topics: Adult; Aged; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Male; Midd | 1982 |
High dose 5-fluorouracil (5-FU) and folinic acid in advanced colorectal cancer resistant to standard dose 5-FU treatment: results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug The | 1995 |
A pilot study of concomitant protracted venous infusion 5-fluorouracil and hyperfractionated radiotherapy in rectal tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Human | 1995 |
[Clinico-pathological studies on three preoperative combined treatments for rectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Hyper | 1995 |
Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 1995 |
Cimetidine and survival with colorectal cancer.
Topics: CD8-Positive T-Lymphocytes; Cimetidine; Colonic Neoplasms; Combined Modality Therapy; Disease-Free S | 1995 |
[Is radiotherapy necessary in the control of colorectal cancer?].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cobalt Radioisotopes; Colectomy; Colonic | 1995 |
Adjuvant post-operative radiotherapy vs radiotherapy plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer. A phase III randomized clinical trial. P.A.R. Cooperative Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorou | 1995 |
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1993 |
Intraoperative radiotherapy for primary and recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 1995 |
[Definition, classification and combined treatment of locally invasive rectal neoplasms].
Topics: Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Neoplasm Invasiveness; Neoplasm | 1994 |
Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.
Topics: Adenocarcinoma; Colonic Neoplasms; Fatty Liver; Female; Fluorouracil; Humans; Interferon alpha-2; In | 1995 |
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Disease-Free Survival; Drug Administration Schedu | 1995 |
Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intestine, Small; Leucovorin; Neopl | 1995 |
Continuous hepatic arterial infusion of 5-fluorouracil for unresectable colorectal liver metastases: phase II study.
Topics: Abdominal Pain; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Stu | 1995 |
Different dose regimens of 5-fluorouracil and interferon-alpha in patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Sc | 1995 |
Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case | 1995 |
Double modulation of 5-fluorouracil in advanced colorectal cancer with low-dose interferon-alpha 2b and folinic acid. The "GISCAD" experience. Italian Group for the Study of Digestive Tract Cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; | 1994 |
Efficacy of postoperative 5-FU, high-dose leucovorin, and sequential radiation therapy for clinically resectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1995 |
A pilot clinical trial of surgical adjuvant treatment with high-dose 6S-leucovorin/5-fluorouracil and radiation therapy for high-risk rectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 1994 |
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1995 |
[Preoperative radiochemotherapy in primary non-resectable rectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Chemotherapy, Adjuvant; Female; Fluorouracil; | 1995 |
Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in previously untreated patients with metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1994 |
A phase I-II study of N-(phosphonacetyl)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neop | 1994 |
[Adjuvant therapy in colorectal carcinomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 1994 |
The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival; Fluor | 1994 |
5-Fluorouracil-interferon-alpha 2b adjuvant treatment of Dukes C colorectal cancer.
Topics: Aged; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Colonic Neoplasms; Confidence | 1994 |
Adjuvant intraperitoneal 5-fluorouracil and intravenous leucovorin after colorectal cancer surgery: a randomized phase II placebo-controlled study.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Par | 1994 |
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Therapy, Combination | 1994 |
Downstaging of advanced rectal cancer following combined preoperative chemotherapy and high dose radiation.
Topics: Adult; Aged; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Fluorouracil; | 1994 |
Local excision and postoperative radiation therapy for rectal cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Anal Canal; Brachytherapy; Chemotherapy, Adjuvan | 1994 |
Preoperative combined treatment with radiation, intraluminal hyperthermia, and 5-fluorouracil suppositories for patients with rectal cancer.
Topics: Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Hyperthermia, Induced; Male; Middle A | 1993 |
Randomized comparison of fluorouracil and leucovorin therapy versus fluorouracil, leucovorin, and cisplatin therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms | 1994 |
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Colonic Neoplasms; Drug Admin | 1993 |
Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Combined Modality Therapy; Drug Administration Schedule; | 1994 |
A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-Resp | 1993 |
Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diarrhea; Female; Fluorouracil; Humans; Leucovorin; | 1993 |
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N | 1993 |
Nonparametric estimation for the difference or ratio of median failure times.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Mathematics; Models, Statistical; Rectal Neoplasms; Surviva | 1993 |
Determination of the optimal dose of 5-fluorouracil when combined with low dose D,L-leucovorin and irradiation in rectal cancer: results of three consecutive phase II studies. EORTC Radiotherapy Group.
Topics: Combined Modality Therapy; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Met | 1993 |
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; F | 1993 |
[Phase I study of 5-fluorouracil and l-leucovorin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1993 |
Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1993 |
Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1993 |
The efficacy of preoperative 5-fluorouracil, high-dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.
Topics: Aged; Brachytherapy; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; | 1993 |
[Possible effect of administration methods on pharmacological action. Study of cytostatic therapy in advanced cancer].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neop | 1995 |
Prognostic evaluation of preoperative combined treatment for advanced cancer in the lower rectum with radiation, intraluminal hyperthermia, and 5-fluorouracil suppository.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 1996 |
Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1996 |
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cost of Illness; Fluorouraci | 1996 |
A phase II trial of weekly infusional 5-fluorouracil in combination with low-dose leucovorin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Sche | 1995 |
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent pelvic tumors with or without radiotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1996 |
Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-F | 1996 |
Intraoperative radiation therapy in integrated treatment of rectal cancers. Results of phase II study.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Per | 1996 |
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Colon | 1997 |
A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neop | 1997 |
[Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coloni | 1997 |
[Reversible liver steatosis in patients treated with 5-fluorouracil and interferon-alpha].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Fatty Liver; Female; Fluo | 1997 |
Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic N | 1997 |
Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Sur | 1997 |
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluo | 1997 |
Fluorouracil and high-dose leucovorin with radiotherapy as adjuvant therapy for rectal cancer. Results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 1997 |
Improved surgical results after combining preoperative hyperthermia with chemotherapy and radiotherapy for patients with carcinoma of the rectum.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Hyperthermia, Ind | 1997 |
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1997 |
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, An | 1997 |
[A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer].
Topics: Adenocarcinoma; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma: a phase II trial.
Topics: Abdominal Pain; Adult; Aged; Alkaline Phosphatase; Angiography; Antimetabolites, Antineoplastic; Ant | 1997 |
Chemoradiation therapy and IORT in locally advanced rectal cancer: preliminary results in 36 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1997 |
[Preoperative intraluminal 5-FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy | 1996 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dis | 1997 |
Postsurgical sequential methotrexate, fluorouracil, and leucovorin for advanced colorectal carcinoma: a preliminary study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 1997 |
Increased apoptosis rate by hyperthermochemoradiotherapy for advanced rectal cancers.
Topics: Administration, Rectal; Antimetabolites, Antineoplastic; Apoptosis; Chemotherapy, Adjuvant; Fluorour | 1997 |
Association between blood transfusion and survival in a randomised multicentre trial of perioperative adjuvant portal chemotherapy in patients with colorectal cancer. The Swiss Group for Clinical Cancer Research (SAKK).
Topics: Aged; Antimetabolites, Antineoplastic; Blood Transfusion; Chemotherapy, Adjuvant; Colonic Neoplasms; | 1997 |
Is chemoradiation feasible in elderly patients? A study of 17 patients with anorectal carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Mo | 1997 |
Preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer.
Topics: Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinati | 1997 |
[Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 1997 |
Five-day continuous infusion of 5-fluorouracil and pulsed folinic acid in patients with metastatic colorectal carcinoma: an effective second-line regimen.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Sche | 1997 |
Postoperative adjuvant radiotherapy and 5-fluorouracil chemotherapy for rectal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hu | 1998 |
Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colon | 1998 |
Acute treatment-related diarrhea during postoperative adjuvant therapy for high-risk rectal carcinoma.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Diarrhea; Fluorouracil; Huma | 1998 |
Oxaliplatin combined to 5-fluorouracil and folinic acid: an effective therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1998 |
Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinoma; Cohort Studie | 1998 |
Adjuvant portal-vein infusion of fluorouracil and heparin in colorectal cancer: a randomised trial. European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group, the Gruppo Interdisciplinare Valutazione Interv
Topics: Aged; Anticoagulants; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di | 1998 |
Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 1998 |
Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Prot | 1998 |
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Inte | 1998 |
Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-F | 1995 |
[Phase II study on preoperative radio-chemo-thermotherapy in locally advanced rectal carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Follo | 1998 |
[Chemoradiotherapy in treatment of cancer of the anal canal].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemotherapy, | 1998 |
[Adjuvant radiochemotherapy with 5-FU and folinic acid in Dukes stage B and C rectum carcinoma: an interim analysis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorou | 1998 |
Hyperthermia for treatment of rectal cancer: evaluation for induction of multidrug resistance gene (mdr1) expression.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Combined M | 1999 |
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antidotes; Antineoplastic Combined Chemotherapy P | 1999 |
Comparative evaluation of the complex treatment of rectal cancer patients (chemotherapy and X-ray therapy, Ukrain monotherapy).
Topics: Adult; Aged; Alkaloids; Antineoplastic Agents; Berberine Alkaloids; Combined Modality Therapy; Femal | 1998 |
Local excision of rectal carcinoma: a safe alternative for more advanced tumors?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1999 |
Continuous delivery of venous 5-fluorouracil and arterial 5-fluorodeoxyuridine for hepatic metastases from colorectal cancer: feasibility and tolerance in a randomized phase II trial comparing flat versus chronomodulated infusion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Clocks; Colonic Neoplasms; C | 1999 |
[Systemic palliative chemotherapy with 5-fluorouracil and leucovorin in disseminated colorectal cancer].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; | 1999 |
Phase I study of 5-fluorouracil administered by protracted venous infusion, leucovorin, and pelvic radiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Combined Modality | 1999 |
Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperative Onco
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1999 |
[Combination chemotherapy of continuous infusion 5-FU and daily low-dose CDDP in colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1999 |
[Clinical evaluation of intermittent hepatic arterial infusion therapy with CDDP and 5-FU for liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1999 |
[Weekly hepatic arterial infusion of high dose 5-fluorouracil for liver metastasis from colorectal cancer].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorourac | 1999 |
[Evaluation of intermittent hepatic arterial infusion chemotherapy for multiple liver metastasis of colorectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Femal | 1999 |
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2000 |
Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Follo | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2000 |
Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2000 |
Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Dose-Resp | 2000 |
Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2000 |
Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters.
Topics: Age Factors; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Follo | 2000 |
Preoperative chemotherapy and pelvic radiation for tethered or fixed rectal cancer: a phase II dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2000 |
A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disea | 2000 |
Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients.
Topics: Amifostine; Chemotherapy, Adjuvant; Combined Modality Therapy; Dose Fractionation, Radiation; Fluoro | 2000 |
Preliminary analysis of a randomized clinical trial of adjuvant postoperative RT vs. postoperative RT plus 5-FU and levamisole in patients with TNM stage II-III resectable rectal cancer.
Topics: Adjuvants, Immunologic; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Antineop | 2000 |
[Short-term hypofractionated radiotherapy followed by total mesorectal excision].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2000 |
[First results of neoadjuvant simultaneious radiochemotherapy in advanced rectal carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Dose | 2000 |
Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma.
Topics: Adenocarcinoma; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free | 2001 |
Intravenous 5-fluorouracil versus oral doxifluridine as preoperative concurrent chemoradiation for locally advanced rectal cancer: prospective randomized trials.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Floxuridin | 2001 |
Randomized adjuvant study comparing two schemes of 5-fluorouracil and leucovorin in stage B2 and C colon adenocarcinoma: study design and preliminary safety results. Groupe d'Etude et de Recherche Clinique en Oncologie Radiotherapies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admini | 2001 |
Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2001 |
A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2001 |
[Randomized trial of adjuvant chemotherapy with or without radiotherapy in rectal cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Leucov | 2001 |
Adjuvant versus neoadjuvant radiochemotherapy for locally advanced rectal cancer. A progress report of a phase-III randomized trial (protocol CAO/ARO/AIO-94).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; | 2001 |
Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2001 |
Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2001 |
A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Combined | 2001 |
Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: preliminary results.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fracti | 2001 |
Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female | 2001 |
Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2001 |
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; C | 2001 |
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 2001 |
[Clinical study on treatment of rectal carcinoma with Chinese herbal medicine and high dose fluorouracil emulsion via rectal infusion].
Topics: Adenocarcinoma; Administration, Rectal; Adult; Antimetabolites, Antineoplastic; CD4-CD8 Ratio; Drug | 1999 |
Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Endosonography; Fem | 2001 |
Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distributi | 2002 |
Phase II study of a weekly 8-hour 5-fluorouracil and leucovorin infusion for patients with advanced colorectal cancer: dose adjusted according to its toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 2001 |
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combin | 2002 |
Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2002 |
Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas | 2002 |
Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe?
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu | 2002 |
Prolongation of postoperative disease-free interval and survival in human colorectal cancer by B.C.G. or B.C.G. plus 5-fluorouracil.
Topics: Administration, Oral; BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Fol | 1976 |
Adjuvant chemotherapy in large-bowel cancer: demonstration of effectiveness of single agent chemotherapy in a prospectively controlled,, randomized trial.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Palliative Care; Prognosis; Rando | 1978 |
Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
Topics: Bacterial Vaccines; Colonic Neoplasms; Corynebacterium; Dacarbazine; Female; Fluorouracil; Humans; I | 1978 |
[Initial experiences with a nation-wide Austrian study of adjuvant chemo- and immunotherapy of colorectal cancer following radical surgery].
Topics: Antineoplastic Agents; Austria; Colectomy; Colonic Neoplasms; Drug Therapy, Combination; Fluorouraci | 1979 |
A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: a preliminary report.
Topics: Administration, Oral; Aged; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Drug Admi | 1977 |
Gastrointestinal cancer--colon (surgery-radiotherapy). The role of radiation therapy in the management of rectosigmoid cancer.
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Neoplasm Me | 1977 |
Management of gastrointestinal cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluor | 1977 |
Intraluminal fluorouracil chemotherapy adjunct to surgical procedures for respectable carcinoma of the colon and rectum.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; H | 1977 |
Adjuvant liver perfusion in colorectal cancer: initial results of a clinical trial.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; England; Female; Fluorouracil; Follow-Up Studies; | 1977 |
Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Eval | 1978 |
Randomized trial of melphalan plus 5-fluorouracil (5-FU) versus methyl-CCNU plus 5-FU in patients with advanced colorectal cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Phase II trial of 5-fluorouracil plus melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinat | 1978 |
Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Blood Cell Count; Clinical Trials as Topic; Colonic Neoplasms; Doxorubi | 1978 |
Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Ther | 1978 |
Phase II trial of a combination of cyclosphamide, vincristine, and methotrexate in advanced colorectal carcinoma.
Topics: Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, | 1978 |
Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Eva | 1978 |
Sequential chemoimmunotherapy of colorectal cancer: evaluation of methotrexate, Baker's Antifol and levamisole.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neopl | 1978 |
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Cyc | 1978 |
A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Digestive System; D | 1979 |
Phase I study of thymidine plus 5-fluorouracil infusions in advanced colorectal carcinoma.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1979 |
Adjuvant therapy in colorectal cancer. (A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with the methanol extraction residue of BCG, MER).
Topics: BCG Vaccine; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluor | 1979 |
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study.
Topics: Adenocarcinoma; Catheterization; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; | 1979 |
Adjuvant chemotherapy for large bowel cancer: an optimistic appraisal.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Postoperati | 1979 |
Adriamycin, mitomycin C, and 5-fluorouracil in combination for advanced colorectal adenocarcinoma previously treated with 5-fluorouracil.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Dru | 1979 |
Adjuvant cytotoxic liver perfusion for colorectal cancer.
Topics: Adenocarcinoma; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; England; Female; | 1979 |
Cytotoxic perfusion for colorectal liver metastases.
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Evaluation Studies as Topi | 1978 |
Chemotherapy of large intestinal carcinoma. Current results and future prospects.
Topics: Administration, Oral; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms | 1975 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
Nitrosoureas: useful agents for the treatment of advanced gastrointestinal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combin | 1976 |
Current protocol approaches in large bowel cancer.
Topics: Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Th | 1976 |
Randomized comparison of melphalan and 5-fluorouracil in the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Biliary Tract Diseases; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; F | 1976 |
Adjuvant chemotherapy with 5-fluorouracil after surgical resection of colorectal carcinoma (COG protocol 7041). A preliminary report.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Prospective Studies; Rectal N | 1977 |
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem | 1977 |
Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.
Topics: Arylsulfatases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo | 1977 |
A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studie | 1975 |
Therapy of advanced colorectal cancer with a combination of 5-fluorouracil, methyl-1,3-cis(2-chlorethyl)-1-nitrosourea, and vincristine.
Topics: Antineoplastic Agents; Colonic Neoplasms; Cyclohexanes; Evaluation Studies as Topic; Female; Fluorou | 1975 |
Chemotherapy as an adjuvant to surgery for colorectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Postoperative Care; P | 1975 |
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administratio | 1975 |
Phase II study of epirubicin sequential methotrexate and 5-fluorouracil for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 1992 |
[Multicenter cooperative study of pre- and post-operative adjuvant chemotherapy in the treatment of colorectal cancer. North Kyushu Co-operative Study Group for Cancer Chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni | 1992 |
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; F | 1992 |
Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1992 |
Interferon alpha-2b, 5-fluorouracil, and folinic acid combination therapy in advanced colorectal cancer: preliminary results of a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1992 |
Treatment of refractory colorectal carcinomas with fluorouracil, folinic acid, and interferon alfa-2a.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1992 |
Fluorouracil plus interferon + folinic acid in regional and systemic therapy in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1992 |
Combined modality therapy of rectal cancer: decreased acute toxicity with the preoperative approach.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1992 |
Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin; | 1992 |
A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intra | 1992 |
A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.
Topics: Adult; Aged; Blood Glucose; Bone Marrow; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinati | 1991 |
Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Breast | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1991 |
NCI advocates use of adjuvant therapy for rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Nat | 1991 |
Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1990 |
A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1987 |
[Concepts in the prevention and treatment of liver metastases of colorectal cancer by regional chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Colonic Ne | 1988 |
A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Epirubicin; Fluorouracil; Humans; Neoplasm Metastasis; Ran | 1989 |
[Comparison of surgical therapy and combined irradiation in rectal cancer--first report, effect of irradiation on the tumor. Study Group of Surgical Therapy and Combined Irradiation in Rectal Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Adminis | 1989 |
[Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; | 1988 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U | 1985 |
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf | 1989 |
Chemotherapy of large bowel carcinoma--fluorouracil (FU) + hydroxyurea (HU) vs. methyl-CCNU, oncovin, fluorouracil, and streptozotocin (MOF-Strep). An Eastern Cooperative Oncology Group study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1985 |
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic Neoplasms; Drug Evaluat | 1985 |
Systemic infusional chemotherapy for liver metastasis: an improved schedule for 5-fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Floxuridine; Fluorouracil | 1986 |
A Northern California Oncology Group randomized trial of leucovorin plus 5-fluorouracil versus sequential methotrexate, 5-fluorouracil, and leucovorin in patients with advanced colorectal cancer who failed treatment with 5-fluorouracil or 5-fluorodeoxyuri
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Drug Administration Sc | 1987 |
A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxurid | 1988 |
Regional infusion of fluoropyrimidines for hepatic metastases of colorectal cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infu | 1988 |
Systemic cytostatic drug therapy in liver cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; | 1986 |
5-Methyltetrahydrofolic acid (MFH4): an effective folate for the treatment of advanced colorectal cancer with 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; | 1988 |
Adjuvant therapy for colorectal cancer: the NSABP clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Combine | 1988 |
[Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1986 |
[Prospective adjuvant chemotherapy, with mitomycin C plus long-term carmofur in colorectal cancer].
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; D | 1986 |
Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum.
Topics: Actuarial Analysis; Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid | 1986 |
[Cooperative study of surgical adjuvant chemotherapy of colorectal cancer (first report): Investigation of background factors and adverse effects. Cooperative Study Group of Surgical Adjuvant Chemotherapy of Colorectal Cancer in Japan].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorourac | 1987 |
Intraportal chemotherapy in colorectal carcinoma as an adjuvant modality.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1987 |
Mitomycin C plus carmofur (HCFU) adjuvant chemotherapy for noncuratively resected cases of colorectal carcinoma (interim report).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; | 1987 |
Oral ftorafur versus intravenous 5-fluorouracil. A comparative study in patients with colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Blood Platelets; Colonic Neoplasms; Female; Fluorouracil; Humans; | 1987 |
[Prospective adjuvant chemotherapy of mitomycin C plus HCFU for colorectal cancer (2d report)--6-year survival after surgery: Tokai Cooperative Study Group of Surgical Adjuvant Chemotherapy].
Topics: Adjuvants, Immunologic; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colect | 1988 |
Pilot study on the regional treatment of colorectal liver metastases by intermittent arterial ischaemia with degradable starch microspheres and arterial and portal infusion with mitomycin C plus 5-fluorouracil--a clinical trial led by the Gastrointestinal
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Emboliz | 1988 |
Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Th | 1988 |
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1988 |
A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: a Hoosier Oncology Group trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1988 |
Surgical adjuvant therapy of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modali | 1988 |
Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine | 1988 |
Adjuvant therapy of colorectal cancer. Why we still don't know.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neopla | 1988 |
Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col | 1988 |
Systemic therapy of colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Colonic Neoplas | 1988 |
Chemotherapy of advanced colorectal cancer. A randomized trial of sequential methotrexate and 5-fluorouracil.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Female; | 1987 |
A randomized clinical trial of combination chemotherapy in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1987 |
Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukocyte M | 1987 |
Continuous-infusion cisplatin and bolus 5-fluorouracil in colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1987 |
Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colonic | 1987 |
Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Fluorou | 1987 |
A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Topics: Adult; Aged; Antineoplastic Agents; Aspartic Acid; Colonic Neoplasms; Drug Administration Schedule; | 1988 |
Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.
Topics: Adenocarcinoma; Biological Availability; Colonic Neoplasms; Fluorouracil; Hematopoiesis; Humans; Inf | 1987 |
Clinical studies of biochemical modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer by the North Central Cancer Treatment Group and Mayo Clinic.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Colonic Neoplasms; Dose-Respon | 1987 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; | 1986 |
Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C | 1986 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1986 |
5-Fluorouracil chemotherapy and pelvic radiation in the treatment of large bowel cancer. Decreased toxicity in combined treatment with 5-fluorouracil administration through the intraperitoneal route.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule | 1986 |
Clinical trial of cisplatin and intensive course 5-fluorouracil for the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co | 1986 |
Hepatic arterial ligation and portal vein infusion: a clinical trial by the Gastrointestinal Tract Cancer Group of the European Organization for Research and Treatment of Cancer.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arter | 1986 |
Fluorouracil in chemoprophylaxis of colorectal cancer. Results of a controlled clinical trial.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; | 1986 |
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne | 1987 |
Adjuvant immunochemotherapy in colorectal cancer Dukes C.
Topics: Adjuvants, Immunologic; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Fema | 1987 |
Pilot trial of prolonged continuous-infusion 5-fluorouracil and weekly cisplatin in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical | 1987 |
Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Sched | 1987 |
Nonlinear pharmacokinetic characteristics of 5-fluorouracil (5-FU) in colorectal cancer patients.
Topics: Adult; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Half-Life; Humans; | 1987 |
Toxicity studies of adjuvant intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Fluorouracil; Humans | 1986 |
A randomized trial of oral 5-fluorouracil versus placebo as adjuvant therapy in colorectal cancer Dukes' B and C: results after 5 years observation time.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Double-Blind Method; Fluorou | 1985 |
A randomized controlled trial of adjuvant portal vein cytotoxic perfusion in colorectal cancer.
Topics: Aged; Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1985 |
Clinical trial of adjuvant chemotherapy after surgical resection of colorectal cancer metastatic to the liver.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1985 |
Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer.
Topics: Adult; Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorourac | 1985 |
Prospective randomized trial of intravenous v intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer.
Topics: Adult; Catheters, Indwelling; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Colo | 1985 |
Optimal schedule for 5-fluorouracil chemotherapy. Intermittent bolus or continuous infusion?
Topics: Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusi | 1985 |
Radiation therapy alone or in combination with chemotherapy in the treatment of residual or inoperable carcinoma of the rectum and rectosigmoid or pelvic recurrence following colorectal surgery. Radiation Therapy Oncology Group study (76-16).
Topics: Abscess; Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical T | 1985 |
[Results of phase III study of lentinan].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1985 |
The need for pilot studies and surgery-only controls in adjuvant therapy trials for large-bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi | 1985 |
Experience with continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. A prospective randomized study.
Topics: Chemical and Drug Induced Liver Injury; Cholestasis; Colonic Neoplasms; Combined Modality Therapy; F | 1985 |
Combination chemo-radiotherapy for residual, recurrent or inoperable carcinoma of the rectum: E.C.O.G. study (EST 3276).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cobalt Radioisotopes; Combined Modality Therapy; Fem | 1985 |
Adrenal function in patients treated with testosterone and fluorinated pyrimidines.
Topics: 17-Ketosteroids; Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormon | 1968 |
A pilot study for the evaluation of a new regime of combined therapy for the radical treatment of marginally operable rectal (or colo-rectal) cancer.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluor | 1974 |
[Main problems of the method of clinical study of new antineoplastic agents].
Topics: Antineoplastic Agents; Biopsy; Clinical Trials as Topic; Female; Fluorouracil; Humans; Intestinal Po | 1966 |
Comparison of antimetabolites in the treatment of breast and colon cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites; Breast Neoplasms; Child; Clinical Trials a | 1967 |
Intraluminal chemotherapy (HN2 or 5-FU) adjuvant to operation for cancer of the colon and rectum. II. Follow-up report of 97 cases.
Topics: Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Fluorouracil; Follow-Up Studies; Humans; M | 1967 |
A five year progress report on the effectiveness of intraluminal chemotherapy (5-fluorouracil) adjuvant to surgery for colorectal cancer.
Topics: Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Mechloret | 1968 |
[Tolerance of 5-fluorouracil in intensive treatment with high doses: 4 or 24-hour perfusions?].
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections, Intraven | 1968 |
1625 other studies available for fluorouracil and Cancer of Rectum
| Article | Year |
|---|---|
CHEMOTHERAPY IN RECTAL CANCER.
Topics: Disease-Free Survival; Fluorouracil; Humans; Neoplasm Staging; Rectal Neoplasms | 2021 |
Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Hum | 2021 |
Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the REVOLT study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Colorectal Neopl | 2022 |
Cost-minimisation analysis of rectal cancer neoadjuvant chemoradiotherapy based on fluoropyrimidines (capecitabine versus 5-fluorouracil).
Topics: Capecitabine; Fluorouracil; Humans; Neoadjuvant Therapy; Rectal Neoplasms; Retrospective Studies | 2021 |
[Drug Approval: Nivolumab plus ipilimumab for patients with MSI -high metastatic colorectal cancer previously treated with 5-fluorouracilchemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemo | 2022 |
Rapid Initiation of Neoadjuvant Chemoradiotherapy After Diagnosis is Associated With Improved Pathologic Response in Locally Advanced Rectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Disease-Free | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
Neoadjuvant Therapy for Rectal Cancer: Updates From the UNICANCER-PRODIGE 23 Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; | 2022 |
The survival impact of preoperative FOLFOX for resectable locally advanced rectal cancer: the R-NAC-01 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male; Midd | 2022 |
Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2022 |
[A Resected Case of Advanced Lower Rectal Cancer with Neoadjuvant Chemotherapy by FOLFOXIRI plus Cetuximab].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Fluorouracil; Humans | 2021 |
[A Case of Hyperammonemic Encephalopathy following mFOLFOX6 plus Panitumumab Therapy for Rectal Cancer].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Fluorouracil; Hum | 2021 |
[A Case of R0 Resection, with Preservation of Bladder Function, of Advanced Rectal Cancer Infiltrating the Bladder with a Single Metastatic Liver Tumor Due to Preoperative Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2021 |
[A Long-Survival Case of Lower Rectal Cancer with Unresectable Liver Metastases Treated with FOLFOXIRI plus Bevacizumab(BEV)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Fem | 2021 |
Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoembryonic Antigen; | 2022 |
A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
[A Case of Rectal Cancer and Multiple Lung Metastases That Had Complete Response Treated by XELOX plus Bevacizumab after Primary Lesion Resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Female; Fluorouracil; Hum | 2022 |
Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms | 2022 |
Long-Term Safety Data on S-1 Administered After Previous Intolerance to Capecitabine-Containing Systemic Treatment for Metastatic Colorectal Cancer.
Topics: Capecitabine; Cardiotoxicity; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Hand-Foot Syndr | 2022 |
Safety and effectiveness of aflibercept in combination with FOLFIRI in Korean patients with metastatic colorectal cancer who received oxaliplatin-containing regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Conjunctivitis associated with capecitabine treatment in a patient with colon cancer: The importance on educating patients into identifying adverse reactions.
Topics: Aged, 80 and over; Capecitabine; Colonic Neoplasms; Conjunctivitis; Fluorouracil; Humans; Male; Rect | 2022 |
Robotic low anterior resection of rectal metastasis from small bowel adenocarcinoma: A case report.
Topics: Adenocarcinoma; Aged; Duodenal Neoplasms; Female; Fluorouracil; Humans; Keratin-20; Keratin-7; Leuco | 2022 |
Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Ne | 2022 |
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2022 |
Genetic variants involved in the cGAS-STING pathway predict outcome in patients with metastatic colorectal cancer: Data from FIRE-3 and TRIBE trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colonic Neopla | 2022 |
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; | 2022 |
Real-world overall survival of patients receiving cetuximab in later lines of treatment for metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neoplasms; Colorect | 2022 |
Capecitabine plus oxaliplatin in the treatment of metastatic colorectal cancer at Tygerberg Hospital: a retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasms; Colorectal N | 2022 |
Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.
Topics: Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasms, Second Primary; | 2023 |
MicroRNA-19b Plays a Key Role in 5-Fluorouracil Resistance and Predicts Tumor Progression in Locally Advanced Rectal Cancer Patients.
Topics: Fluorouracil; Humans; MicroRNAs; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Rectal Neoplasms | 2022 |
Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coloni | 2023 |
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Circulating MicroRNA; Colonic Neoplasm | 2023 |
Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; Colore | 2023 |
Could the concomitant use of beta blockers with bevacizumab improve survival in metastatic colon cancer?
Topics: Adrenergic beta-Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Ne | 2023 |
An integrated multiomics analysis of rectal cancer patients identified POU2F3 as a putative druggable target and entinostat as a cytotoxic enhancer of 5-fluorouracil.
Topics: Antineoplastic Agents; Chemoradiotherapy; Fluorouracil; Humans; Multiomics; Neoadjuvant Therapy; Oct | 2023 |
[A Case of Recurrent Rectal Cancer with Acute Lower Extremity Arterial Occlusion during Treatment with Bevacizumab].
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorourac | 2023 |
Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant | 2023 |
Effect of short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy on organ preservation in locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolidation Chemotherapy; Fluor | 2023 |
Maintenance therapy with Fluoropyrimidine and cetuximab or bevacizumab after first line FOLFOX-chemotherapy in metastatic colorectal cancer according to RAS or BRAF
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Factors; Cetuximab; Colonic | 2023 |
[A Case of Squamous Cell Carcinoma of the Lower Rectum].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Fluorouracil; Humans; Male | 2023 |
Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Chemotherapy, Adjuva | 2023 |
Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cohort Studies; Colonic N | 2023 |
Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.
Topics: Abdominal Pain; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Female; Fluorouracil; Human | 2023 |
A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fem | 2023 |
Short-Course Radiation and Consolidation Chemotherapy for Rectal Cancer-The Rise and Fall of a Treatment Strategy-Rest in Peace.
Topics: Chemoradiotherapy; Consolidation Chemotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Rectal Neo | 2023 |
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasm | 2023 |
[Preoperative treatment of rectal cancer-Critical comments on the US-American PROSPECT trial].
Topics: Fluorouracil; Humans; Neoplasm Staging; Preoperative Care; Rectal Neoplasms; United States | 2023 |
Treatment of metastatic colorectal cancer with BRAF V600E mutation: A multicenter real-world study in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colonic Neoplasms; Colorecta | 2023 |
[Neoadjuvant FOLFOX chemotherapy of locally advanced rectal cancer-Results of the PROSPECT study].
Topics: Fluorouracil; Humans; Neoadjuvant Therapy; Prospective Studies; Rectal Neoplasms; Rectum | 2023 |
Cetuximab as first-line treatment for metastatic colorectal cancer (mCRC): a model-based economic evaluation in Indonesia setting.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Col | 2023 |
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biological Prod | 2023 |
Quality of life, effectiveness, and safety of aflibercept plus FOLFIRI in older patients with metastatic colorectal cancer: An analysis of the prospective QoLiTrap study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2023 |
Negative hyperselection of elderly patients with RAS and BRAF wild-type metastatic colorectal cancer receiving initial panitumumab plus FOLFOX or 5-FU/LV.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Col | 2023 |
YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2020 |
Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Camptothecin; Colon | 2019 |
A rectal cancer organoid platform to study individual responses to chemoradiation.
Topics: Animals; Chemoradiotherapy; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Neoplasm Me | 2019 |
Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an exper
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2019 |
[A Case of Lung Metastases from Rectal Cancer Treated for Quite Long with FOLFIRI plus Ramucirumab as a Late Line of Therapy].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2019 |
In vitro and in vivo studies on the association of long non‑coding RNAs H19 and urothelial cancer associated 1 with the susceptibility to 5‑fluorouracil in rectal cancer.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy; Cell Proliferation; Computational Biology; Drug Resistance, | 2019 |
Results of Tri-Modality Therapy for Rectal Cancer in Elderly Patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemor | 2019 |
Neoadjuvant chemotherapy without radiotherapy for patients with locally advanced rectal cancer. Oncologic outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free S | 2020 |
[A Case of FOLFOXIRI plus BV Therapy Responding to Liver Metastasis of Rectal Cancer with the Portal Venous Tumor Thrombi(Vp4)as Oncologic Emergency].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Hepatectom | 2019 |
Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2019 |
Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols | 2019 |
Adjuvant chemotherapy for locally advanced rectal cancer in elderly patients after neoadjuvant chemoradiotherapy and surgery: Toxicity and survival outcomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Fem | 2020 |
Modeling rectal cancer to advance neoadjuvant precision therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Fluorouracil; Heterografts; Huma | 2020 |
FOLFOX and capecitabine-induced hepatic granuloma mimicking metastasis in a rectal cancer patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemi | 2020 |
[Two Cases of Advanced Colorectal Cancer Achieving Complete Response by FOLFOXIRI plus Bevacizumab-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colonic Neoplasms; | 2019 |
[A Case of Long-Term Clinical Complete Response after Chemotherapy for Locally Advanced Rectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colostomy; Fluorouracil; Humans; Leucovorin; Male; R | 2019 |
Improved Outcomes for Responders After Treatment with Induction Chemotherapy and Chemo(re)irradiation for Locally Recurrent Rectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Femal | 2020 |
Metformin as an Alternative Radiosensitizing Agent to 5-Fluorouracil During Neoadjuvant Treatment for Rectal Cancer.
Topics: Animals; Case-Control Studies; Chemoradiotherapy; Combined Modality Therapy; Female; Fluorouracil; H | 2020 |
ADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED RECTAL CANCER: DECIDING ON THE OPTIMAL STRATEGY.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival | 2020 |
RHBDD2 overexpression promotes a chemoresistant and invasive phenotype to rectal cancer tumors via modulating UPR and focal adhesion genes.
Topics: Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Adhesion; Cell Movement; Cell Proliferation; Dru | 2020 |
[Long-Term Survival of a Patient with Advanced Recurrent Rectal Cancer Treated with a Multidisciplinary Therapy including Five Operations-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Fluorouracil; Humans; Ne | 2020 |
[Bladder-Sparing Surgery with Preoperative Chemotherapy for Rectal Cancer with Urinary Bladder Involvement-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Neoadj | 2020 |
[Locally Advanced Rectal Cancer Curatively Resected after Modified FOLFOXIRI plus Bevacizumab Chemotherapy-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Human | 2020 |
[A Case of Malignant Lymphoma Undergoing HAI Treatment for Multiple Liver Metastases of Carcinoid That Appeared about Nine Years after Resection of Rectal Carcinoid with Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Chemoembolization, Therapeuti | 2020 |
MRI T2-weighted sequences-based texture analysis (TA) as a predictor of response to neoadjuvant chemo-radiotherapy (nCRT) in patients with locally advanced rectal cancer (LARC).
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Female; Fluoroura | 2020 |
TRIBE2 results and toxicity - Authors' reply.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Leu | 2020 |
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; | 2020 |
A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy.
Topics: Aged; Biopsy; CD3 Complex; CD8-Positive T-Lymphocytes; Cell Lineage; Cell Proliferation; Disease-Fre | 2020 |
Feasibility of relatively low neoadjuvant radiation doses for locally advanced rectal cancer: A propensity score-matched analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2019 |
Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasm | 2021 |
5-Fluorouracil-induced encephalopathy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Female; Fluorouracil; Humans; | 2020 |
Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen: Case report.
Topics: Acidosis, Lactic; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 2020 |
Real-world outcomes for neoadjuvant capecitabine versus infusional 5-fluorouracil in the treatment of locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Capecitabine; Fluorouracil; Humans; Neoad | 2021 |
A Prospective, Single-arm, Multicenter Trial of Diverting Stoma Followed by Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE Study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura | 2022 |
The Older Adults With Rectal Cancer-Does Age Matter?: A Single-center Experience.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Comorbidity; Female; Fluorouracil; Hospitalization; H | 2020 |
Even a partial pathological response is associated with lower relapse rates in patients with operable rectal cancer undergoing neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase | 2021 |
Total Neoadjuvant Treatment for Rectal Cancer: Preliminary Experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female; Fl | 2021 |
Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels.
Topics: Adenocarcinoma; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Antineoplasti | 2021 |
Organ Preservation in the Treatment of Stage II and III Rectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colectomy; | 2020 |
[A Case of Locally Advanced Rectal Cancer Treated by Robot Assisted Intersphincteric Resection after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Neoa | 2021 |
[Two Cases of Resectable Liver Metastasis from Colorectal Cancer with Pathological Complete Response after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Female; Flu | 2020 |
[Laparoscopic Abdominoperineal Resection Following Intensive Chemotherapy for Stage Ⅳ Rectal Cancer with Unresectable Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Fluorouracil; Hum | 2020 |
[A Case of Advanced Rectal Cancer Successfully Treated with Preoperative Radiochemotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy | 2020 |
Hepatectomy for liver metastasis from rectal cancer in a patient with mitochondrial disease.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diabetes Mellitus, Type 2; Fema | 2021 |
Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Consolidation Chemot | 2021 |
Beneficial effects of modulated electro-hyperthermia during neoadjuvant treatment for locally advanced rectal cancer.
Topics: Fluorouracil; Humans; Hyperthermia; Hyperthermia, Induced; Middle Aged; Neoadjuvant Therapy; Neoplas | 2021 |
Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic | 2021 |
Safety and efficacy of preoperative mFOLFOX6 regimen chemotherapy for locally resectable advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Fluorouracil; Humans; Neoadjuvant Therapy; Ne | 2021 |
Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Diabetes Mell | 2021 |
Risk factors for sexual dysfunction after rectal cancer surgery in 948 consecutive patients: A prospective cohort study.
Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch | 2021 |
Hyperammonemia-induced impaired consciousness following mFOLFOX6 therapy in a patient with recurrent rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Consciousness; Female; Fluorouracil; Humans; Hyperam | 2021 |
Are we already in the era of total neoadjuvant treatment for rectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; | 2021 |
Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capeci | 2021 |
Improved response rate in patients with prognostically poor locally advanced rectal cancer after treatment with induction chemotherapy and chemoradiotherapy when compared with chemoradiotherapy alone: A matched case-control study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Case-Control Studie | 2021 |
Real-world Patterns of Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation for Patients With Resected Rectal Adenocarcinoma.
Topics: Adenocarcinoma; Alberta; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fem | 2021 |
Concomitant Use of Proton Pump Inhibitors With Capecitabine Based Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: Is it Safe?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2021 |
Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Female; Fluorouracil; Huma | 2021 |
Relation between body composition and severe diarrhea in patients treated with preoperative chemoradiation with capecitabine for rectal cancer: a single-centre cohort study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine; Cohort Studies; Deox | 2021 |
Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Circ | 2017 |
Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Colectomy; Female; Fluorouracil; | 2017 |
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 2017 |
[A Case Report on a Successful Resection after FOLFIRI plus Cetuximab Therapy for Unresectable Colorectal Cancer with Multiple Liver Metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colectomy; Combined M | 2017 |
[A Case of Effective Chemoradiotherapy Using mFOLFOX6 for Locally Advanced Rectal Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Drug Combinations; | 2017 |
The Role of Concomitant Radiation Boost in Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Fe | 2017 |
Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Capecit | 2017 |
Prognostic significance of tumour regression grade after neoadjuvant chemoradiotherapy for a cohort of patients with locally advanced rectal cancer: an 8-year retrospective single-institutional study.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouraci | 2017 |
Relationship Between Expression of Proteins ERCC1, ERCC2, and XRCC1 and Clinical Outcomes in Patients with Rectal Cancer Treated with FOLFOX-Based Preoperative Chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; DNA-Bindin | 2017 |
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2017 |
Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy | 2017 |
Comparing pathological complete response rate using oral capecitabine versus infusional 5-fluorouracil with preoperative radiotherapy in rectal cancer treatment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2018 |
[A Case of Bilateral Lymph Node Metastases of Rectal Cancer Treated with Chemotherapy and Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Fluoro | 2017 |
Outcomes of patients with abdominoperineal resection (APR) and low anterior resection (LAR) who had very low rectal cancer.
Topics: Anal Canal; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Digestive System Surgi | 2017 |
Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients.
Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Female; Fluorouracil; Humans; Magnetic | 2018 |
The Role of Oxaliplatin in Chemoradiotherapy for Rectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant | 2017 |
Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2018 |
Authors' reply to "Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: potential pitfalls of a multicentre observational study".
Topics: Fluorouracil; Humans; Neoplasm Staging; Preoperative Care; Rectal Neoplasms; Rectum | 2018 |
[A Case of Laparoscopic Surgery Performed for Locally Advanced Rectal Cancer Suspected of Invasion to Prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Laparoscopy; Leucovorin; Male; | 2017 |
[Experience of Ramucirumab plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer in Our Hospital].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2017 |
Could early tumour volume changes assessed on morphological MRI predict the response to chemoradiation therapy in locally-advanced rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2018 |
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Prognostic Impact of R0 Resection and Targeted Therapy for Colorectal Cancer with Synchronous Peritoneal Metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; | 2018 |
Does Adjuvant Chemotherapy After Preoperative Chemoradiation Improve Overall Survival in Patients With Rectal Cancer?
Topics: Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Fluorouracil; Humans; Radiotherapy | 2018 |
Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemot | 2018 |
[A Case of Colon Cancer with Brain, Liver and Lung Metastasis Successfully Treated with Bevacizumab plus Xelox Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Capecitabine; Deoxycyt | 2018 |
Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Carcinoma, Signet Ring | 2018 |
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!]
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trial | 2018 |
Management of Locoregional Rectal Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Disease-Free Survival; Fluorourac | 2018 |
Therapeutic effects of oxaliplatin-based neoadjuvant chemotherapy and chemoradiotherapy in patients with locally advanced rectal cancer: a single-center, retrospective cohort study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemoradiotherapy, A | 2018 |
[Research progress of neoadjuvant therapy for locally advanced rectal cancer].
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant | 2018 |
[A Case of Rectal Cancer and Multiple Liver Metastases Treated Using mFOLFOX and Bevacizumab under Maintenance Dialysis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Fluorouracil; Glomerulonephritis, IGA; | 2018 |
[A Case Describing Treatment with FOLFIRI plus Bevacizumab after a Self-Expandable Metallic Stent Placement for Local Recurrence].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Fluorouracil; Humans; Int | 2018 |
Radiation therapy damages external anal sphincter and perineal muscle floor.
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Arterioles; Collagen; Dilatation, Pathol | 2018 |
Identification of Predictors of Recurrence in Patients with Lower Rectal Cancer Undergoing Neoadjuvant Chemotherapy: A Direct Comparison of Short-Course and Long-Course Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C | 2019 |
[Primary Small Bowel Tumor with Simultaneous Lung Metastases from Rectal Cancer - A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Intestinal Neoplasms; | 2018 |
Adjuvant Chemotherapy in Rectal Cancer Patients Treated With Preoperative Chemoradiation and Total Mesorectal Excision: A Multicenter and Retrospective Propensity-Score Matching Study.
Topics: Aged; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluoro | 2019 |
C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; C-Reactive Pr | 2018 |
[A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Female; | 2018 |
Complete pathological response following neoadjuvant FOLFOX chemotherapy in BRCA2-mutant locally advanced rectal cancer: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Fluorouracil; Humans; Leucovor | 2018 |
Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemoradiotherapy; Fluorouracil; Humans | 2019 |
Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Combined Modal | 2019 |
[A Case of Complete Response to Lower Rectal Cancer after Preoperative Chemotherapy with CapeOX Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fluorouracil; Humans; Male; Neoa | 2018 |
[A Case of Resistance to Systemic Therapy in Hypermutation of Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluorouracil; Humans; Le | 2018 |
Rapidly progressing ulcer and a urine drainage bag.
Topics: Adrenal Cortex Hormones; Aged; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemothera | 2018 |
Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C | 2019 |
Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; F | 2019 |
[Curative Transanal Resection after Neoadjuvant Chemotherapy for Lower Rectal Cancer-A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Middle Aged; Neoadjuva | 2019 |
[Two Cases of Locally Advanced Rectal Cancer and Lower Rectal Cancer Resected Successfully That Enabled Anus Preservation after Preoperative Chemotherapy].
Topics: Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Middle | 2019 |
Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Hu | 2019 |
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N | 2019 |
Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2019 |
[Locally Advanced Rectal Cancer Presenting with Perforation That Was Successfully Resected after Preoperative Chemotherapy with mFOLFOX6 plus Panitumumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Orga | 2019 |
Reply to C. Kersten et al and D.A. Parikh et al.
Topics: Cetuximab; Fluorouracil; Humans; Leucovorin; Oxaliplatin; Rectal Neoplasms | 2019 |
Induction Chemotherapy Reduces Patient-reported Toxicities During Neoadjuvant Chemoradiation with Intensity Modulated Radiotherapy for Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2019 |
Neutrophil-to-Lymphocyte Ratio in Rectal Cancer-Novel Biomarker of Tumor Immunogenicity During Radiotherapy or Confounding Variable?
Topics: Aged; Biomarkers, Tumor; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; H | 2019 |
Interleukin-17A polymorphisms predict the response and development of tolerance to FOLFOX chemotherapy in colorectal cancer treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cross-Sectional Stud | 2020 |
[A Case of a Patient with Locally Recurrent Rectal Cancer Who Underwent Surgical Resection after Chemotherapy with FOLFOXIRI plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Hum | 2019 |
ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Disease-Free Survival; DNA-Binding Prot | 2019 |
Achieving a Complete Clinical Response After Neoadjuvant Chemoradiation That Does Not Require Surgical Resection: It May Take Longer Than You Think!
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Ma | 2019 |
[A Case of Curatively Resected Rectosigmoid Colon Cancer That Invaded the Urinary Bladder after Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Neoadj | 2019 |
Effects of metformin and phenformin on apoptosis and epithelial-mesenchymal transition in chemoresistant rectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; | 2019 |
Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy: a case report.
Topics: Abdominal Pain; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothe | 2020 |
Pretreatment blood biomarkers predict pathologic responses to neo-CRT in patients with locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcin | 2019 |
[A case with multiple liver metastases from rectal cancer responding completely to FOLFOX for a long duration without exacerbation of peripheral neuropathy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucovorin; Live | 2013 |
Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma; Chemoradiotherapy; C | 2013 |
Novel single-nucleotide polymorphism markers predictive of pathologic response to preoperative chemoradiation therapy in rectal cancer patients.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Capecitabine; | 2013 |
Routine defunctioning stoma after chemoradiation and total mesorectal excision: a single-surgeon experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colostomy; Dose Fractiona | 2013 |
Update: NCCN colon and rectal cancer clinical practice guidelines.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2004 |
Modern multidisciplinary treatment of rectal cancer based on staging with magnetic resonance imaging leads to excellent local control, but distant control remains a challenge.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine | 2013 |
[Tolerance and efficacy of preoperative radiation therapy for elderly patients treated for rectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Dose Fractionation, Radiatio | 2013 |
[Immediate results of complex treatment of resectable rectal neoplasms of distal localization].
Topics: Adenocarcinoma; Antineoplastic Agents; Case-Control Studies; Disease-Free Survival; Female; Fluorour | 2013 |
Histopathological regression grading matches excellently with local and regional spread after neoadjuvant therapy of rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Chi-Square Distributio | 2013 |
Neoadjuvant-intensified treatment for rectal cancer: time to change?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Oxaliplatin-induced acquired long QT syndrome with torsades de pointes and myocardial injury in a patient with dilated cardiomyopathy and rectal cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiomyopathy, Dilated | 2013 |
Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose Fractionation, | 2013 |
Evolving role of neoadjuvant therapy in rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com | 2013 |
Therapy-related acute promyelocytic leukemia after chemoradiotherapy with capecitabine for rectal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bone Marrow; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leu | 2014 |
[A case of necrotizing fasciitis developed in a patient with recurrent rectal cancer treated with chemotherapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
[Successful management using laparoscopic splenectomy for splenomegaly and thrombocytopenia caused by oxaliplatin-based chemotherapy for advanced rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Fluorouracil; Humans; Laparoscopy; Le | 2013 |
[Successful treatment of a patient using mFOLFOX6 after laparoscopic surgery for rectal cancer with peritoneal dissemination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Lap | 2013 |
Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2013 |
Clinical outcome of neoadjuvant chemoradiation therapy with oxaliplatin and capecitabine or 5-fluorouracil for locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothe | 2013 |
The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy | 2013 |
Aggressive strategy for the treatment of synchronous metastatic anal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2013 |
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Adolescent; Adult; Aged; Aged, 80 and over; Anti | 2014 |
[Adjuvant chemotherapy for patients with rectal cancer].
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Fluorouracil; Humans; Magnetic Resonance Imaging; Pos | 2013 |
Long-term quality-of-life after neoadjuvant short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Cross-Sectional Studies; Disease-Free Survival; F | 2013 |
Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Anastomosis, Surgical; Anastomotic Leak; | 2013 |
[Use of hydrogel tissues with 5-fluorouracil and sodium alginate, "COLETEX-5-FTUR," for radiomodification in cancer patients receiving radiation therapy].
Topics: Adult; Aged; Alginates; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fluorouracil; Glucuronic A | 2013 |
Acute effects of pelvic irradiation on the adult uterus revealed by dynamic contrast-enhanced MRI.
Topics: Adult; Antimetabolites, Antineoplastic; Chemoradiotherapy; Contrast Media; Endometrium; Female; Fluo | 2013 |
Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
Topics: Adenocarcinoma; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2013 |
Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Colonoscop | 2014 |
The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2014 |
Impact of chemotherapy on normal tissue complication probability models of acute hematologic toxicity in patients receiving pelvic intensity modulated radiation therapy.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Bone Marrow; Chemoradiotherapy; Cisplatin; Drug Adminis | 2013 |
Comparison of two preoperative chemoradiotherapy regimens for locally advanced rectal cancer: capecitabine alone versus capecitabine plus irinotecan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
C-reactive protein as predictor of recurrence in patients with rectal cancer undergoing chemoradiotherapy followed by surgery.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto | 2013 |
[A case of hepatitis B virus reactivation in a patient with prior resolved hepatitis B infection during bevacizumab plus FOLFIRI treatment].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; China; | 2014 |
Preoperative chemoradiation with or without induction oxaliplatin plus 5-fluorouracil in locally advanced rectal cancer. Long-term outcome analysis.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2014 |
[Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro | 2013 |
[A case of metastatic colorectal cancer with hyperammonemic encephalopathy induced by 5-FU in a patient continuously treated with XELOX therapy].
Topics: Amino Acids, Branched-Chain; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases, Metabol | 2013 |
[A case of advanced rectal cancer treated with leucovorin, fluorouracil, and oxaliplatin plus panitumumab preoperative chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; F | 2013 |
[A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor | 2013 |
[A case of successful radical resection of rectal cancer with neo-adjuvant chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Humans; Leucovorin; | 2013 |
[Neoadjuvant chemoradiotherapy with capecitabine and oxaliplatin for the treatment of locally advanced lower rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine | 2013 |
[A case of good response in a rectal cancer patient with decreased dihydropyrimidine dehydrogenase activity because of strict control of the 5-fluorouracil dose].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Dihydrouracil Dehydrogenase (NADP); Fluo | 2013 |
[A case of rectal endocrine cell carcinoma treated by laparoscopic assisted intersphincteric resection after neoadjuvant chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Endocrine Cells; Fluorouraci | 2013 |
[Two cases of locally advanced colorectal cancer curatively resected after neoadjuvant chemotherapy with 5-fluorouracil, leucovorin, and oxaliplatin plus panitumumab].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans | 2013 |
[A case of locally advanced colorectal cancer with abscess responding to 5-fluorouracil, leucovorin, and oxaliplatin plus bevacizumab].
Topics: Abscess; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizu | 2013 |
Chemoradiotherapy response in recurrent rectal cancer.
Topics: Adult; Aged; Chemoradiotherapy; Fluorouracil; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imag | 2014 |
Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; China; | 2014 |
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi | 2014 |
Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2014 |
Laparoscopic abdominosacral resection for locally advanced primary rectal cancer after treatment with mFOLFOX6 plus bevacizumab, followed by preoperative chemoradiotherapy.
Topics: Abdomen; Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2014 |
A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.
Topics: Algorithms; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Female; Fluor | 2014 |
MRI and FDG-PET for assessment of response to neoadjuvant chemotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Chemoth | 2014 |
Over compliance with capecitabine oral chemotherapy.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Hu | 2014 |
Cetuximab-induced esophageal ulcer: the first report in literature.
Topics: Abdomen, Acute; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2014 |
Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2014 |
[Concomitant use of romiplostim and chemotherapy for advanced rectal cancer associated with idiopathic thrombocytopenic purpura].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorou | 2014 |
Preoperative chemoradiotherapy in rectal cancer induces changes in the expression of nuclear β-catenin: prognostic significance.
Topics: Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Capecitabine; Chemoradiotherapy; Colorecta | 2014 |
A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2014 |
[Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Feas | 2014 |
Primary squamous cell carcinoma of the most distal rectum: a dilemma in origin and management.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemoradioth | 2014 |
P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Biomarkers, Tumor; Cell Adhesion Molecules, Neuronal; | 2014 |
Gastrointestinal: bevacizumab-induced reversible posterior leukoencephalopathy syndrome in patient with rectal cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
The effects of neoadjuvant chemoradiotherapy on physical fitness and morbidity in rectal cancer surgery patients.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Cohort Studies; De | 2014 |
The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemoradiot | 2014 |
Late complications after proctectomy in rectal cancer patients who underwent radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Agents; Case-C | 2014 |
Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Biopsy; Chemoradiotherapy; Combined Modality Therapy | 2014 |
Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecit | 2014 |
Interval between neoadjuvant treatment and definitive surgery in locally advanced rectal cancer: impact on response and oncologic outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Digestive | 2014 |
[A case of advanced rectal cancer that showed complete response to the addition of XELOX+bevacizumab therapy to preoperative chemoradiotherapy with S-1/CPT-11].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp | 2014 |
[The combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj | 2014 |
Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Prolife | 2014 |
Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Anastomotic Leak; Antimetabolites, Anti | 2014 |
Helical tomotherapy combined with capecitabine in the preoperative treatment of locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluo | 2014 |
Post-chemoradiation intraoperative electron-beam radiation therapy boost in resected locally advanced rectal cancer: long-term results focused on topographic pattern of locoregional relapse.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; E | 2014 |
Risk factors for bowel dysfunction after sphincter-preserving rectal cancer surgery: a prospective study using the Memorial Sloan Kettering Cancer Center bowel function instrument.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2014 |
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co | 2014 |
Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineopl | 2014 |
EGFR ligands and DNA repair genes: genomic predictors of complete response after capecitabine-based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Co | 2015 |
Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb | 2014 |
Multidrug resistance-associated protein 3 confers resistance to chemoradiotherapy for rectal cancer by regulating reactive oxygen species and caspase-3-dependent apoptotic pathway.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell | 2014 |
Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carbamoyl-Phosphate Syntha | 2014 |
S-1-Based versus capecitabine-based preoperative chemoradiotherapy in the treatment of locally advanced rectal cancer: a matched-pair analysis.
Topics: Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Humans; Mal | 2014 |
Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy | 2015 |
Adjuvant chemotherapy for patients with rectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluorouracil; Humans; Leu | 2014 |
Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe?
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Blood Loss, Su | 2014 |
Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2014 |
Intussusception due to rectal adenocarcinoma in a young adult: a case report.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B | 2014 |
Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemoth | 2014 |
Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Cyclooxygenase 1; Cyclooxygenase 2; | 2014 |
IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; | 2015 |
[Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv | 2014 |
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2017 |
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemoradiot | 2014 |
[A case of mFOLFOX6-induced lactic acidosis in a patient with colon cancer].
Topics: Acidosis, Lactic; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; | 2014 |
Association between the cytogenetic profile of tumor cells and response to preoperative radiochemotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Ad | 2014 |
Comparative survival effectiveness between pre-operative and postoperative chemoradiotherapy for locally advanced rectal cancer: a retrospective study in Phramongkutklao Hospital.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modalit | 2014 |
Pathological response of locally advanced rectal cancer to preoperative chemotherapy without pelvic irradiation.
Topics: Adult; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Chemor | 2015 |
[Combined treatment of patients with locally advanced rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2014 |
Relationships between SMAD3 expression and preoperative fluoropyrimidine-based chemoradiotherapy response in locally advanced rectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2015 |
Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo | 2015 |
Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Clinical Trials, Phase | 2015 |
Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2015 |
Observational study of adjuvant therapy with capecitabine in colon cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2015 |
Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Female; Fluorouracil; F | 2015 |
[Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; | 2014 |
[Surgical resection after chemotherapy for advanced rectal cancer - report of a case].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc | 2014 |
[A case of pathological complete response with neoadjuvant XELOX chemotherapy for locally advanced rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hum | 2014 |
[Irradiation with carbon ions for locally recurrent rectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Heavy Io | 2014 |
[A case of neoadjuvant chemotherapy for locally advanced rectal cancer, which had a invasion into the vagina followed by curative resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Laparoscopy; Leucovori | 2014 |
[A case of stage IV rectal cancer successfully resected after chemotherapy (mFOLFOX6 plus panitumumab)].
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther | 2014 |
[A case of rectal cancer with brain metastasis successfully treated with combined modality therapy - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2014 |
[A case of metastatic rectal cancer with fulminant hepatitis caused by XELOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Hep | 2014 |
Safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin and 5-fluorouracil after mesorectal excision with lateral pelvic lymph node dissection for stage iii lower rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 2015 |
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro | 2015 |
Sustaining Blood Lymphocyte Count during Preoperative Chemoradiotherapy as a Predictive Marker for Pathologic Complete Response in Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Biomarkers, Pharmacological; Chemoradiotherapy; Female; Fluorouracil; Humans; Lymphocyt | 2016 |
Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiothera | 2017 |
[The present status of CapeOX as adjuvant chemotherapy for colorectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2015 |
Inferior mesenteric artery chemoembolization and chemotherapy for advanced rectal cancer: report of a clinical case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Female | 2015 |
Adjuvant Chemotherapy for Locally Advanced Rectal Cancer: Is It a Given?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; | 2015 |
Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer.
Topics: Adenocarcinoma; Chemoradiotherapy; Female; Fluorouracil; Gene Expression Profiling; Gene Expression | 2015 |
[Predictive value of preoperative imaging and postoperative pathology on clinical complete response after neoadjuvant chemoradiation for locally advanced rectal cancer].
Topics: Chemoradiotherapy; Fluorouracil; Humans; Magnetic Resonance Imaging; Neoadjuvant Therapy; Neoplasm S | 2015 |
Evaluating Variations of Bladder Volume Using an Ultrasound Scanner in Rectal Cancer Patients during Chemoradiation: Is Protocol-Based Full Bladder Maintenance Using a Bladder Scanner Useful to Maintain the Bladder Volume?
Topics: Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Gamma Rays; Humans; Leucovorin; Logistic M | 2015 |
Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; | 2015 |
Role of Adjuvant Chemotherapy in ypT0-2N0 Patients Treated with Preoperative Chemoradiation Therapy and Radical Resection for Rectal Cancer.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chem | 2015 |
High levels of X-linked Inhibitor-of-Apoptosis Protein (XIAP) are indicative of radio chemotherapy resistance in rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Baculoviral | 2015 |
Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab | 2015 |
The outcome of 5-fluorouracil chemotherapy after the completion of neoadjuvant chemoradiotherapy, administered until 2 weeks before rectal cancer resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorour | 2015 |
Neoadjuvant therapy does not affect lymph node ratio in rectal cancer.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; I | 2016 |
[A Case of Concurrent Cancer in a Giant Rectal Villous Adenoma That Resulted in Extensive Lymph Node Metastases].
Topics: Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2015 |
The outcome and the frequency of pathological complete response after neoadjuvant radiotherapy in curative resections for advanced rectal cancer: a population-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Cohort Studies; Digestive | 2016 |
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2015 |
Chemoradiation for High-grade Neuroendocrine Carcinoma of the Rectum and Anal Canal.
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptotheci | 2017 |
Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F]FDG PET/CT scans in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Disease-Free | 2016 |
[Using "Collegel" complex in combined therapy of rectum cancer].
Topics: Administration, Rectal; Alginates; Antineoplastic Combined Chemotherapy Protocols; Combined Modality | 2015 |
[A Case of Radical Resection of Rectal Cancer with Multiple Liver and Lung Metastases after Preoperative Chemotherapy].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; F | 2015 |
Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Che | 2016 |
Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fem | 2015 |
[Long-Term Successful Management of Recurrent Rectal Cancer in the Predialysis State with FOLFIRI Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dialysis; Fatal Outcome; Fluorou | 2015 |
Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cellular Senescence; Doxorubicin; Epithelial- | 2016 |
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
Topics: Adenocarcinoma; Aged; Case-Control Studies; Chemoradiotherapy, Adjuvant; Colostomy; Disease-Free Sur | 2016 |
Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case | 2016 |
Capecitabine-Induced Severe Toxicity Secondary to DPD Deficiency and Successful Treatment with Low Dose 5-Fluorouracil.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Dihydropyrimidine Dehydrogenase Deficiency; Dose-Resp | 2017 |
[A Patient with Rectal Cancer and Multiple Lung Metastases Treated with XELOX plus Bevacizumab (Bev) Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Deoxycyt | 2015 |
[Two Cases of Curative Resection of Locally Advanced Rectal Cancer after Preoperative Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Methot | 2015 |
[A Patient with Recurrent Ulcerative Colitis-Associated Rectal Cancer Attaining a Complete Response with FOLFIRI plus Bevacizumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colitis, Ulcerative; Comb | 2015 |
[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot | 2015 |
[Conversion Therapy of Initially Unresectable Rectal Cancer with Perforation via FOLFOX4 Chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colostomy; Combined | 2015 |
[A Case of Rectal Cancer with Multiple Liver, Lung, and Para-Aortic Lymph Node Metastases Successfully Treated with FOLFOX4 plus Bevacizumab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Bevacizumab; Chemotherapy, Adjuvant; Fl | 2015 |
[A Case of Thrombotic Thrombocytopenic Purpura in a Patient Undergoing FOLFOX6 plus Panitumumab Therapy for Unresectable Recurrent Rectal Cancer with a Rapidly Progressive Course].
Topics: ADAM Proteins; ADAMTS13 Protein; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Stu | 2015 |
Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Fluoro | 2016 |
Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothe | 2016 |
NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2016 |
Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Dig | 2016 |
Long-Term Bone Marrow Suppression During Postoperative Chemotherapy in Rectal Cancer Patients After Preoperative Chemoradiation Therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Dise | 2016 |
[Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; | 2016 |
[Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dru | 2016 |
[A Case of an Unresectable Locally Advanced Rectal Cancer with Surrounding Organ Invasion Successfully Resected after Chemotherapy with mFOLFOX6 plus Cetuximab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Fluorouracil; Humans; Leucovorin; Male; M | 2016 |
[Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy].
Topics: Chemoradiotherapy; Digestive System Surgical Procedures; Fluorouracil; Humans; Neoadjuvant Therapy; | 2016 |
[Analysis of clinical predictive factors of pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
Topics: Adenocarcinoma; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Radiotherapy, Intensit | 2016 |
Intensity-Modulated Radiotherapy in Neoadjuvant Concurrent Chemoradiotherapy for Locally Advanced Rectal Cancer.
Topics: Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Radiotherapy, Intensity-Modulated; Rec | 2016 |
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2016 |
[A Case of Unresectable Rectal Cancer with Multiple Liver Metastases Treated Effectively with 22 Courses of XELOX Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; L | 2016 |
[A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2016 |
Non-surgical management of rectal cancer. Series of 68 cases, long follow up in two leading centres in Argentina.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Argentina; Chemoradiotherapy; Disease-F | 2016 |
[Research hotspot and progress of preoperative chemoradiotherapy for rectal cancer].
Topics: Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Chemoradiotherapy; Deoxyc | 2016 |
[Clinical study on locally advanced rectal cancer patients with pathological complete response after neoadjuvant chemoradiotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothe | 2016 |
[Expression of CD133 in rectal cancer tissues and its relationship with neoadjuvant chemoradiotherapy].
Topics: AC133 Antigen; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deox | 2016 |
Calnexin, an ER stress-induced protein, is a prognostic marker and potential therapeutic target in colorectal cancer.
Topics: Biomarkers, Tumor; Calnexin; Cell Death; Cell Survival; Clone Cells; Colorectal Neoplasms; Endoplasm | 2016 |
Genetic polymorphisms in 5-Fluorouracil-related enzymes predict pathologic response after neoadjuvant chemoradiation for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Databases, Factual; Female; Fluorouracil; Genotyp | 2016 |
[A Case of Fournier's Gangrene Caused by Small Intestinal Perforation during Bevacizumab Combination Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemoradiotherapy; Drainage; Fatal Outc | 2016 |
DNA Mismatch Repair Deficiency in Rectal Cancer: Benchmarking Its Impact on Prognosis, Neoadjuvant Response Prediction, and Clinical Cancer Genetics.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benchmarking; Biomarkers, Tumor; Chemoradioth | 2016 |
[Short-term efficacy comparison between preoperative three dimensional conformal radiotherapy and volumetric modulated arc therapy concurrently combined with chemotherapy in the treatment of locally advanced rectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fema | 2016 |
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Chemoradiother | 2016 |
Outcomes of Preoperative Chemoradiotherapy and Combined Chemotherapy with Radiotherapy Without Surgery for Locally Advanced Rectal Cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capeci | 2016 |
[A Case of Liver Metastasis from Colorectal Cancer That Showed a Pathological Complete Response to mFOLFOX6 plus Cetuximab].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Combined Modality Therapy; Fluorour | 2016 |
Adjuvant chemoradiotherapy instead of revision radical resection after local excision for high-risk early rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2016 |
Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer-a real-world outcome study.
Topics: Age Factors; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Diarrhea; Disease-Free Surviv | 2016 |
Management of rectal cancer: the 2016 French guidelines.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Chemoradiotherap | 2017 |
Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Da | 2016 |
Discriminating cancer-related and cancer-unrelated chemoradiation-response genes for locally advanced rectal cancers.
Topics: Aged; Algorithms; DNA Repair; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; | 2016 |
A Retrospective Analysis on Two-week Short-course Pre-operative Radiotherapy in Elderly Patients with Resectable Locally Advanced Rectal Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2016 |
Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-F | 2017 |
Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2017 |
Reply to I. Gounaris and M. Hall et al.
Topics: Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Prostatic Neoplasms; Rectal Neoplasms | 2017 |
We Have the Tools: It's Time to Use Them Correctly!
Topics: Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Rectal Neoplasms; Research Design | 2017 |
Comment on the FOWARC Study Report.
Topics: Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Rectal Neoplasms; Rectum | 2017 |
[Two Cases of Metastatic Rectal Cancer Patients Who Received Chemotherapy with FOLFOXIRI plus Bevacizumab].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorourac | 2016 |
[A Patient with Colon Cancer Local Site Recurrence Who Experienced Difficulty Tolerating Intensive Chemotherapy Was Treated Effectively with sLV5FU2 Therapy].
Topics: Abdominal Neoplasms; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil | 2016 |
[Pathological Complete Response in a Case of Multiple Liver Metastases from Rectal Cancer Treated with XELOX plus Bevacizumab(Bev)Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colectomy; Combined Modal | 2016 |
[A Case of Rectal Cancer with Unresectable Liver Metastasis Responding to Rechallenge with FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Fluorouracil; | 2016 |
[A Case of Advanced Rectal Cancer Resulting in a Pathologically Complete Response after Neoadjuvant Chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deo | 2016 |
Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2017 |
Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuva | 2017 |
Prinzmetal angina (Coronary vasospasm) associated with 5-fluorouracil chemotherapy.
Topics: Administration, Sublingual; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Coronary Ang | 2017 |
FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; F | 2017 |
Pneumatosis cystoides intestinalis after fluorouracil chemotherapy for rectal cancer.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
Combined cetuximab, capecitabine, oxaliplatin, and radiotherapy in rectal cancer: Dr. Jekyll or Mr. Hyde? In regard to Rödel et al. (Int J Radiat Oncol Biol Phys 2008;70:1081-1086.).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2008 |
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survi | 2008 |
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Age Factors; Aged; Chemotherapy, Adjuvant; Cohort Studies; Colectomy; Female; Fluoro | 2009 |
Granulocyte-colony stimulating factor producing rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colectomy; Fatal Outcome; | 2008 |
[Pathomorphosis of rectal cancer after irradiation on the background of intra-arterial regional chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouraci | 2008 |
Accuracy of endorectal ultrasonography in staging locally advanced rectal cancer after preoperative chemoradiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Endosonography; Fem | 2008 |
[Combination chemotherapy composed of mFOLFOX 6, FOLFIRI 2 and surgery and radiation therapy for locoregional recurrences and multiple lung metastases from rectal cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Cisplatin; C | 2008 |
[5-FU/LV therapy for a rectal cancer patient undergoing continuous hemodialysis with multiple hepatic metastases--a case report].
Topics: Biomarkers, Tumor; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Rectal Neop | 2008 |
[Rectal adenocarcinoma metastasis to the facial skin--case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Facial Neopl | 2008 |
Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Desensitization, Immunologic; | 2008 |
Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
Topics: Antimetabolites, Antineoplastic; Cell Hypoxia; Combined Modality Therapy; Dideoxynucleosides; Fluoro | 2008 |
Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2008 |
Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohor | 2008 |
A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2008 |
[A case with liver resection of metastasis from rectal cancer after FOLFOX4+bevacizumab treatment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2008 |
[A case of increased resectability with preoperative chemotherapy FOLFOX4 for unresectable rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonoscopy; Fluorouracil; | 2008 |
Hepatic arterial infusion chemotherapy combined with venous embolization in a patient with hepatic metastases with an arteriovenous shunt.
Topics: Angiography; Antimetabolites, Antineoplastic; Arteriovenous Fistula; Combined Modality Therapy; Cont | 2009 |
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.
Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2009 |
[A case of diffusely infiltrating rectal cancer with pulmonary lymphangitis carcinomatosa successfully treated with mFOLFOX6 chemotherapy as salvage].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Fluorouracil; Humans | 2008 |
[A case of metastatic lung and liver tumors from rectal cancer treated with oral UFT and CPT-11 by hepatic arterial infusion followed by FOLFOX and FOLFIRI].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptotheci | 2008 |
[Epiphora in a patient receiving FOLFOX therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Lacrimal Apparatus Disea | 2008 |
Can an FDG-PET/CT predict tumor clearance of the mesorectal fascia after preoperative chemoradiation of locally advanced rectal cancer?
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fasci | 2008 |
Regression of rectal cancer with radiotherapy with or without concurrent capecitabine--optimising the timing of surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female | 2009 |
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2009 |
Neo-adjuvant chemoradiotherapy in advanced rectal carcinoma: a note of caution.
Topics: Adenocarcinoma; Fatal Outcome; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Rectal | 2008 |
Alterations in hormone levels after adjuvant chemoradiation in male rectal cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Follicle Stimula | 2009 |
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
[Our experiences of preoperative chemo-radiotherapy for T4 primary rectal cancer].
Topics: Antineoplastic Agents; Drug Combinations; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Thera | 2008 |
[A case of huge advanced rectal cancer invaded into the surrounding organs resected successfully after preoperative chemotherapy with mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Male; Neoadj | 2008 |
[Modified FOLFOX6 treatment for obstructive jaundice caused by hepatic lymph-node metastasis from liver metastases of rectal cancer--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Fluorouracil; Huma | 2008 |
[A case report of a patient with hand-foot syndrome induced by bolus 5-fluorouracil therapy].
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Fluorouracil; Foot; Hand; Humans; Male; Middle Age | 2008 |
[A case report of complete remission of relapsed rectal cancer liver metastasis after systemic chemotherapy successfully treated by radiofrequency ablation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Fluorouracil; Humans; Leucovorin; | 2008 |
[Complete response of advanced rectal cancer with combined therapy of S-1 + chemo-radiation plus FOLFIRI--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; | 2008 |
[Hepatic artery infusion chemotherapy to three liver metastasis cases in which systemic chemotherapy was impossible or ineffective].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Female; Fluorouracil; Hepa | 2008 |
Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod | 2009 |
Caveolin-1 as a prognostic marker for local control after preoperative chemoradiation therapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Caveolin 1; Deoxycytidine | 2009 |
Risk of hypogonadism from scatter radiation during pelvic radiation in male patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Brachytherapy; Fluorouracil; Follic | 2009 |
[Pharmacokinetic monitoring of 5-fluorouracil may improve the clinical benefit with an individualized regimen-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Monitoring; Fluorouracil; Humans; Liver N | 2009 |
[A CR case of colorectal cancer given 39 courses of FOLFOX].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; | 2009 |
To widen the setting of cancer patients who could benefit from metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxyc | 2009 |
Complete peritonectomy and intraperitoneal chemotherapy for recurrent rectal cancer with peritoneal metastasis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2009 |
[Two cases of interstitial lung diseases in patients treated with oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX)].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; L | 2009 |
[Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Male | 2009 |
Fertility preservation for young women with rectal cancer--a combined approach from one referral center.
Topics: Adult; Antimetabolites, Antineoplastic; Cryopreservation; Female; Fluorouracil; Humans; Infertility, | 2009 |
Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls.
Topics: Aged; Aged, 80 and over; Algorithms; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fea | 2009 |
A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Female; Fluorouracil; Heart Failure; Humans; Middle | 2009 |
Synchronous isolated adrenal metastasis from rectum adenocarcinoma.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Female; Flu | 2009 |
[A case of locally advanced rectal cancer responding to FOLFOX].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Magnetic Resonance | 2009 |
[A successfully resected case of rectal cancer with liver metastases treated with mFOLFOX6 and bevacizumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2009 |
[A case report of complete response to RPMI regimen for multiple lymph node metastases following rectal cancer surgery].
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Fluorouracil; Humans; Leucovorin; Lymphatic Metastas | 2009 |
Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fascia; Female; Fluorouracil; | 2009 |
Lymph node harvest after proctectomy for invasive rectal adenocarcinoma following neoadjuvant therapy: does the same standard apply?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2009 |
The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorodeoxyglucose F18; Flu | 2009 |
Suppression of the postoperative neutrophil leucocytosis following neoadjuvant chemoradiotherapy for rectal cancer and implications for surgical morbidity.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fl | 2010 |
A case report of pathologically complete response of a huge rectal cancer after systemic chemotherapy with mFOLFOX6.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; DNA-Binding Proteins; Dru | 2009 |
Complete pathologic response after preoperative rectal cancer chemoradiotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Fr | 2009 |
Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2009 |
[A case of advanced gastric and rectal cancer (double cancer) successfully treated with mFOLFOX6 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Intestinal permeability, vitamin A absorption, alpha-tocopherol, and neopterin in patients with rectal carcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Aged; alpha-Tocopherol; Antimetabolites, Antineoplastic; Antioxidants; Carbohydrates | 2010 |
A case of 5-fluorouracil-induced acute psychosis.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
Postoperative morbidity with diversion after low anterior resection in the era of neoadjuvant therapy: a single institution experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, | 2009 |
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers | 2009 |
Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model.
Topics: Antimetabolites, Antineoplastic; Diarrhea; Dose-Response Relationship, Radiation; Fluorouracil; Huma | 2010 |
Rectal angiosarcoma after adjuvant chemoradiotherapy for adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fatal Outcome; Fluorouracil | 2009 |
[The pharmacokinetics and safety of oxaliplatin in a hemodialysis patient treated with mFOLFOX6 therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deox | 2010 |
Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chi-Square Distribution; Female; Fl | 2009 |
Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dih | 2009 |
[Prognostic analysis of 443 cases of stage II colorectal cancer and the value of adjuvant chemotherapy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecita | 2009 |
[Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic An | 2009 |
[Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-1 | 2009 |
[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr | 2009 |
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant | 2009 |
[A case of rectal cancer with liver metastases successfully treated with modified FOLFOX6 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluorouracil; He | 2009 |
[Practical neoadjuvant and adjuvant therapies for rectal cancer. How many patients are actually recruited in multimodality therapy concepts? An analysis of the Tumour Centre Schwerin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities; Chemotherapy, Adjuvant; Comb | 2009 |
Recommendation preoperative 5-FU/RT fir T1-3, N0 disease.
Topics: Algorithms; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; Practice Guideli | 2003 |
Effects of preoperative chemoradiotherapy on anal sphincter functions and quality of life in rectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 2010 |
[Metachronous metastasis from rectal adenocarcinoma to the penis--case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2009 |
NCCN guideline updates: colon and rectal cancers, version 1.2004.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2004 |
Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2010 |
Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2010 |
[A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen | 2009 |
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; | 2010 |
Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colectomy; Deoxycytid | 2010 |
Chemoradiotherapy in the management of primary squamous-cell carcinoma of the rectum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, | 2011 |
Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
[Two cases of advanced rectal cancer resected successfully after neoadjuvant chemotherapy with FOLFOX regimen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Male; Midd | 2009 |
[Assessment of chemoradiation therapy for advanced rectal cancer invaded the pelvic organ].
Topics: Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modalit | 2009 |
[A case report of metastatic liver tumor from rectosigmoid colon cancer demonstrating a pathological complete response with FOLFOX and FOLFIRI treatment].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2009 |
[A case of liver metastasis of rectal cancer demonstrating complete response for more than two years to mFOLFOX6].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; M | 2009 |
[A case of advanced rectal cancer with severe liver dysfunction due to multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans; Infusion | 2009 |
[Two case reports of metastatic liver carcinoma with the effective treatment of radiofrequency ablation and intraarterial chemotherapy].
Topics: Aged; Catheter Ablation; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Infu | 2009 |
[A case of surgical approach to the recurrence of the para-aortic lymph nodes after resection of rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Combined Modality Therapy; Female; | 2009 |
High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2010 |
Drug monitoring during FOLFOX6 therapy in a rectal cancer patient on chronic hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chronic Disease; Drug Monitoring; | 2010 |
[A case of advanced rectal cancer with liver and lung metastasis showing a complete response by neo-adjuvant FOLFOX4 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Topics: Amino Acid Substitution; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cape | 2010 |
Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy | 2010 |
Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG-PET-CT findings.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; De | 2010 |
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Combined Modality Therapy; | 2010 |
[Herpes simplex virus bronchopneumonitis in patient with acute respiratory failure after surgery].
Topics: Acute Disease; Acyclovir; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antiviral Agents; B | 2010 |
Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Combined Modality Th | 2010 |
Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Diarrhea; Feasibility Studies | 2010 |
Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Neoadjuvant chemotherapy in MRI-staged rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Humans; N | 2010 |
Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer. In regard to MG Zampino et al. (Int J Radiat Oncol Biol Phys 2009;75:421-427).
Topics: Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouraci | 2010 |
Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2010 |
Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Digestiv | 2011 |
Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2010 |
Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.
Topics: Adult; Aged; Female; Fluorouracil; Gene Expression Profiling; Genetic Association Studies; Genotype; | 2011 |
[Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2010 |
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin | 2010 |
Role of neo-adjuvant chemoradiation in locally advanced rectal cancers.
Topics: Chemotherapy, Adjuvant; Fluorouracil; Humans; Immunosuppressive Agents; Infusions, Intravenous; Leuc | 2010 |
Correlations of clinicopathological factors with protein expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyltransferase in colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluor | 2010 |
[Drug eruption (erythema multiforme type) following chemoradiotherapy with mitomycin C and 5-fluorouracil administration for squamous cell carcinoma of the anal canal].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modal | 2010 |
[Pathologically complete response of multiple liver metastases from rectal cancer treated with mFOLFOX6 plus bevacizumab].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2010 |
Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2011 |
Anal function and intersphincteric resection.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; | 2010 |
Circulating lymphocyte number has a positive association with tumor response in neoadjuvant chemoradiotherapy for advanced rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Ther | 2010 |
[A case or resection of synchronous multiple liver metastases from rectal cancer after FOLFOX4 therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neopla | 2010 |
[Elderly patient with recurrent rectal cancer successfully responded to modified FOLFOX6 chemotherapy with bevacizumab--a case report].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combine | 2010 |
Sexual function in females after radiotherapy for rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coitus; Cross-S | 2010 |
Preoperative chemoradiotherapy for rectal cancer: a comparison between intravenous 5-fluorouracil and oral capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; | 2010 |
Development of bronchiolitis obliterans organizing pneumonia with platinum-based chemotherapy for metastatic rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2010 |
[Efficacy observation of accelerated hyperfractionation recourse radiotherapy plus concurrent capecitabine in the treatment of locoregional recurrent rectal cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dose Fractionation, Radia | 2010 |
[Two cases of unstable angina in patients treated with bevacizumab].
Topics: Aged; Angina, Unstable; Angiogenesis Inhibitors; Angiography; Antibodies, Monoclonal; Antibodies, Mo | 2010 |
Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape | 2011 |
Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidi | 2010 |
Radiosensitizing drugs: lessons to be learned from the oxaliplatin story.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modal | 2010 |
Are we ready to use an early alternative end point as the primary end point of a phase III study in rectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trial | 2010 |
Patterns of response after preoperative intensity-modulated radiation therapy and capecitabine/oxaliplatin in rectal cancer: is there still a place for ecoendoscopic ultrasound?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deox | 2011 |
Preliminary experience with bladder preservation for lower rectal cancers involving the lower urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Feasibility | 2010 |
[Two cases of colorectal cancer presenting with periodic, transient elevation of serum iron due to hemolysis after chemotherapy including 5-FU].
Topics: Aged; Bilirubin; Colonic Neoplasms; Female; Fluorouracil; Hemolysis; Humans; Iron; Male; Middle Aged | 2010 |
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; | 2010 |
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoth | 2011 |
Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorodeox | 2011 |
Perirenal hematoma associated with bevacizumab treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2012 |
Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorouraci | 2011 |
A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2010 |
Criteria for three-dimensional anorectal ultrasound assessment of response to chemoradiotherapy in rectal cancer patients.
Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, | 2011 |
A gene expression signature for chemoradiosensitivity of colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Surviv | 2010 |
L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Biopsy; Cell Membrane; Fluorouracil; Humans; Hyperthermia, Induced; Lar | 2010 |
Imunoexpression of Ki-67 and p53 in rectal cancer tissue after treatment with neoadjuvant chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Mo | 2011 |
A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Dihydropyrimidine Dehydrogenase Defic | 2011 |
[Successful treatment with cetuximab combination chemotherapy in a case of FOLFOX-refractory rectal cancer with previously unresectable multiple liver metastases leading to complete resection].
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas | 2010 |
Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoembryonic Anti | 2011 |
Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dihydropyrimidine Dehydrogenase Defici | 2010 |
Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose Fractionation, Radiation | 2011 |
Hepar lobatum carcinomatosum associated with metastatic rectal carcinoma: an unusual cause of liver dysmorphy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Liver; Liver Neoplasms; Male; | 2011 |
[A case of liver metastases from rectal cancer showed a complete response by FOLFIRI and bevacizumab chemotherapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2012 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma | 2010 |
Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Digestive System Surgi | 2011 |
Adjuvant 5-fluorouracil-induced colitis necessitating completion colectomy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colitis; Fluorou | 2011 |
Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2011 |
[Long-term control of sacral metastasis from rectal cancer with S-1 + radiation treatment (RT) and mFOLFOX6 combination therapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Dru | 2010 |
[A case with liver resection of metastasis from rectal cancer after bevacizumab treatment].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[The efficacy of cetuximab for metastatic colorectal cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2010 |
[Two cases of venous thrombosis confirmed during the bevacizumab combination chemotherapy for colorectal cancer].
Topics: Aged; Angiogenesis Inducing Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antin | 2010 |
[A long-term survival case of rectal cancer with Virchow's lymph node metastasis by multimodality therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2010 |
[Idiopathic thrombocytopenic purpura during chemotherapy for liver metastasis of rectal cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[A long-term disease-free survival case of advanced rectal cancer with massive metastasis to the lateral pelvic and para-aortic lymph nodes].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined C | 2010 |
[A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2010 |
[A case report of advanced rectal cancer showing a pathological complete response by neo-adjuvant FOLFOX chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor | 2010 |
[A case of rectal cancer with synchronous multiple liver metastases successfully treated with combined chemotherapy of modified FOLFOX6 and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2010 |
[Long-term survival case after liver resection and postoperative hepatic arterial infusion for multiple liver metastases from rectal cancer].
Topics: Antimetabolites, Antineoplastic; Disease-Free Survival; Fluorouracil; Hepatectomy; Humans; Infusions | 2010 |
Rectal cancer: mucinous carcinoma on magnetic resonance imaging indicates poor response to neoadjuvant chemoradiation.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma | 2012 |
Toxicity and complications of preoperative chemoradiotherapy for locally advanced rectal cancer.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemot | 2011 |
5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Capecitabine; Deoxycytidine; | 2011 |
Postoperative low pelvic radiotherapy and chemotherapy for stage II and III rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Drug Admin | 2012 |
Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemorad | 2012 |
Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2011 |
[Effective cetuximab monotherapy for a case of recurrence rectal cancer after multiple previous chemotherapy treatment (FOLFOX, FOLFIRI)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
[A case of unresectable rectal cancer with severe pelvic infiltration responding to FOLFOX].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Leu | 2011 |
Accelerated hyperfractionation field-involved re-irradiation combined with concurrent capecitabine chemotherapy for locally recurrent and irresectable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas | 2012 |
An evaluation of whether neoadjuvant therapy delays closure of defunctioning loop ileostomy following anterior resection for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplast | 2011 |
Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Diffus | 2012 |
Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2011 |
The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2012 |
Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer : prognostic significance of tumor regression.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcin | 2011 |
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema | 2011 |
Rectal motion in patients receiving preoperative radiotherapy for carcinoma of the rectum.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Contrast Media; Fluorouracil; Humans; Mo | 2011 |
[Ileitis following capecitabine use].
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Ileitis; M | 2011 |
MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2011 |
Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2011 |
Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Com | 2011 |
A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Diss | 2011 |
Short-course versus standard chemoradiation in T3 rectal cancer.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Radiation | 2011 |
Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Combination of differentiation and T stage can predict unresponsiveness to neoadjuvant therapy for rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease-Free Surv | 2011 |
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptotic Protease- | 2012 |
[Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcino | 2011 |
Clinical outcomes of mild hyperthermia for locally advanced rectal cancer treated with preoperative radiochemotherapy.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adj | 2011 |
[Eighty-five-year-old patient with recurrent rectal cancer effectively treated with CapeOX chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Deo | 2011 |
[A case of advanced rectal cancer resected successfully after preoperative XELOX chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deox | 2011 |
Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem | 2011 |
[Effect of the duration of time between chemo-radiotherapy and surgical intervention on the results of the combined treatment of rectal cancer].
Topics: Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 2011 |
Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonoscopy; Endosonography; | 2011 |
[Pilot study of preoperative mFOLFOX6 chemotherapy for advanced rectal cancers which were difficult to ensure surgical margins].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Leu | 2011 |
A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; De | 2012 |
The prognostic value of grade of regression and oncocytic change in rectal adenocarcinoma treated with neo-adjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2011 |
[Neoadjuvant radiochemotherapy for rectal cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Hu | 2011 |
[A resected case of locally invasive rectal cancer successfully treated with neoadjuvant capecitabine, oxaliplatin, bevacizumab and radiation therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2011 |
Molecular changes consistent with increased proliferation and invasion are common in rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Case-Control Stu | 2011 |
The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ch | 2012 |
TS and DPD mRNA levels on formalin-fixed paraffin-embedded specimens as predictors for distant recurrence of rectal cancer treated with preoperative chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dihydrouracil Dehydrogenase (NADP); | 2012 |
Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; | 2011 |
The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Colonic Neoplasms; Female; Fluorouracil; Humans; | 2012 |
Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Ch | 2012 |
Total mesorectal excision of initially unresectable locally advanced rectal cancer infiltrating the pelvic wall after treatment with FOLFOX4 plus bevacizumab and preoperative chemoradiation: report of a case.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chem | 2012 |
Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2011 |
Safety and outcome of chemoradiotherapy in elderly patients with rectal cancer: results from two French tertiary centres.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycyti | 2012 |
Pathologic complete response after FOLFOX7 in a locally advanced rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu | 2012 |
A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biopsy; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine | 2012 |
[A case of recurrent rectal cancer with paraaortic lymph node metastasis treated by FOLFIRI therapy leading to complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Female; Fluorouracil; Humans; L | 2011 |
[A case of metastatic rectal cancer in an extremely aged patient successfully treated with mFOLFOX6 plus bevacizumab].
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combin | 2011 |
[Repeated resections for originally unresectable liver metastasis from colorectal cancer after multiagent chemotherapy].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemothera | 2011 |
[A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucov | 2011 |
[A case of no recurrence over 10 years in advanced rectal cancer with bleeding treated by urgent arterial embolization followed by synchronous liver resection and extended lymph node dissection].
Topics: Aged; Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Combined Modality Therapy; Fe | 2011 |
[Diffusion-weighted MR imaging in patients with rectal cancer: our initial experience].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Diffusion Magnetic Resonance Imagin | 2011 |
Optimal lymph node harvest in rectal cancer (UICC stages II and III) after preoperative 5-FU-based radiochemotherapy. Acetone compression is a new and highly efficient method.
Topics: Acetone; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; | 2012 |
A observational study of the efficacy and safety of capecitabine versus bolus infusional 5-fluorouracil in pre-operative chemoradiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidin | 2012 |
"The only thing I know is that I know nothing": 5-fluorouracil in human milk.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Feeding; Chromatography, High Pressure Liquid; Female | 2012 |
In regard to "Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer" (Int J Radiat Oncol Biol Phys 2011;81:669-676).
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Polymorphism | 2012 |
Adjuvant chemotherapy with or without pelvic radiotherapy after simultaneous surgical resection of rectal cancer with liver metastases: analysis of prognosis and patterns of recurrence.
Topics: Adult; Aged; Analysis of Variance; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycyt | 2012 |
Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2012 |
[Huge unresectable multiple hepatic metastases of rectum cancer responding to combined therapy with FOLFIRI +bevacizumab - a case report].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biop | 2012 |
Development of a standardized method for contouring the lumbosacral plexus: a preliminary dosimetric analysis of this organ at risk among 15 patients treated with intensity-modulated radiotherapy for lower gastrointestinal cancers and the incidence of rad
Topics: Anatomic Landmarks; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Fluorouracil; Hu | 2012 |
Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Response of glutathione S-transferase Pi (GSTP1) to neoadjuvant therapy in rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; F | 2012 |
Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemor | 2012 |
Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycy | 2012 |
Severe hypertriglyceridaemia associated with the use of capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Hypertriglycerid | 2012 |
[A case of resected rectal cancer with hepatic node and multiple liver metastases effectively treated by preoperative modified FOLFOX6 and sLV5FU2 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Human | 2012 |
MR imaging of rectal cancer before and after chemoradiation therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fema | 2012 |
Dose--volume effects on patient-reported acute gastrointestinal symptoms during chemoradiation therapy for rectal cancer.
Topics: Aged; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Defecation; Deoxycytidine; Diarrhea; F | 2012 |
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
Topics: Adenocarcinoma; Aged; Anastomotic Leak; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant | 2012 |
Evaluation of the efficacy of modified De Gramont and modified FOLFOX4 regimens for adjuvant therapy of locally advanced rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemorad | 2011 |
Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidi | 2012 |
Short-term results and long-term oncologic outcomes between neoadjuvant chemoradiotherapy and adjuvant postoperative chemoradiotherapy for stage III rectal cancer: a case-matched study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemoradiotherapy; Female; Flu | 2012 |
[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2012 |
[A case of rectal hemorrhage during chemotherapy with bevacizumab for local recurrence of rectal cancer].
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols | 2012 |
[Complete clinical and pathological response to mFOLFOX6 neoadjuvant chemotherapy in a case of advanced rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Neoa | 2012 |
[A case of locally advanced rectal cancer had a pathological complete response to XELOX Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic Antigen; Deoxycytidin | 2012 |
Hand-foot syndrome related to chemotherapy.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Hand-Foot Syndrome; Humans | 2012 |
[A case of remnant liver metastases after resection of liver metastases from rectal cancer following treatment with 5-FU, L-OHP and CPT-11, with markedly effective treatment by cetuximab plus S-1].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, | 2012 |
Long-term results with oral fluoropyrimidines and oxaliplatin-based preoperative chemoradiotherapy in patients with resectable rectal cancer. A single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Drug Administration | 2012 |
Capecitabine in the treatment of rectal cancer.
Topics: Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Humans; | 2012 |
[A case of response to panitumumab as third-line chemotherapy for multiple liver metastases and portal venal tumor embolus of rectal cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Embol | 2012 |
[A case report of pathologically complete response of locally advanced rectal cancer after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2012 |
Squamous cell carcinoma of the rectum: a single institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2012 |
[Increased INR from concomitant use of acenocoumarol and capecitabine].
Topics: Acenocoumarol; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Atrial Fibrillati | 2012 |
[Evaluation of modified OPTIMOX1 plus bevacizumab as the neoadjuvant therapy for highly advanced rectal cancers].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2012 |
Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp | 2012 |
Early prediction of histopathological response of rectal tumors after one week of preoperative radiochemotherapy using 18 F-FDG PET-CT imaging. A prospective clinical study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothe | 2012 |
Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; De | 2013 |
Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Use of adjuvant chemotherapy in stage C (III) rectal cancer: comparison of data from matched patients in a teaching hospital's clinico-pathological database.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2012 |
[A case of huge advanced rectal cancer resected successfully after chemotherapy with mFOLFOX6].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Combined Modality Therapy; Female; Flu | 2012 |
Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Topics: 3' Untranslated Regions; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 2013 |
Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy, | 2012 |
[A case of adenocarcinoma occurring at colostomy site 7 years after abdominoperineal resection for rectal cancer resected after preoperative mFOLFOX6 chemotherapy].
Topics: Abdominal Wall; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colost | 2012 |
In regard to Samuelian et Al.
Topics: Antineoplastic Agents; Data Interpretation, Statistical; Diarrhea; Fluorouracil; Humans; Postoperati | 2012 |
Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2012 |
Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemothe | 2013 |
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2013 |
[Evaluation of the efficacy and prognostic factors for colorectal liver metastases treated with transcatheter arterial chemoembolization].
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Carcinoembryonic Antigen; | 2012 |
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Combi | 2012 |
Small bowel dose parameters predicting grade ≥ 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Female; Fluorouracil; Humans; Intestin | 2013 |
What is the incidence of metastatic lymph node involvement after significant pathologic response of primary tumor following neoadjuvant treatment for locally advanced rectal cancer?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, A | 2013 |
Rectal cancer in pregnancy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Neo | 2013 |
Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
Topics: Adenocarcinoma; Aged; Anal Canal; Brazil; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Mic | 2013 |
Which way is forward in the treatment of rectal cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 2013 |
5-FU-induced cardiac toxicity--an underestimated problem in radiooncology?
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cardiotoxins; Chemoradiotherapy; Electrocardiograp | 2012 |
[Complete response obtained by preoperative chemotherapy in a case of T4 rectal cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Comb | 2012 |
[Two cases of interstitial pneumonia caused by cetuximab plus mFOLFOX6 therapy in metastatic colorectal cancer patients].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2012 |
[A case of advanced rectal cancer treated effectively with intersphincteric resection and preoperative chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Leu | 2012 |
[A case of a colon cancer patient with liver metastasis subjected to hepatectomy after achieving radiographic complete response with preoperative chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Hepat | 2012 |
[A case of advanced rectal cancer with lung and bone metastasis that was successfully treated with mFOLFOX6+bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone | 2012 |
[A case report of recurrent lung metastasis after surgery for rectal cancer for which lung radiofrequency ablation therapy and long-term administration of FOLFIRI were effective].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheter Ablation; Fluorouracil; Human | 2012 |
[A case report of successful treatment for rectosigmoid cancer with peritoneal dissemination after neoadjuvant chemoradiotherapy with XELOX and bevacizumab].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cape | 2013 |
[A case of an ulcer of the sigmoid colon during chemotherapy with FOLFOX4 and bevacizumab for recurrence of rectal carcinoma].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab | 2013 |
[A case of advanced rectal cancer with bladder carcinoma salvaged from myocardial infarction during operation, showing tumor regression by XELOX treatment, good quality of life].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluo | 2013 |
Impact of adjuvant chemoradiotherapy for rectal cancer on the long-term quality of life and late side effects: a multicentric clinical evaluation by the Turkish Oncology Group.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora | 2012 |
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; | 2013 |
Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antine | 2013 |
Neoadjuvant therapy for rectal cancer decreases the number of lymph nodes harvested in operative specimens.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorour | 2013 |
Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy in patients with locally advanced rectal cancer: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Dose Fractionation | 2013 |
Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2012 |
Pelvic radiation therapy combined with hepatic artery chemotherapy for resected rectal carcinoma with liver metastases.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hepat | 1996 |
Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Male; | 2002 |
Long-term results of reirradiation for patients with recurrent rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2002 |
Radio-chemotherapy as a preoperative treatment for advanced rectal cancer. Evaluation of down-staging and morbidity.
Topics: Adult; Aged; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studi | 2002 |
Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti | 2002 |
[A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administr | 2002 |
Phenytoin toxicity as a result of 5-fluorouracil administration.
Topics: Anticonvulsants; Antimetabolites, Antineoplastic; Drug Interactions; Epilepsy; Female; Fluorouracil; | 2002 |
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sc | 2002 |
Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Lymph Nodes; Preop | 2002 |
Oral uracil/ftorafur (UFT) plus leucovorin as first-line chemotherapy and salvage therapy with weekly high-dose 5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Diarrhea; Dose-Response Relationship, Drug; D | 2002 |
Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; ErbB Rec | 2002 |
Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; ErbB Rec | 2002 |
Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; ErbB Rec | 2002 |
Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; ErbB Rec | 2002 |
[A case of locally extended rectal cancer responding to intra-arterial infusion therapy via the internal iliac artery].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouraci | 2002 |
[A case of metastatic vaginal tumor of rectal cancer].
Topics: Adenocarcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged; | 2002 |
Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Col | 2003 |
A favourable pathological stage after neoadjuvant radiochemotherapy in patients with initially irresectable rectal cancer correlates with a favourable prognosis.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Recurrence, | 2003 |
Response to preoperative chemoradiation increases the use of sphincter-preserving surgery in patients with locally advanced low rectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Digest | 2003 |
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol | 2002 |
Combined-modality therapy in locally advanced primary rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2003 |
[The interest of radiotherapy in cancer of the rectum].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Neo | 2003 |
Distal intramural spread is an independent prognostic factor for distant metastasis and poor outcome in patients with rectal cancer: a multivariate analysis.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluoroura | 2003 |
[Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2003 |
Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2003 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Adminis | 2003 |
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Ch | 2003 |
[Clinical outcome of intra-hepatic arterial infusion therapy for multiple liver metastases from colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 2003 |
Physical training during intrahepatic chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Exercise Therapy; Fluorouracil; Forced Expiratory V | 2003 |
Feasibility and morbidity of combined hyperthermia and radiochemotherapy in recurrent rectal cancer--preliminary results.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progress | 2003 |
Minidose warfarin is associated with a high incidence of International Normalized Ratio elevation during chemotherapy with FOLFOX regimen.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 2003 |
Cardiac toxicity associated with capecitabine therapy.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diagnosis, Differential; Electrocardio | 2003 |
The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.
Topics: Academic Medical Centers; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Chemotherapy, | 2003 |
Isolated chemotherapeutic perfusion of the pelvis for advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Chemotherapy, Cancer, | 2003 |
Capecitabine-related neurotoxicity presenting as trismus.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Central Nervous System; Confusion; Deoxycytidine; Dia | 2003 |
P27 does not predict histopathological response to radiochemotherapy in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins | 2003 |
Response to preoperative chemoradiation in stage II and III rectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; | 2003 |
5-Fluorouracil in the treatment of inoperable carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Rectum; | 1962 |
CHEMOTHERAPY OF METASTATIC LIVER CANCER BY PROLONGED HEPATIC-ARTERY INFUSION.
Topics: Alkaline Phosphatase; Bile Duct Neoplasms; Bilirubin; Chemotherapy, Cancer, Regional Perfusion; Colo | 1964 |
METHODOLOGY OF PRELIMINARY CHEMOTHERAPEUTIC TRIALS IN PATIENTS WITH MALIGNANT SOLID TUMORS.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Cyclophosp | 1963 |
PERCUTANEOUS VISCERAL CATHETERIZATION FOR INFUSION CANCER CHEMOTHERAPY.
Topics: Biomedical Research; Catheterization; Fluorouracil; Geriatrics; Humans; Injections, Intra-Arterial; | 1964 |
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
SERIAL ENZYME CHANGES IN CANCER PATIENTS UNDERGOING CHEMOTHERAPY.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Clinical Enzyme Tests; Colonic Neoplasms; D-Alani | 1964 |
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N | 1964 |
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
FLUOROURACIL COLON-RECTUM ADJUVANT CHEMOTHERAPY.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Therapy; Fluorouracil; Humans; Infusions, Parenteral | 1964 |
5-FLUOURACIL IN THE TREATMENT OF DISSEMINATED COLON AND RECTAL CARCINOMA.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Geriatrics; Neoplasm Metastasis; Pharmacology; Rect | 1964 |
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast | 1964 |
A LESS TOXIC FLUOROURACIL DOSAGE SCHEDULE.
Topics: Alopecia; Breast Neoplasms; Colonic Neoplasms; Diarrhea; Drug Eruptions; Epistaxis; Female; Floxurid | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
COMBINED SPLIT-COURSE THERAPY WITH 5-FLUOROURACIL AND MEGAVOLTAGE IRRADIATION.
Topics: Colonic Neoplasms; Drug Therapy; Fluorouracil; Lung Neoplasms; Neoplasms; Radiography, Thoracic; Rad | 1964 |
PELVIC PERFUSION AND CARCINOMA OF THE RECTUM.
Topics: Carcinoma; Chemotherapy, Cancer, Regional Perfusion; Equipment and Supplies; Fluorouracil; Humans; M | 1965 |
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm | 1965 |
COMPARISON OF 5-FLUOROURACIL (NSC-19893) AND 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) IN TREATMENT OF PATIENTS WITH ADVANCED ADENOCARCINOMA OF COLON OR RECTUM.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Deoxyuridine; Drug Therapy; Fluorouracil; | 1965 |
[Effectiveness of preoperative radio-chemo-thermotherapy with respect to thermometry in locally advanced rectal carcinoma].
Topics: Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluoroura | 1998 |
Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Dihydrouracil Dehy | 2003 |
Total cystectomies in the surgical treatment of rectal cancer with prior chemoradiation: analysis of postoperative morbidity and survival.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystecto | 2004 |
Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gene Expression; | 2003 |
Catheter occlusion by calcium carbonate during simultaneous infusion of 5-FU and calcium folinate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcium Carbonate; Catheterization, Central Venous; | 2003 |
[Male gonadal dose in adjuvant 3-d-pelvic irradiation after anterior resection of rectal cancer. Influence to fertility].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fractionation, Radiati | 2003 |
[A case of liver and lung metastases of rectal cancer responding well to 5-FU hepato-arterial infusion (HAI) with combined use of oral UFT].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sche | 2003 |
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2003 |
[A case of unresectable liver metastases from rectosigmoid colon cancer with survival for over 3 years after multidisciplinary treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Admini | 2003 |
[A case of locally extended rectal carcinoma quickly responding to local intraarterial infusion therapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2003 |
Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Combi | 2003 |
Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic | 2003 |
Rectal adenocarcinoma with germ-cell differentiation: report of a case.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin | 2003 |
Presentations from the Walter Reed Army Medical Center. Case 1: rectal carcinoma.
Topics: Adenocarcinoma, Mucinous; Adult; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; N | 2003 |
Accuracy of endoscopic ultrasound for restaging rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Diagnostic Errors; Dose Fractionati | 2004 |
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2003 |
[Principles of postoperative therapy in rectal carcinoma].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen | 2004 |
[A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female | 2004 |
18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluorodeoxyglucos | 2004 |
[Preoperative radiation with chemotherapy for rectal cancer: its impact on downstaging of disease and the role of endorectal ultrasound].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma in Situ; Chemotherapy, Adjuvant; | 2004 |
Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chemotherapy | 2004 |
Extracapsular spread of nodal metastasis as a prognostic factor in rectal cancer.
Topics: Actuarial Analysis; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Mod | 2004 |
Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Thera | 2004 |
Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colectomy; Combined Modality Therap | 2003 |
Changes in apoptotic and mitotic index, bcl2, and p53 expression in rectum carcinomas after short-term cytostatic treatment.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Apoptosis; Biopsy; Female; Fluorouracil; Genes | 2003 |
[Analysis of microsatellite instability and p53 LOH in advanced colorectal cancers--first report of the No. 3 protocol].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Drug Admi | 2004 |
[Colorectal cancer: what should be the management of primary tumour?].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colon; Colonoscopy; Colorectal Neoplasms; D | 2004 |
[Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 2004 |
Sphincter preservation in locally advanced rectal cancer due to the addition of continuous infusion 5-FU to preoperative radiation therapy or advances in surgical techniques?
Topics: Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Lymph | 2004 |
Hypersensitivity reactions to oxaliplatin: a case report and the success of a continuous infusional desensitization schedule.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Desen | 2004 |
Substitution of oral fluoropyrimidines for infusional fluorouracil with radiotherapy: how much data do we need?
Topics: Administration, Oral; Aminoacridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2004 |
Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Colectomy; Fluorodeoxyglucose F18; Fluorouracil; Huma | 2004 |
[Choice of chemotherapeutic drugs for colorectal cancers by DPD and OPRT activities in cancer tissues].
Topics: Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female | 2004 |
Anti-metastatic effect of capecitabine on human colon cancer xenografts in nude mouse rectum.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorourac | 2004 |
[Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2004 |
[Effecting observation of 3-dimensional conformal radiotherapy combined with chemotherapy for rectal cancer of postoperative local recurrence].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; F | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Chemoradiotherapy for rectal cancer--when, why, and how?
Topics: Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; | 2004 |
[Relationship between expression of thymidylate synthase and colorectal carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Femal | 2004 |
[A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2004 |
Expression of p27 in residual rectal cancer after preoperative chemoradiation predicts long-term outcome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2004 |
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; D | 2004 |
[Successful treatment of liver metastasis and extrahepatic metastasis with hepatic arterial infusion of CDDP, CPT-11, and 5-FU].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2004 |
[A case of postoperative pelvic metastasis and multiple liver metastases of the rectal cancer successfully treated by arterial infusion therapy with 5-FU/leucovorin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans; Iliac Artery; | 2004 |
[A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2004 |
[Evaluation of intra-arterial infusion chemotherapy associated with radiotherapy for two cases of local recurrence of rectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female; | 2004 |
[Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2004 |
Immunohistochemical evaluation of thymidylate synthase (TS) and p16INK4a in advanced colorectal cancer: implication of TS expression in 5-FU-based adjuvant chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; C | 2004 |
Cardiotoxicity and neurotoxicity of high-dose continuous fluorouracil as a result of degradation compounds in the drug vials.
Topics: Acetaldehyde; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Carcinoma; Chemistry, Pharmaceu | 2004 |
Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square | 2004 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans; | 2005 |
Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2004 |
[A case of advanced rectal cancer responding to 5-fluorouracil based preoperative chemoradiation therapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administratio | 2005 |
Update on design of the National Surgical Adjuvant Breast and Bowel Project trial R-04.
Topics: Breast Neoplasms; Clinical Trials, Phase III as Topic; Female; Fluorouracil; Humans; Rectal Neoplasm | 2005 |
Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.
Topics: Adult; Aged; Antineoplastic Agents; Caenorhabditis elegans Proteins; Chemotherapy, Adjuvant; DNA, Ne | 2005 |
[Present treatment strategies for rectal carcinoma].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Endosonography; Fluorourac | 2005 |
[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2005 |
Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuvant; Colo | 2005 |
Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem | 2005 |
Expression level of thymidylate synthase is a good predictor of chemosensitivity to 5-fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Drug Screeni | 2005 |
The effects of capecitabine in Raynaud's disease: a case report.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Fluorouracil; Follow-Up Studie | 2005 |
[A case of bilateral multiple liver metastases with distant lymph node metastases due to rectal cancer successfully treated with hepatic arterial infusion (HAI) of levofolinate (l-LV)/5-fluorouracil (5-FU) and radiotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2005 |
Radiofrequency ablation therapy of remnant colorectal liver metastases after a course of hepatic arterial infusion chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Catheters, Indwe | 2005 |
[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dihydroura | 2005 |
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo | 2005 |
Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2005 |
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. Results of 8-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Dose Fractionat | 2005 |
Prognostic and predictive value of the thymidylate synthase expression in patients with non-metastatic colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; | 2005 |
Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Midd | 2005 |
Complete pathologic response after chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hu | 2005 |
Preoperative chemoradiation in rectal cancer: why we need a common language.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Progression; Dose F | 2005 |
Outcome after the introduction of a multimodality treatment program for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2005 |
Leflunomide and peripheral neuropathy: a potential interaction between uracil/tegafur and leflunomide.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Comorbidity; Disease Progression; Drug Administra | 2005 |
Combined-modality neoadjuvant therapy for rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; | 2005 |
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Aspir | 2005 |
Rectal cancer clinical practice guidelines in oncology.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Live | 2005 |
[Retrospective analysis on efficacy and toxicity of 5-fluorouracil (5-FU) and l-leucovorin (l-LV) in advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Admin | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
Capecitabine as third line therapy in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogen | 2005 |
Technique and long-term results of intersphincteric resection for low rectal cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; | 2005 |
Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Caspase 8; Caspases; F | 2005 |
Response to neoadjuvant therapy for rectal cancer: influence on long-term results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Modal | 2005 |
Serpentine supravenous streaks induced by 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Hyperpigmentation; Inf | 2005 |
The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2005 |
Immunohistochemical analysis of thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer (cUICC II/III): correlation with histopathologic tumor regression after 5-fluorouracil-based long-term neoadjuvant chemorad
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2005 |
Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Moda | 2005 |
Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bra | 2006 |
[Expression of mRNA levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mRNA levels in association with response to 5-FU based treatment].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dihydrouracil Dehydr | 2005 |
Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecit | 2006 |
Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorouracil; Follow-U | 2006 |
[Pseudomembranous colitis after 5-fluorouracil chemotherapy in rectal cancer patient].
Topics: Antimetabolites, Antineoplastic; Colon; Colonoscopy; Enterocolitis, Pseudomembranous; Fluorouracil; | 2005 |
[Colorectal carcinoma].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2005 |
[Five cases of locally advanced rectal cancer or local recurrence performed intra-arterial infusion chemotherapy via the internal iliac artery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Iliac Artery; Infusion | 2005 |
Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Cohort Studies; Combined Modal | 2005 |
Preoperative sequential short-term radiotherapy plus chemotherapy can induce complete remission in T3N2 rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidi | 2005 |
Upregulation of thymidine phosphorylase in rectal cancer tissues by mitomycin C.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Che | 2006 |
Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect | 2005 |
Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Transformation, Neopl | 2006 |
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2006 |
Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase | 2006 |
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience.
Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Femal | 2005 |
Weekly oxaliplatin and preoperative radiotherapy as a new neoadjuvant therapy for locally-advanced rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Administration Sched | 2006 |
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2006 |
[A case of advanced rectal cancer responding to l-Leucovorin (LV)/5-fluorouracil( 5-FU) therapy as neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis | 2006 |
Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom | 2006 |
Neoadjuvant radiochemotherapy for patients with locally advanced rectal cancer leads to impairment of the anal sphincter.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Antineoplastic Agents; | 2006 |
Long-term results after neoadjuvant radiochemotherapy for locally advanced resectable extraperitoneal rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil | 2006 |
Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Fe | 2006 |
Capecitabine as an alternative in a case of fluorouracil-induced photodermatitis.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Ph | 2006 |
Bevacizumab in metastatic colorectal cancer: a left intracardiac thrombotic event.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2006 |
Feasibility of 5-Fluorouracil resumption in a patient experiencing drug-induced acute Prinzmetal angina.
Topics: Adenocarcinoma; Angina Pectoris, Variant; Electrocardiography; Fluorouracil; Humans; Male; Middle Ag | 2006 |
Capecitabine chemoradiation for rectal cancer after curative surgery.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co | 2006 |
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco | 2006 |
Effects of radiotherapy on different histopathological types of rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci | 2006 |
Multiple periungual pyogenic granulomas following systemic 5-fluorouracil.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Fluorouracil; Granul | 2006 |
Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.
Topics: Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ca | 2006 |
Intraventricular metastases from rectal-sigmoid adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiac Tamponad | 2006 |
Poloxamer 188 and propylene glycol-based rectal suppository enhances anticancer effect of 5-fluorouracil in mice.
Topics: Administration, Rectal; Alanine Transaminase; Animals; Antimetabolites, Antineoplastic; Aspartate Am | 2006 |
Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2006 |
[Treatment efficacy of surgical management for liver metastasis from colorectal cancer--a report of 198 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplas | 2006 |
MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: treatment with radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2006 |
Defunctioning stomas in the treatment of rectal cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Neoadjuvant Therap | 2006 |
Preoperative chemoradiation in rectal cancer: Retrospective comparison between capecitabine and continuous infusion of 5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2006 |
Neoadjuvant radiochemotherapy in the treatment of fixed and semi-fixed rectal tumors. Analysis of results and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; | 2006 |
Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant | 2006 |
Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modali | 2006 |
[Second-line chemotherapy with pharmacokinetic modulating chemotherapy for unresectable colorectal carcinoma recurrences resistant to 5-FU-based chemotherapy].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Co | 2006 |
Chemotherapy with bevacizumab, irinotecan, 5-fluorouracil and leucovorin (IFL) associated with a large, embolizing thrombus in the thoracic aorta.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2006 |
Quality of Life assessment through the EORTC questionnaires of locally advanced rectal cancer patients treated with preoperative chemo-radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Image; Emotions | 2006 |
[The lethal effect of combined MDR1 antisense RNA with oxaliplatin and 5-FU on drug-resistant rectal carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Drug Syne | 2006 |
Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Combined Modality The | 2006 |
Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation.
Topics: Adult; Aged; Chemotherapy, Adjuvant; Cross-Sectional Studies; Female; Fluorouracil; Gene Expression | 2006 |
A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2006 |
Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation.
Topics: Adipose Tissue; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Intestin | 2006 |
Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; Fe | 2006 |
Analysis of clinical outcomes and prognostic factors of neoadjuvant chemoradiotherapy combined with surgery: intraperitoneal versus extraperitoneal rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Fema | 2006 |
Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy.
Topics: Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Female; | 2006 |
Prognostic markers of local relapse in rectal cancer: are we any further forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-F | 2006 |
Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuva | 2006 |
Just how useful an endpoint is complete pathological response after neoadjuvant chemoradiation in rectal cancer?
Topics: Antimetabolites, Antineoplastic; Endpoint Determination; Fluorouracil; Humans; Neoadjuvant Therapy; | 2006 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2006 |
[A case of advanced rectal carcinoma, preoperative chemo-radiation therapy leading to histological complete response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colostomy; Combined Modality Therapy; Dru | 2006 |
Neoplastic mesorectal microfoci (MMF) following neoadjuvant chemoradiotherapy: clinical and prognostic implications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; F | 2006 |
Acute proctocolitis with commencement of neoadjuvant chemoradiation for rectal cancer.
Topics: Acute Disease; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; | 2006 |
Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deficiency Diseases; Deoxycyt | 2006 |
[Effectiveness of preoperative chemoradiotherapy for advanced rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Admini | 2006 |
[A case of effective multidisciplinary treatment with hepatic resection for synchronous multiple liver metastases from rectal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubic | 2006 |
[Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemoth
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat | 2006 |
Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-fluorouracil for rectal cancer: a matched-pair analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chi-Square Distributi | 2006 |
Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2007 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop | 2007 |
Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality The | 2007 |
[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant | 2006 |
Combined surgery and chemoradiation as a treatment for the Buschke-Löwenstein tumour.
Topics: Abdominal Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinom | 2006 |
Treatment of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Leu | 2006 |
Treatment of rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Guideline A | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Patterns of failure and survival for nonoperative treatment of stage c0 distal rectal cancer following neoadjuvant chemoradiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Female; Flu | 2006 |
Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2007 |
Optimal time interval between capecitabine intake and radiotherapy in preoperative chemoradiation for locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine | 2007 |
[Utility of arterial infusion chemotherapy and radiation therapy for the pelvic local recurrence of rectal cancer].
Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intra-Arterial; | 2006 |
[A case report of successful local control with chemoradiation for unresectable rectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; M | 2006 |
Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Addition of weekly oxaliplatin to standard preoperative chemoradiation for locally advanced rectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clini | 2007 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2007 |
Toxicities and survival among octogenarians and nonagenarians with colorectal cancer treated with chemotherapy or concurrent chemoradiation therapy.
Topics: Age Factors; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2007 |
Analysis of early postoperative morbidity among patients with rectal cancer treated with and without neoadjuvant chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; Combined Modality Therapy; Female | 2007 |
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm | 2007 |
Outcomes of hepatic artery infusion therapy for hepatic metastases from colorectal carcinoma after radiological placement of infusion catheters.
Topics: Aged; Angiography; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Car | 2007 |
Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro | 2007 |
Chemotherapy or no chemotherapy in clear margins after neoadjuvant chemoradiation in locally advanced rectal cancer: CHRONICLE. A randomised phase III trial of control vs. capecitabine plus oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; C | 2007 |
Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
Adjuvant therapy for stage II and III colorectal cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agent | 2007 |
A case of capecitabine-induced coronary microspasm in a patient with rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytidine; Dihydrouraci | 2007 |
[A case report of a patient with advanced rectal cancer who was administered chemotherapy in collaboration with a clinical pathway and visiting nursing care].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Community Health Nurs | 2006 |
Preoperative radiotherapy in elderly patients with rectal cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; APACHE; Chi-Square Distributi | 2007 |
Capecitabine-induced headache responding to diltiazem.
Topics: Adult; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Diltiazem; Female; Fluorouracil | 2007 |
Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; | 2007 |
Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; | 2007 |
Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 2007 |
[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi | 2007 |
Images in clinical medicine. Diffuse chemoradiotherapy-related enterocolitis.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Colon; Combined Modality Therapy | 2007 |
Does preoperative chemo-radiotherapy enhance the expression of vascular endothelial growth factor in patients with rectal cancer?
Topics: Aged; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Line, Tumor; Cell Survival; Combined Modal | 2007 |
Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Adm | 2007 |
Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2007 |
[Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape | 2007 |
Squamous-cell carcinoma of the rectum: a rare but curable tumor.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Squam | 2007 |
Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Microsatellite Instabilit | 2007 |
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2007 |
Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoembryonic Antigen; Combined Modal | 2007 |
[Laparoscopic ovarian transposition and cryopreservation of ovarian tissue before chemo-radiotherapy for rectal cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Cryo | 2007 |
Analysis of anal sphincter preservation rate according to tumor level and neoadjuvant chemoradiotherapy in rectal cancer patients.
Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2008 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Trans | 2007 |
Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Digestive Syst | 2008 |
Bevacizumab-associated reversible hypotension.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic C | 2007 |
Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemother | 2007 |
Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Dose Fractionation, Radiation; Dose-R | 2007 |
Daily low-dose/continuous capecitabine combined with neo-adjuvant irradiation reduces VEGF and PDGF-BB levels in rectal carcinoma patients.
Topics: Antimetabolites, Antineoplastic; Becaplermin; Capecitabine; Carcinoma; Combined Modality Therapy; De | 2008 |
Therapy of colon carcinoma: an oncology perspective. Interview with Piotr M. Czaykowski by Paul C. Adams.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2007 |
Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; | 2007 |
Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorourac | 2007 |
The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea; Female; Fluorou | 2008 |
Adjuvant management of rectal cancer: the more we learn, the less we know.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoadj | 2007 |
Preoperative chemoradiation followed by transanal excision for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 2008 |
[A case of metastatic rectal cancer showing a sustained complete response to chemotherapy with FOLFIRI followed by UFT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; L | 2007 |
Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine.
Topics: Acetyltransferases; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tu | 2008 |
[Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopla | 2007 |
[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2007 |
Laparoscopic total mesorectal excision after neoadjuvant chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; Female; Fluorouracil; F | 2007 |
[Long- term remission survival with a case of rectal carcinoid tumor with metastasis in the soft tissue effectively treated with the combination therapy of irinotecan/5-fluorouracil/levofolinate followed by resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoid Tumor; Chemotherapy, Adjuvan | 2007 |
Cryptogenic organizing pneumonitis during oxaliplatin chemotherapy for colorectal cancer: case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Cryptogenic Organizing | 2007 |
[Two cases of advanced low rectal cancer, preoperative chemo-radiation therapy leading to complete histological response].
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Humans; Lymph Node Excision; M | 2007 |
Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2008 |
[Treatment for locally-advanced rectal cancer].
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Digestive System | 2007 |
Isolated chemotherapeutic perfusion of pelvis as neoadjuvant or palliative therapy for advanced cancer of the rectum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2008 |
Preoperative irinotecan/5-FU/leucovorin plus concurrent radiotherapy in rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; D | 2008 |
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb | 2008 |
Oxaliplatin-induced immune mediated thrombocytopenia.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Plat | 2008 |
[A case of multiple liver metastases from rectal cancer in poor performance status successfully treated with hepatic arterial infusion chemotherapy plus CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Fluorouracil; Human | 2007 |
Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase II as | 2008 |
Capecitabine-related cardiotoxicity: recognition and management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic Neoplasms; Deo | 2008 |
[It's a good ability to keep all your bases covered].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Liver Neoplasms; N | 2008 |
Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemotherap | 2008 |
[Treatment of rectal cancer and follow up].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonoscopy; Endoscopy; Female; Fluorouraci | 2007 |
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
Topics: Adenocarcinoma; Female; Fluorouracil; Gene Expression; Humans; Ki-67 Antigen; Male; Middle Aged; Neo | 2008 |
Preoperative chemoradiation with capecitabine in locally advanced rectal cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality | 2008 |
Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Confidence I | 2008 |
Sphincter-preserving operations following preoperative chemoradiation: an alternative to abdominoperineal resection for lower rectal cancer?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Colectomy; Female | 2008 |
A case of 5-fluorouracil-induced peripheral neuropathy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electromyography; Female; Fluorouracil; Humans; Low | 2008 |
Administration of oxaliplatin to a pregnant woman with rectal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease-Free Survival | 2009 |
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De | 2008 |
[A case of liver metastasis of rectal cancer demonstrating complete response for three years to 5-FU/l-leucovorin].
Topics: Aged; Carcinoembryonic Antigen; Colonoscopy; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; | 2008 |
Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluor | 2007 |
[A case of recurrent rectal cancer with lymphangiosis carcinomatosa successfully treated with modified FOLFOX6 therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucovorin; Lung Neopl | 2008 |
[A case of advanced rectal cancer responding to neoadjuvant chemotherapy with CPT-11, 5-FU and l-LV after coronary artery bypass graft].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Coronary | 2008 |
Intra-arterial chemotherapy in advanced pelvic tumors.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Injections, Int | 1967 |
[Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxoru | 1984 |
[Current status of chemotherapy of gastric and colorectal cancer].
Topics: Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm Invasivene | 1981 |
Adjuvant and palliative treatment of colorectal cancer with fluorinated pyrimidines. A pharmacological and clinical review.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorine; Fluorouracil; Humans; Liver | 1981 |
Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer.
Topics: Adenocarcinoma; Adenoma; Antigens, Neoplasm; Carcinoembryonic Antigen; Colonic Neoplasms; Epitopes; | 1982 |
Colorectal cancer. Radiotherapy.
Topics: Animals; Carcinoembryonic Antigen; Colonic Neoplasms; Dose-Response Relationship, Radiation; Fluorou | 1982 |
Hepatic artery infusion with 5-fluorouracil and mitomycin-C in metastatic colorectal carcinoma phase II study.
Topics: Adult; Aged; Catheterization; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; | 1982 |
Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma.
Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Female; Fluorouracil; Humans; Hypoxanthines | 1983 |
Ten years' experience with a multimodality treatment of advanced stages of rectal cancer.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Re | 1983 |
Palliative therapy of pelvic tumors by intra-arterial infusion of cytotoxic drugs.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Doxorubicin; Fe | 1983 |
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; Fluorouracil; Humans; Infusions, Parenter | 1982 |
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu | 1982 |
Continuous five-day infusion of PALA and 5FU: a pilot phase II trial.
Topics: Adult; Aged; Aspartic Acid; Carcinoma; Colonic Neoplasms; Drug Administration Schedule; Drug Eruptio | 1983 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1983 |
[Local infusion therapy in liver metastases of colorectal cancers. Results of a phase-II study].
Topics: Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusio | 1984 |
[Cardiotoxicity of 5-fluorouracil].
Topics: Aged; Breast Neoplasms; Dose-Response Relationship, Drug; Electrocardiography; Female; Fluorouracil; | 1984 |
Phase II study of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin in advanced colorectal cancer. By the Gastrointestinal Tumor Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fluorour | 1984 |
[Up-date of the chemotherapy of carcinoma of the colo-rectum: our experience with 5-fluorouracil and folinic acid in high doses].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Leu | 1984 |
[Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). A non-controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ev | 1984 |
Prognostic factors and in vitro cytotoxic sensitivity in colorectal cancer.
Topics: Antineoplastic Agents; Cell Division; Cell Survival; Cells, Cultured; Colonic Neoplasms; Floxuridine | 1984 |
[Treatment of rectocolic and gastric adenocarcinomas with 5-fluorouracil associated with high doses of folinic acid. Results of an experimental study].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leu | 1982 |
[Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors].
Topics: Carcinoma, Hepatocellular; Catheters, Indwelling; Colonic Neoplasms; Floxuridine; Fluorouracil; Hepa | 1983 |
Patterns of failure after surgical cure of large liver tumors. A change in the proximate cause of death and a need for effective systemic adjuvant therapy.
Topics: Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Colonic Neoplasms; Combined Modali | 1984 |
Sequential methotrexate and 5-fluorouracil: improved response rate in metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colonic Neoplasms; Drug | 1984 |
Potentiation of the antitumor action of 5-fluorouracil with 5-ethyl-2'-deoxyuridine in human colorectal tumor xenografts.
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Coloni | 1984 |
Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Leucovorin; Male; Mid | 1984 |
Immune capability of rats with colorectal carcinoma treated by resection with or without 5-fluorouracil or levamisole.
Topics: Animals; B-Lymphocytes; Cell Migration Inhibition; Colonic Neoplasms; Cytotoxicity, Immunologic; Flu | 1984 |
[Isolated liver perfusion in advanced metastases of colorectal cancers].
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; | 1984 |
Continuous intravenous administration of 1-(2-tetrahydrofuryl)-5-fluorouracil [FT] by intravenous hyperalimentation (IVH)--stability of FT in IVH solution and tumor levels of 5-fluorouracil (5-FU).
Topics: Colonic Neoplasms; Dose-Response Relationship, Drug; Fluorouracil; Humans; Parenteral Nutrition, Tot | 1983 |
Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1983 |
[A study on postoperative long-term continuous immuno-chemotherapy with PSK and 5-FUDS for advanced gastric and colo-rectal cancers].
Topics: Aged; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Human | 1983 |
[Intra-arterial infusion chemotherapy for metastatic hepatic tumor of colo-rectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1983 |
Combination of dacarbazine, mitomycin C, 5-fluorouracil and vincristine in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dacarbazine; Female; | 1983 |
[Cooperative phase II study of spansule tegafur (SF-SP)].
Topics: Administration, Oral; Aged; Breast Neoplasms; Capsules; Colonic Neoplasms; Delayed-Action Preparatio | 1984 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
Treatment of metastatic colorectal carcinoma with 5-FU, mitomycin, vincristine, and methotrexate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1984 |
[The case studies on oral administration of tegafur encapsulated with slow releasing granule (SF-SP) for three rectal patients].
Topics: Adenocarcinoma; Administration, Oral; Aged; Capsules; Delayed-Action Preparations; Female; Fluoroura | 1984 |
Intra-arterial infusion chemotherapy in rectal cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluoroura | 1984 |
[Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect].
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr | 1984 |
[Study on the concentration of FT-207 and 5-FU in serum, lymph nodes and tissues after administration of FT-207 suppositories].
Topics: Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphoma, Non-Hodgkin; Mal | 1984 |
[Morphologic, ultrastructural and histochemical changes in rectal cancer after intrarectal fluorouracil therapy].
Topics: DNA, Neoplasm; Fluorouracil; Histocytochemistry; Humans; Rectal Neoplasms | 1984 |
[Combined treatment data on rectal cancer].
Topics: Aged; Fluorouracil; Humans; Kyrgyzstan; Male; Neoplasm Staging; Rectal Neoplasms; Rectum | 1981 |
Studies on surgical adjuvant chemotherapy for colorectal cancer and administration of neocarzinostatin into the lumen of the colon or rectum using a double balloon catheter and iontophoresis.
Topics: Animals; Antibiotics, Antineoplastic; Catheterization; Colonic Neoplasms; Dogs; Fluorouracil; Humans | 1981 |
Adjuvant therapy for carcinoma of the colon and rectum.
Topics: Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; L | 1984 |
A combination of 5-fluorouracil and thymidine in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colonic Neoplasms; Drug Sy | 1984 |
Clinical trial of sequential N-phosphonacetyl-L-aspartate, thymidine, and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Ataxia; Colonic Neoplasm | 1984 |
Comparative levels of tissue enzymes concerned in the early metabolism of 5-fluorouracil in normal and malignant human colorectal tissue.
Topics: Aged; Colon; Colonic Neoplasms; Epithelium; Female; Fluorouracil; Humans; Male; Middle Aged; Pentosy | 1984 |
[Adjuvant chemotherapy in cancers of the stomach, pancreas and intestine].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined M | 1984 |
Evaluation of a sequential 5-FU and hydroxyurea combination in advanced bowel cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; | 1984 |
Sequential combination chemotherapy with methotrexate and 5-fluorouracil in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1984 |
Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Fluorouracil; | 1984 |
[Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo | 1983 |
[Evaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancers].
Topics: Adolescent; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; | 1983 |
Clinical and in vivo response following surgery or surgery plus adjuvant chemotherapy or immunotherapy for colorectal carcinoma in a rat model.
Topics: Animals; Colonic Neoplasms; Combined Modality Therapy; Disease Models, Animal; Fluorouracil; Levamis | 1983 |
[A clinical study (phase II) of a combination of 5-fluorouracil, vincristine and methyl CCNU in patients with advanced carcinoma of the large intestine].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; | 1983 |
First histologic findings in metastases of colorectal carcinoma following isolated liver perfusion with cytostatics.
Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; L | 1983 |
Intra-arterial perfusion therapy with 5-fluorouracil in patients with metastatic colorectal carcinoma and intractable pelvic pain.
Topics: Adult; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Fluor | 1983 |
Transient repeated dearterialization combined with intra-arterial infusion of oncolytic drugs in the treatment of liver tumors.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Combined Modality Therapy; Cyclophosphamide; Duod | 1983 |
First experimental and clinical results of isolated liver perfusion with cytotoxics in metastases from colorectal primary.
Topics: Animals; Antineoplastic Agents; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Colonic N | 1983 |
5-Fluorouracil, vincristine and hydroxyurea combination chemotherapy in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Hyd | 1983 |
[Treatment of advanced cancer of the colon and rectum with the combination of 5-fluorouracil, imidazolecarboxamide and vincristine].
Topics: Aged; Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; | 1983 |
Sequential methotrexate plus 5-FU in advanced breast and colorectal cancers: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Drug Evaluation | 1984 |
Chemoradiotherapeutic prevention of local recurrence after stapled anastomoses in rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Follow-Up Studies; Humans; | 1981 |
Comparative efficacy of antitumor treatment for liver metastases from colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1981 |
Chemotherapy of carcinomas of the digestive tract.
Topics: Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Esop | 1982 |
Intrahepatic artery 5-fluorouracil and mitomycin-C in previously untreated patients with hepatic metastases from colorectal carcinoma.
Topics: Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Mitomyci | 1982 |
[Adjuvant treatment in surgery of colon and rectal cancer].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Prognosis; Rectal Neoplasms; Thiotepa | 1982 |
Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cytarabine; Fluorescent Antibody Technique; Fluorouraci | 1982 |
[Clinical trial of UFT in recurrent or advanced cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasm | 1982 |
[Clinical study of serum and tissue concentrations of FT-207 and 5-FU in patients with cancer of the large intestine following preoperative application of FT-207 suppositories].
Topics: Adult; Aged; Biological Assay; Female; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; | 1982 |
[Gastrointestinal tumors: chemotherapeutic preparations].
Topics: Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gast | 1983 |
[Treatment of cancers of the colon and rectum].
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Rectal Ne | 1983 |
Chemotherapy of chemically-induced colorectal tumours.
Topics: Animals; Colonic Neoplasms; Dimethylhydrazines; Disease Models, Animal; Female; Fluorouracil; Neopla | 1983 |
Metastatic colorectal cancer. Combination chemotherapy in patients previously treated with 5-fluorouracil.
Topics: Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Middl | 1980 |
Rectal adenocarcinoma treated with intra-arterial 5-fluorouracil. Prolonged remission.
Topics: Adenocarcinoma; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neop | 1982 |
Sequential methotrexate and 5-FU in the treatment of colorectal cancer.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Follow-Up | 1982 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Gastrointesti | 1982 |
Preoperative use of 5-fluorouracil suppository for carcinoma of the rectum.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Intestinal Mucosa; Male; Methods; Middle Aged; Preoperati | 1982 |
[Sequential methotrexate and fluorouracil in metastasizing colorectal carcinomas. Results of a phase II pilot study (author's transl)].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Life Expectancy; Male; Methotrexate; M | 1982 |
Fluorouracil for colorectal cancer: a sobering look.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Rectal Neoplasms | 1982 |
[Immunotherapy in the treatment of colorectal cancers in the aged].
Topics: Aged; Aging; BCG Vaccine; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle | 1982 |
Phase II study of sequential methotrexate-5-FU therapy in advanced measurable colorectal cancer.
Topics: Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combination; Fluorou | 1982 |
[Chemotherapy of colorectal cancer].
Topics: Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 1982 |
Sequential phase II studies of chemotherapy for colorectal cancer with 5-fluorouracil and vindesine with or without methyl-1,3 cis(2 chloroethyl)-1-nitrosourea.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; F | 1982 |
Colorectal cancer. Chemotherapy.
Topics: Adjuvants, Pharmaceutic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; | 1982 |
Colorectal cancer. Prospects in management.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Colonic Neoplasms; Fluorouracil; Humans; Postoperat | 1982 |
Combination chemotherapy in patients with advanced colorectal carcinoma previously treated with 5-FU.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Nitrosourea Compou | 1982 |
Therapy of liver tumors metastatic from colorectal cancer with whole-liver radiation combined with 5-FU, adriamycin, and methotrexate.
Topics: Aged; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Liver | 1982 |
Clinical trials and the consent of the patient.
Topics: Aged; Clinical Trials as Topic; Ethics Committees, Research; Ethics, Medical; Female; Fluorouracil; | 1982 |
[Results of surgical and complex treatment of colonic and rectal cancer].
Topics: Colectomy; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Lomustine; Neoplasm Staging; P | 1982 |
[Isolated liver perfusion with 5-fluorouracil (5-FU) in the human].
Topics: Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neo | 1982 |
[Clinical studies on 5-fluorouracil suppository for rectal cancer].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Rectal Neoplasms; Rectum; Suppositorie | 1982 |
Treatment of asymptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes.
Topics: Antineoplastic Agents; Catheters, Indwelling; Cisplatin; Colonic Neoplasms; Drug Therapy, Combinatio | 1982 |
Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1981 |
Chemotherapy of human colorectal tumor xenografts in athymic mice with clinically active drugs: 5-fluorouracil and 1-3-bis-(-2-chloroethyl)-1-nitrosourea (BCNU). Comparison with doxorubicin derivatives: 4'deoxydoxorubicin and 4'-O-methyldoxorubicin.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Doxorubicin; Fluorouracil; Humans; Mice; Mic | 1981 |
[Analysis of radiobiological parameters of radiation therapy of local rectum carcinomas after preceding synchronization of the tumour cell cycle (author's transl)].
Topics: Adenocarcinoma; Adult; Aged; Cell Cycle; Fluorouracil; Humans; Middle Aged; Rectal Neoplasms | 1981 |
Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil vincristine and streptozotocin (MOF-Strep).
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorourac | 1980 |
[Treatment of inoperable liver metastases: preliminary results with intrahepatic chemotherapy via a new type of indwelling catheter (author's transl)].
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; | 1981 |
Studies in an animal model on the effectiveness of adjuvant chemotherapy with 5-FU and BCNU in cases of colorectal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluoroura | 1981 |
Inoperable rectal cancer.
Topics: Activities of Daily Living; Aged; Female; Fluorouracil; Home Care Services; Home Nursing; Humans; Re | 1981 |
[Intra-arterial injection of antineoplastic agents in colorectal neoplasms].
Topics: Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Mitomyci | 1981 |
Long-term survivors with nonresectable advanced carcinoma of the rectum.
Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Prognosis; Recta | 1981 |
Transfemoral hepatic artery infusion for metastatic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Female; Femoral Artery; Fluorour | 1981 |
Phase I study of protracted venous infusion of 5-fluorouracil.
Topics: Adult; Aged; Catheters, Indwelling; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Admini | 1981 |
Response of metastatic cloacogenic carcinoma to treatment with semustine.
Topics: Anus Neoplasms; Carcinoma, Transitional Cell; Drug Administration Schedule; Female; Fluorouracil; Hu | 1981 |
[Gastrointestinal tumors. Prognostic factors and chemotherapy of today].
Topics: Carmustine; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans | 1981 |
[Current aspects of precautional therapy of colorectal neoplasms].
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Postoper | 1980 |
The value of lymphocyte transformation in carcinoma of the colon and rectum.
Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Lymphocyte Activa | 1980 |
Adjuvant chemotherapy of human colorectal adenocarcinoma after growth on mice with congenital thymic dysplasia ("nude"). 2. Tumor remission following treatment with 5-FU and VCR of xenotransplanted primary human colorectal adenocarcinomas.
Topics: Adenocarcinoma; Animals; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mice; Mice, | 1980 |
Treatment of carcinoma of the rectum and squamous carcinoma of the anus by combination chemotherapy, radiotherapy and operation.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; | 1980 |
Chemotherapy for gastrointestinal malignancy.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Esophageal Neoplasms; Fluoroura | 1980 |
Comparison of two combination chemotherapy regimens in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorourac | 1980 |
[Adjuvant chemotherapy of human colorectal adenocarcinoma after growth on mice with congenital thymic dysplasia ("nude"). 1. Experiments to test the feasibility of combined chemotherapy with VCR and 5-FU (author's transl)].
Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Mice; M | 1980 |
Clinical studies of intrarectal administration of 5-FU emulsion as an adjunct to surgical treatment of rectal cancer.
Topics: Emulsions; Fluorouracil; Humans; Lymphatic Metastasis; Preoperative Care; Rectal Neoplasms; Rectum; | 1980 |
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; M | 1981 |
[Clinical and morphological determination of the effectiveness of preoperative radiologic and combined radiologic-chemotherapeutic therapy in locally metastasized rectal cancer].
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; Preoperative Care | 1980 |
Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; Me | 1981 |
Preoperative chemoradiation downstages locally advanced ultrasound-staged rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middl | 1995 |
5-Fluorouracil/levamisole induced intrahepatic fat infiltration imitating liver metastasis.
Topics: Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Diagnosis, Differential; Fatty Liver; Fluorour | 1995 |
The style of early clinical research reporting: what are we saying and how do we say it?
Topics: Abstracting and Indexing; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car | 1993 |
Preoperative infusional chemoradiation therapy for stage T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Administration Sched | 1995 |
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino | 1993 |
[Adjuvant therapy after curative resection of rectal carcinoma].
Topics: Chemotherapy, Adjuvant; Disease-Free Survival; Fluorouracil; Humans; Radiotherapy, Adjuvant; Rectal | 1995 |
Cardiotoxicity related to 5-fluorouracil chemotherapy: a report of two cases.
Topics: Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Myocardial Infarction; Nasopharyngeal Neoplas | 1995 |
Interaction of 5-fluorouracil with folates.
Topics: Aged; Colonic Neoplasms; Drug Interactions; Drug Therapy, Combination; Female; Fluorouracil; Folic A | 1995 |
[Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac | 1994 |
[The immediate results of the combined treatment of rectal cancer using intra-arterial selective polychemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin; Female; Fluorou | 1994 |
Colo-rectal carcinoma in a tropical African population: an overview report.
Topics: Adenocarcinoma; Administration, Rectal; Adolescent; Adult; Aged; Anus Neoplasms; Ascites; Colonic Ne | 1994 |
Adjuvant treatment for cancer of the colon and rectum.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Rectal N | 1994 |
[Endolymphatic polychemotherapy with local ultra high frequency hyperthermia for the combined treatment of invasive rectal cancer].
Topics: Adenosarcoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; | 1993 |
Treatment of patients with irresectable liver metastases from colorectal cancer by chemo-occlusion with degradable starch microspheres.
Topics: Adult; Aged; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver | 1994 |
[A case report of rectal cancer with lymph node metastasis effectively treated by neoadjuvant chemotherapy of 5-FU oral and low-dose CDDP transarterial administration].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla | 1994 |
Treatment of advanced colorectal cancer with folinic acid and 5-fluorouracil in combination with cisplatinum.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; Fluorour | 1994 |
[Therapy of anal cancer].
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Combined Modality Therap | 1994 |
Necrosis in a meningioma following systemic chemotherapy. Case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Embolizat | 1994 |
[Radiotherapy versus radiotherapy plus 5-FU in inoperable or recurrent rectal cancer].
Topics: Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal Neoplasms | 1994 |
Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1994 |
Laparoscopic intestinal stomas.
Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Colonic Diseases; Colostomy; | 1994 |
[Reservoir system implantation technique via the inferior epigastric artery for local recurrence of rectal cancer].
Topics: Aged; Cisplatin; Embolization, Therapeutic; Evaluation Studies as Topic; Female; Fluorouracil; Human | 1993 |
Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Dihydrouracil Dehydrogenase (NADP); Female; Fluoro | 1993 |
[Protracted infusion versus bolus administration of 5-FU in adjuvant radiochemotherapy of rectal cancer].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Rectal Neoplasms | 1994 |
Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura | 1994 |
Preoperative irradiation and fluorouracil chemotherapy for locally advanced rectosigmoid carcinoma: phase I-II study.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Gastrointestinal Diseases; Humans; Mal | 1993 |
Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines.
Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid | 1993 |
Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diar | 1993 |
[Clinical application of drug delivery system of anti-cancer drugs--the pharmacokinetics and clinical results].
Topics: Antibodies, Monoclonal; Drug Delivery Systems; Fluorouracil; Humans; Immunotoxins; Iodized Oil; Mito | 1993 |
[Metachronous liver metastases treated with repeated liver resections and chemotherapy].
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neop | 1993 |
[A new sequential chemotherapy of methotrexate with 5-fluorouracil against advanced colo-rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; D | 1993 |
Preoperative chemotherapy and radiation therapy for locally advanced primary and recurrent rectal carcinoma. A report of surgical morbidity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality | 1993 |
[Medical treatment of colorectal cancers: evaluation].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colon | 1993 |
Endorectal ultrasound of T3 and T4 rectal cancers after preoperative chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; Follow | 1996 |
Preoperative "chemoradiation" for stages II and III rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl | 1996 |
Preoperative adjuvant radiation with chemotherapy for rectal cancer: its impact on stage of disease and the role of endorectal ultrasound.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorour | 1996 |
The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1996 |
Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antimetabolites, Antineoplastic; Cohort Studies; Combined M | 1996 |
Curative reoperations for locally recurrent rectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Ma | 1996 |
Locally advanced rectal cancer: resection and intraoperative radiotherapy using the flab method combined with preoperative or postoperative radiochemotherapy.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Intraoperative Period | 1996 |
Thymidylate synthase in advanced gastrointestinal and breast cancers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Colonic Neoplasms; Fem | 1996 |
Suppository delivery of 5-fluorouracil in rectal cancer.
Topics: Administration, Rectal; Animals; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liqu | 1996 |
Application of anticancer agent embolism in Miles' operation.
Topics: Adult; Blood Loss, Surgical; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Fluo | 1995 |
[Dual biochemical modulation therapy using 5-FU, leucovorin and cisplatin on human rectal carcinoma xenografts in nude mouse].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Fe | 1996 |
[Regression of 4th-stage cancer of the rectum].
Topics: Adenocarcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Rectal Neoplas | 1996 |
Comparison by carcinoembryonic antigen doubling time of hepatic injection and infusion for unresectable hepatic metastasis from colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; Female; F | 1995 |
[Preoperative chemoradiation therapy for lower rectal cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modalit | 1996 |
Ileostomy dysfunction with adjuvant chemoradiation for rectal carcinoma requiring in-hospital management: a cause for concern.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Dehydration; Fluorouracil; Hospi | 1996 |
Modified clearing technique to identify lymph node metastases in post-irradiated surgical specimens from rectal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Ly | 1996 |
Preoperative radiotherapy for rectal cancer: benefits and controversies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neopl | 1996 |
Month-long postoperative radiotherapy and 5-FU improve survival in rectal cancer.
Topics: Antimetabolites, Antineoplastic; Disease-Free Survival; Drug Administration Schedule; Fluorouracil; | 1996 |
p53 gene mutation is not directly related to tumoricidal effects of preoperative radiochemohyperthermia therapy for rectal cancers.
Topics: Alleles; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromosome Deletion; Chromosomes, | 1996 |
Progress in rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1996 |
Intraoperative electron and external beam irradiation with or without 5-fluorouracil and maximum surgical resection for previously unirradiated, locally recurrent colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therapy; Female; | 1996 |
Locally advanced primary colorectal cancer: intraoperative electron and external beam irradiation +/- 5-FU.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1997 |
"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival.
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined Mod | 1997 |
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin | 1997 |
Adjuvant therapy for colon and rectal cancer.
Topics: Algorithms; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined Mod | 1997 |
[Adjuvant combined radiochemotherapy of rectum carcinoma with long-term 5-fluorouracil infusion].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Hu | 1997 |
Neoadjuvant treatment of local recurrence of rectal cancer: our experience.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1997 |
Retrospective comparative analysis of 5FU + low-dose folinic acid vs. 5FU + high-dose folinic acid in the treatment of metastatic colorectal cancer. The Ottawa experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplast | 1997 |
[The acute toxicity of the simultaneous radiochemotherapy of rectal carcinoma].
Topics: Acute Disease; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Female; Fluoroura | 1997 |
Pre-operative radiotherapy and chemotherapy for non-resectable rectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; M | 1997 |
[Adjuvant treatment in operable colonic and rectal cancer. A new possibility].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modality Therap | 1997 |
Synergistic effects of hyperthermia in preoperative radiochemotherapy for rectal carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Evaluatio | 1997 |
[Arterial infusion chemotherapy in pelvic space for advanced rectal cancer].
Topics: Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Administration Schedule; Fl | 1997 |
[A case of multiple liver metastasis and local recurrence from rectal cancer effectively treated by arterial infusion chemotherapy using low-dose 5-fluorouracil, cisplatin and LV].
Topics: Adult; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sch | 1997 |
[Circadian chemotherapy in cancer patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Circadian Rhythm; Drug Administration Schedule; Female | 1997 |
[Preoperative chemoradiation therapy for advanced rectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 1997 |
[Long-term complete response in two cases of liver metastases from rectal and gastric cancer treated with intra-arterial infusion chemotherapy of leucovorin and 5-fluorouracil].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1997 |
Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer.
Topics: Adenocarcinoma; Administration, Rectal; Animals; Antibiotics, Antineoplastic; Chromatography, High P | 1997 |
[Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma].
Topics: Antioxidants; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Femal | 1997 |
Locally advanced rectal cancer: surgical complications after infusional chemotherapy and radiation therapy.
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil | 1998 |
[The formation of a small intestine-large intestine anastomosis: the end to the side method].
Topics: Animals; Antineoplastic Agents; Dogs; Fluorouracil; Humans; Radiation Dosage; Rectal Neoplasms; Retr | 1997 |
[Palliative treatment with cytostatics of metastatic colorectal cancer in general practice. A model].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Administration | 1997 |
[No improvement of therapeutic results by modulation of 5-fluorouracil with leucovorin and/or levamisole in adjuvant radiochemotherapy in rectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Leu | 1997 |
Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Combined Modality Therapy; DNA Fragmentation; DNA, Neopl | 1998 |
[A case of fluorouracil-induced pneumonitis].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Hypersensitivity; Fluorouracil; Hu | 1997 |
Weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin in patients with advanced colorectal cancer: Taiwan experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1998 |
[A case of hepatic metastasis of rectal cancer with familial adenomatous polyposis treated by transarterial administration of low-dose leucovorin and 5-FU].
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administrati | 1998 |
Changes in tumor proliferation of rectal cancer induced by preoperative 5-fluorouracil and irradiation.
Topics: Adult; Aged; Aged, 80 and over; Cell Division; Combined Modality Therapy; Female; Fluorouracil; Huma | 1998 |
Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial.
Topics: Abdomen; Adenocarcinoma; Adjuvants, Immunologic; Anal Canal; Antidotes; Antimetabolites, Antineoplas | 1998 |
Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro | 1998 |
[Continuous intraportal chemotherapy for prevention of metachronous hepatic metastasis in colorectal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedul | 1998 |
[Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern].
Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Female; Flow Cytometry; Flu | 1998 |
A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Demyelinating Diseases; Female; | 1998 |
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta | 1998 |
[Proliferation and apoptosis before and after preoperative simultaneous radiochemotherapy of rectal carcinomas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Biopsy; Cell Division | 1998 |
Costoclavicular pinching: a complication of long-term central venous catheters. A report of three cases.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cathete | 1998 |
[p53 expression and response to hepatic intraarterial infusion chemotherapy in patients with colorectal cancer metastasis to liver].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Administration Sc | 1998 |
Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Mo | 1998 |
The impact of 5-fluorouracil and intraoperative electron beam radiation therapy on the outcome of patients with locally advanced primary rectal and rectosigmoid cancer.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, A | 1998 |
Low-dose cisplatin-5-fluorouracil prevents postoperative suppression of natural killer cell activity in patients with gastrointestinal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colectomy; | 1998 |
Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Disease Progression; Fem | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo | 1998 |
[Complete remission of liver metastasis from rectal cancer following continuous oral administration of tegafur-uracil after intrahepatic arterial single injection of CDDP and 5-FU].
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinat | 1998 |
Alcohol consumption enhances liver metastasis in colorectal carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Analysis of Variance; Antineoplastic Agents; Blood | 1998 |
High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinom | 1998 |
Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T | 1998 |
p53 immunohistochemical staining predicts residual disease after chemoradiation in patients with high-risk rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Cell Dif | 1997 |
Clinical applications of the histoculture drug response assay.
Topics: Antineoplastic Agents; Cell Culture Techniques; Chemotherapy, Adjuvant; Colonic Neoplasms; Colorecta | 1995 |
Supraventricular arrhythmia: a complication of 5-fluorouracil therapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atr | 1998 |
[Prognostic factors in combined radiochemotherapy of the anal canal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1998 |
The effectiveness of chemotherapy with cisplatin and 5-fluorouracil for recurrent small cell neuroendocrine carcinoma of the rectum: report of a case.
Topics: Adenoma, Villous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcino | 1999 |
Five fractions of preoperative radiotherapy for selected cases of rectal carcinoma: long-term tumor control and tolerance to treatment.
Topics: Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; | 1999 |
Inguinal lymph node metastases from rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colostomy; Combined Mod | 1999 |
[An addendum to the article by C. Rödel, W. Hohenberger, R. Sauer. Adjuvant and neoadjuvant radiochemotherapy of rectal carcinoma. Strahlenther Onkol 1998; 174: 497-504 (Nr. 10)].
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Fluorouracil; Humans; Radiothera | 1999 |
High inter- and intrapatient variation in 5-fluorouracil plasma concentrations during a prolonged drug infusion.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Colonic Neoplasms; Digestive System Neo | 1999 |
[Palliative chemotherapy in colorectal cancer--can we afford it?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Denmark; Drug Costs; Fluorouracil | 1999 |
Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Thera | 1999 |
[Total pelvic exenteration and rectal cancer. Apropos of 20 cases].
Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che | 1999 |
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Flu | 1999 |
Experience with 5-fluoro-uracil and levamisole in the management of advanced rectal carcinoma.
Topics: Adjuvants, Immunologic; Adult; Antimetabolites, Antineoplastic; Colostomy; Combined Modality Therapy | 1996 |
Colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 1999 |
Infusional 5-fluorouracil can be a pain in the neck: A case for repositioning displaced Hickman lines.
Topics: Aged; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Fluorouracil; Humans; Infusi | 1999 |
[A case of local recurrence of rectal cancer responding to local intraarterial infusion therapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Huma | 1999 |
Pathology of rectal adenocarcinoma following preoperative adjuvant radiotherapy and chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Female; Fibrosis; | 1999 |
Continuous infusion 5-fluorouracil as salvage chemotherapy in patients with advanced colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Catheterization, Central Venous; Cohort Studies; Colonic | 1999 |
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; | 1999 |
Pre-operative chemoradiotherapy in locally advanced rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplast | 1999 |
Preoperative combined radiotherapy and chemotherapy for rectal cancer does not affect early postoperative morbidity and mortality in low anterior resection.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Case-Control St | 1999 |
Improved outcome following preoperative radiochemotherapy: 40.5 Gy accelerated hyperfractionation and 5-fluorouracil suppositories for patients with carcinoma of the lower rectum.
Topics: Administration, Rectal; Aged; Antimetabolites, Antineoplastic; Carcinoma; Case-Control Studies; Comb | 1999 |
[Efficacy of adjuvant hepatic arterial infusion chemotherapy following resection of colorectal liver metastases].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined Modalit | 1999 |
Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopla | 1999 |
Rectal cancer and inguinal metastases: prognostic role and therapeutic indications.
Topics: Abdominal Neoplasms; Adenocarcinoma; Aged; Aged, 80 and over; Biopsy; Female; Fluorouracil; Follow-U | 1999 |
P53 alterations have no prognostic or predictive significance in Dukes' C rectal carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; DNA, Neoplasm; Drug Therapy, C | 1999 |
Chemoradiation with or without intraoperative radiation therapy in patients with locally recurrent rectal carcinoma: prognostic factors and long term outcome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combi | 1999 |
Malar metastasis from rectal carcinoma: a case report.
Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fatal Outcome; Female | 1999 |
Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Cisplati | 1999 |
Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Carcinoembryonic Antigen; Female; | 1999 |
[Long-term complete response in a case of unresectable rectal cancer following chemoradiation].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2000 |
Cisplatin-5-fluorouracil therapy with remarkable effect and 5-year survival for paraaortic lymph node metastases of rectal carcinoma in females: a case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Female; Fluo | 1999 |
Investigation of the comparative toxicity of 5-FU bolus versus 5-FU continuous infusion circadian chemotherapy with concurrent radiation therapy in locally advanced rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chronotherapy; Disease-Free Su | 2000 |
Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Diarrhea | 2000 |
Sphincter-sparing surgery after preoperative radiotherapy for low rectal cancers: feasibility, oncologic results and quality of life outcomes.
Topics: Aged; Anal Canal; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Feasib | 2000 |
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
Topics: Adenocarcinoma; Age Factors; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoembryonic | 2000 |
Change of telomerase activity in rectal cancer with chemoradiation therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Th | 2000 |
Preoperative radiation with concurrent 5-fluorouracil for locally advanced T4-primary rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2000 |
Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Fluorodeoxyglucose F18; Fluorouracil; Gly | 2000 |
Targeted chemoembolization of tumors with poly(2-hydroxyethyl methacrylate) particles.
Topics: Anticoagulants; Carcinoid Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Dalteparin; Doxo | 2000 |
Prospective trial of preoperative concomitant boost radiotherapy with continuous infusion 5-fluorouracil for locally advanced rectal cancer.
Topics: Adult; Aged; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorou | 2000 |
A pilot study of preoperative continuous infusion 5-fluorouracil, external microwave hyperthermia, and external beam radiotherapy for treatment of locally advanced, unresectable, or recurrent rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility Studies; Female | 2000 |
[Initial locoregional chemotherapy in recurrent and locoregional advanced or inoperable stages of pelvic uterine and anorectal cancers].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bleomycin; Cisplatin; D | 1995 |
Continuous intra-arterial 5-FU chemotherapy in a patient with a repeated recurrence of rectal cancer: report of a case.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Fluorouracil; Humans; Infusions, In | 2000 |
Pre-operative chemo-radiotherapy in locally advanced rectal cancer: is this the way of future management?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fra | 1999 |
Cost-effectiveness of hepatic arterial chemoembolization for colorectal liver metastases refractory to systemic chemotherapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benchmarking; C | 2000 |
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Colonic Neopla | 2000 |
[A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modal | 2000 |
Absorbable mesh sling prevents radiation-induced bowel injury during "sandwich" chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Case-Control Studies; Chemotherapy, Adjuvant; Dose-Response Relationshi | 2000 |
Combined preoperative chemotherapy and radiation for locally advanced rectal carcinoma.
Topics: Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Radiot | 2000 |
Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; | 2000 |
Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Critical Care; Drug Monitoring; Drug Therapy, | 2000 |
[The importance of delay in patients with tumors exemplified by pretreatment of locally advanced rectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Endosonography; Fluorouracil; Humans; Le | 2000 |
Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; | 2000 |
[A study of liver metastasis from colorectal cancer in which hepatic resection was performed after hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Combined Modalit | 2000 |
[Intra-arterial infusion therapy for unresectable liver metastasis of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neop | 2000 |
[Evaluation by FDG-PET of arterial infusion chemotherapy for unresectable metastatic liver tumor].
Topics: Aged; Antimetabolites, Antineoplastic; Female; Fluorodeoxyglucose F18; Fluorouracil; Hepatic Artery; | 2000 |
[A case of locally advanced rectal carcinoma with liver metastasis treated with a combination of CRT, HAI, and systemic chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Combined Modality | 2000 |
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
Topics: Adult; Aged; Alleles; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Dihydrou | 2000 |
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm | 2000 |
Effective pelvic symptom control using initial chemoradiation without colostomy in metastatic rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Cohort Studie | 2001 |
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; D | 2001 |
Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer.
Topics: Adenocarcinoma; Aged; Anal Canal; Antimetabolites, Antineoplastic; Case-Control Studies; Female; Flu | 2001 |
[Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru | 2001 |
Idiosyncratic reaction after oxaliplatin infusion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chills; Fever; Fluorouracil; | 2001 |
Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Female; Fluorouracil; Gene Expr | 2001 |
Drug-induced modulation of carcinoembryonic antigen (CEA) expression in neoplastic cells from a patient with rectal cancer.
Topics: Adult; Carcinoembryonic Antigen; Female; Flow Cytometry; Fluorouracil; Humans; Interferon-gamma; Rec | 2000 |
Intraoperative irradiation for locally recurrent colorectal cancer in previously irradiated patients.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Colonic Neoplasms; Female; Fluor | 2001 |
Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouraci | 2001 |
External beam radiotherapy for synchronous rectal and prostatic tumors.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplas | 2001 |
Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm | 2001 |
Addition of oxaliplatin to continuous fluorouracil, l-folinic acid, and concomitant radiotherapy in rectal cancer: the Lyon R 97-03 phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2001 |
[Treatment of rectal carcinoma].
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Combined Modality Therapy; Drug Therapy, Combination | 2001 |
P27kip1 expression is associated with tumor response to preoperative chemoradiotherapy in rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Combined Modal | 2001 |
Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2001 |
[Successful resection of multiple liver metastases from rectal cancer following initial treatment using hepatic arterial infusion chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Adm | 2001 |
[A case of multiple liver metastases from rectal carcinoid tumor successfully treated with arterial infusion chemotherapy using degradable starch microspheres (DSM)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cisplatin; Drug Administration Sche | 2001 |
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch | 2001 |
Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Lung; Male; Mid | 2001 |
T4 rectal cancer treated with preoperative chemoradiation to the posterior pelvis followed by multivisceral resection: patterns of failure and limitations of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Mo | 2001 |
[Therapy results of locoregional recurrences in rectal cancer].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Combined Modality Therapy | 2001 |
[Anastomotic protection with a transanal tube after rectum resection and total mesorectal excision].
Topics: Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Combined Mod | 2001 |
Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2001 |
Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Topics: Adult; Aged; Alternative Splicing; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neopla | 2001 |
Fatigue during preoperative chemoradiation for resectable rectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fatigue; Female; Fluorourac | 2001 |
Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Agents; Colon; Combin | 2001 |
Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2001 |
Transanal excision for T1 and T2 rectal cancer--efficacy of local resection vs. adjuvant therapy. Extended abstract.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Dose Fractionation, Radiat | 2001 |
Complete response to neoadjuvant chemoradiation for rectal cancer does not influence survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Colectomy; | 2001 |
The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.
Topics: Acute Disease; Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modal | 2002 |
Preoperative neoadjuvant therapy for rectal cancer also enables autologous transfusion.
Topics: Antimetabolites, Antineoplastic; Blood Transfusion, Autologous; Fluorouracil; Humans; Neoadjuvant Th | 2002 |
[Efficacy of postoperative adjuvant chemotherapy for colorectal cancer].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic | 2002 |
[The proper opportunity of surgery for rectal cancer after preoperative adjuvant chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluorouracil; | 1999 |
[Effects of selective preoperative intra-arterial infusion chemotherapy on apoptosis and proliferation of rectal cancer cells].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cisplati | 2000 |
Apoptosis as a cellular predictor for histopathologic response to neoadjuvant radiochemotherapy in patients with rectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Chemotherapy, Adjuvant; Dise | 2002 |
[A case of hepatic metastasis from rectal carcinoma successfully treated with pharmacokinetic modulating chemotherapy (PMC)-CPT-11 therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality | 2002 |
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin | 2002 |
[A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug C | 2002 |
[A case of recurrent rectal cancer responding to weekly low-dose CPT-11/isovorin/5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Fl | 2002 |
A breakthrough in cryosurgery.
Topics: Antimetabolites, Antineoplastic; Bronchial Fistula; Carcinoma; Cryosurgery; Fistula; Fluorouracil; H | 2002 |
Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Comorbidity; Femal | 2002 |
Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Comor | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Mesorectal microfoci adversely affect the prognosis of patients with rectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2002 |
Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.
Topics: Administration, Oral; Angina Pectoris; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Res | 2002 |
Letter: 5-Fluorouracil and angina.
Topics: Adult; Aged; Angina Pectoris; Female; Fluorouracil; Humans; Infusions, Parenteral; Injections, Intra | 1975 |
Cancer of the colon and rectum. A review.
Topics: Barium Sulfate; Carcinoembryonic Antigen; Colonic Neoplasms; Cystadenoma; Electrocoagulation; Fiber | 1975 |
The value of combined 5-fluorouracil and x-ray therapy in the palliation of locally recurrent and inoperable rectal carcinoma.
Topics: Fluorouracil; Humans; Neoplasm Recurrence, Local; Palliative Care; Radiotherapy Dosage; Rectal Neopl | 1975 |
Letter: Immunotherapy for colorectal cancer.
Topics: BCG Vaccine; Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Humans; Rectal Neoplasms | 1976 |
[Incurable colorectal cancer. Possibilities and limits of differentiated therapy (author's transl)].
Topics: Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Palliative Care; Recta | 1977 |
Failure of methyl-C.C.N.U. and 5-fluorouracil in colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Dacarbazine; Drug Evaluation; Drug Therapy, Combination; Female; Flu | 1978 |
[Chemotherapy of colorectal carcinomas].
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Palli | 1978 |
[The state of chemotherapy of colorectal neoplasms].
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine | 1978 |
Non-surgical palliation of carcinoma of the rectum.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Palliative Care; Rectal Neoplasms; Ter | 1979 |
Colorectal carcinoma: overview of management techniques.
Topics: BCG Vaccine; Carcinoembryonic Antigen; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Radioth | 1979 |
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
Topics: Adenocarcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusi | 1979 |
Carcinoma of the rectum in adolescence.
Topics: Adenocarcinoma, Mucinous; Adolescent; Age Factors; Cyclophosphamide; Fluorouracil; Humans; Hydroneph | 1975 |
Clinical management of advanced gastrointestinal cancer.
Topics: Adenoma, Islet Cell; Carcinoma, Hepatocellular; Carmustine; Colonic Neoplasms; Cytarabine; Drug Ther | 1975 |
Walter Hubert lecture Chemotherapy of upper gastrointestinal carcinoma.
Topics: Adenoma, Islet Cell; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Hepatocellular; Carcinoma, S | 1976 |
Colorectal carcinoma in adolescents implications regarding etiology.
Topics: Adenocarcinoma, Mucinous; Adolescent; Adult; Child; Colonic Neoplasms; Female; Fluorouracil; Humans; | 1977 |
Current trends and prospects in surgical adjuvant trials.
Topics: Antineoplastic Agents; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Dianhydroga | 1978 |
[Status and problems of the treatment of metastatic rectal cancer].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Neoplasm Recurren | 1979 |
Treatment of hepatic metastases by percutaneous hepatic arterial infusion.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastroint | 1979 |
[Therapeutic effect of ftorafur].
Topics: Adenocarcinoma; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Mammary Gland | 1977 |
Chemoimmunotherapy of metastatic large bowel cancer: nonspecific stimulation with BCG and levamisole.
Topics: BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Levamisole; Lomusti | 1977 |
Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; Middle Aged; Re | 1977 |
Chemoimmunotherapy with BCG and FT 207 (II).
Topics: BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Tegafur | 1978 |
Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Central Nervous System; Colonic Neoplasms; Drug Evaluation; Female; Flu | 1979 |
Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Colonic Neoplasms; Digestive System; Drug Evaluation; Drug | 1979 |
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas | 1979 |
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
Topics: Adenocarcinoma; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female; | 1979 |
Intraarterial infusion chemotherapy (5-fluorouracil) in patients with inextirpable or locally recurrent rectal cancer.
Topics: Adult; Aged; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Me | 1979 |
Delayed complications in colo-rectal carcinoma treated by combination radiotherapy and 5-fluorouracil--Eastern Cooperative Oncology Group (E.C.O.G.) pilot study.
Topics: Aged; Colonic Diseases; Colonic Neoplasms; Connective Tissue; Constriction, Pathologic; Female; Fluo | 1979 |
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus | 1979 |
Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Blood Cells; Colonic Neoplasms; Drug Administration Schedule; Dr | 1979 |
[Experience with weekly intravenous 5-fluorouracil in advanced colonic and rectal neoplasms].
Topics: Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Int | 1979 |
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil vs. intravenous 5-fluorouracil in patients with hepatic metastases from colo-rectal cancer: a Central Oncology Group Study (COG 7032).
Topics: Colonic Neoplasms; Evaluation Studies as Topic; Fluorouracil; Hepatic Artery; Humans; Infusions, Int | 1979 |
Neutropenia associated with metronidazole.
Topics: Agranulocytosis; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Metronidazole; | 1979 |
Combination chemotherapy of colorectal cancer with 5-fluorouracil, methyl-1,3-cis(2-chloroethyl)-1-nitrosourea, and vincristine.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combination; Female; Fluoro | 1979 |
[Preoperative irradiation of rectal carcinoma wit 5-fluorouracil].
Topics: Adenocarcinoma; Cobalt Radioisotopes; Fluorouracil; Humans; Infusions, Parenteral; Preoperative Care | 1978 |
Fluorouracil as an adjuvant to colorectal cancer surgery.
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Middle Aged; Postoperative Care; Rectal Neopla | 1977 |
Fluorouracil and colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms; Solubility | 1977 |
Lack of effectiveness of combined 5- fluorouracil and methyl-CCNU therapy in advanced colorectal cancer.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Humans | 1977 |
[Practice in the treatment of rectal carcinoma. Recommendations of the Deutschen Gesellschaft für Chirurgie].
Topics: Anus Neoplasms; Female; Fluorouracil; Germany, West; Humans; Intestinal Polyps; Male; Neoplasm Metas | 1977 |
Chemotherapy, immunotherapy and chemoimmunotherapy of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Lomustine; Methotrexate; Mitomycins; Rectal | 1977 |
Chemotherapy of colorectal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Rectal Ne | 1978 |
Multidisciplinary preoperative approach to the management of epidermoid carcinoma of the anus and anorectum.
Topics: Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male; Middle Ag | 1978 |
Sequential 5-fluorouracil and hydroxyurea therapy for metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Hydroxyurea; Neoplasm Metastasis; Rectal Ne | 1978 |
Evaluation of single-agent therapy in human colorectal tumour xenografts.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mice; Neoplas | 1978 |
Treatment of advanced colorectal cancer with a combination of 5-fluorouracil and methyl-CCNU.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Nitrosourea Comp | 1978 |
Phase II study of melphalan in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male; | 1978 |
Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H | 1978 |
Treatment of symptomatic metastatic cancer to the liver from primary colon and rectal cancer by the intraarterial administration of chemotherapy and radioactive isotopes.
Topics: Catheters, Indwelling; Colonic Neoplasms; Femoral Artery; Fluorouracil; Hepatic Artery; Humans; Infu | 1978 |
Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion.
Topics: Adult; Aged; Bone Marrow Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combin | 1978 |
Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Doxorubicin; Drug Therapy, Com | 1978 |
Cancer of the large bowel with special reference to incidence and etiology.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Prognosis; Rectal N | 1978 |
Ongoing trials in the surgical adjuvant management of colorectal cancer.
Topics: Antineoplastic Agents; BCG Vaccine; Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; F | 1978 |
Multimodal surgical adjuvant therapy for a broad spectrum of tumors in humans.?
Topics: Adult; Altretamine; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carmustine; Colonic Neo | 1976 |
Adjuvant treatment of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunotherapy; Rectal Neoplasms | 1977 |
Adjuvant treatment of cancer I. Large bowel cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Immunity, Cellular; Immunotherapy; Rectal Neoplasms | 1977 |
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer (Dukes' class C): prolongation of disease-free interval and survival.
Topics: BCG Vaccine; Carcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplasm | 1977 |
Gastrointestinal cancer. Treatment with fluorouracil-nitrosourea combinations.
Topics: Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neo | 1976 |
Chemoprophylaxis for patients with colorectal cancer. Prospective study with five-year follow-up.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Follow-Up Stu | 1976 |
Editorial: Progress in the treatment of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Rectal Neoplasms | 1976 |
Editorial: Adjuvant chemotherapy in colorectal cancer.
Topics: Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Neoplasm Metastasis; Rectal Neoplasms | 1976 |
Fluorouracil as an adjuvant to colorectal cancer surgery; the breakthrough that never was.
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Middle Aged; Postoperative Care; Rectal Neopla | 1976 |
Fluorouracil as an adjuvant to colorectal cancer surgery.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Postoperative Care; Rectal Neoplasms | 1976 |
5-Fluorouracil (NSC-19893), DTIC (NSC-45388), BCNU (NSC-409962), and vincristine (NSC-67574) in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Dacarbazine; Drug Therapy, Combin | 1976 |
[Late results of the prophylactic treatment with 5-fluorouracil of cancer of the large intestine and rectum].
Topics: Adult; Aged; Female; Fluorouracil; Follow-Up Studies; Humans; Intestinal Neoplasms; Intestine, Large | 1976 |
5-Fluorouracil (5-FU), methyl-CCNU, and vincristine in the treatment of advanced colorectal cancer: phase II study utilizing weekly 5-FU.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Drug Evaluation; Drug Therapy, Combina | 1976 |
Results of regional portal infusion of 5-fluorouracil in patients with primary and secondary liver cancer.
Topics: Adult; Aged; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infu | 1976 |
Fluorouracil as an adjuvant to colorectal cancer surgery.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Postoperative Care; Rectal Neoplasms | 1976 |
Survival among patients with liver metastases from cancer of the colon and rectum.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Bilirubin; Colonic Neoplasms; F | 1976 |
Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
Topics: BCG Vaccine; Breast Neoplasms; Colonic Neoplasms; Dacarbazine; Doxorubicin; Female; Fluorouracil; Hu | 1976 |
Comparison of 5-fluorouracil with 5-fluorouracil, cyclophosphamide, and methotrexate in metastatic colorectal carcinoma.
Topics: Colonic Neoplasms; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Fluorouraci | 1975 |
End results of radiation therapy, alone and combination with 5-fluorouracil in colorectal cancers.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Perineum; Radiotherapy; Radiothe | 1975 |
Combined 5-fluorouracil and hydroxyurea therapy for gastrointestinal cancer.
Topics: Administration, Oral; Ataxia; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Gastrointe | 1975 |
Arylsulfatse B in colorectal cancer.
Topics: Adult; Aged; Chondro-4-Sulfatase; Colonic Neoplasms; Female; Fluorouracil; Humans; Isoenzymes; Male; | 1975 |
Adjuvant immunotherapy and chemoimmunotherapy in colorectal cancer of the Dukes' C classification. Preliminary clinical results.
Topics: BCG Vaccine; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms | 1975 |
The gasteointestinal oncology clinic. A multidisciplinary approach to cancer diagnosis and management at a University Medical Center.
Topics: Adenocarcinoma; Colitis, Ulcerative; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination; | 1976 |
Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract.
Topics: Adult; Aged; BCG Vaccine; Bile Duct Neoplasms; Carcinoma; Colonic Neoplasms; Cyclophosphamide; Femal | 1976 |
[Chemotherapy in gastrointestinal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Meth | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Current thoughts on the surgical treatment of rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil; | 1976 |
Intraarterial 5-FU-infusion and simultaneous radiotherapy as palliative treatment of recurrent rectal cancer.
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Iliac Artery; Infusions, Intra | 1992 |
Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18; | 1992 |
[Cancers of the colon and the rectum: news in 1992].
Topics: Amifostine; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusio | 1992 |
Nonresectable adenocarcinoma of the rectum assessed by MR imaging before and after chemotherapy and irradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1992 |
The antitumor activity and immunosuppressive effects of 5-fluorouracil suppositories in rectal cancer patients.
Topics: Aged; Female; Fluorouracil; Humans; Lymph Nodes; Lymphocyte Subsets; Male; Middle Aged; Premedicatio | 1992 |
Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Com | 1992 |
A case of linitis plastica of the rectum treated by pelvic exenteration after aggressive immunochemotherapy.
Topics: Adult; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intra-Arterial; Injections, Intra | 1992 |
Adjuvant chemotherapy and radiotherapy in the management of colorectal cancer.
Topics: Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Mal | 1992 |
[Neo-adjuvant chemotherapy with tegafur suppository for rectal cancer--evaluation of the antitumor effects, tissue levels of 5-FU and inhibition of thymidylate synthase. Tochigi Colorectal Cancer Study Group].
Topics: Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Male; Rectal Neoplasms; Suppositories; Tegafur | 1992 |
Adjuvant postoperative radiation therapy for rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Fol | 1992 |
[Continuous intra-arterial infusion chemotherapy in colorectal cancer patients with nonresectable metastatic liver cancer].
Topics: Colonic Neoplasms; Drug Administration Schedule; Fluorouracil; Humans; Infusion Pumps; Infusions, In | 1992 |
Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1992 |
Combined modality preoperative therapy for unresectable rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem | 1992 |
[Indication for chemoembolization of liver tumors. An interdisciplinary concept and initial results].
Topics: Adult; Chemoembolization, Therapeutic; Colonic Neoplasms; Female; Fluorouracil; Germany, West; Human | 1992 |
[A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion | 1992 |
Combined modality adjuvant treatment of high-risk rectal cancer: a treatment of choice or a choice of treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1992 |
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in metastatic colorectal cancer: a 3-day/3-week schedule. Group d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD)
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; F | 1992 |
Levamisole plus 5-fluorouracil inhibits the growth of human colorectal xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour | 1992 |
Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response.
Topics: Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; Liver Neoplasms; Rectal Neoplasms; Re | 1992 |
A comparison of 5-fluorouracil metabolism in human colorectal cancer and colon mucosa.
Topics: Adenosine Triphosphate; Aged; Aged, 80 and over; Colon; Colonic Neoplasms; Fluorodeoxyuridylate; Flu | 1991 |
Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1992 |
Preoperative radiation therapy for locally advanced carcinoma of the rectum. Clinicopathologic correlative review.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Stag | 1992 |
[Studies on a slow releasing anticancer agent for prevention of peritoneal recurrence of advanced gastrointestinal carcinomas (clinical study)].
Topics: Delayed-Action Preparations; Duodenal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Lactat | 1992 |
[Adjuvant treatment of resected colon cancers using a 5-fluorouracil-levamisole combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1991 |
Effect of leucovorin on 5-fluorouracil induced inhibition of thymidylate synthase in patients with colon cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Humans; Leu | 1991 |
[Myocardial damage after use of 5 fluorouracil in digestive pathology].
Topics: Aged; Fluorouracil; Humans; Male; Myocardial Infarction; Rectal Neoplasms | 1991 |
The effects of gamma-interferon combined with 5-fluorouracil or 5-fluoro-2'-deoxyuridine on proliferation and antigen expression in a panel of human colorectal cancer cell lines.
Topics: Antibodies, Monoclonal; Carcinoembryonic Antigen; Cell Division; Cell Line; Colonic Neoplasms; Drug | 1991 |
Clinical trials referral resource. Adjuvant therapy for rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1991 |
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hep | 1991 |
[Evaluation of continuous intra-arterial infusion chemotherapy after hepatic resection of liver metastases in colorectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1991 |
[Interstitial hyperthermia (MINERVE) for perineal local recurrence of rectal cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cispl | 1991 |
Cancer-associated hemolytic-uremic syndrome with spontaneous resolution. A case report.
Topics: Antineoplastic Agents; Female; Fluorouracil; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Mitomyc | 1991 |
Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases.
Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Brachytherapy; Colonic Neoplasms; Colonoscopy; Combined | 1991 |
Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: results of a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 1991 |
Sphincter preservation in rectal cancer by local excision and postoperative radiation therapy.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Brachytherapy; Combined Modality Therapy; Female; Fluoroura | 1991 |
Combined-modality therapy for rectal carcinoma--the time has come.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal | 1991 |
Preoperative high-dose leucovorin/5-fluorouracil and radiation therapy for unresectable rectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Fluorourac | 1991 |
A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.
Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Combined Modality Therapy; Female; Fluorouracil; Humans; Ma | 1991 |
[Treatment of colorectal cancers. Recommendations of the French Foundation of Digestive Cancerology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Digestive System Neoplasms; Fluor | 1991 |
[Intra-arterial chemotherapy in inoperable and recurrent rectal tumors].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Injections, Intr | 1990 |
Oral carmofur in advanced gastrointestinal cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Drug Admini | 1990 |
[Adjuvant treatment of colon and rectum carcinoma: one step ahead].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; Fluorou | 1990 |
Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic N | 1990 |
[Clinical reevaluation of continuous intravenous infusion of 5-fluorouracil--plasma concentrations and clinical dose by continuous intravenous and 60-min infusions].
Topics: Adult; Aged; Drug Administration Schedule; Evaluation Studies as Topic; Female; Fluorouracil; Humans | 1990 |
A new catheter to simplify portal vein cannulation for adjuvant cytotoxic liver perfusion following resection of rectal cancer.
Topics: Catheterization, Peripheral; Combined Modality Therapy; Fluorouracil; Humans; Portal Vein; Postopera | 1990 |
[Current status of chemotherapy for colonic, rectal and anal carcinoma].
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Colonic Neoplasms; Combi | 1990 |
[Chemotherapy and total body hyperthermia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Colonic Neoplasms; Combined Mo | 1985 |
Unresectable and locally recurrent rectal cancer treated with radiotherapy or bilateral internal iliac artery infusion of 5-fluorouracil.
Topics: Adult; Aged; Fluorouracil; Humans; Iliac Artery; Infusions, Intra-Arterial; Middle Aged; Neoplasm Re | 1986 |
External beam radiotherapy for rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A | 1987 |
5-Fluorouracil and isoprinosine in the treatment of advanced colorectal cancer. A limited phase I, II evaluation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Female; Fl | 1988 |
Continuous low-dose infusion of fluorouracil: is the benefit worth the cost?
Topics: Colonic Neoplasms; Cost-Benefit Analysis; Fluorouracil; Humans; Infusions, Intravenous; Injections, | 1989 |
Postoperative adjuvant chemotherapy and radiotherapy for cancer of the large bowel and rectum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cecal Neoplasms; Colonic Neop | 1989 |
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neop | 1989 |
Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum. Results from two consecutive studies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1989 |
Local chemotherapy for rectal polyposis: intraluminal administration of 5-fluorouracil for postoperative control of adenomas in the retained rectum in familial polyposis.
Topics: Adenomatous Polyposis Coli; Administration, Rectal; Adult; Colectomy; Combined Modality Therapy; Ene | 1989 |
Adjuvant therapy for rectal cancer: is 5-FU effective without MeCCNU.
Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Rectal Neoplasms; Semustine | 1989 |
Radiation therapy with/without simultaneous weekly 5 F.U. in locally recurrent carcinoma of the recto-sigmoid.
Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal | 1989 |
Immunochemotherapy of advanced colorectal cancer with alpha-interferon and 5-fluorouracil. 1. Toxicological studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1989 |
5-Fluorouracil-induced angina.
Topics: Aged; Angina Pectoris; Coronary Vasospasm; Female; Fluorouracil; Humans; Liver Neoplasms; Platelet A | 1989 |
Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Carcinoembryonic Antigen; | 1987 |
Perianal Paget's disease. Report of three cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anus Neoplasms; Female; Fluorouracil; Humans; Male; Neoplas | 1988 |
Hepatic artery infusion chemotherapy for colorectal metastases: a personal experience.
Topics: Adult; Aged; Carcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans | 1985 |
Incorporation of intermediary products of 5-FU anabolism into colorectal cancer.
Topics: Aged; Colon; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Intestinal Mucosa; Male; | 1986 |
Implantable vascular access devices in the treatment of colorectal liver metastases.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arter | 1986 |
Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA).
Topics: Colonic Neoplasms; Colony-Forming Units Assay; Culture Techniques; Dose-Response Relationship, Drug; | 1986 |
[Chemoprophylaxis of liver metastasis of colonic and rectal cancers].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms; Neoplasm Metastasis; Portal Vein; Rectal N | 1986 |
The relationship between plasma pharmacokinetics and tissue metabolites of 5-fluorouracil (5-FU) in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Colon; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Kineti | 1987 |
Regional and systemic chemotherapy for colorectal metastases to the liver.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans | 1987 |
[Locoregional chemotherapy of hepatic metastases of colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Infusion Pumps; I | 1987 |
Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells.
Topics: Cell Line; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Floxuridine; Fluorour | 1988 |
Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.
Topics: Angina Pectoris; Brain Diseases; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Evaluation; Elect | 1985 |
Palliation of pelvic recurrence of colorectal cancer with intra-arterial 5-fluorouracil and mitomycin.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; C | 1985 |
Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.
Topics: Animals; Antibodies; Biliary Tract Neoplasms; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; C | 1986 |
[Combination chemotherapy of cis-diamminedichloroplatinum (CDDP) and 5-fluorouracil (5-FU) in gastrointestinal tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; C | 1986 |
[Angiographic and computed tomographic findings in intra-arterial cytostasis of colorectal liver metastases].
Topics: Angiography; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arteri | 1986 |
Treatment of metastatic colorectal cancer with hepatic artery combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Fluorouracil; Follow- | 1986 |
Combination chemotherapy for advanced colorectal cancer. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ | 1986 |
Squamous cell carcinoma of the rectum: a multimodality approach.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; | 1986 |
Clinical evidence of feasibility and efficacy of simultaneous irradiation and chemotherapy in advanced squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Brachytherapy; Carcinom | 1986 |
An aggressive, sequential combination chemotherapy regimen in the treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 1986 |
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu | 1986 |
[Surgery and adjuvant therapy of cancer of the large intestine].
Topics: BCG Vaccine; Colonic Neoplasms; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule | 1986 |
[5-FU concentration in the blood and tissue of patients with gastric and colorectal cancer after administration of UFT or tegafur].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Male; Rats | 1986 |
Intraarterial chemotherapy and hyperthermia for pain control in patients with recurrent rectal cancer.
Topics: Aged; Female; Fluorouracil; Humans; Hyperthermia, Induced; Infusions, Intra-Arterial; Male; Middle A | 1986 |
Rationale and indications for perfusion in liver tumors: current data.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 1987 |
[Serum concentration of 5-FU and tegafur (FT-207) after administration of tegafur (FT-207) suppository with the colostomy].
Topics: Adult; Aged; Colostomy; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; | 1987 |
[Human colorectal carcinoma is more sensitive to HCFU than 5-FU and tegafur in in vitro and in vivo drug sensitivity tests].
Topics: Animals; Colonic Neoplasms; Fluorouracil; Humans; Mice; Rectal Neoplasms; Subrenal Capsule Assay; Te | 1988 |
[Antitumor effect of intermittent oral administration of UFT against human rectal cancer xenografted in nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Adm | 1988 |
Phase II study of a 5-fluorouracil, teniposide and mitomycin-C combination chemotherapy in advanced colorectal carcinomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Colonic Neoplasms; Diarrhea; D | 1988 |
[Intra-arterial chemotherapy of colorectal liver metastases with 5-fluorouracil (5-FU) and mitomycin C (MMC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1987 |
Colorectal carcinoma in vitro is more sensitive to 1-hexylcarbamoyl-5-fluorouracil compared with six other antitumor drugs: carboquone, Adriamycin, mitomycin C, aclacinomycin A, cisplatin, 5-fluorouracil.
Topics: Aclarubicin; Antineoplastic Agents; Carbazilquinone; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug | 1988 |
[The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in patients with gastric and colorectal cancers after oral administration of UFT].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci | 1988 |
[Results of intra-arterial infusion chemotherapy in colorectal cancer patients with metastatic liver cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Colonic Neoplasms; Combined Modality Th | 1988 |
Combined modality preoperative therapy in poor prognostic rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb | 1988 |
Treatment of colorectal cancer hepatic metastases by hepatic artery chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carmustine; Colonic Neoplasms; Floxuridine; Fluorour | 1985 |
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo | 1988 |
[Continuous infusion of anti-cancer drug with balloon infusors].
Topics: Aged; Breast Neoplasms; Colonic Neoplasms; Evaluation Studies as Topic; Female; Fluorouracil; Humans | 1988 |
Postoperative radiation therapy with weekly 5 fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Hum | 1988 |
[Route and preparation of 5-Fu administration as preoperative adjuvant chemotherapy in rectal cancer. I. Concentration and distribution of 5-Fu in tissues monitored by 14C-isotopically tagged 5-Fu].
Topics: Absorption; Administration, Rectal; Animals; Carbon Radioisotopes; Emulsions; Fluorouracil; Humans; | 1988 |
[Route and preparation of 5-Fu administration as preoperative adjuvant chemotherapy in rectal cancer. II. Morphologic, ultrastructural and histochemical changes of the cancer cells after intrarectal and intravenous 5-Fu administration].
Topics: Administration, Rectal; DNA, Neoplasm; Emulsions; Fluorouracil; Humans; Premedication; Rectal Neopla | 1988 |
[Intra-arterial 5-fluorouracil chemotherapy in liver metastases of colorectal cancer].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arter | 1988 |
Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati | 1988 |
Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1988 |
High-dose folinic acid and 5-fluorouracil in advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Gastr | 1988 |
Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Colonic Neopla | 1988 |
Pharmacodynamics of 5-fluorouracil and leucovorin.
Topics: Adenocarcinoma; Animals; Bone Marrow; Colonic Neoplasms; Deoxyuracil Nucleotides; Fluorodeoxyuridyla | 1988 |
Phase II evaluation of sequential hepatic artery infusion of 5-fluorouracil and hepatic irradiation in metastatic colorectal carcinoma.
Topics: Colonic Neoplasms; Combined Modality Therapy; Drug Evaluation; Female; Fluorouracil; Humans; Infusio | 1988 |
Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients.
Topics: Adenocarcinoma; Adult; Age Factors; Colonic Neoplasms; Female; Fluorouracil; France; Humans; Male; R | 1988 |
[Prevention of immunodeficiency induced by cancer chemotherapy with BCG].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Neoplasms; Cytarabine; Fe | 1988 |
[Studies of 5-FU concentrations associated with microangiography in colorectal cancer tissue].
Topics: Adult; Aged; Angiography; Colonic Neoplasms; DNA, Neoplasm; Female; Fluorouracil; Humans; Male; Midd | 1988 |
Intraperitoneal infusion of 5-FU in liver metastases from colorectal cancer.
Topics: Abdomen; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Liver Neoplasms; Mal | 1988 |
[Preliminary results of preoperative regional chemotherapy of cancer of the rectum].
Topics: Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Mal | 1988 |
Pharmacokinetics and pharmacodynamics of locoregional 5 fluorouracil (5FU) in advanced colorectal liver metastases.
Topics: Albumins; Angiotensin II; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans; Injections, Intra | 1988 |
Colorectal cancer chemotherapy: meta-analysis or large-scale trials?
Topics: Clinical Trials as Topic; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Rectal | 1988 |
Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil.
Topics: Adult; Cisplatin; Colonic Neoplasms; Echocardiography; Electrocardiography; Female; Fluorouracil; He | 1988 |
Preoperative irradiation and 5-fluorouracil suppository for carcinoma of the rectum.
Topics: Aged; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neop | 1988 |
Hepatic arterial ligation with and without portal infusion in metastatic colorectal cancer.
Topics: Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Hum | 1988 |
[Transcatheter arterial chemoembolization and selective hepatic arterial infusion using totally implantable reservoir].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Embolization, Therap | 1988 |
Intra-hepato-arterial chemotherapy with CDDP and 5-FU for metastases to the liver from colorectal and gastric cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Admi | 1988 |
Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma; Colonic Neoplasms; Co | 1987 |
Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Antineoplastic Agents; Cell Survival; Colonic Neoplasms; | 1987 |
A new technique for hepatic infusional chemotherapy.
Topics: Catheterization, Peripheral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Liv | 1986 |
Principia of cancer therapy. XIX. Effects of per rectum carmofur on radiotherapeutic efficacy of rectal carcinomas.
Topics: Carcinoembryonic Antigen; Carcinoma; Fluorouracil; Humans; Metabolic Clearance Rate; Rectal Neoplasm | 1987 |
[Prevention of hepatic metastasis in patients operated on for colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Epirubicin; Fluorour | 1987 |
Sequential methotrexate--5-FU--leucovorin (MFL) in advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1986 |
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1986 |
[Chemotherapy of advanced and recurrent colorectal cancer].
Topics: Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality | 1986 |
Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema | 1986 |
Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 1987 |
Severe and fatal toxic effects observed in treatment with high- and low-dose leucovorin plus 5-fluorouracil for colorectal carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea | 1987 |
High-dose folinic acid (HDFA) combined with 5-fluorouracil (5-FU) in first line chemotherapy of advanced large bowel cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Female; Fl | 1987 |
Sequential 5-fluorouracil and methotrexate. Negative experience in metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration Schedule; Fem | 1987 |
Biologic modulation of 5-fluorouracil with high-dose leucovorin and combination chemotherapy of 5-fluorouracil and cisplatin in metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-R | 1987 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Gas | 1987 |
[Whole-body hyperthermia and hyperglycemia in the combined treatment of rectal cancer].
Topics: Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Glucose; Humans; Hyperglycemia; Hyperthe | 1987 |
[Response to hepatic intra-arterial chemotherapy for metastases of colorectal cancer. Anatomo-pathological evaluation apropos of 3 cases of secondary hepatic excision].
Topics: Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Infusions, Intra-Arteria | 1987 |
Cannulation of the portal vein for cytotoxic liver perfusion in colorectal carcinomas: an alternative approach.
Topics: Adenocarcinoma; Antineoplastic Agents; Catheterization; Colonic Neoplasms; Fluorouracil; Humans; Liv | 1987 |
Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study.
Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Inf | 1987 |
[Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].
Topics: Adult; Aged; Colonic Neoplasms; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Female; | 1987 |
[The effect and CT imaging of FAM hepatic infusion chemotherapy in patients with liver metastasis from colorectal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Female; Fluorouracil | 1987 |
Treatment modalities for colorectal cancer.
Topics: Colonic Neoplasms; Colostomy; Combined Modality Therapy; Fluorouracil; Humans; Rectal Neoplasms | 1986 |
Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1987 |
Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Fe | 1987 |
Tumor and liver drug uptake following hepatic artery and portal vein infusion.
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; In | 1987 |
[Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump].
Topics: Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusion Pumps; Infusions, Intra-Arterial; In | 1987 |
[Angina pectoris during regional chemotherapy of liver metastases].
Topics: Angina Pectoris; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Rectal Neoplasms | 1987 |
Combination chemotherapy of cisplatin and 5-FU in advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Drug Eval | 1986 |
Ambulatory hepatic artery infusion chemotherapy for cancer of the liver.
Topics: Adult; Aged; Ambulatory Care; Catheters, Indwelling; Colonic Neoplasms; Female; Fluorouracil; Gastro | 1986 |
Determinants of survival after intraarterial infusion of 5-fluorouracil for liver metastases from colorectal cancer: a multivariate analysis.
Topics: Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusion | 1986 |
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration | 1986 |
Phase II-study vindesine + 5-Fluoro-Uracil combination chemotherapy in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fluorouracil; Hu | 1986 |
Chemotherapy with or without anticoagulation as initial management of patients with operable colorectal cancer: a prospective study with at least 5 years follow-up.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Fluoro | 1986 |
[Early adjuvant intraportal chemotherapy after hepatectomy for metastases of colorectal origin].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Infusions, Parenter | 1986 |
Phase II study of hepatic artery infusion with 5-fluorouracil, adriamycin, and mitomycin C (FAM) in liver metastases from colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Doxorubicin; Drug Ev | 1986 |
Chemotherapy in colorectal cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo | 1986 |
Treatment of advanced colorectal and gastric cancer with cisplatinum and 5-fluorouracil. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Female; F | 1986 |
5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Femal | 1986 |
Response of colo-rectal hepatic metastases to concomitant radiotherapy and intravenous infusion 5 fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; | 1986 |
[Successful cure of rectal cancer by conservative methods (a case report)].
Topics: Aged; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Male; Rectal Neoplasms; Re | 1987 |
Weekly 5-fluorouracil combined with PALA: toxic and therapeutic effects in colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Central Nervous System D | 1987 |
Thymidylate synthase gene amplification in a colon tumor resistant to fluoropyrimidine chemotherapy.
Topics: Colonic Neoplasms; DNA, Neoplasm; Drug Resistance; Fluorouracil; Gene Amplification; Humans; Male; M | 1987 |
Colorectal cancer (Duke's group B2, C1, C2): adjuvant chemotherapy and toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chemical and Drug Induced | 1985 |
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl | 1985 |
Selective modulation of 5-fluorouracil action in patients with colorectal carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Humans; Ki | 1985 |
Preoperative radiation therapy with sensitizers in the management of carcinoma of the rectum.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Mit | 1985 |
Long-term survivors of colorectal cancer with unresectable hepatic metastases.
Topics: Administration, Oral; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Female; Fluorouracil; Human | 1985 |
[Colony assay for clinical application].
Topics: Adult; Agar; Aged; Antineoplastic Agents; Cell Count; Cell Division; Cells, Cultured; Colonic Neopla | 1985 |
The use of radiation therapy combined with chemotherapy in the management of squamous cell carcinoma of the anus and marginally resectable adenocarcinoma of the rectum.
Topics: Aged; Antibiotics, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Combined Modality Thera | 1985 |
Anorectal squamous cell carcinoma at Mississippi Baptist Medical Center: results of the last five years of the Nigro schedule.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; C | 1985 |
[Multimodality therapy of colorectal cancer].
Topics: Aged; Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Administration Schedule; Emboliz | 1985 |
Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil.
Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus | 1985 |
Sequential therapy with methotrexate and 5-fluorouracil in the treatment of advanced colorectal carcinoma.
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neopl | 1986 |
Methyl-CCNU and methotrexate therapy in patients with advanced colorectal cancer after failure of 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil | 1986 |
[Distribution of 1-hexycarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Mal | 1986 |
Phase II study of sequential methotrexate and 5-FU combination in the treatment of advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Flu | 1986 |
[Adjuvant chemotherapy in colorectal carcinoma].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Rectal Neoplasms | 1985 |
[Preoperative treatment with 5-fluorouracil (5-FU) in gastric and colorectal cancer].
Topics: Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Injections, In | 1985 |
Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modal | 1985 |
Phase I evaluation and pharmacokinetic study of weekly iv thymidine and 5-FU in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administration | 1985 |
[Chemotherapy protocol for metastasizing colorectal carcinoma. Methotrexate, 5-fluorouracil and cytarabine].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Cytarabine; Drug Adm | 1985 |
[Therapy-induced tumor regression. Morphological findings in malignant primary and secondary liver tumors following intensive regional cytostatic treatment].
Topics: Adenocarcinoma; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Doxoru | 1985 |
[Radiotherapy. Locally advanced colorectal cancer with and without 5-fluorouracil].
Topics: Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle Aged; | 1985 |
[Risk-related surgical treatment of colorectal tumors].
Topics: Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Post | 1985 |
Unresectable hepatic metastases from carcinoma of the colon and rectum.
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Carcinoembryon | 1985 |
Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1985 |
Continuous 5-day regional chemotherapy by 5-fluorouracil in colon carcinoma: pharmacokinetic evaluation.
Topics: Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Hepatic Artery; Hum | 1985 |
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic | 1985 |
A phase II study of sequential methotrexate and fluorouracil in advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Ev | 1985 |
Allopurinol mouthwashes and 5-fluorouracil induced oral toxicity.
Topics: Allopurinol; Colonic Neoplasms; Fluorouracil; Humans; Intestinal Mucosa; Mouth Mucosa; Mouthwashes; | 1985 |
Treatment of metastatic colorectal carcinoma with cisplatin and 5-FU.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop | 1985 |
Colorectal cancer: speculations on the role of intraperitoneal therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Coloni | 1985 |
Adjuvant therapy in rectal cancer: a protocol proposal.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Humans; Inf | 1985 |
Highly sensitive determination of 5-fluorouracil in human plasma by capillary gas chromatography and negative ion chemical ionization mass spectrometry.
Topics: Alkylation; Bromouracil; Colonic Neoplasms; Fluorouracil; Gas Chromatography-Mass Spectrometry; Huma | 1985 |
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige | 1985 |
Cellular basis for the inefficacy of 5-FU in human colon carcinoma.
Topics: Cell Count; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Colony-Forming Units Assay; | 1985 |
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug | 1985 |
The chemotherapy of colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, | 1974 |
[Attack on liver cancer--what's the value of diagnosis and treatment?].
Topics: Adult; Aged; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms; Middle | 1974 |
Prolonged intra-aortic infusion therapy with anti-tumor agents for advanced cancer of the stomach, colon and rectum.
Topics: Adult; Aged; Antineoplastic Agents; Aorta; Bleomycin; Catheterization; Colonic Neoplasms; Cytarabine | 1971 |
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female; | 1970 |
[Study of the action of antitumor compounds on primary explants from human tumors].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An | 1967 |
[Loco-regional and sequential chemotherapy of advanced cancer].
Topics: Adult; Carcinoma; Carcinoma, Hepatocellular; Chemotherapy, Cancer, Regional Perfusion; Dysgerminoma; | 1968 |
Metastatic colorectal carcinoma. Response to hepatic infusion. A review.
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infusions, Parenteral; Liver Neoplasms | 1970 |
Echographic evaluation of abdominal tumor regression during antineoplastic treatment.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorub | 1974 |
Chemotherapy of cancer of the colon and rectum.
Topics: Antineoplastic Agents; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Nitrosourea Compounds; | 1972 |
Practical aspects of investigation and treatment of colorectal cancer.
Topics: Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusions, Parenteral; Liver Function | 1972 |
Chemotherapy of colon and rectal cancer.
Topics: Administration, Oral; Antigens, Neoplasm; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasm | 1972 |
Effect of resection of the primary neoplasm on responsiveness to chemotherapy of patients with large bowel cancer.
Topics: Adenocarcinoma; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Nitrosourea Compounds; Rectal | 1972 |
Chemotherapy of gastrointestinal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; Esophageal Neoplasms; Floxuridine; Fluorouracil; Gastroint | 1972 |
Intra-arterial combined cancer chemotherapy in technically inoperable carcinoma of the anus and rectum.
Topics: Aged; Animals; Anus Neoplasms; Daunorubicin; Depression, Chemical; Dogs; Drug Therapy, Combination; | 1974 |
Infusion chemotherapy in hepatoma and metastatic liver tumors.
Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; | 1967 |
[Treatment of cancer of the liver by regional perfusion].
Topics: Adult; Aged; Angiography; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Fluorouraci | 1968 |
[Pathologic anatomy of rectal cancer treated by intra-arterial administration of 5-fluoruracil].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; | 1970 |
Carcinoma of the colon and rectum in patients up to 25 years of age.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Age Factors; Colonic Neoplasms; Female; | 1971 |
Experience with infusion and resection in cancer of the liver.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Hepatocellular; Catheterization; Colonic Neoplasms; Female | 1974 |
The chemotherapy of large-bowel cancer. Present status and future prospects.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cricetinae; Culture Techniques; Cyclohexanes; Cyc | 1974 |
Section meeting on reexamination of the old and prospects for new approaches to therapy.
Topics: Colectomy; Colonic Neoplasms; Cyclohexanes; Cyclophosphamide; Drug Therapy, Combination; Fluorouraci | 1974 |
Intraluminal and intravenous 5-FU chemotherapy adjuvant to surgery for resectable colorectal cancer.
Topics: Administration, Topical; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Postopera | 1974 |
Systemic 5-fluorouracil in hepatic metastases from primary colon or rectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Hepatic metastases from rectal and colon cancers. Treatment by infusion of 5-fluorouracil into umbilical vein.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Liver Neoplasms; Neoplasm Metastas | 1972 |
Adjuvant chemotherapy in resectable cancer of the colon and rectum.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Postoperative Complications; Rectal Neoplasms; Thiotepa | 1972 |
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens; | 1972 |
Results of 27 cases with hepatic metastases treated by combination chemotherapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Fluorouracil; Humans; | 1972 |
FIVB--a new combination of drugs in the treatment of cancer.
Topics: Adenocarcinoma; Aged; Amides; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Imi | 1973 |
[Cytostatic therapy of metastazing rectal carcinoma].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Fluorouracil; Humans; Injections, Intra | 1973 |
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex | 1973 |
[Postoperative chemotherapy as means of prophylaxis of recurrences and metastases of cancer of the rectum].
Topics: Aged; Female; Fluorouracil; Humans; Injections, Intravenous; Neoplasm Metastasis; Neoplastic Cells, | 1973 |
A comprehensive modeling procedure for the human granulopoietic system: over-all view and summary of data.
Topics: Aged; Animals; Blood Platelets; Bone Marrow Cells; Erythropoiesis; Feedback; Female; Fluorouracil; H | 1973 |
Scan evidence of decrease in size of intrahepatic tumors after chemotherapy. A case report.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cecal Neoplasms; Doxorubicin; Female; Fluorouracil; Human | 1974 |
[Effects of 5-FU (5-fluorouracil) in 4.3MeV Linac x-ray treatment of advanced cancer].
Topics: Adult; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Fl | 1968 |
[Clinico-morphologic analysis of the results of long-term intra-arterial chemotherapy of the far advanced stages of rectal cancer].
Topics: Adenocarcinoma; Adult; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluoroura | 1968 |
5-Hydroxyindole-secreting rectal carcinoid tumour.
Topics: Adult; Carcinoid Tumor; Duodenal Ulcer; Female; Fluorouracil; Humans; Hydroxyindoleacetic Acid; Live | 1972 |
Chemotherapy of colorectal cancer.
Topics: Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Neoplasm Recurrence, Local; Rectal Neoplasms | 1972 |
Results of treatment of malignant tumors with ftorafur.
Topics: Antimetabolites; Antineoplastic Agents; Brain Neoplasms; Breast Neoplasms; Colonic Neoplasms; Deoxyr | 1972 |
[Combined application of drugs in cancer chemotherapy with special reference to the combination of mitomycin C, 5-fluorouracil, and cytosine arabinoside].
Topics: Cytarabine; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Mitomycins; Neoplasm | 1972 |
[Local intra-arterial infusion chemotherapy of malignant tumor--successful treatment by intra-arterial infusion of 5-fluorouracil and mitomycin C in cases of unresectable cancer of the liver, stomach, colon and rectum].
Topics: Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Infant; Injections, Intra-Arterial; Li | 1971 |
Circulating cancer cells: pre- and post-chemotherapy observations.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Female; Filtration; Fluorouracil; Humans; Male; | 1971 |
Treatment of metastatic colorectal carcinoma with 5-fluorouracil by mouth.
Topics: Administration, Oral; Aged; Bone Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver C | 1971 |
Chemotherapy for metastatic colorectal liver carcinoma by intra-aortic infusion.
Topics: Antineoplastic Agents; Aorta, Abdominal; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms | 1971 |
[Electrolyte secreting rectal tumor].
Topics: Adenoma; Aged; Fluorouracil; Humans; Male; Rectal Neoplasms; Water-Electrolyte Balance | 1971 |
Combination cancer chemotherapy by regional intra-arterial or intra-aortic infusion of 5-fluorouracil and mitomycin-C with or without irradiation.
Topics: Aorta; Cobalt Radioisotopes; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hea | 1971 |
Cytotoxic penetration and concentration in human malignant tumours.
Topics: Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Injections | 1969 |
The use of chemotherapy in advanced carcinoma of the rectum.
Topics: Cyclophosphamide; Fluorouracil; Humans; Injections, Intra-Arterial; Leukopenia; Male; Mechlorethamin | 1969 |
Comparative study of monthly courses versus weekly doses of 5-fluorouracil (NSC-19893).
Topics: Adult; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplas | 1969 |
Survival of patients treated with systemic fluorouracil for hepatic metastases.
Topics: Adult; Age Factors; Aged; Carcinoma; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Hum | 1970 |
Treatment of hepatic tumours.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Hepatic Artery; Humans; Laparotomy; Lei | 1970 |
[Treatment of metastases to the liver in the course of sigmoid and rectal cancer].
Topics: Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Male; Methods; Neoplasm Metastasis | 1970 |
One-shot infusion of non-surgically administered mitomycin C in the celiac artery for liver metastases. Clinical effects.
Topics: Adult; Aged; Angiography; Blood Cell Count; Blood Platelets; Celiac Artery; Colonic Neoplasms; Femal | 1970 |
[5-fluorouracil concentration in the blood of patients with rectal cancer following regional drug administration].
Topics: Fluorouracil; Humans; Injections, Intra-Arterial; Injections, Intravenous; Rectal Neoplasms | 1970 |
[Intra-portal infusion of 5-fluorouracil for metastasis of rectal cancer into the liver].
Topics: Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Liver Neoplasms; Middle | 1970 |
[The possibilities of drug therapy in metastazing carcinoma of the large intestine].
Topics: Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Metastasis; Rectal Neoplasms | 1967 |
Clinical evaluation of combined radiation and chemotherapy in gastrointestinal malignancies.
Topics: Bone Marrow; Bone Marrow Cells; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; | 1968 |
Carcinoma of the colon and rectum.
Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic | 1968 |
The role of chemotherapy in the treatment of colorectal cancer.
Topics: Colonic Neoplasms; Fluorouracil; Humans; Rectal Neoplasms | 1968 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |
[Clinical application of 5-fluorouracil--with special reference to the evaluation of the intravenous administration method].
Topics: Adult; Antineoplastic Agents; Female; Fluorouracil; Humans; Injections, Intravenous; Male; Methods; | 1968 |
Prolonged continuous hepatic infusion. Results with fluorouracil for primary and metastatic cancer in the liver.
Topics: Adult; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Female; Fluorou | 1969 |
Local injection of fluorouracil in skin cancer.
Topics: Adenocarcinoma; Fluorouracil; Humans; Injections; Male; Middle Aged; Neoplasm Recurrence, Local; Per | 1969 |
Intraluminal chemotherapy adjuvant (HN2 or 5-FU) to operation for cancer of the colon and rectum. Follow-up report of 83 cases.
Topics: Adult; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Humans; Mechlorethamine; Middle | 1965 |
Chemotherapy for liver cancer by protracted ambulatory infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans | 1965 |